


VOLUME 73

EDITED BY

George F. Vande Woude

George Klein



Advances in
**CANCER
RESEARCH**

Cumulative Subject Index, Volumes 50-72



Advances in
**CANCER
RESEARCH**

Volume 73

Cumulative Subject Index

Volumes 50–72

This Page Intentionally Left Blank

Advances in **CANCER RESEARCH**

Volume 73
Cumulative Subject Index
Volumes 50–72

Edited by

George F. Vande Woude

*ABL—Basic Research Program
National Cancer Institute
Frederick Cancer Research and Development Center
Frederick, Maryland*

George Klein

*Microbiology and Tumor Biology Center
Karolinska Institutet
Stockholm, Sweden*



ACADEMIC PRESS

San Diego London Boston
New York Sydney Tokyo Toronto

This book is printed on acid-free paper. ∞

Copyright © 1998 by ACADEMIC PRESS

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, Massachusetts 01923), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-1998 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters.
0065-230X/98 \$25.00

Academic Press

a division of Harcourt Brace & Company
525 B Street, Suite 1900, San Diego, California 92101-4495, USA
<http://www.apnet.com>

Academic Press Limited
24-28 Oval Road, London NW1 7DX, UK
<http://www.hbuk.co.uk/ap/>

International Standard Book Number: 0-12-006673-4

PRINTED IN THE UNITED STATES OF AMERICA

97 98 99 00 01 02 BB 9 8 7 6 5 4 3 2 1

Contents

Contents of Volumes 50–72 vii

Subject Index 1

Contributor Index 233

This Page Intentionally Left Blank

Contents of Volumes 50–72

VOLUME 50

Biological Markers of Cell Proliferation and Differentiation in Human Gastrointestinal Diseases

Martin Lipkin and Paul Higgins 1

Chemical Carcinogenesis: From Animal Models to Molecular Models in One Decade

Stuart H. Yuspa and Miriam C. Poirier 25

Oncogenes and the Nature of Malignancy

Ian Buckley 71

The Epstein–Barr Virus Proteins

Joakim Dillner and Bengt Kallin 95

Stromal Involvement in Malignant Growth

A. van den Hooff 159

Tumor Clonality and Its Biological Significance

Michael F. A. Woodruff 197

Newborn Macrosomy and Cancer

Lev M. Berstein 231

Louvain Rat Immunocytomas

Hervé Bazin, Warren S. Pear, and Janos Sumegi 279

VOLUME 51

The Etiopathogenesis of Prostatic Cancer with Special Reference to Environmental Factors

Maarten C. Bosland 1

Transforming Growth Factor β

Anita B. Roberts and Michael B. Sporn 107

Oncogene Activation in Chemical Carcinogenesis

Allan Balmain and Ken Brown 147

The Intracisternal A-Particle Gene Family: Structure and Functional Aspects

Edward L. Kuff and Kira K. Lueders 183

Immunologic Unresponsiveness to Murine Leukemia Virus Antigens: Mechanisms and Role in Tumor Development

Luigi Chieco-Bianchi, Dino Collavo, and Giovanni Biasi 277

Advances in Human Retroviruses

Angus Dalgleish and Miroslav Malkovsky 307

Homing Receptors and Metastasis

Beverly Taylor Sher, Robert Bargatze, Bernard Holzmann, W. Michael Gallatin, Dana Matthews, Nora Wu, Louis Picker, Eugene C. Butcher, and Irving L. Weissman 361

Dehydroepiandrosterone and Structural Analogs: A New Class of Cancer Chemopreventive Agents

Arthur G. Schwartz, Jeannette M. Whitcomb, Jonathan W. Nyce, Marvin L. Lewbart, and Laura L. Pashko 391

VOLUME 52**Primary Chromosome Abnormalities in Human Neoplasia**

Sverre Heim and Felix Mitelman 1

T Cell Receptor and Immunoglobulin Gene Rearrangements in Lymphoproliferative Disorders

M. D. Reis, H. Griesser, and T. W. Mak 45

Structure, Function, and Genetics of Human B Cell-Associated Surface Molecules

Edward A. Clark and Jeffrey A. Ledbetter 81

Adenovirus Proteins and MHC Expression

Svante Pääbo, Liv Severinsson, Mats Andersson, Ingrid Martens, Tommy Nilsson, and Per A. Peterson 151

Multidrug Resistance

Alexander M. van der Blik and Piet Borst 165

Glutathione Transferases as Markers of Preneoplasia and Neoplasia

Kiyomi Sato 205

Aberrant Glycosylation in Tumors and Tumor-Associated Carbohydrate Antigens

Sen-itiroh Hakomori 257

VOLUME 53

Serum-Inducible Genes

Barrett J. Rollins and Charles D. Stiles 1

Malaria, Epstein–Barr Virus, and the Genesis of Lymphomas

Christine A. Facer and J. H. L. Playfair 33

A Review of Kaposi's Sarcoma

Jane Armes 73

The Relationship between MHC Antigen Expression and Metastasis

Jacob Gopas, Bracha Rager-Zisman, Menashe Bar-Eli, Günter J. Hämmerling, and Shraga Segal 89

Genetics of Tumor Susceptibility in the Mouse: MHC and Non-MHC Genes

P. Demant, L. C. J. M. Oomen, and M. Oudshoorn-Snoek 117

Perspectives on the Role of MHC Antigens in Normal and Malignant Cell Development

Bruce E. Elliott, Douglas A. Carlow, Anna-Marie Rodricks, and Andrew Wade 181

Antioxidants—Carcinogenic and Chemopreventive Properties

Nobuyuki Ito and Masao Hirose 247

VOLUME 54

The Role of DNA Methylation in Cancer

Peter A. Jones and Jonathan D. Buckley 1

Genetic and Epigenetic Losses of Heterozygosity in Cancer Predisposition and Progression

Heidi J. Scrabble, Carmen Sapienza, and Webster K. Cavenee 25

Genetic and Molecular Studies of Cellular immortalization

James R. Smith and Olivia M. Pereira-Smith 63

The Function of *RAS* Genes in *Saccharomyces cerevisiae*

James R. Broach and Robert J. Deschenes 79

Retroviral Integration in Murine Myeloid Tumors to Identify *evi-1*, a Novel Locus Encoding Zinc-Finger Protein

N. G. Copeland and N. A. Jenkins 141

Metastatic Inefficiency

Leonard Weiss 159

Growth Regulatory Factors for Normal, Premalignant, and Malignant Human Cells *in Vitro*

Meenhard Herlyn, Roland Kath, Noel Williams, Istvan Valyi-Nagy, and Ulrich Rodeck 213

The Lymphopoietic Microenvironment in Bone Marrow

Paul W. Kincade 235

Structure and Function of the B-Lymphocyte Epstein–Barr Virus/C3d Receptor

Glen R. Nemerow, Margaret D. Moore, and Neil R. Cooper 273

The Opportunistic Tumors of Immune Deficiency

Harry L. Ioachim 301

A Note on Concomitant Immunity in Host–Parasite Relationships: A Successfully Transplanted Concept from Tumor Immunology

Graham F. Mitchell 319

VOLUME 55

***jun*: Oncogene and Transcription Factor**

Peter K. Vogt and Timothy J. Bos 1

Proto-Oncogene *c-fos* as a Transcription Factor

Robert J. Distel and Bruce M. Spiegelman 37

Studies on the Polyoma Virus Tumor-Specific Transplantation Antigen (TSTA)

Tina Dalianis 57

Growth Dominance of the Metastatic Cancer Cell: Cellular and Molecular Aspects

R. S. Kerbel 87

The Pathogenesis of Burkitt's Lymphoma

Ian Magrath 133

Mechanisms of Signal Transduction to the Cell Nucleus

Erich A. Nigg 271

VOLUME 56

Control of *c-myc* Regulation in Normal and Neoplastic Cells

Charlotte A. Spencer and Mark Groudine 1

T Cell Receptors: Adhesion and Signaling

Barbara E. Bierer and Steven J. Burakoff 49

Localizing the Genes for Ataxia-Telangiectasia: A Human Model for Inherited Cancer Susceptibility

Richard A. Gatti 77

***In Situ* Carcinoma-Associated Immunogenicity: Therapeutic and Prophylactic Implications in Breast Cancer Patients**

Maurice M. Black and Reinhard E. Zachrau 105

Transforming Activity of Bovine and Human Papillomaviruses in Cultured Cells

Daniel DiMaio 133

Analysis of Cancer Incidence Data on the Basis of Multistage and Clonal Growth Models

W. D. Stein 161

Mouse Retrotransposons: A Cellular Reservoir of Long Terminal Repeat (LTR) Elements with Diverse Transcriptional Specificities

Eli Keshet, Rachel Schiff, and Ahuva Itin 215

Chemistry and Biology of α -Fetoprotein

Harold F. Deutsch 253

Autocrine Regulation of Normal and Malignant B Lymphocytes

John Gordon and Jennifer A. Cairns 313

Transformation by Herpesvirus Saimiri

Ronald C. Desrosiers 335

VOLUME 57***myc* Family Oncogenes in the Development of Normal and Neoplastic Cells**

Frederick W. Alt 1

Transcriptional and Transforming Activities of the Adenovirus E1A Proteins

Thomas Shenk and Jane Flint 47

Mitogenic Action of Lysophosphatidic Acid

Wouter H. Moolenaar 87

Expression and Interactions of the Src Family of Tyrosine Protein Kinases in T Lymphocytes

Joseph B. Bolen, Peter A. Thompson, Elisa Eiseman, and Ivan D. Horak 103

Implicating the *bcr/abl* Gene in the Pathogenesis of Philadelphia Chromosome-Positive Human Leukemia

George Q. Daley and Yinon Ben-Neriah 151

Oncoprotein Kinases in Mitosis

David Shalloway and Suresh Shenoy 185

Current Status of the *BCR* Gene and Its Involvement with Human Leukemia

Martin L. Campbell and Ralph B. Arlinghaus 227

p53 and Human Malignancies

Varda Rotter and Miron Prokocimer 257

Directed Plasminogen Activation at the Surface of Normal and Malignant Cells

Jari Pöllänen, Ross W. Stephens, and Antti Vaheri 273

Epstein–Barr Virus-Associated Lymphoproliferative Disorders in Immunocompromised Individuals

J. Alero Thomas, Martin J. Allday, and Dorothy H. Crawford 329

ADF, A Growth-Promoting Factor Derived from Adult T Cell Leukemia and Homologous to Thioredoxin: Involvement in Lymphocyte Immortalization by HTLV-1 and EBV

Junji Yodoi and Thomas Tursz 381

The Hunt for Endogenous Growth-Inhibitory and/or Tumor Suppression Factors: Their Role in Physiological and Pathological Growth Regulation

Olav Hilmar Iversen 413

VOLUME 58**Epstein–Barr Virus in B Lymphocytes: Viral Gene Expression and Function in Latency**

Robert P. Rogers, Jack L. Strominger, and Samuel H. Speck 1

The Physiology of Transforming Growth Factor- α

Rik Derynck 27

The Role of Raf-1 Phosphorylation in Signal Transduction

Gisela Heidecker, Walter Kölch, Deborah K. Morrison, and Ulf R. Rapp 53

G Protein-Controlled Signal Transduction Pathways and the Regulation of Cell Proliferation

Klaus Seuwen and Jacques Pouyssegur 75

Regulation of Muscle Cell Growth and Differentiation by the MyoD Family of Helix–Loop–Helix Proteins

Li Li and Eric N. Olson 95

Molecular Genetic Characterization of CNS Tumor Oncogenesis

C. David James and V. Peter Collins 121

Tumor Eradication by Adoptive Transfer of Cytotoxic T Lymphocytes

Cornelis J. M. Melief 143

Toward a Genetic Analysis of Tumor Rejection Antigens

Thierry Boon 177

VOLUME 59**Lev Zilber, The Personality and the Scientist**

Lev L. Kisselev, Gary I. Abelev, and Feodor Kissel'ov 1

The Genetics of Wilms' Tumor

Daniel A. Haber and David E. Housman 41

p53 Expression in Human Breast Cancer

Adrian L. Harris 69

***c-erbA*: Protooncogene or Growth Suppressor Gene?**

Klaus Damm 89

The FGF Family of Growth Factors and Oncogenes

Claudio Basillico and David Moscatelli 115

Hepatitis B Viruses and Hepatocellular Carcinoma

Marie Annick Buendia 167

Cytotoxic T Lymphocytes: Specificity, Surveillance, and Escape

Andrew McMichael 227

**Cancer Immunotherapy: Are the Results Discouraging?
Can They Be Improved?**

Eli Kedar and Eva Klein 245

VOLUME 60**Structural and Functional Diversity in the FGF Receptor
Multigene Family**

Daniel E. Johnson and Lewis T. Williams 1

**Protein Tyrosine Kinase Growth Factor Receptors and Their
Ligands in Development, Differentiation, and Cancer**

Andrew F. Wilks 43

The Molecular and Genetic Characterization of Human Soft Tissue Tumors

Colin S. Cooper 75

Genomic Instability and Tumor Progression: Mechanistic Considerations

Keith C. Cheng and Lawrence A. Loeb 121

Function and Regulation of the Human Multidrug Resistance Gene

Khew-Voon Chin, Ira Pastan, and Michael M. Gottesman 157

Relationship between MYC Oncogene Activation and MHC Class I Expression

Peter I. Schrier and Lucy T. C. Peltenburg 181

Immunosuppressive Factors in Human Cancer

Dov Sulitzeanu 247

Lysosomes, Lysosomal Enzymes, and Cancer

Michael J. Boyer and Ian F. Tannock 269

VOLUME 61**Cancer Prevention Research Trials**

Peter Greenwald, Winfred F. Malone, Mary E. Cerny, and Harriet R. Stern 1

Molecular Genetic Changes in Human Breast Cancer

Marc J. van de Vijver 25

Molecular Approaches to Cancer Therapy

Mark A. Israel 57

Regulation and Mechanism of Mammalian Gene Amplification

George R. Stark 86

Unraveling the Function of the Retinoblastoma Gene

Eldad Zacksenhaus, Rod Bremner, Zhe Jiang, R. Montgomery Gill, Michelle Muncaster, Mary Sopta, Robert A. Phillips, and Brenda L. Gallie 115

Tumor Promotion by Inhibitors of Protein Phosphatases 1 and 2A: The Okadaic Acid Class of Compounds

Hirota Fujiki and Masami Suganuma 143

Oncogenic Basis of Radiation Resistance

Usha Kasid, Kathleen Pirollo, Anatoly Dritschilo, and Esther Chang 195

VOLUME 62**FOUNDATIONS IN CANCER RESEARCH****Chromosomes and Cancer: The Evolution of an Idea**

Peter C. Nowell 1

Pathways of Ras Function: Connections to the Actin Cytoskeleton

George C. Prendergast and Jackson B. Gibbs 19

The Role of the *Adenomatous Polyposis Coli (APC)* Gene in Human Cancers

Yusuke Nakamura 65

Molecular Cytogenetics of Renal Cell Tumors

Gyula Kovacs 89

Reverse Transformation, Genome Exposure, and Cancer

Theodore T. Puck and Alphonse Krystosek 125

Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation

Pramod K. Srivastava 154

The Association of Epstein–Barr Virus (EBV) with T Cell Lymphoproliferations and Hodgkin’s Disease: Two New Developments in the EBV Field

Gorm Pallesen, Stephen J. Hamilton-Dutoit, and Xiaoge Zhou 180

The Role of Direct Cellular Communication during the Development of a Humoral Immune Response

E. Charles Snow and Randolph J. Noelle 241

VOLUME 63**FOUNDATIONS IN CANCER RESEARCH****Alone on the Heart of the Earth: An Immunogeneticist’s Journey into the Past**

Jan Klein 2

FOUNDATIONS IN CANCER RESEARCH**Hemopoietic Regulators and Leukemia Development:
A Personal Retrospective**

Donald Metcalf 41

**MAP Kinases ERK1 and ERK2: Pleiotropic Enzymes in a
Ubiquitous Signaling Network**David J. Robbins, Erzhen Zhen, Mangeng Cheng, Shuichan Xu, Douglas Ebert,
and Melanie H. Cobb 95**How DNA Viruses Perturb Functional MHC Expression to Alter
Immune Recognition**

Grant McFadden and Kevin Kane 118

Viral Transformation of Human T Lymphocytes

Ralph Grassmann, Bernhard Fleckenstein, and Ronald C. Desrosiers 211

**Lymphomagenesis in AKR Mice: B Cell Lymphomas as a Model of
Tumor Dormancy**

Nechama Haran-Ghera 245

The Tumor Biology of Gastrin and Cholecystokinin

Jens F. Rehfeld and Wouter W. van Solinge 295

VOLUME 64**Interactions between Papillomavirus Proteins and Tumor
Suppressor Gene Products**

Karen H. Vousden 1

The Retinoblastoma Tumor Suppressor Protein

Jean Y. J. Wang, Erik S. Knudsen, and Peter J. Welch 25

SH2 and SH3 Domains in Signal Transduction

Tony Pawson 87

**Activation of the Src Family of Tyrosine Kinases in
Mammary Tumorigenesis**

Senthil K. Muthuswamy and William J. Muller 111

Oncogenic Properties of the Middle T Antigens of Polyomaviruses

Friedemann Kiefer, Sara A. Courtneidge, and Erwin F. Wagner 125

Selective Involvement of Protein Kinase C Isozymes in Differentiation and Neoplastic Transformation

JoAnne Goodnight, Harald Mischak, and J. Frederic Mushinski 160

Fc γ Receptors in Malignancies: Friends or Enemies?

János Gergely and Gabriella Sármay 211

Dissecting Molecular Carcinogenesis: Development of Transgenic Mouse Models by Epidermal Gene Targeting

David A. Greenhalgh and Dennis R. Roop 247

VOLUME 65**Genetics in the Thirties**

James F. Crow 1

Historical Origins of Current Concepts of Carcinogenesis

P. D. Lawley 18

From the Melanocyte to Melanoma to Tumor Biology

Wallace H. Clark, Jr. 113

The Origins of the Small DNA Tumor Viruses

Arnold J. Levine 141

Retroviruses and Wild Mice: An Historical and Personal Perspective

Murray B. Gardner 169

Sol Spiegelman

Gunther S. Stent 203

Growth Dysregulation in Cancer Cells

Arthur B. Pardee 213

VOLUME 66**FOUNDATIONS IN CANCER RESEARCH****The Adventures of a Biologist: Prenatal Diagnosis, Hematopoiesis, Leukemia, Carcinogenesis, and Tumor Suppression**

Leo Sachs 1

FOUNDATIONS IN CANCER RESEARCH

From Aristotle, through Spemann, to Tumor Immunology: A Personal Experience

Michael Feldman 42

Tumor Suppressor *p53* Mutations and Breast Cancer: A Critical Analysis

Michelle A. Ozbun and Janet S. Butel 72

***p53*: A Cell Cycle Regulator Activated by DNA Damage**

Galina Selivanova and Klas G. Wiman 143

Cyclins and Cyclin-Dependent Kinases: Theme and Variations

Jonathon Pines 181

Molecular Genetics of 11q23 Chromosome Translocations

Eli Canaani, Peter C. Nowell, and Carlo M. Croce 213

Role of Scatter Factor and the *c-met* Protooncogene in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma

Peter J. Polverini and Brian J. Nickoloff 235

REL/NF- κ B/I κ B Story

Shigeki Miyamoto and Inder M. Verma 255

Radiation Leukemia Virus-Induced Leukemogenesis: A Paradigm of Preleukemia and Its Control by Preventive Therapy

Eitan Yefenof and Moshe Kotler 293

The Insertion of Foreign DNA into Mammalian Genomes and Its Consequences: A Concept in Oncogenesis

Walter Doerfler 313

VOLUME 67

FOUNDATIONS IN CANCER RESEARCH

Mutation and Cancer: A Personal Odyssey

Alfred G. Knudson, Jr. 1

Oncogenic Role of "Master" Transcription Factors in Human Leukemias and Sarcomas: A Developmental Model

A. Thomas Look 25

Pathways of Chromosome Alteration in Human Epithelial Cancers

Bernard Dutrillaux 59

Genetics of Murine Lung Tumors

Tommaso A. Dragani, Giacomo Manenti, and Marco A. Pierotti 83

Molecular Pathogenesis of AIDS-Related Lymphomas

Gianluca Gaidano and Riccardo Dalla-Favera 113

HLA Class I Antigens in Human Tumors

Federico Garrido and Teresa Cabrera 155

Molecular Epidemiology of Epstein–Barr Virus Infection

Jan W. Gratama and Ingemar Ernberg 197

Scatter Factor and Angiogenesis

Eliot M. Rosen and Itzhak D. Goldberg 257

Role of VEGF-Fit Receptor System in Normal and Tumor Angiogenesis

Masabumi Shibuya 281

VOLUME 68**FOUNDATIONS IN CANCER RESEARCH****Viruses in Human Tumors—Reminiscences and Perspectives**

Harald zur Hausen 1

Signaling by the Cytokine Receptor Superfamily in Normal and Transformed Hematopoietic Cells

James N. Ihle 23

Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer

Marcia Hall and Gordon Peters 67

Myc Proteins: Essential Regulators of Cell Growth

Marie Henriksson and Bernhard Lüscher 109

The Role of the Insulin-like Growth Factor System in Human Cancer

Haim Werner and Derek LeRoith 184

Genetic Basis and Clonal Evolution of Human Prostate Cancer

Olli-P. Kallioniemi and Tapio Visakorpi 225

VOLUME 69

FOUNDATIONS IN CANCER RESEARCH

The Pastorian: A Legacy of Louis Pasteur

Harold Varmus 1

Cell Cycle Control in Fission Yeast and Mammals: Identification of New Regulatory Mechanisms

Hiroto Okayama, Akihisa Nagata, Shigeki Jinno, Hiroshi Murakami, Koichi Tanaka, and Naomi Nakashima 17

Cytogenetics and Molecular Genetics of Bone and Soft Tissue Tumors

Nils Mandahl 63

Plasminogen Activation on Tumor Cell Surface and Its Involvement in Human Leukemia

Hannele Tapiovaara, Riitta Alitalo, and Antti Vaheri 101

How Tumors Become Angiogenic

Noël Bouck, Veronica Stellmach, and Stephanie Hsu 135

Immunity to Human Papillomavirus-Associated Cervical Neoplasia

Peter L. Stern 175

Strategies Involved in Developing an Effective Vaccine to EBV-Associated Diseases

Denis J. Moss, Christopher Schmidt, Suzanne Elliott, Andreas Suhrbier, Scott Burrows, and Rajiv Khanna 213

VOLUME 70

FOUNDATIONS IN CANCER RESEARCH

Fundamentals of Cancer Cell Biology

Michael Stoker 1

FOUNDATIONS IN CANCER RESEARCH**The Step-by-Step Development of Epithelial Cancer:
From Phenotype to Genotype**

Emmanuel Farber 21

**Genetics of the Nevoid Basal Cell Carcinoma
Syndrome**

Abirami Chidambaram and Michael Dean 49

**Transforming Growth Factor- β System and Its Regulation by
Members of the Steroid-Thyroid Hormone Superfamily**

Katri Koli and Jorma Keski-Oja 63

***c-Myc* in the Control of Cell Proliferation and
Embryonic Development**

Jean-Marc Lemaitre, Robin S. Buckle, and Marcel Méchali 95

**Identification of the Genes Encoding Cancer Antigens:
Implications for Cancer Immunotherapy**Steven A. Rosenberg, Yutaka Kawakami, Paul F. Robbins,
and Rong-fu Wang 145**The MEN II Syndromes and the Role of the *ret* Proto-oncogene**

Bruce A. J. Ponder and Darrin Smith 179

VOLUME 71***p53* and ATM: Cell Cycle, Cell Death, and Cancer**

Susan E. Morgan and Michael B. Kastan 1

**Deletions of the Short Arm of Chromosome 3 in Solid Tumors
and the Search for Suppressor Genes**

Klaas Kok, Susan L. Naylor, and Charles H. C. M. Buys 27

**Mutations Predisposing to Hereditary Nonpolyposis
Colorectal Cancer**

Päivi Peltomäki and Albert de la Chapelle 93

**Functional Aspects of Apoptosis in Hematopoiesis and
Consequences of Failure**

Sharon L. McKenna and Thomas G. Cotter 121

Cyclin-Dependent Kinase Regulation during G1 Phase and Cell Cycle Regulation by TGF- β

Michael J. Ravitz and Charles E. Wenner 165

The Natural Somatic Mutation Frequency and Human Carcinogenesis

Andrew J. G. Simpson 209

CD44: Structure, Function, and Association with the Malignant Process

David Naor, Ronit Vogt Sionov, and Dvora Ish-Shalom 243

Human Papillomaviruses and Cervical Cancer

Luisa Lina Villa 321

HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer

Mary L. Disis and Martin A. Cheever 343

VOLUME 72

FOUNDATIONS IN CANCER RESEARCH

Foulds' Dangerous Idea Revisited: The Multistep Development of Tumors 40 Years Later

George Klein 1

FOUNDATIONS IN CANCER RESEARCH

Cancer Cells Exhibit a Mutator Phenotype

Lawrence A. Loeb 25

Increasing Complexity of Ras Signal Transduction: Involvement of Rho Family Proteins

Roya Khosravi-Far, Sharon Campbell, Kent L. Rossman, and Channing J. Der 57

B-Myb: A Key Regulator of the Cell Cycle

Mark Saville and Roger Watson 109

Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

Stephen B. Baylin, James G. Herman, Jeremy R. Graff, Paula M. Vertino, and Jean-Pierre Issa 141

Ara-C: Cellular and Molecular Pharmacology

Steven Grant 197

This Page Intentionally Left Blank

Subject Index

Boldface numerals indicate volume number.

A

- A1 protein, apoptosis and, **71**:126
- Abelson murine leukemia virus
bcr/abl gene and, **57**:153, 156–157, 160, 167
 in leukemia and, **57**:171–172
- BCR gene in leukemia and, **57**:231, 244
- Burkitt's lymphoma and, **55**:245
- myc* family oncogenes and, **57**:23–24, 31
- oncogenes and, **50**:82
- abl*
BCR gene in leukemia and, **57**:227–229, 232, 252–253
- leukemia and, **57**:153–155, 157
 activation, **57**:160–163
 animal models, **57**:174–175
 c-Abl protein, **57**:157–158
 malignancy, **57**:163–167, 163–169
- oncoprotein kinases and, **57**:198
- p53* and human malignancies and, **57**:263, 267
- Philadelphia chromosome, **57**:154–155
- soft tissue tumors and, **60**:88–89, 107
- synergism with *c-myc*, **68**:155–156
- tyrosine kinase product, **68**:155
- tyrosine protein kinases and, **57**:108
- Abl protein
BCR gene in leukemia and, **57**:229, 252
- leukemia and, **57**:157–163, 160–165, 167–168, 171, 175, 177
- oncoprotein kinases and, **57**:196
- Abl tyrosine kinases, apoptosis and, **71**:129
- Acanthifolicin
 biochemical and immunological effects, **61**:160
- isolation, **61**:151
- Accessory chain, FcγRs, **64**:218
- Acetylation
 chemical carcinogenesis and, **50**:41
- fibroblast growth factors and, **59**:122
- Acetylcholine, B cell-associated surface molecules and, **52**:98
- N*-Acetylglucosamine, α-fetoprotein and, **56**:265, 266, 268, 269
- β-*N*-Acetylglucosaminidase, lysosomes and, **60**:272–276
- N*-Acetyl-L-cysteine, *in vitro* testing, **61**:9
- Achondroplasia, age and risk of, **71**:230
- Acidic fibroblast growth factor multigene family, **60**:35
 early studies, **60**:6
 ligand binding, **60**:24–27
 mitogens, **60**:2–3, 5
 multiple forms, **60**:17–18, 20–21
- Acid phosphatase, lysosomes and, **60**:272–274, 276, 280–281, 283
- Acoustic neuroma, chromosome 3 losses in, **71**:51
- Acquired immunodeficiency syndrome, **51**:341–342; *see also* Human immunodeficiency virus
 in Africa, **51**:317–320, 337–339
- apoptosis and, **71**:122, 142–143
- cancer and, **51**:338, 342, 344
- in children, **51**:338, 340–341
- dermatological manifestations of, **51**:337–338
- diseases indicative of, **51**:337–339
- earliest evidence of, **51**:339
- Epstein-Barr virus, **62**:187, 224
 associated disorders and, **57**:364–366, 371
- viral genes and, **58**:2–3
- fungal diseases and, **51**:337, 338
- Haitians and, **51**:335–336
- herpes viruses and, **51**:324
- heterosexual transmission of, **51**:336–339
- immune surveillance of tumors and, **54**:313–315
- from infection to disease in, **51**:341–342

- Acquired immunodeficiency syndrome
(*continued*)
insect vector transmission and, 51:
335–336, 338
Kaposi's sarcoma and, 53:73–85
neurological manifestations of, 51:342, 343
opportunistic infections and, 51:337–338
opportunistic tumors of, 54:301–315
origins of, 51:339–340
therapy for
drugs, 51:346–348
general considerations, 51:345–346,
350–351
genetic approaches, 51:349–350
immunotherapy, 51:348–349
vaccines, 51:349–350
tumors associated with, 54:308–311,
309–311
- Acrocephalosyndactyly, age and risk of, 71:230
- Actin
gastrointestinal diseases and, 50:18, 19
oncoprotein kinases and, 57:200
as PKC substrate, 64:172–173
plasminogen activation and, 57:276–279,
282
Ras function and, *see* Ras function,
pathways
reverse transformation and, 62:140
stress fiber formation, 72:82–83
stroma and, 50:170, 177
- F-Actin, gastrointestinal diseases and, 50:18
- Actinomycin D, Epstein–Barr virus proteins
and, 50:141
- Activating transcription factor, adenovirus
E1A proteins and
sequence specificity, 57:55–66
transactivation, 57:70, 72–73
- Activation
ADF and, 57:388–389, 403–407
 α -fetoprotein and, 56:291, 292, 294, 296,
298, 299
B cell-associated surface molecules and, 52:
127–132
Bgp95, 52:116
biochemically defined molecules, 52:119
CD20, 52:91–99
CD21, 52:103
CDw40, 52:114, 115
expression, 52:127–132
pathway, 52:83–85
receptors, 52:125–127
T cells, 52:132
BCR gene in leukemia and, 57:244, 251
B lymphocytes and, 56:314, 315, 318, 329,
331
CD23 molecule, 56:321, 322
interleukin-1, 56:320
EBV-associated disorders and, 57:
335–336, 340
NHL and AIDS, 57:364, 366
organ transplants, 57:355, 358, 360
glutathione transferase and, 52:233
glycosylation in tumors and, 52:258, 312
growth regulation and, 57:419–420
Herpesvirus saimiri and, 56:336
human papillomavirus and, 56:150
MAPK cascade, 72:61–65
mouse retrotransposons and, 56:228
expression of neighboring genes, 56:230
LTRs, 56:235–237, 241, 242
oncogenes, 72:4–6
T-cell receptors and, 56:50, 54–57, 59–62
antigens, 56:51, 58, 70, 71
leukocyte integrin family, 56:63, 65, 66
VLA family, 56:67
- Activator protein 1, G protein signal
transduction and, 58:80
- Activins
fibroblast growth factors and, 59:142
homology to TGF- β 1, 70:65
TGF and, 51:121–123
TGF- β receptors responding to, 70:68
- Acute transforming viruses, 51:278, 280–282
- ACY1 gene, 71:67–68
- ACY1 protein, 71:67
- Acyclovir
EBV-associated disorders and, 57:363–364
Epstein–Barr virus genes and, 58:21
Epstein–Barr virus proteins and, 50:99
- Acylation, fatty, in membrane localization of
yeast RAS proteins, 54:97–98
- Adaptations, evolutionary, in cancer
development, 70:41–42
- Adaptive cellular therapy, 61:73–74
- Additive effects, cancer immunotherapy and,
59:260–262
- Addressins, 71:245
- Adducts
benzo[a]pyrene dial-epoxide-DNA,
determination, 65:82
bulky, carcinogenicity of tobacco and, 65:
81–82

Adenocarcinoma

- APC gene in human cancers and, 62:80–83
- chemical carcinogenesis and, 50:29, 32
- chromosome 3 losses in, 71:47–48
- endogenous growth inhibitors and, 57:444
- gastrointestinal diseases and, 50:7, 10, 16, 18
- genomic instability and, 60:147
- lung, 71:55
- metastatic cancer cells and, 55:92
- microsatellite instability and, 71:215
- myc* family oncogenes and, 57:28
- neovascularization, 69:138
- oncogenes and, 50:89
- stroma and
 - basement membranes, 50:176
 - disorders, 50:180–182
 - epithelium, 50:166

Adenoma

- APC gene in human cancers and, 62:65–66, 71, 76–79
- associated with HNPCC, 71:96
- chemical carcinogenesis and, 50:50
- gastrointestinal diseases and, 50:11, 12, 14, 22
- metastatic cancer cells and, 55:113
- renal cell tumors, molecular cytogenetics, 62:109–111, 116

Adenomatosis, stroma and, 50:177

Adenomatous polyp, mutations and, 71:111

Adenomatous polyposis, familial, *see*

Familial adenomatous polyposis

Adenomatous polyposis coli gene

- in human cancers, 62:82–83
- colorectal tumors, somatic mutations
 - adenomas, formation, 62:76–79
 - detection, 62:74–76
 - disruption by mobile genetic element, 62:79
- desmoid tumors, 69:66
- familial adenomatous polyposis, germline mutations in
 - clinical phenotypes, 62:70–72
 - detection, 62:66–69
 - diagnosis, 62:72–74
- gastric cancer, somatic mutations in, 62:80–82
- identification, 62:65–66
- mutations, 71:111, 114
- mutations in prostate cancer, 68:239

Adenosine diphosphate

- peptide-binding heat shock proteins and, 62:162

Ras function and, 62:45

Adenosine triphosphatase, *see* ATPase

Adenoviruses, 56:144, 145, 149, 154

adenovirus 12

- DNA fragments, 66:326–328
- genomic persistence, 66:319–324
- apoptosis and, 71:131, 132
- cytotoxic T lymphocytes and, 59:236, 238
- developmental stages, 65:148–150
- effect on MHC expression
 - cellular immune response, 63:158–160
 - characteristics, 63:155–158
 - MHC-I, 60:189–190, 224
 - modulation by oncogenes, 60:195–197, 202, 204, 211–212, 216, 221
 - post-translational control, 63:162–164
 - transcriptional control, 63:160–162

MHC-II, 63:164–165

Epstein-Barr virus proteins and, 50:102

molecular biology, 65:156–158

multidrug resistance gene and, 60:172

polyoma virus TSTA and, 55:40

soft tissue tumors and, 60:102–103

type, 68:12

chromosomal damage induction, 68:12–13

tumor induction in mice, 68:3

Adenovirus-induced tumors, cytotoxic

T lymphocytes and, 58:157–158

Adenovirus proteins, 52:151–154, 160, 161

E1A, 57:47–48

apoptosis and, 71:130, 131, 132

binding to p110^{Rbl}, 61:120–121

endogenous growth inhibitors and, 57:437–438

homology with c-Myc, 68:163–164

organization, 57:48–50

perspectives, 57:78–79

transactivation, 57:50

domain, 57:51–53

general transcription factors, 57:66–69

mechanisms, 57:69–73

properties, 57:53–55

sequence-specific factors, 57:55–66

transformation, 57:73–74

- Adenovirus proteins (*continued*)
 domains, 57:74–75
 mechanism, 57:75–78
 oncogene status, 57:78
 MHC expression
 E19 protein, 52:155–157
 early region 1A, 52:154, 155
 viral pathogenicity, 52:157–159
 viral tumorigenicity, 52:159, 160
 Adenovirus system, foreign DNA insertion,
 66:316–324
 Adenylate cyclase
 lysophosphatidic acid and, 57:94–96, 101
 in Ras-cAMP pathway, 54:101–105
 biochemical characterization of, 54:104
 and RAS proteins, direct interaction of, 54:
 104–105
 Ras-responsive domains of, 54:102–103
 signal transduction and, 55:274
 structure of, 54:101–102
 Adenylate cyclase, G protein signal
 transduction and, 58:77, 80–82, 84–87
 ADF, *see* Adult T cell leukemia-derived
 factor
 Adhesion
 cell and substrate, 70:12
 EBV-associated disorders and, 57:361
 metastasis and, 51:364–367, *see also*
 Metastasis, organ-specific
 oncoprotein kinases and, 57:202–203, 213
 plasminogen activation and, 57:274–275
 directed cell surface, 57:300, 302, 308, 311
 interactions, 57:275–284
 Src family of tyrosine protein kinases and,
 57:134
 stroma and, 50:186
 epithelium, 50:168
 glycoproteins, 50:170–172
 T-cell receptors and, 56:50, 54, 56, 60, 62
 antigens, 56:51, 70, 71
 leukocyte integrin family, 56:63–66
 lymphocyte homing receptors, 56:68, 70
 pathways, 56:59
 VLA family, 56:67
 Adhesion plaques
 oncoprotein kinases and, 57:201–203
 plasminogen activation and, 57:276, 300
 Adipocytes
c-fos protooncogene and, 55:42, 43
 chemical carcinogenesis and, 50:49
 newborn macrosomy and, 50:255
 Adipogenesis, in bone marrow, 54:261
 Adjuvant therapy, breast cancer and, 56:124,
 127, 129
 Adoptive immunization, MuLV and, 51:
 279–280
 ADP ribosylation, G protein signal
 transduction and, 58:82
ADR1 as target of cAMP-dependent protein
 kinase, 54:117–118
 Adrenal gland
 DHEA and, 51:391–392
 medulla, *ret* expression, 70:209–210
 Adrenaline, biochemical testing, 70:183
 Adrenocorticotrophic hormone, DHEA and,
 51:391
 Adriamycin
 glutathione transferase and, 52:241
 multidrug resistance and, 52:167
 coamplified genes, 52:194
 P-glycoprotein, 52:172, 173, 180, 189
 TGF and, 51:138
 Adult T-cell leukemia-derived factor, 57:
 381–383
 analyses
 amino acid sequences, 57:392–395
 mRNA induction, 57:395–396
 thioredoxin, 57:396–397
 biological activities
 3B6 cell proliferation, 57:400–401
 3B6–IL-1 activity, 57:399–400
 HTLV-II(+) cells, 57:401
 IL-2 reactivity, 57:398
 insulin-reducing activity, 57:397–398
 polyclonal antibodies, 57:398–399
 synergy with IL, 57:401
 EBV, 57:403–404
 environment, 57:406–407
 HTLV-I-induced ATL, 57:402–403
 identification
 biological properties, 57:385–388
 IL-2R, 57:385, 388–389
 isolation, 57:389–392
 production, 57:384–385
 lymphocyte activation, 57:404–406
 Adult T-cell leukemia/lymphoma, HTLV-I
 and, 51:313–315
 Adult T-cell leukemia virus, 51:313
 AF6/Rsb1, candidate Ras effector, 72:74
 Affinity maturation, apoptosis and, 71:140
 Aflatoxin B₁
 carcinogenicity, reasons for, 65:87

- induced transformation, androgenic steroids and, 51:400
 - p53* mutations and, in definition of relationship to hepatitis B virus, 65:38–39
 - viral infectious hepatitis and, relationship, 65:88
- Aflatoxins
 - cancer incidence data and, 56:185, 187, 188
 - chemical carcinogenesis and, 50:39, 41, 57
 - genomic instability and, 60:146
 - hepatitis B viruses and, 59:170, 178, 185, 209–210
 - p53* mutations and, 59:75
 - soft tissue tumors and, 60:101–102
- Africa, AIDS and, 51:337–339
- AG-490, 71:154
- Agammaglobulinemia, opportunistic tumors associated with, 54:305–306
- Age
 - cancer and, 71:230
 - cancer incidence data and, 56:161–175, 210, 211
 - cohort data, 56:181, 184
 - hepatocellular carcinoma, 56:188
 - lung cancer stages, 56:196, 200, 202, 207
 - two-stage model, 56:188–193
 - dependent incidence of cancer, 67:5–7
 - genomic instability and, 60:126
 - MHC Class I expression and, 60:182
 - prostatic cancer and, 51:2, 17–18
 - Wilms' tumor and, 59:44, 47
- Aging
 - associated with promoter CpG island methylation, 72:178–181
 - newborn macrosomy and, 50:261, 265
- Agnogenic myeloid metaplasia, chromosome abnormalities and, 52:18
- Agonistic antigens, T-cell receptors and, 56:58
- AIDS, *see* Acquired immunodeficiency syndrome
- AIDS-related complex, 51:316
- AIDS-related viruses, 51:317
- AIDS-SNCCCL, *see* Small noncleaved cell lymphomas, AIDS-related
- Air pollution
 - carcinogenicity studies, 65:169–170
 - prostatic cancer and, 51:76–79
- AKR mouse
 - lymphomas, *see* Lymphomagenesis in thymic leukemia study, 63:46–47
- AKXD RI mouse strains, 54:143–151
 - lymphomas in
 - susceptibility to, 54:144
 - viral integration in, variation in repertoire of cellular protooncogenes activated by, 54:144, 145
 - myeloid tumors in, *Evi-1* identification in, 54:145–151
- AL-721, AIDS and, 51:346
- Albumin, α -fetoprotein and, 56:299
 - activities, 56:281
 - binding, 56:271–275, 277, 279
 - gene expression, 56:294–298
 - glycoid studies, 56:265
 - immunoregulation, 56:282, 283
 - preparation, 56:256, 257
 - properties, 56:261–264
 - synthesis, 56:289, 291–293
- Alcohol
 - intake, hepatitis B viruses and, 59:178–179, 210
 - prostatic cancer and, 51:41–42
- Alcoholism, newborn macrosomy and, 50:264
- Alkaline exonuclease, Epstein–Barr virus proteins and, 50:145, 146
- Alleles, *see also* Genes
 - APC* gene in human cancers and, 62:73, 76–79, 82
 - ataxia-telangiectasia genes and, 56:83
 - breast cancer, *p53* expression in, 59:71
 - cancer incidence data and, 56:162
 - central nervous system tumor oncogenesis and, 58:128, 133–134
 - c-erbA* and, 59:106
 - chromosomes and, 62:12–13
 - c-myc* regulation and, 56:18, 28–40
 - cytotoxic T lymphocytes and, 58:160–161; 59:228, 238, 240
 - epigenetic inactivation of, in human cancer, 54:49–58
 - predisposition and, 54:51–56
 - progression and, 54:56–58
 - Epstein–Barr virus genes and, 58:20
 - for genetic control of MuLV in LC mice
 - Fv-1^b* resistant, 65:188
 - Fv-4* resistant, 65:188–189

- Alleles (*continued*)
 genomic instability and, 60:123, 142–144
 hepatocellular carcinoma and, 59:205, 208–209
 methylation spreading across, 72:180–181
 MHC Class I expression and, 60:231
 cancer, 60:186, 188, 190–195
 downmodulation, 60:222, 224, 228–230
 modulation by oncogenes, 60:196, 205–206, 208
 muscle cell regulation and, 58:107
myc family oncogenes and, 57:17–18, 25–26, 35
p53 and human malignancies and, 57:258, 264, 266–267
 protein tyrosine kinase GFRs and development, 60:50–52, 55–57
 structure, 60:45
 tumorigenesis, 60:64
 Raf-1 phosphorylation and, 58:68
 renal cell tumors, molecular cytogenetics, 62:90
 chromophobe renal cell carcinoma, 62:117
 nonpapillary renal cell tumors, 62:94–95, 97–98, 102–103
 papillary renal cell tumors, 62:107–109
 reverse transformation and, 62:138
 soft tissue tumors and, 60:85, 101, 103
 tumor rejection antigens and, 58:191, 193, 201
 Wilms' tumor and, 59:44, 49–51, 58–60
 Allelic losses, *see also* Heterozygosity, loss of HLA, from tumor cells, 67:172–173
 tumor clonality and, 50:209, 210
 in tumors, 71:32–33
 Allobiophoria, Zilber and, 59:9
 Alloenzymes, tumor clonality and, 50:224
 animal tumors, 50:218, 219
 distinction, 50:202–205, 211
 human tumors, 50:217
 pleoclonal tumors, 50:212, 214, 215
 Allografts
 rejection
 effector-cell identity in, 53:214–215
 MHC antigen expression and, 53:216
 tumor, 66:44–46
 Allotype
 Louvain rat immunocytomas and, 50:281, 282
 tumor clonality and, 50:210
 Alloxan, newborn macrosomy and, 50:271
 Alpha-fetoprotein, *see* α -Fetoprotein
 Alternative splicing
 fibroblast growth factors and, 59:130, 155
ret, 70:194–195
 Wilms' tumor and, 59:54–56
 Alu repeat elements, adjacent CpG island sites, 72:183–184
 Alveolar rhabdomyosarcoma, chromosomal aberrations and, 52:30; 69:76–77, 90
 Alveolar soft part sarcoma, chromosomal aberrations, 69:82
 Amines
 aromatic
 electrophiles and, metabolic generation, 65:64–65
in vivo chemical modifications of DNA, 65:60–64
 structural requirements, physical organic chemistry studies, 65:70–73
 chemical carcinogenesis and experimental models, 50:27, 29
 mechanisms, 50:39, 41, 42
 Amino acids
 adenovirus E1A proteins and, 57:48
 transactivation, 57:51–52, 62, 71
 transformation, 57:74–77
 adenovirus proteins and, 52:154–157
 ADF and, 57:389–390, 392–396, 403
 biological activities, 57:399–400
 α -fetoprotein and, 56:257–261, 299
 B cell-associated surface molecules and
 CD20, 52:93, 97–99
 CD22, 52:107
 CD23, 52:109, 110
 CDw40, 52:113
 BCR gene in leukemia and, 57:229, 234, 241–242, 245
 bovine papillomavirus and, 56:135, 136, 138, 142
 Burkitt's lymphoma and
c-myc, 55:158, 162, 164
 EBV, 55:235, 237
c-erbA and, 59:92–93, 99, 105–107
 multiple loci, 59:94–95
 mutations, 59:103–104
 structure, 59:96–97
c-fos protooncogene and, 55:38–40, 47, 48
 chemical carcinogenesis and, 50:46
 chromosome abnormalities and, 52:37

- c-*myc* regulation and, 56:2–4, 6
- cytotoxic T lymphocytes and, 58:144, 147, 150, 158; 59:228, 231–233
- endogenous growth inhibitors and, 57:434, 440
- Epstein–Barr virus
 - viral genes and, 58:7
 - viral proteins and
 - transformed cells, 50:110, 114, 118, 127, 130, 134
 - virus-produced cells, 50:145
- FGF receptor multigene family and, 60:2, 35
 - alternative splicing, 60:15
 - characterization, 60:8–14
 - Drosophila*, 60:30–31
 - mitogens, 60:3, 5
 - multiple forms, 60:18–19, 21–23
 - signal transduction, 60:32
- fibroblast growth factors and, 59:117, 131, 147, 151
 - protein structure, 59:117, 119–122, 124–125
- gene rearrangements and, 52:46, 50–53
 - glutathione transferase and
 - molecular forms, 52:216, 221, 222
 - preneoplasia, 52:208, 232, 233
- hepatitis B viruses and, 59:175, 180
 - genomes, 59:185, 187, 189
 - oncogenesis of viral proteins, 59:197, 199
- Herpesvirus saimiri* and, 56:348, 350
- humoral immune response and, 62:251
- immunosuppression and, 60:253–254
- jun* oncogene and, 55:1
 - DNA binding, 55:4–6
 - family of related genes, 55:9
 - leucine zipper, 55:17–21
 - oncogenicity, 55:26
 - signals, 55:12, 13
- metastatic cancer cells and, 55:117
- MHC Class I expression and, 60:218
 - cancer, 60:186–187
 - downmodulation, 60:229–230
 - modulation by oncogenes, 60:197, 201
- multidrug resistance and, 52:180, 181, 187, 188
- multidrug resistance gene and, 60:160, 175
- muscle cell regulation and, 58:99–100, 103–104
- myc* family oncogenes and, 57:6, 8–11
 - oncoprotein kinases and, 57:193, 195, 200
 - p53* and human malignancies and, 57:260, 267–268
 - plasminogen activation and, 57:281
 - directed cell surface, 57:302, 310
 - proteolytic modulation, 57:284–285, 287, 296, 298, 300
 - polyoma virus TSTA and, 55:63, 72, 75–78, 80–82
 - protein tyrosine kinase GFRs and, 60:58–59, 63
 - Raf-1 phosphorylation and, 58:63, 65
 - Ras function and, 62:25–27
 - reverse transformation and, 62:127
 - signal transduction and, 55:283
 - Src family of tyrosine protein kinases and, 57:122, 126, 133
 - patterns of expression, 57:115, 118
 - properties, 57:105, 108, 110
 - stroma and, 50:161
 - T-cell receptors and, 56:52, 53, 56, 59, 70
 - transforming growth factor- α and, 58:30–32, 34, 36
 - tumor clonality and, 50:215
 - tumor rejection antigens and, 58:180, 182
 - Wilms' tumor and, 59:55–56, 60, 62
- Amino acid structure, VEGF, 67:284–286
- 6-Aminocaproic acid, plasminogen binding, 69:102
- δ -Aminolevulinic synthetase gene, *c-erba* and, 59:104
- Ammonium 21 tungsto-9-antimoniate, AIDS and, 51:347, 356
- Ammonium chloride, lysosomes and, 60:284–285
- Amphiregulin, transforming growth factor- α and, 58:28, 37
- Amphoterin, plasminogen binding, 69:106
- Amphotropic viruses
 - development, from MuLV cancer resistant mice, 65:177
 - effect of *Fv-4^R* on, 65:190
- Amplification, *see* Gene amplification
- Amplified DNA, evolution, 61:108–110
- Amyloidosis, cutaneous lichen, with MEN IIA, 70:186–187
- Anaphylaxis with desensitization reaction, Zilber and, 59:26–27
- Anaplastic astrocytoma, oncogenesis of, 58:124–125

- Anatomy
 CpG islands in tumor suppressor genes, 72: 182–184
 DNA methylation in higher-order eukaryotes, 72:147–150
- Androgen receptor gene
 amplification in prostate cancer, 68: 247–248
 mutations in prostate cancer metastasis, 68: 246
- Androgens
 diet and, 51:63–64
 endogenous growth inhibitors and, 57:436
 mouse retrotransposons and, 56:231, 240, 242
 prostatic cancer and, 51:31–32
- Anemia
 chromosome abnormalities and, 52:13
 DHEA and, 51:418
 protein tyrosine kinase GFRs and, 60: 52–53
 refractory, *see* Refractory anemia
- Aneuploidy
 carcinogenesis and, role in cellular transformation, 65:21
 chemical carcinogenesis and, 50:33
 genomic instability and, 60:122, 124, 135–136
 p53 mutations and, 71:7–8
- Angiogenesis
 in embryo chorioallantoic membrane, okadaic acid-induced, 61:164
 FGF receptor multigene family and, 60: 2–3, 35
 fibroblast growth factors and, 59: 115–116, 122, 155
 biological function, 59:140–142
 tumors, 59:149, 153–155
 in human cancers, 67:266–267
 and IL-6 production, 66:11
 inhibitors, 69:139–140, 142
in vivo assays, 67:263–266
 in Kaposi's sarcoma, 53:83–84
 normal cells, 69:135
 occurrences, natural, 69:141
 protein tyrosine kinase GFRs and, 60:50
 regulation by VEGF-Flt receptors, 67: 281–282
 role of SF, 67:271–275
 and scatter factor, 66:245
 separate from solid tumor development, 72: 18–19
 therapeutic strategies using, 69:160–161
 transforming growth factor- α and, 58:47
 tumor
 macrophage role, 67:269–270
 PDGF role, 67:295–296
 suppression, 67:309–310
 tumor cells, 69:135–136, 161–162
 inducers, 69:142–149
 inhibitor down-regulation, 69:149–156
 mechanisms, 69:136–137
 phenotype, 69:139–141, 156–159
 subversion of normal physiological system, 69:141–142
- Angiogenin, 69:144
- Angioimmunoblastic lymphadenopathy, *see* Lymphadenopathy, angioimmunoblastic
- Angioliopoma, chromosomal aberrations, 69: 69–72
- Angiopeptin, breast cancer therapy, 68:212
- Angiostatin, 69:150, 151
- Angiotensin II, 69:144
- Animal models
 DNA methylation changes in cancer, 72: 175–176
 lung carcinogenesis, p16 gene studies, 72: 162–163, 187
- Aniridia, Wilms' tumor and, 59:47–50, 53–54, 62
- Ankyrin repeat domain, in I κ B proteins, 66: 266–269
- Antagonism, muscle cell regulation and, 58: 108–114
- Antagonistic effects, cancer immunotherapy and, 59:262
- Anthracyclins
 α -fetoprotein and, 56:280, 287
 lysosomes and, 60:284–285
 multidrug resistance and, 52:170, 193
- Antiandrogens, prostatic cancer and, 51:2
- Antiangiogenic agents, 69:160–161
- Antibodies, *see also* Immunoglobulins;
 Monoclonal antibodies
 4D5, HER-2/neu immunotherapy, 71:362
 A.11, 51:372–373
 adenovirus E1A proteins and, 57:58, 65
 ADF and, 57:398–399, 406
 α -fetoprotein and, 56:255–257, 262, 269, 281, 285–287

- anti-growth factor, in autocrine growth stimulation inhibition, 54:230
- anti-nuclear Ki-67, 61:4
- B cell-associated surface molecules and, 52:84, 85
- Bgp95, 52:115
- biochemically defined molecules, 52:118, 120
- CD19, 52:99
- CD20, 52:93
- CD21, 52:103, 104
- CD23, 52:109, 111
- expression on activated cells, 52:128, 129
- history, 52:86, 87
- receptors, 52:126
- bcr/abl* gene in leukemia and, 57:155, 163
- BCR* gene in leukemia and, 57:235, 241–242
- hematopoietic cells, 57:243–245, 247, 249–250
- B lymphocytes and, 56:315, 323, 327
- bovine papillomavirus and, 56:137
- breast cancer, *p53* expression in, 59:75–76, 78–79, 84
- Burkitt's lymphoma
- and *c-myc* structural changes, 55:178
- EBV, 55:223, 225, 227, 229, 235, 237
- features, 55:145, 148
- cancer immunotherapy and, 59:250, 293
- chemoimmunotherapy, 59:281
- current strategies, 59:257, 264, 266, 270, 273
- improvement attempts, 59:286, 290–291
- central nervous system tumor oncogenesis and, 58:138
- c-fos* protooncogene and, 55:39, 41, 43–45
- chemical carcinogenesis and, 50:54, 55
- cytotoxic T lymphocytes and, 58:148, 150–151, 162, 167; 59:228, 233, 235
- Epstein–Barr virus and, 62:185
- EBV-associated disorders and, 57:331–334
- immunodeficiency states, 57:344
- organ transplants, 57:362
- X-linked lymphoproliferative syndrome, 57:337–338, 341
- EBV genes and, 58:17–18
- EBV proteins and
- diseases, 50:97–100
- virus-produced cells, 50:140, 142, 147, 148
- EBV-specific responses, 67:237–239
- FcyRII-regulated production, 64:230–232, 237
- FGF receptor multigene family and, 60:8
- fibroblast growth factors and, 59:121, 137, 152
- biological function, 59:140, 142
- oncogenic potential, 59:146, 149
- gene rearrangements and, 52:46
- B cell antigen receptor, 52:46–48
- hematological neoplasias, 52:58, 67
- simultaneous occurrence, 52:69
- T cell antigen receptor, 52:49–51
- genomic instability and, 60:124, 133
- glutathione transferase and, 52:209, 224, 225, 227, 238, 239
- glycosylation in tumors and, 52:259, 260, 317, 318
- carbohydrate antigens, 52:264, 286, 289–291
- diagnostic applications, 52:302–309
- glycolipid antigens, 52:261, 262, 269, 270, 274, 275, 277, 280, 283
- Hanganutziu-Deicher antigens, 52:296, 297
- histo-blood group ABH antigens, 52:294
- histo-blood group P antigens, 52:295
- preneoplastic tissues, 52:297
- requirements, 52:298–302
- therapeutic applications, 52:310–316
- G protein signal transduction and, 58:79
- hepatitis B viruses and, 59:172, 175–176, 178, 197
- Hodgkin's disease, 57:368; 62:213, 216–218, 220, 222–223, 226, 228
- human antimurine, development, 61:71–72
- humoral immune response and, 62:252, 256, 258, 260
- immunosuppression and, 60:253–254, 259
- jun* oncogene and, 55:14, 19
- Louvain rat immunocytomas and, 50:287, 306
- lysophosphatidic acid and, 57:96
- MEL-14, 51:370–371
- metastasis and, 51:363–364
- MHC Class I expression and, 60:190, 194, 205, 227–228

- Antibodies (*continued*)
 M-MuLV and, 51:284–287
 multidrug resistance and, 52:195–197
 amplified genes, 52:176
 clinic, 52:194
 P-glycoprotein, 52:175, 189–191
 MuLV and, 51:280
myc family oncogenes and, 57:31
 newborn macrosomy and, 50:259
 oncogenes and, 50:84
 oncoprotein kinases and, 57:200,
 205–206, 208, 211
 to p53, 66:116–119
 peptide-binding heat shock proteins and,
 62:160, 163–164, 174
 plasminogen activation and adhesive
 interactions, 57:276, 280
 directed cell surface, 57:305, 308–309
 proteolytic modulation, 57:291, 294
 polyoma virus TSTA and, 55:58–62, 65, 66
 production, network theory, 61:64–65
 Ras function and, 62:30–31, 44
 recombinant chimeric, 67:275
 reverse transformation and, 62:144
 signal transduction and, 55:293
 Src family of tyrosine protein kinases and,
 57:140
 T-cell activation, 57:122–126, 128–129,
 131
 T-cell proliferation, 57:133, 137
 T-cell lymphoproliferation, 62:188–190,
 199
 T-cell receptors and, 56:49, 54, 55, 60
 leukocyte integrin family, 56:65
 lymphocyte homing receptors, 56:69
 transformed cells, 50:105, 107, 113, 114,
 119, 121, 124, 126–128, 133, 134,
 136
 transforming growth factor- α and, 58:45
 tumor clonality and, 50:215
 tumor rejection antigens and, 58:187
 Zilber and, 59:8, 32–33
 Antibody-dependent cellular cytotoxicity,
 cancer immunotherapy and, 59:273,
 279, 290
 Antibody epitopes, yeast Ras proteins and,
 54:95
 Antibody responses in malaria, 53:63
 Antibody therapy, in AIDS–KS, 66:249
 Anticancer drugs
 lysosomes and, 60:278, 284–286
 in molecular therapy, 61:61–63
 multidrug resistance gene and, 60:
 158–159, 166, 176
 Anticomplement immunofluorescence,
 Epstein–Barr virus proteins and, 50:104,
 105, 107, 109, 110, 112–114, 121
 Antiestrogens, TGF and, 51:133
 Antigenicity without immunogenicity, 53:
 216–218
 Antigen presentation, role of Fc γ Rs, 64:218
 Antigen-presenting cells
 B lymphocytes and, 56:316
 humoral immune response and, 62:242,
 245, 247–248, 259–260
 M-MuLV and, 51:293–295
 Src family of tyrosine protein kinases and,
 57:120–121, 125, 130
 T-cell receptors and, 56:50, 51, 54, 55, 59,
 60, 62
 expression, 56:71
 leukocyte integrin family, 56:64
 tumor rejection antigens and, 58:180, 206
 Antigens, *see also* Epitopes; *specific antigen*
 adenovirus E1A proteins and, 57:74, 77
 adenovirus proteins and, 52:151, 152, 160,
 161
 MHC expression, 52:153, 155, 158, 159
 ADF and, 57:390, 403
 α -fetoprotein and, 56:255, 281, 283–285,
 299
 ataxia-telangiectasia genes and, 56:79, 84
 B cell-associated surface molecules and, 52:
 83, 84, 89–91, 134
 Bgp95, 52:115, 116
 biochemically defined molecules, 52:
 116–119, 121–123
 expression on activated cells, 52:
 128–130, 133
 history, 52:86, 87
 receptors, 52:127
 T cells, 52:132
 B lymphocytes and, 56:314, 315, 318, 328
 CD23 molecule, 56:321–323
 interleukin-1, 56:320
 breast cancer and, 56:105–107, 115,
 127–129
 Burkitt's lymphoma and
 B cell differentiation, 55:165
 chromosomal translocations, 55:197
 c-myc, 55:157, 161, 163
 EBV, 55:223, 225–240

- Antigens, Burkitt's lymphoma and (*continued*)
 features, 55:145
 genetic abnormalities, 55:220, 221
 phenotype, 55:150, 152–154
 synthesis, 55:243, 244, 249
 cancer, molecular identification, 70:
 169–172
 cancer immunotherapy and, 59:247, 292
 critical factors, 59:248, 251–255
 current strategies, 59:256–259, 266,
 273, 281
 improvement attempts, 59:284–288, 291
 CD, *see* CD antigens
c-erbA and, 59:92
c-fos protooncogene and, 55:39
 chronic stimulation, role in AIDS-SNCCCL
 pathogenesis, 67:123–124
 cytotoxic T lymphocytes and, 58:143–145,
 167; 59:227–229
 escapes of tumor cells from immune
 T cells, 58:160–161, 163
 function, 59:237–240
 immunogenicity of tumors, 58:145–150,
 152
 melanoma antigens, 58:166–167
 processing, 59:233–235
 virus-induced tumors, 58:154, 156, 159
 differentiation, 61:64
 and DNA viruses, MHC expression effects
 adenoviruses, 63:155–165
 control sites, 63:187, 189
 cytomegalovirus, 63:165–173
 hepatitis B virus, 63:173–180
 herpesviruses, 63:165–173
 immune recognition by T cells
 antigen diversity, 63:124–126
 antigen structure, 63:124–126
 cytokine regulation of gene
 expression, 63:141–145
 mechanisms, 63:185–190
 modulation, 63:145–146
 presentation, 63:118–119
 restriction, 63:122–123
 subset roles, 63:120–122
 T cell repertoire development, 63:
 119–120
 transcription regulation, 63:135–140
 viral peptide–MHC complexes, 63:
 126–127
 papillomavirus, 63:181–185
 poxviruses, 63:145, 147–155
 Epstein–Barr virus and, 57:330–332, 334;
 62:180, 182–184
 endogenous growth inhibitors and, 57:
 437
 Hodgkin's disease, 57:368–369; 62:
 216–217, 219–220, 222
 immunodeficiency states, 57:344
 marker detection, 62:184–185
 NHL and AIDS, 57:364
 organ transplants, 57:346, 351,
 356–358, 360, 362
 peripheral T cell lymphomas, 62:202,
 205–206
 T-cell lymphoproliferation, 62:187, 190,
 193, 196–197, 208
 viral genes, 58:4–7, 9–16, 18–21
 viral proteins
 genome, 50:103
 latent infection membrane protein, 50:
 133, 134, 137
 transformed cells, 50:104–131
 virus-produced cells, 50:138–140,
 142, 147
 X-linked lymphoproliferative syndrome,
 57:337–341
 gastrointestinal diseases and, 50:14
 gene rearrangements and, 52:46
 B cell antigen receptor, 52:46–49
 hematological neoplasias, 52:58, 62, 63,
 68
 simultaneous occurrence, 52:69
 T cell antigen receptor, 52:49–57
 glutathione transferase and, 52:205,
 210
 glycosylation in tumors and, *see*
 Glycosylation in tumors
 hepatitis B viruses and, 59:168, 180, 202
 epidemiology, 59:170, 172–178
 genomes, 59:191–192, 194
 oncogenesis of viral proteins, 59:195,
 197–198
 Hermes-1, metastasis and, 51:385–386
Herpesvirus saimiri and, 56:339, 341, 348
 human leukocyte, *see* HLA antigens
 human papillomavirus and, 56:144, 145,
 148
 humoral immune response and, 62:
 241–242, 245, 260–261
 B7, 62:253
 B cell activation, 62:246–256
 follicular B cell survival, 62:257–258

Antigens (*continued*)

- lymphoid tissue architecture, 62:242–245
 - immunosuppression and, 60:252
 - jun* oncogene and, 55:7, 15
 - LFA, down-regulation, 67:135
 - Louvain rat immunocytomas and, 50:288, 291, 305
 - lymphocyte-determined membrane, 67:239
 - lymphocyte function-associated
 - EBV-associated disorders and, 57:330–331, 334, 357–358, 361
 - humoral immune response and, 62:248, 254–255
 - LFA-1, 71:244
 - Epstein–Barr virus genes and, 58:20
 - T-cell receptors and, 56:59, 63–66, 71
 - LFA-3
 - Epstein–Barr virus genes and, 58:8, 19–20
 - T-cell receptors and, 56:59–62, 71
 - Src family of tyrosine protein kinases and, 57:134–135
 - lymphocyte recirculation and, 51:367–368
 - lysosomes and, 60:282
 - malaria, lymphocyte transformation and, 53:56–57
 - melanocyte, 70:150
 - melanoma
 - expressed in normal testes, 70:161–163
 - MAGE, 70:147–149
 - T cell recognition of, 70:149–169
 - membrane, Epstein–Barr virus and, 62:184–185, 208, 224
 - metastatic cancer cells and, 55:111, 113
 - multidrug resistance and, 52:183
 - multidrug resistance gene and, 60:162, 171
 - myc* family oncogenes and, 57:8, 28–29
 - newborn macrosomy and, 50:261, 262
 - oncofetal, 61:64
 - oncogenes and, 50:72–74, 87–89
 - malignant genotype, 50:84, 86, 87
 - malignant phenotype, 50:74, 79
 - maturation arrest, 50:92
 - oncoprotein kinases and, 57:191, 196–197, 199
 - p53* and human malignancies and, 57:263, 265, 269
 - plasminogen activation and, 57:279–280, 291, 300–303, 308
 - polyoma virus, *see* Polyoma virus TSTA
 - processing hypothesis, 63:32–33
 - signal transduction and, 55:282, 283, 293
 - soft tissue tumors and, 60:100, 102
 - specificity of rhadinovirus-transformed
 - T cell lines, 63:228–231
 - Src family of tyrosine protein kinases and, 57:119, 132, 135, 140
 - T-cell activation, 57:124–131
 - SV40 large T, transgenic mice expressing, 67:99–100
 - T-cell receptors and, 56:49–52
 - activation, 56:60–62
 - adhesion pathways, 56:59
 - agonists, 56:58
 - CD4 and CD8, 56:53–56
 - expression, 56:70, 71
 - leukocyte integrin family, 56:66
 - lymphocyte homing receptors, 56:67, 68
 - VLA family, 56:67
 - truncated surface, MHC regulation by, 63:179
 - tumor, and HLA, 67:170–171
 - tumor-associated transplantation, polymorphism, 67:170–171
 - tumor clonality and, 50:210, 211
 - tumor-specific, 61:64; 70:166–169
 - molecularly characterized, 66:56–59
 - transplantation, 66:46–47
 - viral capsid, Epstein–Barr virus and, 62:184–185, 208, 213–214, 224
 - Wilms' tumor and, 59:53
 - Zilber and, 59:8, 25–27, 29, 32–33
- Anti-growth factor receptor antibodies in autocrine growth stimulation inhibition, 54:229
- Anti-idiotypic antibody therapy, 61:64
- Antioncogenes, *see also* Tumor suppressor genes
 - chromosome abnormalities and, 52:31–34, 38
 - myelodysplastic syndromes, 52:15
 - solid tumors, 52:29
- endogenous growth inhibitors and, 57:437–438
- hepatocellular carcinoma and, 59:209
- interaction with tumor antigens, 67:18
- p53*, 67:272
 - human malignancies and, 57:257, 263–268
- RB1*, 67:12–14
- Antioncoproteins, oncoprotein kinases and, 57:196

- Antioxidants, 53:247–293
 carcinogenesis by, modification of, 53:
 270–288
 antipromoting activity and, 53:285–286
 by blocking nitrosamine formation, 53:
 286–288
 by posttreatment, 53:279–285
 by timing of treatment, 53:271–279
 as chemopreventers of carcinogenesis, 53:
 288–291
 as human hazards, evaluation of, 53:
 288–291
 induction of new phenotype, 70:30
 and lung cancer, 61:19
 NF- κ B sensitivity, 66:276
 tumorigenic effects of, 53:249–258
 histopathological characteristics of, 53:
 258–263
- α_2 -Antiplasmin, 69:108–110
 plasminogen activation and, 57:274, 286,
 309
- Antiretroviral therapy, 67:114, 122
- Antisense oligonucleotides
B-myb, 72:127–128
 inhibition of gene expression by, 61:
 75–77
- Antisense RNA, for radiosensitization, 61:
 225
- Antithymocyte globulin, EBV-associated
 disorders and, 57:348, 350
- Antithyroid antibodies, newborn macrosomy
 and, 50:259, 261
- Antitumor effects, cancer immunotherapy
 and, 59:293
 chemoimmunotherapy, 59:275, 279–280
 current strategies, 59:259–261, 263, 267,
 272–273
 improvement attempts, 59:283, 291
- AP-1
 adenovirus E1A proteins and, 57:63–66,
 70
c-fos protooncogene and, 55:43–45
jun oncogene and, 55:2, 6–8
 dimerization, 55:14–17
 oncogenicity, 55:26, 28
 regulation, 55:21, 22
 signals, 55:13
 MHC Class I expression and, 60:200, 210,
 215
 multidrug resistance gene and, 60:
 173–174
- AP-1 binding sites, interaction with
 transcription factors, 70:77
- AP-2, c-Myc complex, 68:128, 134
- APC, *see* Adenomatous polyposis coli gene
- APC gene
 frameshift mutations, 72:48
 soft tissue tumors and, 60:81–82, 100, 109
- APEH gene, 71:67
- APO-1, apoptosis and, 71:129
- APO complexes, ataxia-telangiectasia genes
 and, 56:90, 92, 96, 98
- Apoprotein-a, plasminogen, 69:109
- Acetylation
 chemical carcinogenesis and, 50:41
 fibroblast growth factors and, 59:122
- Acetylcholine, B cell-associated surface
 molecules and, 52:98
- N-Acetylglucosamine, α -fetoprotein and, 56:
 265, 266, 268, 269
- β -N-Acetylglucosaminidase, lysosomes and,
 60:272–276
- Apoptosis, 71:123–124
 antagonism by survival factors, 68:
 149–150
 ara-C role, 72:209–210, 223–225
 associated with JNK activation, 72:66–67
 ATM gene product, 71:12
bcl-2 gene, 71:9, 128, 139–140
 CD44 and, 71:283–284
 cell morphology, 68:145
 and c-Myc, 70:130–134
 c-Myc-induced
 accelerating factors, 68:151
 functional domains, 68:147
 independence of apoptosis on c-Myc, 68:
 150–151
 ornithine decarboxylase role, 68:147
 overexpression induction of apoptosis,
 68:146–147
 regulation of apoptosis
 Bcl-2, 68:147–148
 growth factors, 68:195
 p53, 68:148–149, 151–152
 cytokine and gene control, 66:17–19
 cytokines and, 71:133–134, 135, 153
 death domains, 71:129
 defined, 71:121, 123
 distal pathway defects, 72:213
fas gene, 71:129–130, 135, 141–142
 genes regulating, 72:9–11
 and growth inhibition, 66:120

- Apoptosis (*continued*)
 hematopoietic growth factor effect, 72:223
 hematopoietic system, 71:122–123, 131, 133
 affinity maturation, 71:140
 AIDS, 71:142–143
 autoimmunity and, 71:142
 B-cell differentiation, 71:138–140
 B-cell lymphoma, 71:143–144
 cytotoxic T-lymphocytes, 71:138
 immune response downregulation, 71:140–141
 inflammation and, 71:122, 141–142
 leukemia, 71:144–152
 malignancy, 71:143
 survival factors, 71:133–135
 T-cell differentiation, 71:137–138
- induction
 by chemotherapeutics, 66:16, 18–20
 by tumor necrosis factor α , 68:150
- inhibition in tumors, 68:145–146, 149, 195
- molecular mechanisms, 71:125
 Abl tyrosine kinases, 71:129
bcl-2 gene family, 71:125–126
 Gas antigen, 71:129–130
 ICE-related cysteine proteases, 71:130
myc gene, 71:126–127
p53 gene, 71:126
 RAS gene, 71:127
 viruses and, 71:130–131
- morphology, 71:123
p53 effects, 66:26; 71:8–9, 12, 127, 128
 programmed, 64:259
 regulation of, 71:121–122
 role of *p53*, 66:86
 signals, 68:145
 survival signals, 71:128, 131, 133–135
 of tumor cells, 71:18
 and wild-type *p53*, 66:146–147
- Apoptotic threshold, 71:153
 APR gene, 71:68
 APRT gene, CpG islands, protection mechanisms, 72:182–184
 Quercetin, 61:62
 AR, *see* Androgen receptor gene
 1- β -D-Arabinofuranosylcytosine, *see* ara-C
 1- β -D-Arabinofuranosylcytosine 5'-triphosphate, *see* ara-CTP
 ara-C
 cytotoxicity
 mechanism, 72:205–210
 modulation, 72:220–225
 resistance mechanisms, 72:210–213
 signaling pathways and oncogene interactions, 72:213–220
 structure and metabolism, 72:200–205
- Arachidonic acid
 α -fetoprotein and, 56:300
 activities, 56:281
 binding, 56:271, 273, 276, 278
 cellular uptake, 56:279
 immunoregulation, 56:282–284, 286
 chemical carcinogenesis and, 50:52
 lysophosphatidic acid and, 57:94–96
- ara-C monophosphate, conversion to ara-CTP, 72:203–204
 ara-CTP
 dephosphorylation, 72:211
 formation, 72:205
- Aralkylating agents, mutagenic action studies, 65:83
- ARC, 51:316
- Arginine, Epstein–Barr virus proteins and, 50:112, 114, 127, 141
- Aristotle, 66:42
- Arsenic, cancer incidence data and, 56:185, 206–208, 211
- Arsenite, multidrug resistance gene and, 60:170
- Arthritis, CD44 and, 71:286–287
- Artificial insemination, HIV and, 51:336
- ARV, 51:317
- Arylsulfatase, lysosomes and, 60:272, 274
- Asbestos
 cancer incidence data and, 56:208, 209, 211
 chemical carcinogenesis and, 50:28
 stroma and, 50:181
- Asbestos-exposed workers, 61:19
- Ascites
 formation, role of VEGF, 67:310
 tumor clonality and, 50:199
- Askin tumor, chromosomal aberrations, 69:86–87
- Aspergillus nidulans*, genomic instability and, 60:132
- Aspirin, protective role in colorectal cancer, 61:6
- Astrocytoma
 CD44 and, 71:292
 chromosome 3 losses in, 71:51
 oncogenesis of, 58:122–125, 131–133

- progression of, loss of heterozygosity and, 54:38–40
 specific PKC isozyme expression, 64:187–188
- Ataxia-telangiectasia, 71:9–10, 213
 and breast cancer, 61:47
 EBV-associated disorders and, 57:343–344
 gene rearrangements and, 52:75
 genomic instability and, 60:136
 opportunistic tumors associated with, 54:307
p53 response to ir, 66:148
- Ataxia-telangiectasia genes, localization of, 56:77, 78, 95, 99
 genetic linkage, 56:98
 11q23, 56:89–93
 location scores, 56:93–95
 methods, 56:86–89
 high resolution karyotyping, 56:97, 98
 mapping, 56:96, 97
 phenotype
 abnormal clonal expansion, 56:83–86
 complementation groups, 56:81–83
 diagnosis, 56:78, 79
 postmortem examination, 56:79–81
 pulsed field gel electrophoresis, 56:98
- ATF2, binding and transcription activation by *p110^{Rbl}*, 61:128
- Atherosclerosis
 DHEA and, 51:419–420
 newborn macrosomy and, 50:263, 265, 269
- A-T hook motif, in human acute leukemia, 67:26–38
- ATLL, *see* Adult T-cell leukemia/lymphoma
- ATL, 51:313
- ATM* gene, 71:12
- ATM* gene product, 71:1, 2, 10
 apoptosis, 71:12
 cell cycle control and, 71:10–16
 p53-dependent signal transduction pathway, 71:9–12
 structural and phenotypic homologs, 71:12–16
- Atomic bomb explosions, prostatic cancer and, 51:76–79
- ATP (adenosine 5'-triphosphate)
 adenovirus E1A proteins and, 57:60–61
 bcr/abl gene in leukemia and, 57:165
 BCR gene in leukemia and, 57:234, 241
 multidrug resistance gene and, 60:159–160, 162–165
 oncoprotein kinases and, 57:207, 209–210
 and *p53*, 66:102, 104
 peptide-binding heat shock proteins and, 62:161–162, 164–165
 protein tyrosine kinase GFRs and, 60:63
 Raf-1 phosphorylation and, 58:64
 Ras function and, 62:45–46
 Src family of tyrosine protein kinases and, 57:109, 119, 123
- ATPase
 lysosomes and, 60:269
 peptide-binding heat shock proteins and, 62:162, 164–165, 173
 polyoma virus TSTA and, 55:81
- ATP-binding cassette, multidrug resistance gene and, 60:162–163
- Atresia, Wilms' tumor and, 59:48
- Atrophic gastritis, gastrointestinal diseases and, 50:5, 7
- AUG codons, fibroblast growth factors and, 59:119, 124, 131, 148
- Autoantibodies in malaria, 53:61–62
- Autocrine control
 ADF and, 57:402–403
 B lymphocytes, *see* B cells, autocrine regulation of
 stimulation of human tumor cells, 54:226–231
 inhibition of, 54:229–231
- Autocrine growth factors
 ADF and, 57:390, 401, 403–404, 406
 growth regulation and, 57:417
 metastatic cancer cells and, 55:89, 111, 115–120
- Autoimmune thyroiditis, newborn macrosomy and, 50:259, 261
- Autoimmunity, apoptosis and, 71:122, 142
- Autologous lymphocyte cytotoxicity, cancer immunotherapy and, 59:284
- Autologous tumor specificity, cytotoxic T lymphocytes and, 58:166–167
- Autologous tumor stimulation, cancer immunotherapy and, 59:284
- Autophosphorylation
 Flt family, 67:302–303
 as molecular switch, 64:88
 and SH2 binding sites, 64:94
- Autoradiography, tumor clonality and, 50:204

- Autoregulation
 in amplification, 66:11
myc family oncogenes and, 57:22–23, 27
 Rel/NF- κ B and κ B, 66:277
- Autoregulation domain, c-Myc protein, 70:101
- Autosomal dominant Gardner syndrome, chromosomal aberrations, 69:65–66
- Autosomes
 genomic instability and, 60:132
 MHC Class I expression and, 60:230
 protein tyrosine kinase GFRs and, 60:66
 soft tissue tumors and, 60:80–81, 83, 86–87
- Avian erythroblastosis virus, *c-erbA* and, 59:90–93, 96, 98, 101–102
- Avian hepadnaviruses
 genomes, 59:189
 pathogenicity, 59:184–185
- Avian leukemia virus, 51:278, 279
- Avian leukosis virus, Burkitt's lymphoma and, 55:170, 215, 216
- Avian myeloblastosis virus
 effects resembling Wilms' disease, 67:2–3
 oncogenes and, 50:83
- Avian myelocytomatosis virus, oncogenes and, 50:83
- Avian sarcoma virus 17, *jun* oncogene and, 55:2–4, 25
- axl*, protein tyrosine kinase GFRs and, 60:63, 65–66
- 5-Azacytidine, muscle cell regulation and, 58:97
- Azaserine, chemical carcinogenesis and, 50:29
- 3'-Azido-3'-deoxythymidine, 51:346, 347
- B**
- Baboon endogenous virus, 51:310, 311–313
- Back-crossing, mouse strains, 67:95–99
- Bacteria
 Epstein-Barr virus proteins and, 50:108, 114, 146
 immunosuppression and, 60:259
jun oncogene and, 55:6–8
 Louvain rat immunocytomas and, 50:305
 polyoma virus TSTA and, 55:72, 73
 stroma and, 50:162
 Zilber and, 59:8, 30
- Bacterial extracts, vaccinations from, 61:63
- Bacterial infection, AIDS and, 51:337, 338
- Bacteriophages
 Lwoff's experiments, 69:5–7
 M13, DNA, diet-ingested, 66:315, 338–339
 replication mechanism, work of Spiegelman on, 65:210–211
- Baculoviruses, 71:131
- Bad protein, apoptosis and, 71:126
- BaEV, 51:310, 311–313
- Bak protein, apoptosis and, 71:126
- Bam*HI
 Epstein-Barr virus genes and, 58:5, 7, 10, 12, 15–16; 67:200–244
 N fragment, LMP-1 coding region in, 67:214–218
- Barret's epithelium, gastrointestinal diseases and, 50:2
- Barrett esophagus, 71:215, 224
- Base excision repair, 72:42
- Base excision repair system, 71:212
- Basement membrane
 as barrier to invasion by cancer, 54:162
 fibroblast growth factors and, 59:138–139, 141
 metastatic cancer cells and, 55:88, 95, 108–110
 oncogenes and, 50:77
 plasminogen activation and, 57:275, 285, 290–292
 stroma and, 50:186
 alterations, 50:184
 epithelium, 50:161, 166
 glycoproteins, 50:172
 invasiveness, 50:173–176
- Basic fibroblast growth factor multigene family, 60:34–35
 early studies, 60:6
 ligand binding, 60:24–27
 mitogens, 60:2–3, 5
 multiple forms, 60:17–21
- Bat web experiment, endogenous growth inhibitors and, 57:424–428
- bax* gene
 apoptosis and, 71:9
p53 and, 71:7
- Bax protein, apoptosis and, 71:126
- BC3H1, muscle cell regulation and, 58:106–107, 112
- B-cell antigen receptor, gene rearrangements and, 52:46–49

- B cell-associated surface molecules, 52:82, 83, 134, 135
 activation, 52:83–85
 biologically defined molecules
 BLA, 52:121, 122
 CD10, 52:116–118
 CD24, 52:118, 119
 CD37, 52:119, 120
 CD39, 52:120, 121
 expression, 52:122–124
 differentiation antigens
 Bgp95, 52:115, 116
 CD19, 52:99–102
 CD20, 52:91–99
 CD21, 52:102–104
 CD22, 52:105–108
 CD23, 52:108–112
 CDw40, 52:112–115
 expression, 52:89–91
 expression on activated cells, 52:127–129
 early, 52:129, 130
 late, 52:130–132
 history
 heteroantisera, 52:85–87
 monoclonal antibodies, 52:87–89
 receptors, 52:125–127
 T cells, 52:132–134
- B-cell chronic lymphocytic leukemia, 56:325, 326, 331
- B-cell Epstein–Barr virus/C3d receptor, structure and function of, 54:273–295
- B-cell growth factors, 52:84, 85
 ADF and, 57:389, 403–404
 autocrine regulation of, 56:315–317, 324, 327, 331
 CD23 molecule, 56:321, 323
 production, 56:319, 320
- biochemically defined molecules, 52:120
 CD19, 52:102
 CD20, 52:92, 96
 CD21, 52:104
 CD23, 52:110–112
 CDw40, 52:114, 116
 Epstein–Barr virus proteins and, 50:96, 137
 expression on activated cells, 52:129
 receptors, 52:126, 127
- B-cell hyperplasia, EBV-associated disorders and, 57:352
- B cells
 activation, CR2 in, 54:290–293
 ADF and, 57:383, 407
 EBV, 57:403–404
 identification, 57:388–392
 lymphocyte activation, 57:404–405
 α -fetoprotein and, 56:280, 281, 285
 antibody production, regulation by Fc γ RII, 64:230–233
 ataxia-telangiectasia genes and, 56:79, 82–84
 autocrine regulation of, 56:313, 314, 330, 331
 activation, 56:314, 315
 balance of factors, 56:327–330
 B cell growth factors, 56:316, 317, 319, 320
 B cell neoplasia, 56:325–327
 CD23 molecule, 56:321–324
 Epstein–Barr virus, 56:317–319, 324, 325
 interleukin-1, 56:320, 321
 progression, 56:315
bcr/abl gene in leukemia and, 57:157
 breast cancer, *p53* expression in, 59:85
 Burkitt's lymphoma and, 55:135, 136, 141, 142
 chromosomal translocations, 55:203, 204
c-myc expression, 55:187
 deregulation, 55:209–216
 differentiation, 55:165–170
 EBV, 55:226, 227, 230–234, 238–240
 features, 55:145, 147, 148
 genetic abnormalities, 55:216, 218
 nonrandom chromosomal translocations, 55:156, 157
 phenotype, 55:150, 153, 154
 synthesis, 55:243–246, 248, 250
 cancer immunotherapy and, 59:285–286
 CD44 transition during activation, 71: 258–259
 chromosome abnormalities and
 acute lymphoblastic leukemia, 52:18, 20–22
 chronic lymphoproliferative disorders, 52:22, 23
 malignant lymphoma, 52:26
 chronic antigenic stimulation, 67:122–124
 clonal expansion in AIDS-NHL, 67: 118–120
c-myc regulation and, 56:34, 37
 abnormal regulation, 56:26, 27

B cells (*continued*)

- Burkitt's lymphoma, 56:27, 32, 35–39
 - expression, 56:18
- CR2 in, 54:287–289
- cytotoxic T lymphocytes and, 58:151; 59:236
- differentiation, 55:167, 168; 71:138–140
 - CR2 expression during, 54:290–291
 - effect of c-MYC protein expression, 67:135–136
- EBV-associated disorders and, 57:330–333
 - Burkitt's lymphoma, 57:334–336
 - Hodgkin's disease, 57:369, 371
 - immunodeficiency states, 57:344–345
 - NHL and AIDS, 57:364, 366
 - organ transplants, 57:345–364
 - X-linked lymphoproliferative syndrome, 57:337–343
- Epstein–Barr virus and, 62:180–184, 188; 69:213, 214, 218
 - Hodgkin's disease, 62:219–220, 225
 - pathogenetic models, 62:209–212
 - T-cell lymphoproliferation, 62:187–190, 192–193, 196, 199, 202
- Epstein–Barr virus proteins and, 50:149, 150
 - biology, 50:96
 - diseases, 50:98, 99, 100
 - transformed cells, 50:104, 120, 132, 133, 135, 136
 - virus-produced cells, 50:138
- expansions, EBV-infected, 67:126–130
- FcγR expression, 64:221
- FcγRII expression, 64:213, 224–225
- gene rearrangements and, 52:46
 - B cell antigen receptor, 52:46–49
 - hematological neoplasias, 52:58, 59, 64, 65, 68
 - simultaneous occurrence, 52:70, 72
 - T-cell antigen receptor, 52:55, 56
- genomic instability and, 60:124, 133, 137, 139
- glutathione transferase and, 52:240
- hepatitis B viruses and, 59:177
- Herpesvirus saimiri* and, 56:335, 341
- in humoral immune response, 62:241–242, 260–261
 - activation, 62:246–256
 - follicular B cell survival, 62:256–259
 - isotype switching, 62:259–260
 - lymphoid tissue architecture, 62:242–243, 245
 - Th cell activation, 62:245
 - immunosuppression and, 60:247, 249, 256, 259
 - and κB-binding, 66:278–279
 - latently infected with EBV, 67:200–204
 - Louvain rat immunocytomas and, 50:306
 - Ly-1*, characteristics, 63:279–281
 - MHC Class I expression and, 60:195, 203, 213–214, 219, 223
 - myc* family oncogenes and
 - gene expression, 57:15, 18–19
 - oncogenic activities, 57:25–27, 29–32
 - PKC isozymes in, 64:179–180
 - reverse transformation and, 62:137
 - Src family of tyrosine protein kinases and, 57:113, 116–118, 121, 136
 - T-cell receptors and, 56:49, 54, 59, 64
 - tumor clonality and, 50:210
- 3B6 cells, ADF and, 57:390–392, 400, 404
- B cell-stimulating factor 1, *see* Interleukin-4
- B cell-stimulating factor 2, *see* Interleukin-6
- BCG, cancer immunotherapy and, 59:256, 287
- Bcl-1*
 - locus, 68:75
 - translocation, 68:75, 77
- Bcl-2*
 - acute lymphocytic leukemia, 71:147–148
 - apoptosis and, 71:9, 128, 139–140; 72:9–10
 - B-cell survival, 71:139–140
 - chronic lymphocytic leukemia, 71:146
 - and c-Myc, in apoptosis, 68:148, 151–152, 156; 70:132
 - drug resistance in chemotherapy and, 71:152
 - gene synergism with c-*myc*, 68:156–157
 - gene translocation, 68:156
 - hematopoiesis and, 71:135, 136
 - interaction with ara-C, 72:215–216
 - lymphoma and, 71:143–144
 - p53 gene and, 71:127
 - role in development, 68:147–148
 - subcellular localization, 68:147
 - transcription, inhibition by p53, 67:272
- Bcl-2* gene family, 71:125–126
- bcl-2* protein, apoptosis and, 71:125, 126
- Bcl-6*, as prognostic marker, 67:136
- Bcl-x* gene
 - apoptosis and, 71:126

- hematopoiesis and, 71:135
- Bcl-x_l* gene, 71:126, 135, 139
- Bcl-x_s* gene, 71:126, 132
- bcr*
 - in leukemia, 57:227–228, 252–253
 - animal models, 57:174–175, 177
 - CML, 57:228–229
 - expression, 57:235, 240–243
 - hematopoietic cells, 57:243–244
 - BCR/Abl complexes, 57:250–252
 - BCR protein complexes, 57:244–250
 - malignancy, 57:163–167
 - organization, 57:232–240
 - P210 BCR/Abl, 57:231–232
 - Philadelphia chromosome, 57:154–155, 229–231
 - soft tissue tumors and, 60:88–89, 107
- bcr/abl*
 - in leukemia, 57:228–229, 231–232, 241, 252; 64:90
 - Abelson murine leukemia virus, 57:156–157
 - abl* in malignancy, 57:163–169
 - animal models, 57:173–179
 - biological activity, 57:169–173
 - c-abl* activation, 57:160–163
 - c-Abl protein, 57:157–160
 - chronic myelogenous leukemia, 57:151–152
 - Philadelphia chromosome, 57:152–154
 - characterization, 57:154–156
 - and Ras activation, 64:102–103
- BCR/*abl* protein, leukemia and, 57:231–232, 243–245, 247, 249–253
 - animal models, 57:174, 176–178
 - biological activity, 57:169–173
- Bcr-Abl tyrosine kinase
 - apoptosis and, 71:129
 - chronic myeloid leukemia and, 71:145
 - myelodysplastic syndrome, 71:149
- BCR protein
 - BCR gene in leukemia and, 57:234, 241–253
 - leukemia and, 57:161, 164–165, 167–168
- Beas-2B cells, *see* Immortalized human bronchial epithelial cells
- Beckwith–Wiedemann syndrome, 54:42–46; 71:198
 - soft tissue tumors and, 60:85, 103
 - Wilms' tumor and, 59:47, 49–51
- bek*
 - amplification in breast cancer, 61:38–39
 - protein tyrosine kinase GFRs and, 60:64
- Benign cartilaginous tumors, chromosomal aberrations, 69:84
- Benign prostatic hyperplasia, prostatic cancer and
 - latent carcinoma and, 51:9–14
 - prostatitis and, 51:19–21
- Benign tumors
 - genomic instability and, 60:124
 - soft tissue tumors and, 60:76–77, 80, 85–87, 94
- Benzene, stroma and, 50:188
- Benzo[a]pyrene
 - as archetypal environmental carcinogen, 65:44
 - oncogene activation and, 51:154, 157, 159, 170
- β -associated transcripts, MHC Class I expression and, 60:230
- Beta cells, Fc γ RII expression, 64:224
- Betaglycan, TGF- β type III receptor, 70:68–69
- Bgp95, B cell-associated surface molecules and, 52:115, 116, 124
- bHLH region, muscle cell regulation and, 58:100, 104–105, 113
- BHRF1 protein, 69:215
 - cellular proliferation, 71:131
 - Epstein–Barr virus genes and, 58:4, 9, 15–16
- Biguanides, newborn macrosomy and, 50:270, 271
- Bile acids, gastrointestinal diseases and, 50:11
- Binding proteins
 - phosphotyrosine, and *ret*, 70:204–207
 - TATA box, interaction with c-Myc, 70:115
 - TGF- β , 70:67–70
- Bioassay, transplantation, 66:299–300
- Biochemical modulation, ara-C-associated cytotoxicity, 72:221–222
- Biological functions, Flt family, 67:301–302
- Biological markers
 - of intermediate endpoints, 61:13
 - as surrogate endpoints, 61:20
- Biological response modifiers, cancer immunotherapy and, 59:247, 293
 - critical factors, 59:253, 255
 - current strategies, 59:266–267
 - improvement attempts, 59:283, 287

- Biologic therapy
 active immunotherapy, 61:63–66
 passive immunotherapy, 61:66–74
- Biology
 cellular, cancer, 70:1–17
 EBV infections, 67:241–246
 role of VEGF in normal tissues, 67:290
- Biomonitoring, chemical carcinogenesis and, 50:54–58
- Birth cohorts, prostatic cancer and, 51:18, 25, 32–38
- Birth order, newborn macrosomy and, 50:235, 236
- Bisindolylmaleimides, PKC-specific inhibitor, 64:167
- Bisppecific antibodies, 71:364–365
- Bisphosphatase as target of cAMP-dependent protein kinase, 54:115–116
- BK virus, simian virus 40 and, similarities, 65:155
- Black populations, prostatic cancer and, 51:3–4, 7–9, 17, 25–28, 89–90
 diet and, 51:33
 hormonal system and, 51:83–85
 latent carcinoma and, 51:10
- Bladder
 carcinoma of
 angiogenesis in, 69:159
 aromatic amines and, 65:25–26, 60–64
 cancer immunotherapy and, 59:264–265
 CD44 and, 71:298–299
 chromosome 3 losses in, 71:52–53, 75
 chromosome abnormalities and, 52:29
 cyclin D1 amplification, 68:88
 incidence of, 56:174, 175
 lysosomes and, 60:276
 MHC Class I expression and, 60:190, 205, 223
 p16 gene mutations, 68:91–94
 plasminogen activators and, 69:112
 progression of, from *in situ* to invasive, 54:165
 prostatic cancer and, 51:19
 chemical carcinogenesis and, 50:29, 39, 57
 stroma and
 alterations, 50:184, 185
 disorders, 50:181
 epithelium, 50:162
- Blast cells, IAPs in, 51:265
- Blast crisis
 bcr/abl gene in leukemia and, 57:152, 176, 178
 BCR gene in leukemia and, 57:228–229
 p53 and human malignancies and, 57:267–268
- Bleeding, in leukemic patients, plasminogen activation, 69:119–121
- Bleomycin, multidrug resistance and, 52:167
- blk*, tyrosine protein kinases and, 57:105, 112, 115–116
- Blood–brain barrier, infiltration through, 69:121
- Bloodstream
 foreign DNA in, 66:338–341
 recombinogenic fragments in, 66:315
- Blood vessels
 permeability, in cancer progression, 67:282
 tumor, 69:136, *see also* Angiogenesis
- Bloom's syndrome
 genomic instability and, 60:126, 136
 molecular cytogenetics, 62:101
- Blue-green algae, microcystin-containing, 61:172–177
- B lymphocyte carcinoma cross-reacting antigen, 52:115, 120, 124, 131, 133
- B lymphocyte dysfunction, AIDS and, 51:325–326
- B lymphoid tumors, Louvain rat immunocytomas and, 50:306
- Bmi-1
 alteration of *Hox* genes, 68:159–160
 gene synergism with *c-myc*, 68:159–160
 transcriptional regulation, 68:159
 transgenic mice, 68:159
- Body weight
 cancer and, 51:401–404
 DHEA and, 51:396–400
- Bombesin
 G protein signal transduction and, 58:85, 87
 ras genes and, 51:149
- Bone
 Burkitt's lymphoma and, 55:149
 c-fos protooncogene and, 55:42
 TGF and, 51:114–117, 132
- Bone and soft tissue tumors
 chromosomal aberrations, 69:64
 bone-forming tumors, 69:82–83
 cartilage-forming tumors, 69:84–85
 endothelial tumors of blood and lymph vessels, 69:77

- Ewing sarcomas and related tumors, 69:82, 86–87, 90, 92
- fibrohistiocytic tumors, 69:67–69
- fibrous tissue tumors, 69:65–67
- giant cell tumors of bone, 69:85–86
- lipomatous tumors, 69:69–74
- miscellaneous tumors, 69:82
- neural tumors, 69:80–82
- perivascular tumors, 69:78
- sacral chordoma, 69:87
- shared by several tumor types, 69:88–91
- skeletal muscle tumors, 69:76
- smooth muscle tumors, 69:74–76
- synovial tumors, 69:78–79
- diagnosis and prognostication, 69:65, 91–93
- Bone-forming tumors, chromosomal aberrations, 69:82–83
- Bone marrow
 - adipogenesis in, 54:261
 - α -fetoprotein and, 56:282
 - bcr/abl* gene in leukemia and, 57:152–153, 172–178
 - BCR* gene in leukemia and, 57:228, 231, 240
 - B lymphocytes and, 56:325, 327
 - Burkitt's lymphoma and, 55:138
 - deregulation, 55:210, 212
 - EBV, 55:225, 226
 - features, 55:143, 144, 149
 - genetic abnormalities, 55:218
 - cancer immunotherapy and, 59:254, 286
 - c-erbA* and, 59:90
 - chromosome abnormalities and
 - acute lymphoblastic leukemia, 52:18
 - acute nonlymphocytic leukemia, 52:10, 11
 - cytogenic data, 52:7, 8
 - myelodysplastic syndromes, 52:13, 16
 - cultures of, long-term, 54:240–241
 - initiation of, 54:245–246
 - lymphocytes in, 54:242–245
 - EBV-associated disorders and, 57:336, 338–339, 344
 - endogenous growth inhibitors and, 57:414, 416, 434
 - Epstein–Barr virus proteins and, 50:100
 - gastrointestinal diseases and, 50:19
 - gene rearrangements and, 52:58
 - hepatitis B viruses and, 59:177, 181
 - lymphopoietic microenvironment in, 54:235–264
 - differentiation steps and lineages in, 54:241–242
 - experimental approaches to, evolution of, 54:237–40
 - MHC Class I expression and, 60:230
 - microenvironment of, essential cells of, 54:246–250
 - multidrug resistance gene and, 60:168
 - from mutant *p53* mice, 66:147–148
 - oncogenes and, 50:82
 - parental, lethal effects, 66:45–46
 - preleukemic cells emerging in, 66:299
 - reconstitution, and PymT expression, 64:144–148
 - Src family of tyrosine protein kinases and, 57:113–117, 132
 - stroma and, 50:188
 - tumor clonality and, 50:199, 208
- Bone marrow-specific lymphocyte homing receptor, 51:374
- Bone marrow transplant, EBV-associated disorders and, 57:332, 345, 356–357, 372
 - B cell tumors, 57:351–353, 363–364
 - NHL, 57:347–348
- Bone morphogenetic proteins, similar to TGF- β , 70:65
- Boveri, Theodor, somatic mutation theory and, 65:20
- Bovine papillomavirus, transforming activity of, 56:133–135, 155
 - stable assays, 56:135–140
 - transient assays, 56:140–142
- Bowel, gastrointestinal diseases and, 50:18
- BP, oncogene activation and, 51:154, 157, 159, 170
- Brain, fibroblast growth factors and, 59:144, 152
- Brain abscess, AIDS and, 51:343
- Brain cancer, plasminogen activators and, 69:112
- Brain IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
- Brain tumor
 - chemical carcinogenesis and, 50:30
 - CD44 and, 71:291–293
- Breakpoint cluster region, 66:cloning, 11q23, 217–221

- Break points
 on chromosomes 8 and 14, 67:134
 in human acute leukemia, 67:28–38
 in human sarcomas, 67:40–43
 T-cell translocations, reverse genetics at, 67:50
- Breast cancer, 61:27–28
 abnormal karyotypes, 67:68–71
 adjuvant therapy with tamoxifen, 61:17
 angiogenesis, 69:155, 158, 159
 and ataxia telangiectasia, 61:47
 ataxia-telangiectasia genes and, 56:78, 98
 autologous
 cell-mediated immunity, 56:110–115, 119–121
 therapeutic implications, 56:124–126
 Breast Cancer Prevention Trial, 61:17
 CD44 and, 71:301–302
 chromosomal alterations in, 61:39–40
 chromosome 3 losses in, 71:48–49
 clinical management, 61:48–49
 correlation with prostatic cancer, 51:18–19
 cyclin D1 amplification, 68:82–85, 89
 cyclin E *in vivo* expression, 65:226
 DHEA and, 51:392–394, 405(*f*)
 diagnosis, 61:29–30
 dietary factors and, 51:27–28
 double minutes, 61:40
 effect of radiation, 65:90
 frequency of carcinoma types, 61:28
 gene amplifications
bek and *flg* genes, 61:38–39
c-myc gene, 61:36–37
 EGF receptor gene, 61:37
 IGF-1 receptor gene, 61:37–38
 list of, 61:31
 llq13 region, 61:34–36
neu gene, 61:32–34
 genetic changes, 66:120–126
 genetic predisposition to, 61:46–47
 geographic variations in, 51:18–19
 HER-2/*neu* gene amplification and, 71:346–348, 357
 hereditary, 61:46–47
 histological types, 61:27–29
 4-HPR trials, 61:16
 immunogenicity and, *see In situ* carcinoma-associated immunogenicity
 immunosuppression and, 60:251–252, 255, 260–261
 immunotherapy and, 59:252
 inactivation of tumor suppressor genes, 61:40–41
 DCC gene, 61:45
p53 gene, 61:41–43
 prohibitin gene, 61:44–45
 Rb gene, 61:43–44
 lesions, 61:28–29
 life-style and, 51:27
 and Li-Fraumeni cancer syndrome, 61:47
 lobular carcinoma *in situ*, 61:27–28
 loss of heterozygosity in, 61:30–31, 41
 lysosomes and, 60:277
 MHC Class I expression and, 60:194, 204, 206, 223
 model of genetic changes in, 61:48
 molecular cytogenetics, 62:116
 multidrug resistance gene and, 60:166, 169
 newborn macrosomy and, 50:233
 accelerated development, 50:267
 case histories, 50:239
 characteristics, 50:241, 242, 245
 factors, 50:258, 259
 prognosis, 50:247, 249, 250
 risk factors, 50:267, 268
 normal breast histology, 61:26–27
p53 expression in, 59:69
 assay methods, 59:76–77
 discovery, 59:69–70
 dominant oncogene, 59:70
 function, 59:71–72
 function mutants, 59:70–71
 immunochemistry, 59:78–80
 lesions, *in situ*, 59:83–84
 Li-Fraumeni syndrome, 59:80–82
 loss of heterozygosity, 59:74, 77–78
 mutations, 59:75, 80–81
 prognosis, 59:82–83
 receptors, 59:82
 recessive oncogene, 59:70
 studies, 59:77
 therapeutic possibilities, 59:84–85
 viral proteins, 59:72–74
 and *p53* mutations, 66:108–120
 peptide-binding heat shock proteins and, 62:169
 plasminogen activation and, 57:291, 312, 314
 plasminogen activators and, 69:112, 113
 point mutations in, 61:39
 prevalence, 68:82

- progression
 estrogen role, 70:82–84
 from *in situ* to invasive, 54:164–165
 protein tyrosine kinase GFRs and,
 60:64–65
 RER+ phenotype, 67:74–75
 retroviruses and, 51:309, 311
 role of estrogens, 65:22
 role of insulin-like growth factors,
 68:206–208
 SF and tumor angiogenesis as prognostic
 indicators, 67:267
 soft tissue tumors and, 60:78, 80, 82, 101,
 104–105
 somatic changes, 66:72–73
 somatostatin analog therapy, 68:212
 sporadic, 61:46
 stroma and
 disorders, 50:181
 epithelium, 50:165–169
 fibroblasts, 50:178
 glycoproteins, 50:171
 susceptibility genes, 72:15–16
 tamoxifen and, 51:129–130
 tamoxifen trials, 61:16
 TGF and, 51:133
 treatment
 against altered gene products, 61:50
 Ki-67 epitope information, 61:4
 types of, 61:29–30
 Wilms' tumor and, 59:47
 Breast cells, cyclin changes, 65:224–225
 Breast-feeding, avoidance, for prevention of
 human type C retrovirus transmission,
 65:196
 Breast milk, AIDS and, 51:340
 Breeding, selective, leading to gene fixation,
 72:13
 Brefeldin A, cytotoxic T lymphocytes and, 59:
 233
 Bridge-breakage-fusion cycles, in CAD gene
 amplification, 61:98–99
 Bronchial tumors
 cholecystokinin expression, 63:325
 gastrin expression, 63:321
 Brunner's glands, gastrointestinal diseases
 and, 50:16
 Bruton's type agammaglobulinemia,
 opportunistic tumors associated with, 54:306
 Bryostatin
 in neoplasia, 64:289
 PKC activation, 64:164–165
 Bryostatin-1, effect on ara-C-induced
 apoptosis, 72:224
 Bulky adducts, carcinogenicity of tobacco
 and, 65:81–82
 Burkitt's lymphoma, 55:135–137, 140,
 144
 ADF and, 57:383
 African endemic, 53:33–67
 animal models, 55:250
 ataxia-telangiectasia genes and, 56:85
 B cell-associated surface molecules and
 biochemically defined molecules, 52:
 120–122, 124
 differentiation antigens, 52:92, 108,
 116
 expression on activated cells, 52:129,
 131
 history, 52:87
 receptors, 52:126
 T cells, 52:133
 BL-associated antigen, 57:334
 B lymphocytes and, 56:314, 321–323,
 329–331
 cells expressing mutant p53, 66:146–148
 cellular expression of CD77, 72:11
 cellular origins, 55:243–245
 chromosomal translocations, 55:195–197;
 67:11, 27–31; 68:5, 73
 c-myc expression, 55:197, 198
 absence of, 55:201–205
 c-myc mRNA, 55:198, 199
 c-myc promoters, 55:199–201
 immunoglobulin sequences, 55:205–208
 chromosome abnormalities and
 acute lymphoblastic leukemia, 52:21
 chronic myeloproliferative disorders,
 52:23
 malignant lymphoma, 52:25
 oncogenes, 52:34, 35, 37
 chromosomes and, 62:11
 clinical differences, 55:246–248
 clinical significance, 55:250, 251
c-myc, 55:157
 cell proliferation, 55:164, 165
 deregulation, 55:208; 56:37–41
 chicken bursal lymphoma, 55:215,
 216
 transgenic mice, 55:208–213
 viral promoter, 55:214, 215
 expression, 55:186–192

- Burkitt's lymphoma (*continued*)
 gene structure, 55:158, 159
 protein functions, 55:160–164
 regulation, 56:2, 9, 12, 17, 18, 21–23, 25, 26–28, 31–37
 gene topography, 56:5, 6, 8, 28–31
 regulation of transcription, 55:159, 160
 structural changes, 55:176–185
 definition, 55:137–141
 endemic, 53:33–67; 57:333–335, 365–366, 372–373
 chromosomal translocations and, 53:42–44
 cytotoxicity of cells in, 53:45–46
 epidemiology of, 53:38–40
 etiology of, malaria and, evidence linking, 53:51
 evidence linking EBV with, 53:41–42
 genesis of, cofactors in, 53:44–45
 histology of, 53:41
 oncogenes and, 53:42–44
 target cell in, nature of, 53:46
 environmental factors, 55:245–246
 Epstein–Barr virus and, 55:223–225; 57:333–336; 62:180; 67:198, 202–204; 68:3–6; 69:216, 225
 biology, 62:182–183
 epidemiology, 55:225–227
 features, 55:141–143
 clinical findings, 55:149, 150
 distribution of tumor, 55:143, 144
 environment, 55:144, 145
 geography, 55:145, 146
 immunosuppression, 55:146–149
 genetic abnormalities, 52:49, 64, 73; 55:216, 217
 anti-oncogenes, 55:220–222
 defects in DNA repair, 55:222, 223
 viral oncogenes, 55:217–220
 geography, 55:192–195
 glycosylation in tumors and, 52:283, 298
 hepatocellular carcinoma and, 59:211
Herpesvirus saimiri and, 56:335, 341, 342
 HIV⁺ and HIV⁻, 67:211–213
 Hodgkin's disease, 62:224, 230
 latent gene expression, 55:235–238
 Louvain rat immunocytomas and, 50:297–300
 lymphocyte transformation, 55:227–232
 MHC Class I expression and, 60:190, 195, 202–203, 205
 molecular consequences, 55:246
myc family oncogenes and, 57:5, 17–20, 25–26
 NHL and AIDS, 57:364–366
 non-random chromosomal translocations, 55:154–157
 organ transplants, 57:351, 358, 361
p53 and human malignancies and, 57:263
 pathogenesis, 55:240, 241
 phenotype, 55:150–154
 soft tissue tumors and, 60:88
 sporadic, 57:333–336, 365–366
 similar to AIDS-SNCCCL, 67:134
 subset, 55:249, 250
 T-cell cytolysis, 55:238–240
 T-cell lymphoproliferation, 62:202, 210
 T-cell recognition, 55:233–235
 transactivator gene, 55:241, 242
 translocation
 mechanism, 55:171–176
 timing, 55:165–170
 tumor clonality and, 50:208, 210, 216, 223
 viral genes, 58:2
 viral proteins
 biology, 50:96
 diseases, 50:96–98
 transformed cells, 50:105, 108, 109, 128, 133, 135, 136
 virus-produced cells, 50:138
 X-linked lymphoproliferative syndrome, 57:340, 343
 mutated *p53*, 72:17
 phenotype, 55:150, 153
 Butylated hydroxyanisole
 carcinogenicity of, 53:249–253
 excretion of, 53:263–264
 in forestomach tumorigenesis
 chemical effects on, 53:267–268
 mechanism of action of, 53:263–270
 metabolism of, 53:264–267
 detection of radicals during, 53:268–270
 tissue distribution of, 53:263–264
 Butylated hydroxytoluene, carcinogenicity of, 53:253
tert-Butylhydroquinone, tumorigenic activity of, 53:253–255

- Bystander effect, 61:75, 79
 BZLF1, 69:215
 Epstein–Barr virus and, 62:184–185, 208, 210, 224
- C**
- C3d, 54:284
 C3dg, 54:284
 and gp350/220, sequence similarity of, role of, in CR2 binding, 54:285–286, 287, 288
 C3d receptor and EBV receptor, functional relationship of, 54:274
 C3H 10T1/2 cells, TGF- β cell cycle kinetics and, 71:187, 190, 191
 C6 glioma, angiogenesis, 69:138–139
c-abl, interaction with ara-C, 72:219
cad, *c-myc* targeting, 68:135–136
 CAD gene, amplification
 bridge-breakage-fusion cycles, 61:98–99
 centromere recombinations, 61:99
 telomeric fusions, 61:98–99
 unequal sister chromatid exchange, 61:96–97
- E-Cadherin
 expression in prostate cancer, 68:238–239, 243
 gene locus, 68:238
- E-Cadherin gene
 CpG islands, 72:183–185
 loss of expression in tumors, 72:164–165
- Cadherins, 71:244
- Cadmium, prostatic cancer and, 51:51–55, 73–75
- Caenorhabditis elegans*
 Ras function and, 62:21, 24–25, 49
 Ras signaling cascade, 72:62–63
- Caffeine, prostatic cancer and, 51:35–37, 42–43
- CAK, *see* cdk-activating kinase
- Calcitonin, thyroid cells secreting, 70:208
- Calcium
 α -fetoprotein and, 56:256
 B cell-associated surface molecules and, 52:89
 Bgp95, 52:116
 biochemically defined molecules, 52:120, 121, 124
 CD19, 52:101, 102
 CD20, 52:93, 97
 CD21, 52:104
 CD22, 52:107
 expression on activated cells, 52:133
 B lymphocytes and, 56:315, 317, 318, 323
 Burkitt's lymphoma and, 55:164
 c-myc regulation and, 56:11
 dietary, and colorectal cancer, 61:6
 effects on familial colon cancer, clinical trials, 61:13–15
 FGF receptor multigene family and, 60:31
 fibroblast growth factors and, 59:134
 gene rearrangements and, 52:50
 glutathione transferase and, 52:209
 G protein signal transduction and, 58:84–86
 humoral immune response and, 62:247, 254–255
 jun oncogene and, 55:7
 in keratinocytes, 70:80
 lysophosphatidic acid and, 57:90, 94–95, 99–100
 lysosomes and, 60:284
 metastatic cancer cells and, 55:123
 multidrug resistance and, 52:171, 193
 oncoprotein kinases acid, 57:208–209, 213
 papillomaviruses and, 56:139, 151
 peptide-binding heat shock proteins and, 62:162
 plasminogen activation and, 57:278
 Raf-1 phosphorylation and, 58:60
 reverse transformation and, 62:135, 139, 140–142
 signal transduction and, 55:276, 277, 292
 Src family of tyrosine protein kinases and, 57:119, 128, 131, 136
 T-cell receptors and, 56:51, 59
 transforming growth factor- α and, 58:35, 48
 tumor rejection antigens and, 58:188
- Caleyelin, 53:11, 12
- California Institute of Technology, Max Delbruck and phages, 69:9–10, 14–15
- Calmette-Guerin bacillus, 61:63
- Calmidazolium, effect on RB phosphorylation, 64:47
- Calmodulin, metastatic cancer cells and, 55:123
- Calmodulin-dependent kinase 11, muscle cell regulation and, 58:112
- Calphostin C, PKC-specific inhibitor, 64:167

- Calyculin A, biochemical and immunological effects, 61:160
- Calyculins
 biochemical activity, 61:168–170
 structure, 61:168–170
 tumor promotion
 comparison with okadaic acid, 61:172
 on mouse skin, 61:170–172
- Cambridge, England, cancer studies, 70:3–5
- cAMP, *see* Cyclic AMP
- cAMP-dependent protein kinase
 in Ras-cAMP pathway, 54:105–107
 targets of, 54:111–122
 ADR1 as, 54:117–118
 bisphosphatase as, 54:115–116
 in feedback regulation of Ras-cAMP pathway, 54:118–120
 glutamate dehydrogenase as, 54:116–117
 glycogen phosphorylase as, 54:114–115
 glycogen synthase as, 54:113–114, 115
 inositol phospholipid synthesis as, 54:121–122
 phosphofruktokinase-2 as, 54:115–116
 proteins in carbon metabolism as, 54:112–118
 proteins in growth control as, 54:120–122
 sugar-transport systems as, 54:117
 transcription factors as, 54:120–121
 trehalase as, 54:112–113
 trehalose synthase as, 54:112–113
 YAK1 as, 54:122
- Cancer, *see also specific sites and types*
 abnormalities at 12p12–13.1, 71:197
 age and risk of, 65:30–31; 67:5–7; 71:230
 antigens, molecular identification, 70:169–172
 ATM gene product, 71:17
 breast, *see* Breast cancer
 CD44 and, 71:243, 287–288, 291–304
 cell cycle control and, 71:16–17
 cellular proliferation as risk factor for, 71:222–224
 chemotherapy, and apoptosis, 66:16, 18–20
 chromosomes and, 62:14
 clinical, MHC expression in, 53:193–196
 control genes, 69:32, 35
 cyclin overexpression in, 71:196
 defined, 71:195
 development, multistep theory, 72:1–20
 DNA hypomethylation, 72:151–152
 DNA methylation changes, 72:148–150
 clinical implications, 72:189–190
 epithelial, development from phenotype to genotype, 70:21–44
 exogenous sources, radiation and soot, 65:23–25
 genes hypermethylated in, 72:166–167
 HER-2/neu gene amplification, 71:345
 hereditary, 67:7–9
 human
 angiogenesis, 67:266–267
 in children, 67:1–2
 gene therapy, 66:55
 human papillomavirus and, 71:327–332
 human squamous cell
 marker proteins in radioresistant and radiosensitive cells, 61:218
 radioresistance, 61:200–203
 immunosurveillance theory of, 53:182–184
 immunotherapy, 59:275; 70:145–172
 loss of TGF- β receptors, 71:185
 malignant phenotype, 71:243
 malignant process, 71:143–152, 243, 245, 287–291, 304–305
 metastasis, 66:45–46; 71:245
 mixed
 genome imprinting and, 54:55–56
 loss of heterozygosity and, 54:42–49, 55–56
 mutation rate and, 71:234–235
 mutations and, 71:243
 p53 and, 71:7–8, 16–17
 phenotype, liver, 70:36–37
 plasminogen activators and, 69:112–114
 predisposition in LFS families, 66:114–115
 prevention, mutator phenotype role, 72:50–51
 progression *in vivo*, role of blood vessels, 67:282
 renal cell tumors, molecular cytogenetics, 62:109–110, 116
 reverse transformation and, 62:146
 SF and *c-met* up- and down-regulation, 67:267
 smoking-induced, hereditary influences versus environmental factors, 65:27–28
 somatic mutations and, 71:210

- TGF- β , 71:168
- Cancer cells
- arrest of, in metastatic process, 54:172–176
 - death of, postintrasavasation
 - rapid phase of, 54:174–176
 - slow phase of, 54:176
 - genome, increased DNA-methyltransferase activity, 72:171–172
 - invasive delay and, 54:166
 - metastatic, 55:87–90, 125–127
 - clonal dominance, 55:97–105
 - ectopic gene expression, 55:125
 - growth factors
 - autocrine growth factors, 55:115–120
 - growth inhibition molecules, 55:120–122
 - tissue specificity, 55:122, 123
 - human malignant melanoma, 55:105–115
 - phenotype, 55:90–96
 - pleiotropy, 55:123, 124
 - number of mutations, 72:33–34, 51
- Cancer incidence data, 56:161, 162, 208–211
- cancer incidence data and, 56:162–175
 - cohort data
 - cervical cancer, 56:180–185
 - cutaneous melanoma, 56:175–178
 - stomach cancer, 56:178–180
 - hepatocellular carcinoma, 56:185–188
 - lung cancer stages, 56:195, 196
 - arsenic, 56:206–208
 - asbestos, 56:208, 209
 - clonal growth models, 56:203–206
 - multihit models, 56:196–203
 - two-stage model, 56:188–195
- Cancer prevention
- carcinogenesis research, 61:5–6
 - cell biology research, 61:3–5
 - Chemoprevention Program, 61:2–3
 - Diet and Cancer Program, 61:2–3
 - drug combination studies, 61:11–12
 - epidemiologic research, 61:6–7
 - molecular genetic research, 61:3–5
 - research strategies
 - in vitro* testing, 61:8
 - in vivo* testing, 61:8–11
- Cancer research
- cancer development basic to, 70:22–23
 - carcinogens, 70:41–42
 - Cancer therapy
 - breast cancer, *p53* expression in, 59:84–85
 - cancer antigens, 70:169–172
 - molecular diagnosis, 61:60–61
 - molecular disorders, 61:58–59
 - repair of oncogenic genetic alterations, 61:74–75
 - antisense oligonucleotides, 61:75–77
 - gene therapy, 61:77–80
- Cancrophilia syndrome, newborn
- macroscopy and, 50:232, 261–263
 - accelerated development, 50:266
 - epidemiology, 50:264
 - factors, 50:261
 - prophylaxis, 50:270, 271
- Carbohydrate
- adenovirus proteins and, 52:156
 - B cell-associated surface molecules and biochemically defined molecules, 52:118
 - differentiations antigens, 52:100, 105, 106, 115, 116
 - gastrointestinal diseases and, 50:18
 - jun* oncogene and, 55:25
 - multidrug resistance and, 52:172, 174, 183
 - newborn macroscopy and, 50:232
 - cancrophilia syndrome, 50:263
 - case histories, 50:241, 245
 - factors, 50:255, 258, 259, 261
 - prognosis, 50:250
 - prophylaxis, 50:270
 - retrospective data, 50:254
 - transplacental carcinogenesis, 50:254, 255
 - signal transduction and, 55:280, 281
 - stroma and, 50:168, 169
 - Carbohydrate antigens, glycosylation in tumors and, 52:258, 260, 262–266, 316–318
 - background, 52:283, 284
 - glycoprotein, 52:287–291
 - lacto-series antigens, 52:284, 285
 - peptide, 52:291, 292
 - requirements, 52:298–302
 - T antigens, 52:285–287
 - therapeutic applications, 52:309–316
 - Carbohydrate intake, prostatic cancer and, 51:40, 44–45, 60–62
- Carbon
- metabolism, proteins in, as target of cAMP-dependent protein kinase, 54:112–118

Carbon (*continued*)

source of signals for *ras* genes, 54:122–125

Carbonic anhydrase, *c-erbA* and, 59:99

Carbonic anhydrase II gene, *c-erbA* and, 59:104

Carbon tetrachloride, α -fetoprotein and, 56:289, 296

Carboxyl-terminal modification of yeast Ras proteins, 54:97–101

Carcinoembryonic antigen, glycosylation in tumors and, 52:285, 308

Carcinogenesis

aromatic amines and nitrosamines, and *in vivo* modifications of DNA, 65:60–64

breast cancer, 59:75, 84

cell proliferation, 71:224

and cell death in, 65:18

cervical, model, 64:4

chemical, exogenous sources, 65:23–28

early stage, role of p53, 64:283

effect of hormonal factors, 65:22

experimental, radiation source, 65:23–25

fibroblast growth factors and, 59:147, 150, 155

gene alterations in, identification, 65:35

genetic events, 67:16–18

genomic instability and, 60:126

hepatitis B viruses and, 59:167, 169, 188, 209–210

epidemiology, 59:170, 178–179

oncogenesis of viral proteins, 59:195–196, 199

pathogenicity, 59:182–185

heterozygosity and, 71:29

humoralist concept, 65:21–22

inducers, 66:21–24

KS, 66:246–249

lysosomes and, 60:270

Malthus's views on, 65:18

MHC Class I expression and, 60:187–188

multistage

cooperation between Ha-*ras* and *fos*, 64:258

and mouse models, 64:248

role of PKC, 64:191–192

multistage model, 61:2

multistep, molecular biology, 72:14–17

multistep carcinogenesis and somatic

mutations, 71:221–222

p53 mutations and, 65:38

psychosomatic factor involvement, theories, 65:21–22

research, 61:5–6

skin

Ha-*ras* role, 64:257

models representing discrete stages, 64:288–289

TGF α role, 64:267–268

soft tissue tumors and, 60:78, 83

somatic mutations, 71:210

somatic mutation theory

originator, 65:20

support for, and *Tp53* mutation changes, 65:88–89

theories of, 71:224

tobacco, historical origins, 65:26–27

tumor viruses involved, 65:39

two-stage, and polycyclic aromatic

hydrogens, relationship, 65:46–47

Wilms' tumor and, 59:43, 61–62

Zilber and, 59:19

Carcinogens

cancer research, 70:41–42

chemical

detoxification, enzymes involved, 65:74–75

development of rapid screening system, 64:286–288

effects of, on DNA methylation, 54:11–13

cytotoxic T lymphocytes and, 58:151–152, 159, 161, 164

effects on cell proliferation, 70:29–30

endogenous growth inhibitors and, 57:414, 428, 437, 441–442, 447

epidermal cells, 57:444–447

environmental

in multistep oncogenic process, 64:3

and *p53* mutations, 66:116

potential targets, 64:248

role in context of known genetic insults, 64:289

transformed cells, 66:21–24

growth-inhibitory activity, in rats, 65:49

induction of lung tumors in mice, 67:87–91

methylation, in analysis of molecular

mechanisms of carcinogenicity, 65:78

and somatic mutations, 67:4–7

tumor rejection antigens and, 58:178, 195

Carcinoma, basal cell

hereditary and sporadic, 70:57–58

tumor clonality and, 50:217

- c-arg* gene, leukemia and, 57:165
 β -Carotene, clinical studies, 61:19
 Carotene and Retinol Efficacy Trial, 61:19
 Cartilage-forming tumors, chromosomal aberrations, 69:84–85
 Cartilage link proteins, 71:245
CAS1 in Ras-cAMP pathway, 54:110
 Case-control studies, lung tumors in humans, 67:102–104
 Casein kinase, phosphorylation of p53, 66:79, 167–168
 Casein kinase II
 breast cancer, p53 expression in, 59:72
 c-Myc as substrate, 70:113
 G protein signal transduction and, 58:78–80
 muscle cell regulation and, 58:112
 myc family oncogenes and, 57:11–12
 Castration, prostatic cancer and, 51:2, 83
CAT, Epstein–Barr virus genes and, 58:6–7, 15
 Catalase
 radiation protection by, 61:221
 Wilms' tumor and, 59:53
 Catalysis, Epstein–Barr virus proteins and, 50:146
 α -Catenin, expression in prostate cancer, 68:239
 β -Catenin, mutated product, 70:168–169
 β -Catenin gene, 71:69
CAT gene
 c-myc, regulation and, 56:15, 16, 25
 p53 and human malignancies and, 57:261–262
 Cathepsin D, TGF and, 51:129
 Cathespin
 lysosomes and, 60:271–277, 279–281, 286
 stroma and, 50:162
 Cat tumors, IAP gene family and, 51:259
c-Bcr protein, leukemia and, 57:165
 C2C12 cells, myogenesis inhibition by okadaic acid, 61:167
 C cells
 developmental role of *ret*, 70:207–209
 tumors derived from, 70:181–188
 CD antigens
 CD1
 B cell-associated surface molecules and, 52:133
 CD2
 B cell-associated surface molecules and, 52:85, 133, 134
 humoral immune response and, 62:254–255
 Src family of tyrosine protein kinases and, 57:120, 130–131
 T-cell receptors and, 56:52, 58–62
 CD3
 ataxia-telangiectasia genes and, 56:91, 92
 B cell-associated surface molecules and, 52:88, 133
 cytotoxic T lymphocytes and, 58:155
 gene rearrangements and
 hematological neoplasias, 52:60–63, 67
 T cell antigen receptor, 52:50, 52
 Raf-1 phosphorylation and, 58:59
 Src family of tyrosine protein kinases and, 57:119–120, 123–131
 T-cell receptors and, 56:51, 54–62, 65
 CD4, 51:321–322, 322–323, 345, 350–351
 ADF and, 57:382
 in AIDS-NHL, 67:121–122
 antibody, 51:321–322
 antigen, 51:322–323, 345, 350–351
 ataxia-telangiectasia genes and, 56:84
 B cell-associated surface molecules and, 52:85, 88, 108
 cancer immunotherapy and, 59:248–249, 291
 cytotoxic T lymphocytes and, 58:167
 clinical results of adoptive therapy, 58:164–166
 escapes of tumor cells from immune T cells, 58:161–162
 immunogenicity of tumors, 58:146, 153
 virus-induced tumors, 58:154–157
 decreased, and lymphoma development, 67:139–142
 in EBV⁺ AIDS-NHL, 67:127–130
 EBV-associated disorders and, 57:338, 341
 gene rearrangements and
 hematological neoplasias, 52:60, 61, 63
 T cell antigen receptor, 52:49, 51
 humoral immune response and, 62:250–251

- CD antigens (*continued*)
 Raf-1 phosphorylation and, 58:58, 67
 Src family of tyrosine protein kinases and, 57:137
 patterns of expression, 57:113, 120
 T-cell activation, 57:120–126, 128–129, 131
 T-cell receptors and, 56:52–58, 66, 69
 tumor rejection antigens and, 58:180, 207
- CD5
 B cell-associated surface molecules and, 52:88, 132, 133
 humoral immune response and, 62:254
- CD8
 ataxia-telangiectasia genes and, 56:84
 B cell-associated surface molecules and, 52:85
 cancer immunotherapy and, 59: 248–249, 291–292
 cytotoxic T lymphocytes and, 58: 166–168
 clinical results of adoptive therapy, 58: 164–166
 escapes of tumor cells from immunel T cells, 58:160–162
 immunogenicity of tumors, 58:146, 152–154
 virus-induced tumors, 58:154–159
- EBV-associated disorders and, 57:338, 341
 gene arrangements and
 hematological neoplasias, 52:60, 63
 T cell antigen receptor, 52:49, 51
 Src family of tyrosine protein kinases and
 patterns of expression, 57:113, 119–120
 T-cell activation, 57:120, 125–127, 129
 T-cell receptors and, 56:52–58, 66
 tumor rejection antigens and, 58:180, 207
- CD10, B cell-associated surface molecules and, 52:100, 116–118
- CD18, B cell-associated surface molecules and, 52:85
- CD19, 52:91, 97, 99–102, 116, 124, 135
- CD20, 52:91–99, 102, 103, 110, 114, 124, 135
 activation, 52:91–99
- CD21, 52:85, 102–104, 131
 B lymphocytes and, 56:317
 Epstein–Barr virus and, 62:196–197, 216–217
 Epstein–Barr virus genes and, 58:6–7
 humoral immune response and, 62:258
- CD22, 52:91, 97, 105–108
- CD23, 52:85, 108–112, 114, 121
 ADF and, 57:403–404
 B lymphocytes and, 56:321–324, 328, 331
 EBV-associated disorders and, 57:331, 358, 360, 364
 Epstein–Barr virus genes and, 58:6, 8
 expression on activated cells, 52:128, 131
 humoral immune response and, 62:258
- CD24 molecules, 52:118, 119
- CD25, EBV-associated disorders and, 57: 340
- CD28, humoral immune response and, 62: 253
- CD36, macrophage surface receptor, apoptosis, 71:124
- CD37, 52:97, 119, 120, 123
- CD39, 52:97, 116, 120, 121
- CD40, humoral immune response and, 62: 251–252, 258
- CD44, 71:137, 242, 243, 305–307
 apoptosis and, 71:283–284
 cancer, 71:243, 287–288, 291
 bladder cancer, 71:298–299
 breast cancer, 71:301–302
 cervical carcinoma, 71:299–300
 chronic myeloid leukemia, 71: 303–304
 colorectal cancer, 71:295–296
 head and neck tumors, 71:293–294
 liver cancer, 71:298
 lung carcinoma, 71:294
 malignant process, 71:245, 287–291, 304–305
 melanoma, 71:302
 mesothelioma, 71:295
 nasopharyngeal carcinoma, 71:294
 nervous system tumors, 71:291–293
 non-Hodgkin lymphoma, 71:303–304
 ovarian cancer, 71:300–301
 pancreatic cancer, 71:297–298
 prostate cancer, 71:299
 stomach cancer, 71:296–297
 thyroid carcinoma, 71:294

- cytoplasmic tail, 71:250, 252–253, 264–267
- expression
 in embryo, 71:253–255
 in epithelial cells, 71:255–257
 genetic control of, 71:275
 isoforms, 71:257–259
- functions, 71:275, 306
 cell aggregation, 71:282–283
 cell binding to endothelium, 71:278–279
 cell traffic, 71:280–282
 cytokine and growth factor presentation, 71:284–285
 growth signal transmission, 71:275–277
 HIV infection and, 71:287
 homing receptor, 71:277–278
 hyaluronic internalization and degradation, 71:279–280
 lymphohematopoiesis and apoptosis, 71:283–284
 malaria resistance, 71:286
 menstrual cycle, 71:285–286
 rheumatoid arthritis and, 71:286–287
 wound healing, 71:285
- genomic organization, 71:247, 249, 250
 glycosylation, 71:270–272
 hyaluronic acid, 71:243, 259–272, 281–282
- isoforms, 71:242–243, 246, 250–252
 expression, 71:257–259
- ligands
 hyaluronic acid, 71:243, 259–272, 281–282
 non-HA, 71:272–274, 307
 nomenclature, 71:245–246
 soluble CD44, 71:274–275
 standard CD44, 71:247, 250
 T-cell receptors and, 56:70
- CD44E, 71:242–243, 251
 CD44H, 71:242, 262
 CD44s, 71:242, 247, 250, 255, 262, 264, 285
 CD44v, 71:251, 253, 255
 CD44V3–10, 71:243, 251, 256
 CD44V4–7, 71:251, 252, 262, 290
 CD44V5, 71:296
 CD44V6–7, 71:251
 CD44V8–10, 71:251, 256, 262
- CD45
 humoral immune response and, 62:245–247
 Src family of tyrosine protein kinases and, 57:131
- CD77
 expressed by Burkitt's lymphoma cells, 72:11
 CD95, apoptosis and, 71:129
 CDw40, 52:112–115
- Cdc2–Cdc13 complex, 69:42, 44
 Cdc2–Cig1 complex, 69:42
 Cdc2–cyclin B complex, 69:42
 Cdc2 kinase, 69:39
 breast cancer *p53* expression, 59:72
 complex with cyclin B, 66:185–187
 muscle cell regulation and, 58:112
 phosphorylation of human *p53*, 66:79
- CDC6, 69:47–48
 CDC10 protein, start control for mitotic cycle, 69:23–25
 Cdc28 kinase, in budding yeast, 66:204
- CDC42
 candidate effectors, 72:86–91
 constitutively activated, 72:79, 82–85
 effect on actin cytoskeleton, 72:82–83
 CDC42/Rac/interactive/binding motif, 72:87, 89–90
- cdc* genes
cdc2
 inhibition by phosphorylation, 71:173
 mammalian cell cycle and, 71:168
 phosphorylation, 71:172
cdc2⁺
 cell cycle start control, 69:21
 DNA synthesis, 69:28
 mitotic start control, 69:40, 50
cdc6, cell cycle start control, 69:32
cdc10⁺
 cell cycle start control, 69:18
 DNA synthesis, 69:28
cdc13⁺, mitotic start control, 69:40
cdc18⁺, cell cycle start control, 69:21, 23, 29, 47
cdc22⁺, start control of mitotic cycle, 69:23, 29
cdc25, in Ras-cAMP pathway, 54:108–110
cdc25⁺, mitotic start control, 69:41, 45
cdc25A, cell cycle start control, 69:33
cdc25B, mitotic start control, 69:50–51
cdc25C, mitotic start control, 69:51

- cdc* genes (*continued*)
 oncoprotein kinases and, 57:186–187
- CDI
 p21, 66:201
 in yeast and mammalian cells, 66:191–193
- cdk*, *see* Cyclin-dependent kinase
- cdk2* gene, cell cycle start control, 69:31, 34, 35
- cdk4* gene, cell cycle start control, 69:31–32, 34, 35, 38
- cdk5* gene, cell cycle start control, 69:32–33, 35
- cdk6* gene, cell cycle start control, 69:35
- cdk7/MO15* gene, cell cycle start control, 69:32
- cdk42* gene, overexpression in cancer, 71:196
- cdk*-activating kinase, 71:5, 172
- cdki*, *see* Cyclin-dependent kinase inhibitors
- Cdk inhibitors
 genes p15 and p16, role in solid tumors, 72:158–163
 as negative regulatory proteins, 72:130–132
- CDKN2*, *see* p16
- cdr1⁺/nim1⁺* gene, mitotic start control, 69:41
- cds1⁺* gene, mitotic start control, 69:42, 46, 47
- CDw40, B cell-associated surface molecules and, 52:134, 135
 biochemically defined molecules, 52:123
 differentiation antigens, 52:97, 112–116
 expression on activated cells, 52:128
- Cecum, Louvain rat immunocytomas and, 50:283, 305
- CED-3*, apoptosis and, 71:130
- CED-4*, apoptosis and, 71:130
- c-eltk*, soft tissue tumors and, 60:95
- Cell activation, and FcγR expression, 64:224–225
- Cell adhesion molecules, 71:243–245
 cancer immunotherapy and, 59:259
 EBV-associated disorders and, 57:330, 340, 358, 361
 EBV immune evasion, 69:225–226
- ICAM
 Burkitt's lymphoma and, 55:240
 humoral immune response and, 62:248, 254–255
- ICAM-1, 71:244, 263
 cancer immunotherapy and, 59:253, 285
- EBV-associated disorders and, 57:331, 334, 340, 358, 361
- Epstein–Barr virus genes and, 58:8, 20
- Src family of tyrosine protein kinases and, 57:134–135
- identification, 70:12
- NCAM, 71:244, 251
- transforming growth factor-α and, 58:37
- VCAM-1, 71:244
- Cell aggregation, CD44 and, 71:282–283
- Cell–cell recognition, 66:43
- Cell culture
 development, historical origins, 65:143–144
 food, 70:9
 foundations, 70:5
 Louvain rat immunocytomas and, 50:293
- systems
 for cloning and differentiation, 66:3–6
 feeder layers in, 66:21
 in study of neoplastic transformation, 66:122
- Cell cycle
 checkpoint control, tumor suppressor gene role, 72:6–8
- checkpoints, 68:68–69
 control in G₁ by p53, 66:145, 148–149
 description, 66:182–183
- control point, B-*myb* transcription as, 72:122–123
- endogenous growth inhibitors and, 57:444–448
- G1 arrest
 p53 gene, 71:2–7, 10
 role of p53, 66:86–90, 97
 and tumor cell growth suppression, 66:144–145
- G1–S and G2–M phase transitions, 71:2
- G1–S phase, associated cyclins, 66:199–201
- G2, c-Myc role, 70:117
- G2–M defect, 71:11
- genes governing, 72:40–41
- G phase
 B lymphocytes and, 56:317–319, 329
- G protein signal transduction and, 58:77, 80
- oncoprotein kinases and, 57:185–186, 214–216
- protooncoprotein tyrosine kinases and, 57:200, 204, 206

- machinery of cancer cells, 61:59
 M phase, oncoprotein kinases and, 57:
 187–188, 213–216
 c-Mos, 57:207–211
 phosphatases, 57:211–213
 protooncoprotein tyrosine kinases, 57:
 195, 199–207
 phases, 68:192
 progression
 inhibition by p110^{RBL}, 61:129
 and RB phosphorylation, 64:74
 radiation survival response and, 61:
 223–224
 regulated phosphorylation of RB, 64:
 32–48
 regulation, 71:2
 ATM, 71:10–16
 cancer and, 71:16–17, 17–19, 195–198
 c-Myc, 68:131, 136–138
 cyclin D1, 68:82
 cyclin-dependent kinases, 68:69–70, 194;
 71:165–168
 downstream effectors, 71:179–184
 G1 and S phases, 71:169–179
 in mammals, 71:168–169
 epidermal growth factor, 68:193–194
 fission yeast
 control genes, 69:18–23
 meiotic cycle, 69:28–31
 mitotic cycle, 69:23–28
 G1 arrest, 71:2–7
 hyperphosphorylation effects, 61:162
 insulin-like growth factor I, 68:192–194
 mammals, 68:68–70
 control genes, 69:31–34
 DNA damage-responsive checkpoint
 control, 69:38–40
 start control, 69:34–38
 p53, 68:134–135, 148
 p53 gene, 66:143–180; 71:2–9
 platelet-derived growth factor, 68:
 192–194
 retinoblastoma protein, 68:95
 TGF- β activity and, 71:167, 188–195
 transition points, 71:170
 S phase
 cyclins, 66:201–203
 G protein signal transduction and, 58:
 77, 80
 oncoprotein kinases and, 57:185, 187,
 197, 200, 216
 stage, and B-*myb* transcription, 72:
 116–117
 Cell cycle genes, CDE and CHR, 72:120–121
 Cell death, *see also* Apoptosis
 necrosis, 71:123
 p53 and, 71:1–19
 of tumor cells, 71:17–18
 Cell death pathway, defects, 72:213
 Cell differentiation, modulation in cancer
 therapy, 61:59
 Cell-free system, integrative recombination
 in, 66:326–328
 Cell fusion, suppression of malignancy by,
 57:439–440
 Cell fusion products, short-term analysis of,
 54:64–67
 with heterokaryons, 54:64–67
 with reconstructed cells, 54:67
 Cell growth, *see* Cell proliferation
 Cell lineages
 hematopoietic, 66:29
 myeloid, 66:3–6
 myeloid and hematopoietic, 66:216–217
 Cell lines, *see also specific cell lines*
 32D, differentiation, role of PKC, 64:
 178–179
 BHK21, 66:336–338
 BL/VL3, 66:296
 and cell strains, development, 70:8–9
 c-Myc-induced apoptosis, 70:130–131
 epithelial outgrowth and TM, 66:123–125
 immortalized, and tumor cells, *flt-1*
 mRNA, 67:308
 Jijoye, Burkitt's lymphoma-derived, 67:
 220–221
 lymphoblastoid
 EBV ebotypes in, 67:231–234
 with EBV latency III, 67:202–210
 EBV-transformed, 67:226–231
 Epstein–Barr virus and, 62:181–183,
 218
 M1 myeloid leukemia, IL-6 effect, 72:129
 NIH 3T3
 Flt-overexpressing, 67:303
 transfection, 70:203
 RIE1, transformational studies, 72:67–68
 tumor-derived, and elevated c-Src kinase,
 64:117
 tumor-infiltrating lymphocytes, 70:
 151–152
 Cell loss, accompanying proliferation, 70:35

- Cell-mediated immunity, breast cancer and autologous, 56:110–112
 glycoprotein, 56:55, 112, 113
 invasive, 56:115–117
 prognosis, 56:113–115
 specific immunity, 56:107, 109, 119–123
 therapeutic implications, 56:123, 124, 126, 127
- Cell migration
 CD44 and, 71:280–282
 plasminogen activation, 69:114–116
- Cell motility, CD44 and, 71:282
- Cell proliferation, 71:131
 arrest, preventive role of E6, 64:16
 as cancer risk factor, 71:222–224
 carcinogen effect, 70:29–30
 and cell loss, sequence, 70:41
c-myc control, 70:95–134
 hepatocyte, 70:33–36
 inhibition in culture, 64:31–32
 regulation, 64:5–7
 requirement for B-Myb, 72:127–132
 role of p53, 66:87–88
 TGF- β dual effects, 70:70–72
 T lymphocytes, 71:194–195
 and tumor suppressor genes, 64:6
- Cell selection, tumor promoters and, 51:162
- Cell size, onset of mitosis, 69:49
- Cell surface glycoconjugates, gastrointestinal diseases and, 50:17
- Cell transformation *in vitro*, by okadaic acid class compounds, 61:157–158
- Cellular differentiation, TGF and, 51:135
- Cellular heterogeneity, in tumor progression, 72:187–189
- Cellular immortalization, genetic and molecular studies of, 54:63–75
- Cellular metabolism, TGF and, 51:135–136
- Cellular radiation survival, *see* Radiation survival
- Center for the Study of Human Polymorphisms, 56:90, 92–95
- Central nervous system
 Burkitt's lymphoma and, 55:143, 149
c-fos protooncogene and, 55:41
 EBV-associated disorders and, 57:349–350
 effects of MuLV spongiform polioencephalopathy, analysis by induction into wild mice, 65:184–185
 fibroblast growth factors and, 59:144
 growth regulation and, 57:420
 metastatic cancer cells and, 55:108
myc family oncogenes and, 57:13, 15
 tumor oncogenesis, 58:121–122
 gene alterations, 58:132–137
 histopathology, 58:122–123, 129–132
 molecular genetic analysis, 58:123–128
 comparisons to histopathology, 58:129–132
 implications for treatment, 58:137–139
 Zilber and, 59:9
- Centrioles, genomic instability and, 60:134
- Centromeres
 ataxia-telangiectasia genes and, 56:85, 92, 93, 96
 chromosome abnormalities and, 52:6
 gene rearrangements and, 52:55, 75
 genomic instability and, 60:134–135
 metastatic cancer cells and, 55:95
 recombinations in CAD gene amplification, 61:99
 Wilms' tumor and, 59:54
- Centrosomes
 nucleating ability, 66:203
 oncoprotein kinases and, 57:188, 190, 201
- Ceramide, glycosylation in tumors and, 52:301, 302
- c-erbA*, 59:89–90, 108–109
 avian erythroblastosis virus, 59:90–93
 function, 59:105–106
 mutations, 59:106–108
 gene expression, 59:104–105
 hepatocellular carcinoma and, 59:204
 multiple loci, 59:94–96
 mutations, biological activity, 59:102–104
 protein function, 59:97–98
 competition, 59:101–102
 DNA binding, 59:98–99
 hormone binding, 59:98
 transcription factors, 59:99–101
 structure, 59:96–97
 thyroid hormone receptor, 59:93–94
- c-erbB-2*, soft tissue tumors and, 60:104–105
- Cerebellum
 ataxia-telangiectasia genes and, 56:80, 82, 83
 IAP gene expression in mouse somatic cells, 51:228–230
- Cerebral tumors, cholecystokinin expression, 63:327
- Ceruloplasmin, 69:144

- Cervical dysplasia, 69:179
- Cervical intraepithelial neoplasia, 69:176, 179–180, 182
- Cervical neoplasia
epidemiology, 69:176–177
HLA expression, 69:190–193
- Cervical secretions, HIV and, 51:336
- Cervix
carcinoma of
CD44 and, 71:299–300
chromosome 3 losses in, 71:49–50
cytotoxic T lymphocytes and, 58:157
development, role of pRB activity loss, 64:7
E6 and E7 expression, 64:18
epidemiology, 68:6, 10–11
FRA3B fragile region, 71:71
herpesvirus role, 68:6–8, 13
HPV-positive, and somatic *p53* mutations, 64:14
human papillomavirus and, 56:151, 153–155; 71:71, 321–335
incidence of, 56:172, 180–185, 211
malignant conversion of warts, 68:7
MHC Class I expression and, 60:204, 224
papillomavirus role, 68:8–11
progression of, from *in situ* to invasive, 54:164
prostatic cancer and, 51:67
relation to HPV, 64:1–3
chemical carcinogenesis and, 50:29
histology, 69:179
newborn macrosomy and, 50:239, 267, 268
stroma and, 50:177
tumor clonality and, 50:217, 225
- c-fgr*, tyrosine protein kinases and, 57:105, 112–114
- c-fos*, 53:18–20; *see also fos* gene
adenovirus E1A proteins and, 57:54, 64, 68
altered MHC expression and, 53:202–203
in angiogenesis, 69:148
down-regulation, 64:263
FGF receptor multigene family and, 60:31
G protein signal transduction and, 58:79
MHC Class I expression and, 60:200–201, 219
regulation and, 56:7
relation to MHC class I expression, 67:178
role in epidermal carcinogenesis, 64:258–259
transcription and, 55:37, 38, 50, 51
cell growth, 55:40–42
DNA binding, 55:42, 43, 46–48
gene expression, 55:38–40
jun, 55:43–45
protein complexes, 55:49
TRE, 55:45, 46, 49, 50
tyrosine protein kinases and, 57:139
- c-Fos protein, *myc* family oncogenes and, 57:8–10
- c-fps* oncogene, angiogenesis, 69:148
- CFS, *see* Colony-stimulating factors
- CGH, *see* Comparative genomic hybridization
- Chain terminator, ara-C role, 72:206–207
- Chalones, endogenous growth inhibitors and, 57:414, 435, 441–443, 445, 448
growth regulation, 57:420, 423
hemoregulatory inhibitory peptide, 57:433–434
keratinizing cells, 57:433
- Chaperones, heat shock proteins as, 67:163–164
- Chaperonins, peptide-binding heat shock proteins and, 62:170–171
- C-Ha-*ras*, *c-myc* regulation and, 56:26
- Checkpoint control, cell cycle, 69:38–40, 44–49
- Chediak-Higashi syndrome, Epstein-Barr virus proteins and, 50:100
- Chelerythrine chloride, PKC-specific inhibitor, 64:167
- Chemical carcinogenesis, 50:25, 26, 59, 60
biological concepts
genetic changes, 50:36–38
multistage tumor development, 50:33–35
tumor clonality, 50:35, 36
tumor promotion, 50:38, 39
biomonitoring, 50:54–58
experimental models
animal, 50:26–30
cell culture, 50:30–33
mechanisms, cellular basis for tumor promotion, 50:49–51
DNA interactions, 50:41–45
metabolism, 50:39–41
oncogene activation, 50:45–48
phenotype of initiated cells, 50:48, 49

- Chemical carcinogenesis (*continued*)
 phorbol ester tumor promotion, 50:51–54
 transgenic mice, 50:58, 59
- Chemical carcinogens
 detoxification, enzymes involved, 65:
 74–75
 effects of, on DNA methylation, 54:11–13
 exogenous sources, 65:23–28
 growth-inhibitory activity in rats, 65:
 49–50
 prostatic cancer and, 51:80–82, *see also*
specific carcinogens
 tumor rejection antigens and, 58:178
- Chemically induced tumors, cytotoxic T
 lymphocytes and, 58:148–149, 152, 161
- Chemoimmunotherapy, cancer, 59:274–281
- Chemokines, CD44 and, 71:284–285
- Chemoprevention Program
 NSAID clinical trials, 61:7
 research strategies, 61:2–3
- Chemotaxis
 FGF receptor multigene family and, 60:34
 immunosuppression and, 60:249, 252
 protein tyrosine kinase GFRs and, 60:54
- Chemotherapy
 α -fetoprotein and, 56:280, 286, 287, 293,
 300
 alkylating agent cytotoxic activity, BCNU
 incorporation in analysis, 65:79
 angiogenesis targeted, 69:160–161, 162
 and apoptosis induction, 66:16, 18–20
 cancer immunotherapy and, 59:247
 chemoimmunotherapy, 59:274–277,
 281
 critical factors, 59:249–250, 254–255
 current strategies, 59:260–261, 264,
 269
 immunomodulatory effects, 59:277–278
 immunosuppression, 59:280
 improvement attempts, 59:284–287
 suppressor cells, 59:278–280
 chemical carcinogenesis and, 50:45, 55
 disseminated intravascular coagulation, 69:
 120
 genomic instability and, 60:131, 145
 hepatitis B viruses and, 59:173
 immunosuppression and, 60:248
 multidrug resistance gene and, 60:
 157–158, 166–170, 174
 soft tissue tumors and, 60:104–105
 and mutations of oncogenes, 65:78–79
 prostatic cancer and, 51:2
 reverse transformation and, 62:145
 Wilms' tumor and, 59:43, 60, 62
- Chick embryo, studies by Aristotle, 66:42
- Chicken sarcoma, viral etiology, 68:1
- Childhood cancers, 67:1–2
 incidence of
 age profiles, 56:162, 163, 165, 167, 174
 two-stage model, 56:193, 194
- Chimeras
 AML1–ETO protein, 67:38–39
 E2A–HLF, 67:48–50
 E2A–PBX1, 67:32–34
 EGFR–*ret*, 70:205–207
 embryonic stem cell, 64:135–140
 radiation, 66:46
 tumor clonality and
 animal tumors, 50:217–219
 distinction, 50:202, 207, 211
 origin, 50:199
- Chimeric genes
 BCR gene in leukemia and, 57:228–229
 DSRCT, 69:82
 liposarcomas, 69:74
 rhabdomyosarcomas, 69:77
 synovial sarcomas, 69:79
- Chinese hamster ovary cells
 fibroblast growth factors and, 59:
 133–134, 136
 genome exposure and
 defect, 62:127, 129–131
 restoration, 62:132
 signal transduction, 62:140
 reverse transformation and, 62:126–127,
 143
 differentiation induction in malignant
 cells, 62:133–134
 DNase I sensitivity, 62:137–138
chk1⁺ gene, cell cycle start control, 69:49
chk1⁺/*rad27*⁺ gene, mitotic start control, 69:
 42
- Chloramphenicol acetyltransferase
 adenovirus E1A proteins and, 57:53–54,
 65
 ADF and, 57:387–388
c-erbA and, 59:100–101, 104
 fibroblast growth factors and, 59:129
 glutathione transferase and, 52:232
 MHC Class I expression and, 60:211–213,
 220
 multidrug resistance gene and, 60:170, 175

- Cholecystokinin
 biology
 normal
 cellular release, 63:311–314
 genes, 63:301–304
 mRNAs, 63:301–304
 procholecystokinin, post-translational processing, 63:309–312
 receptors, 63:314–316
 tumor
 bronchial tumors, 63:325
 cerebral tumors, 63:327
 gastrointestinal tumors, 63:324–325
 neuroendocrine tumors, 63:326–327
 definition, 63:296–298, 300–301
 function, 63:296
 future research, 63:336–337
 gene expression at peptide level, 63:312, 325
 identification, 63:295
 measurement
 methods, 63:333–336
 requirements, 63:331–333
 as tumor growth factor, 63:330–331
- Cholera toxin, G protein signal transduction and, 58:82–83
- Choleratoxin, metastatic cancer cells and, 55:116, 120
- Cholesterol, newborn macrosomy and, 50:242
- Chondroblastoma, chromosomal aberrations, 69:84
- Chondroitin sulfate, stroma and, 50:168
- Chondroma, chromosomal aberrations, 69:84, 89, 93
- Chondromyxoid fibroma, chromosomal aberrations, 69:84
- Chondrosarcoma
 chromosomal aberrations, 69:84–85, 90, 92
 soft tissue tumors and, 60:99–100
- CHOP* gene, liposarcomas, 69:74, 89
- Choriocarcinoma, MHC Class I expression and, 60:194
- Chromatidic telomere fusion model, integration with amplification regulation, 61:104–107
- Chromatids
 chemical carcinogenesis and, 50:53
 genomic instability and, 60:134, 138
 renal cell tumors, molecular cytogenetics, 62:98, 101
- Chromatin
 Burkitt's lymphoma and, 55:141
 B cell differentiation, 55:166, 168
 chromosomal translocations, 55:154, 203–205
c-myc, 55:159
c-myc expression, 55:192
 synthesis, 55:243, 246, 247
 translocation mechanism, 55:176
c-fos protooncogene and, 55:42
c-myc regulation and, Burkitt's lymphoma, 56:32, 35–40
 configuration of DNA sequences, 66:325
 Epstein–Barr virus proteins and, 50:104
 gene rearrangements and, 52:72
 gene topography, 56:7–9
 genome exposure and, 62:129–130, 132, 140–143
 Louvain rat immunocytomas and, 50:304, 306
 MHC Class I expression and, 60:217
 restructuring, 66:223–224
 reverse transformation and, 62:134–138, 143, 145–146
- Chromatin pattern, transcribed genes, 72:149–150
- Chromatography
 adenovirus E1A proteins and, 57:58, 68
 ADF and, 57:385
 α -fetoprotein and, 56:257, 267, 268, 273, 278
 high performance liquid, *see* High performance liquid chromatography
 plasminogen activation and, 57:280
 Raf-1 phosphorylation and, 58:62
- Chromophobe renal cell carcinoma, *see* Renal cell tumors, molecular cytogenetics
- Chromosomal aberrations, 52:2–4, 37, 38
 acute lymphoblastic leukemia, 52:18–22
 acute nonlymphocytic leukemia, 52:9–13
 antioncogenes, 52:30–34
 bone and soft tissue tumors, 69:64–93
 chronic myeloproliferative disorders, 52:16–18
 cytogenic data, 52:7–9
 cytogenic nomenclature, 52:4–7
 in leukemia, 63:73
 malignant lymphoma, 52:24–27

- Chromosomal aberrations (*continued*)
multiplicity in tumors, 72:26–30, 33–34
myelodysplastic syndromes, 52:13–16
oncogenes, 52:30, 31, 34–37
patterns of cytogenetic aberrations, 69:
89–91
Philadelphia chromosome, 69:64–65
in retinoblastoma tumor cells, 61:117
shared by several tumor types
involving 12q13–15, 69:88–89
involving 22q12, 69:89
numerical aberrations, 69:90, 91
ring chromosomes, 69:88
solid tumors, 52:27–30
- Chromosomal analyses, of breast cancer
cells, 61:39–40
- Chromosomal rearrangements, tumor-
specific, 61:60–61
- Chromosomal translocations, endemic
Burkitt's lymphoma and, 53:42–44
- Chromosome 1, q region, allele loss on, 61:45
- Chromosome 2, 72:12–13
- Chromosome 3
deletion analysis
bladder cancer, 71:52–53
breast cancer, 71:48–49
cervical carcinoma, 71:49–50
endometrial cancer, 71:50
gastrointestinal tumors, 71:47–48
head and neck squamous cell carcinoma,
71:45–47
in vitro studies, 71:53–54
lung cancer, 71:35–42
malignant melanoma, 71:52
malignant mesothelioma, 71:51
multiple endocrine neoplasia type 2, 71:
52
ovarian carcinoma, 71:50
renal cell carcinoma, 71:42–45
salivary gland adenoma, 71:52
skin cancers, 71:51
testicular germ cell tumors, 71:51
thyroid carcinoma, 71:52
uveal melanoma, 71:52
esophageal, 71:47–48, 115
evolutionary aspects, 71:73–74
microcell hybrids, 71:35
MSHZ mutation mapped to, 72:12–13
p13–p14 band, tumor suppressor genes
from, 71:70–73, 76
p14.2 band, 71:70–73, 76
p21.3 band, 71:56–58, 67–70, 75
tumor suppressor genes from, 71:56,
67–70, 75
p21 genes, 71:67
transfer into human tumor cell lines
lung adenocarcinoma, 71:55
ovarian cancer, 71:55
renal cell carcinoma, 71:54–55
transfer into human tumor cell lines oral
squamous cell carcinoma, 71:55
transfer into rodent lines, 71:56–58
tumor suppression, functional assay, 71:54–58
- Chromosome 6
Kras2 locus, 67:97–102
Pas1 locus, 67:97–102, 105
- Chromosome 7, q region, allele loss on, 61:45
- Chromosome 8
p region, loss of heterozygosity in prostate
cancer, 68:235–236
q24 translocations, 67:132–134
- Chromosome 9, NBCCS region, 70:53–56
- Chromosome 11
p region
allele loss on, 61:45
CpG island methylation, 72:153
- q13
amplification in breast cancer, 61:34–36
characterization of amplicons, 68:80–82
map, 68:73
markers, 68:81, 86
translocations
BCL1 and cyclin D1, 68:75, 77
breast cancer, 68:82–85
esophageal cancer, 68:86–87
head and neck squamous cell
carcinoma, 68:85–86
hepatocellular carcinoma, 68:87
mantle cell lymphoma, 68:74, 77
- q23
abnormalities, 66:214–216; 67:36–38
breakpoint cluster region, 66:217–221
clinical considerations, 66:216–217
- Chromosome 12, q13, amplification and
cancer, 68:89–90
- Chromosome 13
esterase D gene on, 67:13–14
- q14
deletions in retinoblastoma, 54:30–31
retinoblastoma susceptibility gene
mapping, 61:117
q region, allele loss on, 61:43–44

- Chromosome 17
 H2 complex, 67:98–99
 p region
 allele loss on, 61:41–43
 loss of heterozygosity on, 66:111
 p53 expression in breast cancer, 59:77
 q region
 allele loss on, 61:44–45
 breast cancer susceptibility gene, 61:46
- Chromosome 18
 LOH on, 67:61–62
 q region, allele loss on, 61:45
- Chromosome breakage-acentric element
 model, of gene amplification, 61:100–102
- Chromosomes, 62:1, 14
 adenovirus E1A proteins and, 57:48, 53–54, 78
 α -fetoprotein and, 56:264, 296
 alteration pathways in human epithelial cancers, 67:59–78
 APC gene in human cancers and, 62:65–66, 76, 81–83
 ataxia-telangiectasia genes and, 56:96, 97, 99
 genetic linkage, 56:88–90, 92
 phenotype, 56:79, 81, 82, 84, 85
 banding, 62:7–10
 B cell-associated surface molecules and, 52:130, 131
 BCR gene in leukemia and, 57:232–235, 249, 252
 breast cancer, *p53* expression in, 59:70, 76–77
 Burkitt's lymphoma and, 55:135–137, 140–142
 B cell differentiation, 55:165–168
 clinical significance, 55:251
 c-myc expression, 55:186–192
 c-myc structural changes, 55:176, 177, 180–183, 185
 deregulation, 55:208, 215
 EBV, 55:230, 241, 242
 features, 55:145, 147, 149
 genetic abnormalities, 55:218, 220
 geography, 55:192–194
 nonrandom translocations, 55:154–157
 phenotype, 55:152
 synthesis, 55:242, 245–250
 translocation, 55:171–176, 195–208
 central nervous system tumor oncogenesis and, 58:124–126, 128–129, 131–134, 137–138
 c-erbA and, 59:89, 94
 changes, and tumor suppression, 66:24–28
 chemical carcinogenesis and, 50:33, 38, 53
 c-myc regulation and, 56:27–30, 32–35, 37, 40
 cytotoxic T lymphocytes and, 59:239
 early studies, 62:1–3
 EBV-associated disorders and, 57:335–336, 355, 364, 366, 372
 endogenous growth inhibitors and, 57:437, 439
 Epstein–Barr virus genes and, 58:2–3, 9, 17
 Epstein–Barr virus proteins and diseases, 50:98
 transformed cells, 50:104, 109, 110, 112, 113, 138
 FGF receptor multigene family and, 60:3
 fibroblast growth factors and, 59:115, 126, 150
 gene rearrangements and
 B cell antigen receptor, 52:49
 hematological neoplasias, 52:58, 64
 T-cell antigen receptor, 52:52, 53, 55
 T-cell receptor, 52:72–75
 genome exposure and, 62:130, 141
 genomic instability and, 60:121–127, 144, 147
 mechanisms, 60:131–141
 glutathione transferase and, 52:233
 hamster, 66:336–338
 hepatitis B viruses and, 59:169
 genetic alterations, 59:208–209
 viral DNA, 59:200, 203–204, 207
 jun oncogene and, 55:8, 9
 loss, and malignancy, 70:16
 loss of heterozygosity in murine and human lung tumors, 67:93–95
 Louvain rat immunocytomas and, 50:295–299, 301, 306
 mammalian cells, 66:2–3
 metastatic cancer cells and, 55:97, 103, 111, 113
 MHC Class I expression and, 60:185, 203, 230
 molecular cytogenetics, 62:10–14
 mouse retrotransposons and, 56:216

- Chromosomes (*continued*)
- insertion, 56:224–227
 - LTRs, 56:234, 236
 - mouse genome, 56:218, 219
 - multidrug resistance and, 52:176, 178
 - muscle cell regulation and, 58:107, 114
 - myc* family oncogenes and, 57:3, 24
 - oncoprotein kinases and, 57:200, 212
 - p53* and human malignancies and, 57:266–267
 - papillomaviruses and, 56:139, 148
 - Philadelphia, 62:5–6, 12, 91; 69:64–65; 71:144, 145, 147
 - abnormality in CML, 67:5, 10, 16
 - BCR* gene in leukemia and, 57:227–232, 243–244, 250–253
 - break point cloning, 67:32–33
 - chromosome abnormalities and, 52:2, 3, 16, 17, 21
 - p53* and human malignancies and, 57:267–268
 - tumor clonality and, 50:208, 209
 - plasminogen activation and, 57:287, 296, 298
 - prebanding era, 62:5–7
 - protein tyrosine kinase GFRs and, 60:51, 66
 - Raf-1 phosphorylation and, 58:53
 - rearranged, distribution in relation to ploidy, 67:69–71
 - renal cell tumors, molecular cytogenetics, 62:90, 118
 - chromophobe renal cell carcinoma, 62:117–118
 - differential genetics, 62:91–92
 - nonpapillary renal cell tumors, 62:91, 93–105
 - papillary renal cell tumors, 62:105–115
 - renal oncocytoma, 62:115–117
 - reverse transformation and, 62:136–138, 143, 145–146
 - soft tissue tumors and, 60:78
 - abnormalities, 60:89–100
 - cloning, 60:107–108
 - gene amplification, 60:104–105
 - predictors of behavior, 60:105
 - ras* gene, 60:87
 - susceptibility, 60:81, 84–85
 - tumor suppressor genes, 60:100–104
 - Src family of tyrosine protein kinases and, 57:133
 - stemline concept, 62:3–5
 - T-cell receptors and, 56:52, 59, 63
 - tumor clonality and
 - animal tumors, 50:219
 - distinction, 50:202, 203, 205–210
 - origin, 50:199
 - pleoclonal tumors, 50:215, 216
 - Wilms' tumor and, 59:41–42
 - 11p13, 59:47–49, 51–54, 61–62
 - 11p15, 59:49–53, 61
 - 17p, 59:47
 - functional studies, 59:61–63
 - genetic loci, 59:46–53
 - Knudson model, 59:44, 47
 - WT1* gene, 59:53–54
 - X, MAGE-1 on, 67:171
 - yeast artificial, 66:217–218
- Chromosome transfer
- chromosome 3, 71:54–55
 - mismatch repair, 71:55–56
- Chronic antigen stimulation, role in AIDS-SNCCCL pathogenesis, 67:123–124
- Chronic atrophic gastritis, gastrointestinal diseases and, 50:6, 19
- Chronic immune stimulation hypothesis, 51:298–299
- Chronic lymphoproliferative disorders, chromosome abnormalities and, 52:22–24
- Chronic mononucleosis, Epstein–Barr virus proteins and, 50:99
- Chronic myeloproliferative disorders, chromosome abnormalities and, 52:16–18, 22–24
- Chronic myelosis, chromosome abnormalities and, 52:13
- Chronic transforming viruses, 51:278, *see also* Murine leukemia virus antigens
- Chronic ulcerative colitis, gastrointestinal diseases and, 50:9, 16
- Chymotrypsin, Epstein–Barr virus proteins and, 50:131
- cig1*⁺ gene, cell cycle start control, 69:35
- cig2*⁺/*cyc17*⁺ gene, cell cycle start control, 69:22
- Cimetidine, cancer immunotherapy and, 59:256, 279, 289
- Circumcision, prostatic cancer and, 51:67
- Cirrhosis
 - hepatitis B viruses and, 59:170, 178–179, 182–183, 185
 - prostatic cancer and, 51:83

- Cis-acting regulatory sequences, in class I expression, 67:157–159
- Cis elements, *c-myc* regulation and, 56:13, 20, 25, 30
- Cisplatin
cancer immunotherapy and, 59:276–277
chemical carcinogenesis and, 50:45, 58
cotreatment of tumor cells with neu antibody and, 71:361–362
- Citron, Rho-binding element, 72:93–94
- c-jun*, 53:20; 55:43–46, 48–50
adenovirus E1A proteins and, 57:64
G protein signal transduction and, 58:79, 83
interaction with ara-C, 72:214
MHC Class I expression and, 60:200
okadaic acid-induced expression and transcription, 61:166
regulation and, 56:7
- c-Jun protein, *myc* family oncogenes and, 57:8
- c-kit*, protein tyrosine kinase GFRs and, 60:46, 51–56, 60
- Clark, William, studies by
Beth Israel Hospital and Harvard Medical School, 65:131–137
biologic forms of primary cutaneous melanoma, at Massachusetts General Hospital, 65:121–123
melanocytes, at Tulane University, 65:117–120
with the Pigmented Lesion Group, 65:126–131
Temple University, 65:123–126
tumor biology, in Maine, 65:115–117
- Classification
nuclear proteins, 67:26–27
pathological, AIDS-NHL, 67:115–116
- Class I regulatory element, role in determining class I expression, 67:159–160
- Cleavage
Epstein–Barr virus proteins and, 50:112, 131
plasminogen activation and, 57:274
directed cell surface, 57:302–303
proteolytic modulation, 57:284, 288–289, 296, 298
- Clinical implications, altered DNA methylation in cancer, 72:189–190
- Clinical trials
Breast Cancer Prevention Trial, 61:17
Carotene and Retinol Efficacy Trial, 61:19
cytokines in cancer immunotherapy, 59:276–277
dietary fat/fiber association with colon cancer, 61:18–19
Linixian esophageal cancer prevention trial, 61:19–20
list of chemoprevention trials, 61:14–15
medical setting, 61:13–17
NSAIDs, 61:7
public health setting, 61:17–20
recombinant TNF- α , 61:68
thymidine labeling index, 61:4
toxicologic and safety evaluations for, 61:7
- Clofibrate, induced hepatocyte phenotype, 70:28
- Clonal dominance
metastatic cancer cells and, 55:96–105
randomness and selection in metastasis and, 54:183, 186–187
- Clonal evolution, in tumor progression, 72:28–29
- Clonal expansion
hepatocyte, 70:25, 29, 32–35
and promoter hypermethylation, 72:187–188
role in multiple mutations, 72:34–35
- Clonality, *see* Tumor clonality
- Clonally derived cell lines, heterogeneity in radiation survival responses, 61:199–200
- Clonal origin, cancers, 70:2
- Clonal selection, multiple rounds, 72:27
- Clones
adenovirus E1A proteins and, 57:62–63
adenovirus proteins and, 52:158
ADF and, 57:385, 402–403, 405
analyses, 57:392–395
biological activities, 57:399–400
ataxia-telangiectasia genes and, 56:83–86, 90, 95, 99
B cell-associated surface molecules and, 52:96, 97, 102, 104, 120
bcr/abl gene in leukemia and, 57:152–155, 157, 164
animal models, 57:174, 176–178
biological activity, 57:172–173
BCR gene in leukemia and, 57:228, 240, 252
B lymphocytes and, 56:316, 321

Clones (*continued*)

- breast cancer, *p53* expression in, 59:70
- Burkitt's lymphoma and, 55:135, 147, 148
 - B cell differentiation, 55:166, 167
 - chromosomal translocations, 55:196, 197, 203
 - c-myc*, 55:161, 177, 185, 190, 191
 - deregulation, 55:209, 210, 212, 213
 - EBV, 55:226, 227, 233, 234, 236
 - genetic abnormalities, 55:218
 - nonrandom chromosomal translocations, 55:154
 - phenotype, 55:150, 154
 - translocation mechanism, 55:172, 175
- cancer immunotherapy and, 59:248, 253, 255, 272–273, 291
- cancer incidence data and, 56:162, 164, 169, 171
- central nervous system tumor oncogenesis and, 58:121
- c-erbA* and, 59:90, 92–95, 97
- c-fos* protooncogene and, 55:37, 49
- chemical carcinogenesis and, 50:60
 - biological concepts, 50:35–38
 - experimental models, 50:31, 32
 - mechanisms, 50:48, 49, 51
 - transgenic mice, 50:59
- chromosome abnormalities and, 52:38
 - acute lymphoblastic leukemia, 52:18
 - acute nonlymphocytic leukemia, 52:9
 - cytogenic nomenclature, 52:7
 - myelodysplastic syndromes, 52:16
 - solid tumors, 52:29
- chromosomes and, 62:4, 6–10, 13
- c-myc* regulation and
 - Burkitt's lymphoma, 56:33, 34, 36
 - expression, 56:11, 15, 17
 - gene topography, 56:6
- cytotoxic T lymphocytes and, 59:229, 239
 - clinical results of adoptive therapy, 58:165
 - escapes of tumor cells from immune T cells, 58:162
 - immunogenicity of tumors, 58:146–147
 - melanoma antigens, 58:166–167
 - virus-induced tumors, 58:155–160
- D⁺ and D⁻, differentiation, 66:12–16
- EBV-associated disorders and, 57:335, 342, 353–355, 363, 365, 372–373
- Epstein–Barr virus and, 62:181, 186
 - Hodgkin's disease, 62:215–216
 - T-cell lymphoproliferation, 62:191, 195, 202, 210–211
- Epstein–Barr virus genes and, 58:10–12, 15, 18
- Epstein–Barr virus proteins and
 - biology, 50:96
 - genome, 50:102, 103
 - transformed cells, 50:104, 109, 117, 124, 126, 127, 129, 130, 133, 136, 137
- FGF receptor multigene family and, 60:2–3, 23–25
 - characterization, 60:8–9, 11
 - Drosophila*, 60:30–31
 - multiple forms, 60:18, 20, 23
- fibroblast growth factors and, 59:117, 119, 138
 - oncogenic potential, 59:145–146
 - receptors, 59:132, 134
- gastrointestinal diseases and, 50:17
- gene rearrangements and, 52:46
 - B cell antigen receptor, 52:48
 - hematological neoplasias, 52:57–59, 63, 64, 66, 68
 - simultaneous occurrence, 52:69, 70, 72
 - T cell antigen receptor, 52:49–52
- genomic instability and, 60:132, 136, 142–143
- glutathione transferase and, 52:216, 232, 233
- glycosylation in tumors and, 52:290, 312
- G protein signal transduction and, 58:75, 82, 86
- hepatitis B viruses and, 59:168
 - genomes, 59:185, 188
 - pathogenicity, 59:180, 184
 - viral DNA, 59:200–201, 204
- Herpesvirus saimiri* and, 56:343, 347
- humoral immune response and, 62:242, 256–258, 260
- jun* oncogene and, 55:3, 4, 7, 11
- Louvain rat immunocytomas and, 50:302
- lysophosphatidic acid and, 57:87
- mast cells and granulocytes, 66:4–6
- metastatic cancer cells and, 55:88, 121, 125
 - human malignant melanoma, 55:107, 110, 113
 - phenotype, 55:90, 95
- MHC Class I expression and cancer, 60:184, 188

- downmodulation, 60:222, 224, 228, 230
- modulation by oncogenes, 60:197–198, 200–201, 205
- regulation by oncogenes, 60:214, 218
- mouse retrotransposons and, 56:232
- insertion, 56:225, 226
- LTRs, 56:234, 235, 237, 239
- mouse genome, 56:218, 220, 221, 224
- multidrug resistance and, 52:185
- multidrug resistance gene and, 60:159–163
- muscle cell regulation and, 58:97
- myc* family oncogenes and, 57:21–22, 29, 35
- oncogenes and, 50:90
- p53* and human malignancies and, 57:258–259, 261–263
- papillomaviruses and, 56:134
 - bovine, 56:137
 - human, 56:142, 144, 145, 147, 151
- plasminogen activation and, 57:310
- Ras function and, 62:26–27, 32, 37
- renal cell tumors, molecular cytogenetics, 62:115, 117, 119
 - nonpapillary renal cell tumors, 62:97, 104
 - papillary renal cell tumors, 62:108, 113
- reverse transformation and, 62:132
- soft tissue tumors and, 60:78, 110
 - chromosomal abnormalities, 60:88, 91–92
 - gene amplification, 60:105
 - ras* gene, 60:87
 - susceptibility, 60:81, 84–85
 - translocation breakpoints, 60:107–109
 - tumor suppressor genes, 60:100, 103
- Src family of tyrosine protein kinases and, 57:105, 117, 125, 127, 131
- stroma and, 50:166
- T-cell receptors and, 56:52, 55, 59, 63, 66
 - antigens, 56:51
 - lymphocyte homing receptors, 56:68, 69
 - VLA family, 56:67
- transforming growth factor- α and, 58:28, 30
- tumor rejection antigens and autologous CTLs, 58:201–203, 205
 - P815, 58:197–199
 - tum-antigens, 58:183–191, 197
 - Wilms' tumor and, 59:44, 54, 61
- Cloning
 - 3LL carcinoma cells, 66:50–53
 - 11q23 breakpoint cluster region, 66:217–221
 - advances, 70:5–9
 - Cactus* gene, 66:282
 - genes encoding
 - I κ B proteins, 66:267–270
 - NF- κ B and I κ B, 66:256
 - genomic breakpoints, 66:228
 - normal hematopoietic cells, 66:3–6
- Clonogemc assay, for cellular response to radiation, 61:197
- c-met*
 - in AIDS–KS, 66:235–253
 - in KS carcinogenesis, 66:246–249
 - RNA expression, 67:273–274
- c-met* receptors
 - and scatter factor, 66:245–246
 - SF-activated, 67:258
- c-mos*
 - angiogenesis, 69:148
 - IAP element transposition in, 51:244–249
 - mouse retrotransposons and, 56:237
- c-Mos*, oncoprotein kinases and, 57:207–211
- cmyc*, see *myc* genes
- c-neu* genes, *myc* family oncogenes and, 57:28
- Coal tar
 - benzo[a]pyrene as carcinogenic agent in, 65:80
 - carcinogenicity, role of polycyclic aromatic hydrocarbons, 65:73
 - fluorescence pattern, 65:43
- Coffee, prostatic cancer and, 51:28, 36–37, 42–43
- Cohort data
 - cancer incidence and, 56:162, 210, 211
 - cervical cancer, 56:180–185
 - cutaneous melanoma, 56:175–178
 - lung cancer stages, 56:208
 - stomach cancer, 56:178–180
- Colchicine, multidrug resistance gene and, 60:158, 170
- Cold target inhibition assay, MuLV and, 51:288–289
- Collagen
 - CD44 binding to, 71:272–273
 - c-fos* protooncogene and, 55:42, 43
 - metastatic cancer cells and, 55:108
 - plasminogen activation and, 57:280–281, 283, 303

- Collagen (*continued*)
 stroma and
 alterations, 50:183–185
 basement membranes, 50:174, 175
 disorders, 50:179–182
 epithelium, 50:160–167, 169, 170
 glycoproteins, 50:171, 172
 TGF and, 51:137–138
- Collagenase
c-fos protooncogene and, 55:45
jun oncogene and, 55:7
 metastatic cancer cells and, 55:90, 96, 104, 110, 124
 plasminogen activation and, 57:290, 294
 stroma and
 alterations, 50:183
 basement membranes, 50:173, 175
 epithelium, 50:161–164
- Collagenolysis, stroma and, 50:186
 alterations, 50:183, 184
 basement membranes, 50:174
 epithelium, 50:162–165
- Colon
 age-related hypermethylation patterns, 72:179–180
 chemical carcinogenesis and, 50:29, 50
 gastrointestinal diseases and, 50:9–13
 modulators, 50:13–15
 normal, 50:7–9
 stomach, 50:4, 6
 newborn macrosomy and, 50:264
 stroma and, 50:168, 182
 tumor clonality and, 50:222, 225
- Colon cancer
 chromosomes and, 62:13
 correlation with prostatic cancer, 51:18–19
 cytotoxic T lymphocytes and, 59:238
 development, 70:38–39
 dietary factors, 51:27–28; 61:5–6, 18–19
 elevated pp60^{c-src}, 64:115
 genomic instability and, 60:126
 geographic variations in, 51:18–19
 immunotherapy and, 59:252
 chemoimmunotherapy, 59:276–277, 280
 current strategies, 59:256, 264–265
 incidence of, 56:168, 169
 life-style and, 51:27
 lysosomes and, 60:273
 MHC Class I expression and, 60:194
 downmodulation, 60:223–224, 227
 modulation by oncogenes, 60:201, 203–204, 206
 regulation by oncogenes, 60:217
 multidrug resistance gene and, 60:171, 174
p53 expression in, 59:75, 80, 82
 pathogenesis, cell genetic changes, 61:3–5
 and PKC substrate changes, 64:195–196
 plasminogen activation and, 69:114
 role of oncogenes and tumor suppressor genes, 65:35
 soft tissue tumors and, 60:80–81, 101, 109
 tumor cell invasion, 69:111
- Colon carcinoma, *see also* Colon cancer, Hereditary nonpolyposis colon cancer
 DNA-methyltransferase transcript levels, 72:170–171
 estrogen receptor gene hypermethylation, 72:165–166
- Colonic mucoprotein antigen,
 gastrointestinal diseases and, 50:16
- Colon-specific antigens, gastrointestinal diseases and, 50:16
- Colony-inhibition assay, polyoma virus
 TSTA and, 55:60, 61
- Colony-stimulating factor genes
 cloning, 63:52
 granulocyte–macrophage
 induced production, 63:74
 insertional mutagenesis, 63:75
 multi-colony-stimulating factors
 induced production, 63:74
 insertional mutagenesis, 63:75
- Colony-stimulating factor receptor, Raf-1
 phosphorylation and, 58:56, 67, 70
- Colony-stimulating factors, *see also specific type*
 apoptosis and, 71:133
 cancer immunotherapy and, 59:280, 286
 CSF-1
 G protein signal transduction and, 58:78
 protein tyrosine kinase GFRs and, 60:45, 49, 62
 receptor kinases, 68:24
 transforming growth factor- α and, 58:37
 discovery, 66:6–8
 immunosuppression and, 60:255–257, 261
 immunotherapy with, 61:69
 and leukemia development
 biological actions, 63:52–58

- characterization, 63:50–51, 82–83
- detection, 63:50
- differentiation commitment, 63:54–56, 83
- excess extrinsic levels, 63:82–84
- gene cloning, 63:52
- maturation induction, 63:54–55
- membrane receptors, 63:71–72
- myeloid leukemia initiation, 63:62–70
- myeloid leukemic cell proliferation, 63:60–62
- production by macrophages, 63:74
- study, 63:49–50
- macrophage production, stimulation by okadaic acid, 61:164
- multi, *see* Multi-colony-stimulating factors
- protection of abnormal cells from
 - apoptotic death, 63:83
- stimulation of myelopoiesis, 66:19–20
- as viability factors, 66:17
- Colorectal cancers
 - adenocarcinoma, cytogenetics, 67:61–68
 - anal canal cancer tumors, chromosome 3 losses in, 71:48
 - CD44 and, 71:295–296
 - cell turnover rates, 61:4
 - chromosome 3 losses in, 71:47
 - and dietary calcium and vitamin D, epidemiologic study, 61:6
 - etiology, 71:97
 - growth factor secretion and growth factor receptor expression by, 54:227–229
 - hereditary nonpolyposis colorectal cancer associated with, 71:95
 - HNPCC and, 71:96
 - immunosuppression and, 60:251
 - metastatic cancer cells and, 55:113, 114, 124
 - microsatellite instability, 71:100
 - mutations and, 71:113
 - newborn macrosomy and, 50:239, 258
 - noninvasive genetic screening, 61:4
 - plasminogen activators and, 69:112, 113
 - progression of, from in situ to invasive, 54:165
 - protective role for aspirin and NSAIDs, epidemiologic study, 61:6–7
 - reverse transformation and, 62:145
- Colorectal tumors
 - APC gene in human cancers and, 62:81–83
 - adenomas, 62:65–66, 76–77
 - polyposis, 62:70–72
 - somatic mutations, 62:74–79
 - gastrin expression, 63:318–321
 - molecular cytogenetics, 62:104
 - sequence of events, 72:15
- Common acute lymphoblastic leukemia
 - antigen, EBV-associated disorders and, 57:334
- Comparative genomic hybridization, chromosome loss detection, 68:234–235, 244–245
- Comparative mapping, human and murine chromosomal regions, 67:104
- Competence
 - establishment of, gene expression requirement for, 53:7–8
 - in mitogenic response to serum, 53:4
- Competence factors, *c-fos* protooncogene and, 55:41
- Competence genes, 53:2, 14–15
- Competition
 - c-erbA* and, 59:101–102
 - c-myc* regulation and, 56:17, 18
- Complement, activation and regulation of, CR2 in, 54:293–294
- Complementary DNA
 - adenovirus E1A proteins and, 57:58, 62, 74
 - ADF and, 57:385, 392–395
 - biological activities, 57:399–400
 - EBV, 57:403
 - lymphocyte activation, 57:405
 - α -fetoprotein and, 56:259, 262, 263
- B cell-associated surface molecules and, 52:134, 135
- biochemically defined molecules, 52:120, 121
- CD20, 52:96, 97
- CD21, 52:104
- CD22, 52:105, 106
- CD23, 52:109
- CDw40, 52:113, 115
- T cells, 52:133
- bcr/abl* gene in leukemia and, 57:155, 157, 164, 169, 177
- BCR* gene in leukemia and, 57:229, 232, 234, 240, 242
- B lymphocytes and, 56:316, 321, 323
- breast cancer, *p53* expression in, 59:76

- Complementary DNA (*continued*)
 central nervous system tumor oncogenesis
 and, 58:135–136
c-erbA and, 59:93, 100
c-fos protooncogene and, 55:49
c-myc regulation and, 56:4, 6
 cytotoxic T lymphocytes and, 58:163
 endogenous growth inhibitors and, 57:437
 Epstein–Barr virus and, 62:189
 Epstein–Barr virus genes and, 58:8, 10–12,
 16
 Epstein–Barr virus proteins and
 genome, 50:102, 103
 transformed cells, 50:124, 126, 127,
 129, 130, 136, 137
 FGF receptor multigene family and, 60:
 2–3, 7, 23, 30
 alternative splicing, 60:15, 25–26
 characterization, 60:8–9, 11
 multiple forms, 60:17–23
 fibroblast growth factors and, 59:117, 119
 oncogenic potential, 59:145–148
 receptors, 59:132–135
 tumors, 59:151–152
 gene rearrangements and, 52:50–52
 glutathione transferase and
 molecular forms, 52:216, 218, 222
 multidrug resistance, 52:242
 preneoplasia, 52:209, 223, 224, 231–233
 glycosylation in tumors and, 52:290
 hepatitis B viruses and, 59:189
 human papillomavirus and, 56:145
 immunosuppression and, 60:259
jun oncogene and, 55:9, 11
 libraries, differential screening of, growth
 factor-inducible mRNAs detected by,
 53:10–17
 MEKs, isolation, 63:103–104
 metastatic cancer cells and, 55:117
 MHC Class I expression and, 60:214
 mouse retrotransposons and, 56:220, 232,
 235, 236, 239
 multidrug resistance and, 52:197
 clinic, 52:193
 P-glycoprotein, 52:175, 176, 180, 184,
 185, 188, 191
 multidrug resistance gene and, 60:160,
 162, 175
 muscle cell regulation and, 58:97–100
p53 and human malignancies and, 57:
 258–259, 261, 265
 peptide-binding heat shock proteins and,
 62:159
 plasminogen activation and, 57:296, 298,
 310
 protein tyrosine kinase GFRs and, 60:
 46–47
 Ras function and, 62:27, 32, 38, 47
 reverse transformation and, 62:132
 signal transduction and, 55:289
 soft tissue tumors and, 60:100, 102, 108
 Src family of tyrosine protein kinases and
 patterns of expression, 57:114,
 117–118
 T-cell activation, 57:121, 127
 T-cell proliferation, 57:132–133
 T-cell receptors and, 56:52, 53, 59, 65, 68,
 70
 transforming growth factor- α and, 58:30,
 47
 Wilms' tumor and, 59:54
 Complementation
 ataxia-telangiectasia genes and, 56:97, 99
 genetic linkage, 56:87–89, 93, 94
 phenotype, 56:81–83
 human papillomavirus and, 56:145, 148
 Complement component C7, plasminogen
 binding, 69:106
 Complement-fixing antibodies, polyoma
 virus TSTA and, 55:62
 Complement receptor type 2
 in B-cell activation, 54:292–293
 binding of, C3dg and gp350/220 in, 54:
 285–286, 287, 288
 cDNA clones encoding, isolation and
 characterization of, 54:276–277
 cellular and tissue distribution of, 54:
 287–291
 in complement activation and regulation,
 54:293–294
 expression of, during B-cell development,
 activation and differentiation, 54:
 290–291
 functional properties of, 54:291–294
 identification and characterization of, 54:
 274–276
 in ligand internalization, 54:291–292
 ligands of, structure and function of, 54:
 284–286
 membrane-associated, expression of, in
 rodent cells, 54:280, 281
 in multigene family, 54:277–280

- recombinant, expression and analysis of, 54:280–283
- soluble forms of, expression of, in Baculovirus vector system, 54:281–283
- structure of, 54:276–283
- ConA protooncogenes, IAPs and, 51:229
- Concanavalin A
- α -fetoprotein and, 56:256, 266–268, 275, 278
- c-myc* regulation and, 56:20
- Concomitant immunity
- in host-parasite relationships, 54:319–329
- in parasitized mice, 54:320–327
- with *Leishmania major* infection, 54:323–325
- with *Schistosoma japonicum* infection, 54:325–326
- with *Schistosoma mansoni* infection, 54:325–326
- with *Taeniae taeniaeformis* infection, 54:320–322
- Condylomata acuminatum, *see* Genital warts
- Conflict of interest model, apoptosis, 70:134
- Conformation
- alteration, and *p53* activation, 66:168–170
- changes induced by κ B sites, 66:259–260, 265
- in DNA binding, 66:92
- and stability, *p53*, 66:101–103, 166–167
- Congenital fibrosarcomas, chromosomal aberrations, 69:66
- Connectin, stroma and, 50:172
- Connective tissue
- stroma and, 50:159, 160, 186
- alterations, 50:184
- disorders, 50:178, 180, 182
- epithelium, 50:168
- glycoproteins, 50:171
- TGF and, 51:134
- tumor clonality and, 50:198
- Connexin 37, octapeptide mutein of, 66:55–56
- Connexin 43, oncoprotein kinases and, 57:203
- Contact inhibition
- and density-dependent inhibition, 70:10–11
- transformation effects, 66:22
- Contamination, cell cultures by bacteria, 70:5
- Contiguous gene syndromes, Wilms' tumor and, 59:47
- Control genes, cell cycle start control fission yeast, 69:18–23
- mammals, 69:31–34
- Cooperative binding, adenovirus E1A proteins and, 57:57–59, 61
- Cornea
- neovascularization, *in vivo* assay, 67:264–266
- stroma and, 50:163
- Cornification, role for *fos*, 64:259, 263–264
- Cornified envelope, keratinocyte, formation, 70:79–80
- Corticosteroids, cancer immunotherapy and, 59:249, 262
- Cortisol, TGF and, 51:135
- COS cells, *c-erbA* and, 59:99
- Cosmid constructs, and integration reaction, 66:328
- Cosmids
- chromosome 9-specific, 70:54–55
- tumor rejection antigens and, 58:188, 190–191, 199
- cot* gene
- and acquisition of radiation-resistant phenotype, 61:212
- c-cot*, resistance to gamma-rays conferred by, 61:209
- Cotransfection
- c-erbA* and, 59:100–102, 106, 109
- c-myc* regulation and, 56:17
- hepatitis B viruses and, 59:198
- papillomaviruses and, 56:138, 140, 145, 150, 154
- Cottontail rabbit papillomavirus, 56:134, 138
- Covalent linkage, *see* Integration
- Covalently closed circular DNA, hepatitis B viruses and, 59:189, 191, 193
- Cowpox virus, 71:131
- Cp, Epstein-Barr virus genes and, 58:11–12, 14
- CpG islands
- 11p region, 72:153
- aberrant methylation in neoplasia, 72:177–186
- associated with gene 5' regulatory regions, 72:148–150
- DNA methylation and, 54:2–4
- hypermethylation

- CpG islands (*continued*)
 in fibroblasts, 72:175
 in neoplastic cells, 72:154–167
 protection in normal cells, 72:182–185
 unmethylated, 72:141–142
- CpG sites, breast cancer, *p53* expression in, 59:75, 80
- CPP32, 71:130
- CR1, Raf-1 phosphorylation and, 58:59–60
- CR2
 Epstein–Barr virus genes and, 58:3–4
 Raf-1 phosphorylation and, 58:59–60
- c-raf*
 leukemia and, 57:168
 MHC Class I expression and, 60:202
 tyrosine protein kinases and, 57:137
- c-raf1*, tyrosine protein kinases and, 57:124
- c-ras*, G protein signal transduction and, 58:78–79
- CRC, *see* Colorectal cancer
- CREB, *see* Cyclic AMP response element-binding protein
- c-rel*, derived *v-rel*, 66:260–262
- CrmA protein, cellular proliferation, 71:131
- Cross-linkage
 BCR gene in leukemia and, 57:244
 FcγRs, 64:218–220
 FGF receptor multigene family and, 60:6–7, 17–18
 Raf-1 phosphorylation and, 58:58, 67
 Src family of tyrosine protein kinases and, 57:122–127, 129–130, 134
- Cryostat section adherence technique, metastasis and, 51:364–365
- Crypt foci, aberrant, 70:39
- Cryptic determinants, self-peptides, 70:164–165
- Cryptorchidism, Wilms' tumor and, 59:48–49, 60
- CSF, *see* Colony-stimulating factors
- c-Src*, oncoprotein kinases and, 57:195, 198, 209
- c-src*, tyrosine protein kinases and, 57:104, 107–108, 111, 116–117
- CT26 cells, cytotoxic T lymphocytes and, 58:153
- C-terminal methyl esterification, in membrane localization of yeast Ras proteins, 54:99
- CTL, *see* Cytotoxic T cells
- CTNNB1* gene, 71:69
- CTP synthase, alterations, 72:212
- CUG codons
c-myc, 70:100
 fibroblast growth factors and, 59:119, 124, 131, 147
- Cutaneous lichen amyloidosis, with MEN IIA, 70:186–187
- CV1 cells, *c-erbA* and, 59:100–102
- Cybernetic models, growth regulation and, 57:420–421
- Cyclamate, chemical carcinogenesis and, 50:29
- Cyclic AMP
 adenovirus E1A proteins and, 57:61, 70
c-erbA and, 59:105
c-fos protooncogene and, 55:49, 50
 effect on RB phosphorylation, 64:47
 gastrointestinal diseases and, 50:8
 genome exposure and, 62:127, 132, 140, 142
 G protein signal transduction and, 58:82–84, 87
 growth regulation and, 57:417
 humoral immune response and, 62:253, 255
jun oncogene and, 55:9, 23
 lysophosphatidic acid and, 57:95–96
 MHC Class I expression and, 60:210
 multidrug resistance gene and, 60:170, 175
 oncoprotein kinases and, 57:203, 213
 plasminogen activation and, 57:280
 Ras function and, 62:25, 30
 reverse transformation and, 62:126–127, 134–137, 145
 signal transduction and
 mechanisms, 55:287–291, 296, 297
 plasma membrane receptor, 55:274, 277
 Src family of tyrosine protein kinases and, 57:108
- Cyclic AMP response element-binding protein
 adenovirus E1A proteins and, 57:55, 59, 61–66
 G protein signal transduction and, 58:80, 83
 muscle cell regulation and, 58:112
- Cyclin
 –cdk2 complex, 71:168–169
 E2F-p107 complex and, 71:183
 –cdk complexes
 balance of, 71:198
 cell cycle control, 71:166, 171
 p21 and, 71:174

- p21* gene and, 71:5–6
 - p27 and, 71:175, 178
 - ratio to *ckis*, 71:178
- oncprotein kinases and, 57:187–188, 195, 210–211
- transcription, regulation, 70:119–120
- Cyclin A, 71:169
 - cdk2* complex
 - formation, 71:172–173
 - inactive, 71:177
 - gene locus, 68:71–72
 - hepatocellular carcinoma and, 59:204–205
 - mitotic start control, 69:50
 - overexpression in cancer, 71:196
 - TGF- β and, 71:192
 - tumorvirus effects, 68:71
- Cyclin B
 - cdc2* complex, 66:205
 - mitotic start control, 69:50
- Cyclin binding, *cdk* activation by, 71:169–172
- Cyclin box consensus, 66:183
- Cyclin C, 71:170
- Cyclin–cyclin-dependent kinase complex, inhibition, 72:8
- Cyclin D, 71:170, 171
 - cdk2* complexes, *p21* and, 71:5
 - cdk4* complex
 - inactive, 71:177
 - p27 and, 71:193
 - phosphorylation by, 71:189
 - TGF- β and, 71:189
 - in differentiation, 66:198–199
 - and loss of *p16* gene, 72:159
 - as regulators of *Rb*, 66:197–198
- Cyclin D1
 - activation by retrovirus integration, 68:78–79
 - amplification in tumors, 68:71
 - bladder cancer, 68:88
 - breast cancer, 68:82–85
 - characterization of amplicon, 68:80–82
 - detection methods, 68:79–80, 85–86
 - esophageal cancer, 68:86–87
 - head and neck squamous cell carcinoma, 68:85–86
 - hepatocellular carcinoma, 68:87
 - lung cancer, 68:88
 - melanoma, 68:88
 - messenger RNA, 68:88–89
 - cell cycle regulation, 68:82
 - c-myc* targeting of gene, 68:136–137
 - gene locus, 68:71–72
 - gene synergism with *c-myc*, 68:157–158
 - identified as *PRAD1*, 66:196–197
 - immunoglobulin gene translocations, 68:72–75, 77
 - mantle cell lymphoma role and diagnosis, 68:77–78
 - overexpression in cancer, 71:196
 - rearrangement in parathyroid adenomas, 68:78
 - TGF- β and, 71:192
 - truncation of mRNA, 68:77
- Cyclin D1* gene, cell cycle start control, 69:32, 34
- Cyclin D2
 - activation by retrovirus integration, 68:78–79
 - amplification in tumors, 68:71
 - gene locus, 68:71–72
 - truncation of mRNA, 68:77
- Cyclin-dependent kinase
 - activation
 - by binding cyclins, 66:187–188
 - during cell cycle, 68:69–70, 194
 - by cyclin binding, 71:169–172
 - by phosphorylation, 71:5, 172–173
 - cancer and, 71:195–198
 - cdk2*, 71:169
 - inactivation, 71:193–194
 - inhibition by phosphorylation, 71:173
 - phosphorylation, 71:172
 - cdk4*, 71:170–171
 - inhibition by INK family *ckis*, 71:173
 - TGF- β and, 71:192–193
 - Cdk4* amplification and cancer, 68:89–91
 - cdk6*, 71:171
 - inhibition by INK family *ckis*, 71:173
 - TGF- β and, 71:192
 - cdk7*, 71:172
 - cell cycle control and, 71:165–168
 - downstream effectors, 71:179–184
 - G1 and S phases, 71:169–179
 - in mammals, 71:168–169
 - c-myc* targeting of genes, 68:137
 - critical role in cell cycle, 72:110
 - cyclin complexes
 - loss of *p21*, 66:157–158
 - modulation, 66:188–191
 - drug targeting, 68:96
 - G₁-specific, role of *PIC1*, 64:17

- Cyclin-dependent kinase (*continued*)
 gene loci, 68:71–72
 growth-promoting signals, 72:130–132
 inhibition
 INK family, 71:173–174
 p21, 71:174–175
 p27, 71:175–179, 189
 p57, 71:175–178
 by phosphorylation, 71:173
 phosphorylation and activation, 68:70
 RB as substrate, 64:33–34
 in regulation of cell growth, 64:5–6
 retinoblastoma protein as substrate, 68:
 95–96
 TGF- β activity and, 71:167, 188–195
 Cyclin-dependent kinase inhibitors, 68:70,
 91, 94; 71:165
 INK family, 71:173–174
 p21, 71:5, 174–175
 p27, 71:175–179, 189
 p57, 71:177, 178
 TGF- β and, 71:193–194
 tumor suppressor genes, 71:195
 Cyclin D family
 association with RB, 64:62–63, 68
 complex with pRB, 64:8, 10
Cyclin D gene, cell cycle start control, 69:32,
 34
 Cyclin E, 71:170, 171, 192
 expression during G1–S transition, 71:182
 overexpression in cancer, 71:196
 TGF- β and, 71:192
 Cyclin E-cdk2 complex
 formation, 71:172–173
 inactive, 71:174, 175, 177
 p21 and, 71:5
 Rb phosphorylation, 71:180
 TGF- β and, 71:192
 Cyclin E/Cdk2 complex, in B-Myb
 hyperphosphorylation in S phase,
 72:124
 Cyclin E-cdk2 kinase, 71:180, 190
Cyclin E gene, cell cycle start control, 69:32, 34
 Cyclin E-H1 kinase, interaction with ara-C,
 72:220
 Cyclin G, *p53* and, 71:6, 7
 Cyclin H, 71:172
Cyclin H gene, cell cycle start control, 69:32
 Cyclins
 B-Myb transactivation function dependent
 on, 72:125–127
 and cell cycle regulation in eukaryotic cells,
 65:222–223
 defined, 71:5
 in G₁ to S phase, 66:199–201
 mitotic and nonmitotic, 66:203–206
 overexpression in cancer, 71:196
 regulation by proteolysis, 66:183–187
 S-phase, 66:201–203
 Cycloheximide
 Epstein–Barr virus proteins and, 50:141,
 142, 144
 IAPs and, 51:229–230
 Cyclooxygenase, cancer immunotherapy and,
 59:279, 289
 Cyclophosphamide
 cancer immunotherapy and, 59:249
 chemoimmunotherapy, 59:275–278
 current strategies, 59:256, 260, 269
 cytotoxic T lymphocytes and, 58:156, 159,
 161–162, 166
 enhancement of TIL effectiveness, 61:
 73–74
 lymphoma and, 51:296
 Cyclosporin
 cancer immunotherapy and, 59:249
 EBV-associated disorders and, 57:333,
 346–350, 362
 multidrug resistance and, 52:171, 195
 for RadLV leukemogenesis, 66:305–308
 c-yes, tyrosine protein kinases and, 57:105,
 111–112, 117
 Cyproterone acetate, prostatic cancer and, 51:
 2
 Cysteine
 adenovirus E1A proteins and, 57:52
 B cell-associated surface molecules and, 52:
 97, 99, 110, 113
 Louvain rat immunocytomas and, 50:287
 Raf-1 phosphorylation and, 58:60
 Src family of tyrosine protein kinases and,
 57:115, 122, 126
 transforming growth factor- α and, 58:28,
 31, 37
 Cysteine proteases, 71:130
 Cysteine proteinase inhibitors, lysosomes
 and, 60:276–277
 Cysteine residues, TGF and, 51:121–123
 Cytidine deaminase, in ara-C deamination,
 72:204
 Cytidinephospho-diacylglycerol,
 lysophosphatidic acid and, 57:89–90

- Cytochrome P450, hepatocellular carcinoma and, 59:209
- Cytogenetics
 11q23 abnormalities, 66:214–216
 bone and soft tissue tumors, 69:64–87
 chromosomal aberrations, 69:64–93
 chromosomes and, 62:4–14
 colorectal adenocarcinoma, 67:61–68
 diagnosis and prognostication, 69:65, 91–93
 renal cell tumors and, *see* Renal cell tumors, molecular cytogenetics
 of retinoblastoma, 54:30–31
 salivary chromosomes, 65:14
- Cytokeratin, *p53* expression in breast cancer, 59:76, 78
- Cytokine receptors, soluble, 66:308
- Cytokine receptor superfamily
 homology in cytoplasmic domains, 68:25
 ras signaling pathway activation, 68:37–39
 Stat recruitment, 68:49–50
 type I receptor
 ligands, 68:25
 motifs, 68:24–25
 signal-transducing chains, 68:25, 27
 type II receptor
 signal-transducing chains, 68:27
 structure, 68:25
 tyrosine kinases, 68:30–37
- Cytokines, *see also specific cytokines*
 aberrant, networks, 66:235–236
 affecting lymphohematopoiesis, 54:252–254
 localization of, in microenvironment, 54:256–257
 apoptosis and, 71:133–134, 135, 153
 B cell-associated surface molecules and, 52:125–127
 B lymphocytes and, 56:314, 315, 329, 330
 cancer immunotherapy and, 59:246, 293
 chemoimmunotherapy, 59:275–277, 280–281
 critical factors, 59:248, 253
 current strategies, 59:257–268, 272–273
 improvement attempts, 59:286–292
 CD44 and, 71:284–285
 chronic lymphocytic leukemia, 71:146
 deregulation in AIDS-related lymphomagenesis, 67:124–126
 effect on FcγR expression, 64:223–224, 238
 genes, transduced tumor cells, 66:59–63
 hematopoietic
 network, 66:8–12
 therapeutic use, 66:19–20
 host cell-derived, 66:249
 immunosuppression and, 60:247, 252, 255, 257–261
 for immunotherapy, 61:66–69
 in malaria, 53:62, 64
 malaria-stimulated production, 53:58
 multigene, network, 66:28–29
 myeloid differentiation and, 71:135–136
 normal, and leukemia development, 66:12–16
p53 mediated apoptosis, 71:9
 regulation of MHC gene expression, 63:141–145
 regulation of SF production, 67:270–271
 release induced by FcγR cross-linking, 64:218
 signaling, and STAT proteins, 64:96–97
 stem cell viability and, 71:134–135
 stromal cell responses to, 54:259–261
 T-cell receptors and, 56:65, 70
 tumor cell production of, 61:79
- Cytokinetic resistance, ara-C, 72:212
- Cytomegalovirus, 51:324, *see also* Human cytomegalovirus
 amplification of latent tumorvirus genomes, 68:13
 in classical and African KS, 66:237–238
 Kaposi's sarcoma and, 53:82–83
 as model for herpesviruses effect on MHC expression, 63:165–173
 tumor rejection antigens and, 58:193
- Cytoplasm
 adenovirus proteins and, 52:156, 157
 α-fetoprotein and, 56:289, 292
 B cell-associated surface molecules and, 52:83
bcl2 gene in leukemia and, 57:159, 162, 167, 170
 BCR gene in leukemia and, 57:244–245, 247, 250
 biochemically defined molecules, 52:124
 B lymphocytes and, 56:327
 bovine papillomavirus and, 56:141
 breast cancer *p53* expression in, 59:72, 80
 Burkitt's lymphoma and, 55:150

- Cytoplasm (*continued*)
- chromosomal translocations, 55:199
 - c-myc*, 55:162, 163
 - EBV, 55:232
 - CD19, 52:100–102
 - CD20, 52:91, 98, 99
 - CD21, 52:104
 - CD22, 52:105–107
 - CD23, 52:110
 - CDw40, 52:113
 - central nervous system tumor oncogenesis and, 58:136
 - c-fos* protooncogene and, 55:37
 - c-myc* regulation and, 56:22, 23
 - cytotoxic T lymphocytes and, 58:145, 147
 - Epstein–Barr-associated disorders and, 57:330, 353
 - Epstein–Barr virus genes and, 58:8, 15
 - Epstein–Barr virus proteins and, 50:102, 109
 - expression on activated cells, 52:133
 - fibroblast growth factors and, 59:120, 136
 - gene rearrangements and, 52:59
 - hepatitis B viruses and, 59:189, 197, 199–200
 - Herpesvirus saimiri* and, 56:349
 - jun* oncogene and, 55:1, 2, 15
 - Louvain rat immunocytomas and, 50:283, 287
 - lysophosphatidic acid and, 57:92, 95
 - lysosomes and, 60:269, 271, 275, 278, 281, 285
 - MHC Class I expression and, 60:213
 - multidrug resistance and, 52:182, 183
 - multidrug resistance gene and, 60:159
 - myc* family oncogenes and, 57:6, 11
 - oncoprotein kinases and, 57:188–199, 207
 - plasminogen activation and, 57:276–278
 - polyoma virus TSTA and, 55:64
 - Raf-1 phosphorylation and, 58:66, 69
 - signal transduction and, 55:273, 274
 - mechanisms, 55:284, 286, 287, 289–293, 295–297
 - nuclear pores, 55:278, 280, 282
 - plasma membrane receptor, 55:277
 - Src family of tyrosine protein kinases and, 57:108, 120, 122, 126, 133, 135
 - stroma and, 50:177
 - T-cell receptors and, 56:51–53, 56, 57
 - leukocyte integrin family, 56:63
 - LFA-3, 56:59, 61, 62
 - lymphocyte homing receptors, 56:69, 70
 - transforming growth factor- α and, 58:30–31, 37–38, 45
- Cytoplasmic staining, *p53* expression, in breast cancer, 59:78
- Cytoreductive factors, cancer immunotherapy and, 59:280, 286, 292
- Cytosine
 - methylation in higher-order eukaryotes, 72:144–150
 - tumor clonality and, 50:205
- Cytosine arabinoside, *see* ara-C
- Cytoskeleton
 - genome exposure and, 62:129, 132, 140–143
 - humoral immune response and, 62:247, 255
 - oncoprotein kinases and, 57:188, 201, 203, 213
 - plasminogen activation and, 57:273–274, 278–280, 282
 - Ras function and, *see* Ras function, pathways
 - reverse transformation and, 62:126–127, 135, 138–139, 144, 146
- Cytosol
 - glutathione transferase and, molecular forms, 52:212, 214, 215, 220, 222
 - preneoplasia, 52:225, 229, 236
- Cytostatic factor
 - oncoprotein kinases and, 57:208–209
 - Src family of tyrosine protein kinases and, 57:113
- Cytotoxic adjuvant therapy, breast cancer and, 56:127
- Cytotoxic drugs, multidrug resistance gene and, 60:158–159, 168
- Cytotoxicity
 - ara-C
 - mechanism, 72:205–210
 - modulation, 72:220–225
 - cancer immunotherapy and chemioimmunotherapy, 59:276, 278, 280
 - current strategies, 59:259, 269, 271–272
 - improvement attempts, 59:285, 292
 - chemical carcinogenesis and, 50:60
 - experimental models, 50:30, 31
 - mechanisms, 50:43, 49, 50, 53
 - coupling with immune response, 64:289

- Epstein–Barr virus proteins and, 50:98, 133, 134
 gastrointestinal diseases and, 50:18
 immunosuppression and, 60:253
 lysosomes and, 60:284–285
 Cytotoxic T cells, 59:227–228, 240–241; 71: 138, 349
 adenovirus proteins and, 52:151, 158, 159
 antigen processing, 59:233–235
 antitumor, H-2K^b-restricted, 66:55–56
 antitumor immunity by, MHC regulation by, 53:93–97
 autologous, 66:58–59
 tumor rejection antigens and, 58: 201–205
 cancer immunotherapy and, 59:248, 255, 257, 272, 273, 275, 291–292
 $\alpha\beta$ CD8⁺, 67:166–168
 epitopes
 HLA-A11–restricted, 67:240–244
 peptide candidates as, 67:167–168
 Epstein–Barr-associated disorders and, 57: 331–332, 334
 Epstein–Barr-specific reactivities, 67: 239–241
 Epstein–Barr virus, 62:182, 190; 69: 221–228
 infection response, 63:212
 viral genes and, 58:3, 19–20
 function, 59:235–240
 hepatitis B viruses and, 59:173, 177
 immunosuppression and, 60:248–249, 251, 253
 influenza matrix peptide, 59:229–233
 melanoma-reactive, 70:147–149, 153–158, 165
 and MHC antigens
 adenovirus infection
 cellular immune response, 63: 158–159
 regulation, significance, 63:164–165
 poxvirus infection
 mechanism of regulation, 63:153–154
 MHC-I regulation, 63:151–152
 MHC-II regulation, 63:153
 response to, 63:149
 vaccinia virus infection response, 63:148
 MHC Class I expression and cancer, 60: 183–184, 188
 downmodulation, 60:225
 modulation by oncogenes, 60:196–197, 202
 MuLV and, 51:280, 282
 peptide-binding heat shock proteins and, 62:156, 161–163, 165, 167, 169–174
 peptide MHC, 59:228–229
 peptide presentation by MHC class I, 66: 47–49
 Src family of tyrosine protein kinases and, 57:125, 127
 T-cell receptors and, 56:54, 64, 66
 tumor eradication by adoptive transfer of, 58:167–168
 antigen recognition, 58:144–145
 chemically induced tumors, 58:148–149
 clinical results, 58:163–166
 escapes from immune T cells, 58: 160–163
 immunogenicity of tumors, 58:145–146
 melanoma antigens, 58:166–167
 mutagenized tumors, 58:149–151
 spontaneous tumors, 58:151–154
 T cell immunity, 58:143–144
 UV-light induced tumors, 58:148–149
 virus-induced tumors, 58:146–148, 154–160
 tumor rejection antigens and, 58:178–180, 182
 P815, 58:197–201
 recognition, 58:201–205
 tum⁻ antigens, 58:184–188, 193
- D**
- Dacarbazine, cancer immunotherapy and, 59: 277
 Darwin, Charles, views on origin of cancer, 65:18
 Darwinism, and Mendelian inheritance, comparison, 65:19
 Daunomycin, multidrug resistance gene and, 60:170
 Daunorubicin
 lysosomes and, 60:284
 multidrug resistance and, 52:167, 171, 195
 DBA/2 mice, tumor rejection antigens and, 58:184–185, 197, 200
 Dbl family proteins, effect on Rho protein function, 72:80
 DCC gene, 61:45
 Deamination, ara-C, 72:204
 enhanced, 72:211

- Debrisoquin
 chemical carcinogenesis and, 50:41
 metabolism, role in lung cancer, 65:74
- Decapentaplegic gene complex, TGF and, 51:121–123
- Defense mechanism, cellular, 66:329–331, 335
- Deficits, oncogenes and, 50:88
 cellular heterogeneity, 50:91
 malignant phenotype, 50:76, 79
 maturation arrest, 50:92
- Degradation
 cyclin, 66:185–187
 I κ B, 66:284
 I κ B α , 66:275–276
 stroma and, 50:186
 alterations, 50:184
 basement membranes, 50:173, 175
 epithelium, 50:160, 162–164, 169, 170
 wild-type p63, 66:81
- Dehydroepiandrosterone
 antiaging effects of, 51:418–419
 antiatherogenic effects of, 51:419–420
 antiautoimmune effects of, 51:418–419
 antidiabetic activity of, 51:417–418
 antiobesity action of, 51:396–400
 breast cancer and, 51:392–394
 cancer preventive effects of
 general considerations, 51:400–404, 406
 inhibition of DNA synthesis, 51:407–412
 inhibition of superoxide formation, 51:412–415
 general considerations for, 51:391–392
 G6PDH and, 51:394–396, 397, 399, 415–417
in vitro testing, 61:9
 NADPH and, 51:397, 409–413, 417, 420
 synthetic analogs and, 51:420–421
 topical, 51:404, 407–408
 TPA and, 51:396, 397, 408, 409, 413, 414, 416, 419–421
- Delayed-type hypersensitivity
 cancer immunotherapy and, 59:257
 glycosylation in tumors and, 52:315
 immunosuppression and, 60:253, 258
- Delbruck, Max, 69:10, 13, 14–15
- Deletion analysis
 chromosome 3
 bladder cancer, 71:52–53
 breast cancer, 71:48–49
 cervical carcinoma, 71:49–50
 endometrial carcinoma, 71:50
 gastrointestinal tumors, 71:47–48
 head and neck squamous cell carcinoma, 71:45–47
in vitro studies, 71:53–54
 lung cancer and, 71:35–42
 malignant melanoma, 71:52
 malignant mesothelioma, 71:51
 multiple endocrine neoplasia type 2, 71:52
 ovarian carcinoma, 71:50
 renal cell carcinoma, 71:42–45
 salivary gland adenoma, 71:52
 skin cancers, 71:51
 testicular germ cell tumors, 71:51
 thyroid carcinoma, 71:52
 uveal melanoma, 71:52
 comparative genome and RNA analysis, 71:33–34
 localizing tumor suppressor genes, 71:32
- Deletions
 in 17p arm in monosomic-type tumors, 67:67–68
 30–base pair, and single-base mutations, 67:217–218
 in 51q arm in familial adenomatous polyps, 67:65
 adenovirus E1A proteins and, 57:59
 ADF and, 57:388
 ataxia-telangiectasia genes and, 56:82, 98
 in band 11q23, 66:215
bcr/abl gene in leukemia and, 57:159–161, 164, 167
 chromosome abnormalities and acute lymphoblastic leukemia, 52:20
 acute nonlymphocytic leukemia, 52:12
 cytogenic nomenclature, 52:6
 malignant lymphoma, 52:26
 myelodysplastic syndromes, 52:15
c-myc regulation and, 56:15–18, 21, 24, 30
 in colon cancer gene, expression in prostate cancer, 68:239
 EBV-associated disorders and, 57:331, 335, 355
 gene rearrangements and, 52:63–65
 genomic instability and, 60:139, 141
Herpesvirus saimiri and, 56:343–348, 350
 internal, Ad2 genomes with, 66:321

- long arm of chromosome 6, 67:138–139
- MHC Class I expression and, 60:182, 213
- mouse retrotransposons and, 56:234, 238
- multidrug resistance gene and, 60:160
- myc* family oncogenes and, 57:11–12
- oncoprotein kinases and, 57:199
- p53* and human malignancies and, 57:261, 264, 266–267, 269
- as *p53* mutation, 66:110
- polyoma virus TSTA and, 55:65–67
- protein tyrosine kinase GFRs and, 60:62
- 13q14 in retinoblastoma, 54:30–31
- tumor clonality and, 50:208, 209
- unmasking of recessive mutations, 67:59–61
- Demethylation
 - α -fetoprotein and, 56:297, 298
 - muscle cell regulation and, 58:97, 107
- DEN, oncogene activation and, 51:170
- Dendrites, B cell-associated surface molecules and, 52:92, 103
- Dendritic cells
 - CR2 in, 54:290
 - HER-2/neu epitopes, 71:350–351
 - humoral immune response and, 62:258
 - scatter factor immunostaining, 66:242–243
- Deoxyadenosine, chemical carcinogenesis and, 50:46
- Deoxycholic acid, gastrointestinal diseases and, 50:14, 15
- Deoxycytidine kinase
 - ara-C phosphorylation, 72:203–204
 - loss, and ara-C resistance, 72:210–211
- Deoxycytidine triphosphate
 - pool sizes, 72:204
 - increased, 72:211–212
 - reduced, 72:221–222
 - role in ara-C metabolism, 72:201
- Deoxycytidylate inhibitor, dTHU, effect on ara-C metabolism, 72:204
- Deoxyguanosine
 - chemical carcinogenesis and, 50:42, 44
 - role in carcinogenicity of nitrosamines, 65:65–66
- Deoxyribonucleic acid, *see* DNA
- Dephosphorylation
 - adenovirus E1A proteins and, 57:66, 68
 - ara-CTP, 72:211
 - oncoprotein kinases and, 57:186, 194, 198, 207, 212, 214
 - RB by phosphatase, 64:34–36
 - Src family of tyrosine protein kinases and, 57:110–111
 - tyrosine residue in pp60^{c-src}, 64:114
- Deprimones, endogenous growth inhibitors and, 57:441
- De Quervian subacute granulomatous thyroiditis, 51:308
- DER, protein tyrosine kinase GFRs and, 60:56–57
- Deregulation, Burkitt's lymphoma and, 55:136, 137
 - chromosomal translocations, 55:195, 202
 - c-myc*, 55:208–216
 - expression, 55:186, 187, 192
 - structural changes, 55:181, 182
- EBV, 55:237, 241
 - genetic abnormalities, 55:216, 217, 219
 - nonrandom chromosomal translocations, 55:155, 157
 - synthesis, 55:243, 245, 247–249
 - translocation mechanism, 55:176
- Derepression, cdk inhibitors, 70:120
- Dermatofibrosarcoma protuberans,
 - chromosomal aberrations, 69:67, 88, 93
- Dermatological manifestations, AIDS and, 51:337–338
- DES, *see* Diethylstilbestrol
- Desmoids, soft tissue tumors and, 60:81–82
- Desmoid tumors, chromosomal aberrations, 69:65–66, 90, 92, 93
- Desmoplasia, stroma and disorders, 50:180–182
 - epithelium, 50:160, 165–170
 - glycoproteins, 50:171
- Desmosomes, intercellular junctions resembling, 66:246
- Destruction box consensus, 66:183–185
- Development
 - AIDS-related lymphomas
 - contributing factors, 67:120–126
 - pathogenic pathways, 67:139–142
 - embryonic, *see* Embryonic development
 - epithelial cancer, from phenotype to genotype, 70:21–44
 - genomic instability and, 60:124, 142
 - MHC Class I expression and, 60:210
 - normal mammalian, role of oncogenic transcription factors, 67:46–48

- Development (*continued*)
 protein tyrosine kinase GFRs and, 60:49–50
 mutants of *Drosophila*, 60:56–60
 mutants of mouse, 60:50–56
 tissues involved in MEN II, 70:207–211
- Developmental malformations, tumors and, 54:42–46
- Dexamethasone
 α-fetoprotein and, 56:292, 293, 295
 HPV and, 71:330
 human papillomavirus and, 56:150, 153
 mouse retrotransposons and, 56:240
 plasminogen activation and, 57:297, 303
 uPA and plasmin suppression, 69:122
- DHEA, *see* Dehydroepiandrosterone
- Diabetes
 DHEA and, 51:417–418
 IAP gene expression and, 51:252–253
 newborn macrosomy and, 50:237–239, 272
 case histories, 50:241, 245
 epidemiology, 50:264
 factors, 50:255, 257, 259
 prognosis, 50:248
 prophylaxis, 50:270, 271
- Diabetic retinopathy, FGF receptor multigene family and, 60:4, 35
- Diacylglycerol
 chemical carcinogenesis and, 50:51
 G protein signal transduction and, 58:84, 88
 lysophosphatidic acid and, 57:88–90, 94
 in PKC activation, 64:162–164
 Src family of tyrosine protein kinases and, 57:136
- Diacylglycerol kinase, lysophosphatidic acid and, 57:90, 100
- Diagnosis
 mutator phenotype role, 72:48–49
 based on genetic analysis of tumors, 69:65, 91–93
- Diagnostic marker, gene amplification as, 72:33
- Diet
 effects on MNU-induced mammary tumors, 61:5–6
 fat, as risk factor, 66:72
 fat intake and prostatic cancer, 51:32–34, 37–39, 43–44, 60–66
 fiber in
 effects on colon tumors, 61:5–6
 effects on MNU-induced mammary tumors, 61:5–6
 prostatic cancer and, 51:41, 45
 ingested foreign DNA, 66:314–316, 338–341
 mycotoxins in, as cause of liver cancer, 65:86–87
 Pritikin, 51:65
 Diet and Cancer Program, 61:2–3
 Diethylenetriaminepentaacetic acid, glycosylation in tumors and, 52:308, 309
 Diethylnitrosamine, oncogene activation and, 51:170
 Diethylstilbestrol
 α-fetoprotein and, 56:275, 278, 279
 chemical carcinogenesis and, 50:30
 growth-inhibitory potential in tumors, 65:51
- Differentiation
 adenovirus E1A proteins and, 57:60
 ADF and, 57:404, 407
 anomalous keratinocyte, 64:279
 associated inactivation of RB phosphorylation, 64:39–43
 B cell, and κB-binding, 66:278–279
 B cell-associated surface molecules and, 52:82, 134
 biochemically defined molecules, 52:118, 119, 122
 expression on activated cells, 52:128
 history, 52:86, 87
 pathway, 52:83–85
 receptors, 52:125
 T cells, 52:132
 B cell-associated surface molecules and antigens, *see* Antigens
bcr1abl gene in leukemia and, 57:152, 157, 173–175, 178
 BCR gene in leukemia and, 57:228, 251–253
 Burkitt's lymphoma and, 55:135
 B cell, 55:165–170
 chromosomal translocations, 55:197, 198, 204, 205, 207
c-myc, 55:165, 179
 deregulation, 55:210, 212, 213
 EBV, 55:225
 genetic abnormalities, 55:217, 218
 phenotype, 55:150, 154

- synthesis, 55:243, 244
c-erbA and, 59:89, 95, 108
 avian erythroblastosis virus, 59:92–93
 function, 59:105–106
 gene expression, 59:104–105
c-fos protooncogene and, 55:37, 38,
 41–43, 50
 chemical carcinogenesis and, 50:26, 60
 mechanisms, 50:48–50, 52
 and *c-myc*, 70:128–130
 EBV-associated disorders and, 57:335,
 340, 344, 352, 357
 effect on apoptosis, 66:86
 endogenous growth inhibitors and, 57:433,
 435, 439–440, 442–443, 448
 epidermal
 fos role, 64:263
 TGF α role, 64:265
 Epstein–Barr virus proteins and, 50:97,
 149, 150
 FGF receptor multigene family and, 60:2,
 4, 32, 34
 fibroblast growth factors and, 59:129,
 142–143, 151, 155
 gastrointestinal diseases and
 antigenic determinants, 50:15–22
 esophagus, 50:2, 3
 large intestine, 50:7–15
 stomach, 50:3–7
 genomic instability and, 60:124, 133, 137,
 140
 growth regulation and, 57:415–416,
 418–419
 immunosuppression and, 60:256, 261
jun oncogene and, 55:2
 keratinocyte, 64:182–183
 retinoid role, 70:78–81
 Louvain rat immunocytomas and, 50:283
 and malignant progression, 64:3–4
 metastatic cancer cells and, 55:106, 121
 MHC Class I expression and, 60:181–183,
 195
 modulation by oncogenes, 60:200–203,
 206
 regulation by oncogenes, 60:210,
 213–215, 221
 muscle cell regulation and, 58:95–97, 114
myc family oncogenes and, 57:2, 31, 34
 gene expression, 57:14–18, 20, 22
 protein structure, 57:8–9
 myeloid, 64:177–179
 myeloid cells
 leukemic, 66:12–16
 normal, 66:7–9
 neuroblastoma, role of PKC, 64:186–187
 neuronal, and neurite outgrowth, 64:
 185–186
 normal hematopoietic cells, 66:3–6
 oncogenes and, 50:72, 73, 87, 88
 cellular heterogeneity, 50:89, 91
 malignant genotype, 50:80–87
 malignant phenotype, 50:76–79
 maturation arrest, 50:92
 oncoprotein kinases and, 57:205
 and PKC isoforms, 64:176–187
 and PKC isozyme expression, 64:170
 plasminogen activation and, 57:276
 protein tyrosine kinase GFRs and, 60:45,
 60, 64
 regulation by TGF- β , 70:72
 role of D cyclins, 66:198–199
 role of wild-type p53, 66:145
 signal transduction and, 55:271, 298
 soft tissue tumors and, 60:76, 78, 86, 93,
 104, 110
 Src family of tyrosine protein kinases and,
 57:103, 125, 132
 patterns of expression, 57:112–114,
 116–117, 119
 stroma and, 50:188
 basement membranes, 50:173, 175,
 176
 glycoproteins, 50:170, 172
 terminal, 64:5
 tumor clonality and, 50:199
 tumor rejection antigens and, 58:
 200–201
 Differentiation antigens, 61:64
 oncogenes and, 50:72–74, 87–89
 malignant genotype, 50:84, 86, 87
 malignant phenotype, 50:74, 76
 2-Difluoromethylornithine, *in vitro* testing,
 61:9
 Di George's syndrome, opportunistic tumors
 associated with, 54:306
 Digestive tract, tautomycin effects, 61:
 182–183
 Dihydrofolate reductase
 Herpesvirus saimiri and, 56:341, 347, 348,
 350
 interaction with *c-Myc*, 70:122
 1,25-Dihydroxyvitamin D, 69:150

- Dimerization
 adenovirus E1A proteins and, 57:62–63, 65
BCR gene in leukemia and, 57:251
 Burkitt's lymphoma and, 55:163, 164
c-erbA and, 59:99, 106
c-fos protooncogene and, 55:47, 48
c-Myc protein DNA-binding domain, 70:104–107
 defective *p53* molecules, 66:95
 FGF receptor multigene family and, 60:32
jun oncogene and, 55:15–21, 26, 28–30
 leucine zipper protein, 66:227
 with Max, requirement in cell fate, 70:133
 MHC Class I expression and, 60:218
myc family oncogenes and, 57:8–10, 36
p53, 66:82–83
p53 α -helix in, 66:152–153
 plasminogen activation and, 57:281
 protein tyrosine kinase GFRs and, 60:56
 signal transduction and, 55:285
 Src family of tyrosine protein kinases and, 57:122, 126
- Dimerization domains, homologies with
 DNA-binding domains, 67:43–46
- Dimethylbenzanthracene
 androgenic steroids and, 51:400, 401
 oncogene activation and, 51:150, 153, 154, 156–158, 169, 170, 171
in vivo, 51:173–176
 tumor promoters and, 51:161
- Dimethylhydrazine, gastrointestinal diseases and, 50:10, 11, 18
- Dimethylnitrosamine, *see* Nitrosamines
- Dimethylsulfoxide
 gastrointestinal diseases and, 50:21, 22
 Src family of tyrosine protein kinases and, 57:114–115, 117
- Dimethyl sulfoxide, *c-myc* regulation and, 56:11, 19, 20, 23, 24
- Dinophysis fortii*, dinophysistoxin-1 isolation, 61:151
- Dinophysistoxin-1
 apparent activation of protein kinases, 61:162
 biochemical and immunological effects, 61:160
 isolation, 61:151
 structure-activity relationships, 61:158–161
 tumor promotion on mouse skin, 61:151–154
- Direct repeats, hepatitis B viruses and, 59:199, 201–202
- Discodermia calyx*, calyculin A isolation, 61:168
- Disseminated intravascular coagulation, chemotherapy, 69:120
- Disulfide bonds, B cell-associated surface molecules and, 52:98, 105
- DMBA, *see* Dimethylbenzanthracene
- DNA
 adenovirus E1A proteins and
 transactivation, 57:51–52, 57–64, 66
 transactivation mechanism, 57:71–72
 transcription, 57:68
 transformation, 57:77–78
 adenovirus proteins and, 52:152–154
 ADF and, 57:383, 387–388, 403, 405
 α -fetoprotein and, 56:280, 293–297
 amplified, evolution, 61:108–110
 APC gene in human cancers and, 62:67, 69, 72–73, 78, 80
 ataxia-telangiectasia genes and, 56:98, 99
 genetic linkage, 56:87, 90–93
 phenotype, 56:79, 81, 83, 84, 86
 base excision repair system, 71:212
 B cell-associated surface molecules and, 52:89, 96
bcr/abl gene in leukemia and, 57:154, 157, 166, 175
BCR gene in leukemia and, 57:227, 230, 232, 234–235
 B lymphocytes and, 56:314, 318, 328
 B cell neoplasia, 56:326
 CD23 molecule, 56:321, 323
 breast cancer, 56:108, 109
p53 expression in, 59:71, 73, 76
 Burkitt's lymphoma and
 B cell differentiation, 55:165, 166, 169, 170
 chromosomal translocations, 55:200, 203–205
c-myc, 55:160, 161, 163, 164
 expression, 55:187, 190
 structural changes, 55:177, 179, 182, 185
 deregulation, 55:209, 215
 EBV, 55:223, 224, 227–231, 237
 features, 55:144
 genetic abnormalities, 55:220–223
 synthesis, 55:244, 248

- translocation mechanism, 55:171, 172, 175, 176
- cancer immunotherapy and, 59:258, 288
- cellular, methylation, 66:336–338
- central nervous system tumor oncogenesis and, 58:127–128, 135–136
- c-erbA* and, 59:93, 106–108
 - gene expression, 59:104–105
 - multiple loci, 59:94–95
 - mutations, 59:102–104
 - protein function, 59:98–102
 - structure, 59:97
- c-fos* protooncogene and, 55:42–49
- chemical alkylation
 - biological consequences, 65:66
 - cytotoxic action, analysis with mustards, 65:58–59
 - effect on hydrolysis abilities, 65:55–56
 - effects of mustard gas, 65:55
- chemical carcinogenesis and
 - biomonitoring, 50:54–58
 - experimental models, 50:31
 - mechanisms, 50:40–46, 48, 49, 53
- chromosome abnormalities and, 52:3, 38
 - antioncogenes, 52:31, 32
 - chronic myeloproliferative disorders, 52:17
 - malignant lymphoma, 52:26
 - oncogenes, 52:35
- c-myc* regulation and, 56:1, 2, 25
 - expression, 56:10, 11, 17, 20
 - gene topography, 56:2, 7, 9
- cytotoxic T lymphocytes and, 59:238
- damage, 71:2–7
- de novo* methylation, 66:329–335
- DHEA inhibition of, 51:407–412
- double-stranded, hepatitis B viruses and, 59:189
- EBV-associated disorders and, 57:330, 371–372
 - Burkitt's lymphoma, 57:333–335
 - Hodgkin's disease, 57:369–371
 - immunodeficiency states, 57:344–345
 - NHL and AIDS, 57:364–365
 - organ transplants, 57:346, 351, 353–356, 363
 - X-linked lymphoproliferative syndrome, 57:339, 342
- and EBV typing, 67:204–226
- effects of *in vivo* carcinogens, 65:57–58
- endogenous growth inhibitors and, 57:434–435, 441, 444, 447–448
- epidermal principle, 57:445
- growth regulation, 57:416–419
- keratinizing cells, 57:429, 433
- retinoblastoma gene, 57:437–438
- Epstein–Barr virus and, 62:181
 - Hodgkin's disease, 62:214–215, 222, 224, 226, 228–229
 - marker detection, 62:185–187
 - peripheral T cell lymphomas, 62:198, 201–202, 205, 208
 - T-cell lymphoproliferation, 62:189–192, 196
- Epstein–Barr virus genes and, 58:2, 4–5, 7
- Epstein–Barr virus proteins and, 50:150
 - diseases, 50:98
 - genome, 50:100–102
 - transformed cells, 50:104, 109, 112, 114, 118, 120, 121, 126, 127, 137
 - virus-produced cells, 50:140, 143, 146, 147
- FGF receptor multigene family and, 60:5, 11, 18
- fibroblast growth factors and, 59:140, 150
 - gene expression, 59:126, 129, 131
 - oncogenic potential, 59:145–148
- foreign, *see* Foreign DNA
- fragmentation, ara-C role, 72:209–210
- gastrointestinal diseases and
 - esophagus, 50:2
 - large intestine, 50:8, 10, 13, 14
 - stomach, 50:5–7
- gene rearrangements and, 52:45
 - B cell antigen receptor, 52:47
 - hematological neoplasias, 52:57–59, 64, 65
 - T-cell antigen receptor, 52:52, 53
- genome exposure and, 62:129–130, 132, 141–142
- genomic instability and, 60:124–125, 145, 147
 - mechanisms, 60:129–142
 - quantitative considerations, 60:144–145
- glutathione transferase and
 - molecular forms, 52:218, 222
 - multidrug resistance, 52:242
 - preneoplasia, 52:223, 224, 231, 232, 237
- G protein signal transduction and, 58:83, 86, 87

DNA (*continued*)

- hepatitis B viruses and, 59:168–169, 210–211
 - epidemiology, 59:170, 177
 - genetic alterations, 59:208–209
 - genomes, 59:185–187, 189–191, 193
 - oncogenesis of viral proteins, 59:195, 198–199
 - pathogenicity, 59:180–182, 184
 - viral DNA, 59:199–208
- Herpesvirus saimiri* and, 56:335, 336, 351
 - genome, 56:344, 345, 348–350
 - model system, 56:339–342, 344
- humoral immune response and, 62:259
- hybridization studies, 67:10–12
- hypomethylation in cancer, 72:151–152
- IAP gene expression and, 51:195–202, 221–224
- immunosuppression and, 60:253
- incorporation of ara-C, 72:206–207
- internucleosomal fragmentation, okadaic acid-related, 61:165
- jun* oncogene and, 55:2
 - binding, 55:4–6
 - dimerization, 55:14, 15
 - family of related genes, 55:8, 9
 - hierarchical order of functions, 55:28–30
 - leucine zipper, 55:17–21
 - oncogenicity, 55:27
 - regulation, 55:23
 - signals, 55:12, 13
 - transcription factor AP-1, 55:7, 8
- loss on chromosome 11q13 in breast cancer, 61:34–35
- Louvain rat immunocytomas and, 50:297, 300, 302, 303
- lysophosphatidic acid and, 57:87, 91–92, 95–96, 99, 101
- lysosomes and, 60:281, 284
- metastatic cancer cells and, 55:94, 97, 99
- MHC Class I expression and, 60:183
 - modulation by oncogenes, 60:197–198, 200
 - regulation by oncogenes, 60:208–210, 213–216
 - regulation in tumor cells, 60:218–220
- mouse retrotransposons and, 56:220, 221, 223, 224, 226
- multidrug resistance and, 52:166, 167
 - amplified genes, 52:176, 178
 - P-glycoprotein, 52:179, 180, 183, 186
 - multidrug resistance gene and, 60:173
 - muscle cell regulation and, 58:97, 99, 101–104, 107, 109–112
 - mutations and, 71:233
 - myc* family oncogenes and, 57:8–12, 19–20
 - naked, 70:171
 - newborn macrosomy and, 50:232, 263
 - nucleotide excision repair system, 71:212
 - oncogenes and, 50:84, 87
 - oncoprotein kinases and, 57:196
 - p53* and human malignancies and, 57:259–261, 263–265
 - papillomaviruses and, 56:133, 134
 - bovine, 56:135–142
 - human, 56:142–154
 - peptide-binding heat shock proteins and, 62:159, 172
 - plasminogen activation and, 57:293
 - polyoma virus TSTA and, 55:62, 63, 65, 70, 81
 - protein tyrosine kinase GFRs and, 63–64
 - radioresistant synthesis, 71:11
 - Raf-1 phosphorylation and, 58:69
 - Ras function and, 62:24, 33, 40
 - recombinant
 - eukaryotic genes and, composition studies, 65:162
 - simian virus 40 DNA and, importance, 65:158
 - regional hypermethylation in cancer, 72:152–154
 - renal cell tumors, molecular cytogenetics, 62:90, 118
 - chromophobe renal cell carcinoma, 62:117–118
 - differential genetics, 62:91–92
 - nonpapillary renal cell tumors, 62:94–95, 97, 101, 106
 - renaturation, 66:160–161
 - repair, *p53* signal for, 67:15–16
 - repair systems, 71:212
 - restriction fragment length
 - polymorphisms, *see* Restriction fragment length polymorphisms
 - reverse transformation and, 62:134–139, 143–144, 147
 - signal transduction and, 55:271, 278, 284, 286, 293
 - single-stranded, RPA binding, 66:89, 165

- soft tissue tumors and, 60:80, 87, 102, 108
 - chromosomal abnormalities, 60:89, 92, 94, 99
 - gene amplification, 60:104–105
 - predictors of behavior, 60:105–106
- Src family of tyrosine protein kinases and, 57:119, 139
- strand breaks, in *p53* activation, 66:170–173
- synthesis *de novo*, alteration after gamma radiation, 61:206–207
- TGF and, 51:136
- transfection of tumor, in isolation of genes causing cancer, 65:34–35
- transforming growth factor- α and, 58:34
- tumor clonality and, 50:205, 207, 209, 210, 225
- tumor rejection antigens and, 58:187–188, 190, 198–199, 205
- ultraviolet absorption spectrum
 - alterations, effect of mustard gas, 65:55
- viral, effect on class I molecules, 67:181–182
- Wilms' tumor and, 59:49–50, 53–56, 58
- Zilber and, 59:4, 9, 25
- DNA binding
 - NF- κ B, 66:260, 268, 272
 - p53*, sequence-specific, 66:84, 90–93 and transactivation, 66:105–107
 - wild-type *p53*, sequence-specific, 66:150–154
- DNA-binding domains
 - B-Myb, 72:112–113
 - c-Myc protein, 70:104–107
 - homologies with dimerization domains, 67:43–46
- DNA-binding factors, class I promoter, 67:159–160
- DNA damage
 - activation of *p53*, 66:143–180
 - checkpoint control, 69:38–40, 45–49
 - inducing agents, 66:80–82, 86–87, 93
 - induction of *p53*, 72:8–9
 - in mutation origin, 72:37–38
- DNA helicases, targets for mutator phenotype, 72:42
- DNA ligases, genomic instability and, 60:136, 138
- DNA methylation
 - abnormalities in neoplasia, 72:150–167
 - altered
 - clinical implications in cancer, 72:189–190
 - role in tumor progression, 72:186–189
 - anatomy in higher-order eukaryotes, 72:147–150
 - in cancer, 54:1–19
 - changes in neoplastic cells, underlying mechanisms, 72:167–186
 - effects of chemical carcinogens on, 54:11–13
 - in eukaryotes, history, 72:142–144
 - genomic imprinting and, 54:16–19
 - in oogenesis, 54:14–15
 - pattern establishment, DNA-methyltransferase role, 72:145–147
 - in prokaryotes, 72:144–145
 - in spermatogenesis, 54:14–15
 - in tumor cells, 54:7–8
 - in tumor diversification, 54:13–14
- DNA-methyltransferase
 - increased activity in neoplastic cells, 72:167–171
 - role in
 - DNA methylation pattern establishment, 72:145–147
 - tumor progression, 72:171–176
- DNA mismatch repair, 71:209; 212
 - biochemical analysis, 71:98–99
 - in *E.coli*, 71:98
 - in HNPCC, 71:93, 95
 - in humans, 71:98–99
 - microsatellite instability and, 71:99–101, 211–213
- DNA-PK protein, function of, 71:13, 14–15
- DNA ploidy, in breast and colorectal cancers, 67:70–71
- DNA polymerase- α , competition with *p53*, 66:89, 149
- DNA polymerase β , mutations in cancer cells, 72:39
- DNA polymerases
 - candidate target mutator genes, 72:38–40
 - Epstein-Barr virus genes and, 58:15
 - Epstein-Barr virus proteins and, 50:142, 144–146
 - genomic instability and, 60:127–129, 147
 - hepatitis B viruses and, 59:170, 187–188, 191
 - inhibitory effects of ara-C, 72:205–206

- DNA polymerases (*continued*)
 misincorporation, 72:36–40
dnaQ, genomic instability and, 60:129
 DNA repair, in mutation origin, 72:37–38
 DNA repair genes
 candidate targets for mutator phenotype, 72:41–42
 role in tumor progression, 72:8–9
 DNA replication
 checkpoint control, 69:45, 46
 checkpoint control, 69:46, 47
 and c-Myc, 70:124–125
 control genes, 69:28
 cycle, in analysis of physicochemical nature of genes, 65:19
 genomic instability and, 60:127–130, 132, 134, 136, 138, 144
 MHC Class I expression and, 60:187
 in mutation origin, 72:36–37
 p110^{RBI} effects, 61:131–134
 postmitotic G₁ cells, 66:200
 regulation by p53, 66:149–150, 165
 senescence and, studies of
 with heterokaryons, 54:64–67
 with reconstructed cells, 54:67
 DNA replication complex model (MRC), 72:207
 DNA replication genes, candidate targets for mutator phenotype, 72:41–42
 DNase, *c-myc* regulation and
 Burkitt's lymphoma, 56:30, 35, 36
 expression, 56:17, 19
 gene topography, 56:7, 8
 DNase I
 genome exposure and, 62:129–130, 132–133
 reverse transformation and, 62:135–139, 147
 hypersensitive sites, 62:136–139, 143
 model, 62:143
 DNA synthesis, infidelity, 72:28, 39–40
 DNA viruses, 70:15
 activities of *RB1* and *TP53*, 67:14–16
 developmental stages, 65:148–150
 effects on MHC expression
 cellular immune response, 63:158–160
 characteristics, 63:155–158
 control sites, 63:187, 189
 hepatitis B virus
 cellular immune response, 63:175
 characteristics, 63:173–174
 MHC regulation
 mechanisms, 63:177–180
 MHC-I, 63:175–177
 MHC-II, 63:177
 herpesviruses
 cellular immune response, 63:167–169
 characteristics, 63:165–167
 MHC regulation
 mechanisms, 63:172–173
 MHC-I, 63:169–171
 MHC-II, 63:171–172
 immune recognition of viral antigens by T cells
 class I molecules
 assembly with peptide, 63:131–132
 peptide complexes, 63:129–131
 structure, 63:123–124
 class II molecules
 binding of peptide antigens to, 63:133–134
 biosynthesis, 63:133
 endosomal targeting, 63:133
 restriction, 63:134–135
 structure, 63:123–124
 cytokine regulation of gene expression, 63:141–145
 diversity of antigens, 63:124–126
 mechanisms, 63:118–119, 185–190
 modulation, 63:145–146
 pathway
 class I, 63:127–129, 132
 class II, 63:132, 135
 restriction, 63:122–123
 structure of antigens, 63:124–126
 T cells
 repertoire development, 63:119–120
 subset roles, 63:120–122
 transcription regulation, 63:135–140
 viral peptide–MHC complexes, 63:126–127
 MHC regulation
 MHC-I post-translational control, 63:162–164
 MHC-I transcriptional control, 63:160–162
 MHC-II, 63:164
 significance of, 63:164–165
 papillomavirus
 cellular immune response, 63:181–182

- characteristics, 63:180–181
- MHC regulation
 - mechanism, 63:184–185
 - MHC-I, 63:182–183
 - MHC-II, 63:183–184
- poxviruses
 - cellular immune response, 63:149–151
 - characteristics, 63:145, 147–148
 - MHC regulation
 - mechanisms, 63:153–155
 - MHC-I, 63:151–152
 - MHC-II, 63:152–153
- Docosahexaenoic acid, α -fetoprotein and, 56:271, 283, 284, 286
- N-Dodecylimidazole, lysosomes and, 60:286
- Dog tumors, IAP gene family and, 51:259
- Dormancy, tumor, B cell lymphoma as model, 63:245
- Dose response, cancer immunotherapy and, 59:263, 274
- Double minutes, 61:40
- Double-transgenic mice, *myc* family oncogenes and, 57:29
- Downregulation
 - HLA alleles, 67:156
 - immunosuppression and, 60:261
 - LFA antigens, 67:135
 - MHC Class I expression and, 60:231, 233
 - biological consequences, 60:222–231
 - cancer, 60:189–195
 - by oncogenes, 60:196–199, 204–208, 212, 217–220
 - and up regulation, SF and *c-met*, 67:267
- Downstream repression site, B-*myb* E2F, 72:120–121
- Doxorubicin
 - anti-HER-2/neu immunoliposomes and, 71:363
 - apoptosis and, 71:142
 - cancer immunotherapy and, 59:276–277, 289
 - lysosomes and, 60:284
 - multidrug resistance gene and, 60:158–159, 167–168
- DP-1, phosphorylation, 71:181
- Drash syndrome, Wilms' tumor and, 59:48, 60
- Drosophila melanogaster*
 - BCR gene in leukemia and, 57:242
 - BP and, 51:154
 - breeding tests, in gene phenotype determinations, 65:5
 - chromosomes and, 62:9
 - c-myc* regulation and, 56:7
 - developmental regulatory proteins, 67:43–50
 - Dorsal, dif, and Cactus, 66:281–283
 - FGF receptor multigene family and, 60:30–31
 - fibroblast growth factors and, 59:126
 - genomic instability and, 60:135, 147
 - jun* oncogene and, 55:9
 - Louvain rat immunocytomas and, 50:303
 - MAPK cascade activation, 72:62
 - MHC Class I expression and, 60:214
 - muscle cell regulation and, 58:100, 103
 - myc* family oncogenes and, 57:9
 - oncogenes and, 50:75, 82, 85
 - oncoprotein kinases and, 57:195, 209
 - plasminogen activation and, 57:280
 - protein tyrosine kinase GFRs and, 60:45, 46, 49–50, 56–60
 - radiation carcinogenesis, confirmation studies, 65:24
 - Ras function and, 62:21, 39, 49
 - GAPs, 62:30, 35
 - Ras guanine nucleotide exchange factors, 62:24, 28
 - Src family of tyrosine protein kinases and, 57:105
 - TGF and, 51:121–123
 - trithorax* gene, 66:223–224
- Drug combinations, research, 61:11–12
- Drug discovery, Raf MEK MAPK kinase cascade role, 72:97
- Drug-metabolizing enzymes, prostatic cancer and, 51:80–81
- Drug resistance, *see also* Multidrug resistance leukemia, 71:151–152
 - metastatic cancer cells and, 55:95, 97, 98, 104, 105
- Drugs, *see also specific drug*
 - cyclase-associated, Ras function and, 62:48
 - cytotoxic, reverse transformation and, 62:145, 146
- DTIC, cancer immunotherapy and, 59:276
- Dual tropic viruses, lymphomagenesis role in AKR mouse, 63:246, 249, 254–256, 286–287

- Duck hepatitis virus
 genomes, 59:189, 193–194
 oncogenesis of viral proteins, 59:197
 pathogenicity, 59:184–185
 viral DNA, 59:201–202
- Ductal carcinoma *in situ*, 61:27–28
 mammographic characterization, 61:30
- Duke's staining system, metastatic cancer cells and, 55:114
- Dulbecco, Renato, 69:10, 14
- Dulbecco modified Eagle's medium, 70:9
- Duncan's syndrome, immunoregulatory defects in, 53:37–38
- Duodenum, gastrointestinal diseases and, 50:6
- Dupuytren contracture, chromosomal aberrations, 69:65, 90
- Dynamic heterogeneity
 metastatic cancer cells and, 55:94–96
 randomness and selection in metastasis and, 54:183, 184–185
- Dysgammaglobulinemias
 Epstein–Barr virus proteins and, 50:100
 opportunistic tumors associated with, 54:306
- Dysplastic nevus, precursor state, 65:130
- E**
- E1A*, MHC Class I expression and, 60:212, 224
 cancer, 60:189–190, 195
 modulation by oncogenes, 60:195–197, 201, 204
- E1A* adenovirus, effects of, on normal cells in microinjection experiments on cellular immortalization, 54:75
- E2F protein, 71:188
 adenovirus *E1A* proteins and, 57:55–61
 apoptosis and, 71:130, 132
p53 and, 71:130
- E2F transcription factor
 interaction with *ara-C*, 72:217
 role in G₁/S transition, 72:110–111, 119–122
 tumor suppressor function, 72:7
- E6
 and E7
 and HPV immortalization, 64:4–5
 and targeting common pathway, 64:16–18
 HPV, targeting, 64:269–274
 HPV16, cooperation with *Ha-ras*, 64:273
- interactions with *p53*, 64:11
 interactions with *p53*, consequences, 64:13–15
 in oncogenesis, 64:14–15
- E7
 HPV, targeting, 64:269–274
 interactions with pRB family, 64:7
 consequences, 64:9–11
 pRB-independent activities, 64:11
- Earle, W.R., cloning studies, 70:6–8
- Early antigens
 Burkitt's lymphoma and, 55:223, 225, 228
 Epstein–Barr virus and, 62:184–185, 213, 224
 Epstein–Barr virus-associated disorders and, 57:330, 344, 353, 368
 organ transplants, 57:356, 362
 X-linked lymphoproliferative syndrome, 57:337–339
 Epstein–Barr virus proteins and diseases, 50:97
 transformed cells, 50:120
 virus-produced cells, 50:139, 144, 147
- Early event, mutator phenotype as, 72:47–48
- Early growth response-1 gene, interaction with *ara-C*, 72:220
- Early growth response genes, Wilms' tumor and, 59:55–56
- Early transposons, 56:220, 224, 245
 insertion, 56:227, 228
 LTRs, 56:231, 234, 235, 239, 243
- EBNA, *see* Epstein–Barr nuclear antigens
- Ebnotyping, Epstein–Barr virus, 67:226–237
- E-box motif, binding of Myc/Max dimers, 70:112–113
- EBP, *see* Enhancer-binding protein
- EBV, *see* Epstein–Barr virus
- EC, *see* Endothelial cells
- ECA39*, *c-myc* targeting, 68:135
- Ecotropic viruses, development from MuLV cancer resistant mice, 65:177–178
- Ectomesenchymoma, loss of heterozygosity in, 54:48–49
- Ectopic environment, metastatic cancer cells and, 55:89, 93, 114
- Ectopic gene expression, metastatic cancer cells and, 55:125
- Ectopic viral integration site 1, 54:141–155, *see also Evi-1*

- Effector cells, MHC Class I expression and, 60:182, 185, 187, 189, 226
- Effector domains of yeast RAS proteins, 54:95–96
- EGF, *see* Epidermal growth factor
- Eggs
- prostatic cancer and, 51:39
 - regulation and mosaic, 66:44
- EiB 55K protein, apoptosis and, 71:131
- Ejaculation, prostatic cancer and, 51:56, 66–67
- Elastase, stroma and, 50:162
- Elastin, stroma and, 50:186
- alterations, 50:183
 - epithelium, 50:160, 165, 168, 169
- Elastogenesis, stroma and, 50:168
- Elastolysis, stroma and, 50:168
- Elastosis, stroma and, 50:165, 168
- Electron microscopy
- Burkitt's lymphoma and, 55:223
 - Epstein–Barr virus and, 62:187, 196, 208
 - Epstein–Barr virus proteins and, 50:113
 - gastrointestinal diseases and, 50:14
 - Louvain rat immunocytomas and, 50:283
 - multidrug resistance and, 52:189
 - plasminogen activation and, 57:276, 300
 - renal cell tumors, molecular cytogenetics, 62:115, 117
 - retroviruses and, 51:309
 - reverse transformation and, 62:141
 - signal transduction and, 55:279
 - stroma and, 50:165, 175, 183
- Electrophiles, metabolic generation, 65:64–65
- Electrophoresis
- adenovirus E1A proteins and, 57:58
 - α -fetoprotein and, 56:257, 265, 282
 - interaction with lectins, 56:267–269
 - properties, 56:258, 262 - oncoprotein kinases and, 57:188–190, 197–198
 - p53* and human malignancies and, 57:260–261
 - soft tissue tumors and, 60:94, 99, 108
 - tumor clonality
 - and animal tumors, 50:218
 - distinction, 50:203–206, 211
- ELISA
- chemical carcinogenesis and, 50:55
 - Epstein–Barr virus proteins and, 50:107
 - ellipse*, protein tyrosine kinase GFRs and, 60:56–57
- Elongin complexes, 71:61, 62
- Elongin III, 71:61
- EM, retroviruses and, 51:309
- Embryo
- Burkitt's lymphoma and, 55:208, 215, 218, 222
 - c-fos* protooncogene and, 55:42, 46
 - jun* oncogene and, 55:24–27
 - metastatic cancer cells and, 55:97
 - mouse, IAPs in, 51:230–236
 - polyoma virus TSTA and, 55:65
 - signal transduction and, 55:295
- Embryogenesis
- B-myb* expression throughout, 72:117–118
 - chick, sequential stages, 66:42–44
 - FGF receptor multigene family and, 60:4–5, 8, 29
 - Flt* gene family expression, 67:304–308
 - genomic instability and, 60:121
 - MHC Class I expression and, 60:201, 210
 - mouse retrotransposons and, 56:227, 230, 235, 241–243
 - muscle cell regulation and, 58:106, 108
 - protein tyrosine kinase GFRs and, 60:45, 49–50, 52–58
 - soft tissue tumors and, 60:87, 97, 100, 104
 - stroma and, 50:176, 186
 - tumor clonality and, 50:203
 - VEGF mRNA levels during, 67:289–290
- Embryonal carcinoma cells
- c-erbA* and, 59:109
 - c-myc* regulation and, 56:10, 11, 22, 24
 - fibroblast growth factors and, 59:128–131, 151
 - metastatic cancer cells and, 55:95
 - MHC Class I expression and, 60:210, 213
 - mouse retrotransposons and, 56:220, 242–244
- Embryonal rhabdomyosarcomas,
- chromosomal aberrations, 69:76, 77, 90
- Embryonic development
- bcr/abl* gene in leukemia and, 57:174–175
 - c-myc* role, 70:125–128
 - myc* family oncogenes and, 57:14, 17, 36
 - oncoprotein kinases and, 57:213
 - plasminogen activation and, 57:274, 276, 294–295

- Embryonic development (*continued*)
 renal cell tumors, molecular cytogenetics,
 62:103, 108, 113
- EMS, *oncogene activation and*, 51:170
- Encephalitis
 AIDS and, 51:343
 experimental immune, 51:376
 Zilber and, 59:9–13, 15, 18, 20, 24
- Enchondroma, chromosomal aberrations,
 69:84
- Endocrine cells, gastrointestinal diseases and,
 50:3, 4, 9
- Endocrine disturbances, newborn
 macrosomy and, 50:232, 233
 cancrophilia syndrome, 50:263
 prophylaxis, 50:270, 271
 risk factors, 50:267
- Endocrine system
 diet and, 51:63–66
 prostatic cancer and, 51:83
- Endocytosis
 cancer immunotherapy and, 59:266, 270
 cytotoxic T lymphocytes and, 58:144
 immune complexes, FcγR-mediated, 64:218
 stroma and, 50:162
 tumor rejection antigens and, 58:180, 187
- Endogenous growth inhibitors, 57:413–415,
 441–442
 colonic epithelial cells, 57:434–435
 deprimerones, 57:441
 epidermal content, 57:444
 epidermal principle, 57:444–447
 growth regulation, 57:415–417
 cybernetic models, 57:420–421
 mechanisms, 57:417–420
 theoretical biological model, 57:
 421–423
 Volterra model, 57:423–424
- hemoregulatory inhibitory peptide, 57:
 433–434
- hormonal systems, 57:436
- keratinizing cells
 bat web experiment, 57:424–428
 epidermal chalone, 57:428–433
- kidney cells, 57:435
- mammary epithelial cells, 57:435
- parenchymal liver cells, 57:435
- retinoblastoma gene, 57:436–439
- suppression of malignancy, 57:439–440
- transforming growth factor, 57:8,
 440–441
 treatment of cancer, 57:447–449
 tumors, 57:442–444
- Endoglin, TGF-β1 binding, 70:69
- Endometrial cancer
 cytogenetic data, 67:73–74
 microsatellite instability, 67:76–77
 newborn macrosomy and, 50:239, 250,
 258, 267
- Endometrial carcinoma
 chromosome 3 losses in, 71:50
 mutations and, 71:113
- Endometrial polyps, chromosomal
 aberrations, 69:75–76, 89
- Endonuclease, genomic instability and, 60:
 132, 138
- Endoplasmic reticulum
 adenovirus proteins and, 52:156, 157, 160,
 161
 breast cancer, *p53* expression in, 59:
 78–79, 82–83
 cytotoxic T lymphocytes and, 59:233–234
 fibroblast growth factors and, 59:124
 hepatitis B protein accumulation, 70:
 35–36
 hepatitis B viruses and, 59:191–192, 196,
 202
 multidrug resistance and, 52:189
 multidrug resistance gene and, 60:162
 peptide-binding heat shock proteins in, *see*
 Heat shock proteins, peptide-binding
- Endoreduplication
 ara-C, 72:207
 in breast cancer, 67:69–70
 in non-small-cell lung cancer, 67:71–73
- Endosomes
 cytotoxic T lymphocytes and, 58:144–145
 transforming growth factor-α and, 58:35
- Endothelial cells
 derived tumor cells, VEGF expression,
 67:293
 FGF receptor multigene family and, 60:
 3–4, 6, 8, 24, 28
 gastrointestinal diseases and, 50:19
 multidrug resistance gene and, 60:165
 phenotypic conversion, 66:240–245
 plasminogen activation and, 57:313
 directed cell surface, 57:301–302, 312
 proteolytic modulation, 57:289, 291,
 294, 296, 299
 proliferation and tubular formation, 67:
 286–288

- PymT-transformed, 64:149–153
 soft tissue tumors and, 60:76
 somatic mutation, 66:247–249
 Src family of tyrosine protein kinases and, 57:118
 T-cell receptors and, 56:64, 65, 70
 tumor clonality and, 50:198
 vascular, as SF producer cell and target cell, 67:259–261
 Endothelial tumors, blood and lymph vessels, chromosomal aberrations, 69:77
 Endothelin B receptor, G protein-coupled, 70:191
 Endothelium
 adhesive properties of, 51:365
 Burkitt's lymphoma and, 55:240
 fibroblast growth factors and, 59:116, 128, 154
 biological function, 59:140–141
 env genes, fibroblast growth factors and, 59:151
 protein structure, 59:120, 122
 lymphocyte homing receptors and, 51:376
 metastatic cancer cells and, 55:88, 117, 122
 reverse transformation and, 62:146
 Enhancer A, regulatory element, 67:158–159
 Enhancer-binding protein
 Burkitt's lymphoma and, 55:163
 c-fos protooncogene and, 55:48
 jun oncogene and, 55:19, 21, 29
 Enhancers
 MHC Class I expression and
 modulation by oncogenes, 60:197, 203, 207–208
 regulation by oncogenes, 60:209–216
 regulation in tumor cells, 60:217, 219–221
 multidrug resistance gene and, 60:173
 ENU, *see* Ethylnitrosourea
env
 cytotoxic T lymphocytes and, 58:146
 mouse retrotransposons and, 56:218, 223, 224, 231
 protein tyrosine kinase GFRs and, 60:62
 tumor rejection antigens and, 58:182
Env-gene recombinants of M-MuLV, 51:283
 Environment
 Burkitt's lymphoma and, 55:244, 245
 genomic instability and, 60:124, 132, 145–146
 soft tissue tumors and, 60:81
 Enzyme-linked immunosorbant assay, *see* ELISA
 Enzymes, *see also* Lysosomal enzymes
 adenovirus E1A proteins and, 57:53
 ADF and, 57:401, 405
 ataxia-telangiectasia genes and, 56:82
 bcr/abl gene in leukemia and, 57:163, 167–169
 breast cancer, *p53* expression in, 59:72
 Burkitt's lymphoma and
 B cell differentiation, 55:166, 170
 c-myc structural changes, 55:183, 184
 EBV, 55:224
 genetic abnormalities, 55:222, 223
 translocation mechanism, 55:171, 172, 174, 175
 cancer immunotherapy and, 59:257
 c-erbA and, 59:99
 chemical carcinogenesis and
 biomonitoring, 50:55
 experimental models, 50:28
 mechanisms, 50:40, 43, 46, 51, 52
 chemical carcinogens and, 51:80–81
 cytotoxic T lymphocytes and, 59:227
 Epstein-Barr virus genes and, 58:15
 Epstein-Barr virus proteins and transformed cells, 50:104, 105
 virus-produced cells, 50:141, 144–148
 fibroblast growth factors and, 59:141
 gastrointestinal diseases and, 50:13, 17
 genomic instability and, 60:129, 131, 138, 147
 G protein signal transduction and, 58:76, 78, 80, 88
 growth regulation and, 57:419
 hepatitis B viruses and, 59:187, 189, 202
 immunosuppression and, 60:258
 jun oncogene and, 55:5
 metastatic cancer cells and, 55:88, 97, 110, 123
 MHC Class I expression and, 60:216
 newborn macrosomy and, 50:234
 plasminogen activation and, 57:274, 313–314
 adhesive interactions, 57:282, 284
 directed cell surface, 57:301, 305–306, 308
 proteolytic modulation, 57:284, 286, 289–292, 294–295, 298

Enzymes (*continued*)

- Raf-1 phosphorylation and, 58:54, 59–60, 65, 67
- signal transduction and, 55:274, 278, 292, 293
- Src family of tyrosine protein kinases and patterns of expression, 57:119
- properties, 57:108–111
- T-cell activation, 57:122, 124–125, 127, 129–131
- T-cell proliferation, 57:133
- stroma and, 50:186
 - basement membranes, 50:173, 174
 - epithelium, 50:160–162, 164, 168, 169
- tumor clonality and
 - animal tumors, 50:218
 - distinction, 50:204–206, 211
 - pleoclonal tumors, 50:215, 216
- tumor rejection antigens and, 58:190
- Wilms' tumor and, 59:53
- Eosinophilia, apoptosis and, 71:141
- Eosinophils, chromosome abnormalities and, 52:12
- EPH*, protein tyrosine kinase GFRs and, 60:65–66
- Ephrussi, Boris, 69:10, 13
- Epiandrosterone, 51:400
- Epidemiology
 - AIDS–KS, 66:236–237
 - AIDS-related lymphomas, 67:113–114
 - in cancer prevention, 61:6–7
 - EBV infection, 67:197–246
 - genomic instability and, 60:131, 147
 - hepatitis B viruses and, 59:170–171
 - hepatocellular carcinoma, 59:177–179
 - progression, 59:173–177
 - transmission, 59:171–174
 - Zilber and, 59:5, 8
- Epidermal cells
 - endogenous growth inhibitors and, 57:413–414, 435, 443–447
 - growth regulation, 57:416–418, 422–424
 - keratinizing cells, 57:424, 426–433
 - oncogenes and, 50:77, 78, 90
 - p53* alternative roles, 64:285
- Epidermal growth factor
 - activation, 71:190
 - α -fetoprotein and, 56:264
 - angiogenesis, 69:143
 - apoptosis suppression, 68:195
 - bovine papillomavirus and, 56:138, 140
 - cell cycle regulation, 68:193–194
 - c-erbA* and, 59:92
 - c-fos* protooncogene and, 55:50
 - FGF receptor multigene family and, 60:9
 - gastrointestinal diseases and, 50:14
 - gene expression inducible by, 53:15
 - G6PDH and, 51:411–412
 - G protein signal transduction and, 58:78–79
 - identification, 70:10
 - lysophosphatidic acid and, 57:87, 92, 94
 - metastatic cancer cells and, 55:117, 119, 120
 - mouse retrotransposons and, 56:235
 - multidrug resistance and, 52:172
 - oncogenes and, 50:82
 - oncoprotein kinases and, 57:199–200, 204, 206, 214
 - physiology of, 58:28–30, 37–40, 42
 - tumor development, 58:44–46, 48
 - plasminogen activation and, 57:280, 287, 289
 - protein tyrosine kinase GFRs and, 60:45, 49, 56, 60–61, 64
 - Ras function and, 62:23–24, 44, 48
 - in serum, 53:5
 - in serum medium, 66:122–123
 - T-cell receptors and, 56:69
 - TGF and, 51:108, 110–114
- Epidermal growth factor receptors
 - central nervous system tumor oncogenesis and, 58:124–127, 129, 134–138
 - c-erbA* and, 59:90
 - gene amplification in breast cancer, 61:37
 - okadaic acid-stimulated phosphorylation, 61:165–166
 - p53* expression in breast cancer, 59:78–79, 82
 - physiology of, 58:34–36, 40
 - PKC phosphorylated, 64:173
 - and prognostic value of *p53*, 66:117
 - Raf-1 phosphorylation and, 58:67, 70
 - Ras function and, 62:31–32
 - reverse transformation and, 62:146
 - TGF- α and, 51:112–113
 - TGF- α binding, 64:268
- Epidermal pentapeptide, endogenous growth inhibitors and, 57:431–433, 443, 445–446
- Epidermal proliferative unit, chemical carcinogenesis and, 50:45

- Epidermis
 differentiation, 70:80–81
 IAP gene expression in mouse somatic cells, 51:228–230
 stroma and
 alterations, 50:184
 disorders, 50:179, 180
 epithelium, 50:163
 tumor clonality and, 50:211
- Epigenetic changes, superimposed in DNA-level changes, 72:3
- Epigenetic DNA modification, genomic instability and, 60:140–141
- Epigenetic inactivation of alleles in human cancer, 54:49–58
 predisposition and, 54:51–56
 progression and, 54:56–58
- Episomes
 Epstein–Barr virus and, 62:215–216
 Epstein–Barr virus proteins and, 50:100, 113, 137
- Epithelial basal cell carcinoma, chromosome 3 losses in, 71:51
- Epithelial cancers, human, chromosome alteration pathways, 67:59–78
- Epithelial CD44, *see* CD Antigens, CD44E
- Epithelial cells
 ADF and, 57:406–407
 BCR gene in leukemia and, 57:240
 CD44 isoforms expressed on, 71:255–257
 cervical, human papillomavirus and, 56:143, 152, 153
 CR2 in, 54:290
 developmental patterns of cancers, 70:23–27
 EBV-associated disorders and, 57:330–332, 340, 369, 371–372
 endogenous growth inhibitors and, 57:414, 416, 429, 434–435
 FGF receptor multigene family and, 60:6
 HPRT mutation in, 71:217–219
 immunosuppression and, 60:249–252
 inhibitory effects of TGF- β in, 71:188
 lysophosphatidic acid and, 57:91
 lysosomes and, 60:276
 MHC Class I expression and, 60:198, 202
 multidrug resistance gene and, 60:165, 171
 normal proliferation, perturbed by HPV types, 64:4
 papillomaviruses and, 56:133, 134, 155
 bovine, 56:135
 human, 56:142, 143, 149, 150, 152, 153
 plasminogen activation and, 57:277, 282
 protein tyrosine kinase GFRs and, 60:57
 soft tissue tumors and, 60:95
 somatic mutations and, 71:210
 TGF and, 51:132–133
 TGF- β and, 71:167
 transformational studies, 72:67–68
 tumorigenesis in, MHC effects, 53:166–169
- Epithelial outgrowth, cell lines, 66:123–125
- Epithelial tumors
 EBV⁺, 67:198–199
 microsatellite instability, 67:74–77
 susceptibility to, MHC and, 53:150–169
- Epithelioma
 neovascularization, 69:138
 oncogenes and, 50:89
 stroma and, 50:179
- Epithelium
 APC gene in human cancers and, 62:83
 Burkitt's lymphoma and, 55:135, 225, 226
 chemical carcinogenesis and, 50:60
 biological concepts, 50:33, 35
 experimental models, 50:28, 30–32
 mechanisms, 50:41, 49, 50
 Epstein–Barr virus and, 62:181, 185, 201, 223
 Epstein–Barr virus genes and, 58:1–2, 4, 11, 21
 Epstein–Barr virus proteins and, 50:150
 biology, 50:95, 96
 diseases, 50:98
 virus-produced cells, 50:138
 fibroblast growth factors and, 59:125, 128–129
 gastrointestinal diseases and
 antigenic determinants, 50:16, 17, 19, 22
 esophagus, 50:2, 3
 large intestine, 50:7–10, 12–15
 stomach, 50:3–6
 G protein signal transduction and, 58:83
 intestinal, okadaic acid effects, 61:163–164
 metastatic cancer cells and, 55:88, 109, 113, 120, 121
 oncogenes and, 50:77
 Raf-1 phosphorylation and, 58:56
 renal cell tumors, molecular cytogenetics, 62:111, 115

Epithelium (*continued*)

- reverse transformation and, 62:146
 - stroma and, 50:160, 186, 188
 - alterations, 50:183–185
 - basement membranes, 50:173–176
 - collagen, 50:160, 167
 - collagenases, 50:161
 - collagenolysis, 50:163–165
 - collagenolytic enzymes, 50:162
 - desmoplasia, 50:165–167
 - disorders, 50:180–182
 - elastogenesis, 50:168
 - fibroblasts, 50:177
 - glycoproteins, 50:171, 172
 - plasminogen activator, 50:162, 163
 - productive changes, 50:165
 - proteoglycans, 50:168, 169
 - reactivity, 50:169, 170
 - transforming growth factor- α and, 58:38, 40–42
 - tumor development, 58:44–47
 - Wilms' tumor and, 59:57–58
- Epitopes
- α -fetoprotein and, 56:270, 286
 - B cell-associated surface molecules and, 52:134
 - biochemically defined molecules, 52:118–120
 - CD19, 52:100
 - CD21, 52:103, 104
 - CD22, 52:105, 107
 - CD23, 52:109, 111
 - CDw40, 52:113, 115
 - breast cancer *p53* expression, 59:76–77, 84
 - Burkitt's lymphoma and, 55:151, 234, 239
 - cancer immunotherapy and, 59:255–256
 - cytotoxic T lymphocytes and, 58:146–148; 59:240
 - antigen processing, 59:233–234
 - function, 59:237, 239
 - influenza matrix peptides, 59:232–233
 - peptide MHC, 59:228–229
 - Epstein-Barr virus and, 62:188–190
 - Epstein-Barr virus proteins and, 50:121, 125, 126
 - gastrointestinal diseases and, 50:17
 - gene rearrangements and, 52:47
 - glycosylation in tumors and, 52:317
 - carbohydrate antigens, 52:262, 286–292, 302

- diagnostic applications, 52:303, 305, 308
- glycolipid antigens, 52:283–285
- histo-blood group ABH antigens, 52:294
- therapeutic applications, 52:311, 314, 316
- jun* oncogene and, 55:7, 14
- MHC Class I expression and, 60:187, 195–196
- multidrug resistance and, 52:183, 189
- nonmutated, T cell response, 70:163–166
- peptide-binding heat shock proteins and, 62:165, 169–171
- polyoma virus TSTA and, 55:65, 73, 75–82
- T-cell receptors and, 56:60, 65
- T cell recognition, 66:47–49
- tumor rejection antigens and, 58:193, 199
- tumor-specific immunogenic, 66:55–56
- Epoxide hydrolase, glutathione transferase and, 52:210
- Epstein-Barr nuclear antigens, 57:331–335, 338–341; 58:4–7, 10–21; 69:214
 - biology, 62:182–184
 - Burkitt's lymphoma and
 - chromosomal translocations, 55:204
 - c-myc*, 55:162
 - genetic abnormalities, 55:221, 222
 - phenotype, 55:151
 - synthesis, 55:244, 250
 - transactivator gene, 55:242
 - cytotoxic T lymphocytes and, 58:146–147; 59:236, 239
- EBNA-1, 69:214–216, 223, 224, 226–227
 - in EBV-transformed cells, 67:227
- EBNA-2
 - in AIDS-related lymphomas, 67:141–142
 - defective EBV genotypes, 67:220–224
 - encoded by EBV types A and B, 67:227–228
 - expression patterns in AIDS-NHL, 67:129–130
 - genetic variation, 50:117–119
 - and LMP-1, 67:129–130
 - PCR assay, 67:211
- EBNA-2 and LMP-1, 67:141–142
- EBNA-3
 - in ebnotyping, 67:228–230
 - genetic variation, 50:121–124
- EBNA-4, 50:124–127

- in ebnotyping, 67:228–230
 - type A, containing HLA-A11–restricted CTL epitopes, 67:240–241
- EBNA-5, 50:127–131
 - consistent with *Bam*HI W exon coding capacity, 67:230
- EBNA-6
 - in EBV-transformed cells, 67:228–230
 - PCR assay, 67:211
- EBNAs and LMP-1 and -2, 67:200–204
- Hodgkin's disease, 57:368–369; 62:213, 217, 221–224, 226, 230
- immunodeficiency states and, 57:344–345
- marker detection, 62:184–185
- mRNA expression, 67:200–204
- NHL and AIDS and, 57:364, 366
- organ transplants and, 57:355–362
- peripheral T-cell lymphomas, 62:202–203, 206–208, 210
- polymorphisms, 67:236–237
- T-cell lymphoproliferation, 62:188–189, 191
- tumor rejection antigens and, 58:182
- Epstein–Barr virus, 51:324; 53:34–38; 62:180–181; 69:213–214; 71:131
- ADF and, 57:383, 396, 403–404
- environment, 57:406–407
- identification, 57:389–392
- α -fetoprotein and, 56:280
- ataxia-telangiectasia genes and, 56:79, 84
- B cell-associated surface molecules and biochemically defined molecules, 52:121
- CD19, 52:100
- CD20, 52:93, 99
- CD21, 52:102–104
- CD23, 52:108, 112
- expression on activated cells, 52:131, 133
- history, 52:88
- receptors, 52:126
- B-cell neoplasia and, 53:38
- biology, 62:181–182
 - gene expression, 62:182–184
 - latent gene products, 62:183–184
- B lymphocytes and, 56:314, 317–322, 324, 325, 328–330
- B type, 69:213, 223, 224
- Burkitt's lymphoma and, 55:135–137, 142, 223–225; 68:3–6
 - chromosomal translocations, 55:197, 199, 200, 203, 204
 - clinical significance, 55:250
 - c-myc* expression, 55:187
 - c-myc* structural changes, 55:181–183
 - deregulation, 55:211
 - epidemiology, 55:225–227
 - features, 55:144–148
 - genetic abnormalities, 55:216, 218, 219, 221
 - geography, 55:194
 - latent gene expression, 55:235–238
 - lymphocyte transformation, 55:227–232
 - pathogenesis, 55:240, 241
 - phenotype, 55:151–153
 - synthesis, 55:243–246, 248–250
 - T-cell cytolysis, 55:238–240
 - T cell recognition, 55:233–235
 - transactivator gene, 55:241, 242
 - carrier status, 67:231–234
 - chemical carcinogenesis and, 50:53
 - c-myc* regulation and, 56:22, 26, 27, 32, 34
 - cycle of, immunological control and, 53:35–37
 - cytotoxic T lymphocytes and, 58:146–147; 59:235–236, 239
 - de novo* methylated genome, 66:330
 - diseases associated with, 69:224–228, 235–238
 - CTL response, 69:220–221
 - healthy carriers, 69:222–224
 - primary infection, 69:221–222
 - T cell-mediated control of EBV-associated tumors, 69:224–228
 - humoral response, 69:220
 - immunological control, 69:228–238
 - developing, 69:228–232
 - latency II diseases, 69:232–235
 - latency I/III tumors, 69:235–238
 - DNA in tumors, 68:4–6, 14–15
 - ebnotyping, 67:226–237
 - encoded RNA (EBERs), 57:335
 - biology, 62:182–183
 - Hodgkin's disease, 62:217, 219–222, 225–227, 230
 - marker detection, 62:187
 - pathogenetic models, 62:209, 211–212
 - peripheral T cell lymphomas, 62:199–207
 - T-cell lymphoproliferation, 62:194, 198

- Epstein-Barr virus (*continued*)
- endemic Burkitt's lymphoma and, 53:41-42
 - genome and gene expression, 67:200-204
 - genotypes
 - defective, 67:220-224, 244-245
 - differential recognition by immune system, 67:237-241
 - and ebotypes, sorting, 67:241-243
 - genotyping, 67:204-226
 - glycosylation in tumors and, 52:283
 - gp350/220 envelope proteins of, 54:284-285
 - hepatocellular carcinoma and, 59:210-211
 - Herpesvirus saimiri* and, 56:335, 336, 351
 - genome, 56:345, 348, 349
 - model system, 56:340-343
 - history of, 58:1-4
 - Hodgkin's disease and, EBV genomes in tissues, 62:214-217
 - EBV infection, 62:228-231
 - EBV replication, 62:224
 - epidemiological evidence, 62:212-213
 - histological subtype, 62:225
 - latent EBV gene products in tissues, 62:217-224
 - population studies, 62:225-228
 - prognosis, 62:228
 - serological evidence, 62:212-214
 - host-virus relationships, 69:214
 - latency, 69:214-219
 - virus replication cycle, 69:219-220
 - immunoregulatory defects and, 53:37-38
 - induction of lymphomas, 63:73
 - jun* oncogene and, 55:9, 21
 - malaria and, 53:54-58
 - marker detection
 - viral antigens, 62:184-185
 - viral nucleic acids, 62:185-187
 - nasopharyngeal cancer role, 68:4-5
 - p53* and human malignancies and, 57:261-262
 - particle synthesis, 68:6
 - pathogenesis, 67:244-246
 - replication cycle, 69:219-220
 - role in AIDS-related lymphomagenesis, 67:126-130
 - role in human carcinogenesis, 65:39
 - Src family of tyrosine protein kinases and, 57:113
 - T-cell lymphoproliferation, 62:187-190
 - acute infection, 62:190-191
 - Asian populations, 62:197-202
 - clinico-pathological spectrum, 62:194-197
 - neoplastic T cells, 62:206-208
 - pathogenetic models, 62:209-212
 - peripheral T-cell lymphomas, 62:194-206, 209-212
 - prognosis, 62:208
 - T-cell lymphomas, 62:191-194
 - western populations, 62:202-206
 - T-cell receptors and, 56:64
 - T-cell transformation by, 63:212
 - transmission
 - in bone marrow transplants, 67:198-199, 235-236, 244
 - existing concepts, 67:244
 - study with RFLP, 67:224
 - via salivary contact, 67:198, 231, 244
 - tumor clonality and, 50:223
 - A type, 69:213, 223, 224
 - types A and B, differential detection, 67:205-213
 - vaccine, 69:228-238
- Epstein-Barr virus-associated disorders, 57:330, 372-373
- B cell immortalization, 57:330-331
 - B lymphoproliferative disorders, 57:333
 - Burkitt's lymphoma, 57:333-336
 - Hodgkin's disease, 57:367-371
 - immune response, 57:332
 - immunocompromised individuals, 57:336-337
 - immunodeficiency states, 57:343-345
 - infection, 57:331-333
 - NHL and AIDS, 57:364-366
 - nonhuman primates, 57:371
 - organ transplants, 57:345-346
 - B cell tumors, 57:351-355, 363-364
 - pathogenesis, 57:358-361
 - postgraft disorders, 57:355-358
 - postgraft NHL, 57:346-349
 - serological status, 57:361-362
 - tumor presentation, 57:349-351
 - X-linked lymphoproliferative syndrome, 57:337-343
- Epstein-Barr virus/C3d receptor
- B-lymphocyte, structure and function of, 54:273-275
 - immunochemical analysis of, 54:275-276
- Epstein-Barr virus genes, B lymphocytes and expression

- EBERS, 58:9–10
 membrane proteins, 58:8–9
 nuclear antigens, 58:4–7
- LCL model, 58:17–21
 transcription
 EBNA genes, 58:10–15
 viral membrane proteins, 58:15–17
- Epstein–Barr virus proteins, 50:149, 150; 69:213–215
 biology
 lymphoblastoid cell line, 50:96
 viral tropism, 50:95, 96
- diseases
 Burkitt's lymphoma, 50:96–98
 infectious mononucleosis, 50:98–100
 lymphoproliferative disorder, 50:100
 nasopharyngeal carcinoma, 50:98
- ErbA, *c-erbA* and, 59:97–102
- genome
 DNA structure, 50:100–102
 transcription, 50:102, 103
- transformed cells, 50:137, 138
 differential expression, 50:134–136
 EBNA, 50:104
 EBNA-1, 50:104–113
 EBNA-2, 50:113–121
 EBNA-3, 50:121–124
 EBNA-4, 50:124–127
 EBNA-5, 50:127–131
 identification, 50:136, 137
 latent infection membrane protein, 50:131–134
 virus-produced cells, 50:138, 139
 early genes, 50:141–147
 gene map, 50:140, 141
 productive cycle, 50:139, 140
 virus particle, 50:147–149
- Equilibrium, stroma and, 50:169, 170
- v-erbA* oncogene, angiogenesis, 69:147
- ErbB-2, breast cancer, *p53* expression in, 59:82–83
- v-erbB* oncogene, angiogenesis, 69:148
- Erbstatin, 61:62
- Ergastoplasmic reticulum, Louvain rat
 immunocytomas and, 50:283, 287
- ERG* gene, liposarcomas, 69:74
- ERK, *see* Extracellular signal-regulated protein kinases
- Erucamide, angiogenesis, 69:144
- Erythroblasts, *see also* Avian erythroblastosis virus
c-erbA and, 59:92–93, 104–105
- Erythrocytes
c-erbA and, 59:92, 95, 104–105
 Wilms' tumor and, 59:53
 Zilber and, 59:30
- Erythroid cells, *c-erbA* and, 59:92–93, 101, 103–105
- Erythropoietin, 71:134
 immunotherapy with, 61:69
- Erythropoietin receptors, gp55 binding, 66:304–305
- Escape mechanisms, tumor cell from host control, 72:17–19
- Escherichia coli*
 ADF and, 57:396–398, 400, 405
 Burkitt's lymphoma and, 55:235
 Epstein–Barr virus proteins and, 50:146, 147
 β -galactosidase production, components regulating, 65:216
 genomic instability and, 60:128–132, 138–139
 metabolic regulation studies using, 65:216
 mismatch repair genes, 72:44–45
 multidrug resistance and, 52:184
 oncogene activation and, 51:157
 Ras function and, 62:27
- Esophageal adenocarcinoma
 chromosome 3 losses in, 71:47–48
 microsatellite instability and, 71:215
- Esophageal cancer
 cyclin D1 amplification, 68:86–87, 89
 p16 gene mutations, 68:91–94
 vitamin/mineral supplement effects trials, 61:19–20
- Esophagus
 APC gene in human cancers and, 62:82
 chemical carcinogenesis and, 50:30, 49
 gastrointestinal diseases and, I-3, 50:13
- est1*, genomic instability and, 60:136
- Esterase D
 and recessive hypothesis, 67:13
 Wilms' tumor and, 59:53
- Estradiol
 α -fetoprotein and, 56:278, 279, 281, 293
 diet and, 51:65
 gastrointestinal diseases and, 50:9
- Estrogen receptor gene, CpG island
 hypermethylation, 72:165–166
- Estrogen receptors, and prognostic value of p53, 66:117

- Estrogens
 α-fetoprotein and, 56:256, 270, 271, 276–278, 281
 angiogenesis, 69:144
 in breast cancer progression, 70:82–84
 diet and, 51:63–64
 gastrointestinal diseases and, 50:8
myc family oncogenes and, 57:37
 newborn macrosomy and, 50:250
 prostatic cancer and, 51:2
 role in breast cancer, 65:22
 serum levels, fiber effects, 61:19
 synthetic, growth-inhibitory potential in tumors, 65:51
 TGF and, 51:135
 transforming growth factor-α and, 58:40
- Estrone
 α-fetoprotein and, 56:278, 279
 role in breast cancer, 65:45
- Eta-1, CD44 binding to, 71:273
- Ethionine, chemical carcinogenesis and, 50:31
- Ethnic groups, NBCCS occurrence, 70:57–58
- Ethylmethanesulfonate, oncogene activation and, 51:170
- Ethylnitrosourea, oncogene activation and, 51:154, 159, 160
- Eukaryotes
 adenovirus E1A proteins and, 57:55, 67, 77
 adenovirus proteins and, 52:156
 cell cycle regulation, effect of cyclins, 65:222–223
 DNA methylation, history, 72:142–144
 genomic instability and, 60:129–130, 135–136, 142
 hepatitis B viruses and, 59:197, 202
 higher-order, cytosine methylation roles, 72:144–150
 MHC Class I expression and, 60:208
 multidrug resistance and, 52:185
 multidrug resistance gene and, 60:162, 172
myc family oncogenes and, 57:19–20
 oncoprotein kinases and, 57:187, 215
 transcriptional control and regulation, 65:162
 Zilber and, 59:9
- Evi-1*
 encoding of evolutionarily well-conserved zinc protein by, 54:149–151
 identification of
 in AKXD myeloid tumors, 54:145–151
 retroviral integration in murine myeloid tumors in, 54:141–155
 locus of, proviruses integrated in, location and orientation of, 54:149
 mapping of, to mouse chromosome 3, 54:147, 148
 rearrangements of, detection of, in primary NFS/N myeloid tumors and cell lines, 54:147
 relationship of, to other zinc-finger proteins, 54:151–153
 transcription of, activation of, by viral integration in *Fim-3*, 54:154
- Evolution
 chromosome 3, 71:73–74
c-Myc, 70:114
c-myc, 70:96–100
 monosomic, breast cancers, 67:75
 mouse retrotransposons and, 56:225, 235, 242, 244
 phylogenetic, *fms/flt* supergene family, 67:297–298
 viral, under immunological pressure, 67:243–244
- Evolutionary conservation
 B-Myb, 72:111–112
 DNA-methyltransferase, 72:146–147
- Ewing's sarcoma
 chromosomal aberrations, 69:82, 86–87, 90, 92
 chromosome abnormalities and, 52:30
 t(11;22) translocation, 67:40–43
- EWS domain, fusions in human sarcomas, 67:42–43
- EWS gene, 69:82, 87
- Exons
 adenovirus E1A proteins and, 57:48, 51
bcr/abl gene in leukemia and, 57:159–160, 163–166
BCR gene in leukemia and, 57:227–233, 235, 252
c-myc regulation and
 Burkitt's lymphoma, 56:33, 34, 36, 37, 40
 expression, 56:15–21, 24, 25
 gene topography, 56:2–7, 30, 31
Herpesvirus saimiri and, 56:347
 mouse retrotransposons and, 56:230
myc family oncogenes and, 57:3, 6, 13
 gene expression, 57:18–20

- oncogenic activities, 57:26
 - p53* and human malignancies and, 57:258, 262, 268
 - Src family of tyrosine protein kinases and, 57:113, 116, 118–119
 - Exonuclease, genomic instability and, 60:129
 - Exostosis genes, 69:84
 - Experimental systems, cancer
 - immunotherapy and, 59:275–276
 - Experimental tumors, cancer immunotherapy and, 59:248–250
 - Expression
 - gene, *see* Gene expression
 - libraries, for generation of new monoclonal antibodies, 61:72
 - systems, insertion of cancer antigens, 70:170–172
 - EXT* genes, cartilage-forming tumors, 69:84, 85
 - Extracellular domain, *ret*, 70:194
 - cysteine mutations, 70:200–202, 211–212
 - Extracellular matrix
 - fibroblast growth factors and, 59:116, 126, 136, 138–140, 154
 - lysosomes and, 60:275–276, 280
 - metastatic cancer cells and, 55:88
 - plasminogen activation and, 57:273
 - adhesive interactions, 57:275–284
 - directed cell surface, 57:301–302
 - proteolytic modulation, 57:285–286, 292–293, 297, 299–300
 - reverse transformation and, 62:127, 143–144, 146
 - signal transduction and, 55:271
 - Extracellular matrix receptor III, 71:246
 - Extracellular signal-regulated protein kinases
 - cell function regulation, 63:111
 - cloning, 63:96–97
 - distribution, 63:95–96
 - MEK
 - activation, 63:104–105
 - cDNAs, isolation, 63:103–104
 - identification, 63:102–103
 - purification, 63:102–103
 - regulation, 63:104
 - network, regulation by G proteins, 63:105–106
 - phosphorylation, 63:94–95, 99–100, 107
 - properties, 63:100–102
 - purification, 63:96–97
 - signal transduction
 - mechanisms, 63:93–94
 - phosphorylation role, 63:94–95
 - substrates
 - primary sequence specificity, 63:108
 - sites of possible physiological consequence, 63:109–111
 - Extracolonic cancer, HNPCC and, 71:95–96
 - Extravasation in metastatic process, 54:176–177
 - Ex vivo* genome modifications, 61:79–80
 - Eye
 - protein tyrosine kinase GFRs and, 60:57–58
 - Wilms' tumor and, 59:47
- F**
- 2F10–A, in treatment of lymphoma, 66:306
 - FACS, 51:383–385
 - FADD protein, apoptosis and, 71:129
 - FAF-1 protein, apoptosis and, 71:129
 - Familial adenomatous polyposis, 71:94
 - angiogenesis, 69:149
 - APC* gene in human cancers and, 62:65, 81
 - germline mutations, 62:66–74
 - somatic mutations, 62:77, 79
 - plasminogen activators and, 69:113
 - soft tissue tumors and, 60:80–81
 - and tumor development, 67:65
 - Familial aggregation, prostatic cancer and, 51:21–22, 25–26
 - Familial cancer, incidence of, 56:175
 - Familial colon cancer, calcium supplementation trials, 61:13–15
 - Familial hepatocellular carcinoma, 59:178
 - Familial polyposis, vitamins/fiber effects, 61:17–18
 - Familial studies, lung tumors in humans, 67:102–104
 - Fanconi anemia complementation group, gene mapping, 70:52–55
 - Fanconi's anemia, genomic instability and, 60:136
 - FAR1 protein, 71:176
 - Farmworkers, prostatic cancer and, 51:68–69, 79–80
 - Farnesyltransferase inhibitors, blocking of Ras function, 72:96–97
 - Fas antigen, *p53* gene and, 71:127
 - Fas* gene
 - apoptosis and, 71:129–130, 135, 141–142
 - B lymphocyte differentiation, 71:140

- Fas* gene (*continued*)
 chronic lymphocytic leukemia, 71:146–147
 eosinophilia, 71:142–143
 T-cell viability, 71:138
- Fat
 clinical trials, 61:5–6, 17–19
 metastatic cancer cells and, 55:108
 newborn macrosomy and, 50:250
 saturated, effects on colon tumors, 61:5–6
 soft tissue tumors and, 60:76, 86, 94
- Fatty acids
 α -fetoprotein and, 56:287, 299, 300
 activities, 56:281
 binding, 56:270–274, 276, 279
 cellular uptake, 56:280
 immunoregulation, 56:282–284, 286
 newborn macrosomy and, 50:232, 263, 264
- Fatty acylation, in membrane localization of yeast RAS proteins, 54:97–98
- FBL-3, cytotoxic T lymphocytes and, 58:146, 155–157
- Fc γ R, *see* Fc γ receptor
- Fc receptor
 expression on tumor cells, 64:233–235
 mediated clearance, HIV and, 51:326
 soluble and membrane-bound
 in immune defense, 64:238
 in malignancies, 64:235–237
- Fc γ receptor
 binding sites, and ligand binding, 64:215–217
 class I
 active binding site, 64:216
 structural features, 64:213
 class II
 conformational alteration, 64:233
 role in antibody regulation, 64:230–232
 structural features, 64:213–214
 class III
 cross-linking, 64:220
 specificity and signal-inducing capacity, 64:216
 structural features, 64:214–215
 expression, 64:221–225
 mediated signal transduction, 64:219–221
 membrane-bound, 64:217–219, 227–230
 regulatory role, 64:230–233
 sFc γ R production by proteolytic cleavage, 64:228–230
 shedding, 64:228
 soluble, 64:225–227
 regulatory role, 64:230–233
- FDC-P1 cells, transformation
 by CSFs, 63:66–67, 70, 75
 by oncogenes, 63:74
 by viruses, 63:74, 76
- 2F10–dgA, synergy with cyclosporin A, 66:306–307
- Feedback
 endogenous growth inhibitors and, 57:424–425, 441, 445
 growth regulation and, 57:418, 420–422
 oncoprotein kinases and, 57:207, 209, 214
 stroma and, 50:170
- Feedback loop, positive, and START, 66:193–194
- Feeder layers
 in cell culture system, 66:5–6, 21
 development, 70:6
- Feline leukemia viruses, AIDS and, 51:317
- Fertility, prostatic cancer and, 51:22–23, 28
- Fertilizers, prostatic cancer and, 51:69
- fes/fps* gene family, tyrosine protein kinases and, 57:108–109
- α -Fetoprotein, 56:253–255, 298–300
 activities, 56:280, 281
 ataxia-telangiectasia genes and, 56:79, 81, 83
 binding, 56:270–279
 cellular uptake, 56:279, 280
 chemotherapy, 56:286, 287
 gene expression, 56:294–298
 glycoid studies, 56:265, 266
 immunoregulation, 56:281–286
 interaction with lectins, 56:266–270
 preparation, 56:255–257
 properties, 56:257–264
 synthesis, 56:287–294
- FGF receptor multigene family, 60:2, 33–35
 alternative splicing, mRNA, 60:28–29
 characterization, 60:11–15
 FGFR 1, 60:8–11
Drosophila, 60:30–31
 early studies, 60:6–7
 expression, 60:28–30
 FGFR 1, 60:8–15, 34
 alternative splicing, 60:28–29
Drosophila, 60:30–31
 expression, 60:29–30
 ligand binding, 60:24–27
 multiple forms, 60:15–23

- signal transduction, 60:32
 - FGFR 2, 60:11–15, 19, 23
 - alternative splicing, 60:28
 - expression, 60:29–30
 - ligand binding, 60:24–28
 - multiple forms, 60:20–23
 - signal transduction, 60:32
 - FGFR 3, 60:11–14, 23–24
 - expression, 60:29–30
 - signal transduction, 60:32
 - FGFR 4, 60:11–15, 23, 31
 - expression, 60:29–30
 - ligand binding, 60:27
 - ligand binding, 60:24–25
 - alternative splicing, 60:25–27
 - specificities, 60:27–28
 - mitogens, 60:2–5
 - multiple forms, 60:23
 - alternative splicing, 60:15–16
 - FGFR 1, 60:15–19
 - FGFR 2, 60:20–23
 - nomenclature, 60:7–8
 - signal transduction, 60:31–33
- FHIT* gene, 71:71–72
- Fiber, dietary
 - effects on colon tumors, 61:5–6
 - effects on MNU-induced mammary tumors, 61:5–6
 - prostatic cancer and, 51:41, 45
- Fibrils, stroma and, 50:162, 165, 183
- Fibrin
 - plasminogen activation and, 57:307, 313
 - adhesive interactions, 57:285, 288, 292, 296, 298
 - plasminogen binding, 69:106
- Fibrin clots, dissolved by plasmin, 70:83–84
- Fibrinogen, plasminogen activation and, 57:294, 312
- Fibrinolysis, plasminogen activation and, 57:285, 292, 297, 312
- Fibroadenomatosis, newborn macrosomy and, 50:242
- Fibroblast growth factor, 59:115–118, 155–156
 - acidic, 59:116
 - biological function, 59:140–144
 - extracellular matrix, 59:139
 - gene expression, 59:126, 128, 130–132
 - oncogenic potential, 59:148–149
 - protein structure, 59:122–124
 - receptors, 59:132, 134–135
 - tumors, 59:152–154
 - angiogenic activity, 67:282–283; 69:143
 - basic, 59:116; 69:157
 - biological function, 59:140–144
 - expression in glioblastoma multiform, 67:292
 - extracellular matrix, 59:138–139
 - gene expression, 59:126, 128–132
 - metastatic cancer cells and, 55:116, 117, 124, 125
 - oncogenic potential, 59:148–149
 - plasminogen activation and, 57:292, 294, 297
 - protein structure, 59:117, 119–122, 119–124
 - receptors, 59:132, 134–136
 - tumors, 59:152–153
- biological function, 59:140–144
- extracellular matrix, 59:138–140
- FGF-3
 - biological function, 59:142–143, 145
 - gene expression, 59:126, 128, 131–132
 - oncogenic potential, 59:147–148
 - protein structure, 59:124
 - tumors, 59:149–152, 155
- FGF-5
 - biological function, 59:141, 143–144
 - gene expression, 59:126, 129, 131–132
 - oncogenic potential, 59:145, 147–148
 - protein structure, 59:125
- FGF-6
 - gene expression, 59:126, 129, 132
 - oncogenic potential, 59:149
 - protein structure, 59:125
- gene expression, 59:126, 128–132
- G protein signal transduction and, 58:78, 85
- induced angiogenesis, 67:265–266
- muscle cell regulation and, 58:108
- oncogenic potential, 59:144–149
- protein structure
 - HST/K-FGF, 59:124–125
 - INT-2, 59:124
 - keratinocyte growth factor, 59:125–127
- receptors, 59:132–137
- tumors, 59:149–155
- Fibroblast growth factor-1, *see* Fibroblast growth factor, acidic
- Fibroblast growth factor-2, *see* Fibroblast growth factor, basic
- Fibroblast growth factor-4, *see* HST/K-FGF

- Fibroblast growth factor-7, *see* Keratinocyte growth factor
- Fibroblast growth factor receptor
 protein tyrosine kinase GFRs and, 60:46, 64
 Raf-1 phosphorylation and, 58:56
- Fibroblasts
 ataxia-telangiectasia genes and, 56:78, 95
 genetic linkage, 56:87, 89
 phenotype, 56:79, 81–84
bclrl1 gene in leukemia and, 57:153, 157, 160–162, 167
 biological activity, 57:169–172
BCR gene in leukemia and, 57:240
 Burkitt's lymphoma and, 55:162, 164
 chromosomal translocations, 55:198, 202
 EBV, 55:231, 232
c-erbA and, 59:90, 92, 98
c-fos protooncogene and, 55:38, 39, 41
 chemical carcinogenesis and, 50:33, 43, 50
c-myc regulation and
 Burkitt's lymphoma, 56:33
 expression, 56:11, 17, 20, 22–24
 gene topography, 56:4
 CpG island hypermethylation, 72:175
 CREF, bovine papillomavirus and, 56:138, 139
 DNA methylation ability, 72:169
 embryonic, TGF and, 51:131–132
 Epstein–Barr virus and, 62:184
 Epstein–Barr virus proteins and, 50:105, 120, 132, 137, 150
 F6, specific PKC isozyme expression, 64:188
 gastrointestinal diseases and, 50:9, 14
 gene rearrangements and, 52:52, 59
 genome exposure and, 62:129, 132, 140–141
 genomic instability and, 60:126
 G protein signal transduction and, 58:76, 83–87
Herpesvirus saimiri and, 56:336
 IAP gene expression and, 51:228–230, *see also* Intracisternal A-particle gene family
 immunosuppression and, 60:249
jun oncogene and, 55:3, 23, 25–27
 Louvain rat immunocytomas and, 50:304
 lysophosphatidic acid and, 57:91–92, 94, 96, 99
 lysosomes and, 60:274–275, 277, 280, 282
 metastatic cancer cells and, 55:119
 MHC Class I expression and, 60:201, 226
 mitogen-activated RB phosphorylation, 64:36–38
 mouse retrotransposons and, 56:232, 237
 muscle cell regulation and, 58:97–100, 107, 109, 112
myc family oncogenes and, 57:12–13, 29, 33, 36–37
 nontumorigenic skin, in Li-Fraumeni families
 altered DNA *de novo* synthesis, 61:206–207
 radioresistance, 61:20, 205
 topoisomerase activity levels, 61:206
 oncogene activation and, 51:171, 173
 oncoprotein kinases and, 57:208–209, 211–214
p53 and human malignancies and, 57:259, 263–265
 papillomaviruses and, 56:133
 bovine, 56:135, 138–140
 human, 56:143, 147, 148, 153, 154
 peptide-binding heat shock proteins and, 62:163
 plasminogen activation and
 adhesive interactions, 57:276–278, 283–284
 directed cell surface, 57:300–301
 proteolytic modulation, 57:291, 294, 296
 protein tyrosine kinase GFRs and, 60:62
 protooncoprotein tyrosine kinases and, 57:188, 197, 201, 203–205
 Raf-1 phosphorylation and, 58:56
 Ras function and, 62:23, 40, 43–44
 rat embryo, *myc* family oncogenes and, 57:12–13, 29, 33, 36
 renal cell tumors, molecular cytogenetics, 62:116
 reverse transformation and, 62:127, 133, 135
 soft tissue tumors and, 60:76–77, 83, 87, 100, 109–110
 Src family of tyrosine protein kinases and, 57:108, 112, 117–119, 121
 stroma and, 50:186
 alterations, 50:183
 epithelium, 50:163–169

- generalized changes, 50:177, 178
 - glycoproteins, 50:171
 - local changes, 50:177
- T-cell receptors and, 56:64, 65
- TGF and, 51:131–132, 134
- transforming growth factor- α and, 58:
 - 43–44, 46–47
- tumor clonality and, 50:198, 199, 206
- tumor rejection antigens and, 58:191, 193, 201
- Wilms' tumor and, 59:61
- Fibrohistiocytic tumors, chromosomal aberrations, 69:67–69
- Fibromatosis
 - angiogenesis, 69:157
 - bovine papillomavirus and, 56:139
 - chromosomal aberrations, 69:65, 66
 - fibroblast growth factors and, 59:153
 - soft tissue tumors and, 60:80–82, 100
- Fibronectin
 - glycosylation in tumors and, 52:291, 317
 - oncoprotein kinases and, 57:203
 - plasminogen activation and
 - adhesive interactions, 57:275, 277–278, 280–284
 - directed cell surface, 57:301–303, 311–312
 - proteolytic modulation, 57:285, 290, 292, 294
 - plasminogen binding, 69:106
 - Ras function and, 62:45, 48–49
 - reverse transformation and, 62:127, 133, 140
 - stroma and
 - basement membranes, 50:173
 - epithelium, 50:160
 - glycoproteins, 50:170–172
- Fibronexus, plasminogen activation and, 57:276–277, 300
- Fibropapillomaviruses, 56:138, 139, 142, 147
- Fibrosarcoma
 - adult, chromosomal aberrations, 69:66
 - angiogenesis, 69:157
 - fibroblast growth factors and, 59:152–153
 - gastrointestinal diseases and, 50:19
 - lysosomes and, 60:282
 - MHC Class I expression and, 60:189, 217
 - oncogene activation in, 51:151–153
 - papillomaviruses and, 56:139, 146
 - soft tissue tumors and, 60:76, 78, 80, 87
 - chromosomal abnormalities, 60:95, 99–100
 - tumor suppressor genes, 60:100
 - stroma and, 50:161
 - tumor cell invasion, 69:111
 - tumor clonality and, 50:225
 - animal tumors, 50:217, 219, 223
 - distinction, 50:204, 206, 211
 - pleoclonal tumors, 50:212, 214
- Fibrosarcoma cells, plasminogen activation and, 57:299–300
- Fibrosis, stroma and, 50:180–183, 186
- Fibrous tissue tumors, chromosomal aberrations, 69:65–67
- Filaments, Epstein–Barr virus proteins and, 50:147
- Filopodia, induction by CDC42, 72:82–83
- Fim-3*, activation of transcription of *Evi-1* by viral integration in, 54:154
- Finite urn model, cancer incidence data and, 56:175, 180, 188
- FISH, *see* Fluorescence *in situ* hybridization
- Fisher, R.A., role in study of population genetics, 65:6
- Five-stage model, cancer incidence data and, 56:197, 199–201, 205, 211
- Fixation
 - chemical carcinogenesis and, 50:42
 - Epstein–Barr virus proteins and, 50:139
- FKBP-12, TGF- β receptors, 71:185
- FKHR* gene, rhabdomyosarcomas, 69:77
- flb*, protein tyrosine kinase GFRs and, 60:56–57
- flg* gene
 - amplification in breast cancer, 61:38–39
 - protein tyrosine kinase GFRs and, 60:64
- Flg receptor, fibroblast growth factors and, 59:133–136
- FLI1* gene, 69:87
- Flt receptor family, for VEGF, 67:296–308
 - biological functions, 67:301–302
 - signal transduction, 67:302–304
 - structural characteristics, 67:297–301
- Fludarabine, interaction with ara-C, 72:221
- Fluorescence
 - chemical carcinogenesis and, 50:57
 - Epstein–Barr virus proteins and, 50:110, 139, 140
 - lysosomes and, 60:271
 - oncogenes and, 50:84
 - T-cell receptors and, 56:55

- Fluorescence (*continued*)
 tumor clonality and, 50:204
- Fluorescence activated cell sorter, 51:
 383–385
- Fluorescence *in situ* hybridization
 bone and soft tissue tumors, 69:64–91
 chromosome loss detection, 68:234, 245
- 5-Fluorouracil, cancer immunotherapy and,
 59:276–277, 280
- Flutamide, gastrointestinal diseases and, 50:8
- fmr-1*, genomic instability and, 60:140–141
- fms* gene, effects on radiation response, 61:210
- Fms/Kit/PDGFR, 67:5–Ig-type receptors,
 297–299
- Focal proliferation
 hepatocyte phenotypes, 70:31–32
 preceding cancer, 70:25–27
- Folding, p53, 66:101–102
- Follicle-stimulating hormone, secretion, TGF
 and, 51:135
- β -Follicle-stimulating hormone, Wilms'
 tumor and, 59:54
- Follicular thyroid carcinoma, chromosome 3
 losses in, 71:52
- Foods and foodstuffs, prostatic cancer and,
 51:38–41
- Foreign DNA
 diet-ingested, 66:314–316
 insertion mechanism, 66:324–326
 integrated, *de novo* methylation, 66:
 329–335
 uptake through GI tract, 66:338–339
- Forssman antigens, glycosylation in tumors
 and, 52:294–296
- fos* gene *see also c-fos*
 activated, targeting, 64:258–264
c-fos expression and transcription, okadaic
 acid-induced, 61:166–167
 complex with alternative *jun* members,
 64:259
 cooperation with
 Ha-*ras*, 64:274–278
 TGF α , 64:278–280
 G protein signal transduction and, 58:80
 human papillomavirus and, 56:150
jun oncogene and, 55:2, 22
 lysosomes and, 60:277
 MHC Class I expression and, 60:199, 220
- Fos protein
jun oncogene and
 dimerization, 55:14–17
 hierarchical order of functions, 55:29
 leucine zipper, 55:17–21
 oncogenicity, 55:28
 regulation, 55:23
 signals, 55:31
myc family oncogenes and, 57:8–10
- Foulds, L., multistep theory of tumor
 development, 72:1–20
- Founding mutations, 71:110–111
- fps*, leukemia and, 57:174
- v-fps* oncogene, angiogenesis, 69:147
- FR3T3 cells, bovine papillomavirus and, 56:
 138, 139, 141
- FRA3B region, 71:70–71
- Fractionation, Epstein–Barr virus proteins
 and, 50:113, 124
- Fragile histidine triad gene, 71:71
- Fragile sites, 71:70–71
- Fragile X syndrome, 66:335
 genomic instability and, 60:140–141
- Free radicals, genomic instability and, 60:
 145–147
- French-American-British classification,
 chromosome abnormalities and, 52:9,
 12, 13, 18
- Friend erythroleukemia cells, gastrointestinal
 diseases and, 50:19, 21
- Friend leukemia virus
 cytotoxic T lymphocytes and, 58:146,
 155–157, 162
 tumor rejection antigens and, 58:182
- Frog virus 3, methylated genome, 66:
 333–334
- Fucose, α -fetoprotein and, 56:265, 267, 269,
 270
- Fucosylation, glycosylation in tumors and, 52:
 316, 317
 diagnostic applications, 52:303
 glycolipid antigens, 52:268–270,
 273–275, 277
- Fujinami sarcoma virus, oncogenes and,
 50:82
- Fungal diseases, AIDS and, 51:337, 338
- FUS* gene, bone and soft tissue tumors, 69:74
- Fusion
 cell, 70:15–16
 tumor clonality and, 50:198, 217
- Fusion genes
BCR-ABL, 67:32–33
E2A-PBX1, 67:32–34
EWS-WT1, 67:42–43

- fv-Abl protein, leukemia and, 57:161
 fyn, tyrosine protein kinases and, 57:105, 111–112, 118–120
- G**
- gadd45*, 71:3
- gag* gene
c-erbA and, 59:97
 cytotoxic T lymphocytes and, 58:146
 fibroblast growth factors and, 59:151
 leukemia and, 57:161–162, 167, 169
 mouse retrotransposons and, 56:223, 224, 228
 protein tyrosine kinase GFRs and, 60:62
 tumor rejection antigens and, 58:182
- Gag protein
 cytotoxic T lymphocytes and, 59:237
 IAPs and, 51:187, 204–208
 leukemia and, 57:161–162, 167, 169
 oncoprotein kinases and, 57:211
- Gain of function
 mutant forms of p53, 66:99, 106, 108
p53 mutations leading to, 66:155
- Galactose, α -fetoprotein and, 56:267, 268
- β -Galactosidase
 Epstein-Barr virus proteins and, 50:105, 109, 110, 124, 125, 130, 131, 134
 polyoma virus TSTA and, 55:73
 production, components regulating, 65:216
- GALV, *see* Gibbon ape leukemia virus
- Ganglio-series antigens, glycosylation in tumors and, 52:277–281, 316
- Gangliosides, glycosylation in tumors and, 52:259, 317
 carbohydrate antigens, 52:298, 300, 302
 diagnostic applications, 52:306, 307, 309
 glycolipid antigens, 52:262, 277–281
 histo-blood group ABH antigens, 52:296, 297
 therapeutic applications, 52:311, 312, 315, 316
- Gangliosylceramide, glycosylation in tumors and
 carbohydrate antigens, 52:299, 301, 311
 glycolipid antigens, 52:261, 280
 oncogenes, 52:267
- GAP, *see* GTPase-activating protein
- Gap-junction proteins, oncoprotein kinases and, 57:203–204
- Gap junctions, identification, 70:11–12
- Gap proteins, regulation of pair-rule gene expression, 67:45–46
- Gardner syndrome
 gastrointestinal diseases and, 50:12
 soft tissue tumors and, 60:81–82
- Gastric cancer, APC gene in, 62:80–83
- Gastric tumors, gastrin expression, 63:323
- Gastrin
 biology
 normal
 cellular release, 63:311–314
 genes, 63:301–304
 mRNAs, 63:301–304
 progastrin, post-translational processing, 63:304–309
 receptors, 63:314–316
 tumor
 bronchial tumors, 63:321
 colorectal tumors, 63:318–321
 gastric tumors, 63:323
 neuroendocrine tumors, 63:323–324
 ovarian tumors, 63:320–322
 pancreatic endocrine tumors, 63:316–318
 pancreatic exocrine tumors, 63:318
 definition, 63:296–299, 301
 function, 63:296
 future research, 63:336–337
 gastrointestinal diseases and, 50:4, 5
 gene expression at peptide level, 63:308, 322
 identification, 63:295
 measurement
 methods, 63:333–336
 requirements, 63:331–333
 as tumor growth factor, 63:327–330
- Gastrinoma, gastrointestinal diseases and, 50:4
- Gastritis, gastrointestinal diseases and, 50:6
- Gastrointestinal diseases, 50:1, 2
 antigenic determinants, 50:15–22
 esophagus, 50:2, 3
 large intestine, 50:7–13
 modulators, 50:13–15
 stomach, 50:3–7
- Gastrointestinal tract, uptake of foreign DNA, 66:338–339
- Gastrointestinal tumors, *see also specific sites*
 cholecystokinin expression, 63:324–325
 chromosome 3 losses in, 71:47–48
- GBS, 69:160

- GCN4
c-fos protooncogene and, 55:47, 48
jun oncogene and, 55:4–7, 9
 dimerization, 55:16
 hierarchical order of functions, 55:29
 leucine zipper, 55:17, 19, 21
- G-CSF, *see* Granulocyte colony-stimulating factor
- GDP
 G protein signal transduction and, 58:80
 Ras function and, 62:20, 51
 GAPs, 62:30
 Ras guanine nucleotide exchange factors, 62:23, 25–26, 28
- Gender, hepatitis B viruses and, 59:178
- Gene amplification
 in breast cancer
bek, 61:38–39
flg, 61:38–39
 IGF-1 receptor, 61:37–38
neu, 61:32–34
 central nervous system tumor oncogenesis and, 58:126, 129, 131, 136
 diagnostic marker for malignant cells, 72:33
 EGFR, 67:292
 evolution of amplified DNA, 61:108–110
 genomic instability and, 60:126, 141–142
 HDM2, 66:114
 leiomyosarcomas, 69:76
 liposarcomas, 69:73
 malignant fibrous histiocytomas, 69:68
 MDR, 60:160
 mechanisms
 bridge-breakage-fusion cycles, 61:98–99
 centromere recombination, 61:99
 chromosome breakage-acentric element model, 61:100–102
 telomeric fusions, 61:98–99
 unequal sister chromatid exchange, 61:96–97
 MHC Class I expression and, 60:181, 203
myc family oncogenes and, 57:24, 26–27, 33–34
c-myc, 67:12
 in breast cancer, 61:36–37
 oncogene activation, 72:5–6
 oncogenes and, 51:167
 osteosarcomas, 69:83
 PALA-induced, 66:88–89, 148
 protein tyrosine kinase GFRs and, 60:64–65
 regulation
 integration with chromatid telomere fusion model, 61:104–107
 permissivity, 61:89–91
 probability
 stable stimulation, 61:92–93
 transient stimulation, 61:91
 soft tissue tumors and, 60:99, 104–105
 triplet repeat, methylation, 66:335
 Gene deregulation, *myc* family oncogenes and, 57:24–28, 32–34
 Gene dosage
 central nervous system tumor oncogenesis and, 58:126, 129
 reduction, as *p53* mutation, 66:110–111
 and wild-type *p53* effect, 66:120
 Gene expression
 adenovirus E1A proteins and, 57:47–48, 50, 74
 transactivation, 57:50–55, 60, 68, 71
 ADF and, 57:382–383, 398, 402–403
 analyses, 57:396–397
 identification, 57:384–385, 390, 392
bcr/abl gene in leukemia and, 57:157, 163
 animal models, 57:174–175, 177
 biological activity, 57:169–171, 173
 BCR gene in leukemia and, 57:232, 235, 240–243, 245
c-erbA and, 59:97, 100, 104–105
 cytotoxic T lymphocytes and, 59:238
 differential, and radiation response, 61:217–218
 EBV-associated disorders and, 57:331, 372
 Burkitt's lymphoma, 57:333–335
 immunodeficiency states, 57:345
 NHL and AIDs, 57:364–366
 organ transplants, 57:355–361, 363
 X-linked lymphoproliferative syndrome, 57:339–340
 and EBV genome, 67:200–204
 endogenous growth inhibitors and, 57:438
 Epstein-Barr virus genes and, 58:6, 11, 17–21
 fibroblast growth factors and, 59:150, 155
 oncogenic potential, 59:145–146
 protein structure, 59:126, 128–132
Flt family, 67:304–308
 genomic instability and, 60:124, 140–141

- G protein signal transduction and, 58:80, 83
- hepatitis B viruses and, 59:177, 192–195
- in human and murine lung cancers, 67: 91–93
- inhibition, by antisense oligonucleotides, 61:75–77
- lysophosphatidic acid and, 57:87
- multidrug resistance gene and, 60: 157–169
- muscle cell regulation and, 58:104, 106–107, 111
- myc* family oncogenes and, 57:2
- differentiation, 57:14–17
- future perspectives, 57:34, 37
- oncogenic activities, 57:24–34
- regulation, 57:17–24
- oncoprotein kinases and, 57:187, 207–208, 214
- p53* and human malignancies and, 57:257, 259–266, 268–269
- pair-rule, regulation by gap proteins, 67: 45–46
- plasminogen activation and, 57:301–302, 312–313
- adhesive interactions, 57:283–284
- proteolytic modulation, 57:289, 291, 294, 296, 299
- Raf-1 phosphorylation and, 58:70
- RB1* gene, regulation, 61:122–123
- Src family of tyrosine protein kinases and, 57:105, 131
- patterns, 57:112–120
- T-cell proliferation, 57:132–133, 135, 139
- tumor rejection antigens and, 58:192, 199
- VEGF, 67:289–294
- Gene knockout, *B-myb*, 72:128
- Gene mapping, retinoblastoma susceptibility to 13q14.2, 61:117
- Gene products
- cellular, interaction with *p53*, 66:83
- gelsolin, 66:124
- mutated, 70:166–169
- viral, 66:326, 337
- Genes, *see also specific genes*
- activated by wild-type *p53*, 66:155–158
- affecting lung tumor, site of action of, 53: 153–154
- ALL-1*, 66:214–231
- fusion to partner genes, 66:224–228
- homolog of *trithorax*, 66:223–224
- human, cloning, 66:221–223
- BCL-2*, 62:11
- bcl-2*, 66:18–19
- follicular lymphoma development role, 63:57
- bcl-2* and *bax*, 66:146–147
- BCL-6*, 67:136
- BNLF1*, 67:205, 214–218
- breast cancer susceptibility, 72:15–16
- cancer immunotherapy and, 59:257
- candidate, isolation strategies, 70:54–57
- c-fos* and *c-jun*, 66:54–55
- cholecystokinin, 63:301–304, 308, 325
- chromosomes and, 62:4, 6–13
- cig1* and *cig2*, 66:195
- CIP1/WAF1* and *GADD45*, 66:93, 96–98, 156–158
- CIP1/WAF1/SDI1*, 66:87–89
- c-myc*, 66:18–19; 67:12
- colony-stimulating factor, *see* Colony-stimulating factor genes
- competence, 53:2, 14–15
- cytokine, transduced tumor cells, 66: 59–63
- cytokine regulation of MHC gene expression, 63:141–145
- DCC*, 67:17
- in DNA repair and replication, 72:41–42
- DNA replication cycle, Watson-Crick model, 65:19
- early
- induction, and PKC, 64:167–168
- induction and PKC, 64:167–168
- early viral, E1 and E4, 66:331
- encoding cancer antigens, 70:145–172
- encoding IκB proteins, 66:267–270
- Epstein-Barr virus and
- biology, 62:181–184
- Hodgkin's disease, 62:220–224, 226, 229–231
- marker detection, 62:186
- peripheral T cell lymphomas, 62: 206–210
- T-cell lymphoproliferation, 62:192–193, 202
- expression of
- EGF-inducible, 53:15
- for establishment of competence, 53:7–8
- IGF-inducible, 53:15–16
- PDGF-inducible, 53:14–15

Genes (*continued*)

- serum-inducible, 53:10–14
- TGF- β -inducible, 53:16
- fibroblast growth factors and, 59:117, 133, 150
- flt-1*
 - and *flt-4*, 67:300–301
 - and *KDR*, 67:297
- fos*, reverse transformation and, 62:137
- fusion, 66:214
- Fv-4*, major features, tabular presentation, 65:189
- GAGE, 70:162
- gastrin, 63:301–304, 312, 322
- globin, reverse transformation and, 62:137–138
- governing cell cycle, 72:40–41
- growth factor-inducible, 53:22, 23
 - in nonhematologic cells, 53:24
- growth inhibitory, role of RB, 64:76
- H-2* complex, *see H-2* complex
- H-2K*, 66:49–56
- HDM2, 66:113–114
- hematopoietic cytokines, 66:11
- HLA, 67:184
 - transfection, 66:52–54
- HLF*, 67:34–36
- homeobox, *Hox2.4*, 66:16
- host, associated with SV40 transformation, 53:16–17
- HOX11*, 67:32–33, 46–47
- human cancer, 67:7–12
- humoral immune response and, 62:247, 250, 253, 255–256, 261
- hypermethylated during aging, 72:186–187
- interstitial collagenase, 67:288
- Ir-1*, research, 63:15, 18–26
- Kras2*, 67:86–91
- lung tumor susceptibility, candidate, 67:100–102
- major histocompatibility complex,
 - expression, *see* Antigens, and DNA viruses
- mdm2*, and p53, 66:113–114
- MDM2, and wild-type p53 activity, 66:156–157
- MHC, 53:186–188
- MLL*, 67:36–38
- molecular isolation of, from genetic mapping to, 53:135–137
- multidrug resistance
 - mdr*, 61:80
 - regulation of expression, 60:169–176
 - transporter, 60:160, 162–163
 - mdr1*, 66:106
 - regulation of expression, 60:169–175
 - soft tissue tumors and, 60:106
 - transporter, 60:162, 165–168
- muscle cell regulation and, 58:96, 98, 100–105, 108–111, 113
- mutations, in murine lung tumors, 67:86–91
- MYC and TCR, 67:27–31
- nature of, 65:9, 1930s studies regulating
- neu*, peptide-binding heat shock proteins and, 62:169–170
- non-MHC and MHC, interactions of, 53:140–141
- nucleic acid structure, 65:10, 1930s views
- ODC, 70:121–122, 131
- oncogenes, *see* Oncogenes
- p53*, 67:91
- PAX*, 67:47
- peptide-binding heat shock proteins and, 62:154, 163
- peptide transported, abnormalities, 67:180
- promoter regions
 - aging-associated CpG island
 - methylation, 72:178–181
 - mutational changes, 72:181–182
 - protein tyrosine kinase GFRs and, 60:58–59, 64–66
- ras*, 54:79–131; 67:11–12, *see also ras* genes
- Ras function and, 62:19, 36, 38, 47–50
 - GAPs, 62:30, 32
 - Ras guanine nucleotide exchange factors, 62:24–25
- RB1* and *TP53*, 67:14–18
- regulating apoptotic cell death, 72:9–11
- reverse transformation and, 62:135–139, 143–145, 147
- R κ B, 66:264
- serum-inducible, 53:1–25
- soft tissue tumors and, 60:78–79, 109–110
 - chromosomal abnormalities, 60:88
 - cloning, 60:107–108
 - gene amplification, 60:104–105
 - predictors of behavior, 60:105
 - ras* gene, 60:87–88
 - susceptibility, 60:85

- tumor suppressor genes, 60:102–103
- SOS, Ras function and, 62:24–25, 28
- stp*, T lymphocyte transformation by, 63:231–236
- target, *see* Target genes
- c-Myc, 70:121–123
- temperature-sensitive, Rous sarcoma virus, 67:4
- TP53, 67:67–68, 75
- transcriptional control, alteration, 67:26–43
- TRP-1*, 70:159–160
- tumor suppression, tumor susceptibility genes and, 53:121–123
- tumor suppressor, *see* Tumor suppressor genes
- tumor susceptibility, 53:117–170, *see also*
 - Tumor susceptibility genes
 - with and without CpG islands, 72:148–150, 152
- Gene targeting, in study of carcinogenesis, 64:249
- Gene therapy, 61:77–80
 - cytokine, 66:60
 - efficacy, 66:66
 - and foreign DNA insertion, 66:316
 - human cancer, 66:55
 - and transgenic models, 64:289
 - and transgenic research, 66:339–341
- Genetic analysis, Epstein–Barr virus genes and, 58:5
- Genetic approaches to AIDS treatment, 51:350
- Genetic changes, in breast cancer, 66:120–126
- Genetic counseling, for breast cancer, 61:49
- Genetic defects, bypassing, 66:27–28
- Genetic engineering, cancer immunotherapy and, 59:272–273, 288
- Genetic events, in carcinogenesis, 67:16–18
- Genetic instability, *see also* Microsatellite instability
 - p53* and, 71:7–8
- Genetic lesions
 - in AIDS-NHL, 67:120
 - preceded or followed by chronic antigen stimulation, 67:124
 - role in AIDS-related lymphomas, 67:132–139
- Genetic linkage, ataxia-telangiectasia genes and, 56:86–95, 98
- Genetic linkage studies, in murine lung tumorigenesis, 67:95–99
- Genetic markers, metastatic cancer cells and, 55:97
- Genetic mechanisms
 - prostatic cancer and, 51:21–22
 - TPA and, 51:166–167
- Genetic reversion, Ras function and, 62:47–48
- Genetics, 66:11q23 translocations, 213–234
 - breast cancer, *p53* expression in, 59:69–71, 74
 - cancer and, 54:25–58
 - cancer immunotherapy and, 59:258, 292
 - cancer predisposition and, 54:29–36
 - in Fc γ R differential expression, 64:221–222
 - generality in rules of, 65:10–11
 - hepatitis B viruses and, 59:169, 178, 210
 - alterations, 59:208–210
 - genomes, 59:185–189
 - pathogenicity, 59:180, 184
 - viral DNA, 59:207–208
 - human lung tumors, 67:102–104
 - of lung tumor susceptibility, 53:150–152
 - molecular, of predisposition to retinoblastoma, 54:31–36
 - murine lung tumors, 67:83–106
 - nevoid basal cell carcinoma syndrome, 70:49–59
 - population
 - historical origins, 65:6
 - importance of randomness and Mendelism, during 1930s, 65:19
 - retrovirus, history, 69:12
 - techniques for study, in 1930s, 65:13–14
 - of tumor susceptibility, 53:117–170, *see also* Tumor susceptibility genes
- Gene transfer, cancer immunotherapy and, 59:272
- Genistein, 61:62
- Genital warts, HPV, 69:176, 180
- Genitourinary malformation, *see also* WAGR syndrome
 - Wilms' tumor and, 59:43, 47–49, 60
- Genome imprinting
 - DNA methylation and, 54:16–19
 - in epigenetic allele inactivation, 54:50
 - in familial Wilms' tumor, 54:52–54
 - in mixed cancers, 54:55–56
 - tumor progression and, 54:56–58

- Genomes
- adenovirus E1A proteins and, 57:48, 56, 66
 - ADF and, 57:382, 406
 - bcr/abl* gene in leukemia and, 57:154–155, 164
 - cancer cell, increased DNA-methyltransferase activity, 72:171–172
 - EBV-associated disorders and, 57:331, 372
 - Hodgkin's disease, 57:367, 369–370
 - organ transplants, 57:354, 356
 - Epstein–Barr virus, 62:214–217, 229
 - eukaryotic, presence of DNA methylation, 72:143–144
 - exposure, reverse transformation and, 62:125–127
 - defect, 62:127, 129–131
 - DNase I sensitivity, 62:137, 139
 - restoration, 62:132–133
 - ex vivo* modifications, 61:79–80
 - hepatitis B viruses and, 59:185
 - gene expression, 59:192–195
 - organization, 59:185–189
 - structure, 59:189–191
 - virion assembly, 59:191–192
 - Herpesvirus saimiri* and, 56:335, 344
 - dihydrofolate reductase, 56:347
 - model system, 56:337, 339–343
 - proteins, 56:348, 349
 - small RNAs, 56:345–347
 - HPV, and replication, 64:4
 - mouse retrotransposons and, 56:215, 216, 218–224, 232
 - insertion, 56:225, 226, 228
 - LTRs, 56:234, 236, 237, 239
 - myc* family oncogenes and, 57:3, 21–22
 - p53* and human malignancies and, 57:258–259, 263–264
 - Src family of tyrosine protein kinases and, 57:139
 - tumor-cell, manipulation, 61:65
 - viral and cell, integration, 70:14–15
- Genomic alterations, pathways, and tumor type, 67:67–68
- Genomic DNA, mutation rate, 68:229
- Genomic heterogeneity, LMP-1 coding region in *BamHI* N fragment, 67:214–218
- Genomic hybridization, bone and soft tissue tumors, 69:64–91
- Genomic imprinting, loss in insulin-like growth factor II gene, 68:204–205
- Genomic instability, tumor progression and, 60:121–124, 145–147
- definitions, 60:124–126
 - implications, 60:126–127
 - mechanisms, 60:141–142
 - checkpoints, 60:133–134
 - chromosomes, 60:136
 - DNA damage, 60:130–132
 - DNA replication, 60:127–129
 - epigenetic DNA modification, 60:140–141
 - immunoglobulin gene hypermutation, 60:133
 - ploidy, 60:134–136
 - postreplicative mismatch correction, 60:130
 - recombination, 60:137–140
 - quantitative considerations, 60:142–145
- Genomic organization
- of IAPs, 51:185–191
 - of retroviruses, 51:327–329
- Genotoxicity, chemical carcinogenesis and, 50:34, 35, 60
- Genotypes
- breast cancer, 59:74
 - correlation with phenotype, in MEN II, 70:198
 - genomic instability and, 60:146
 - malignancy and, 50:74, 79–81, 86–88
 - dominant oncogenes, 50:81–85
 - recessive oncogenes, 50:85, 86
 - multidrug resistance gene and, 60:167
 - multiple transgenic, development, 64:274–286
 - neoplasia, 70:40–41
 - phenotype to, conceptual approach, 70:42–44
 - protein tyrosine kinase GFRs and, 60:54
 - single transgenic, development, 64:250–274
- Genotyping, Epstein–Barr virus, 67:204–226
- Geographic distribution
- C/D and F/f polymorphisms, 67:219–220
 - EBV genotypes, 67:210–213, 224–226
- Geographic variation, prostatic cancer and, 51:3–6, 23–24, 32–33
- Geography, Burkitt's lymphoma and, 55:192–195, 246
- Gerbil cells, IAP gene family and, 51:258

- Germinal center, humoral immune response and, 62:256–259
- Germinal vesicle breakdown, oncoprotein kinases and, 57:206, 208–210
- Germ-line insertions, mouse retrotransposons and, 56:224–226
- Giant cell tumors, chromosomal aberrations, 69:85–86
- Gibbon ape leukemia virus, 51:310, 312–313
- β -Glucuronidase, lysosomes and, 60:272, 274–276, 281, 283
- Glandular cells, TGF and, 51:135
- gli*, soft tissue tumors and, 60:89, 92, 94, 104
- Glial tumors, genomic instability and, 60:123
- Glioblastoma
- angiogenesis, 69:149, 154, 155, 158, 159
 - CD44 and, 71:292
 - mutations and, 71:114
 - oncogene activation and, 51:153
 - oncogenesis of, 58:122–124, 126, 129, 135–138
 - progression of, loss of heterozygosity and, 54:38–40
- Glioblastoma multiform, expression of VEGF mRNA, 67:291–292
- Glioma
- CD44 and, 71:292, 293
 - cytotoxic T lymphocytes and, 58:159
 - oncogene activation and, 51:155, 159
 - oncogenesis of, 58:122, 124, 126–127, 128, 133–135
 - p16 gene mutations, 68:91–94
- Glioma cells, immunosuppression and, 60:249, 252
- GLN family, mouse retrotransposons and, 56:220–223, 232
- β -Globin, *c-myc* regulation and, 56:32, 35
- Globo-series antigens, glycosylation in tumors and, 52:281–283, 316
- Glucocorticoid receptors, *c-erbA* and, 59:93–94, 106
- Glucocorticoids
- ADF and, 57:405
 - α -fetoprotein and, 56:291
 - mouse retrotransposons and, 56:236, 240
 - myc* family oncogenes and, 57:28
 - plasminogen activation and, 57:303
 - signal transduction and, 55:296
- Glucose
- newborn macrosomy and, 50:232
 - cancrophia syndrome, 50:263
 - epidemiology, 50:265
 - factors, 50:255, 257, 261
 - prophylaxis, 50:271
 - retrospective data, 50:254
 - transplacental carcinogenesis, 50:254, 255
 - Ras activity and, 54:122–125
- Glucose-6-phosphate dehydrogenase
- gene rearrangements and, 52:58
 - (G6PDH) inhibition, DHEA and, 51:394–396, 397, 399, 415–417
 - tumor clonality and, 50:224
 - distinction, 50:203–207, 209
 - human tumors, 50:216, 217
 - pleoclonal tumors, 50:212, 215, 216
- Glucose phosphate isomerase, tumor clonality and, 50:211, 218
- Glutamate dehydrogenase, as target of cAMP-dependent protein kinase, 54:116–117
- Glutathione
- intracellular levels, and Raf-1 activation, 61:22
 - radiation protection by, 61:221
- Glutathione-S-transferase- π gene, hypermethylated in cancer, 72:167
- Glutathione transferase, 52:205–207, 242, 243
- human GT- π , 52:239, 240
 - molecular forms, 52:221, 222
 - human, 52:218–220
 - mouse, 52:220, 221
 - properties, 52:212–215
 - rat, 52:215–218
- multidrug resistance, 52:241, 242
- preneoplastic markers, 52:223, 226, 238, 239
- hepatic enzymes, 52:207–211
 - nonhepatic enzymes, 52:211, 212
- rat GT-P
- application, 52:237
 - extrahepatic preneoplasia, 52:237, 238
 - function, 52:233, 234, 236, 237
 - gene expression, 52:231–233
 - hepatocarcinogenesis, 52:225, 227–229
 - identification, 52:222, 224
 - specificity, 52:229–231, 235
 - tissue distribution, 52:224, 225
- Glycine, Epstein–Barr virus proteins and, 50:127
- Glycogen phosphorylase as target of cAMP-dependent protein kinase, 54:114–115

- Glycogen synthase as target of cAMP-dependent protein kinase, 54:113–114, 115
- Glycoid, α -fetoprotein and, 56:257, 258, 278, 299
interaction with lectins, 56:267–270
studies, 56:265, 266
- Glycolipid, gastrointestinal diseases and, 50:18
- Glycolipid antigens, glycosylation in tumors and, 52:259, 260, 317
carbohydrate, 52:264
diagnostic applications, 52:302, 303, 308
ganglio-series, 52:277–281
globo-series, 52:281–283
histo-blood group P antigens, 52:295
lacto-series, 52:268–277
oncogenes, 52:267
preneoplastic tissues, 52:297
requirements, 52:298, 300–302
therapeutic applications, 52:313, 314
- Glycokadaic acid, isolation, 61:151
- Glycoprotein, *see also* Permeability glycoprotein
adenovirus proteins and, 52:152, 156
B cell-associated surface molecules and biochemically defined molecules, 52:117, 119, 121, 123, 124
differentiation antigens, 52:100, 103, 108, 113, 115, 116
cancer immunotherapy and, 59:276
cytotoxic T lymphocytes and, 59:227, 237
EBV-associated disorders and, 57:330–331, 373
Epstein–Barr virus proteins and, 50:146, 148
gene rearrangements and, 52:50
glycosylation in tumors and, 52:260, 316, 317
carbohydrate antigens, 52:262, 283–291
diagnostic applications, 52:305–308
glycolipid antigens, 52:267
histo-blood group P antigens, 52:295
therapeutic applications, 52:313–315
metastatic cancer cells and, 55:88, 96
MHC Class I expression and, 60:185
multidrug resistance and, 52:172
multidrug resistance gene and, 60:159
myc family oncogenes and, 57:22
plasminogen activation and
adhesive interactions, 57:275, 279–280
directed cell surface, 57:311–312
proteolytic modulation, 57:284, 287, 289, 296, 299–300
protein tyrosine kinase GFRs and, 60:51, 59
soft tissue tumors and, 60:106
Src family of tyrosine protein kinases and, 57:120, 125, 130, 132–133
stroma and, 50:186
adhesion, 50:170–172
basement membranes, 50:173, 176
epithelium, 50:160, 169
T-cell receptors and, 56:52, 53, 57, 65, 70
Glycoprotein 55, breast cancer and, 56:115
cell-mediated immunity, 56:112, 113, 115, 119, 121
immunoprophylaxis, 56:128
therapeutic implications, 56:123–125
Glycoprotein 85, 71:246
Glycoprotein IIb-IIIa, plasminogen binding, 69:105–106
Glycoproteins
Env, gp70, 66:298, 300
membrane, ara-C effect, 72:208
Glycosaminoglycans
fibroblast growth factors and, 59:116, 135
stroma and, 50:186
alterations, 50:183
basement membranes, 50:175
epithelium, 50:168, 169
Glycosidases, stroma and, 50:169
Glycosphingolipids, glycosylation in tumors and, 52:262, 267, 307, 316
Glycosylases, chemical carcinogenesis and, 50:44
Glycosylation
 α -fetoprotein and, 56:257, 265, 269, 270
B cell-associated surface molecules and biochemically defined molecules, 52:118, 121, 123
differentiation antigens, 52:100, 106, 107, 110, 113
expression on activated cells, 52:131
Epstein–Barr virus proteins and, 50:131, 137, 148
fibroblast growth factors and, 59:124–126, 132
hepatitis B viruses and, 59:191
jun oncogene and, 55:25
multidrug resistance and, 52:173, 175, 183
T-cell receptors and, 56:59, 68

- transforming growth factor- α and, 58:32, 36
- Glycosylation in tumors, 52:258–260, 316–318
 - carbohydrate antigens, 52:262–266
 - background, 52:283, 284
 - glycoprotein, 52:287–291
 - lacto-series, 52:284, 285
 - peptide, 52:291, 292
 - requirements, 52:298–302
 - T antigens, 52:285–287
 - therapeutic applications, 52:309–316
- diagnostic applications
 - earlier studies, 52:302, 303
 - serum antigen-antibody complex, 52:307, 308
 - serum antigen levels, 52:303–307
 - tumor imaging, 52:308, 309
- Forssman antigens, 52:296
- glycolipid antigens, 52:260–262
 - background, 52:267
 - ganglio-series, 52:277–281
 - globo-series, 52:281–283
 - lacto-series type 1 chain, 52:268–271
 - lacto-series type 2 chain, 52:270, 272–277
- Hanganutziu-Deicher antigens, 52:296, 297
- histo-blood group ABH antigens, 52:292–294
- histo-blood group P antigens, 52:294–296
- oncogenes, 52:264, 267
- preneoplastic tissues, 52:297
- Glycosylation lysosomes, 60:269
 - MHC Class I expression and, 60:196
 - multidrug resistance gene and, 60:160, 175
 - protein tyrosine kinase GFRs and, 60:43
- Glycosyl phosphatidylinositol,
 - lysophosphatidic acid and, 57:100
- GM-CSF, *see* Granulocyte-macrophage colony-stimulating factor
- GNAI2 gene, 71:69
- GNAT1 gene, 71:69
- GnH-RH, prostatic cancer and, 51:2
- Goblet cell antigen, gastrointestinal diseases and, 50:16
- Golgi
 - cytotoxic T lymphocytes and, 59:233
 - fibroblast growth factors and, 59:124
- Gonadoblastoma, molecular cytogenetics, 62:106
- Gonadotropin releasing hormone, prostatic cancer and, 51:2
- Gonorrhea, prostatic cancer and, 51:57–58, 67, 91
- Gorlin syndrome, 70:49–50
- Goss-Harris technique, Wilms' tumor and, 59:53
- gp39, humoral immune response and, 62:251–252
- gp75, tyrosine-related, 70:159–161
- GP90^{Hermes}, 71:246
- gp96, peptide-binding heat shock proteins and, 62:155–160
 - antigen presentation, 62:172–173
 - chaperone hypothesis, 62:160–166
 - immunity to cancer, 62:167, 170–172
 - specific immunity, 62:167
- gp100
 - identification as melanoma antigen, 70:157–159
 - immunization trials, 70:171
- G6PDH, *see* Glucose-6-phosphate dehydrogenase
- G proteins
 - BCR gene in leukemia and, 57:243
 - coupled receptors, PKC phosphorylated, 64:174
 - lysophosphatidic acid and, 57:93–96, 98–99, 101
 - ras gene-related, 54:79–81
 - signal transduction and, 55:274
- G protein signal transduction, 58:75–76, 89–90
 - ligand-dependent tyrosine kinase activity, 58:76–80
 - receptors, 58:80–83
 - cAMP, 58:83–84
 - oncogenes, 58:87–88
 - oncogenic mutations, 58:84
 - phosphatidylcholine breakdown, 58:88–89
 - stimulation of cell proliferation, 58:84–87
- Graft, EBV-associated disorders and, 57:349–353, 356, 362, 364
- Graft versus host disease, EBV-associated disorders and, 57:345–346, 348, 351
- Gramicidin, multidrug resistance and, 52:167
- Granulation tissue formation, fibroblast growth factors and, 59:141–142

- Granulocyte colony-stimulating factor
 angiogenesis, 69:143
 cancer immunotherapy and, 59:268, 288
 chronic lymphocytic leukemia, 71:146
 and leukemia development
 characterization, 63:50
 differentiation commitment, 63:55
 myeloid leukemia
 initiation, 63:63–64, 70
 suppression, 63:76–77, 81
 progenitor cell formation, 63:56
- Granulocyte–macrophage colony-stimulating factor
 acute myeloid leukemia, 71:148
 cancer immunotherapy and, 59:267, 290
 as immune response adjuvant, 71:353–354
 and leukemia development
 characterization, 63:50
 membrane receptors, 63:71–72
 myeloid leukemia
 initiation, 63:63–66, 70
 suppression, 63:77, 79, 81
 progenitor cell formation, 63:57
 lymphohematopoiesis and, 54:253
 oncogenes and, 50:82
 radioprotective effects, 61:212
 Raf-1 phosphorylation and, 58:58
- Granulocytes
bcr/abl gene in leukemia and, 57:152, 174–175
BCR gene in leukemia and, 57:228
 clones, 66:5–6
 endogenous growth inhibitors and, 57:414, 434
 immunosuppression and, 60:256
 and myeloid cells, 66:20
 plasminogen activation and, 57:293
 Src family of tyrosine protein kinases, and, 57:113–115, 117, 139
 tumor clonality and, 50:208, 216
- Granulocytosis, *bcr/abl* gene in leukemia and, 57:174, 176–177
- Granuloma, EBV-associated disorders and, 57:345
- Grb2*
 multiple complexes in growth factor-stimulated cells, 64:103
 Ras function and, 62:23–25, 28, 35
- Grb2* adaptor protein, Src homology 2 domain, 72:61
- Groove, class I, peptide-binding, 67:164–165, 167
- Ground squirrel hepatitis virus
 genomes, 59:188, 193
 oncogenesis of viral proteins, 59:197
 pathogenicity, 59:180, 182–184
 viral DNA, 59:201–202, 207
- Ground squirrel hepatocellular carcinoma, 59:207
- Growth
 animal cell, serum requirement for, 53:3
 of human tumor cells, stimulation of autocrine, 54:226–231
 inhibition of, 54:229–231
 of normal human cells *in vitro*, 54:214–215
- Growth advantage
 provided by mutant p53, 66:100–101
 provided by mutant p53, 66:111–112
- Growth control
p53 biological functions in, 66:97–98
 proteins in, as target of cAMP-dependent protein kinase, 54:120–122
 Ras-cAMP pathway and, 54:129–131
- Growth factor receptors
 activated, association with SH2, 64:92
 expression of, by melanoma and colorectal carcinoma cells, 54:227–229
 Raf-1 phosphorylation and, 58:66–68, 70
- Growth factors, *see also* specific growth factor
 adenovirus E1A proteins and, 57:78
 ADF and, 57:383, 390–392, 401, 403–406
 apoptosis and, 71:8–9, 15
bcr/abl gene in leukemia and, 57:172
BCR gene in leukemia and, 57:241
 Burkitt's lymphoma and, 55:143, 154
 B cell differentiation, 55:157, 164
 chromosomal translocations, 55:205
 EBV, 55:231, 232
 synthesis, 55:248
 CD44 and, 71:284–285
c-fos protooncogene and, 55:37
 components, as potential oncogenes, 64:6
 cytotoxic T lymphocytes and, 58:153
 endogenous growth inhibitors and, 57:414, 433, 438, 440
 G protein signal transduction and, 58:76, 84–89
 growth regulation and, 57:415, 417–419
Herpesvirus saimiri and, 56:348, 350

- independence from, in human tumor cells
 from metastatic lesions, 54:224–226
- inducible genes, 53:22, 23
 in nonhematologic cells, 53:24
- inducible mRNAs of identified genes, 53:
 17–21
- jun* oncogene and, 55:1, 2, 24
- lysophosphatidic acid and, 57:87–88, 90,
 92
- metastatic cancer cells and
 autocrine growth factors, 55:115–120
 clonal dominance, 55:103, 104
 growth inhibitory molecules, 55:120–
 122
 human malignant melanoma, 55:88,
 110, 111, 113, 124–127
 tissue specificity, 55:122, 123
- muscle cell regulation and, 58:96, 98,
 108–114
- myc* family oncogenes and, 57:12, 21
- myeloid leukemia initiation role, 63:68–69
 autocrine growth factors, 63:69
 extrinsic growth factors, 63:69
- oncoprotein kinases and, 57:185, 214
- peptides antagonistic to, in autocrine
 growth stimulation inhibition, 54:230
- physiology of, 58:28–30, 40–41
- plasminogen activation and, 57:287, 289,
 294, 301
- Raf-1 phosphorylation and, 58:54–59,
 69–70
- renal cell tumors, molecular cytogenetics,
 62:89, 95
- response of cultured cells, 70:9–10
- secretion of, by melanoma and colorectal
 carcinoma cells, 54:227–229
- self-renewal of cell lines by, 63:75
- signaling, role of PKC, 64:169–170
- signal transduction and, 55:272, 277, 298
- tumor
 cholecystokinin as, 63:330–331
 gastrin as, 63:327–330
- Growth factor sensors, D cyclins as, 66:
 196–197
- Growth inhibitors, endogenous, *see*
 Endogenous growth inhibitors
- Growth-inhibitory molecules, metastatic
 cancer cells and, 55:89, 104, 120–122
- Growth promoter, *p53* as, 66:88
- Growth regulation, endogenous growth
 inhibitors and, 57:415–424
- Growth regulators, adenovirus E1A proteins
 and, 57:78–79
- Growth-regulatory factors, 54:213–231
- Growth signals, CD44 and signal
 transmission, 71:275–277
- Growth stimulation, autocrine
 IL-2–dependent, 66:307–308
 IL-4–dependent, 66:303–304
- Growth suppression
 and induction of G₁ arrest, 66:144–145
 reversal, correlation with RB
 phosphorylation, 64:72–73
 by TGF- β , 71:167
 wild-type p53, 66:85–90
- Growth suppressor genes, *see c-erbA*
- GTB-binding proteins related to ras genes, 54:
 79–81
- GTBP* gene, 71:100
- GTBP protein, 71:98
- GTP
 chemical carcinogenesis and, 50:45
- G protein signal transduction and, 58:75,
 79–80
- lysophosphatidic acid and, 57:93–96
- Ras function and, 62:20, 37, 42, 47, 51
- Ras guanine nucleotide exchange
 factors, 62:20, 25–26, 28–29
- signal transduction pathways, 62:37, 42
- GTP antagonists, 61:62
- GTPase-activating protein
bcr/abl gene in leukemia and, 57:159,
 168
- FGF receptor multigene family and, 60:
 32–33
- G protein signal transduction and, 58:
 78–79
- lysophosphatidic acid and, 57:96, 98
- oncoprotein kinases and, 57:206
- Raf-1 phosphorylation and, 58:67–68,
 70
- soft tissue tumors and, 60:84
- Src family of tyrosine protein kinases and,
 57:109, 124
- GTPase-activating proteins, Ras function
 and, 62:20, 29–35, 52
- Ras guanine nucleotide exchange factors,
 62:23, 25, 29
- signal transduction pathways, 62:40, 42,
 44
- GTPase cascade, activation by Ras, role of
 Rho family proteins, 72:78–85

- GTPases, 61:62
 G protein signal transduction and, 58:75, 79–80
 Ras function and, 62:20, 42–43
 GTP binding and hydrolysis, yeast Ras proteins in, 54:91–95
 G→T transversions, p53 mutations, 72:40–41
 Guanine, ring-fission reactions, 65:56
 Guanine exchange factors, interaction with c-Myc, 70:119
 Guanine nucleotide dissociation inhibitors, Ras, 62:23, 26–27, 29, 52
 Guanine nucleotide dissociation stimulators, Ras, 62:23, 27
 Guanine nucleotide exchange factors, Ras, 62:20–28, 47, 51–52
 GAPs, 62:34–35
 signal transduction pathways, 62:40, 42, 44, 46
 Guillain-Barre syndrome, Epstein-Barr virus proteins and, 50:100
 Guinea pig leukemia, IAP gene family and, 51:258–259
 Gut-associated lymphoid tissue, T-cell receptors and, 56:67, 70
- H**
- H-2 complex, history of research
 early studies, 63:11–15, 17–18
 haplotype study, 63:26–27
 heterozygosity, 63:28
Ir-1 gene research integration, 63:23–26
 protein identification, 63:29–30
 H2 complex, on chromosome 17, 67:98–99
 H-2K^b, abrogated expression, 67:176
 H-2K^k, private specificity loss, 67:156–157
 H2 receptor, cancer immunotherapy and, 59:279, 289
 H-2 region, MHC Class I expression and, 60:190
 downmodulation, 60:222, 224–225, 227
 modulation by oncogenes, 60:197, 201
 regulation by oncogenes, 60:209, 212, 215–217
 H3–8, RFLP, 67:14
 H19, expression in Wilms' tumor, 68:205
 HA, *see* Hyaluronic acid
 Hairy cell leukemia
 B lymphocytes and, 56:327, 331
 chromosome abnormalities and, 52:24
 HTLV-II and, 51:315
 Haitian population, AIDS and, 51:335–336
 Haldane, J.B.S., role in study of population genetics, 65:6
Halichondria okadai, okadaic acid isolation, 61:150–151
 Hallogenated pyrimidines, IAPs and, 51:226
 HAMA, *see* Human anti-mouse antibodies
 Hamartomas, chromosomal aberrations, 69:84, 88, 93
 HamT
 binding to Fyn, 64:131–132
 expression *in vivo*, 64:148
 Hanganutziu-Deicher antigens, glycosylation in tumors and, 52:296, 297
 Haplotype, Louvain rat immunocytomas and, 50:280
 Haplotypes, tumor rejection antigens and, 58:179–180, 187, 200
 Harvey murine sarcoma virus
 MHC Class I expression and, 60:198
 oncogenes and, 50:82, 83
 Hawaiian population, prostatic cancer and diet and, 51:33–34
 vitamin A, 51:46–49
 HBX, hepatitis B viruses and, 59:195–199
 Hck, cytokine activation, 68:30–31
hck, Src family of tyrosine protein kinases and, 57:105, 112, 114–115
 HCP, *see* Hematopoietic cell phosphatase
 H-DNA, *c-myc* regulation and, 56:8, 9, 16
 Head and neck squamous cell carcinoma
 CD44 and, 71:293–294
 chromosome 3 losses in, 71:45–47, 75, 76
 cyclin D1 amplification, 68:85–86, 89
 genes for, 71:93
 incidence, 68:85
 p16 gene mutations, 68:91–94
 Head cancer, 13-*cis*-retinoic acid trial, 61:15
 Heart, lysosomes and, 60:278–279
 Heart IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
 Heat shock
 adenovirus proteins and, 52:154
 multidrug resistance gene and, 60:169–170, 174
 Heat shock protein 70, breast cancer, p53 expression in, 59:70, 72, 76
 Heat shock proteins
 as chaperones, 67:163–164
 cognate, hsc70

- complex with mutant p53, 66:102–105, 116
 - dnaK homolog, 66:92
- cognate hsc70, complex with mutant p53, 66:102–105
- cognate hsc 73, complex with RB, 64:64
- gp96 and hsp70, 66:48–49
- MHC Class I expression and, 60:187, 230
- peptide-binding
 - antigen presentation, 62:172–174
 - chaperone hypothesis, 62:160–166
 - hsp70, 62:155–159, 161, 165–166, 174
 - hsp90, 62:155–159, 166
 - immunity to cancer
 - immunotherapy, 62:171–172
 - specific, 62:166
 - tumor antigens, 62:167–171
 - tumor-specific antigens, 62:154–160
- Heat-shock proteins
 - cytotoxic T lymphocytes and, 58:148, 151
 - tumor rejection antigens and, 58:183
- Heavy chains
 - HLA class I, 67:161
 - MHC class I, abnormalities, 67:176–178
- HEBF, 51:372–373
- HeLa cells
 - adenovirus E1A proteins and, 57:57, 65
 - c-myc* regulation and, 56:4, 6, 16, 18, 20
 - essential requirements, 70:9
 - human papillomavirus and, 56:154
 - jun* oncogene and, 55:6–8, 13
 - oncoprotein kinases and, 57:189, 197, 207
 - poliovirus replication and, limitations, 65:146
 - Src family of tyrosine protein kinases and, 57:126
- Helicase, 71:212
- Helix–loop–helix motif
 - basic, in human acute leukemia, 67:26–33
 - c-Myc protein, 70:104–107
- Helix-loop-helix proteins
 - muscle cell regulation and, 58:100–103, 105, 108–114
 - myc* family oncogenes and, 57:8–10, 12–13
- Hemagglutination, polyoma virus TSTA and, 55:61, 66
- Hemangioblastoma, VHL mutations and, 71:60
- Hemangioma, antiangiogenic therapy, 69:161
- Hemangiopericytoma, chromosomal aberrations, 69:78, 88, 89, 93
- Hematological neoplasias
 - and EBV occurrence, 67:211–212
 - gene rearrangements and, 52:57–68
- Hematopoiesis *see also* Hematopoietic system
 - Burkitt's lymphoma and, 55:137, 202, 250
 - c-fos* protooncogene and, 55:41
 - growth factors, 68:24
 - immunosuppression and, 60:256
 - and leukemia, 66:3–20
 - metastatic cancer cells and, 55:97, 120
 - MHC Class I expression and, 60:189
 - phenotypes, 68:23–24
 - protein tyrosine kinase GFRs and, 60:50, 52–53
 - tumor clonality and, 50:200
 - Vav role, 68:40
- Hematopoietic CD44, *see* CD antigens, CD44H
- Hematopoietic cell phosphatase
 - motheaten* mutation in mice, 68:41
 - recruitment, 68:42
 - structure, 68:41
 - tyrosine kinase binding, 68:41
- Hematopoietic cells
 - bcr/abl* gene in leukemia and, 57:157, 164–165
 - animal models, 57:173–175, 177–178
 - biological activity, 57:171–173
 - BCR gene in leukemia and, 57:227–228, 243–253
 - expression, 57:240–243
 - cancer immunotherapy and, 59:276, 286–287
 - c-erbA* and, 59:90, 92, 108
 - chemical carcinogenesis and, 50:49
 - c-myc* regulation and, 56:37
 - fibroblast growth factors and, 59:135–136
 - gene rearrangements and, 52:72
 - lineages, 66:216–217
 - Louvain rat immunocytomas and, 50:293
 - oncogenes and, 50:82, 83
 - proliferation, TGF- β effect, 70:73–74
 - Src family of tyrosine protein kinases and, 57:112, 114, 118–119
 - stroma and, 50:188
 - T-cell receptors and, 56:49, 54, 67
- Hematopoietic dysplasia, chromosome abnormalities and, 52:13

- Hematopoietic growth factors, combined
with ara-C, 72:220, 222–223
- Hematopoietic stem cells
bcr/abl gene in leukemia and, 57:152, 175–177
gene rearrangements and, 52:49
- Hematopoietic system *see also*
Hematopoiesis
apoptosis, 71:122–123, 131, 133
affinity maturation, 71:140
AIDS, 71:142–143
autoimmunity and, 71:142
B-cell differentiation, 71:138–140
B-cell lymphoma, 71:143–144
cytotoxic T lymphocytes, 71:138
immune response downregulation, 71:140–141
inflammation and, 71:141–142
leukemia, 71:144–152
malignancy, 71:143
survival factors and myeloid differentiation, 71:134–135
survival factors and population control, 71:133–134
T-cell differentiation, 71:137–138
CD isoforms in, 71:253–255, 257–259
newborn macrosomy and, 50:255
- Hemizyosity, Wilms' tumor and, 59:49, 54, 60
- Hemolysin, multidrug resistance and, 52:181–184
- Hemophilia
age and risk of, 71:230
HIV and, 51:336
- Hemopoietic regulators, and leukemia development
colony-stimulating factors, *see* Colony-stimulating factors
early *in vivo* work, 63:42–47
future studies, 63:85–86
inducers, 63:72–76
myeloid leukemia
cells in culture, 63:59–62
suppression, 63:76–82
research perspective, 63:41–42
- Hemoregulatory inhibitory peptide,
endogenous growth inhibitors and, 57:433–434
- Hepadnaviruses, 59:168–169, 211
genomes, 59:185
gene expression, 59:192–195
organization, 59:185–189
structure, 59:189–191
viral DNA, 59:199–200, 202, 205, 207–208
virion assembly, 59:191–192
pathogenicity, 59:179–180
avian, 59:184–185
mammalian, 59:180–184
- Heparan sulfate
fibroblast growth factors and, 59:135–136, 139, 146
plasminogen activation and, 57:282–283
stroma and, 50:169, 172, 173
- Heparan sulfate proteoglycans, fibroblast growth factors and, 59:116, 132, 136, 138
- Heparin
acute promyelocytic leukemia therapy, 69:120–121
FGF receptor multigene family and, 60:3, 5, 7–8
fibroblast growth factors and, 59:116–118, 153
extracellular matrix, 59:138–139
protein structure, 59:120–121, 123–124
receptors, 59:135–137
- Heparin-binding EGF-like growth factor,
physiology of, 58:28, 37
- Heparin-binding growth factor, 59:116
- Hepatic marker enzymes, glutathione transferase and, 52:207–211
- Hepatitis
 α -fetoprotein and, 56:270, 288, 290
breast cancer, *p53* expression, 59:75
- Hepatitis B c antigen, epidemiology, 59:173, 175–176
- Hepatitis B e antigen, epidemiology, 59:170, 172–173, 175–176
- Hepatitis B surface antigen
epidemiology, 59:170, 172–175, 177–179
genomes, 59:191–192, 194
oncogenesis of viral proteins, 59:195, 197
viral DNA, 59:202
MHC-II, 63:177
nucleocapsid protein, 63:178
polymerase/termini protein, 63:177–178
truncated surface antigen, 63:179
X protein, 63:178–179
MHC Class I expression and, 60:198

- Hepatitis B viruses, 59:167–170, 210–211
 adenovirus proteins and, 52:158
 effect on MHC expression
 cellular immune response, 63:175
 characteristics, 63:173–174
 MHC regulation
 HBV–DNA integrations, 63:179–180
 mechanism, 63:177–180
 MHC-I, 63:175–177
 epidemiology, 59:170–171
 hepatocellular carcinoma, association with, 59:177–179
 progression to chronicity, 59:173–177
 transmission, 59:171–174
 genetic alterations, 59:208–210
 genomes
 gene expression, 59:193–195
 organization, 59:185–189
 oncogenesis of viral proteins, 59:195–199
 pathogenicity, 59:179–185
 viral DNA, 59:200–208
- Hepatitis B x antigen
 oncogenesis of viral proteins, 59:197
 viral DNA, 59:203
- Hepatitis C virus, 59:170, 199
- Hepatitis delta virus, 59:179
- Hepatoblastoma, soft tissue tumors and, 60:103
- Hepatocarcinogenesis
 glutathione transferase and, 52:206, 242
 molecular forms, 52:216, 221
 preneoplasia, 52:209, 211, 222, 225, 227–234, 237
- Hepatocellular adenoma, oncogene activation in, 51:151–153
- Hepatocellular carcinoma, 59:167–170, 210
 chromosome 3 losses in, 71:51
 cyclin D1 amplification, 68:87, 89
 epidemiology, 59:170–171, 177–179
 genetic alterations, 59:208–210
 genomes, 59:187
 genomic instability and, 60:146–147
 hepatitis B virus role, 68:87
 oncogene activation in, 51:151–153
 oncogenesis of viral proteins, 59:195–199
 pathogenicity, 59:182–185
 soft tissue tumors and, 60:101
 viral DNA, 59:199–200
 cellular targets, 59:203–205
 integrated sequences, 59:200–203
 myc genes, 59:205–208
- Hepatocyte growth factor
 angiogenesis, 69:143
 and c-Met receptor, 67:306
- Hepatocytes
 α-fetoprotein and, 56:287–289, 291–293, 299
 chemical carcinogenesis and, 50:49
 penetration by microcystins and nodularin, 61:176–177
 rare altered, 70:28–29, 31–32
 tumor clonality and, 50:205, 216
- Hepatoma
 α-fetoprotein and, 56:253, 254, 287, 299
 binding, 56:271
 gene expression, 56:294, 295, 297
 glycoid studies, 56:265
 immunoregulation, 56:282–284, 286
 interaction with lectins, 56:266–270
 properties, 56:258, 259
 synthesis, 56:290–293
 immunosuppression and, 60:252
 lysosomes and, 60:273
 oncogene activation and, 51:151–153, 157
 proteins of, absence of bound dye, 65:51–52
 tumor clonality and, 50:216, 220
- HER-2/neu ECD-specific antibody, 71:364
- HER-2/neu* gene, 71:345
- HER-2/neu protein, 71:343, 344
 immunotherapy, 71:343–345, 360
 autoimmune toxicity, 71:356–358
 enhancement methods, 71:362–367
 immunological escape, 71:358–360
 single-chain antibodies, 71:363–364
 tumor growth and, 71:360–362
 monoclonal antibody therapy, 71:343–345, 356–367
 preexistent immunity to, 71:346–351
 vaccines for cancer therapy, 71:346–356
- Herbimycin, 61:62
- Hereditary nonpolyposis colon cancer
 microsatellite instability, 72:44–45
 mismatch repair mutations, 72:12–13, 48
- Hereditary nonpolyposis colorectal cancer
 3p21–p123 gene and, 71:62
 colorectal adenomas and, 71:96
 colorectal cancer associated with, 71:95
 DNA mismatch repair system, 71:211, 212
 extracolonic cancer and, 71:95–96
 Lynch I/II syndromes, 71:95–96

- Hereditary nonpolyposis colorectal cancer
(*continued*)
MMR genes and, 71:101–109, 111,
112–115
tumors in, 71:213
- Hereditary nonpolyposis colorectal cancers
and absence of breast cancer, 67:75
and tumor development, 67:66–67
- Hermes-1 antigen expression, metastasis and,
51:385–386
- Heron hepatitis B virus
genomes, 59:189
pathogenicity, 59:184
- Herpes simplex virus
adenovirus proteins and, 52:159
Epstein–Barr virus proteins and, 50:141,
142, 144, 146, 147, 149
genomic instability and, 60:128
MHC Class I expression and, 60:197–198
syncarcinogen with HPV, 71:331
- Herpesvirus, 69:229–230, 231
AIDS and, 51:324
amplification of latent tumorvirus
genomes, 68:13
effect on MHC expression
cellular immune response, 63:167–169
characteristics, 63:165–167
cytomegalovirus model, 63:165–173
MHC regulation
mechanism, 63:172–173
MHC-I, 63:169–171
MHC-II, 63:171–172
human herpesvirus type 6, T lymphocyte
transformation by, 63:212–213
stp oncogene, T lymphocyte
transformation by, 63:231–236
T-lymphotropic vector, development of, 63:
219–221
- Herpesvirus saimiri*
human T lymphocyte transformation by,
63:223–228
immortalization, 63:221–223
transformation by, 56:335, 336, 350, 351
genome, 56:344
dihydrofolate reductase, 56:347
proteins, 56:348, 349
small RNAs, 56:345–347
model system, 56:336, 337
deletion mutants, 56:343, 344
Epstein–Barr virus, 56:340–343
induction, 56:337, 338
in vitro, 56:338, 339
viral DNA, 56:339, 340
- Heteroantisera, B cell-associated surface
molecules and, 52:85–87, 97, 115, 122
- Heterodimers
Burkitt's lymphoma and, 55:163, 222
c-erbA and, 59:102
c-fos protooncogene and, 55:46–49
fibroblast growth factors and, 59:137
jun oncogene and, 55:15, 16, 21, 23, 28,
29
- Heterogeneity
 α -fetoprotein and, 56:299
binding, 56:273
glycoid studies, 56:265, 266, 270
properties, 56:257–259
synthesis, 56:289, 291
ataxia-telangiectasia genes and, 56:87, 89,
90
breast cancer and, 56:109, 127
cellular, in tumor progression, 72:187–189
chemical carcinogenesis and, 50:26, 31
clonal, in radiation response, 61:199–200
Epstein–Barr virus proteins and,
transformed cells, 50:99, 128, 142
gastrointestinal diseases and, 50:16, 17
Herpesvirus saimiri and, 56:339, 342
metastatic cancer cells and, 55:94–96
mouse retrotransposons and, 56:226, 234,
237, 239
oncogenes and, 50:72, 73, 87
cellular, 50:89–91
maturation arrest, 50:92
p53 and human malignancies and, 57:258–
260
tumor clonality and, 50:199, 200
within tumors, 72:26
- Heterokaryon, muscle cell regulation and, 58:
100, 107
- Heterozygosity
carcinogenesis and, 71:29
central nervous system tumor oncogenesis
and, 58:124–125, 128, 131
genomic instability and, 60:123, 138, 141–
143, 146
loss of, 71:29, 30, 32
APC gene in human cancers and, 62:73,
81–83
in breast cancer, 61:30–31, 41
breast cancer, *p53* expression in, 59:71,
74, 76–78, 80

- central nervous system tumor
 oncogenesis and, 58:128, 132–134, 137
- genomic instability and, 60:127, 137–138, 143–146
- hepatitis B viruses and, 59:208
- lung cancer, 71:37–41, 75
- in mixed cancer, 54:42–49, 55–56
 tumor progression and, 54:37–41
- in MTC, 70:213
- in murine and human lung tumors, 67:93–95
- and mutations, 66:72–73
- as *p53* mutation, 66:110–111
- renal cell carcinoma, 71:44–45, 76
- renal cell tumors, molecular cytogenetics, 62:90, 93, 95, 108, 113, 115
- in retinoblastoma, 61:116
- in tumor progression, 72:15–16
- Wilms' tumor and, 59:47, 49, 51, 53
- Wilms' tumor and, 59:52, 59, 62
- HEV, 51:368–373, 375, 377–380
- H2F1, MHC Class I expression and, 60:213–214, 217, 219–220
- Hh-1*, MHC Class I expression and, 60:230
- Hibernoma, chromosomal aberrations, 69:72, 93
- HIC1 gene, candidate tumor suppressor gene, 72:166
- High endothelial venules, 51:368–373, 375, 377–380
- T-cell receptors and, 56:67, 68, 70
- High-performance liquid chromatography
 α -fetoprotein and, 56:257, 278
- in analysis of chemical nature of polycyclic aromatic hydrocarbons, 65:80–81
- chemical carcinogenesis and, 50:55
- Hippocampus, fibroblast growth factors and, 59:144
- Hirschsprung disease
 with MEN IIA, 70:187, 199
- summary, 70:191–192
- Histamine
 cancer immunotherapy and, 59:279, 289
- gastrointestinal diseases and, 50:4
- Histidine-rich glycoprotein, plasminogen binding, 69:106
- Histidine triad motif proteins, 71:71
- Histo-blood group ABH antigens,
 glycosylation in tumors and, 52:292–294
- Histo-blood group P antigens, glycosylation in tumors and, 52:294–296
- Histochemistry
 lysosomes and, 60:283
- MHC Class I expression and, 60:190, 205
- Histocompatibility, Louvain rat
 immunocytomas and, 50:280, 281, 292, 294
- Histology, murine lung tumors, 67:85–86
- Histone H1, interaction with ara-C, 72:219
- Histone H3, okadaic acid-stimulated
 phosphorylation, 61:165–166
- Histones
 genomic instability and, 60:135
- MHC Class I expression and, 60:187
- Histopathology
 APC gene in human cancers and, 62:80–81
- central nervous system tumor oncogenesis and, 58:122–123, 129–133, 137
- chromosomes and, 62:1
- renal cell tumors, molecular cytogenetics, 62:103
- Hit kinetics, Wilms' tumor and, 59:46
- HIV, *see* Human immunodeficiency virus
- HL60 cells
 BCR gene in leukemia and, 57:244–246
- c-myc* regulation and, 56:8
- Burkitt's lymphoma, 56:33, 35, 37
- expression, 56:9–11, 19, 21, 23
- differentiation, role of PKC, 64:177–178
- myc* family oncogenes and, 57:16–18, 20
- p53* and human malignancies and, 57:262, 266
- RB phosphorylation, inactivation during differentiation, 64:39–43
- Src family of tyrosine protein kinases and, 57:114–115
- HLA antigens
 ataxia-telangiectasia genes and, 56:88
- breast cancer, *p53* expression in, 59:84–85
- Burkitt's lymphoma and
 EBV, 55:227, 233, 234, 238, 239
- synthesis, 55:244, 245
- cancer immunotherapy and, 59:247, 251–252, 256, 285
- class I

- HLA antigens (*continued*)
 expression, alteration in human tumors, 67:171–183
 expression in normal tissue, 67:157–166
 lack of expression, 67:178–180
 molecular assembly, 67:161–165
 restricted T cells, 66:57–59
 and tumor antigens, 67:170–171
 cytotoxic T lymphocytes and, 58:161; 59:227, 229–234
 function, 59:237–240
 EBV-associated disorders and, 57:330, 332, 338, 341
 Epstein–Barr virus genes and, 58:20
 expression, cervical neoplasia, 69:190–193
 hepatitis B viruses and, 59:177, 198
 HLA-A2
 cancer immunotherapy and, 59:252
 cytotoxic T lymphocytes and, 58:144, 166; 59:229–233, 238
 restricted melanoma-reactive CTL, 70:147–148, 151–157
 tumor rejection antigens and, 58:203
 immunosuppression and, 60:249
 MHC Class I expression and, 60:231, 233
 cancer, 60:184, 186–187, 190, 194–195
 downmodulation, 60:222–224, 227–231
 modulation by oncogenes, 60:200–207
 regulation by oncogenes, 60:210–211, 215
 regulation in tumor cells, 60:217, 219–221
 MHC class I molecules, 66:47, 52–53
 soft tissue tumors and, 60:80
 Src family of tyrosine protein kinases and, 57:127
 T-cell receptors and, 56:54, 56, 61, 62
 tumor rejection antigens and, 58:179
 HLH proteins, muscle cell regulation and, 58:100–103, 105, 108–114
 HMGIC gene, lipomas, 69:69, 71, 89
 HMGYI gene, lipomas, 69:71
 hMLH1 gene, 71:62–64, 211
 hMSH2 gene, microsatellite instability and, 71:211
 HNPCC, *see* Hereditary nonpolyposis colon cancer; Hereditary nonpolyposis colorectal cancer
 HNSCC, *see* Head and neck squamous cell carcinoma
 Hodgkin and Reed–Sternberg cells, Epstein–Barr virus and, 62:186, 212, 215–224
 histological subtype in Hodgkin’s disease, 62:186
 infection, 62:229–231
 population studies, 62:225–228
 T-cell lymphoproliferation, 62:192–193, 205
 Hodgkin’s disease, 69:217
 chromosome abnormalities and, 52:24, 26, 27
 cytotoxic T lymphocytes and, 59:240
 EBV-associated disorders and, 57:338, 367–371
 Epstein–Barr virus and, 62:180
 epidemiological evidence, 62:212–213
 genomes, 62:214–217
 histological subtype, 62:225
 infection, significance, 62:228–231
 latent gene products, 62:217–224
 marker detection, 62:186
 population studies, 62:225–228
 prognosis, 62:228
 replication, 62:224
 serological evidence, 62:212–214
 T-cell lymphoproliferation, 62:192, 196–197, 206
 gene rearrangements and, 52:66–68
 lesions, containing EBV types A and B, 67:212–213
 lymphocytic predominance subtype, Epstein–Barr virus and, 62:219–220, 225
 mixed cellularity subtype, Epstein–Barr virus and, 62:213, 217, 220, 224–226
 newborn macrosomy and, 50:251
 nodular sclerosis subtype, Epstein–Barr virus and, 62:213, 220, 224–226
 retroviruses and, 51:311
 tumorvirus search, 68:14–15
 viral etiology of, 51:344
 Homeostasis
 newborn macrosomy and, 50:234, 261
 stroma and, 50:173, 187
 Homing cell adhesion molecule, 71:246
 Homing receptors
 CD44 as, 71:277–278
 Homodimers
 c-fos protooncogene and, 55:46, 49
 jun oncogene and, 55:15, 21, 29
 Max, 70:106–113

- Homogeneity
 Epstein–Barr virus proteins and, 50:112, 145
 Louvain rat immunocytomas and, 50:283
- Homogenous staining regions, metastatic cancer cells and, 55:95
- Homooligomers, formed by *p53* protein, 66:150–154
- Homozygosity
 genomic instability and, 60:123, 138, 141–143, 146
 Wilms' tumor and, 59:50, 52, 54, 58
- Hormone receptors, *c-erbA* and, 59:93, 95, 97
- Hormone response elements
c-erbA and, 59:97, 99, 106–108
 mouse retrotransposons and, 56:240, 242
 signal transduction and, 55:285, 286
- Hormones
 α -fetoprotein and, 56:278, 292
 B cell-associated surface molecules and, 52:113, 125
 B lymphocytes and, 56:331
 carcinogens and, methylcholanthrene in study of, 65:45–46
c-erbA and, 59:90, 106, 108
 function, 59:105–106
 gene expression, 59:104–105
 mutations, 59:102, 104
 protein function, 59:98–101
c-fos protooncogene and, 55:38, 39, 50
 chemical carcinogenesis and
 experimental models, 50:28, 32
 mechanisms, 50:49, 52
 endogenous growth inhibitors and, 57:415, 417–418, 420, 433, 436
 gastrointestinal diseases and, 50:4, 8, 9, 14
 glutathione transferase and, 52:214, 231, 236
 G protein signal transduction and, 58:76, 80, 82, 86, 89
 human papillomavirus and, 56:150
jun oncogene and, 55:1, 30
 lysophosphatidic acid and, 57:90, 94
 mouse retrotransposons and, 56:217, 219, 245
 expression of neighboring genes, 56:231
 LTRs, 56:240–242
 multidrug resistance gene and, 60:171
myc family oncogenes and, 57:37
 newborn macrosomy and, 50:232, 233, 272
 accelerated development, 50:266
 cancrophilia syndrome, 50:261, 263
 case histories, 50:241
 characteristics, 50:241–245
 definition, 50:238
 dependence, 50:269, 270
 epidemiology, 50:266
 factors, 50:261
 prognosis, 50:246, 250
 prophylaxis, 50:270, 271
 retrospective data, 50:254
 risk factors, 50:267, 269
 oncoprotein kinases and, 57:215
 papillomavirus genomes, 71:330
 role in carcinogenesis, 65:22
 signal transduction and, 55:271, 272
 mechanisms, 55:284–286, 294, 297
 plasma membrane receptor, 55:274, 278
 Src family of tyrosine protein kinases and, 57:105, 135
 steroid–thyroid superfamily, 70:63–86
 stroma and, 50:169, 177
 transforming growth factor- α and, 58:43
 tumor clonality and, 50:198, 223
- Hormone therapy, prostatic cancer and, 51:2
- Host–parasite relationships, concomitant immunity in, 54:319–329
- Host tolerance, for therapy, 61:80
- Hox-2.4* gene, 56:230
- HP1*, α -fetoprotein and, 56:296
- HPA-23, AIDS and, 51:347, 356
- HPLC, *see* High-performance liquid chromatography
- hPMS1* gene, microsatellite instability and, 71:211
- hPMS2* gene, microsatellite instability and, 71:211
- 4-HPR, *see* all-*trans*-N4-(Hydroxyphenyl)retinamide
- hprt* gene, 71:217–218
 genomic instability and, 60:139
 somatic mutation, 71:217–221, 228, 230
- HPV, *see* Human papillomavirus
- H-Ras protein, apoptosis, 71:128
- H-ras virus, *bcr/abl* gene in leukemia and, 57:162
- HRS cells, *see* Hodgkin and Reed-Sternberg cells

- hst*, FGF receptor multigene family and, 60:5–6, 24, 27, 35
- HST/K-FGF
 oncogenic potential, 59:145–147
 protein structure, 59:124–125
- HSURs, *Herpesvirus saimiri* and, 56:345–347, 350
- HT-1080 cells, plasminogen activation and, 57:300–307, 309
- HTLV, *see* Human T-cell lymphotropic virus
- Human anti-mouse antibodies, 61:71–72
 cancer immunotherapy and, 59:281
 HER-2/neu immunotherapy, 71:362
- Human B lymphotropic virus, 51:344
- Human cytomegalovirus, 69:229–230
 effect on MHC class I expression, 67:181–182
- Human genetics, cytogenetic studies, in 1930s, 65:6–8
- Human glucocorticoid receptor, *c-erbA* and, 59:93
- Human herpesvirus type 6, T lymphocyte transformation by, 63:212–213
- Human immunodeficiency virus, *see also* Acquired immunodeficiency syndrome
 adenovirus E1A proteins and, 57:54, 68
 ADF and, 57:402
 association with Hodgkin's disease, 67:114
 B lymphocyte dysfunction and, 51:326
 Burkitt's lymphoma and, 55:139, 147–149, 194
 cancer and, 51:342, 344
 CD44 and, 71:287
 cell death and, 51:323–324
c-myc regulation and, 56:19
 cytotoxic T lymphocytes and, 59:233, 235–237
 earliest evidence of, 51:339
 EM of, 51:318–319(*f*)
 epidemiology of, 51:336
 Epstein-Barr virus and, 57:364–366; 62:180, 182, 197, 216, 226; 67:210–213
 etiologic agent of AIDS-NHL, 67:130–131
 Fc receptor-mediated clearance and, 51:326
 hepatitis B viruses and, 59:173, 198
 heterosexual transmission of, 51:336–339
 human T-4 molecule and, 51:322–324
 humoral immunity and, 51:325–326
 infected media, 66:240–245
 KS and, 51:342
 LAV and, 51:319–320, 321–327
 long terminal repeat, 66:262, 280
 molecular biology of, 51:329–335
 monoclonal antibodies and, 51:322
 pathogenesis of, 51:339–340
 pediatric AIDS and, 51:340–341
 proteins, 51:325
 reverse transformation and, 62:144
 role in AIDS-KS, 66:236–240
 serum levels and, 51:326–327
 skin test antigens and, 51:325
 Src family of tyrosine protein kinases and, 57:122
 T cell isolates from, 51:325
 T-cell receptors and, 56:57
 terminology and, 51:317
 thymic abnormalities and, 51:327
- Human leukocyte antigen, *see* HLA antigens
- Human multidrug resistance gene, *see* Multidrug resistance gene, human
- Human papillomavirus, 69:175–176, 203–204; 71:322
 apoptosis and, 71:131
 in cervical cancer, 64:1–3; 71:71, 321–335
 types in, 68:8–11
 in cervical intraepithelial neoplasia, 69:176, 179–180, 182
 in cervical neoplasia
 epidemiology, 69:176
 immunogenetics, 69:194–198
 immunology, 69:182–190
 in cervical screening programs, 71:333–334
 discovery of types, 68:7, 11, 15–16
E4 gene, 71:323
E4 protein, 71:323
E4 proteins, 69:181
E5 gene, 71:324
E5 protein, 69:180–181
E6 gene, 61:80; 71:323
E6 protein, 71:18, 323, 324
E7 gene, 61:80; 71:323
E7 protein, 71:131, 323, 324
 binding to p110^{RH1}, 61:120–121
 effect on MHC expression
 cellular immune response, 63:181–182
 characteristics, 63:180–181
 MHC regulation
 mechanism, 63:184–185
 MHC-I, 63:182–183
 MHC-II, 63:183–184

- encoded oncoproteins, in viral life cycle, **64**:
 15–16
 epidemiological aspects, **71**:327–329
 genome, **71**:322–325
 variability, **71**:326–327
 hepatitis B viruses and, **59**:210–211
 high-risk
 association with malignancies, **64**:2–5
 E6 proteins, interaction with p53, **64**:11
 encoded oncoproteins, **64**:4–5
 versus low-risk, interaction of E7 with
 p107, **64**:16
 oncoproteins, **68**:10
 HPV-11, **69**:176
 HPV-16, **69**:176–178, 183, 186, 187, 189,
 193; **71**:323, 325, 326, 330, 332, 333
 HPV-18, **71**:323, 326, 330
 immune system evasion, **69**:200–201
 HLA expression, **69**:190–193
 viral epitope variation, **69**:198–199
 immunization, **69**:201–203
 infections, **71**:334
 infectious cycle, **69**:180–182
 late genes, **71**:323
 long control region, **71**:322–325
 low-risk, in benign lesions, **64**:2–5
 molecular genetics, **69**:177–178
 oncoproteins, tools and targets, **64**:18–19
 p53 inactivation, **68**:12
 pathology, **69**:179–180
 polymerase chain reaction, **68**:15
 regulation of transcription, **68**:9–10
 role in cancers
 aerodigestive tract, **68**:12, 15
 cervix, **68**:8–11
 skin, **68**:11–12
 subset 18, viral oncogene targeting, **64**:269–
 274
 taxonomy, **71**:325
 transforming activity of, **56**:133–135, 142,
 143, 155
 biochemistry, **56**:154, 155
 cervical carcinoma cells, **56**:153, 154
 primary fibroblasts, **56**:147–149
 primary human cervical cells, **56**:152,
 153
 primary human epidermal keratinocytes,
 56:150–152
 primary rodent epithelial cells, **56**:149,
 150
 rodent cells, **56**:142–147
 tumor development and, **71**:49, 53–54
 type 6, **69**:176
 vaccines, **71**:327
 viral DNA in warts, **68**:6–8
 Human soft tissue tumors, *see* Soft tissue
 tumors, human
 Human T-cell lymphotropic virus
 cell biology of, **51**:320–321
 human T helper lymphocyte
 transformation, **63**:213–221
 immortalization, **63**:221–223
 induction of adult T cell leukemia, **63**:73
 receptors, **51**:323
 type 1, **51**:313–315, 320–321
 adenovirus E1A proteins and, **57**:54
 ADF and, **57**:381–383, 403, 406
 analyses, **57**:392, 395
 biological activities, **57**:399, 401
 identification, **57**:384–388
 associated myelopathy, ADF and, **57**:
 382
 chromosome abnormalities and, **52**:24
 Epstein–Barr virus and, **62**:188, 196,
 198
 gene rearrangements and, **52**:61
 molecular biology, **51**:327–329
 Src family of tyrosine protein kinases
 and, **57**:118, 139
 type 2, **51**:315–316, 320–321
 molecular biology, **51**:327–329
 type 3, **51**:317
 type 4, **51**:319–320, 340
 Humoral immune response, *see* Immune
 response, humoral
 Humoralism, historical origins, **65**:
 21–22
 HUTCH-1, **71**:246
 Hyaladherins, **71**:263
 Hyaluronan fragments, angiogenesis,
 69:144
 Hyaluronate receptor, **71**:246
 Hyaluronic acid
 CD44, internalization and enzymatic
 degradation, **71**:279–280
 CD44 ligand and, **71**:243, 259–272,
 281–282
 stroma and, **50**:168, 169
 Hybridization, *see also* *In situ* hybridization
 ADF and, **57**:393, 400
 bcr/abl gene in leukemia and, **57**:154–155,
 175

Hybridization (*continued*)

- BCR gene in leukemia and, 57:229, 240
- Burkitt's lymphoma and
 - chromosomal translocations, 55:196–198, 202, 203, 205–208
 - c-myc*, 55:181, 185, 187, 190
 - genetic abnormalities, 55:219
 - nonrandom chromosomal translocations, 55:154
- cancer immunotherapy and, 59:290
- central nervous system tumor oncogenesis and, 58:136
- c-erbA* and, 59:103–105
- comparative genomic, renal cell tumors and, 62:117
- DNA, 67:10–12
- DNA–DNA, 66:317–318
- EBV-associated disorders and, 57:353, 355–356, 363, 367, 369–371
- endogenous growth inhibitors and, 57:439, 442
- Epstein–Barr virus and, 62:183, 195, 214
- Epstein–Barr virus genes and, 58:15–16
- Epstein–Barr virus proteins and genome, 50:103
 - transformed cells, 50:110, 118, 121
 - virus-produced cells, 50:142, 145
- filter-based, Epstein–Barr virus and, 62:185–186
- hepatitis B viruses and, 59:170, 199
- jun* oncogene and, 55:8
- Louvain rat immunocytomas and, etiology, 50:295, 297, 300, 302, 303
 - immunoglobulins, 50:288
 - incidence, 50:283
 - in vitro* cell culture, 50:293
 - in vivo* transplantation, 50:293
- metastatic cancer cells and, 55:97, 99
- muscle cell regulation and, 58:98
- myc* family oncogenes and, 57:28
- plasminogen activation and, 57:295
- polyoma virus TSTA and, 55:70, 71
- Ras function and, 62:47
- in situ*
 - chromosomes and, 62:14
 - DNA methylation, 66:336
 - Epstein–Barr virus and, 62:186–187
 - Hodgkin's disease and, 62:215, 217, 219–222, 225–229
 - peripheral T cell lymphomas, and, 62:199, 201–202, 205

- reverse transformation and, 62:132, 144
- in study of KS tumors, 66:239–240
- T-cell lymphoproliferations and, 62:191, 198, 211–212
- stroma and, 50:173
- and suppression of malignancy, 66:26–27
- transforming growth factor- α and, 58:38–39, 41–43
- tumor clonality and
 - distinction, 50:204, 205
 - origin, 50:198, 199
 - pleoclonal tumors, 50:214
- tumor rejection antigens and, 58:187
- Wilms' tumor and, 59:53–54, 57–58

Hybridoma

- B cell-associated surface molecules and, 52:109
- c-myc* regulation and, 56:35
- Epstein–Barr virus proteins and, 50:116
- gastrointestinal diseases and, 50:17
- glycosylation in tumors and, 52:264, 280, 296, 304
- Louvain rat immunocytomas and, 50:293, 294, 306
- metastatic cancer cells and, 55:110
- MHC Class I expression and, 60:200
- T-cell receptors and, 56:56, 61, 62

Hybrids

- adenovirus proteins and, 52:157
- α -fetoprotein and, 56:291, 292
- ataxia-telangiectasia genes and, 56:92, 98
- chromosome abnormalities and, 52:31
- c-myc* regulation and, 56:30, 33–35
 - expression, 56:17, 18, 24
- FGF receptor multigene family and, 60:5, 8, 11, 29
- gene rearrangements and, 52:50, 55, 58, 72, 75
- glutathione transferase and, 52:209
- Herpesvirus saimiri* and, 56:350
- human–mouse, 70:16
- human papillomavirus and, 56:154
- MHC Class I expression and, 60:214, 219, 230
- mouse retrotransposons and, 56:226, 244
- multidrug resistance and
 - amplified genes, 52:175–177
 - P-glycoprotein, 52:179, 187, 189
- proliferation potential of
 - from diploid cell fusions, 54:68–70
 - from immortal cell line fusions with each other, 54:72–73

- long-term, 54:68–73
 - from normal with immortal cell fusion, 54:70–71
- protein tyrosine kinase GFRs and, 60:49, 54, 56, 65–66
- soft tissue tumors and, 60:87, 97–98, 101, 104, 108
- T-cell receptors and, 56:69
- Hydrazine, chemical carcinogenesis and, 50:29
- Hydrocarbons
 - carcinogenic, 66:22–23
 - polycyclic, induced tumors, 66:47–48
- Hydrogen, multidrug resistance gene and, 60:164
- Hydrogen peroxide, genomic instability and, 60:131
- Hydrolysis
 - chemical carcinogenesis and, 50:55, 57
 - FGF receptor multigene family and, 60:31, 33
 - lysophosphatidic acid and, 57:89–90, 94–95
 - stroma and, 50:169
- Hydrophobicity
 - Epstein–Barr virus genes and, 58:9
 - multidrug resistance gene and, 60:158, 160, 162–163
 - transforming growth factor- α and, 58:30
- 8-Hydroxyguanine, genomic instability and, 60:128, 132
- all-*trans*-*N*-4-(Hydroxyphenyl)retinamide
 - clinical trials, 61:16
 - in vitro* testing, 61:9
 - tamoxifen-4HPR combination studies, 61:11–12
- Hydroxytamoxifen, TGF and, 51:133
- Hypercalcemia, transforming growth factor- α and, 58:35, 48
- Hyperdiploidy, renal cell tumors, molecular cytogenetics, 62:111
- Hyperglycemia, newborn macrosomy and, 50:255, 257
- Hyperinsulinemia, newborn macrosomy and cancrophilia syndrome, 50:263
 - characteristics, 50:245
 - definition, 50:238
 - factors, 50:255, 257, 259, 261
 - prophylaxis, 50:271
 - transplacental carcinogenesis, 50:255
- Hyperlipidemia, newborn macrosomy and, 50:263
- Hypermethylation
 - CpG islands
 - in fibroblasts, 72:175
 - in neoplastic cells, 72:154–167
 - and tumor progression, 72:177–186
 - DNA, regions in cancer, 72:152–154
- Hypermutation, genomic instability and, 60:133
- Hyperphosphorylation
 - B-Myb in S phase, 72:123–125
 - of cytokeratins, tautomycin-induced, 61:181–182
 - of intermediate filaments, 61:162–163
- Hyperplasia
 - associated cooperation between *p53* and *Ha-ras*, 64:283
 - Burkitt's lymphoma and, 55:210, 211, 216, 217, 245
 - chemical carcinogenesis and
 - experimental models, 50:28, 29, 32
 - mechanisms, 50:45, 49
 - endogenous growth inhibitors and, 57:414, 416–417, 424–425, 427–428
 - focal, 70:37, 40
 - gastrointestinal diseases and, 50:4, 11
 - and *Ha-ras* activation, 64:277
 - HK1-*fos*-induced, 64:263–264
 - multifocal, in MEN II, 70:182–184
 - newborn macrosomy and, 50:255
 - signal transduction and, 55:296
 - stroma and, 50:179, 180
 - v-*Ha-ras*-induced, 64:257
- Hyperplastic alveolar nodules, as early lesions, 66:121–123
- Hyperproliferation
 - gastrointestinal diseases and, 50:6, 19
 - HPV-induced, 64:2–4
- Hyperthermia
 - cancer immunotherapy and, 59:266
 - lysosomes and, 60:283
- Hypertriglyceridemia, newborn macrosomy and, 50:245
- Hypogammaglobulinemia
 - EBV-associated disorders and, 57:341–343
 - pediatric AIDS and, 51:341
- Hypomethylation, DNA, in cancer, 72:151–152
- Hypospadias, Wilms' tumor and, 59:47–48, 60

- Hypothalamus, newborn macrosomy and, 50:261, 262
- Hypoxanthine phosphoribosyltransferase, Wilms' tumor and, 59:61
- Hypoxia
induced VEGF mRNA, 67:293–294
lysosomes and, 60:278–280
- I**
- I1B 19K protein, apoptosis and, 71:131
- IAP gene family, *see* Intracisternal A-particle gene family
- IAP protein, cellular proliferation, 71:131
- Ibuprofen, *in vitro* testing, 61:9
- ICAM-1, *see* Cell adhesion molecules, ICAM-1
- ICE-like protease
apoptosis and, 71:130
Fas and, 71:129
- Id
muscle cell regulation and, 58:109–110
types and structure, 68:115
- Idiopathic myelofibrosis, chromosome abnormalities and, 52:18
- IGFBP, *see* Insulin-like growth factor binding protein
- IGF-BP3, *p53* and, 71:6, 7
- IGF-I, *see* Insulin-like growth factor I
- IGF-II, *see* Insulin-like growth factor II
- IL-1 converting enzyme, *see* ICE-like protease
- IL-2, *see* Interleukin 2
- IL-3, apoptosis and, 71:9
- Ileocecal lymph nodes, Louvain rat
immunocytomas and, 50:280, 283, 287, 305
- Ileocecal tumors, Louvain rat
immunocytomas and
animals, 50:280, 281
etiology, 50:294, 296, 305
immunoglobulins, 50:282–285
- Ileum, Louvain rat immunocytomas and, 50:283
- Immortality, correlation with permissivity, 61:105–106
- Immortalization
adenovirus E1A proteins and, 57:73–75
bcr/abl gene in leukemia and, 57:172
EBV-associated disorders and, 57:330–332, 339, 360–361
Epstein-Barr virus genes and, 58:3, 5–7, 17, 19, 21
Herpesvirus saimiri and, 56:350
genome, 56:344–348
model system, 56:339, 340, 344
HPV, and E6 and E7, 64:4–5
keratinocyte, 64:273
muscle cell regulation and, 58:97
soft tissue tumors and, 60:77, 83, 100–101
transforming growth factor- α and, 58:44, 46
- Immortalized human bronchial epithelial cells, *raf1* expression-related increase in radiation resistance, 61:209
- Immune complex
bcr/abl gene in leukemia and, 57:168
BCR gene in leukemia and, 57:235, 241, 247, 249
oncoprotein kinases and, 57:211
Src family of tyrosine protein kinases and, 57:114, 129–130
- Immune response
allogeneic, 66:45–46
cancer immunotherapy and, 59:247, 254, 284, 288, 293
coupling with cytotoxicity, 64:289
cytotoxic T lymphocytes and, 59:229, 235, 240–241
downregulation of, 71:140–141
fibroblast growth factors and, 59:155
hepatitis B viruses and, 59:175–176, 181
humoral
AIDS and, 51:325–326
cellular communication during
development, 62:241–242, 260–261
B cell isotype switching, 62:259–260
follicular B cell survival, 62:259–260
immunoglobulin receptor complex, 62:246–249
lymphoid tissue architecture, 62:242–245
membrane immunoglobulin receptors, 62:246–248
naive B cell activation, 62:246–256
T helper cells, 62:245, 248–260
thymus-dependent, 62:242–243, 246
malignancy-triggered, 64:236–237
MHC Class I expression and, 60:182–183, 222, 231–233
cancer, 60:183–189
downmodulation, 60:224–227
modulation by oncogenes, 60:197

- p53-induced, 66:117
 peptide-binding heat shock proteins and, *see* Heat shock proteins, peptide-binding
 polyoma virus TSTA and, 55:59–62, 70, 82
 reverse transformation and, 62:146
 role of heat shock proteins, 66:49
 Src family of tyrosine protein kinases and, 57:134–135
- Immune surveillance
 cytotoxic T lymphocytes and, 59:228, 236, 240
 organ- and tissue-specific effects on, 53:229–231
 tumor rejection antigens and, 58:194–195, 197
- Immune surveillance of tumors, immune deficiency and, 54:313–315
- Immune system
 compartmentalization of, 53:229–230
 differential recognition of EBV genotypes, 67:237–241
 oncogenes and, 50:76
 regulatory role of TGF- β , 70:72–74
 TGF and, 51:135
- Immune T cells, escapes of tumor cells from, 58:160–163
- Immunity
 antitumor
 by cytotoxic T cells, MHC regulation by, 53:93–97
 by NK cells, MHC regulation by, 53:97–103
 concomitant, in host-parasite relationships, 54:319–329, *see also* Concomitant immunity
 Epstein-Barr virus and, 62:206, 229
 Hodgkin's disease, 62:213–214, 219, 221, 224, 226, 231
 T-cell lymphoproliferation, 62:191–193, 210–211
- Immunization
 cancer immunotherapy and, 59:245, 251, 257, 293
 current strategies, 59:287–289
 Epstein-Barr virus, 62:231; 69:228–238
 hepatitis B viruses and, 59:180
 human papillomaviruses, 69:201–203
 metastatic cancer cells and, 55:110
 peptide-binding heat shock proteins and, 62:162–163, 165, 167, 171–173
 polyoma virus TSTA and, 55:58, 65, 68–70, 72–82
 tumor rejection antigens and, 58:178, 183, 185, 205–207
 Zilber and, 59:27
- Immunoassay, chemical carcinogenesis and, 50:57
- Immunocompromised individuals, EBV-associated disorders and, 57:332–333, 336–337, 371–372
 NHL and AIDS, 57:364
 organ transplants, 57:357
- Immunocytochemistry, lysosomes and, 60:274, 277
- Immunocytomas, Louvain rat, 50:279, 280, 305, 306
 animals, 50:280, 281
 description, 50:283, 287
 etiology, 50:294
 chromosomal breakpoints, 50:297–299
 chromosomal translocation, 50:295–297
 incidence, 50:294, 295, 305
 translocation targets, 50:299–304
- immunoglobulins
 history, 50:287
 nomenclature, 50:282, 287, 288
 production, 50:288–291
 incidence, 50:282–286
in vitro cell culture, 50:293
in vivo transplantation, 50:292, 293
 storage, 50:294
- Immunodeficiency
 ataxia-telangiectasia genes and, 56:86, 97
 cancer immunotherapy and, 59:254, 283
 Epstein-Barr virus and, 62:180, 195–196, 226–227
- Immunodeficiency disease, combined, opportunistic tumors associated with, 54:305–306
- Immunoelectrophoresis, Louvain rat immunocytomas and, 50:287, 288
- Immunofluorescence
 in analysis of Epstein-Barr virus, 62:187–188, 190
 Burkitt's lymphoma and, 55:162, 236
 Epstein-Barr virus genes and, 58:8–10, 18
 Epstein-Barr virus proteins and, 50:124, 132

- Immunofluorescence (*continued*)
 gastrointestinal diseases and, 50:19
 polyoma virus TSTA and, 55:62
 Raf-1 phosphorylation and, 58:69
 stroma and, 50:182
 transforming growth factor- α and, 58:32
- Immunogenetics, cervical neoplasia, 69:194–198
- Immunogenicity
 cancer immunotherapy and, 59:292–293
 chemioimmunotherapy, 59:281
 critical factors, 59:251, 254–255
 current strategies, 59:255–257, 259–261, 263, 270
 improvement attempts, 59:282–284, 287–288
 immunosuppression and, 60:259
 MART-1 peptides, 70:153–154
 melanosomal proteins, 70:163–165
 MHC Class I expression and, 60:187–189
 tumors, cytotoxic T lymphocytes and, 58:145–154, 160, 165
- Immunoglobulin-binding factor
 immunoglobulin-induced release, 64:231–232
 relation to Fc γ Rs, 64:226–227
 soluble truncated, 64:237–238
- Immunoglobulin locus, oncogene juxtaposed to, 72:5, 10, 17
- Immunoglobulins, 71:244
 adenovirus E1A proteins and, 57:54, 66, 75
 adenovirus proteins and, 52:152, 157
 APC gene in human cancers and, 62:79
 ataxia-telangiectasia genes and, 56:96, 97
- B cell-associated surface molecules and, 52:83, 118, 120, 122, 124, 129
 biochemically defined molecules, 52:118, 120, 122, 124
 CD19, 52:99, 101, 102
 CD20, 52:91, 93, 96
 CD21, 52:102, 103
 CD22, 52:105–108
 CD23, 52:108–112
 CDw40, 52:114, 115
 expression on activated cells, 52:129
 history, 52:86, 87
 T cells, 52:132
- bcr/abl* gene in leukemia and, 57:157, 173–175
- B lymphocytes and, 56:314, 315
 Burkitt's lymphoma and, 55:135, 136
- B cell differentiation, 55:165–170
 chromosomal translocations, 55:196, 198, 200–208
c-myc, 55:159, 165
 expression, 55:186–188, 190–192
 structural changes, 55:176–178, 180–182, 184
 deregulation, 55:209, 211–213, 216, 217
 EBV, 55:227, 231, 233, 241, 242
 features, 55:145, 147, 148
 genetic abnormalities, 55:217, 218
 nonrandom chromosomal translocations, 55:154–156
 phenotype, 55:150–153
 synthesis, 55:244–249
 translocation mechanism, 55:171–176
- chromosome abnormalities and
 acute lymphoblastic leukemia, 52:20–22
 chronic lymphoproliferative disorders, 52:23
 malignant lymphoma, 52:25, 26
 oncogenes, 52:35
- chromosomes and, 62:11
- c-myc* regulation and
 Burkitt's lymphoma, 56:28–40
 expression, 56:14, 27
 gene topography, 56:5
- EBV-associated disorders and, 57:330, 335–336, 338–342, 344
 NHL and AIDS, 57:364–365
 organ transplants, 57:353–355
- effect on Fc γ R expression, 64:222–223
- Epstein-Barr virus and
 biology, 62:183
 Hodgkin's disease, 62:215–216, 226–227, 230
 T-cell lymphoproliferation, 62:188, 191, 193, 212
- Epstein-Barr virus genes and, 58:2
- FGF receptor multigene family and, 60:23, 34–35
 alternative splicing, 60:28–29
 characterization, 60:8, 13, 15
Drosophila, 60:31
 ligand binding, 60:24–28
 multiple forms, 60:17–21
- fibroblast growth factors and, 59:133–135
 gene rearrangements and, 52:46
 B cell antigen receptor, 52:46–49
 hematological neoplasias, 52:57–68

- simultaneous occurrence, 52:69–72
 - T-cell antigen receptor, 52:50–56
 - T-cell receptor, 52:73
- genomic instability and, 60:124, 133, 138–139
- glycosylation in tumors and
 - carbohydrate antigens, 52:299, 311, 314–316
 - diagnostic applications, 52:302, 304
 - glycolipid antigens, 52:261, 270
- hepatitis B viruses and, 59:211
- humoral immune response and, 62:252–253, 256
- IAP gene family and, 51:249–252
- IgA
 - α -fetoprotein and, 56:281
 - EBV-associated disorders and, 57:368
- IgE, ADF and, 57:403–404
- IgG
 - α -fetoprotein and, 56:255, 281, 285
 - anti-idiotypic, 61:64
 - ataxia-telangiectasia genes and, 56:79
 - cross-linking with Fc γ R, 64:218
 - EBV-associated disorders and, 57:331–332, 337, 341, 368
 - plasminogen binding, 69:106
- IgG-BF, production mechanisms, 64:227–230
- IgH
 - c-myc* regulation and, 56:27, 28, 32, 34, 35
 - in Ly-1⁺ (CD5⁺) B cell lymphoma
 - heavy and light chain loci, analysis, 63:281–284
 - in spleen of grossly normal old and thymectomized mice, rearrangements, 63:284–285
 - mouse retrotransposons and, 56:228
- IgM
 - α -fetoprotein and, 56:285
 - c-myc* regulation and, 56:30
 - EBV-associated disorders and, 57:331, 334, 338, 341, 362, 368
 - T-cell receptors and, 56:65
- immunoglobulin M, humoral immune response and, 62:259
- immunosuppression and, 60:247, 259, 263
- isotypes, differential Fc γ R binding, 64:215–217
- Louvain rat immunocytomas and, 50:279, 280, 305, 306
- animals, 50:281
 - description, 50:283
 - etiology, 50:294, 295, 297, 305
 - history, 50:287
 - incidence, 50:282
 - nomenclature, 50:282, 287, 288
 - production, 50:288–291
 - translocation targets, 50:299–304
- membrane
 - humoral immune response and, 62:242, 256
 - receptors, 62:246–249, 254–255, 257
 - metastatic cancer cells and, 55:97
- MHC Class I expression and, 60:203, 213
- muscle cell regulation and, 58:101–102
- myc* family oncogenes and
 - gene expression, 57:22
 - oncogenic activities, 57:25–26, 28–32
 - protein structure, 57:9–10
- peptide-binding heat shock proteins and, 62:165–166
- reverse transformation and, 62:138
- soft tissue tumors and, 60:107
- Src family of tyrosine protein kinases and, 57:116
- T-cell receptors and, 56:52, 65
- TGF and, 51:135
- tumor clonality and, 50:224, 226
 - animal tumors, 50:223
 - distinction, 50:202, 210
 - human tumors, 50:216
 - pleoclonal tumors, 50:212
- tumor rejection antigens and, 58:191
- Immunohistochemistry
 - detection of p53, 66:109–112, 118, 124–125
 - Epstein–Barr virus and, 62:218, 222
 - multidrug resistance gene and, 60:171
- Immunohistology
 - Epstein–Barr virus and, 62:216, 220–221, 223–224, 226, 230
 - techniques, insensitivity, 67:165–166
- Immunoliposomes, doxorubicin loaded anti-HER-2/neu immunoliposomes, 71:363
- Immunolocalization, fibroblast growth factors and, 59:128
- Immunological control, Epstein–Barr virus cycle and, 53:35–37
- Immunological tolerance, MuLV and, *see* Murine leukemia virus antigens

- Immunology
 breast cancer, *p53* expression in, 59:72, 76–77
 genomic instability and, 60:133
 hepatitis B viruses and, 59:168, 172
 tumor, basis of, 53:182–186
 Zilber and, 59:25–26, 32–35, 37
- Immunomodulation, cancer immunotherapy and, 59:258, 262–263, 277–278
- Immunophenotype, Epstein–Barr virus and, 62:193–194, 212, 226
- Immunophenotyping, ataxia-telangiectasia genes and, 56:84
- Immunoprecipitation
 BCR gene in leukemia and, 57:244–250, 253
 gene rearrangements and, 52:51
 MHC Class I expression and, 60:185, 194
- Immunoprophylaxis, breast cancer and, 56:127, 128
- Immunoregulation, α -fetoprotein and, 56:281–286, 300
- Immunoselection
 MHC-driven, 67:156–157
 randomly produced tumor cell clones, 67:183
 tumor rejection antigens and, 58:203, 205
- Immunosuppression, 60:247–248, 254–255
 acute-phase proteins, 60:257
 Burkitt's lymphoma and, 55:146–149
 EBV, 55:224, 225, 234, 236
 synthesis, 55:244, 245, 250
 cancer immunotherapy and, 59:249, 286
 chemioimmunotherapy, 59:275, 279–281
 current strategies, 59:263
 colony-stimulating factors, 60:255–257
 cytotoxic T lymphocytes and, 58:149, 161, 163; 59:236
 EBV-associated disorders and, 57:366, 371–372
 organ transplants, 57:346–349, 353–354, 359, 361–363
 Epstein–Barr virus and, 62:182, 197
 Epstein–Barr virus genes and, 58:3
 growth-regulatory cytokines, 60:257–261
 lymphocyte blastogenesis inhibitory factor, 60:252
 by malaria, 53:62–64
 MHC Class I expression and, 60:202, 223
 P15E, 60:252–253
 recent evidence, 60:248
 soft tissue tumors and, 60:79
 suppressive E-receptor, 60:253–254
 transforming growth factor- β , 60:249, 251–252
 tumor cells, 60:248–251
 tumor rejection antigens and, 58:184
- Immunosurveillance
 disrupted, and development of AIDS-related lymphoma, 67:120–122
 in EBV pathogenesis, 67:245–246
- Immunosurveillance theory of cancer, 53:182–184
- Immunotherapy, 59:245–248, 292–293; 70:145–172
 active
 nonspecific, 59:258–268
 specific, 59:255–258, 282, 287–292
 adoptive, 59:293
 current strategies, 59:268–274
 improvement attempts, 59:282, 284, 289–292
 AIDS and, 51:348–349
 breast cancer and, 56:123–127
 and cell surface antigens, 66:59–63
 chemioimmunotherapy, 59:274–281
 critical factors, 59:248, 255
 T cell response, 59:248–254
 tumor location, 59:254–255
 gastrointestinal diseases and, 50:18
 HER-2/neu protein, 71:343–345, 356–367, 360
 autoimmune toxicity, 71:356–360
 enhancement methods, 71:362–367
 immunological escape, 71:358–360
 tumor growth and, 71:360–362
 HLA active, 67:184
 improvement attempts
 elimination of suppressor cells, 59:289
 experimental models, 59:282–284
 patient selection, 59:284–286
 tumor debulking, 59:286–287
 multidrug resistance gene and, 60:157
 passive
 adaptive cellular therapy, 61:73–74
 cytokines, 61:66–69
 elimination of PLCs in AKR/J mouse following, 63:267–269
 monoclonal antibodies, 61:69–73
 Immunotoxin, targeted preleukemic cells, 66:306–308
- Inactivation

- gene, promoter region methylation role, 72:185
- tumor suppressor genes, 72:157–159, 176
- Indomethacin, cancer immunotherapy and, 59:256, 262, 279, 286
- Infantile fibrosarcomas, chromosomal aberrations, 69:66, 90, 93
- Infantile X-linked agammaglobulinemia, opportunistic tumors associated with, 54:306
- Infection
 - adenovirus E1A proteins and, 57:47–48
 - transactivation, 57:53, 57–60, 63–65, 69
 - transcription, 57:67–68
 - AIDS and, 51:337–338
 - bcr/abl* gene in leukemia and, 57:172–173, 176–177
 - chronic, in hepatocellular carcinoma
 - epidemiology, 59:173–177
 - viral DNA, 59:199–208
 - EBV, molecular epidemiology, 67:197–246
 - opportunistic, 54:303–304
 - productive and nonproductive, 66:319–324
 - retroviral, 66:294–295
- Infectious mononucleosis
 - EBV-associated disorders and, 57:331–332
 - immunodeficiency states, 57:344
 - organ transplants, 57:349, 352, 361, 363
 - X-linked lymphoproliferative syndrome, 57:337–339, 341–343
- EBV type A in, 67:212–213
- Epstein–Barr virus, 69:218, 221–222
- Epstein–Barr virus genes and, 58:1, 18, 20
- Epstein–Barr virus proteins and diseases, 50:98–100
 - transformed cells, 50:121, 133, 134
- with productive EBV infection, 67:198–199
- Inflammation
 - apoptosis and, 71:122, 141–142
 - cancer immunotherapy and, 59:258–259
 - gastrointestinal diseases and, 50:5
 - genomic instability and, 60:145–147
 - hepatitis B viruses and, 59:168, 181–182
 - immunosuppression and, 60:249, 257
 - lymphocyte homing receptors and, 51:374–376
 - stroma and, 50:184
 - T-cell receptors and, 56:50, 65, 70
 - transforming growth factor- α and, 58:39–40
- Influenza, polyoma virus TSTA and, 55:73
- Influenza matrix peptide, cytotoxic T lymphocytes and, 59:229–233
- Influenza virus
 - cytotoxic T lymphocytes and, 59:237
 - type A, cytotoxic T lymphocytes and, 59:234
- Influenza virus proteins, cytotoxic T lymphocytes and, 59:228–229
- Ingestion, foreign DNA, 66:314–316
- Inhalation, chemical carcinogenesis and, 50:28
- Inheritance, MHC Class I expression and, 60:230
- Inherited predisposition
 - to lung cancer in humans, 67:103–105
 - to lung tumorigenesis in mice, 67:84–95
- Inherited syndromes, genomic instability and, 60:136
- Inhibins
 - homology to TGF- β 1, 70:65
 - TGF and, 51:121–123
- Inhibition
 - α -fetoprotein and, 56:278, 281–284, 292, 293, 299
 - B lymphocytes and, 56:318, 327–330
 - bovine papillomavirus and, 56:137, 138, 141, 142
 - Burkitt's lymphoma and, 55:231, 232, 234
 - B cell differentiation, 55:165
 - chromosomal translocations, 55:197, 202–204
 - c-myc*, 55:162, 163, 165
 - c-myc* structural changes, 55:178, 179
 - deregulation, 55:212, 213
 - genetic abnormalities, 55:222
 - c-fos* protooncogene and, 55:41, 43, 51
 - c-myc* regulation and, 56:17, 25
 - human papillomavirus and, 56:148, 154
 - jun* oncogene and, 55:9, 22
 - metastatic cancer cells and, 55:89, 104, 115–117, 120–122, 124, 127
 - mouse retrotransposons and, 56:230, 236
 - polyoma virus TSTA and, 55:60, 61, 63, 66
 - signal transduction and, 55:281, 285, 286, 289

- Inhibition (*continued*)
- T-cell receptors and, 56:54, 56, 57, 59, 60
 - antigens, 56:51
 - leukocyte integrin family, 56:64–66
 - lymphocyte homing receptors, 56:68
- Inhibitors
- adenovirus E1A proteins and, 57:61, 73, 75–76
 - bcr/abl* gene in leukemia and, 57:178
 - BCR gene in leukemia and, 57:235, 241–242, 249–250
 - breast cancer, *p53* expression in, 59:71–72, 74
 - cancer immunotherapy and, 59:246, 289
 - chemoimmunotherapy, 59:276, 279
 - current strategies, 59:259–260, 262, 268, 273
 - central nervous system tumor oncogenesis and, 58:134, 138
 - c-erbA* and, 59:101–109
 - cytotoxic T lymphocytes and, 58:162
 - EBV-associated disorders and, 57:334, 346, 359, 362–364
 - endogenous growth, *see* Endogenous growth inhibitors
 - FGF receptor multigene family and, 60:2, 4, 32, 34
 - fibroblast growth factors and, 59:131, 142, 146
 - protein structure, 59:119, 121
 - tumors, 59:152, 154
 - genomic instability and, 60:134, 145–146
 - G protein signal transduction and, 58:75, 79–82, 84–87
 - immunosuppression and, 60:248–249, 251–256, 258, 260–261
 - lysophosphatidic acid and, 57:94–96, 98, 101
 - lysosomes and, 60:276, 279, 283
 - MHC Class I expression and, 60:196, 213–214, 218, 226
 - multidrug resistance gene and, 60:167–171
 - muscle cell regulation and, 58:97, 101, 106–114
 - myc* family oncogenes and, 57:12
 - oncoprotein kinases and, 57:208, 210, 212–213, 215
 - p53* and human malignancies and, 57:264–265, 269
 - plasminogen activation and, 57:274, 282, 313–314
 - directed cell surface, 57:301–303, 305–309, 312
 - proteolytic modulation, 57:285, 288, 290–295, 297–300
 - protooncoprotein tyrosine kinases and, 57:189, 191, 197, 199, 206–207
 - Raf-1 phosphorylation and, 58:56
 - soft tissue tumors and, 60:95, 101, 106
 - Src family of tyrosine protein kinases and, 57:110, 114, 119, 127–128, 136
 - transforming growth factor- α and, 58:27, 43, 46
- Initiation
- chemical carcinogenesis and, 50:26, 59, 60
 - biological concepts, 50:33–36, 39
 - biomonitoring, 50:55
 - mechanisms, 50:42, 48–51, 53
 - Epstein–Barr virus proteins and genome, 50:102
 - transformed cells, 50:104, 110, 119, 136
 - hepatocyte phenotypes, 70:27–32
 - stroma and, 50:187
 - tumor clonality and, 50:198
- Initiation complex, adenovirus E1A proteins and, 57:78
- Injurin, SF-inducing, 67:271
- Ink4a
- cancer and, 71:196, 197
 - cdk4 inhibition and, 71:173
- Ink4b
- cdk4 inhibition and, 71:174
 - TGF- β and, 71:193
- Ink family, cdk inhibition by, 71:173–174
- In(Lu)-related p80 glycoprotein, 71:246
- Inositol phospholipid, synthesis as target of cAMP-dependent protein kinase, 54:121–122
- Inositol trisphosphate, lysophosphatidic acid and, 57:88, 90
- Insect vector transmission, AIDS and, 51:335–336, 338
- Insertion
- foreign DNA
 - concept in oncogenesis, 66:313–344
 - mechanism, 66:324–326
 - germ-line, 56:224–226
 - mouse retrotransposons and, 56:216, 226–230
- Insertional activation of *myc* genes, hepatitis B viruses and, 59:205–208
- Insertional mutagenesis hypothesis, 51:278

- In situ* carcinoma-associated immunogenicity, 56:105, 106, 128, 129
autologous breast cancer, 56:110–112
cell-mediated immunity, 56:113–115, 119–123
glycoprotein, 56:55, 112, 113
immunoprophylaxis, 56:127, 128
invasive breast cancer, 56:115–118
second primary breast cancers, 56:117–121, 125, 128
specific immunity
incidence, 56:106, 107
prognosis, 56:107–110
therapeutic implications, 56:123–127
- In situ* carcinomas, progression of, to
invasive carcinoma, inefficiency of, 54:164
- In situ* hybridization, *see also* Fluorescence *in situ* hybridization
 α -fetoprotein and, 56:295
EBV-associated disorders and, 57:356, 369–370
Epstein-Barr virus genes and, 58:15
FGF receptor multigene family and, 60:29
fibroblast growth factors and, 59:125, 128
mouse retrotransposons and, 56:241, 243
plasminogen activation and, 57:295
protein tyrosine kinase GFRs and, 60:49, 54
soft tissue tumors and, 60:98–99
transforming growth factor- α and, 58:38–39, 41
Wilms' tumor and, 59:57–58
- In situ* lesions, breast cancer *p53* expression, 59:83–84
- Insulin
adenovirus E1A proteins and, 57:75
Burkitt's lymphoma and, 55:153
chromosome abnormalities and, 52:18
FGF receptor multigene family and, 60:8–9
protein tyrosine kinase GFRs and, 60:46, 62
G6PDH and, 51:411–412
lysophosphatidic acid and, 57:92
metastatic cancer cells and, 55:117–120
newborn macrosomy and
cancrophia syndrome, 50:263
characteristics, 50:242
factors, 50:257
prophylaxis, 50:271
transplacental carcinogenesis, 50:255
oncoprotein kinases and, 57:199, 204–206, 208
plasminogen activation and, 57:295
signaling
and IRS-1, 64:95
role of PKC, 64:168–169
- Insulin-like growth factor, 51:114
expression inducible by, 53:15–16
in serum, 53:5
- Insulin-like growth factor binding protein
expression in tumors, 68:210–211
family, 68:186, 190
posttranslational modification, 68:190
structure, 68:190
- Insulin-like growth factor I
angiogenesis, 69:143
apoptosis inhibition, 68:195
breast cancer role, 68:206–208
cell cycle regulation, 68:192–194
expression in tumors, 68:199
gene
structure, 68:186–187
transcription regulation, 68:187
lung cancer role, 68:208–209
motility factor activity, 68:205–206
peptide analog therapy, 68:212
precursor processing, 68:186
receptor
antibody therapy, 68:211–212, 214
disruption effects in embryo, 68:186
domains involved in transformation, 68:192
gene structure and regulation, 68:188–189
overexpression in tumors, 68:196–198, 202, 208
phosphorylation
sites, 68:190–191
substrates, 68:191
processing, 68:188
role in transformation, 68:195–196, 198, 214
signal transduction, 68:190–192
suramin effect on ligand binding, 68:213
types, 68:184–185
retinoic acid effect on expression, 68:213
synthesis sites, 68:184
tamoxifen effect on expression, 68:213
- Insulin-like growth factor-I, angiogenesis, 69:143

- Insulin-like growth factor II
 disruption effects in embryo, 68:185–186
 effect on cell morphology, 68:200
 estrogen regulation, 68:207
 expression
 kidney, 68:201–202
 tumors, 68:198–201
 gene
 expression in tumors, 72:179–181
 loss of imprinting, 68:204–205
 mutations and cancer, 68:200–201
 promoters, 68:204
 structure, 68:187
 transcription regulation, 68:187, 201
 hypoglycemia from tumor secretion, 68:209–210
 in tumorigenic process, 72:18
 mannose-6-phosphate receptor
 imprinting, 68:204
 overexpression in tumors, 68:197–198
 signal transduction, 68:189–190
 structure, 68:189
 motility factor activity, 68:205–206
 precursor processing, 68:186, 210
 synthesis sites, 68:184
 Wilms' tumor and, 59:50
- Insulin-like growth factor-1 receptor gene,
 amplification in breast cancer, 61:37–38
- Insulin-like growth factors, metastatic cancer
 cells and, 55:117, 118, 120
- Insulin receptor
 PKC phosphorylation sites, 64:173
 Raf-1 phosphorylation and, 58:56, 64
- Insulin-receptor substrate-1, 68:1
 cytokine signaling role, 68:43
 structure, 68:42–43
- Insulin-reducing activity, ADF and, 57:396–397
- int-1*, soft tissue tumors and, 60:89, 92
- int-2* oncogene, angiogenesis, 69:146, 147
- Integration, adenovirus DNA, 66:317–324
- Integrins, 71:244
 bcr1abl gene in leukemia and, 57:170
 Burkitt's lymphoma and, 55:240
 humoral immune response and, 62:255
 oncoprotein kinases and, 57:201, 203
 plasminogen activation and, 57:278–280, 282–283
 Ras function and, 62:43, 45, 49
 reverse transformation and, 62:140
 T-cell receptors and, 56:63–66, 70, 71
- Integrin α subunit gene, 71:69
- Intercellular adhesion molecules, *see* Cell
 adhesion molecules, ICAM
- Intercellular junctions, resembling
 desmosomes, 66:246
- Interference reflection microscopy,
 plasminogen activation and, 57:276–277
- Interferon- α , 69:150
 cancer immunotherapy and, 59:247
 chemioimmunotherapy, 59:276–277, 279
 critical factors, 59:249–250, 252–253
 current strategies, 59:259–261, 267
 improvement attempts, 59:287, 289–291
 chronic lymphocytic leukemia, 71:146
 effect on RB phosphorylation, 64:45–46
 immunotherapy with, 61:66–67
 MHC Class I expression and, 60:210–211, 215
- Interferon- α/β , induced gene transcription,
 67:160–161
- Interferon- α , chronic lymphocytic leukemia,
 71:146
- Interferon- β , 69:150
 cancer immunotherapy and, 59:265, 290
- Interferon- γ , 66:60–61
 cancer immunotherapy and
 adoptive immunotherapy, 59:269–270, 272–273
 chemioimmunotherapy, 59:280
 critical factors, 59:250, 253
 current strategies, 59:257, 259–263, 265, 267
 improvement attempts, 59:287–299, 291
 cytotoxic T lymphocytes and, 58:153–157; 59:227–228
 immunotherapy with, 61:67
 MHC Class I expression and, 60:197, 207–208, 211, 215, 225
 and MHC regulation
 gene expression, 63:144
 poxvirus infection, 63:149–151
 in p91 activation, 67:160–161
 Src family of tyrosine protein kinases and,
 57:113–115
 transforming growth factor- α and, 58:39
- Interferon- δ , 66:65
- Interferon regulatory factor-1, *see* IRF-1

- Interferon response elements
 MHC Class I expression and, 60:207–212, 215–216, 220
 regulation of MHC gene expression, 63:142–143
- Interferons
 adenovirus proteins and, 52:155, 160
 ADF and, 57:384–385
 B cell-associated surface molecules and, 52:126, 127
 B lymphocytes and, 56:316, 325, 331
 bovine papillomavirus and, 56:137
 Burkitt's lymphoma and, 55:180, 231, 239
 cancer immunotherapy and, 59:246, 249, 291
 chemoimmunotherapy, 59:275–276, 280
 current strategies, 59:258–259, 261–262
 central nervous system tumor oncogenesis and, 58:129, 134, 137–138
 chromosome abnormalities and, 52:12
 chronic lymphocytic leukemia, 71:146
 EBV-associated disorders and, 57:332
 glutathione transferase and, 52:221
 hepatitis B viruses and, 59:177, 198
Herpesvirus saimiri and, 56:351
 HIV and, 51:326, 348
 IAP gene family and, 51:227
 immunosuppression and, 60:253
 MHC Class I expression and, 60:207–212, 215
 and MHC regulation
 gene expression, 63:141–144
 poxvirus infection, 63:154–155
 peptide-binding heat shock proteins and, 62:163–164
 reverse transformation and, 62:146
- Interleukin-1
 ADF and, 57:397, 403–405
 biological activities, 57:399–401
 identification, 57:388–392
 angiogenesis inhibition, 69:150
 B cell-associated surface molecules and, 52:126, 127
 B lymphocytes and, 56:316, 320, 321, 324–326, 328
 cancer immunotherapy and
 chemoimmunotherapy, 59:275, 280
 current strategies, 59:260, 262–263, 265
 improvement attempts, 59:286–289, 292
 FGF receptor multigene family and, 60:3
 humoral immune response and, 62:245, 258
 immunosuppression and, 60:247–248, 251–253, 258
 lymphohematopoiesis and, 54:253
 plasminogen activation, 69:116
 plasminogen activation and, 57:297
 radiation-related transcriptional regulation, 61:68
 Src family of tyrosine protein kinases and, 57:115
 stimulation of SF production, 67:270–271
- Interleukin-2
 ADF and, 57:382, 402, 405
 biological activities, 57:398, 400–401
 identification, 57:384–385, 387, 389–391
 administration, 70:145–146
 AIDS and, 51:349
 ataxia-telangiectasia genes and, 56:84
 B cell-associated surface molecules and, 52:84, 85
 expression on activated cells, 52:127, 130, 132
 receptors, 52:125
 T cells, 52:133
 B lymphocytes and, 56:316, 329
 Burkitt's lymphoma and, 55:157, 164
 cancer immunotherapy and, 59:246–247
 chemoimmunotherapy, 59:275–277, 279–281
 critical factors, 59:249–253
 current strategies, 59:259–273
 improvement attempts, 59:285–288, 290–291
 cytotoxic T lymphocytes and, 58:167
 clinical results of adoptive therapy, 58:163–166
 escapes of tumor cells from immune T cells, 58:162–163
 immunogenicity of tumors, 58:152–153
 virus-induced tumors, 58:154–159
 EBV-associated disorders and, 57:331
 glutathione transferase and, 52:233, 240
 glycosylation in tumors and, 52:312
Herpesvirus saimiri and, 56:339, 350, 351
 humoral immune response and, 62:245, 253–254

- Interleukin-2 (*continued*)
 immunosuppression and, 60:247–248,
 251–253, 258
 immunotherapy with, 61:67
 MHC Class I expression and, 60:183, 225
 mouse retrotransposons and, 56:231
 Raf-1 phosphorylation and, 58:58–59
 retroviruses and, 51:314, 317, 320
 Src family of tyrosine protein kinases and,
 57:129, 131–139
 T-cell receptors and, 56:56, 61, 62
 tumor rejection antigens and, 58:178
- Interleukin-2 receptors
 ADF and, 57:382–383, 398, 402
 analyses, 57:392, 394–395, 397
 identification, 57:384–388, 390
 Src family of tyrosine protein kinases and,
 57:131–139
- Interleukin-3
 apoptosis and, 71:9
bcr/abl gene in leukemia and, 57:157, 172–
 173
 Burkitt's lymphoma and, 55:164
 cancer immunotherapy and, 59:268, 290
 lymphohematopoiesis and, 54:253
 mouse retrotransposons and, 56:230
 Raf-1 phosphorylation and, 58:58–59, 69
 signaling, role of PKC, 64:169
 tumor rejection antigens and, 58:199–200
- Interleukin-4
 B cell-associated surface molecules and, 52:
 134
 differentiation antigens, 52:108, 111,
 114, 116
 expression on activated cells, 52:127
 B lymphocytes and, 56:316, 323
 Burkitt's lymphoma and, 55:231
 cancer immunotherapy and
 current strategies, 59:257, 260, 262,
 265, 269
 improvement attempts, 59:288,
 290–291
 chronic lymphocytic leukemia, 71:146
 effects of, on lymphohematopoietic cells,
 54:260
 humoral immune response and, 62:256
 Raf-1 phosphorylation and, 58:54
 receptors, 52:125–127
 response of preleukemic cells, 66:301–305
 Src family of tyrosine protein kinases and,
 57:136
- Interleukin-5, B cell-associated surface
 molecules and, 52:84
- Interleukin-6
 B cell-associated surface molecules and, 52:
 85, 126, 127, 134
 B lymphocytes and, 56:316, 325–327
 cancer immunotherapy and, 59:260, 262,
 269, 280, 287, 290
 direct stimulation by HIV, 67:125–126
 effect on M1 cells, 72:129
 induced leukemic cell differentiation, 66:17
 –18, 20
 lymphohematopoiesis and, 54:254
 myeloid leukemia suppression, 63:78, 81
 production
 induction by CSFs, 66:8–12
 role of FcγR cross-linking, 64:218
 transduced tumor cells, 66:62
- Interleukin-7, 54:254–256
 lymphohematopoiesis and, 54:252
- Interleukin-8, angiogenesis, 69:143
- Interleukin-10, role in AIDS-related
 lymphoproliferations, 67:125–126
- Interleukin-12, angiogenesis inhibition, 69:
 150
- Interleukins
 gene rearrangements and, 52:50
 TGF and, 51:135, 136
 TGF-β interaction with, 70:73
 tumor rejection antigens and, 58:194,
 206
- Intermediate filaments,
 hyperphosphorylation, 61:162–163
- Internalization
 B cell-associated surface molecules and
 biochemically defined molecules, 52:118
 CD20, 52:92, 93, 96
 CD21, 52:104
 CD23, 52:110, 111
 Epstein–Barr virus proteins and, 50:148
 glycosylation in tumors and, 52:313, 314
- Internal repeat, *see also* Third internal repeat
 array
 Epstein–Barr virus proteins and, 50:100,
 102, 128
- International Congress of Geneticists (1932)
 plant and animal breeding papers
 presented, 65:4
 studies regarding genetics, 65:4–5
- Interphase, and cytoplasmic cyclins, 66:204–
 205

- Intestinal epithelium, okadaic acid effects, 61:163–164
- Intestinal mucosal-specific glycoprotein, gastrointestinal diseases and, 50:16
- Intestine, small, tumorigenesis in, MHC effects on, 53:160–162
- Intracellular adhesion molecule, metastatic cancer cells and, 55:96, 110–113, 125
- Intracellular adhesion molecules, T-cell receptors and, 56:59, 65, 66, 71
- Intracellular immunization, 71:363
- Intracisternal A particles, mouse retrotransposons and, 56:217, 233, 245
expression of neighboring genes, 56:229, 230
insertion, 56:225, 226, 228
LTRs, 56:234–237, 239, 241, 243, 244
mouse genome, 56:219, 221–224
- Intracisternal A-particle gene family
cat tumors and, 51:259
chromosomal distribution of, 51:201–203
component proteins
 envelope, 51:211
 gag, 51:187, 204–208
 general considerations, 51:203–204
 integrase, 51:211
 reverse transcriptase, 51:208–211, 213
diabetes and, 51:252–253
dog tumors and, 51:259
element transposition and, 51:243–249
embryonic development and, 51:230–236
general considerations for, 51:184–185
genomic organization of, 51:185–191
gerbil cells and, 51:258
guinea pig leukemia and, 51:258–259
immunoglobulin regulatory factors and, 51:249–252
- Mus musculus* and, 51:184–193, 194
neoplastic transformation and, 51:259–269
normal somatic cells and, 51:227–230
other retroviruses and, 51:193–201
rat DNA and, 51:195–196, 257–258
regulation
 cell proliferation, 51:225–226
 DNA methylation, 51:221–224
 general considerations, 51:219–221
 halogenated pyrimidines, 51:226
 interferon effects, 51:227
 oncogene effects, 51:224–225
Syrian hamster DNA and, 51:195–202
teratocarcinoma cells and, 51:236–243
transcription of, 51:217–219
transmission, 51:212–214
type I elements, 51:187–189
type II elements, 51:189–190
type R particles, 51:253–257
- Intracisternal A particles, Louvain rat immunocytomas and, 50:287
- Intravasation
 failure of, metastatic inefficiency and, 54:195
 in metastatic process, 54:169–171
- Introns
 α -fetoprotein, 56:294
 bcr/abl gene in leukemia and, 57:164–166
 BCR gene in leukemia and, 57:227, 229–230, 232–233
 c-myc regulation and
 Burkitt's lymphoma, 56:28, 30, 40
 expression, 56:16–18, 20, 21, 24, 25
 gene topography, 56:5, 7, 8
 myc family oncogenes and, 57:3, 6, 13, 26
 p53 and human malignancies and, 57:262–263, 268
- Invasion, oncogenes and, 50:72, 73, 87
 malignant genotype, 50:81
 malignant phenotype, 50:74–76, 79
- Invasion in metastatic process, 54:161–169
 delay of, mechanisms of, 54:166–169
 inefficiency of, in *in situ* cancers, 54:164–166
 mechanisms of, 54:161–164
- Inversion chromosome abnormalities and, 52:6
- In vitro* testing, for chemopreventive agents, 61:8
- In vivo* testing
 of chemopreventive agents, 61:8–10
 for efficacy and toxicity, 61:9–10
- Involucrin, in formation of cornified envelope, 70:79–80
- Iodination, FGF receptor multigene family and, 60:6, 25
- Iodine-131-mAb conjugates, 61:70–71
- IP10, 69:150
- IQGAPs, candidate effectors of Rac1/CDC42, 72:90
- IRA1* in Ras-cAMP pathway, 54:110
- IRF-1, apoptosis and, 71:128
- IRF-1* gene, apoptosis and, 71:128
- Iris, Wilms' tumor and, 59:47

Iron, genomic instability and, 60:131
 Iron and steel foundry workers, prostatic cancer and, 51:75–76
 Iron metabolism, alterations in hepatocyte nodules, 70:33
 IRS-1, and insulin signaling, 64:95
 Ischemia, lysosomes and, 60:278–279
 1-(5-Isoquinolinylnsulfonyl)-2-methylpiperazine, 64:167
 Italian population, diet and, 51:34–35

J

Jacob, Francois, 69:1, 2, 10
 Jak, *see Janus kinase*
 Jak-2 tyrosine kinase inhibitor, 71:154
 Janus kinase
 cytokine specificity in activation, 68:33–34
 gene loci, 68:32–33
 heterodimers, 68:36–37
 homolog in *Drosophila*, 68:32
 homology between types, 68:32
 interferon response, 68:36–37
 interleukin-2 response, 68:37
 kinase domain, 68:32
 phosphorylation and activation, 68:33, 35, 50
 receptor aggregation and activation, 68:35–37, 50
 receptor chain association, 68:33–34, 37
 Stat as substrate, 68:45–46
 transcripts, 68:31–32
 types, 68:31
 Japanese population
 breast cancer and, 51:18
 prostatic cancer and, 51:3–7, 18, 23
 diet, 51:35, 36–37, 63–64
 latent, 51:9–14
 Jaws, Epstein–Barr virus proteins and, 50:97
jun
 G protein signal transduction and, 58:80
 MHC Class I expression and, 60:200
 Jun, adenovirus E1A proteins and, 57:63
 junB, adenovirus E1A proteins and, 57:64
 Junctional communication, in cell cultures, 70:11–12
 Junction sequences, cloning, 66:322
 Jun NH₂-terminal kinase
 cascade, activation, 72:65–67
 transcription factor activation, 72:83–84
jun oncogene, 55:1–4
 dimerization, 55:14–17

DNA binding, 55:4–6
 family of related genes, 55:8–11
 hierarchical order of functions, 55:28–30
 leucine zipper, 55:17–21
 oncogenicity, 55:25–28
 regulation, 55:21–25
 signal conversion, 55:30, 31
 signals, 55:11–14
 transcription factor AP-1, 55:6–8
 jun protein, *myc* family oncogenes and, 57:9

K

K562 cells
 differentiation, role of PKC, 64:183, 197
 RB phosphorylation, inactivation during differentiation, 64:41–42
KAI1, downregulation and prostate cancer metastasis, 68:243
 Kaposi's sarcoma, 51:316, 342; 53:73–85
 AIDS-associated, 54:309
 angiogenesis, role of SF, 67:268
 epidemiology, 66:236–237; 67:113–114
 angiogenic factors in, 53:83–84
 cell of origin of, 53:76, 78–79
 chromosomal aberrations, 69:77
 clinical features of, 53:73–76
 cytotoxic T lymphocytes and, 59:236
 endemic, 53:74–75
 epidemic, 53:75
 epidemiology of, 53:73–76
 etiology of, 53:80–85; 66:237–238
 fibroblast growth factors and, 59:151, 153
 growth medium, 66:240–245
 hormonal influence on, 53:85
 hyperplastic lesions of, 53:79–80
 immunosuppression-associated, 53:75–76
 infectious agent in, 53:80–83
 as neoplasm, 53:79–80
 oncogenes in, 53:84–85
 pathology of, 53:76, 77–78
 phenotype, 66:238–240
 renal transplantation and, 54:307
 sporadic, 53:74
 tumorvirus search, 68:16
 VEGF mRNA levels, 67:293
KAR1 gene, genomic instability and, 60:135
 Karyotype
 abnormal
 in breast cancer, 67:68–71
 in CML, 67:5
 alterations, in tumor subset, 67:63–64

- alterations in band 11q23, 66:214–215, 231
- ataxia-telangiectasia genes and, 56:81, 83, 84, 86, 97, 98
- BCR* gene in leukemia and, 57:227–229
- bovine papillomavirus and, 56:139
- central nervous system tumor oncogenesis and, 58:121
- chromosomes and, 62:3–4, 8–11, 14
- normal
- in hereditary nonpolyposis colorectal cancer, 67:66
 - in tumor subset, 67:64
- oncogenes and, 50:89, 90, 92
- renal cell tumors, molecular cytogenetics
- nonpapillary renal cell tumors, 62:95–97, 100–101, 103, 105
 - papillary renal cell tumors, 62:105–106, 108–111, 113–114
 - renal oncocytoma, 62:115–116
- Wilms' tumor and, 59:46, 50, 54
- Karyotypic changes, tumor progression and, 51:169
- Karyotypic markers, tumor clonality and, 50:202
- Karyotypy
- genomic instability and, 60:122–124, 147
 - soft tissue tumors and, 60:88–89, 91–92, 94–95, 97, 99–100
 - of tumor cells, 71:31–32
- KBF1, MHC Class I expression and, 60:213–214, 217
- KBF1, and NF κ B, 66:53–54
- KDR/Flk-1 receptors, VEGF-binding, 67:301–302
- Keratin
- Burkitt's lymphoma and, 55:225
 - jun* oncogene and, 55:19
- Keratinizing cells, endogenous growth inhibitors and, 57:413, 444
- bat web experiment, 57:424–428
- epidermal chalone, 57:428–433
- Keratinocyte growth factor, 59:116–117
- gene expression, 59:132
 - oncogenic potential, 59:149
 - protein structure, 59:125–126
 - receptors, 59:134–135
- Keratinocyte growth factor multigene family, 60:5–6, 11, 20, 35
- alternative splicing, 60:28
 - ligand binding, 60:24–27
- Keratinocytes
- bovine papillomavirus and, 56:139, 140
 - differentiation, 70:78–81
 - anomalous, 64:279
 - role of PKC, 64:182–183 - HPV infection, 69:180–182
 - human papillomavirus and, 56:143, 150–152, 154
 - immortalization, 64:273
 - metastatic cancer cells and, 55:105, 109
 - near wound lesion, expression of VEGF mRNA, 67:291
 - normal, hyperplasia with, 64:268
 - stroma and, 50:174
 - transforming growth factor- α and, 58:38–41
- Keratinosis, in HK1–fos mice, 64:260–262
- Ketosis, newborn macrosomy and, 50:270
- K-FGF
- biological function, 59:141–143
 - gene expression, 59:126, 128–130
 - oncogenic potential, 59:145–148
 - protein structure, 59:124–125
 - receptors, 59:135–136
 - tumors, 59:149–152
- κ B-binding factors, 66:257–265, 276–277
- Ki-67 anti-nuclear antibody, 61:4
- Kidney, *see also* Renal cell tumors
- α -fetoprotein and, 56:295, 298
 - APC* gene in human cancers and, 62:82
 - Burkitt's lymphoma and, 55:162
 - chemical carcinogenesis and, 50:30
 - Herpesvirus saimiri* and, 56:336
 - human papillomavirus and, 56:149, 150
 - IAP gene expression, 51:228–230
 - multidrug resistance gene and, 60:165–166, 170
 - newborn macrosomy and, 50:251, 255
 - transplantation, tumors associated with, 54:308–309
- Kidney cancer, *see* Wilms' tumor
- Kidney cells
- endogenous growth inhibitors and, 57:435, 440
 - monkey
 - adenovirus production, complications from simian virus 40, 65:150
 - for production of poliovirus stocks and vaccines, 65:147–148
- Killer cells, *see also* Lymphokine-activated killer cells

- Killer cells (*continued*)
 FcγRIII expression, 64:214
- Kinesins, genomic instability and, 60:135
- Kinetics, tumorigenesis, 64:249
- Kinetochores, genomic instability and, 60:135
- Kip1 protein, 71:198
- Kirsten murine leukemia virus, MHC Class I expression and, 60:198
- Kirsten sarcoma leukemia virus, MHC Class I expression and, 60:198
- Kirsten sarcoma virus, TGF and, 51:108
- Klein, Jan, retrospective of life and studies, 63:1–36
- Knockout mice
ret, 70:211
 TGF-β, 70:73–74
- Knudson model, Wilms' tumor and, 59:43–46, 58–59, 61, 63
- K-ras, MHC Class I expression and, 60:201
- KRAS2 activation, in pathogenesis of lung adenocarcinoma, 67:86–91
- Kras2 locus, on chromosome 6, 67:97–102
- K-ras oncogene, angiogenesis, 69:147, 148
- Kringle domains
 plasminogen, 69:102, 108
 in SF truncated form, 67:274–275
- Kringles, plasminogen activation and, 57:284–285, 288, 309
- KS, *see* Kaposi's sarcoma
- L**
- Labeling indices, endogenous growth inhibitors and, 57:443
- Lactation
 chemical carcinogenesis and, 50:28
 newborn macrosomy and, 50:265
- Lacto-series antigens
 glycosylation in tumors and, 52:283–285
 type 1, 52:316
 carbohydrate antigens, 52:262
 glycolipid antigens, 52:268–271
 type 2, 52:316
 carbohydrate antigens, 52:262
 glycolipid antigens, 52:270, 272–277
- LAK cells, *see* Lymphokine-activated killer cells
- Lambda phage, and work on animal viruses, 70:3–4
- Laminin
 lung metastasis and, 51:366–367
 plasminogen activation and, 57:280, 282–283, 285, 291, 311
 stroma and
 alterations, 50:184
 basement membranes, 50:173, 174, 176
 epithelium, 50:160
 glycoproteins, 50:170, 172
 T-cell receptors and, 56:67
- Lamins, reverse transformation and, 62:134, 139, 141
- Large intestine, gastrointestinal diseases and, 50:1, 2, 9–13
 modulators, 50:13–15
 normal, 50:7–9
- Laryngeal carcinoma, chromosome 3 losses in, 71:45–47
- Late genes, papillomaviruses, 71:323
- Latency-associated protein, interaction with TGF-β, 70:66–67
- Latency I, Epstein-Barr virus, 69:214–216
- Latency II, Epstein-Barr virus, 69:216–217
- Latency III
 diseases, vaccines for, 69:232–235
 Epstein-Barr virus, 69:217–218
- Latency patterns, EBV, 67:129–130, 200–201, 245–246
- Latency program
 EBV-infected resting B lymphocytes, 69:218–219
 latency I, 69:214–216
 latency II, 69:216–217
 latency III, 69:217–218
- Latent carcinoma, prostatic, 51:9–14
- Latent infection membrane protein
 genome, 50:103
 transformed cells, 50:131–137
 virus-produced cells, 50:149, 150
- Latent membrane protein, 69:214, 217
 B cell-associated surface molecules and, 52:99
- Burkitt's lymphoma and, 55:228, 231–237, 244, 250
- EBV-associated disorders and, 57:331–332, 334–335, 340, 371
 immunodeficiency states, 57:345
 NHL and AIDS, 57:366
 organ transplants, 57:356–361
- Epstein-Barr virus genes and, 58:2, 4–8, 15–16, 19–20
- Herpesvirus saimiri* and, 56:341, 348, 349

- Latent TGF- β -binding protein, in activation of TGF- β , 70:66–67
- LAV, *see* Lymphadenopathy-associated virus
- Lck, cytokine activation, 68:30
- lck*, Src family of tyrosine protein kinases and, 57:121, 126, 139
 patterns of expression, 57:112–113, 120
 properties, 57:105, 108
- LCL, *see* Lymphoblastoid cell lines
- Leader protein, Epstein–Barr virus genes and, 58:13
- LEC-CAM family, T-cell receptors and, 56:69, 70
- LEC rats, α -fetoprotein and, 56:290
- Lectin
 α -fetoprotein and, 56:257, 258, 299
 binding, 56:278
 interactions, 56:266–270
 ataxia-telangiectasia genes and, 56:79
 B lymphocytes and, 56:316
 glycosylation in tumors and, 52:285, 289, 293, 301, 314
 immunosuppression and, 60:252
 signal transduction and, 55:281
- Leiomyoma
 characterization of
 chromosomal abnormalities, 60:91–94
 susceptibility, 60:81, 85–87
 chromosomal aberrations, 69:74–76, 88, 93
 tumor clonality and, 50:221
- Leiomyosarcoma
 characterization of, 60:76, 87, 99, 101–102, 105
 chromosomal aberrations, 69:76, 90
- Leishmania major* infection, mice with, concomitant immunity in, 54:323–325
- Leitch, work on experimental paraffin cancer, 65:40–41
- Lens, maturation, and c-Myc levels, 70:129
- Lentiviridinae, 51:308, *see also* Retroviruses, human
- Lesions
 breast cancer and, 56:105–107, 116–118, 125
 cancer-precursor, 70:23–24, 37
 c-*myc* regulation and, 56:26, 27
 DNA, oxygen free radical-induced, 72:37–38
 early, in breast cancer, 66:120–122
 focal proliferative, 70:39
 papillomaviruses and, 56:134
in situ, breast cancer, *p53* expression in, 59:83–84
 verrucous, 64:271–274
- Leucine
 c-*fos* protooncogene and, 55:47, 50
jun oncogene and, 55:12, 13, 30
- Leucine zipper
 adenovirus E1A proteins and, 57:62
 Burkitt's lymphoma and, 55:163, 164, 222
jun oncogene and, 55:17–21
myc family oncogenes and, 57:8–10, 12–13
 protein, dimerization, 66:227
 related motif in RelB, 66:262–263
- Leucine zipper motif, c-Myc protein, 70:104–107
- Leucosarcoma, Louvain rat immunocytomas and, 50:280
- Leukemia, *see also specific type*
 α -fetoprotein and, 56:279, 280, 283
 and *ALL-1* rearrangements, 66:218–221
 apoptosis and, 71:122
 ataxia-telangiectasia genes and, 56:77, 83, 93
 B-cell, acute, *see* Burkitt's lymphoma
 B cell-associated surface molecules and biochemically defined molecules, 52:116–118, 120
 differentiation antigens, 52:91, 92, 96, 100, 114
 expression on activated cells, 52:130–132
 history, 52:87
 receptors, 52:125
 blasts, nucleoside transport-binding sites, 72:202
 B lymphocytes and, 56:325–327, 331
 central nervous system tumor oncogenesis and, 58:121
 c-*erbA* and, 59:109
 chromosomal abnormalities in, 52:3, 38; 62:3–10, 12; 63:73
 acute myeloid leukemia, 62:12
 chronic lymphocytic leukemia, 62:6
 chronic myelogenous leukemia, 62:5, 8–9
 chromosomal translocations, 66:216–217
 chronic versus acute, 71:149–151
 c-*myc* regulation and, 56:9, 25, 26

- Leukemia (*continued*)
- development, hemopoietic regulators and, *see* Hemopoietic regulators, and leukemia development
 - drug resistance in, 71:151–152
 - E2A–HLF-associated, 67:34–36
 - Epstein–Barr virus and, 62:187–188, 192, 207
 - fibroblast growth factors and, 59:151
 - Friend virus-induced, cytotoxic T lymphocytes and, 58:155–157, 162
 - gene rearrangements and, 52:59, 62, 63
 - simultaneous occurrence, 52:70–72
 - T-cell antigen receptor, 52:50, 52, 56
 - T-cell receptor, 52:74
 - genomic instability and, 60:125
 - glutathione transferase and, 52:215
 - glycosylation in tumors and, 52:264, 275, 280
 - and hematopoiesis, 66:3–20
 - hemopoietic growth factors plus ara-C, 72:222–223
 - hepatitis B virus and, 59:173
 - Herpesvirus saimiri* and, 56:337, 338
 - Louvain rat immunocytomas and, 50:298
 - lymphoblastic, acute, 71:147–148, 150
 - bcr/abl* gene in, 57:163–164, 166, 177
 - childhood, 67:36–38
 - chromosome abnormalities and, 52:18–22, 25
 - gene rearrangements and
 - hematological neoplasias, 52:65, 66
 - simultaneous occurrence, 52:71
 - T cell antigen receptor, 52:55, 57
 - T cell receptor, 52:75
 - MHC Class I expression and, 60:190
 - p16 gene mutations, 68:91–94
 - remissions, 67:2
 - retroviruses and, 51:312
 - soft tissue tumors and, 60:106
 - lymphocytic
 - acute, 71:147–148, 150
 - BCR gene and, 57:227–228, 230, 243, 252
 - chromosomal translocations, 67:27–38
 - acute B-cell, *myc* family oncogenes and, 57:25
 - chronic, 71:145–147, 149, 150
 - B cell-associated surface molecules and
 - differentiation antigens, 52:100, 103, 105
 - expression, 52:130, 131
 - history, 52:87
 - T cells, 52:132, 133
 - chromosome abnormalities and, 52:22, 23, 26
 - gene rearrangements and, 52:60, 64, 65
 - tumor clonality and, 50:210
 - lysosomes and, 60:273
 - MHC Class I expression and, 60:194, 210, 217
 - mouse retrotransposons and, 56:230, 231
 - multidrug resistance and, 52:195
 - multidrug resistance gene and, 60:166–167, 169, 174
 - myc* family oncogenes and, 57:2, 9, 25
 - myeloblastic, acute, gene rearrangements and, 52:68, 70
 - myelogenous, chronic, 71:144–145, 303–304
 - abnormal karyotype, 67:5
 - bcr/abl* gene in, 57:151–153
 - abl* in malignancy, 57:163–166
 - animal models, 57:173, 175–179
 - biological activity, 57:169, 172–173
 - Philadelphia chromosome, 57:154–155
 - BCR gene and, 57:227–232, 242–244, 250, 252
 - CD44 and, 71:303–304
 - chromosome abnormalities and, 52:2, 3, 16, 17
 - acute lymphoblastic leukemia, 52:21
 - acute nonlymphocytic leukemia, 52:10
 - oncogenes, 52:36, 37
 - gene rearrangements and, 52:73
 - genetic events, 67:16
 - genomic instability and, 60:139–140
 - immunosuppression and, 60:261
 - multidrug resistance gene and, 60:166, 174
 - p53* and human malignancies and, 57:267–268
 - protein tyrosine kinase GFRs and, 60:65
 - reciprocal translocation, 67:10
 - retroviruses and, 51:311
 - soft tissue tumors and, 60:88–90, 101, 108

- Leukemia, myelogenous (*continued*)
 tumor clonality and, 50:208, 209, 216, 217
- myeloid
 acute, 67:38–40; 71:148, 197
bcr/abl gene in, 57:163–164, 174–176
BCR gene and, 57:227
 chromosome abnormalities and, 52:9
 clones from blood of patients, 63:59
 and colony-stimulating factors
 production, 63:61
 proliferation stimulation, 63:79
 regulation of cells, 63:57
EVII expression pattern, 67:38–40
 imbalanced signaling effects, 63:80–81
 loss of sex chromosome, 63:72
 plasminogen activation, 69:118–120, 123
 suppression of hemopoietic cells, 63:69
- cells in culture, 63:59–62
- chronic
 cell culture, 63:59
 and colony-stimulating factor
 regulation of cells, 63:57
 and colony-stimulating factors
 cell proliferation, 63:60–62
 initiation role, 63:62–70
 production by macrophages, 63:74
 suppression, 63:76–81
 initiation by growth factors, 63:68–69
 retroviruses and, 51:311
 suppression
 G-CSF, 63:76–77, 81
 GM-CSF, 63:77, 79, 81
 hemopoietic regulators, 63:76–82
 interleukin-6, 63:78, 81
 leukemia inhibitory factor, 63:78, 81–82
 M-CSF, 63:79
 multi-CSF, 63:79, 81
- myelomonocytic, chronic, chromosome abnormalities and, 52:13, 15, 16
 newborn macrosomy and, 50:251, 259
 nonlymphocytic, acute, chromosome abnormalities and, 52:9–14, 18
 oncogenes and, 50:92
p16 and *p15* genes, 72:163–164
p53 and, 57:263, 266–267
 plasminogen activation
 bleeding, 69:119–121
 infiltration of leukemia cells, 69:121–122
 uPA activity, 69:118–119
- pre-B cell, pathogenesis in MuLV-infected LC mice, 65:183–184
- prolymphocytic
 B cell-associated surface molecules and, 52:92
 chromosome abnormalities and, 52:23, 24
- promyelocytic
 acute
 13–retinoic acid therapy, 69:120–121
c-erbA and, 59:109
 chromosome abnormalities and, 52:12
 disseminated intravascular coagulation, 69:120
 plasminogen activation, 69:119, 120
 transcription factor fusion, 67:39–40
c-myc regulation and, 56:26
- prostatic cancer and, 51:19
- radiation leukemia virus A-RadLV,
 lymphomagenesis in AKR mice by, 63:257–258
- renal cell tumors, molecular cytogenetics, 62:91
- retroviruses and, 51:310, 311–312
 reverse transformation and, 62:134, 145
 role of *BCR-ABL* oncogene, 64:90
 smoldering, Src family of tyrosine protein kinases and, 57:138
- soft tissue tumors and, 60:82, 88, 107–109
- stroma and, 50:188
- structural alterations in cytokine receptors, 68:27–29
- T-cell
 acute, lymphoblastic, gene rearrangements and, 52:62, 63, 66, 73
 adult
ADF and, 57:382
 analyses, 57:392–393, 395
 biological activities, 57:398–401
 chromosome abnormalities and, 52:24
 gene rearrangements and, 52:59, 61
 identification, 57:384–385
 treatment of, 51:344–345
 chronic, lymphocytic
 ataxia-telangiectasia genes and, 56:84–86

- Leukemia, T-cell (*continued*)
 gene rearrangements and, 52:59–61
 fibroblast growth factors and, 59:151
 gene rearrangements and, 52:62, 63, 66, 73
 mouse retrotransposons and, 56:238
myc family oncogenes and, 57:9
 prolymphocytic, gene rearrangements
 and, 52:59, 60
 tumor clonality and, 50:199, 208, 209
 tumor rejection antigens and, 58:183
 Wilms' tumor and, 59:43, 52
- Leukemia cells
 ADF and, 57:385, 388, 402
 differentiation, 66:17–18
 D⁺ myeloid, 66:27–28
 endogenous growth inhibitors and, 57:414,
 434, 440
 lacking wild-type *p53* protein, 66:17–19
 malignancy suppression, 66:14–15, 20
 plasminogen activation and, 57:288, 290,
 308–309
 Src family of tyrosine protein kinases and,
 57:114, 117, 124, 131, 138–140
- Leukemia inhibitory factor, myeloid
 leukemia suppression, 63:78, 81–82
- Leukemia/lymphoma, adult T-cell
 HTLV-I and, 51:313–315
 retroviruses and, 51:321
 treatment of, 51:344–345
 tyrosine protein kinases and, 57:138–140
- Leukemia viruses
 MHC Class I expression and, 60:198–199,
 211, 222
 Zilber and, 59:30
- Leukemic blast cells, oncogenes and, 50:92
- Leukemogenesis
 ADF and, 57:382
bcr/abl gene and, 57:155
 mouse retrotransposons and, 56:232,
 240
 RadLV-induced, 66:295–297
 active intervention, 66:305–308
 role of *RBI* inactivation, 64:28–29
- Leukemogenicity, ALL-1, models, 66:229–
 230
- Leukocyte integrin family of receptors, 56:
 63–66
- Leukocyte migration inhibition, Epstein–Barr
 virus proteins and, 50:131
- Leukocyte migration inhibition test, breast
 cancer and, 56:112
- Leukocytes
 breast cancer and, 56:126
 Epstein–Barr virus genes and, 58:17–18
 Epstein–Barr virus proteins and, 50:131
 stroma and, 50:162, 168
 T-cell receptors and, 56:67, 70
 tumor clonality and, 50:198, 199, 206
- Leukopenia, cancer immunotherapy and, 59:284
- Leukoplakia
 oral, 13–*cis*-retinoic acid trial, 61:15
 oral hairy
 EBV⁺ biopsies, 67:221–224
 PCR analysis, 67:217
- Levamisole, cancer immunotherapy and, 59:
 277, 280, 288
- Lewis lung carcinoma, 66:3LL
 cloning of cell population, 66:50–53
 immunogenic epitope, 66:55–56
 metastasis, 66:63
- Leydig cell IAP gene expression in mouse
 somatic cells, 51:228–230, *see also*
 Intracisternal A-particle gene family
- LFA, *see* Antigens, lymphocyte function-
 associated
- LFS, *see* Li-Fraumeni syndrome
- Life-style
 breast cancer and, 51:27
 colon cancer and, 51:27
 prostatic cancer and, *see* Prostatic cancer,
 environmental factors and
- Li–Fraumeni syndrome, 69:83, 141, 153; 71:
 228
 and breast cancer, 61:47
 breast cancer, *p53* expression in, 59:80–82
 germline mutations in *p53* gene, 61:204–
 205
 germline *p53* mutations in, 66:114–115
 mutant *p53* in, 66:164, 167
 radioresistance
 phenotype, 61:205
 and *raf-1* gene activation, 61:47
 soft tissue tumors and, 60:80, 82–83
TP53 mutant in, 67:17–18
- Ligands
 α -fetoprotein and, 56:299
 binding, 56:273, 275, 276, 278, 279
 immunoregulation, 56:286
- B cell-associated surface molecules and, 52:
 85, 110, 127, 134
- BCR* gene in leukemia and, 57:243
- B lymphocytes and, 56:328

- bovine papillomavirus and, 56:138
- central nervous system tumor oncogenesis and, 58:126, 136
- c-erbA* and, 59:93–94, 97, 106–108
 - mutations, 59:104
 - protein function, 59:97–98, 101
- c-fos* protooncogene and, 55:42, 50
- chromosome abnormalities and, 52:37
- EBV-associated disorders and, 57:330, 361
- FGF receptor multigene family and, 60:31, 34–35
 - alternative splicing, 60:29
 - binding, 60:24–28
 - characterization, 60:8
 - early studies, 60:6
 - mitogens, 60:5
 - multiple forms, 60:15
- fibroblast growth factors and, 59:135, 137
- glycosylation in tumors and, 52:301, 313
- G protein signal transduction and, 58:75–80
- jun* oncogene and, 55:1
- lysophosphatidic acid and, 57:93
- oncoprotein kinases and, 57:204, 206
- plasminogen activation and, 57:278, 280
- protein tyrosine kinase GFRs and, 60:43, 45
 - development, 60:49–51, 53–54, 58–59
 - structure, 60:45–49
 - tumorigenesis, 60:60–62, 64–65
- Raf-1 phosphorylation and, 58:53, 56
- signal transduction and, 55:272, 277, 285, 286, 296
- Src family of tyrosine protein kinases and, 57:105, 111–112
- T-cell receptors and, 56:50, 53, 54, 57
 - adhesion pathways, 56:59
 - antigens, 56:51, 52, 71
 - leukocyte integrin family, 56:65, 66
 - LFA-3, 56:59, 61, 62
 - lymphocyte homing receptors, 56:68
 - VLA family, 56:67
- transforming growth factor- α and, 58:35–38, 45–46
- Light microscopy
 - chromosome abnormalities and, 52:20
 - chromosomes and, 62:7, 9
 - stroma and, 50:174, 175, 183
- LIM domains, transcriptional regulatory proteins, 67:31–32
- Linixian esophageal cancer prevention trial, 61:19–20
- Linkage
 - ataxia-telangiectasia genes and, 56:86–95, 98
 - and mapping, NBCCS, 70:52
 - soft tissue tumors and, 60:82, 85, 98
- Lipid bilayer membrane, okadaic acid interaction, 61:164–165
- Lipidemia, newborn macrosomy and, 50:265
- Lipids
 - cancer immunotherapy and, 59:265–266
 - c-fos* protooncogene and, 55:42
 - glutathione transferase and, 52:213, 234
 - glycosylation in tumors and, 52:258, 259, 262, 302
 - hepatitis B viruses and, 59:191
 - lysophosphatidic acid and, 57:92–96, 99–100
 - biosynthesis, 57:88–90
 - membrane, ara-C effect, 72:208
 - multidrug resistance and, 52:170, 173
 - multidrug resistance gene and, 60:164
 - newborn macrosomy and, 50:232
 - cancerophilia syndrome, 50:263
 - epidemiology, 50:265
 - factors, 50:259
 - prophylaxis, 50:270
 - Raf-1 phosphorylation and, 58:69
 - signal transduction and, 55:292
- Lipoblastoma, chromosomal aberrations, 69:72, 93
- Lipogenic tumors, chromosome abnormalities and, 52:29, 30
- Lipoma
 - atypical, chromosomal aberrations, 69:69–72, 93
 - benign, chromosomal aberrations, 69:69–72
 - characterization of, 60:76
 - chromosomal abnormalities, 60:89–91, 93–94
 - susceptibility, 60:81, 85–86
 - chromosomal aberrations, 69:69–74, 88, 89, 93
 - malignant, chromosomal aberrations, 69:72–74
 - multiple, chromosomal aberrations, 69:69–72
 - pleomorphic, chromosomal aberrations, 69:69–72, 88

- Lipomatous tumors, chromosomal aberrations, 69:69–74
- Lipopolysaccharide, Src family of tyrosine protein kinases and, 57:113–115
- Liposarcoma
 characterization of, 60:76, 87, 102, 108
 chromosomal abnormalities, 60:93–95
 gene amplification, 60:104–105
 chromosomal aberrations, 69:72–74, 92
- Liposomes
 cancer immunotherapy and, 59:265–268, 287, 290
 doxorubicin loaded anti-HER-2/neu immunoliposomes, 71:363
 multidrug resistance gene and, 60:159
 T-cell receptors and, 56:61, 62
- Listeria monocytogenes*, as HER-2/neu vector, 71:356
- LIT tumors, prostatic cancer and, 51:9–11, 14, 25, 88–89
- Liver, *see also* Hepatocytes
 α -fetoprotein and, 56:254, 255, 294–298
 binding, 56:279
 chemotherapy, 56:287
 immunoregulation, 56:282
 interaction with lectins, 56:268–270
 preparation, 56:256
 properties, 56:262
 synthesis, 56:288–290, 292
 APC gene in human cancers and, 62:82
 Burkitt's lymphoma and, 55:164, 210
 cancer immunotherapy and, 59:271
c-fos protooncogene and, 55:41, 48
 chemical carcinogenesis and
 biological concepts, 50:39
 experimental models, 50:27, 31
 mechanisms, 50:41, 42, 49, 50
c-myc regulation and, 56:12, 23
 endogenous growth inhibitors and, 57:414, 435, 445
 genomic instability and, 60:132
Herpesvirus saimiri and, 56:337
 IAP gene expression, 51:228–230
 immunosuppression and, 60:257
 Louvain rat immunocytomas and, 50:283
 lysosomes and, 60:278, 281, 283
 metastasis, 51:364; *see also* Metastasis, organ-specific
 adhesion and, 51:366
 metastatic cancer cells and, 55:113, 121
 MHC Class I expression and, 60:215–216
 microcystin toxicity
 nodularin, 61:172–174
 multidrug resistance gene and, 60:165–166, 169, 172
 nodularin toxicity, 61:172–174
 phenotypes, initiation and progression, 70:27–36
 plasminogen activation and, 57:284
 stroma and, 50:167, 180
 tumor clonality and, 50:205, 225
 tumorigenesis in, MHC effects on, 53:162–163
- Liver cancer, *see also specific types*
 CD44 and, 71:298
 dietary mycotoxins and, 65:86–87
- LMP-1, 69:215
 in AIDS-related lymphomas, 67:141–142
 cytoplasmic domains, 67:245
 expression patterns in AIDS-NHL, 67:129–130
 genomic heterogeneity in *Bam*HI N fragment, 67:214–218
 and LMP-2A and -2B
 expressed during EBV latency, 67:200–204
 transcription, 67:230–231
- LMP-2, 69:215
- LMP2A, 69:223
- Lobular carcinoma *in situ*, 61:27–28
- Locus activation region, *c-myc* regulation and, 56:35–40
- LOD score, for lung tumors, 67:95–98
- Long terminal repeats
 adenovirus E1A proteins and, 57:54, 71
 ADF and, 57:382
 Burkitt's lymphoma and
 chromosomal translocations, 55:202
 deregulation, 55:208, 209, 214, 215
 genetic abnormalities, 55:217–219
c-erbA and, 59:99, 101
c-fos protooncogene and, 55:39, 43
c-myc regulation and, 56:26
 fibroblast growth factors and, 59:147
 hepatitis B viruses and, 59:198
 human papillomavirus and, 56:147
 MHC Class I expression and, 60:198–199
 mouse retrotransposons and, 56:216, 217, 245
 development, 56:242–244
 expression, 56:230–232, 235–239
 hormones, 56:240–242

- insertion, 56:224
 - mouse genome, 56:220–224
 - recombination, 56:233
 - structure, 56:234, 235
- myc* family oncogenes and, 57:28
- Raf-1 phosphorylation and, 58:60, 62
- Src family of tyrosine protein kinases and, 57:139
- Loop–sheet–helix structure, p53, 66:154
- Losses, *see also* Allelic losses
 - MHC class I, mechanisms, 67:182–183
 - total, locus, and allelic, in HLA phenotype, 67:171–173
 - Xho*I restriction site, 67:215–218, 241–243
- Louvain rat immunocytomas, *see* Immunocytomas, Louvain rat
- Lovastatin, mechanism of action, 71:177
- Low-density lipoprotein receptor-related protein, 69:110
- LPA, *see* Lysophosphatidic acid
- Lp-A, 69:109
- Lung
 - APC gene in human cancers and, 62:82–83
 - molecular cytogenetics and renal cell tumors, 62:102
 - small cell lung cancer, 62:94
 - tumor of
 - genes affecting, site of action of, 53:153–154
 - human genetics, 67:102–104
 - murinegenetics, 67:83–106
 - susceptibility to
 - genetics of, 53:150–152; 67:83–106
 - MHC genes and, 53:154–156
 - types of, 53:152–153
- Lung cancer
 - antioxidant trials, 61:19
 - benzo[a]pyrene dial-epoxide–DNA adducts, determination in nontumorous parenchyma, 65:84
 - CD44 and, 71:294
 - chemical carcinogenesis and, 50:28, 41, 49, 55
 - chromosome 3 losses in, 71:35–42, 75, 76
 - chromosome abnormalities and, 52:27
 - cyclin D1 amplification, 68:88
 - genomic instability and, 60:144
 - immunotherapy and, 59:256, 271
 - incidence of, 56:161, 162
 - age profiles, 56:165–169
 - arsenic, 56:206–208
 - asbestos, 56:208, 209
 - clonal growth models, 56:203–206
 - cohort data, 56:185
 - multihit models, 56:196–203
 - stages, 56:195, 196
 - involvement of *TP53* gene mutations, 65:84
 - MHC Class I expression and, 60:190, 194
 - downmodulation, 60:227
 - modulation by oncogenes, 60:200, 203–204, 206
 - microsatellite instability, 67:76
 - multidrug resistance gene and, 60:166–167
 - newborn macrosomy and, 50:259
 - non-small-cell
 - distribution of rearrangements, 67:71–73
 - familial studies, 67:103–104
 - p53* inactivation in, 67:91
 - oncogene activation and, 51:150–151, *see also* Oncogenes, activation in chemical carcinogenesis
 - p53* and human malignancies and, 57:267
 - pharmacogenetic aspects of initiation, 65:74
 - plasminogen activators and, 69:112
 - RARB expression, 71:66
 - role of insulin-like growth factors, 68:208–209
 - skin cancer and, comparison of causes, 65:85
 - small-cell
 - chromosome abnormalities and, 52:27
 - c-myc* regulation and, 56:25, 26
 - myc* family oncogenes and, 57:1, 3, 6, 26–27, 34
 - soft tissue tumors and, 60:101–102
 - stroma and, 50:169, 178, 179, 182
 - TGF and, 51:133
 - transfer of chromosome 3 into, 71:55
 - tumor clonality and, 50:208
- Lung carcinogenesis, p16 gene CpG island hypermethylation, 72:162–163, 187
- Lung IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
- Lung metastasis, adhesion and, 51:366–367
- Lung tumorigenesis
 - DHEA and, 51:406
 - MHC effects, 53:156–160

- Lwoff, Andre
 1965 Nobel Lecture, 69:7, 9
 lysogeny, 69:2
- Ly-24, 71:246
- lyk*, Src family of tyrosine protein kinases
 and, 57:112
- Lymphadenopathy
 angioimmunoblastic
 Epstein Barr virus and
 pathogenetic models, 62:
 211–212
 peripheral T cell lymphomas, 62:200–
 201, 203, 205–208
 T-cell lymphoproliferation, 62:192,
 195–196
 gene rearrangements and, 52:66, 67,
 71
 persistent generalized
 in early AIDS-NHL, 67:118–120
 preceding AIDS-SNCCCL, 67:139–142
 presence of EBV in context of, 67:128–
 129
- Lymphadenopathy-associated virus, 51:317,
 319–320, *see also* Human
 immunodeficiency virus
 HTLV-IV and, 51:340
- Lymph nodes
 breast cancer, *p53* expression in,
 59:83
 breast cancer and, 56:106, 107,
 127
 Burkitt's lymphoma and, 55:149
 cancer immunotherapy and, 59:250, 255,
 278, 284, 289
 deregulation, 55:209–211
 EBV, 55:240
 EBV-associated disorders and, 57:338,
 350, 367
 Epstein Barr virus and, 62:186, 199, 212,
 216–217
 humoral immune response and, 62:242,
 244–245, 260
 Louvain rat immunocytomas and, 50:280,
 283, 294, 305
 metastatic cancer cells and, 55:92, 108,
 115
 newborn macrosomy and, 50:249
 plasminogen activation and, 57:291
 Src family of tyrosine protein kinases and,
 57:119
- Lymphoblastoid cells, 69:214, 217
- Lymphoblastoid cell lines
 ADF and, 57:383, 389–390, 405
 EBV-associated disorders and, 57:330–
 332, 334, 338, 341
 NHL and AIDS, 57:365–366
 organ transplants, 57:358, 360–361
 EBV ebotypes in, 67:231–234
 with EBV latency III, 67:202–210
 EBV-transformed, 67:226–231
 Epstein–Barr virus genes and, 58:3–4, 6,
 12, 14, 16–21
 Epstein–Barr virus proteins and
 biology, 50:96
 transformed cells, 50:119, 120, 128, 133–
 136
- Lymphoblastoid cells
 ataxia-telangiectasia genes and, 56:79, 87
c-myc regulation and, 56:33–35
Herpesvirus saimiri and, 56:340, 342, 347
 MHC Class I expression and, 60:216, 227
 tumor rejection antigens and, 58:201
- Lymphoblasts, chromosome abnormalities
 and, 52:20
- Lymphocyte blastogenesis inhibitory factor,
 immunosuppression and, 60:252, 258,
 261
- Lymphocyte-defined membrane antigen,
 Burkitt's lymphoma and, 55:233, 238,
 244
- Lymphocyte-detected membrane antigen,
 Epstein–Barr virus proteins and, 50:133,
 134
- Lymphocyte functional antigens, Burkitt's
 lymphoma and, 55:240
- Lymphocyte immortalization, ADF and,
see Adult T cell leukemia-derived
 factor
- Lymphocytes, *see also specific type*
 α -fetoprotein and, 56:279, 281–284, 299
 ataxia-telangiectasia genes and, 56:79, 81,
 84
bcr/abl gene in leukemia and, 57:178
 binding to endothelial cells, 71:278
 B lymphocytes, 71:138–140, 258–259
 breast cancer, *p53* expression in, 59:80
 Burkitt's lymphoma and
c-myc, 55:164
 deregulation, 55:210, 215, 216
c-myc regulation and, 56:20
 EBV, 55:224–232, 234, 237, 239, 240
 synthesis, 55:244

- cancer immunotherapy and, 59:246, 293
 critical factors, 59:251, 253
 current strategies, 59:268, 270, 278
 improvement attempts, 59:285–286
chemical carcinogenesis and, 50:59
chromosomes and, 62:6–7
c-myc regulation and, 56:20
EBV-associated disorders and, 57:330–335, 338, 340–341
 Hodgkin's disease, 57:367–369, 371
 immunodeficiency states, 57:344
 organ transplants, 57:352, 361
Epstein–Barr virus and
 biology, 62:18, 23
 Hodgkin's disease, 62:213, 215–222, 224–226, 229
 marker detection, 62:186–187
 peripheral T cell lymphomas, 62:201, 205
 T-cell lymphoproliferation, 62:189, 193, 211–212
Epstein–Barr virus proteins and, 50:100, 120
gene rearrangements and, hematological neoplasias, 52:57, 58, 63, 64, 66, 67
genomic instability and, 60:126, 139
hepatitis B viruses and, 59:173, 177, 181
Herpesvirus saimiri and, 56:336, 351
 genome, 56:349
 model system, 56:336, 337, 339, 341, 344
homing receptors, 56:67–71
HPRT mutation in, 71:219–221
humoral immune response and, 62:242–245, 260–261
immunosuppression and, 60:247–249, 252–253, 257–258, 261
MHC Class I expression and, 60:182–184, 211
myc family oncogenes and, 57:19, 32
polyoma virus TSTA and, 55:59–61
renal cell tumors, molecular cytogenetics, 62:102, 114
reverse transformation and, 62:138
signal transduction and, 55:295
Src family of tyrosine protein kinases and, *see* Src family of tyrosine protein kinases
stroma and, 50:183
T cell antigen receptor, 52:54
T-cell receptors and, 56:67–71
TGF and, 51:133, 136, 138
T lymphocytes, 71:137–139, 194–195
tumor rejection antigens and, 58:182, 184–185, 201, 205
Lymphocytes in bone marrow, 54:242–245
 stromal cells and, recognition and adhesion between, 54:250–252
Lymphocyte subsets in malaria, 53:63
Lymphocyte transformation, malaria antigens and, 53:56–57
Lymphocytic choriomeningitis virus, cytotoxic T lymphocytes and, 59:237
Lymphocytic function antigen-1, down-regulation, 67:135
Lymphohematopoiesis, CD44 and, 71:283–284
Lymphohematopoiesis in bone marrow, cytokines affecting, 54:252–254
Lymphoid cells
 ADF and, 57:384, 395
 ataxia-telangiectasia genes and, 56:86
 bcr/abl gene in leukemia and, 57:152, 157, 167, 171–178
 BCR gene in leukemia and, 57:231, 240
 breast cancer and, 56:111, 125
 Burkitt's lymphoma and
 deregulation, 55:208
 differentiation, 55:165
 EBV, 55:226
 cancer immunotherapy and, 59:246, 260, 271
 c-myc regulation and, 56:20, 27, 36
 CR2 in, 54:287–289
 EBV-associated disorders and, 57:352
 Epstein–Barr virus proteins and, 50:130
 gene rearrangements and, B cell antigen receptor, 52:47
 hematological neoplasias, 52:57, 58, 66, 68
 lysophosphatidic acid and, 57:99
 MHC Class I expression and, 60:203
 mouse retrotransposons and, 56:228, 235, 236, 238
 myc family oncogenes and, 57:15, 29, 31–32
 oncoprotein kinases and, 57:197
 simultaneous occurrence, 52:69–72
 Src family of tyrosine protein kinases and, 57:113, 115
 T-cell receptors and, 56:57

- Lymphoid tissues
 newborn macrosomy and, 50:251
 oncogenes and, 50:80
- Lymphoid tumors
 Louvain rat immunocytomas and, 50:280, 281
myc family oncogenes and, 57:23, 25, 27
- Lymphokine-activated killer cells
 cancer immunotherapy and, 59:246–247
 chemoimmunotherapy, 59:275, 277, 279
 critical factors, 59:249–252, 254–255
 current strategies, 59:262–263, 265, 268–271, 273
 improvement attempts, 59:285, 290–291
 cytotoxic T lymphocytes and, 58:163–167
 Epstein–Barr virus, 69:237
 immunosuppression and, 60:248–249, 259
 MHC Class I expression and, 60:183
 therapy with, 61:73
- Lymphokines, *see also specific lymphokine*
 cancer immunotherapy and, 59:246, 253–254, 262
 cytotoxic T lymphocytes and, 58:152, 157, 163
 Epstein–Barr virus proteins and, 50:131
 gene rearrangements and, 52:49
 immunosuppression and, 60:249
 lymphocyte homing receptors and, 51:375, 376
 polyoma virus TSTA and, 55:61
 T-cell receptors and, 56:51, 54, 62
 leukocyte integrin family, 56:65
 lymphocyte homing receptors, 56:67–70
- Lymphoma
 α -fetoprotein and, 56:279
 AIDS-related, 54:310
 clinicopathologic spectrum, 67:115–118
 development, 67:120–126, 139–142
 epidemiology, 67:113–114
 Epstein–Barr virus and, 62:187, 224
 role of genetic lesions, 67:132–139
 anaplastic large cell, 67:116–117
 Epstein–Barr virus and, 62:194–195, 199, 203–205, 208
 apoptosis and, 71:143–144
 ataxia-telangiectasia genes and, 56:77
 B-cell
 apoptosis and, 71:143–144
bcr/abl gene in leukemia and, 57:156
BCR gene in leukemia and, 57:231
 Burkitt's, *see* Burkitt's lymphoma
 Epstein–Barr virus and, 53:38
 Ly-1⁺
 heavy and light chain loci, analysis, 63:281–284
 role of class I MCF, 63:285–286
 Ly-1⁺ (CD5⁺)
 characteristics, 63:277–281, 287–289
 heavy chain loci analysis, 63:281–284
 IgH rearrangements, 63:284–285
 lack of class I MCF involvement, 63:285–286
 light chain loci analysis, 63:281–284
 as model of tumor dormancy, 63:245
 Burkitt's, *see* Burkitt's lymphoma
 cancer immunotherapy and, 59:277, 290
 chemical carcinogenesis and, 50:59
 chicken bursar, Burkitt's lymphoma and, 55:215, 216
 chromosome abnormalities and
 acute lymphoblastic leukemia, 52:21, 22
 cytogenic data, 52:8
 malignant, 52:24–27
 chromosomes and, 62:11
c-myc regulation and, 56:10, 25–27
 cytotoxic T lymphocytes and, 59:236
 diffuse large cell, AIDS-related
 absence of *BCL-2* rearrangements, 67:137
 disrupted immunosurveillance, 67:120–122
 role of *c-MYC*, 67:132–133
 systemic, 67:116–117, 127
 Epstein–Barr virus and, 62:180, 182, 185–186, 206–207, 224, 225–226, 226, 230
 associated disorders, 57:343–344, 346, 352, 357, 367, 371, 373
 NHL and AIDS, 57:364–366
 organ transplants, 57:350–351, 355–356, 361–363
 X-linked lymphoproliferative syndrome, 57:337, 339, 341–342
 EBV genes, 58:9
 EBV proteins, 50:96, 100, 108
 follicular, *bcl-2* rearrangement in, 72:9–10
 gene rearrangements and
 hematological neoplasias, 52:59–62, 64, 66–68

- simultaneous occurrence, 52:70, 71
- T cell receptor, 52:74
- genomic instability and, 60:139
- Herpesvirus saimiri* and, 56:335, 337, 338, 350
- HIV-associated, 51:344
- immunoblastic, 69:218
- incidence rate in MuLV-infected LC mice, 65:180
- Ki 1⁺ gene rearrangements and, 52:67, 71
- Lennert's, gene rearrangements and, 52:66, 69, 70
- Louvain rat immunocytomas and, 50:298
- metastasis and
 - Hermes-1, 51:385–386
 - HEV assay, 51:369–370
 - HEV binding, 51:377–380
- MHC Class I expression, 60:189–190, 217, 219, 223, 227
- M-MuLV and, 51:296, 297, *see also*
 - Murine leukemia virus antigens
- multidrug resistance gene and, 60:166, 168–169
- myc* family oncogenes and, 57:30
- non-Hodgkin's
 - AIDS-related
 - B-cell clonal expansions, 67:118–120
 - EBV pathogenic role, 67:126–130
 - epidemiology, 67:113–114
 - HIV role, 67:130–131
 - CD44 and, 71:303–304
 - chromosome abnormalities and, 52:24–27
 - cytotoxic T lymphocytes and, 58:166
 - EBV-associated disorders and, 57:342–344
 - AIDS, 57:364–366
 - organ transplants, 57:346–352
 - EBV in, 67:212
 - Epstein–Barr virus and, 62:180
 - Hodgkin's disease, 62:223, 227
 - T-cell lymphoproliferation, 62:192–193, 197–198, 202, 209, 212
 - metastasis and, 51:385–386
- p15 and p16 alterations, 72:164
- p53 and human malignancies and, 57:263–264, 267
- polyoma virus TSTA and, 55:70
- primary central nervous system, AIDS-related
 - classification, 67:115–116
 - EBNA-2 and LMP-1 expression, 67:129–130
 - EBV-positive, 67:142
 - histological homogeneity, 67:117–118
 - protein tyrosine kinase GFRs and, 60:63
 - RadLV-induced, 66:297–300
 - renal transplantation and, 54:308–309
 - reverse transformation and, 62:134
 - soft tissue tumors and, 60:107–108
 - Src family of tyrosine protein kinases and, 57:136
- T-cell
 - cancer immunotherapy and, 59:260
 - cutaneous, gene rearrangements and, 52:59–61
 - EBV-associated disorders and, 57:345
 - genomic instability and, 60:139
 - hepatocellular carcinoma and, 59:205–206
 - myc* family oncogenes and, 57:24–25, 27–28, 31, 33–34
 - peripheral
 - 11–aa repeats, 67:217
 - EBV⁺, 67:198–199
 - EBV genotypes, 67:204–205
 - Epstein–Barr virus and, 62:180, 191–212
 - Hodgkin's disease and, 62:224, 226
 - protein tyrosine kinase GFRs and, 60:63
 - tumor clonality and, 50:208, 210, 212, 222, 223, 225
 - tumor rejection antigens and, 58:206
- Lymphoma cells, cytotoxicity of, 53:45–46
- Lymphomagenesis
 - AIDS-related
 - cytokine role, 67:124–126
 - viral infection role, 67:126–132
 - in AKR mouse
 - characteristics, 63:245–249
 - potential lymphoma cells
 - age-related levels, 63:266
 - bone marrow-derived, proliferation, host effects, 63:252–253
 - B-PLC dormant state maintenance and termination, 63:270–277
 - dormant, levels after prevention of spontaneous T lymphoma development, 63:262–270

Lymphomagenesis (*continued*)

- identification, 63:247–253
- prevention, 63:248–249
- T-cell lymphoma
 - development mechanisms, 63:253–254, 261
 - development pathways, enhanced, 63:253–261
 - dual tropic viruses in, 63:247, 286–287
 - tumorigenesis acceleration by
 - recombinant viruses, 63:254–256
 - fractionated irradiation effect, 63:258–259
 - N*-methyl-*N*-nitrosourea-induced, 63:259–261
 - radiation leukemia virus A-RadLV-induced, 63:257–258
 - SL3–3 ecotropic retrovirus-induced, 63:256–257
 - transplantation studies, 63:287
 - MuLV-induced, MHC and, 53:149
- Lymphomatoid papulosis, gene rearrangements and, 52:64
- Lymphopoietic microenvironment in bone marrow, 54:235–264
- Lymphoproliferation
 - Burkitt's lymphoma and, 55:250
 - Epstein–Barr virus genes and, 58:2–3
 - T cell, Epstein–Barr virus and, 62:187–212
- Lymphoproliferative diseases, Epstein–Barr virus proteins and, 50:99, 100
- Lymphoproliferative disorders, 52:45, 46
 - B cell antigen receptor, 52:46–49
 - hematological neoplasias, 52:57–59
 - acute myeloblastic leukemia, 52:68
 - B cell malignancies, 52:64, 65
 - chronic T cell malignancies, 52:59–61
 - lymphomas, 52:66–68
 - lymphomatoid papulosis, 52:64
 - pre-B cell malignancies, 52:65, 66
 - T cell acute lymphoblastic leukemia, 52:62, 63
 - T cell lymphomas, 52:61, 62
 - T lymphoproliferative disorder, 52:63
 - immunoglobulin genes, 52:69–72
 - T-cell antigen receptor
 - genomic organization, 52:52–56
 - role, 52:49
 - somatic rearrangement, 52:56, 57
 - structure, 52:49–52
 - T-cell receptor
 - chromosomal translocation, 52:72–75
 - simultaneous occurrence, 52:69–72
- Lymphoreticuloendothelial system, breast cancer and, 56:126
 - cell-mediated immunity, 56:111, 112, 123
 - specific immunity, 56:106–109
- Lymphoreticular cells, M-MuLV and, 51:287–289
- Lymphosarcoma
 - Louvain rat immunocytomas and, 50:282, 294, 305
 - metastasis and, 51:364
 - newborn macrosomy and, 50:251
 - retroviruses and, 51:311–312
- Lymphotoxin
 - B cell-associated surface molecules and, 52:84, 112, 127
 - immunotherapy with, 61:68
- Lymphotropic virus, human T-cell, role in human carcinogenesis, 65:39
- Lymproliferative disorders, EBV-associated, *see* Epstein–Barr virus-associated disorders
- Lyn, cytokine activation, 68:30
- lyn*, Src family of tyrosine protein kinases and, 57:105, 112, 118, 140
- Lynch II syndrome, 71:95, 96, 113
- Lynch I syndrome, 71:95
- Lysine-binding sites, plasminogen activation and, 57:285–286
- Lysis
 - Epstein–Barr virus proteins and, 50:133, 134, 137
 - stroma and, 50:186–188
 - basement membranes, 50:173–175
 - epithelium, 50:160, 164, 169
- Lysogeny
 - history, 69:15
 - Lwoff's work, 69:2, 5–7, 14
- Lysophosphatidic acid, 57:87–88
 - biological effects, 57:99
 - biological function, 57:99–101
 - formation in stimulated cells, 57:90–91
 - lipid biosynthesis, 57:88–90
 - mechanism of action
 - cell proliferation, 57:95–98
 - signal transduction, 57:92–95
 - site of action, 57:98–99
 - mitogens, 57:91–92
- Lysophosphatidic acid chelator, 57:94
- Lysosomal enzymes, 60:269–277, 286
 - anticancer therapy, 60:281–283, 285–286
 - tumor microenvironment, 60:278–279
- Lysosomes, 60:269–270, 286

anticancer therapy
 drugs, 60:284–286
 hyperthermia, 60:283
 radiation, 60:281–283
 enzyme activity in tumors, 60:271–275
 methods for study, 60:270–271
 multidrug resistance and, 52:169
 transforming growth factor- α and, 58:35
 tumor invasion, 60:275–277
 tumor microenvironment, 60:278
 hypoxia, 60:278–279
 pH, 60:279–281

M

- M1 cells, RB phosphorylation, inactivation during differentiation, 64:40–41
 M9–27 peptide, in MART-1 protein, 70:153–156
 mAb, *see* Monoclonal antibodies
 Mac-1, T-cell receptors and, 56:63, 66
 Macroglobulin
 HIV and, 51:326–327
 TGF and, 51:130
 α_2 -Macroglobulin, 69:108, 109–110
 TGF- β 1 binding, 70:69–70
 α_2 -Macroglobulin receptor, 69:109, 110
 Macrophage and granulocyte inducers, 66:7–9
 Macrophage colony-stimulating factors, and leukemia development
 characterization, 63:50
 differentiation commitment, 63:55
 membrane receptors, 63:71–72
 myeloid leukemia suppression, 63:79
 production by FDC-P1 cells, 63:76
 Macrophage IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
 Macrophage migration inhibition assay, polyoma virus TSTA and, 55:61, 80, 81
 Macrophages
 ADF and, 57:403
bcr/abl gene in leukemia and, 57:157, 177
 Burkitt's lymphoma and, 55:218
 cancer immunotherapy and, 59:251, 253, 259, 266, 280
c-fos protooncogene and, 55:41, 42
 colony-stimulating factor production, okadaic acid-stimulated, 61:164
 cytotoxic T lymphocytes and, 58:156–157
 EBV-associated disorders and, 57:338
 Fc γ RIII expression, 64:214
 hepatitis B viruses and, 59:177
 humoral immune response and, 62:242–245
 immunosuppression and, 60:247–249, 252, 254, 256, 259, 261
 lysosomes and, 60:271
 in malaria, 53:63–64
 with metachromatic granules, 66:5–6
 in microenvironment of bone marrow, 54:246–247
myc family oncogenes and, 57:13, 16, 33
 newborn macrosomy and, 50:263
 okadaic acid-stimulated prostaglandin E₂ production, 61:164
 oncogenes and, 50:83
 peptide-binding heat shock proteins and, 62:167
 plasminogen activation and, 57:293, 297–298, 307
 role in tumor angiogenesis, 67:269–270
 Src family of tyrosine protein kinases and, 57:113, 117–118
 stroma and, 50:164, 168, 183
 transforming growth factor- α and, 58:40–41
 tumor clonality and, 50:198, 199, 206
 tumor rejection antigens and, 58:180, 184
 Macrophage tumor, oncogene activation and, 51:150–151
 Macrosomy, newborn, 50:231–234, 272, 273
 accelerated development, 50:266, 267
 cancrophilia syndrome, 50:261–263
 case histories, 50:239–241
 characteristics, 50:241–245
 epidemiology, 50:263–266
 factors, 50:255, 257–261
 healthy populations, 50:236
 hormones, 50:269, 270
 pathology, 50:236–239
 prognosis, 50:245–250
 prophylaxis, 50:270, 271
 ranges, 50:235, 236
 retrospective data, 50:250–254
 risk factors, 50:267–269
 transplacental carcinogenesis, 50:254–256
 Mad
 effect on oncogene transformation, 68:164–166
 expression in development, 68:144–145
 gene loci, 68:166–167
 Max association, 68:122–123

Mad (*continued*)

- mutation studies, 68:165
- repression of Myc-activated transcription, 68:125–126
- tumor suppressor activity, 68:167
- Mad1, interaction with Max, 70:109–111
- MAGE-1, on chromosome X, 67:171
- Major histocompatibility complex, 53:89–109
 - adenovirus proteins and, 52:151, 152, 160, 161; 57:54
 - expression, 52:154–160
 - and antigen, interaction of, 53:191–192
 - B cell-associated surface molecules and, 52:83
 - antigens, 52:91–93, 112–114, 116
 - expression, 52:128, 131
 - biology of, 53:186–191
 - cancer immunotherapy and, 59:285
 - critical factors, 59:248, 250–253
 - current strategies, 59:257–259
 - class I
 - expression, 60:182, 233
 - adenoviruses, 63:160–164
 - alteration in tumor cells, 53:226–229; 67:175–182
 - cancer, 60:184–189, 195
 - cytomegalovirus, 63:169–171
 - hepatitis B virus, 63:175–177
 - herpesviruses, 63:169–171
 - immune recognition by T cells
 - mechanism, 63:123–124
 - MHC-I assembly with endogenous peptide, 63:131–132
 - pathway, 63:127–129, 132
 - peptide complexes, 63:129–131
 - transcription regulation, 63:136–138
 - immunogenicity of cancer and, 53:232
 - modulation by oncogenes, 60:204
 - myc* oncogene activation and, 60:181–183, 189–195, 231–233
 - downmodulation, 60:222
 - immune defense, 60:183–189
 - myc* oncogene activation and downmodulation
 - HLA, 60:227–230
 - immune reaction, 60:225–227
 - NK susceptibility, 60:230–231
 - progression, 60:222–224
 - T cells, 60:224–225

- myc* oncogene activation and modulation
 - adenovirus *E1A*, 60:195–197
 - fos*, 60:199–201
 - myc*, 60:203–208
 - raf*, 60:199, 201–202
 - ras*, 60:199, 202
 - viral oncogenes, 60:197–199
- myc* oncogene activation and regulation
 - mechanisms, 60:208–217
 - tumor cells, 60:217–222
 - papillomavirus, 63:182–183
 - poxviruses, 63:151–152
 - regulation by oncogenes, 60:208, 210, 216
 - gene regulation, 67:157–161
 - and metastatic phenotype, 66:49–53
 - peptide presentation, 66:57
 - products, 70:147–148
 - regulation of, in malignancy, 53:225–229
 - viral infection effects, 67:180–182
- class I and II
 - function of, 53:141–143
 - peptide presentation, 66:47–49
- class II
 - expression
 - adenoviruses, 63:164
 - binding factors
 - S box, 63:140
 - X1, 63:139
 - X2, 63:139
 - Y box, 63:139–140
 - cytomegalovirus, 63:171–172
 - hepatitis B virus, 63:177
 - herpesviruses, 63:171–172
 - immune recognition by T cells
 - binding of peptide antigens, 63:133–134
 - biosynthesis, 63:133
 - endosomal targeting, 63:133
 - pathway, 63:132, 135
 - restriction, 63:134–135
 - transcription regulation, 63:138–140
 - papillomavirus, 63:183–184
 - poxviruses, 63:152–153
 - invariant chain (Ii), CD44 binding to, 71:273

- contribution of, to *in vivo* destruction of antigen-bearing tissue, 53:216
- cytotoxic T lymphocytes and, 58:143–145, 166, 168; 59:227–229, 231, 233, 240
- antigen processing, 59:233–234
- function, 59:238–239
- immune T cells, 58:160–161, 163
- immunogenicity of tumors, 58:145–149, 151–152
- results of adoptive therapy, 58:164–165
- virus-induced tumors, 58:154, 156–157, 159
- effects
- on epithelial organ tumorigenesis, 53:166–169
 - on liver tumorigenesis, 53:162–163
 - on lung tumorigenesis, 53:156–160
 - on small intestine tumorigenesis, 53:160–162
- epithelial tumor susceptibility and, 53:150–169
- expression
- altered, biological importance, 53:146–149
 - cell cycle-specific, 53:190–191
 - differentiation and, 53:190–191
 - in malignancy, 53:193–200
 - metastasis and, 53:89–109
 - in normal tissue, 53:188–191
- function of, 53:191–193
- gene family of, 53:186–188
- gene rearrangements and, 52:49–51
- humoral immune response and, 62:242, 246, 248–251, 253, 255
- immunity by NK cells, 53:97–103
- interaction of, 53:191–192
- Louvain rat immunocytomas and, 50:280, 295
- in malignancy
- evidence for role of, 53:200–209
 - function of, proposed, 53:209–219
 - transplantation studies and, 53:209–218
- mammary tumor susceptibility and, 53:163–166
- metastasis and
- in animal models, 53:91–93
 - in humans, 53:103–106
- mouse retrotransposons and, 56:231, 233
- MuLV-induced lymphomagenesis and, 53:149
- in natural resistance, 53:218–220
- in NK recognition, 53:218–220
- nonimmunological role of, 53:192–193
- in normal and malignant cell development, 53:181–234
- ontogeny of, 53:189–190
- peptide-binding heat shock proteins and, 62:160
- antigen presentation, 62:172–174
 - chaperone hypothesis, 62:163–166
 - immunity to cancer, 62:168, 171
 - specific immunity, 62:167
- phenotypes of tumor cells, 53:143–146
- polyoma virus TSTA and, 55:73, 78, 79, 82
- quantitative variation in, effects on afferent-efferent T-cell responses, 53:213–214
- regulation of, oncogenes and, 53:225–226
- in regulation of antitumor immunity by cytotoxic T cells, 53:93–97
- role in T and NK cell recognition, 67:166–169
- Src family of tyrosine protein kinases and, 57:121, 124–127, 132, 135
- structure of, 53:137–1140
- T-cell interaction, 53:191–192
- T-cell receptors and, 56:51, 53–56, 59, 62, 71
- tissue distribution of, 53:188–189
- tumorigenicity and
- in animal models, 53:91–93
 - in humans, 53:103–106
- tumor rejection antigens and, 58:179–180, 182, 191, 193–194
- Major histocompatibility complex genes
- lung tumor susceptibility and, 53:154–156
 - and non-MHC genes, interactions of, 53:140–141
- regulation of
- features of, 53:220–225
 - posttranscriptional, 53:224–225
 - transcriptional, 53:220–224
- transfected, 53:204–209
- protection from NK susceptibility and, 53:208–209
- tumor growth attenuation and, 53:205–208
- Major late promoter, adenovirus E1A proteins and, 57:52–53, 66, 68
- Malaria, 53:46–64
- acquired immunity to, 53:49–50
 - autoantibodies in, 53:61–62

Malaria (*continued*)

- Burkitt's lymphoma and, 55:145, 148, 211, 245
- CD44 and, 71:286
- cytokine production stimulated by, 53:58
- cytokines in, 53:62
- endemicy of, 53:48–49
- Epstein–Barr virus and
 - evidence linking, 53:50–54
 - interaction between, evidence for, 53:54–58
- Epstein–Barr virus proteins and, 50:97, 136
- host immunity in, protective mechanisms of, 53:59–60
- immune system and, 53:58–64
- immunity in, pathological consequences of, 53:61–62
- immunosuppression by, 53:62–64
- parasite mechanisms in, 53:60–61
- rodent, virus-specific Tc responses in, 53:58
- splenomegaly in, 53:62
- Malaria antigens, lymphocyte transformation and, 53:56–57
- Malformations
 - developmental, tumors and, 54:42–46
 - in NBCCS, 70:50, 57–59
- Malic enzyme, 51:412
- Malignancy, *see also* Metastasis, organ-specific; Premalignancy
 - α_2 -macroglobulin, 69:109
 - ADF and, 57:383, 406–407
 - AIDS and, 51:338, 342, 344
 - and altered 12q13–14 region, 66:113
 - bcr/abl* gene in leukemia and, 57:163–169, 174, 177–178
 - BCR* gene in leukemia and, 57:232
 - central nervous system tumor, oncogenesis and, 58:122–124, 132–134, 137
 - and chromosome loss, 70:16
 - cytotoxic T lymphocytes and, 58:166–167
 - EBV-associated disorders and, 57:333, 335, 371–372
 - Hodgkin's disease, 57:367
 - immunodeficiency states, 57:345
 - NHL and AIDS, 57:365
 - organ transplants, 57:345–347, 355, 363
 - X-linked lymphoproliferative syndrome, 57:337, 339, 343
 - endogenous growth inhibitors and, 57:414–415, 438, 442–444, 446, 448
 - and FcR, 64:235–237
 - genomic instability and, 60:122, 127, 131, 143, 145
 - hematopoietic
 - ara-C role, 72:199
 - p16 and p15 genes, 72:163–164
 - HPV-induced, 64:270–271
 - HTLV-II and, 51:316
 - IAP expression and, 51:259–267
 - immunosuppression and, 60:248–249, 251, 253, 258–259
 - lysophosphatidic acid and, 57:87
 - lysosomes and, 60:270, 274, 277, 286
 - MHC expression in, 53:193–200; 60:182, 190, 203, 223
 - role of, 53:200–209
 - multidrug resistance gene and, 60:167
 - muscle cell regulation and, 58:95
 - myc* family oncogenes and, 57:2, 25, 29–30, 34
 - oncogenes and, 50:71–74, 87–89
 - cellular heterogeneity, 50:89–91
 - genotype, 50:79–81, 86, 87
 - dominant, 50:81–85
 - recessive, 50:85, 86
 - maturation arrest, 50:92
 - phenotype, 50:74, 79
 - growth control, 50:76–79
 - positional control, 50:74–76
 - p53* and, *see* p53, human malignancies and plasminogen activation and, 57:274
 - plasminogen activators, 69:111–114
 - regulation of class I MHC in, 53:225–229
 - soft tissue tumors and, 60:76–78, 81, 85, 93, 105
 - Src family of tyrosine protein kinases and, 57:104, 138–140
 - suppression in
 - leukemic cells, 66:14–15, 20
 - sarcoma cells, 66:24–29
 - suppression of, 57:439–440
 - tumor rejection antigens and, 58:197
- Malignant fibrous histiocytoma
 - chromosomal aberrations, 69:67–69, 88, 90
 - soft tissue tumors and, 60:76, 78, 105, 109
 - chromosomal abnormalities, 60:95, 99
 - tumor suppressor genes, 60:101–102

- Malignant mesothelioma, chromosome 3 losses in, 71:51
- Malignant peripheral nerve sheath tumor, soft tissue tumors and, 60:76–77, 84, 95, 100, 104
- Malignant peripheral nerve sheath tumors, chromosomal aberrations, 69:80–81, 90
- Malignant phenotype, 71:243
- Malignant process
 - adhesion molecules, 71:243, 245
 - apoptosis and, 71:143
 - B-cell lymphoma, 71:143–144
 - leukemia, 71:144–152
 - CD44 and, 71:245, 287–291, 304–305
- Malignant progression
 - HPV-infected cells, and cervical cancer, 64:1–3
 - and preneoplastic and benign lesions, 64:289
- Malthus, views on origins of cancer, 65:18
- Mammalian cell cycle, cdk control, 71:168–169
- Mammalian cells
 - cdc25* protein, 66:190–191
 - chromosomes, 66:2–3
 - initiation of *de novo* methylation, 66:331–334
 - integrative recombination, 66:324–326
 - START, 66:196–197
- Mammalian genomes
 - adenovirus DNA integration, 66:319–324
 - insertion of foreign DNA, 66:313–316, 336–338
- Mammals
 - cell cycle start control, 69:31–40
 - control genes, 69:31–34
 - mitotic start control, 69:50–54
- Mammary carcinoma, oncogene activation and, 51:150–151, 153, 155–156
- Mammary-derived growth inhibition, endogenous growth inhibitors and, 57:435
- Mammary epithelial cells, endogenous growth inhibitors and, 57:414, 435
- Mammary gland
 - newborn macrosomy and, 50:255
 - stroma and
 - alterations, 50:185
 - basement membranes, 50:176
 - epithelium, 50:163, 166, 168
 - TGF- β regulation in, 70:81–83
- Mammary glands, transforming growth factor- α and, 58:42–43
- Mammary tumors
 - chemical carcinogenesis and, 50:46, 59
 - MNU-induced, diet effects, 61:5–6
- Mammary tumor susceptibility, MHC and, 53:163–166
- Mammary tumor virus type B, incidence levels in wild mice, 65:192
- Mammography, DCIS characterization, 61:30
- Mantle cell lymphoma
 - chromosomal translocation, 68:74, 83–84
 - diagnosis by cyclin D1 expression, 68:77–78
 - incidence, 68:74
 - survival rate, 68:74
- MAPK, *see* Mitogen-activated protein kinase; Protein kinases, mitogen-activated
- MAP kinase
 - cascade, 66:191
 - cascade activation by Flt family, 67:303–304
- Mapping
 - comparative, human and murine
 - chromosomal regions, 67:104
 - cytotoxic T lymphocytes and, 59:228, 234, 237
 - fibroblast growth factors and, 59:115, 118, 120, 123, 131, 150
 - hepatitis B viruses and, 59:199, 202–203
 - NBCCS
 - comparative, 70:55–57
 - and linkage, 70:52
 - Wilms' tumor and, 59:46, 53–54
- Maps, ataxia-telangiectasia genes and, 56:90, 92–97
- MARCKS, as PKC substrate, 64:172–173 and tumorigenesis, 64:189–190
- Marek's disease, metastasis and, 51:363–364
- Marfan syndrome, age and risk of, 71:230
- Marital status, prostatic cancer and, 51:22–23, 28
- Markel cell carcinoma, chromosome 3 losses in, 71:51
- Marker proteins, identification in radioresistant and radiosensitive cell lines, 61:218
- Marmoset, *Herpesvirus saimiri* and, 56:337–340, 350

- MART-1/Melan-A, expression and immunogenicity, 70:152–157
- Mason-Pfizer monkey virus, 51:310–311, 317, *see also* Monkey viruses
- Mass spectroscopy, peptide-binding heat shock proteins and, 62:160–161, 170
- Mast cell growth factor, protein tyrosine kinase GFRs and, 60:51–54
- Mast cells
bcr/abl gene in leukemia and, 57:157, 177
c-fos protooncogene and, 55:41
 clones, 66:4–5
 stroma and, 50:164
 tumor rejection antigens and, 58:199–201
- Master growth factors, G protein signal transduction and, 58:89
- Mathematical model, number of events in cancer, 67:5–7
- Matrigel
 ECs plated onto, 67:260–261
 in mouse assay of angiogenesis, 67:263–266
- MAV, IA gene family elements and, 51:191–192
- Max
 association with c-Myc protein, 70:106–113
 c-Myc complex
 discovery, 68:111, 119
 DNA binding of complex, 68:123
 protein–protein interaction, 68:161
 role in transactivation, 68:124–125
 conservation in evolution, 68:121–122
 dimerization, requirement in cellular fate, 70:133
 disruption effects in embryo, 68:143–144
 DNA sequence recognition, 68:119
 gene locus, 68:166–167
 gene regulation, 68:121
 half-life, 68:120, 122, 144
 homodimer repression of transcription, 68:123
 Mad association, 68:122–123
 Mxi1 association, 68:122–123
 phosphorylation, 68:122
 role in cell differentiation, 68:143–144, 167–168
 structure, 68:119–120, 122
- Max protein, apoptosis and, 71:127–128
- max* protein, *myc* family oncogenes and, 57:10
- MCA, oncogene activation and, 51:150–151, 154, 157, 159, 170, 171
- MCB, start control for mitotic cycle, 69:23
- MCB binding factor, start control of mitotic cycle, 69:23, 28
- MCC gene, desmoid tumors, 69:66
- MCF, *see* Mink cytopathic focus-forming viruses
- MCL, *see* Mantle cell lymphoma
- Mcl-1 protein, apoptosis and, 71:126
- M-CSF, *see* Macrophage colony-stimulating factors
- MDM2 gene
 amplification, 69:68, 73, 83
 osteosarcomas, 69:83
 p53–medial growth arrest, 71:6
- MDM2 protein, p53 function and, 71:18
- MDS, *see* Myelodysplastic syndrome
- MDX-210, 71:365
- Mean inactivation dose, 61:197
- Mean tumor diameter, polyoma virus TSTA and, 55:73, 74
- Mean tumor loads, polyoma virus TSTA and, 55:78
- Meat consumption, prostatic cancer and, 51:34–36, 38–39
- mec1* mutants, 71:13–14
- Mec1 protein, function of, 71:13, 14
- Mechanisms of genomic instability, tumor progression and, *see* Genomic instability, tumor progression and
- Medium, conditioned, 70:6
- Medullary thyroid carcinoma
 derived from C cells, 70:181–182
 familial, 70:187–188
 hereditary and nonhereditary, 70:184–185
ret mutations
 familial MTC, 70:195–198
 sporadic MTC, 70:199–200
- Medulloblastoma
 in NBCCS, 70:50–51
 oncogenesis of, 58:127, 131–132, 134
- MEF2, muscle cell regulation and, 58:105
- mei-41* mutants, 71:13–14
- Mei-41 protein, 71:13
- Meiosis
 oncoprotein kinases and, 57:186, 212, 215
 c-Mos, 57:207, 209
 protooncoprotein tyrosine kinases, 57:200, 205–206
 plasminogen activation and, 57:295

- Meiotic cycle, start control, 69:28–31
- MEK, phosphorylation by MAPK, 72:65
- MEKK1, interaction with Ras, 72:96
- MEL-14
 metastasis and, 51:380–385
 T-cell receptors and, 56:68, 70
- Melanocyte growth factor, metastatic cancer cells and, 55:116
- Melanocytes
 antigens, 70:150
 FGF receptor multigene family and, 60:24
 melanoma cells and, comparison, 65:128
 MHC Class I expression and, 60:202
 protein tyrosine kinase GFRs and, 60:51–54, 60, 66
 specific PKC isozyme expression, 64:187–188
 study of, historical origins, 65:118
- α -Melanocyte-stimulating hormone, metastatic cancer cells and, 55:117
- Melanocytic cells, human
 anchorage-independent growth of, in soft agar, 54:218–219
 chromosomal abnormalities of, 54:217–218
 life span of, 54:217
 as model for tumor progression studies, 54:216–224
 morphology of, 54:217
 phenotypic characteristics of, 54:217–224
- Melanocytic neoplasia, precursor state, stromal changes in lesions of, 65:134
- Melanogenesis, protein tyrosine kinase GFRs and, 60:50
- Melanoma
 α_2 -macroglobulin, 69:109
 angiogenesis, 69:152, 158, 159
 antigens, as reflection of tumor progression, 65:128
 cancer immunotherapy and, 59:247, 293
 chemoimmunotherapy, 59:276, 278–279
 critical factors, 59:250–253
 current strategies, 59:256, 260–261, 264, 268–272
 improvement attempts, 59:284–285, 287, 289, 292
 CD44 and, 71:302
 chemical carcinogenesis and, 50:27
 chromosome 3 losses in, 71:52
 cutaneous
 determining susceptibility of phenotype, 65:130
 incidence data, 56:175–178, 187, 203
 cyclin D1 amplification, 68:88–89
 cytotoxic T lymphocytes and, 58:152–153, 159, 164–167; 59:235
 expression of multiple growth factor genes by, *in vitro* studies, 65:128
 fibroblast growth factors and, 59:152
 growth factor secretion and growth factor receptor expression by, 54:227–229
 immunosuppression and, 60:253
 lysosomes and, 60:276–277
 MAGE-1, 69:203
 metastasis, attributes predicting, 65:116–117
 MHC Class I expression and
 cancer, 60:184, 188–190, 194–195
 downmodulation, 60:222–224, 227–228
 modulation by oncogenes, 60:204–207
 regulation by oncogenes, 60:218, 220–221
 newborn macrosomy and, 50:239, 267
 plasminogen activators and, 69:112–114
 primary cutaneous, biologic forms, studies, 65:122–123
 protein tyrosine kinase GFRs and, 60:66
 stroma and
 basement membranes, 50:175
 epithelium, 50:162, 163, 169
 fibroblasts, 50:178
 glycoproteins, 50:171
 TGF- β and, 71:197
 TNF- α , 69:146
 tumor invasion, 69:112
 tumor rejection antigens and, 58:201–203, 205
- Melanoma cell-derived growth factor, metastatic cancer cells and, 55:117
- Melanoma cells, metastatic cancer cells and, 55:124–126
 clonal dominance, 55:99
 growth factors, 55:116–118
 human malignancy, 55:105–115
 phenotype, 55:91, 95, 96
- MELC cells
 differentiation, role of PKC, 64:183–184
 RB phosphorylation, inactivation during differentiation, 64:42–43

- Melphalan, carcinogenicity, and mutation rate, 65:79–80
- Membrane antigen
 EBV-associated disorders and, 57:332, 340, 356, 373
 Epstein–Barr virus proteins and, 50:97, 139
- Membrane immunoglobulins, *see* Immunoglobulins, membrane
- Membrane localization of yeast Ras proteins, 54:97–101
- Membrane proteins, Epstein–Barr virus genes and, 58:8–9
- Membrane ruffling
 Rac1(12V)-induced, 72:89–90
 role of Rho family proteins, 72:82–83
- Membranes, lipids and glycoproteins, ara-C effects, 72:208
- Memory, T-cell receptors and, 56:70, 71
- Menarche, newborn macrosomy and, 50:233
 accelerated development, 50:266
 factors, 50:257–260
 risk factors, 50:267
- Mendelian inheritance, as acceptable explanation for gene mutations, in 1930s, 65:19
- Mendelism
 Darwinism and, comparison, 65:19
 symmetry and randomness, influence on study of genetics in 1930s, 65:12–13
- MEN II, *see* Multiple endocrine neoplasia type II
- Meningioma
 chromosomal aberrations, 69:64, 65
 chromosome 3 losses in, 71:51
 chromosome abnormalities and, 52:30
- Meningitis, AIDS and, 51:343
- Menopause, newborn macrosomy and, 50:233, 259, 266
- Menstrual cycle, CD44 expression during, 71:285–286
- Mental retardation, *see also* WAGR syndrome
 Wilms' tumor and, 59:48
- merlin* gene, neurofibromatosis, 69:80
- merlin/SCH* gene, 69:81
- Mesenchymal cells
 chemical carcinogenesis and, 50:30, 35
 stroma and
 alterations, 50:185
 basement membranes, 50:176
 disorders, 50:180
 epithelium, 50:160, 164, 169
 fibroblasts, 50:178
- Mesenchyme cells, soft tissue tumors and, 60:77, 94, 108–109
- Mesnil, Louis, 69:3
- Mesoblastic nephroma, chromosomal aberrations, 69:67
- Mesothelioma
 CD44 and, 71:295
 characterization of, 60:76–77, 79
- Messenger RNA, 53:17–21
 adenovirus E1A proteins and
 organization, 57:48, 50
 transactivation, 57:53, 58–60, 64
 transformation, 57:74
- ADF and, 57:387–388, 395–396, 400, 407
- α -fetoprotein and
 gene expression, 56:294, 295, 298
 properties, 56:259, 262, 264
 synthesis, 56:289–293
- alternative splicing, 64:227–228
- APC gene in human cancers and, 62:79
- B cell-associated surface molecules and, 52:96, 97, 112, 135
- bcr/abl* gene in leukemia and, 57:155, 157, 164–165
- BCR gene in leukemia and, 57:228–231, 241–242, 244
- B lymphocytes and, 56:326
- bovine papillomavirus and, 56:136, 137, 140
- breast cancer, *p53* expression in, 59:76
- Burkitt's lymphoma and *c-myc*, 55:158, 186, 190
 chromosomal translocations, 55:196, 198–201
 EBV, 55:228, 229, 235
 synthesis, 55:248
- central nervous system tumor oncogenesis and, 58:136
- c-erbA* and, 59:94–95, 97, 104
- c-fos*, 53:18–20; 55:39–41, 45, 46
- cholecystokinin, 63:301–304
- chromosome abnormalities and, 52:20, 36, 37
- c-jun*, 53:20
- c-myc*, 53:17–18; 70:126–127
- c-myc* regulation and
 Burkitt's lymphoma, 56:32

- expression, 56:10, 11, 22–24
 gene topography, 56:4, 5
 EBNA, 67:200–204
 endogenous growth inhibitors and, 57:418, 433, 438
 Epstein–Barr virus and, 62:183, 188, 218, 222–224
 Epstein–Barr virus genes and, 58:6, 12, 15–16
 Epstein–Barr virus proteins and
 genome, 50:102, 103
 transformed cells, 50:110, 129, 133, 136, 137, 139
 virus-Droded cells, 50:140, 142
 FGF receptor multigene family and, 60:2, 23, 29, 33–34
 alternative splicing, 60:15, 28–29
 early studies, 60:6
 mitogens, 60:5
 multiple forms, 60:18–20
 fibroblast growth factors and, 59:148
 biological function, 59:143–144
 gene expression, 59:128, 131
 protein struc turf, 59:125–126
flt-1, 67:305–308
 gastrin, 63:301–304
 gene rearrangements and, 52:62, 63, 72, 75
 glutathione transferase and, 52:209, 224, 231–233, 240
 growth factor-inducible
 detected by differential screening of gene and cDNA libraries, 53:10–17
 of identified genes, 53:17–21
 hepatitis B viruses and, 59:189, 195, 199, 204
Herpesvirus saimiri and, 56:345
 humoral immune response and, 62:253
 immunosuppression and, 60:251
jun oncogene and, 55:14, 22, 24
 Louvain rat immunocytomas and, 50:298, 302
 lysosomes and, 60:273, 277
 metastatic cancer cells and, 55:116, 119, 124
 MHC Class I expression and
 cancer, 60:190, 194
 modulation by oncogenes, 60:196, 202, 205
 regulation by oncogenes, 60:208, 210, 214
 regulation in tumor cells, 60:217–218, 221
 mouse retrotransposons and, 56:230, 231
 multidrug resistance and, 52:176, 179, 187, 189
 muscle cell regulation and, 58:96
myc family oncogenes and, 57:3, 6
 future perspectives, 57:37
 gene expression, 57:19–21
 oncogenic activities, 57:32
 oncoprotein kinases and, 57:199–200, 203, 208–210
p53 and human malignancies and, 57:258–259, 261, 264, 266–268
 plasminogen activation and, 57:287, 294–296, 298, 301, 303
 proliferation-specific, serum-induced transcription of, 53:7
 protein tyrosine kinase GFRs and, 60:49, 52, 66
 Ras function and, 62:28, 33, 44, 50
RBI gene, 119–120 tissue distribution, 61:121–122
 Src family of tyrosine protein kinases and, 57:113–119, 133
 surfactant proteins, 67:92–93
 T-cell receptors and, 56:70
 T-lymphocyte specific, 53:21
 transcripts from *p53*, 66:77
 transforming growth factor- α and, 58:30, 39–42, 44
 tumor rejection antigens and, 58:191
 uPA and uPA receptor, 67:259
 VEGF, 67:289–292
 Wilms' tumor and, 59:50, 56–58, 61
 Met 918 Thr, mutation in MEN IIB, 70:202–204, 212
 Metabolism, ara-C, 72:200–205
 Metachromasia, stroma and, 50:183
 Metalloproteinases
 stroma and, 50:161
 TGF and, 51:134
 Metallothionein
 Burkitt's lymphoma and, 55:208, 209
c-fos protooncogene and, 55:44
 chromosome abnormalities and, 52:12
jun oncogene and, 55:7
 Metaphase, Epstein–Barr virus proteins and, 50:104
 Metaplasia, gastrointestinal diseases and, 50:7

Metastasis

- adhesion molecules and, 71:245
- cancer immunotherapy and, 59:255, 292
 - chemoimmunotherapy, 59:277
 - current strategies, 59:260–261, 264–265, 270–271, 273
 - improvement attempts, 59:283–285, 288
- capacity for, tumorigenicity and, 54:194
- and early induction of *p53* antibodies, 66:118–119
- genomic instability and, 60:123, 126
- in heterozygous and homozygous recipients, 66:52–53
- immunosuppression and, 60:258, 261
- inefficiency of, 54:159–203
 - consequences of, 54:199–202
 - documentation of, 54:160–161
 - molecular biology of, 54:187–198
 - random and nonrandom events in, 54:178–187
 - clonal dominance and, 54:183, 186–187
 - dynamic heterogeneity and, 54:183, 184–185
 - transient metastatic compartment and, 54:182–184
- lysosomes and, 60:275–277, 280, 286
- metastatic subpopulations in, 54:178–187
- MHC antigens in
 - in animal models, 53:91–93
 - expression and, 53:89–109
 - in humans, 53:103–106
- MHC class I expression and, 60:233
 - downmodulation, 60:222–223, 225, 227
 - modulation by oncogenes, 60:200–201
- multidrug resistance gene and, 60:157–158
- organ-specific
 - adhesion systems involved in, 51:365–367
 - cryostat sections, 51:364–365
 - endothelial monolayers, 51:365
 - antibody blocking and, 51:363–364
 - general considerations for, 51:361–362
 - heterotropic aggregation and, 51:362
 - lymphocyte homing receptors and
 - Hermes-1, 51:385–386
 - HEV binding, 51:377–380
 - human, 51:372

- lung recirculation, 51:367–368
- MEL-14, 51:380–385
- mouse, 51:370–371
- other, 51:373–376
- peripheral mode, 51:370–371
- rat, 51:372–373
- somatic fusions, 51:376–377
- and *p53* loss, 64:284
- plasminogen activators and, 69:111–112
- process of, 54:161–177
 - arrest of cancer cells in, 54:172–176
 - extravasation in, 54:176–177
 - intravasation in, 54:169–171
 - invasion in, 54:161–169, *see also*
 - Invasion in metastatic process
 - neovascularization in, 54:177
 - in radiation chimeras, 66:45–46
 - role of VEGF, 67:310
 - target organ specificity, 66:63–64
 - tissue site and, 53:230–231
 - tumor
 - induction of immunity, 66:61
 - and mutations in *p53*, 66:108
- Metastatic phenotype, metastatic inefficiency and, 54:196
- Metastatic subpopulations, 54:178–187
- Meth A, peptide-binding heat shock proteins and, 62:155–159, 161
- MethA, tumor rejection antigens and, 58:183, 200, 206
- Methionine, *jun* oncogene and, 55:12
- Methotrexate, multidrug resistance and, 52:168
- 4-Methoxyphenol, tumorigenic activity of, 53:254
- Methylanthrene, endogenous growth inhibitors and, 57:444
- Methylation
 - α -fetoprotein and, 56:297, 298
 - de novo*, integrated foreign DNA, 66:329–335
 - DNA, in cancer, 54:1–19, *see also* DNA methylation
 - genomic instability and, 60:130, 140–141
 - Herpesvirus saimiri* and, 56:340, 342
 - MHC Class I expression and, 60:216–217
 - mouse retrotransposons and, 56:237
 - reverse transformation and, 62:138–139
 - signal for, transduction of, 54:4–7
 - soft tissue tumors and, 60:94
 - tumor clonality and, 50:205

- Methylcholanthrene
 cytotoxic T lymphocytes and, 58:159, 161
 induced tumors, 66:46, 48–49, 61
 oncogene activation and, 51:150–151, 154, 157, 159, 170, 171
 peptide-binding heat shock proteins and, 62:155–156, 168
 tumor clonality and, 50:219, 223
 tumor rejection antigens and, 58:183–185, 197, 200
- 3-Methylcholanthrene, in study of relationship between hormones and carcinogenesis, 65:45–46
- Methylcytosine, genomic origin, 72:143
- O⁶-Methylguanine, repair, ability of human cells, 65:77
- Methyl methanesulfonate, methylation of DNA using, 65:67
- N-Methyl-N-nitrosourea, *see* Nitrosoureas
- N-Methyl-N'-nitro-N-nitrosoguanidine, oncogene activation and, 51:169, 170, 171
- N-Methyl-N'-nitrosoguanidine, tumor rejection antigens and, 58:183–184
- N-Methyl-N-nitrosourea (MNU)
 endogenous growth inhibitors and, 57:445–447
 prostatic cancer and, 51:30–31
- 35-Methylokadaic acid, *see* Dinophysistoxin-1
- Methylphosphonate oligonucleotide analog, 61:76–77
- Methyltransferases, DNA, 66:333–334
- 2-Methoxyestradiol, 69:150
- MET receptors, protein tyrosine kinase GFRs and, 60:46, 63
- MFO system, chemical carcinogenesis and, 50:39, 40
- MHC, *see* Major histocompatibility complex
- MHV-68 virus, 69:231–232
- Microautoradiography, gastrointestinal diseases and, 50:4, 5, 10
- Microcell hybrids, 71:35
- Microcystin-LR, biochemical and immunological effects, 61:160
- Microcystins
 biochemical activity, 61:172–176
 hepatotoxicity, 61:174–179
 isolation, 61:172
 molecular modeling, 61:179–180
 structure, 61:172–176
 target tissues, 61:176–178
 tumor promotion, in liver, 61:178–179
- Microfilaments
 gastrointestinal diseases and, 50:18, 19
 plasminogen activation and, 57:276, 278, 282, 300
- β_2 -Microglobulin
 adenovirus proteins and, 52:152, 155
 association with HLA class I heavy chain, 67:161–162
- β_2 -Microglobulin
 cytotoxic T lymphocytes and, 59:234, 238
 defects, and HLA class I underexpression, 67:178–180
 MHC Class I expression and, 60:185–186, 194
 downmodulation, 60:226–227
 modulation by oncogenes, 60:195–196, 200, 205–206
 regulation by oncogenes, 60:212–213
 peptide-binding heat shock proteins and, 62:164–165
- β_2 -Microglobulin gene, 71:112
- Microsatellite instability
 detection by polymerase chain reaction, 71:213–214
 DNA mismatch repair deficiency, 71:99–101, 211–213
 in epithelial tumors, 67:74–77
 HNPCC, 72:44–45
 HNPCC tumors, 72:12–13
 mutation rate, 71:210
 in normal tissue, 71:215–216
 not due to mismatch repair deficiency, 71:214–215
 nucleotide sequence variations, 72:43–44
 replication errors leading to, 67:66
 sporadic tumors, 72:45–46
 sporadic tumors and, 71:63–64
 TGF- β receptor loss, 71:185
- Microsatellite repeats, 71:99–100
- Microtubule-associated protein kinase, mitosis and, 57:204–207
- Microtubule-associated protein kinases
 characterization, 63:95
 distribution, 63:95–96

- Microtubule-associated protein kinases
(*continued*)
extracellular signal-regulated, *see*
Extracellular signal-regulated protein
kinases
homology with proteins in yeast mating
pathway, 63:97–99
phosphorylation of upstream components
of cascade, 63:107–108
recombinant, *in vitro* regulation, 63:100–
102
regulation, protein–protein interactions in,
63:106–107
- Microtubule organizing center, oncoprotein
kinases and, 57:201, 210
- Microtubules
changes on entering mitosis, 66:203
genomic instability and, 60:134–135
oncoprotein kinases and, 57:189, 210
- Midgestation, *myc* family oncogenes and, 57:
14–15
- Migration
ataxia-telangiectasia genes and, 56:80, 96
B lymphocytes and, 56:319
Burkitt's lymphoma and, 55:158, 234
metastatic cancer cells and, 55:88, 106, 126
oncogenes and, 50:74–78, 89
plasminogen activation and
adhesive interactions, 57:275–278
directed cell surface, 57:301, 311
proteolytic modulation, 57:290, 292–
295
signal transduction and, 55:293, 294
T-cell receptors and, 56:50, 67, 68, 70, 71
- Migration index, polyoma virus TSTA and,
55:61
- Migration studies, prostatic cancer and, 51:6,
25
- mik1*⁺ gene, mitotic start control, 69:41, 45
- Milk consumption, prostatic cancer and, 51:
34–36, 39–40
- Mineral oil, *c-myc* gene and, 51:151, 160
- Minichromosomes, metastatic cancer cells
and, 55:94
- Miniproteins, murine p53, 66:103, 107–108
- Minisatellite sequences
mutation frequency, 71:210
somatic mutations, 71:217
- Mink cytopathic focus-forming viruses, class
I, role in Ly-1⁺ B cell lymphomas, 63:
285–286
- Minor histocompatibility antigens, tumor
rejection antigens and, 58:194, 207
- MIS, TGF and, 51:121–123
- Misincorporation, by DNA polymerases, 72:
36–40
- Mismatch repair, in mutation origin, 72:36–
37
- Mismatch repair genes, 71:95, 212
biochemical and functional properties, 71:
98–99
chromosome 3 and, 71:55–56
in HNPCC, 72:44–45, 48
HNPCC-related, 71:101–109, 111, 112–
115
identification, 71:97–98
microsatellite instability, 71:99–101
mutations, 71:55–56, 62–64, 105–109; 72:
12–13
founding mutations, 71:110–111
mutator phenotype and tumorigenesis,
71:111–112
Turcot syndrome, 71:96
- Missense mutations, 71:105, 107
- Mitochondria
chromosomes and, 62:11
Epstein–Barr virus proteins and, 50:132
genomic instability and, 60:132
renal cell tumors, molecular cytogenetics,
62:91–92, 115–118
- Mitogen
activated RB phosphorylation, 64:36–39
chemical carcinogenesis and, 50:49, 50
Epstein–Barr virus proteins and, 50:133
gastrointestinal diseases and, 50:5
- Mitogen-activated protein kinase
cascade, activation, 72:61–65
G protein signal transduction and, 58:78–
79
interaction with ara-C, 72:218
- Mitogen-activated protein kinase kinase 1,
candidate Ras effector, 72:74
- Mitogenic response to serum, 53:3–5
minor transcriptional changes in, 53:5–6
transcription and translation in, 53:5–8
- Mitogenic signaling network,
lysophosphatidic acid and, 57:87
- Mitogenic signals, radiation response and, 61:
210–215
- Mitogens
ADF and, 57:384
 α -fetoprotein and, 56:284, 299

- bcr/abl* gene in leukemia and, 57:170
 B lymphocytes and, 56:315, 318
 Burkitt's lymphoma and, 55:164
 cancer immunotherapy and, 59:270, 278, 285–286
c-erbA and, 59:92
c-fos protooncogene and, 55:39–41
 chromosome abnormalities and, 52:22
c-myc regulation and, 56:9, 19, 23
 EBV-associated disorders and, 57:341
 FGF receptor multigene family and, 60:2–6, 24, 33–34
 fibroblast growth factors and, 59:115–117, 132, 140, 147
 protein structure, 59:120, 122–123, 125
 tumors, 59:152–153
 G protein signal transduction and, 58:76, 78–79, 84–88
 hepatitis B viruses and, 59:181
 immunosuppression and, 60:247–248, 253–254
 lysophosphatidic acid and, 57:87–88, 91–99, 101
 lysosomes and, 60:277
 metastatic cancer cells and, 55:116, 117
 muscle cell regulation and, 58:108–110
myc family oncogenes and, 57:17–18
 oncoprotein kinases and, 57:204
p53 and human malignancies and, 57:264
 plasminogen activation and, 57:294
 protein tyrosine kinase GFRs and, 60:53
 Raf-1 phosphorylation and, 58:53–54, 58, 63, 69
 renal cell tumors and, 62:107
 signal transduction and, 55:292
 Src family of tyrosine protein kinases and, 57:119, 139
 T-cell receptors and, 56:57
 transforming growth factor- α and, 58:38, 45
 Wilms' tumor and, 59:55
see also Protein kinases, **mitogen-activated**
- Mitomycin, α -fetoprotein and, 56:287, 289
 Mitomycin C, cancer immunotherapy and, 59:278
- Mitosis
 breast cancer, *p53* expression in, 59:71–72, 74
 Burkitt's lymphoma and, 55:230
 chromosomes and, 62:1–4, 6, 13
 EBV-associated disorders and, 57:336
 endogenous growth inhibitors and, 57:433, 435, 443–444, 448
 keratinizing cells, 57:424, 429–431
 Epstein–Barr virus genes and, 58:18
 Epstein–Barr virus proteins and, 50:104, 112
 gastrointestinal diseases and, 50:2, 6, 7
 genomic instability and, 60:133–135, 144
 growth regulation and, 57:416–419
 jun oncogene and, 55:28
 lysosomes and, 60:283
 oncogenes and, 50:72, 87, 89
 malignant phenotype, 50:77–79
 plasminogen activation and, 57:301
 Raf-1 phosphorylation and, 58:64
 Ras function and, 62:49
 related cyclins, 66:203–205
 renal cell tumors and, 62:95, 97–103, 109
 reverse transformation and, 62:142
 soft tissue tumors and, 60:103
 Src family of tyrosine protein kinases and, 57:108, 124
 stroma and, 50:179
 tumor clonality and, 50:208, 210
 Mitotic checkpoint, *p53* and, 71:7, 8
 Mitotic index, soft tissue tumors and, 60:88
 Mitotic rates, endogenous growth inhibitors and, 57:443
- Mitotic start control
 fission yeast, 69:42–44
 control genes, 69:40–42
 S-G2 checkpoint control, 69:44–49
 mammals, 69:50–54
- Mixed-lineage kinase, MLK3, association with CDC42 and Rac1, 72:87–88
- MLH1* gene, 71:62–64, 98, 99
 chromosome 3 and, 71:55–56
 founding mutations, 71:110–111
 HNPCC, 71:93–94, 95
 kindred studies, 71:103, 104
 missense mutations, 71:105, 107
 mutations, 71:105–109, 114
- MLH1 protein, 71:98, 101
- MMR genes, *see* Mismatch repair genes
- M-MSV, *see* Moloney murine sarcoma virus
- MO15 kinase, 71:172
- Model
 cervical carcinogenesis, 64:4
 RB molecular function, 64:69
 transgenic mouse, 64:117–120, 134–144, 247–289

Models

- adenovirus system, 66:316–324
- ALL-1 leukemogenicity, 66:229–230
- animal
 - MEN II, 70:213–214
 - prostatic cancer and, 51:2, 28–31, 72–73
 - retroviruses and, 51:308, 309, 310
- immunotherapy, 66:61–63
- in vitro* murine, 66:121–122
- for *p53* activation, 66:172–173
- transgenic, lung tumorigenesis, 67:99–100
- viral DNA replication, 66:149–150
- Molecular biology, multistep carcinogenesis, 72:14–17
- Molecular genetics
 - bone and soft tissue tumors, 69:64–87
 - cancer prevention research, 61:3–5
 - chromosomal aberrations, 69:64–93
 - diagnosis and prognostication, 69:65, 91–93
 - human papillomaviruses, 69:177–178
 - predisposition to retinoblastoma, 54:31–36
 - renal cell tumors and, *see* Renal cell tumors, molecular cytogenetics
- Molecular markers, Wilms' tumor and, 59:46
- Molecular matchmaker, role of RB, 64:67–70
- Molecular modeling, microcystins and nodularin, 61:179–180
- Molecular targets, of ionizing radiation, 61:218–220
- Molecular therapies
 - antineoplastic agents, 61:61–63
 - immunotherapy
 - active, 61:63–66
 - passive, 61:66–74
 - tumor-specific, 61:60–61
- Moloney leukemia virus
 - c-erbA* and, 59:99, 101
 - fibroblast growth factors and, 59:151
- Moloney murine leukemia virus
 - hepatitis B viruses and, 59:207
 - MHC Class I expression and, 60:198–199, 212, 228
- Moloney murine sarcoma virus, 51:280–282
 - MHC Class I expression and, 60:198, 212
- Moloney virus, Louvain rat immunocytomas and, 50:298

- Monkey, *Herpesvirus saimiri* and, 56:336–338, 342, 344
- Monkey viruses, 51:310–313, 317–320
- Monoclonal antibodies
 - 11B11, anti-IL-4, 66:301, 307
 - ADF and, 57:403
 - α -fetoprotein and, 56:270, 286
 - anti-CD44, 71:252, 261, 274, 276, 277, 280
 - anti-TAC, 51:345
 - B cell-associated surface molecules and, 52:85, 116, 118–124, 134
 - Bgp95, 52:116
 - CD19, 52:100–102
 - CD20, 52:92, 93, 96
 - CD21, 52:102–104
 - CD22, 52:105, 107
 - CD23, 52:108, 109, 111, 112
 - CDw40, 52:113–115
 - expression, 52:127, 129, 130
 - history, 52:87–89
 - T cells, 52:133
 - B lymphocytes and, 56:317, 319, 321
 - Burkitt's lymphoma and, 55:151, 238
 - cancer immunotherapy and, 59:246, 255
 - current strategies, 59:266, 273–274
 - improvement attempts, 59:289–291
 - central nervous system tumor oncogenesis and, 58:138
 - chemical carcinogenesis and, 50:55
 - clonotypic, 66:298
 - combinatorial immunoglobulin gene libraries for, 61:72
 - cytotoxic T lymphocytes and, 58:155, 161
 - defining HLA alterations, 67:171–174
 - EBV-associated disorders and, 57:348, 353, 356, 364
 - Epstein-Barr virus and, 62:185
 - Hodgkin's disease, 62:216–218, 222, 224
 - T-cell lymphoproliferation, 62:188–190, 199, 202, 208
 - Epstein-Barr virus genes and, 58:4, 9
 - Epstein-Barr virus proteins and transformed cells, 50:109, 116, 131
 - virus-produced cells, 50:141, 142, 146
 - fibroblast growth factors and, 59:139
 - gastrointestinal diseases and, 50:17, 18
 - glutathione transferase and, 52:211
 - glycosylation in tumors and, 52:260, 316–318

- carbohydrate antigens, 52:262, 264, 284–289, 291, 300
- diagnostic applications, 52:303–308
- Forssman antigens, 52:296
- glycolipid antigens, 52:261, 267, 269, 273–277, 280, 283
- Hanganutziu-Deicher antigens, 52:293, 294
- oncogenes, 52:267
- therapeutic applications, 52:310–313
- against growth-stimulatory receptors, 61:69
- HIV and, 51:322
- IgM, production in AIDS-SNCCCL, 67:123–124
- immunotherapy with, 61:69–73
- iodine-131 conjugates, 61:70–71
- metastasis and, 51:363–364, 371–373
- metastatic cancer cells and, 55:110
- MHC Class I expression and, 60:211
- multidrug resistance and, 52:174, 175, 183, 189
- multidrug resistance gene and, 60:165, 171
- oncogenes and, 50:76
- oncoprotein kinases and, 57:199, 206
- p53* and human malignancies and, 57:264
- PAb240
 - mutant *p53*-specific, 66:164–166, 170
 - and PAb246 and PAb1620, 66:74–75
- PAb421, PAb1801, and PAb1620, 66:90–92
- PAb1620 and PAb421, 66:169–170
- peptide-binding heat shock proteins and, 62:162
- plasminogen activation and, 57:278, 291, 305–307, 309
- polyoma virus TSTA and, 55:62, 72
- radionuclide conjugates, 61:70–71
- Raf-1 phosphorylation and, 58:64
- Ras function and, 62:31
- reverse transformation and, 62:146
- single-chain antigen proteins, 61:72–73
- soft tissue tumors and, 60:106
- Src family of tyrosine protein kinases and, 57:119, 125, 128–129, 132, 139
- stroma and, 50:176
- T-cell receptors and, 56:54–57, 59–62
- antigens, 56:51, 58
 - leukocyte integrin family, 56:64–66
 - lymphocyte homing receptors, 56:68
- therapies, problems confronting, 61:71–72
- toxin conjugates, 61:70
- tumor clonality and, 50:215
- Monoclonal antibody therapy, HER-2/neu protein, 71:343–345, 356–367
- Monoclonal immunoglobulins, Louvain rat immunocytomas and, 50:280, 288–291, 294, 305, 306
- Monoclonality, 50:198, 224–226
 - animal tumors, 50:218–220
 - definition, 50:201
 - distinction, 50:202–211
 - factors, 50:220–223
 - human tumors, 50:216, 217
 - number, 50:215
- Monocytes
 - ADF and, 57:389–390, 396
 - bcl/abl* gene in leukemia and, 57:176
 - B lymphocytes and, 56:316, 320, 325
 - c-fos* protooncogene and, 55:41, 42
 - c-myc* regulation and, 56:10
 - FcγRII expression, 64:213–214
 - immunosuppression and, 60:253
 - oncoprotein kinases and, 57:213
 - plasminogen activation and
 - directed cell surface, 57:306–308, 311
 - proteolytic modulation, 57:289, 293, 297–298
 - production of SF, 67:270
 - Src family of tyrosine protein kinases and, 57:113–115, 117–118
 - T-cell receptors and, 56:62, 64–66
 - uPARs, 69:115
 - VEGF-induced migration, 67:289
- Monod, Jacques, 69:3, 5, 9
- Mononucleosis
 - acute, Epstein–Barr virus proteins and, 50:113, 135
 - Epstein–Barr virus and, 62:180, 191, 193, 217, 223
 - infectious, Epstein–Barr virus genes and, 58:1, 18, 20
- Monosomy, 62:8
 - chromosome abnormalities and, 52:13, 15, 16, 29, 30
 - in renal cell tumors
 - nonpapillary renal cell tumors, 62:95–96, 99–100, 105
 - papillary renal cell tumors, 62:109–110
- Monosomy 13, osteosarcomas, 69:83

- Monosomy 17, alveolar soft part sarcoma, 69:82
 Monosomy 20, dermatofibrosarcoma protuberans, 69:67
 Monosomy 22
 neurilemmomas, 69:81
 rhabdoid tumors, 69:82
 Mormon population, prostatic cancer and, 51:14–15
 Morphogenesis
 controlling genes, 66:43–44
 plasminogen activation and, 57:274, 276, 280
 Morphology
 adenovirus E1A proteins and, 57:73–74
 bcr/abl gene in leukemia and, 57:169–170
 central nervous system tumor oncogenesis and, 58:122
 EBV-associated disorders and, 57:338, 340, 373
 organ transplants, 57:345, 352, 354–355
 endogenous growth inhibitors and, 57:437–438
 Epstein–Barr virus genes and, 58:2, 7, 18
 Epstein–Barr virus proteins and, 50:122
 gastrointestinal diseases and, 50:2, 18
 lysophosphatidic acid and, 57:88
 mouse retrotransposons and, 56:243
 muscle cell regulation and, 58:98
 newborn macrosomy and, 50:245, 261
 oncoprotein kinases and, 57:203
 p53 and human malignancies and, 57:265
 papillomaviruses and, 56:133, 155
 bovine, 56:135, 136, 138, 140–142
 human, 56:142–149, 151–153
 plasminogen activation and, 57:274, 276, 290, 295, 300
 Raf-1 phosphorylation and, 58:69
 Src family of tyrosine protein kinases and, 57:109
 stroma and, 50:170, 172, 173, 176
 tumor clonality and, 50:217, 219, 225
 MORT1 protein, apoptosis and, 71:129
mos
 MHC Class I expression and, 60:199
 mouse retrotransposons and, 56:230, 231, 233
 Mosaicism, in renal cell tumors, 62:102–103
mos gene
 and acquisition of radiation-resistant phenotype, 61:212
 v-mos, resistance to gamma-rays conferred by, 61:209
 Mos protein, oncoprotein kinases and, 57:196, 211, 214
 Mosquitos, AIDS and, 51:335–336, 338
 Motility, ECs, SF-induced, 67:260–261
 Mouse
 fed bacteriophage M13 DNA, 66:338–339
 in vitro models, 66:121–122
 Lewis lung carcinoma, 66:3LL, 50–53, 55–56
 lung tumors, genetics, 67:83–106
 Matrigel assay of angiogenesis, 67:263–266
 p53 knockout, 66:18, 144–145, 148
 p53 null, relevance to human tumorigenesis, 66:99
 tat transgenic, 66:238, 240, 243
 transgenic, *myc* and *ras* cooperation, 66:199
 tumors, 66:56–57
 wild
 aged populations
 MuLV transmission, milk-borne method, 65:178
 sporadic lymphomas, detection of MuLV p30 antigen, 65:177
 LC (Lake Casitas)
 amphotropic and ecotropic viruses, transmission method, 65:182
 Fv-4 resistance allele, frequency levels, 65:191
 genetic control of MuLV in
 use of *Fv-1supb* resistance allele, 65:188
 use of *Fv-4* ecotropic resistance allele, 65:188–189
 incidence rate of type B mammary tumor virus, 65:192
 lymphomas, incidence rate, 65:180
 MuLV features, tabular presentation, 65:180
 nongenetic control of MuLV, use of selective breeding techniques, 65:187–188
 pre-B cell leukemias, pathogenesis, 65:183–184

- spongiform
 - polioencephalomyelopathy presence, 65:179–181, 184–185
 - transmission methods, 65:194
- RNA tumor viruses, nature and function, 65:171–172
- trapping procedure, 65:173–174
- Mouse C127 cells, papillomaviruses and, 56:135, 141, 142, 146, 147
- Mouse erythroleukemia cells
 - c-myc* regulation and, 56:10, 11, 16, 20, 22, 24
 - myc* family oncogenes and, 57:16–18
- Mouse IAP genetic elements, 51:184–191, 228–230, *see also* Intracisternal A-particle gene family
- Mouse mammary epithelial cell system
 - genetic changes, 66:122–125
 - with mixed *p53* genotypes, 66:100
- Mouse mammary tumor virus
 - adenovirus E1A proteins and, 57:71
 - fibroblast growth factors and, 59:124, 147, 149–151
 - myc* family oncogenes and, 57:28
 - retrotransposons and, 56:216, 217, 219
 - insertion, 56:227
 - LTRs, 56:238, 240, 241
- Mouse retrotransposons, 56:215–217, 244, 245
 - expression of neighboring genes, 56:229–232
 - insertion
 - ongoing, 56:226–229
 - previous germ-line, 56:224–226
- LTRs
 - developmental regulation, 56:242–244
 - expression, 56:235–239
 - hormone responsiveness, 56:240–242
 - structure, 56:234, 235
- mouse genome
 - cellular proviruses, 56:218, 219
 - proviruslike elements, 56:219–224
 - recombination, 56:232, 233
- Mouse strains, RI, as model for identifying novel genes, 54:143–145, *see also* RI mouse strains
- M-phase-promoting factor, oncoprotein kinases and, 57:187–189
 - c-Mos*, 57:208–211
 - phosphatases, 57:211–212
 - protooncoprotein tyrosine kinases, 57:195, 199
- MPMV, *see* Mason-Pfizer monkey virus
- mRNA, *see* Messenger RNA
- MSH2* gene, 71:99
 - chromosome 3 and, 71:56
 - founding mutations, 71:110–111
 - HNPCC, 71:93–94, 95
 - HNPCC kindred studies, 71:103, 104
 - mutations, 71:105–109, 113, 114
- MSH2* protein, 71:101
- MSH3* gene, 71:98, 100
- mSin3 proteins, interaction with Mad1, 70:111–112
- MSM2 protein, 71:98
- MST1* gene, 71:67
- MT-1 cells, ADF and, 57:387–388
- MT2 protein complexes, E2F complexes and, similarities, 65:222
- MTC, *see* Medullary thyroid carcinoma
- MTF, tumor rejection antigens and, 58:194
- MTP-PE, cancer immunotherapy and, 59:267
- MTS, *see* Multiple tumor suppressor [D]MTV, *c-erbA* and, 59:100–101
- Mucin
 - gastrointestinal diseases and, 50:17
 - incomplete glycosylation, 66:59
- Mucosal vascular addressin, CD44 binding to, 71:273
- Muir–Torre syndrome, 71:96, 113
- Muller, H.J., 65:1
 - statements regarding purpose of genes, 65:10
 - views on role of mutations in carcinogenic process, 65:28–29
- Müllerian inhibitory substance, TGF and, 51:121–123
- Multi colony-stimulating factors, and leukemia development
 - characterization, 63:50
 - membrane receptors, 63:71–72
 - myeloid leukemia
 - initiation, 63:65, 67, 70
 - suppression, 63:79, 81
 - progenitor cell formation, 63:57
- Multidrug resistance, 52:165, 166
 - alterations, 52:172–174
 - amplified genes, 52:175–178
 - clinic, 52:194, 195
 - coamplified genes, 52:192–194
 - drugs affected, 52:166–168

- Multidrug resistance (*continued*)
- events, 52:169–171
 - glutathione transferase and, 52:241–243
 - lysosomes and, 60:284–285
 - outlook, 52:195–197
 - P-glycoprotein
 - diversity, 52:185–188
 - expression, 52:189–192
 - genes, 52:178–180
 - mutation, 52:188, 189
 - overproduction, 52:174, 175
 - structure, 52:180–185
 - pharmacological reversal, 52:171, 172
 - soft tissue tumors and, 60:105–107
- Multidrug resistance gene, human, 60:176
- regulation of expression, 60:169
 - development, 60:171
 - P-glycoprotein, 60:175–176
 - promoters, 60:171–174
 - protein kinase, 60:170
 - RNA, 60:169–170
 - tumor progression, 60:174–175
 - transporter, 60:157–158
 - clones, 60:159–163
 - drug efflux pump, 60:159
 - gene expression, 60:165–167
 - inhibitors, 60:168–169
 - in vitro* model systems, 60:158–159
 - in vivo* model systems, 60:167–168
 - mechanism of action, 60:163–165
- Multiple allele hypothesis, origins, 65:7
- Multiple endocrine neoplasia type II
- animal models, 70:213–214
 - chromosome 3 losses in, 71:52
 - clinical varieties, 70:184–191
 - developmental abnormalities in, 70:188–190
 - M918T mutations, 70:212
 - ret* mutations, 70:195–204
 - tumors, 70:181–184
- Multiple myeloma, multidrug resistance gene and, 60:168
- Multiple tumor suppressor, 71:196–197
- Multiplication, cellular, 66:14, 17, 27
- Multiplicity, in phenotypic components, 70:43
- MuLV, *see* Murine leukemia virus
- MuLV-induced lymphomagenesis, MHC and, 53:149
- MuLVs, mouse retrotransposons and, 56:216–219, 223, 233
- expression, 56:230
 - insertion, 56:225, 227
 - LTRs, 56:236, 238–242
- Muramyl dipeptide, cancer immunotherapy and, 59:267
- Murine leukemia virus
- congenital transmission, in LC mice, 65:182
 - genetic control in LC mice
 - use of *Fv-1supb* resistance allele, 65:187–188
 - use of *Fv-4* ecotropic resistance allele, 65:188–189
 - hepatitis B viruses and, 59:205, 208
 - and human type C retrovirus, similarities, 65:192–194
 - IAP elements and, 51:191–192
 - milk-borne transmission method, 65:178
 - myc* family oncogenes and, 57:24, 27, 34
 - nongenetic control in LC mice with
 - selective breeding techniques, 65:187–188
 - occurrence in wild mice, 65:174–175
 - p30 antigen, detection in sporadic lymphomas of wild mice, 65:177
 - polyoma virus TSTA and, 55:57
- Murine leukemia virus antigens, 51:296, 297
- APC and, 51:293–295
 - early work on immunological tolerance to, 51:279–282
 - endogenous, 51:282–287
 - exogenous, 51:287–290
 - general considerations for, 51:277–279, 296–301
 - lymphoma development and, 51:296, 297
 - M-MSV and, 51:280–282
- Murine myeloid tumors, retroviral integration in, 54:141–155
- MuRRs, 56:233
- expression, 56:231
 - insertion, 56:225, 226
 - LTRs, 56:234, 235, 237, 242
 - mouse genome, 56:220–224
- MuRVY, 56:220, 222, 225, 234
- Mus caroli*, tumor clonality and, 50:204, 206, 211
- Muscle cell regulation, 58:95–96, 114
- growth factor signals, 58:108–109
 - HLH proteins
 - inactivation of, 58:109–113
 - inhibition of cell proliferation, 58:113–114

- MyoD family
 activation by cDNAs, 58:97–100
 expression, 58:106–107
 related factors, 58:100–102
 transcription, 58:102–106
 myogenic regulatory genes, 58:96–97
 rhabdomyosarcoma, 58:114
- Muscle creatine kinase, muscle cell regulation and, 58:100–101, 103, 105–106, 109, 111
- Mus musculus*, tumor clonality and, 50:204, 205, 211, 215
- Mustard gas
 cytotoxic effects on DNA, 65:54–55
 as inhibitor of carcinogenesis, 65:48–49
 dermal, mode of action, 65:52
 vesicant action, similarities with radiation, 65:29
- Mutagen, exposure, and oncogenic progression, 64:4
- Mutagenesis
 adenovirus E1A proteins and, 57:54
bcr/abl gene in leukemia and, 57:177–178
 Burkitt's lymphoma and, 55:192
 chemical carcinogenesis and
 experimental models, 50:30
 mechanisms, 50:40, 41, 43, 46, 53
 enhanced, coupled with somatic selection, 72:35–36
 fibroblast growth factors and, 59:130
 gastrointestinal diseases and, 50:5
 hepatitis B viruses and, 59:169, 203–205, 211
 insertional, 66:262, 294–295, 298, 339–341
jun oncogene and, 55:19
 mouse retrotransposons and, 56:216, 217, 229, 230, 245
 muscle cell regulation and, 58:101
myc family oncogenes and, 57:6, 20
 oncoprotein kinases and, 57:203, 207
p53 and human malignancies and, 57:261
 plasminogen activation and, 57:282, 288
 Raf-1 phosphorylation and, 58:60, 64–65
 signal transduction and, 55:282
 switch II, 72:76
 tumor rejection antigens and, 58:183–184, 195
- Mutagenized tumors, cytotoxic T lymphocytes and, 58:149–151
- Mutants
 immunogenic, 66:57
p53, 66:98–108
 Ras effector domain, 72:69–70, 98
- Mutational analysis
 E7, 64:7, 9–10
 for NBCCS, 70:57–59
- Mutational events, and age-specific incidence of cancer, 67:5–7
- Mutation cluster region, *APC* gene in human cancers and, 62:75, 79–80
- Mutation rate, 71:210–211, 214
 age and, 71:210, 230
 as biological pacemaker, 71:231–233
 cancer prevention and, 71:234–235
 importance of measuring, 71:233–234
 in normal tissue, 71:216
 spontaneous, 72:32
- Mutations, 71:210
 β_2m gene, 67:179–180
 accumulation
 mechanisms, 72:46–47
 rate delay, 72:50–51
 adenovirus E1A proteins and
 transactivation, 57:51–52, 56–58, 60–61
 transactivation mechanisms, 57:70–71
 transcription, 57:67
 transformation, 57:74–77
 adenovirus proteins and, 52:154, 158
 ADF and, 57:388
APC gene, 62:66, 82–83; 71:111
 gastric cancer, somatic mutations in, 62:80–82
 ataxia-telangiectasia genes and, 56:97
 base-substitution
 from aralkylating agents, studies in *Escherichia coli*, 65:83
 and oncogene activation, 65:96
- B cell-associated surface molecules and, 52:134
- bcr/abl* gene in leukemia and, 57:153, 155, 157
abl in malignancy, 57:164–165, 167
 animal models, 57:174, 178
 biological activity, 57:170–173
c-abl activation, 57:160–162
c-Abl protein, 57:158–159
BCR gene in leukemia and, 57:232, 252
 as biological pacemaker, 71:231–233
 breast cancer, *p53* expression in, 59:69–77, 80–85

Mutations (*continued*)

- Burkitt's lymphoma and, 55:219, 220, 222
 - chromosomal translocations, 55:199, 201, 202
 - c-myc*, 55:162, 163
 - c-myc* expression, 55:192
 - c-myc* structural changes, 55:177–180, 183, 184
 - EBV, 55:192, 242
 - synthesis, 55:247
 - translocation mechanism, 55:176
- cancer and, 71:243
- cancer immunotherapy and, 59:288
- cancer incidence data and, 56:161, 162, 210
 - age profiles, 56:164–167, 169–171
 - cohort data, 56:175, 178, 179, 184
 - hepatocellular carcinoma, 56:187, 188
 - two-stage model, 56:188, 193–195, 199, 200, 202, 204, 205
- central nervous system tumor oncogenesis and, 58:123, 132–134
- c-erbA* and, 59:89, 106–109
 - avian erythroblastosis virus, 59:90, 92–93, 96
 - mutations, 59:102–104
 - protein function, 59:97–98, 101
 - structure, 59:96–97
- c-fos* protooncogene and, 55:38, 39
- chemical carcinogenesis and, 50:60
 - biological concepts, 50:36, 39
 - experimental models, 50:30
 - mechanisms, 50:42, 43, 46, 48, 54
- chromosome abnormalities and, 52:2, 4, 34
- chromosomes and, 62:7, 9–10, 13
- c-myc* regulation and
 - abnormal regulation, 56:25, 26, 31, 36, 40
 - expression, 56:15, 16, 22
- cytotoxic T lymphocytes and, 58:149–151, 158, 167; 59:228, 233–234, 236–241
- destabilizing, caused by loss of DNA repair functions, 72:11–14
- EBV-associated disorders and, 57:331, 335, 337, 343
- endogenous growth inhibitors and, 57:437
- endometrial carcinoma, 71:113
- Epstein–Barr virus genes and, 58:5, 14
- Epstein–Barr virus proteins and, 50:141
- FGF receptor multigene family and, 60:23, 33, 35
- fibroblast growth factors and, 59:136, 142
 - oncogenic potential, 59:145–146, 149
 - protein structure, 59:120–121, 123
- founding mutations, 71:110–111
- gene products, 70:166–169
- gene promoter regions, 72:181–182
- gene rearrangements and, 52:47, 50
- genomic instability and, 60:123–124, 126–127, 145–147
 - mechanisms, 60:128–134, 136, 138–142
 - quantitative considerations, 60:142–145
- germ line, 67:7–8, 14, 18
- germline, 71:210, 211, 228–231
 - APC* gene in familial adenomatous polyposis, 62:66–74
 - due to endogenous mutations, 71:227–228
 - rate, 71:224–227
 - somatic mutations and, 71:228–231
- glioblastomas, 71:114
- glutathione transferase and, 52:237
- G protein signal transduction and, 58:78–79, 84, 87, 90
- hepatitis B viruses and, 59:176, 187, 189, 191, 202, 208–210
- hereditary nonpolyposis colorectal cancer and, 71:93–116
- Herpesvirus saimiri* and, 56:339, 342–345, 348
- humoral immune response and, 62:256
- induction of SF, 67:272–274
- Kras2*, 67:86–91
- and LOH, 66:72–73
- loss-of-function, 67:46
- Mendelian inheritance as explanation for, 65:19
- in MEN IIA, frequency, 70:185
- in MEN IIB, 70:190–191
- metastatic cancer cells and, 55:87, 90, 93–96
- MHC Class I expression and, 60:181, 201–202, 210, 215
- missense, 66:163; 71:105, 107
- mouse retrotransposons and, 56:234
 - expression of neighboring genes, 56:229, 231, 232
 - LTRs, 56:242, 244
 - mouse genome, 56:218, 219, 223
- Muir–Torre syndrome, 71:113
- multidrug resistance and, 52:167, 196

- amplified genes, 52:175
- coamplified genes, 52:194
- P-glycoprotein, 52:175, 185, 188, 189
- multiple
 - clonal expansion role, 72:34–35
 - somatic selection role, 72:35–36
 - in tumor evolution, 72:27–28
- multiple recessive, 67:78
- muscle cell regulation and, 58:103–104, 109, 113
- myc* family oncogenes and, 57:5
 - future perspectives, 57:35–37
 - oncogenic activities, 57:25–26, 29, 31
 - protein structure, 57:9, 11–13
- null *c-myc*, 70:127–128
- numbers, in cancer cells, 72:33–34, 51
- oncogenes and
 - malignant genotype, 50:82, 83, 85, 86
 - maturation arrest, 50:90
- oncoprotein kinases and, 57:191–192, 200, 206–207, 210
- origins, 72:36–38
- p53*, 67:91; 71:7–8
 - and breast cancer, 66:108–120
 - in cell subpopulations, 72:188
 - human malignancies and, 57:257, 260–261, 263–268
- peptide-binding heat shock proteins and, 62:159, 168–170
- point
 - in breast cancer, 61:39
 - c-erbA* and, 59:98, 101, 107
 - in c-Rel, 66:261
 - fibroblast growth factors and, 59:145
 - hepatocellular carcinoma and, 59:208–210
 - in human tumors, 66:150–154, 170
- polyoma virus TSTA and, 55:65–67, 69, 72, 80, 81
- protein tyrosine kinase GFRs and
 - development, 60:50–60
 - genetics, 60:66
 - tumorigenesis, 60:60–62, 64–65
- Raf-1 phosphorylation and, 58:59–60, 63–66, 68
- Ras function and, 62:48–49, 51
 - GAPs, 62:30–32
 - Ras guanine nucleotide exchange factors, 62:23–27
 - signal transduction pathways, 62:39, 43
- rate, *see* Mutation rate
- RB, naturally occurring, 64:51
- RB1*
 - in tumor progression, 64:29–30
 - tumors, 64:26–30
- renal cell tumors, molecular cytogenetics, 62:90
 - nonpapillary renal cell tumors, 62:101–104
 - papillary renal cell tumors, 62:107, 109, 113
- RER+ phenotype-induced, 67:68
- ret*, in MEN II syndromes, 70:180–181, 183–191, 195–207
- retinoblastoma, 71:29
- reverse transformation and, 62:140, 144
- reversion, 72:29–30
- series, providing cell with selective advantage, 72:2, 6
- signal transduction and, 55:285, 289
- single-base, and 30–base pair deletions, 67:217–218
- soft tissue tumors and
 - ras* gene, 60:87–88
 - susceptibility, 60:80–84
 - tumor suppressor genes, 60:100–101, 103
- somatic, 67:4–7; 71:209–211
 - APC* gene in colorectal tumors, 62:74–79
 - c-erbA* and, 59:106
 - in endothelial cells, 66:247–249
 - HPRT* gene, 71:217–221
 - microsatellite sequences, 71:211–216
 - minisatellite sequences, 71:217
 - multistep carcinogenesis and, 71:221–222
 - rate, 71:229
 - DNA repair level and, 71:212–213
 - importance of measuring, 71:233–234
 - research history, 67:4–7
- Src family of tyrosine protein kinases and, 57:104, 109–110, 130, 136
- T-cell receptors and, 56:56, 62
- tumor clonality and, 50:199, 209, 221
- during tumor progression, 72:47–48
- tumor rejection antigens and, 58:205
 - P815, 58:198–201
 - tumsup*-antigens, 58:191, 193–195, 197
- in tumors, 71:214–215
- Turcot syndrome, 71:114

Mutations (*continued*)

- ultraviolet light-generated, 64:283
- VHL mutations, 71:60
- Wilms' tumor and
 - functional studies, 59:61–63
 - genetic loci, 59:47, 49, 51–52
 - Knudson model, 59:44, 46
 - WT1* gene, 59:57–61
- Zilber and, 59:4
- Mutator phenotype
 - in cancer prevention, 72:50–51
 - candidate target mutator genes, 72:38–43
 - diagnostic role, 72:48–49
 - evidence from microsatellite instability, 72:43–47
 - historical perspective, 72:28–32
 - origins of mutations, 72:36–38
 - prognostic role, 72:49–50
 - requirement for, 72:32–36
 - timing and diversity of mutations, 72:47–48
- mutD*, genomic instability and, 60:129
- mutL* gene, 71:98
- mutM*, genomic instability and, 60:132
- Mxi1
 - effect on oncogene transformation, 68:164–165
 - expression in development, 68:144–145
 - gene locus, 68:166–167
 - Max association, 68:122–123
- mxil*, mutation and prostate cancer, 68:236–237
- Myasthenia gravis, α -fetoprotein and, 56:284, 285
- Myb binding site, transactivation independent of, 72:133–134
- myb* genes
 - b-myb*
 - under cyclin-dependent regulatory mechanisms, 72:134–136
 - DNA-binding domain, 72:112–113
 - evolutionary conservation, 72:111–112
 - expression
 - ablation, 72:127–128
 - developmental regulation, 72:117–118
 - hyperphosphorylation in S phase, 72:123–125
 - myc* family oncogenes and, 57:13
 - negative C-terminal domain, 72:114–115
 - overexpression, 72:129–130
 - possible target genes, 72:133–134
 - requirement in cell proliferation, 72:127–132
 - transactivation function, cyclin dependence, 72:125–127
 - transcription
 - as cell cycle control point, 72:122–123
 - in somatic cells, 72:115–117
 - transcription activation domains, 72:113–114
 - transcriptional control by, 72:132–133
 - transcriptional regulation, 72:118–122
- c-myb*
 - angiogenesis, 69:147
 - conserved region, 72:115
 - IAPs and, 51:229
 - transactivation domain, 72:113–114
- p53* and human malignancies, 57:263
- myc* genes, 57:1–3
 - APC* gene in human cancers and, 62:79
 - apoptosis and, 71:127–128
 - B lymphocytes and, 56:314, 330
 - central nervous system tumor oncogenesis and, 58:127
 - chromosomes and, 62:10–11
- c-myc*, 53:17–18; 57:1–3, 5, 13
 - adenovirus E1A proteins and, 57:54
 - α -fetoprotein and, 56:296
 - amplification in breast cancer, 61:36–37
 - antisense inhibition, 68:141
 - AP-2 complex, 68:128, 134
 - apoptosis-inducing domain, 68:147
 - Burkitt's lymphoma and, 55:136, 137, 140, 142
 - B cell differentiation, 55:169, 170
 - cell proliferation, 55:164, 165
 - chromosomal translocations, 55:195–208
 - clinical significance, 55:251
 - deregulation, 55:208–216
 - EBV, 55:230, 240–242
 - expression in, 53:43–44; 55:186–192; 56:27, 28
 - gene regulation, 56:31–37
 - gene topography, 56:28–31
 - model for deregulation, 56:37–41
 - features, 55:148
 - genetic abnormalities, 55:216–218, 220–222
 - geography, 55:192, 193, 195

- nonrandom chromosomal translocations, 55:154–157
- phenotype, 55:152
- proteins, 55:160–164
- structure, 55:157–159, 175–185
- synthesis, 55:242, 245–249
- transcription, 55:159, 160
- translocation mechanism, 55:171, 175, 176
- cooperating oncogenes
 - abl*, 68:155–156
 - Bcl-2 gene, 68:156–157
 - Bmi-1 gene, 68:159–160
 - cyclin D1 gene, 68:157–158
 - evidence from transgenic mice, 68:154
 - Pim-1 gene, 68:158–159
- cooperation with *bcl-2*, 70:132
- cytotoxic T lymphocytes and, 58:157, 161
- discovery, 68:112; 70:96–98
- disruption effects in embryo, 68:142
- downregulation, TGF- β -mediated, 70:71–72
- EBV-associated disorders and, 57:335–336, 355, 364–365, 372
- evolutionary conservation, 68:112
- expression, 57:14–17
 - in cell cycle, 68:137–138
 - in cell differentiation, 68:139–140
 - regulation of, 57:17–24
- FGF receptor multigene family and, 60:31
- future perspectives, 57:35–36
- G protein signal transduction and, 58:79, 83
- half-life, 68:113
- hepatitis B viruses and, 59:198, 202, 205, 207, 211
- homology with E1A, 68:163–164
- IAPs and, 51:229, 265, 266
- in vitro* transformation assay systems, 68:160–161
- interaction with *ara-C*, 72:215–216
- interaction with p110^{Rbl}, 61:127
- juxtaposition to immunoglobulin locus, 72:5
- Mad repression of Myc-activated transcription, 68:125–126
- Max complex
 - discovery, 68:111, 119
 - DNA binding of complex, 68:123
 - protein–protein interaction, 68:161
 - role in transactivation, 68:124–125
- mediated MHC class I downmodulation, 67:177–178
- MHC expression and, 53:203; 60:183, 231–233
 - downmodulation, 60:222–230
 - modulation by oncogenes, 60:198, 202–207
 - regulation by oncogenes, 60:211, 215, 219–222
- mineral oil and, 51:151, 160
- mRNA, 70:126–127
- multidrug resistance gene and, 60:175
- muscle cell regulation and, 58:110–111
- mutations and cancer, 68:111, 152–153
- nuclear localization signals, 68:118
- oncogenic activities, 57:24–33
- p53* and human malignancies and, 57:262–263
- p107 complex, 68:127–128
- phosphorylation sites and tumorigenicity, 68:118–119, 162–163
- protein–DNA interaction motifs, 68:114–117
- protein structure, 57:6, 9
- rearrangements in AIDS-NHL, 67:120
- regulation, 56:1, 2
 - abnormal regulation, 56:25–27
 - expression, 56:9
 - mRNA stability, 56:22–25
 - steady-state RNA levels, 56:9–13
 - transcription elongation, 56:19–22
 - transcription initiation, 56:13–18
 - gene topography
 - chromatic organization, 56:7–9
 - protein products, 56:6, 7
 - structure, 56:2–6
- retinoblastoma protein functional interaction, 68:127
- role in
 - AIDS-related lymphomas, 67:132–136
 - apoptosis, 68:145–152
 - cell cycle regulation, 68:131, 136–138
 - cell differentiation, 68:141–142
 - cell proliferation, 68:138–139
 - soft tissue tumors and, 60:88, 104–105
 - SSRP1 complex, 68:129
 - structure, 68:113–114

myc genes (*continued*)

- subcellular localization, 68:118, 139
- synergistic effect with *EJ-ras* on
 - radiation-resistant phenotype, 61:208–209, 211
- target genes
 - autorepression of promoter, 68:131
 - cad*, 68:135–136
 - cyclin-dependent kinases, 68:137
 - cyclins, 68:136–137
 - E-box element recognition, 68:116–117
 - ECA39, 68:135
 - identification, 68:132
 - ornithine decarboxylase, 68:134
 - p53, 68:134–135, 152
 - α -prothymosin, 68:132–134
 - role in tumor suppression, 68:130–131
- TBP complex, 68:129
- TFII-I complex, 68:129
- transcriptional activation domain, 68:16–163, 117–118, 124
- transcription factor activity, 68:111, 124–126
- transgenic mice
 - construction, 68:153
 - tumorigenesis, 68:153–154
- YY-1 complex, 68:128
- combined role with *c-raf-1* gene for
 - radiation resistance, 61:213
- disruption effects in embryo, 68:142
- E2F upregulation by, 71:182, 184
- EBV-associated disorders and, 57:342
- Epstein–Barr virus genes and, 58:2, 19
- expression
 - in cell differentiation, 68:139–141, 167
 - differentiation and, 57:14–17
 - regulation of, 57:22–24
 - mechanisms, 57:17–21
 - transgenic mice, 57:21–22
- family members, 68:112–113
- future perspectives, 57:34–35
- null myc* mutations, 57:35–36
 - potential cellular targets, 57:37
 - transdominant mutant proteins, 57:36
- hepatitis B viruses and, 59:169, 205–208, 210
- human papillomavirus and, 56:148
- L-myc*, 57:1–3, 5–6, 13
 - expression, 57:14–15, 17–18, 20–22
 - oncogenic activities, 57:24, 29, 32–34
 - loci, 68:166
 - members, 57:13
 - in metasatasis, 54:191–192
 - MHC Class I expression and, 60:231–233
 - modulation by oncogenes, 60:199, 203–208
 - regulation by oncogenes, 60:218–219
 - mouse retrotransposons and, 56:237
 - muscle cell regulation and, 58:100–101
 - myc* boxes, 68:113, 117–118
 - oncogenic activities
 - in vivo* models, 57:28–33
 - tissue-preferential expression, 57:33–34
 - tumors, 57:24–28
 - p53* and human malignancies and, 57:263
 - protein features, 57:5–6
 - protein structure, 57:6–7
 - domains, 57:6, 8–10
 - nuclear localization, 57:10–11
 - phosphorylation, 57:11–12
 - transforming activity, 57:12–13
 - with *raf* gene, synergistic effects, 61:213
 - Ras function and, 62:50
 - reverse transformation and, 62:138, 146
 - soft tissue tumors and, 60:77, 109
 - structure, 57:3–5
 - v-myc*, synergistic effect with *EJ-ras* on
 - radiation-resistant phenotype, 61:208–209, 211
- Mycobacteria, AIDS and, 51:338
- Mycosis fungoides
 - gene rearrangements and, 52:59–61
 - retroviruses and, 51:314, 317
- Mycotoxins, dietary, as cause of liver cancer, 65:86–87
- c-Myc* protein
 - and apoptosis, 70:130–134
 - and cell proliferation, 70:116–125
 - in embryonic development, 70:125–128
 - myc* family oncogenes and, 57:10–12, 26
 - oncoprotein kinases and, 57:197
 - structural and functional features, 70:101–108
 - as transcription factor, 70:108–116
 - L-myc* protein, 57:11–12, 19
 - L-myc-psi* pseudogene, *myc* family oncogenes and, 57:13
 - myd*, muscle cell regulation and, 58:98
 - Myelin basic protein kinase, mitosis and, 57:205

- Myelodysplastic syndromes, 71:148–149, 150
 chromosome abnormalities and, 52:10, 13–17
- Myeloid cells
 ADF and, 57:306, 388
bcr/abl gene in leukemia and, 57:152, 157, 171–177
BCR gene in leukemia and, 57:228, 240
 differentiation, 71:135–136
 leukemic, differentiation, 66:12–16
 lineages, 66:3–6, 216–217
myc family oncogenes and, 57:33
 normal
 differentiation, 66:7–9
 precursor cells, 66:17
p53 and human malignancies and, 57:266
 Src family of tyrosine protein kinases and, 57:113–115, 117–118
- Myeloma
 IAP element transposition in, 51:244–246
 Louvain rat immunocytomas and, 50:279, 306
 animals, 50:280
 etiology, 50:305
 immunoglobulins, 50:289
 mouse retrotransposons and, 56:228, 230
- Myeloma-associated virus, IAP elements and, 51:191–192
- Myelopathy, AIDS and, 51:343
- Myelopoiesis, CSF-stimulated, 66:19–20
- Myeloproliferative sarcoma virus, *bcr/abl* gene in leukemia and, 57:174–175
- Myeloproliferative syndrome, *BCR* gene in leukemia and, 57:232
- Myelosuppression, cancer immunotherapy and, 59:276, 280–281
- myf*, soft tissue tumors and, 60:110
- Myoblasts
jun oncogene and, 55:3
 muscle cell regulation and, 58:96–98, 107–108, 110
- Myocytes, fibroblast growth factors and, 59:143
- MyoD, 71:174
- MyoD family of muscle-specific regulatory factors, *see* Muscle cell regulation
- Myofibroblasts, stroma and, 50:166
- Myogenesis
 inhibition by okadaic acid (C2C12 cells), 61:167
 muscle cell regulation and, 58:96–100, 102–103, 108–114
- Myogenin, 71:174
 muscle cell regulation and, 58:99, 101–113
myc family oncogenes and, 57:9
- Myoma, chromosomal aberrations, 69:93
- Myosin phosphatase, RhoA-GTP-binding protein, 72:94
- Myositis
 age and risk of, 71:230
 AIDS and, 51:344
- Myotubes, *jun* oncogene and, 55:3
- Myristoylation, *bcr/abl* gene in leukemia and, 57:158–159, 162, 167, 169–172
- MYS
 LTRs, 56:234, 235
 mouse genome, 56:219, 221, 223, 224
- Myxoid liposarcoma, chromosomal aberrations, 69:90
- Myxoid tumors, soft tissue tumors and, 60:94, 100
- Myxomavirus growth factor, physiology of, 58:28
- ## N
- NADPH, DHEA and, 51:397, 409–413, 417, 420
- 2-Naphthylamine, chemical carcinogenesis and, 50:29
- Nasopharyngeal carcinoma
 ADF and, 57:383, 406–407
 CD44 and, 71:294
 chromosome 3 losses in, 71:45–47
 EBV⁺, 67:199, 211–212
 EBV⁺, 67:199
 Epstein-Barr virus and, 62:197, 202, 206, 209, 222–224; 69:217
 Epstein-Barr virus genes and, 58:2, 4
 Epstein-Barr virus proteins and, 50:98, 108, 146, 150
 oncogene activation and, 51:153
 tumors, *XhoI* restriction site loss, 67:215–218
 VHL mutations and, 71:60
- Nasopharynx, Epstein-Barr virus proteins and, 50:96
- National Surgical Adjuvant Breast and Bowel Project, 61:17
- Natural history, AIDS-related lymphomas, 67:118–120

- Natural killer cells
 ADF and, 57:384, 386, 388, 390
 antitumor immunity by, MHC regulation by, 53:97–103
 Burkitt's lymphoma and, 55:233, 239
 cancer immunotherapy and chemioimmunotherapy, 59:277
 critical factors, 59:251, 254
 current strategies, 59:259–260, 271
 improvement attempts, 59:285
 cytotoxic T lymphocytes and, 58:152–153, 160, 163–165; 59:228, 237
 EBV-associated disorders and, 57:332, 338–339
 Epstein–Barr virus, 62:189, 194, 207
 FcγRIII expression, 64:214
 gene rearrangements and, 52:63
 immunosuppression and, 60:247, 249, 253–256
 in metastatic growth, 66:61–62
 MHC class I expression and, 60:182, 231–233
 cancer, 60:183, 185, 187
 downmodulation, 60:224–231
 modulation by oncogenes, 60:202
 recognition of, MHC in, 53:218–220
 response to adenovirus infection, 63:159
 Src family of tyrosine protein kinases and, 57:113, 117–119, 137
 susceptibility, and MHC class I level, 67:168–169
 susceptibility to, protection from, transfected MHC genes and, 53:208–209
 tumor rejection antigens and, 58:201
 Natural resistance, MHC in, 53:218–220
 Natural selection, Darwinian, 72:1, 19–20
 NBCCS, *see* Nevoid basal cell carcinoma syndrome
 Neck cancer, 13-*cis*-retinoic acid trial, 61:15
 Necropsy, Louvain rat immunocytomas and, 50:283
 Necrosis
 different from apoptosis, 71:123
 EBV-associated disorders and, 57:339, 352
 Negative regulatory domain, B-Myb, 72:114–115, 126
 Negative regulatory element, MHC Class I expression and, 60:210, 213, 216, 220
 Negative regulatory elements, fibroblast growth factors and, 59:131
 Negative regulatory sequences, fibroblast growth factors and, 59:146
neo, *Herpesvirus saimiri* and, 56:343
 Neoantigens, oncogenes and, 50:74, 79
 Neomycin, papillomaviruses and, 56:140, 144, 146, 147
 Neoplasia
 α-fetoprotein and, 56:291, 292, 298–300
 B-cell, Epstein–Barr virus and, 53:38
 BCR gene in leukemia and, 57:227, 243
 B lymphocyte and, 56:325–327, 330
 bryostatin efficacy, 64:289
 central nervous system tumor oncogenesis and, 58:121–122, 126–129, 132, 134
 cervical intraepithelial, and HPV, 64:3–4
c-myc regulation and, 56:25, 27
 CpG island aberrant methylation, 72:177–186
 DNA methylation abnormalities, 72:150–167
 EBV-associated disorders and, 57:353, 364, 371–372
 endogenous growth inhibitors and, 57:448
 gastrointestinal diseases and, 50:9–11
 genomic instability and, 60:124
 glutathione transferase and, 52:205, 206, 238
 hematological, gene rearrangements and, 52:57–68
Herpesvirus saimiri and, 56:337
 HPV-induced, 64:270–271
 lysosomes and, 60:270
 melanocytic
 parenchymal–stromal interactions, 65:136–137
 precursor state, stromal changes in lesions, 65:134
 MHC Class I expression and, 60:182–183, 223
myc family oncogenes and, 57:2, 10, 12, 24, 26, 28
 oncoprotein kinases and, 57:186, 214, 216
p53 and human malignancies and, 57:257, 263–264, 267
 plasminogen activation and, 57:291
 protein tyrosine kinase GFRs and, 60:65
 role in mutation of oncogenes and tumor suppressor genes, 65:163

- role of TGF α , 64:265
 soft tissue tumors and, 60:77, 80, 82, 88, 92, 107
 studies by William Clark, 65:123–125
 transforming growth factor- α and, 58:46–47
- Neoplasms**
 AIDS-related, systemic, 67:116–117
 Burkitt's lymphoma and, 55:137, 140, 141
 B cell differentiation, 55:165, 170
 chromosomal translocations, 55:157, 196, 205
 clinical significance, 55:251
c-myc, 55:181, 187
 deregulation, 55:208–213, 216
 EBV, 55:224, 228, 234, 238, 241
 features, 55:142, 147, 148, 150
 genetic abnormalities, 55:216–218
 phenotype, 55:150, 151
 synthesis, 55:248
 translocation mechanism, 55:176
 cancer immunotherapy and, 59:253, 265
 chemical carcinogenesis and, 50:26
 chromosomes and, 62:1, 4–7, 9–10, 12–13
 development of, multistage process of, tumor susceptibility genes and, 53:123–125
 Epstein–Barr virus and
 Hodgkin's disease, 62:219, 228
 T-cell lymphoproliferation, 62:193–194, 201–202, 206–208, 211
 Epstein–Barr virus proteins and, 50:97
 fibroblast growth factors and, 59:154
 gastrointestinal diseases and, 50:18
 gene rearrangements and, 52:70, 72
 hepatitis B viruses and, 59:170, 209
 Louvain rat immunocytomas and, 50:294, 305
 metastatic cancer cells and, 55:89, 125, 127
 growth factors, 55:115, 118, 120–123
 human malignant melanoma, 55:105, 106, 108, 109, 113
 phenotype, 55:90
 renal cell tumors, molecular cytogenetics, 62:91
 reverse transformation and, 62:144
 signal transduction and, 55:272, 300
 spindle cell, 66:239–240
- stroma and
 alterations, 50:184, 185
 basement membranes, 50:175
 disorders, 50:182
 epithelium, 50:167
 fibroblasts, 50:178
 Wilms' tumor and, 59:63
- Neoplastic cells**
 ara-C resistance, 72:210–213
 chemical carcinogenesis and
 biological concepts, 50:34–36, 38
 experimental models, 50:31
 mechanisms, 50:42, 50
 CpG island protection mechanisms, 72:182–185
 increased DNA-methyltransferase activity, 72:167–172
 tumor clonality and, 50:224
 animal tumors, 50:219, 223
 definition, 50:200, 201
 distinction, 50:202, 205, 207, 209, 211
 human tumors, 50:216, 217
 origin, 50:199
 pleoclonal tumors, 50:212
- Neoplastic disease, zinc-finger proteins implicated in, 54:154
- Neoplastic transformation**
 IAP gene family and, 51:259–269
 newborn macrosomy and, 50:232
- Neovascularization**
 aberrant, 66:241
 corneal, SF-induced dose-dependent, 67:264–266
 FGF receptor multigene family and, 60:35
 fibroblast growth factors and, 59:141–142
 metastatic cancer cells and, 55:110
 persistent, abnormal, 67:266–267
 in psoriasis, 67:261
 scatter factor stimulated, 66:249
 transforming growth factor- α and, 58:47–48
- Neovascularization in metastatic process, 54:177
- Nephroblastoma, Wilms' tumor and, 59:62
- Nerve growth factor**
 B cell-associated surface molecules and, 52:113, 114
 Ras function and, 62:23, 39, 48
 receptor, humoral immune response and, 62:252

- Nerve sheath tumors, peripheral, malignant, chromosomal aberrations, 69:80–81, 90
- Nervous system, enteric, *ret* expression, 70:210
- Nervous system tumors, CD44 and, 71:291–293
- Network theory, of antibody production, 61:64–65
- NEU, protein tyrosine kinase GFRs and, 60:63–66
- Neu, protein tyrosine kinase GFRs and, 60:61
- neu* gene, amplification in breast cancer, 61:32–34
- Neural cell adhesion molecule
ataxia-telangiectasia genes and, 56:96
T-cell receptors and, 56:65
- Neural crest, gastrointestinal diseases and, 50:4
- Neural tumors, chromosomal aberrations, 69:80–82
- Neuraminidase, α -fetoprotein and, 56:258, 282
- Neurilemmoma, chromosomal aberrations, 69:80, 81, 90, 93
- Neurite formation, role of PKC, 64:185
- Neuroblastoma
 α -fetoprotein and, 56:279, 280
angiogenesis, 69:154
differentiation, role of PKC, 64:186–187
germ line mutations, 67:7–8
MHC Class I expression and, 60:194–195
modulation by oncogenes, 60:204–207
regulation by oncogenes, 60:218–219, 221
molecular cytogenetics, 62:105
multidrug resistance gene and, 60:166, 171, 174
myc family oncogenes and, 57:2, 16–17, 23, 26–27, 34
newborn macrosomy and, 50:251
oncogene activation and, 51:153
gene amplification and, 51:167
Wilms' tumor and, 59:44
- Neuroectodermal tumor, primitive, t(11;22) translocation, 67:40–43
- Neuroendocrine tumors
cholecystokinin expression, 63:326–327
gastrin expression, 63:323–324
- Neuroepithelioma, peripheral, chromosomal aberrations, 69:86–87
- Neurofibroma
benign, chromosomal aberrations, 69:81
tumor clonality and, 50:224
factors, 50:221, 222
human tumors, 50:216
pleoclonal tumors, 50:212, 213
- Neurofibromatosis type 1, chromosomal aberrations, 69:81
- Neurofibromatosis type 2, chromosomal aberrations, 69:80
- Neurofibromin
Ras function and, 62:23, 29–30, 32, 47
- Neurofibromin protein, 69:81
- Neurological diseases, Zilber and, 59:32
- Neurological manifestations, AIDS and, 51:342, 343
- Neuroma, in MEN IIB, 70:188–189
- Neuron
differentiation, role of PKC, 64:185–186
transplantation, and PymT expression, 64:144
- Neuronal cells
myc family oncogenes and, 57:15
plasminogen activation and, 57:295, 300
- Neurons, fibroblast growth factors and, 59:144
- Neurospora*, *jun* oncogene and, 55:9, 21
- Neurotransmitters, G protein signal transduction and, 58:80, 85
- Neutralizing antibodies
cancer immunotherapy and, 59:281
cytotoxic T lymphocytes and, 59:237
- Neutropenia, genetic, 66:20
- Neutrophil polymorphs, invasion by cancer and, 54:163
- Neutrophils
c-fos protooncogene and, 55:41
Fc γ RII expression, 64:213
Fc γ RIII expression, 64:214
lysosomes and, 60:271
- Nevoid basal cell carcinoma syndrome, genetics, 70:49–59
- Nevus sebaceous of Jadassohn, clinical profile, 70:58–59
- Newborn macrosomy, *see* Macrosomy, newborn
- NF1, candidate Ras effector, 72:71–72
- NF1 gene, 69:81, 154
- NF1 genes, soft tissue tumors and, 60:100, 109
- NF2 gene, 69:80
- NFB cells, muscle cell regulation and, 58:107

- NF κ B, and KBFI, 66:53–54
- NH $_2$ -terminal fragment, p120 GAP, 72:70–71
- NHL, *see* Lymphoma, Non-Hodgkin's
- Niacin, prostatic cancer and, 51:50–51
- Nicotinamide, angiogenesis, 69:144
- NIH 3T3 cells
- DNA-methyltransferase activity increase, 72:172–173
- NIH3T3 cells, papillomaviruses and, 56:138, 142–147
- radioresistance phenotype, *ras* gene activation and, 61:208
- Nijmegen Breakage Syndrome, ataxia-telangiectasia genes and, 56:81, 82
- NIL cells, glycosylation in tumors and, 52:260, 261
- Nitric oxide, secretion by ECs in response to VEGF, 67:289
- Nitrogen cavitation, IAPs and, 51:203
- Nitrosamines
- carcinogenic action, *in vivo* reactions causing, 65:65–69
 - chemical carcinogenesis and, 50:57
 - effect on DNA, *in vivo* chemical modifications, 65:60–64
 - gastrointestinal diseases and, 50:5
 - methylation, correlation with cancer initiation in target tissues, 65:62–63
 - structural requirements, studies using physical organic chemistry, 65:70–73
- N-Nitrosamines, chemical carcinogenesis and, 50:29, 39, 55
- N-Nitroso compounds, chemical carcinogenesis and, 50:28, 29
- N-Nitrosodiethylamine, tumor clonality and, 50:220
- Nitrosomethylurea
- newborn macrosomy and, 50:254
 - oncogene activation and, 51:154, 159
- N-Nitrosomethylurea, newborn macrosomy and, 50:254–256
- Nitrosoureas, tumor induction incidence, in rats, 65:76
- NK, *see* Natural killer cells
- nm23 gene, 61:45
- N-Methyl-N-nitrosourea, lymphomagenesis in AKR mouse by, 63:259–261
- NMU, prostatic cancer and, 51:30–31
- N-*myc*
- effect on class I expression, 67:177–178
 - hepatitis B viruses and, 59:206–207, 211
 - MHC Class I expression and, 60:222, 231
 - modulation by oncogenes, 60:203–208
 - regulation by oncogenes, 60:217–222
- MHC expression and, 53:203
- soft tissue tumors and, 60:104–105
- N-*myc* genes, *myc* family oncogenes and, 57:1–3, 5, 13
- future perspectives, 57:35–36
 - gene expression, 57:14–15, 17
 - regulation of, 57:17–24
 - oncogenic activities, 57:24, 26–29, 31–34
 - protein structure, 57:6, 9
- N-*myc* protein, *myc* family oncogenes and, 57:11–12, 24
- NOB mice, retroviruses and, 51:253
- Nocodazole, oncoprotein kinases and, 57:188–189, 192, 197, 205, 211
- Nodularia spumigeno*, nodularin isolation, 61:174
- Nodularin
- biochemical activity, 61:172–176
 - hepatotoxicity, 61:174–179
 - isolation, 61:174
 - molecular modeling, 61:179–180
 - structure, 61:172–176
 - target tissues, 61:176–178
 - tumor promotion, in liver, 61:178–179
- Nodular tenosynovitis, chromosomal aberrations, 69:78–79
- Nodules, hepatocyte, 70:25–27, 32–36
- Nominal antigens, tumor rejection antigens and, 58:185
- Noncoprotein, endogenous growth inhibitors and, 57:437–439
- Nonesterified fatty acids, newborn macrosomy and, 50:242
- Noninvasive genetic screening, for colorectal cancer, 61:4
- Nonobese diabetic mice, retroviruses and, 51:253
- Nonsteroidal anti-inflammatory drugs, protective role in colorectal cancer, 61:6
- Nonturmeric skin fibroblasts, in Li-Fraumeni families
- altered DNA *de novo* synthesis, 61:206–207
 - resistance to ionizing radiation, 61:205
 - topoisomerase activity levels, 61:206
- Northern blotting
- IAPs and, 51:220, 227, 229
 - T-4 mRNA and, 51:322–323

- Northern hybridization, TGF and, 51:119–120
- NPC, 69:237
- N-(Phosphonacetyl)-L-aspartate, induced gene amplification, 66:88–89, 148
- N-ras, MHC Class I expression and, 60:201
- N-ras gene
 - EBV-associated disorders and, 57:336
 - hepatitis B viruses and, 59:208
 - myc* family oncogenes and, 57:31
- N-ras oncogene, angiogenesis, 69:146, 147, 148
- NSAIDs, protective role in colorectal cancer, 61:6
- Nuclear antigens, Epstein–Barr virus proteins and, 50:120–122, 126, 149
- Nuclear exclusion, inactivation of wild-type p53, 66:112
- Nuclear grade, breast cancer and, 56:108–110, 113, 127
- Nuclear immunofluorescence staining, polyoma virus TSTA and, 55:62
- Nuclear localization
 - c-Myc protein, 70:103
 - myc* family oncogenes and, 57:10–11
- Nuclear localization signal
 - p53, 66:80–81, 103
 - for p110^{RBI}, 61:123
- Nuclear matrix, in transmission events, 66:340
- Nuclear proteins
 - classification, 67:26–27
 - okadaic acid-stimulated phosphorylation, 61:165–166
- Nuclear tethering, RB, 64:65–66
- Nucleocapsids, hepatitis B viruses and, 59:191–193
- Nucleolin, oncoprotein kinases and, 57:195, 216
- Nucleoprotein
 - cytotoxic T lymphocytes and, 59:228, 232–234
 - Zilber and, 59:9, 25–26
- Nucleosides
 - chemical carcinogenesis and, 50:55, 59
 - genomic instability and, 60:132, 142–143
 - multidrug resistance gene and, 60:158
- Nucleosomes, genomic instability and, 60:134
- Nucleotide excision repair, 72:41–42
- Nucleotide excision repair system, 71:212
- Nucleotides
 - adenovirus E1A proteins and, 57:63
 - adenovirus proteins and, 52:155
 - ADF and, 57:389
 - α-fetoprotein and, 56:297
 - BCR gene in leukemia and, 57:229, 241
 - Burkitt's lymphoma and
 - c-myc*, 55:158, 161
 - EBV, 55:225
 - phenotype, 55:151
 - translocation mechanism, 55:173–176
 - c-erbA* and, 59:92, 97, 107
 - c-fos* protooncogene and, 55:49
 - chemical carcinogenesis and, 50:32, 44, 46, 55, 57
 - chromosome abnormalities and, 52:36
 - c-myc* regulation and, 56:3
 - deleted at junction sites, 66:321
 - EBV-associated disorders and, 57:330
 - Epstein–Barr virus proteins and, 50:102, 145
 - fibroblast growth factors and, 59:129
 - gene rearrangements and, 52:47, 53
 - genomic instability and, 60:127–129, 139
 - glutathione transferase and, 52:232
 - hepatitis B viruses and, 59:180, 185, 187–189, 193, 197
 - Herpesvirus saimiri* and, 56:337, 341, 345
 - jun* oncogene and, 55:1, 4, 7, 11, 12, 14
 - metastatic cancer cells and, 55:110
 - MHC Class I expression and
 - modulation by oncogenes, 60:203, 208
 - regulation by oncogenes, 60:211, 213–215, 220
 - mouse retrotransposons and, 56:221, 223, 224
 - multidrug resistance and, 52:181, 196
 - multidrug resistance gene and, 60:165, 172
 - muscle cell regulation and, 58:102, 105
 - myc* family oncogenes and, 57:16
 - p53 and human malignancies and, 57:259
 - polyoma virus TSTA and, 55:81
 - Raf-1 phosphorylation and, 58:64
 - Src family of tyrosine protein kinases and, 57:109, 115
- Nucleotide sequence
 - foreign DNA, 66:331–334
 - variations in microsatellites, 72:43–44
- Nucleus
 - bcr/abl* gene in leukemia and, 57:159

- endogenous growth inhibitors and, 57:438
myc family oncogenes and, 57:11–12
 oncoprotein kinases and, 57:188, 198–199, 207
 signal transduction to, *see* Signal transduction to cell nucleus
null myc mutations, *myc* family oncogenes and, 57:35–36
 Numerical chromosomal aberrations, 69:90; 91
 Nur77 protein, 71:137–138
 Nutrients, sufficiency of, *ras* gene response to, 54:125–127
 Nutrition
 gastrointestinal diseases and, 50:5, 11
 prostatic cancer and, *see* Prostatic cancer, environmental factors and
- O**
- Obesity
 DHEA and, 51:396–400
 endocrine effects of, 51:65
 newborn macrosomy and, 50:259
 prostatic cancer and, 51:60
 Occupational factors, prostatic cancer and, 51:68–76
 Octreotide, breast cancer therapy, 68:212
 Okadaic acid
 biochemical effects, 61:150–151, 160, 164–166
 biological effects, 61:164–166
 compounds synthesized from, 61:151
 derivatives, 61:150–151
 effects on
 cell morphology, 61:165
 intestinal epithelium, 61:163–164
 protein phosphorylation, 61:165–166
 RB phosphorylation, 64:46
 gene expression regulation, 61:166–167
 sup3H-labeled, distribution, 61:163–164
 immunological effects, 61:160
 interaction with lipid bilayer membrane, 61:164–165
 simultaneous treatment with teleocidin or TPA, 61:155–157
 structure, 61:150–151
 transcriptional regulation, 61:166–167
 tumor promotion
 comparison with calyculin A, 61:172
 on mouse skin, 61:151–154
 in rat glandular stomach, 61:154–155
 unique properties induced by, 61:166
 Okadaic acid class compounds
 apparent activation of protein kinases, 61:161–163
 biochemical activities, 61:152
 biochemical and immunological effects, 61:160
 inhibition of PP-1 and PP-2A, 61:146–150
 in vitro cell transformation, 61:157–158
 okadaic acid receptors, 61:146–147
 structure-activity relationships, 61:158–161
 tumor-promoting activities, 61:152
 Okadaic acid pathway
 relation to human cancer, 61:183–186
 schematic, 61:155
 summary of, 61:163
 Okadaic acid response element, 61:167
 Okadaic acid spiroketal I
 biochemical and immunological effects, 61:160
 conformation, 61:159
 Okadaic acid spiroketal II
 biochemical and immunological effects, 61:160
 conformation, 61:159
 Okadaic acid tetramethyl ester, biochemical and immunological effects, 61:160
 Oligodeoxyribonucleotides, synthetic, 66:335
 Oligomerization
 Burkitt's lymphoma and, 55:163, 164
 fibroblast growth factors and, 59:136–137
 Flt receptors, 67:302
 p53, 66:82–84
 p53-mediated, 66:150–154
 and p53 transformation, 66:107–108
 Oligonucleotides
 ADF and, 57:393
 analogs resistant to nucleolytic cleavage, 61:76–77
 antisense
 B-myb, 72:127–128
 c-myc, 70:128–129
 inhibition of gene expression, 61:75–77
 radiosensitizing effects, 61:226
 central nervous system tumor oncogenesis and, 58:136
 c-erbA and, 59:99, 107
 muscle cell regulation and, 58:106
 oncoprotein kinases and, 57:208–210

- Oligosaccharides
 α-fetoprotein and, 56:266, 267, 270
 metastatic cancer cells and, 55:88
- Oltipraz, *in vitro* testing, 61:9–10
 preclinical testing, 61:10–11
- Oncocytoma, renal, molecular cytogenetics, 62:115–117
- Oncofetal antigens, 61:64, 69
- Oncogene products, IAPs and, 51:224–225
- Oncogenes, *see also* Protooncogenes; *specific oncogene*
 activated
 effects variation with γ radiation dose rate, 61:208
 linkage to radiation resistant phenotype, 61:208
 activated tyrosine kinases, 64:89–90
 activation, 72:4–6
 using base-substitution mutations, 65:96
 using mutation of cellular proto-oncogenes, 65:37
 activation in chemical carcinogenesis
 direct versus indirect
 alternative routes, 51:160–161
 carcinogen-specific mutations, 51:156–158
 general considerations, 51:155–156
 neu gene, 51:159
 ras genes, 51:159
 general consideration for, 51:147–148
in vitro
 carcinogens, 51:169–171
 comparison of *in vivo*, 51:173–176
 stage specificity, 51:171–173
in vivo, 51:150–153
 comparison of *in vitro*, 51:173–176
 ras genes, 51:148–154
 tissue-specificity, 51:150–155
 tumor progression and
 gene amplification, 51:167
 karyotypic changes, 51:169
 loss of *ras* alleles, 51:168
 tumor promotion and
 cell communication, 51:162–164
 cell selection, 51:162
 general considerations, 51:161–162
 genetic mechanisms, 51:166–167
 signal transduction and gene activation, 51:164–166
 TGFs, 51:164
 adenovirus E1A proteins and, 57:47, 73–78
 α-fetoprotein and, 56:292, 299
 in AIDS-related lymphomagenesis, 67:132–137
 angiogenesis, 69:156
 angiogenic phenotype, 69:145–148
 ataxia-relangiectasia genes and, 56:96
 Bcl-3, 66:269–270
bcr/abl gene in leukemia and, 57:153, 155, 158, 165
 animal models, 57:178
 biological activity, 57:170, 173
 B lymphocytes and, 56:314, 330, 331
 Burkitt's lymphoma and
 chromosomal translocations, 55:157, 163, 207
 c-myc expression, 55:187, 190
 deregulation, 55:208, 214
 EBV, 55:234
 genetic abnormalities, 55:217–222
 synthesis, 55:248
 cancer immunotherapy and, 59:267, 288
 cancer incidence data and, 56:161, 162
c-erbA and, 59:89–93, 107, 109
 function, 59:105
 mutations, 59:103
 protein function, 59:97–102
c-fos protooncogene and, 55:37, 38, 40
 chemical carcinogenesis and
 biological concepts, 50:36, 38
 mechanisms, 50:45–48, 53, 54
 transgenic mice, 50:58, 59
 chromosome abnormalities and, 52:31, 33–38
 acute lymphoblastic leukemia, 52:19, 20
 acute nonlymphocytic leukemia, 52:12
 malignant lymphoma, 52:25, 26
 myelodysplastic syndromes, 52:15
 chromosomes and, 62:10–12
 cytotoxic T lymphocytes and, 58:167; 59:239
 defined, 71:195
 EBV-associated disorders and, 57:372–373
 effects on radiation response, 61:201–202
 endemic Burkitt's lymphoma and, 53:42–44
 endogenous growth inhibitors and, 57:417, 419
 Epstein–Barr virus and, 62:184, 206, 217, 229–230
 Epstein–Barr virus genes and, 58:19

- Epstein-Barr virus proteins and, 50:98, 109, 120
- FGF receptor multigene family and, 60:11
- fibroblast growth factors and, 59:117, 130, 155-156
- potential, 59:144-149
- tumors, 59:149-155
- gastrointestinal diseases and, 50:18, 19
- gene rearrangements and, 52:49, 57, 73, 75
- genome exposure and, 62:139-140, 142-143
- genomic instability and, 60:137, 140, 142, 146
- glycosylation in tumors and, 52:264, 267, 316
- G protein signal transduction and, 58:84-85, 87-90
- hepatitis B viruses and, 59:168-170, 210-211
- epidemiology, 59:171, 178
- pathogenicity, 59:181-184
- viral DNA, 59:203
- viral proteins, 59:195-199
- Herpesvirus saimiri* and, 56:336-338, 343, 344, 348, 350
- H-*ras*, effects on normal cells in
- microinjection experiments on cellular immortalization, 54:74-75
- human papillomavirus and, 56:143, 148-151, 155
- influence of
- on malignancy, 53:202
- on MHC relation, 53:225-226
- interactions with ara-C, 72:213-220
- in Kaposi's sarcoma, 53:84-85
- leukemia development role
- FDC-P1 cell transformation, 63:74
- induction of CSF production, 63:74
- Louvain rat immunocytomas and, 50:297
- lysosomes and, 60:277
- malignancy and, 50:71-74, 87-89
- cellular heterogeneity, 50:89-91
- genotype, 50:79-81, 86, 87
- dominant, 50:81-85
- recessive, 50:85, 86
- maturation arrest, 50:92
- phenotype, 50:74, 79
- growth control, lack of, 50:76-79
- positional control, lack of, 50:74-76
- in metastasis, 54:189-192
- mouse retrotransposons and, 56:232, 237
- multidrug resistance gene and, 60:174-175
- muscle cell regulation and, 58:97, 99-100, 108
- mutant *p53* alleles, 66:153
- mutated, multiplicity in tumors, 72:30-32
- mutations, from cancer chemotherapy, 65:78-79
- oncoprotein kinases and, 57:186, 200
- peptide-binding heat shock proteins and, 62:169
- polyoma virus TSTA and, 55:58, 59, 64, 78, 82
- potential, and growth factor components, 64:6
- products, redox regulation, 61:221-222
- protein tyrosine kinase GFRs and, 60:60, 62-66
- Raf-1 phosphorylation and, 58:53-55, 59, 63, 68-69
- Ras function and, 62:47-52
- GAPs, 62:30-31
- Ras guanine nucleotide exchange factors, 62:26, 28
- signal transduction pathways, 62:36, 38, 41-42, 44-45
- renal cell tumors, molecular cytogenetics, 62:89
- reverse transformation and, 62:125, 134-135, 144, 146
- single-step, PymT as, 64:143
- soft tissue tumors and, 60:77, 87, 101, 105, 109
- Src family of tyrosine protein kinases and, 57:104-105, 109
- stp*, T lymphocyte transformation by, 63:231-236
- stroma and, 50:164, 187, 188
- transforming growth factor- α and, 58:43-44
- tumor clonality and, 50:220, 223, 225
- tumor rejection antigens and, 58:195
- tumor susceptibility genes and, 53:121-123
- viral, transformed cells, role of PKC, 64:191-193
- virus-activated transcription, 67:10-12
- v-rel*, derived from *c-rel*, 66:260-262
- Wilms' tumor and, 59:58

Oncogenesis

- BCR gene in leukemia and, 57:231
 - and E6, 64:14–15
 - and E6–p53 interaction, 64:11
 - and E7–pRB interaction, 64:7
 - EBV-associated disorders and, 57:372
 - endogenous growth inhibitors and, 57:437
 - and foreign DNA insertion, 66:313–344
 - and gene therapy, 66:339–341
 - lysophosphatidic acid and, 57:87
 - myc* family oncogenes and
 - in vivo* models, 57:28–33
 - tissue-preferential expression, 57:33–34
 - tumors, 57:24–28
 - plasminogen activation and, 57:290
 - progenitor cell, developmental model, 67:25–51
 - retroviruses and, 51:278, 327, *see also*
 - Murine leukemia virus antigens
 - signal transduction and, 55:296–300
- Oncogenetics
- DNA repair genes, 72:8–9
 - genes influencing apoptotic cell death, 72:9–11
 - oncogenes, 72:4–6
 - tumor suppressor genes, 72:6–8
- Oncoprotein kinases, in mitosis, 57:185–188, 213–216
- c-Mos, 57:207–211
 - phosphatases, 57:211–213
 - protooncoprotein tyrosine kinases
 - analog computer function, 57:192–197
 - growth factor receptors, 57:199–200
 - M phase, 57:200–207
 - p150*supc-abl*, 57:198–199
 - pp60*supc-src*, 57:188–197
 - Src family, 57:197–198
- Oncoproteins
- adenovirus E1A, 57:47, 77–78; 66:146, 158–159, 198–199, 202
 - bcl/abl* gene in leukemia and, 57:155
 - endogenous growth inhibitors and, 57:437, 439
 - high-risk HPV-encoded, 64:4–5
 - myc* family oncogenes and, 57:2, 12
 - p53 and human malignancies and, 57:269
 - viral
 - complex with p53, 66:84, 87, 161–162
 - RB-binding, 64:54, 77
- Oncosuppressor genes, endogenous growth inhibitors and, 57:438

Oncoviridinae, 51:307–308, *see also*

- Retroviruses, human

Oocyte maturation, oncoprotein kinases and, 57:187, 212

- c-Mos, 57:207, 209–210

- protooncoprotein tyrosine kinases, 57:200, 203, 205–206

Oogenesis, DNA methylation during, 54:14–15

Oophorectomy, gastrointestinal diseases and, 50:8, 9

Open reading frames

- adenovirus E1A proteins and, 57:58–60

- adenovirus proteins and, 52:154

- ADF and, 57:393

- BCR gene in leukemia and, 57:228, 241

- B lymphocytes and, 56:317

- c-erbA* and, 59:97

- c-myc*, 70:98, 100

- c-myc* regulation and, 56:4, 6

- Epstein–Barr virus genes and, 58:10, 13

- fibroblast growth factors and, 59:132, 148

- hepatitis B viruses and, 59:186–187, 189, 197, 203

- Herpesvirus saimiri* and, 56:350

- mouse retrotransposons and, 56:224, 228

- myc* family oncogenes and, 57:5

- ORF1, gp75, 70:160–161

- p53 and human malignancies and, 57:261, 267

- papillomaviruses and, 56:134

- bovine, 56:136–138, 141

- human, 56:144, 146–149, 151–153

- tumor rejection antigens and, 58:191, 193

- Wilms' tumor and, 59:54

Opportunistic tumors, 54:304–311

- associated with primary immune

- deficiencies, 54:305–307

- distinctive features of, 54:311

- of immune deficiency, 54:301–315

- spontaneous regression of, 54:311–312

Oral cavity carcinoma, chromosome 3 losses in, 71:45–47

Oral hairy leukoplakia

- EBV⁺ biopsies, 67:221–224

- PCR analysis, 67:217

Oral leukoplakia, 13-*cis*-retinoic acid trial, 61:15

Oral squamous cell carcinoma, transfer of chromosome 3 into, 71:55

Orf virus, VEGF-related genes, 67:296

- Organogenesis, stroma and, 50:186
- Organ transplantation, tumors associated with, 54:308–309
- Organ transplants, EBV-associated disorders and, 57:332, 345–364
- Origin, clonal, cancers, 70:2
- oriP*, Epstein–Barr virus genes and, 58:5, 11, 19
- Ornithine carbamoyltransferase, tumor clonality and, 50:205, 216, 220
- Ornithine decarboxylase
c-Myc targeting of gene, 68:134
gastrointestinal diseases and, 50:8, 11
role in c-Myc-induced apoptosis, 68:147
transcription, c-Myc role, 70:121
- Orphan receptors, protein tyrosine kinase GFRs and, 60:46
- Osteoblasts, TGF and, 51:132, 138
- Osteochondroma, chromosomal aberrations, 69:93
- Osteopontin, CD44 binding to, 71:273
- Osteosarcoma
angiogenesis, 69:155
characterization of, 60:84, 101–102
chromosomal aberrations, 69:82–83, 90, 93
chromosome abnormalities and, 52:33
extraskeletal, soft tissue tumors and, 60:76–78
IAPs and, 51:214
newborn macrosomy and, 50:251
retinoblastoma and, 54:35–36
stroma and, 50:167, 178
tumor clonality and, 50:208, 209, 225
Wilms' tumor and, 59:60
- Ovarian carcinoma
antigen-negative variants, 71:358
cancer immunotherapy and, 59:254, 264–265
CD44 and, 71:300–301
chromosome 3 losses in, 71:50
HER-2/neu protein overexpression, 71:357
immunosuppression and, 60:251, 258
lysosomes and, 60:276
MHC Class I expression and, 60:194, 224
multidrug resistance gene and, 60:166, 169
neovascularization, 69:138
plasminogen activators and, 69:112, 113
protein tyrosine kinase GFRs and, 60:65
transfer of chromosome 3 into, 71:55
- Ovarian tumors, gastrin expression, 63:320–322
- Ovary
chemical carcinogenesis and, 50:28
IAP gene expression, 51:228–230
newborn macrosomy and, 50:239, 255, 267
Wilms' tumor and, 59:57
- Overexpression
B-*myb*, 72:129–130
NF1, 72:71
- Overshot effect, cancer immunotherapy and, 59:277
- Overweight, endocrine effects of, 51:65
- Ovulation, plasminogen activation and, 57:294–295
- Owl monkey kidney cells, *Herpesvirus saimiri* and, 56:342, 345, 348
- Oxidative DNA damage, genomic instability and, 60:130–132
- Oxygen
chemical carcinogenesis and, 50:53
genomic instability and, 60:145–147
lysosomes and, 60:279
- Oxygen free radicals, induction of DNA lesions, 72:37–38
- P**
- P1A* genes, tumor rejection antigens and, 58:198–200
- p16^{ROCK}, RhoA-binding protein, 72:94
- P1 cells, tumor rejection antigens and, 58:197
- P1.HTR, tumor rejection antigens and, 58:188, 198
- P3HR-1, EBV mutant, 67:220–224
- P3HR-1 virus, Epstein–Barr virus genes and, 58:5, 7, 9, 15
- P13K
candidate Ras effector, 72:73–74
coprecipitation with Rac1 and CDC42, 72:88–89
- P15E, immunosuppression and, 60:252–254, 259
- p15
in leukemia and hematopoietic malignancies, 72:163–164
role in solid tumors, 72:158–163
- p15 protein, 70:169
cancer and, 71:197
cdk4 inhibition, 71:174
TGF- β and, 71:193

- p15^{INK4B} protein, 69:34
- p16
 Cdk4 association, 68:91, 164
 deletion or mutation in cancer, 68:91–94
 gene locus, 68:71–72, 91
 hypermethylated alleles, 72:187
 in leukemia and hematopoietic malignancies, 72:163–164
 role in solid tumors, 72:158–163
 similarity with p15, 68:94
 suppression of oncogenic transformation, 68:164
- p16 protein, 69:37
 cancer and, 71:197
 cdk inhibition by, 71:173, 174
- p16superINK4 protein, 69:34, 35, 37
- p18 protein, 69:34, 35
- p19 protein, 69:35
- p21 (CDC42/Rac)-activated kinase, activation of JNK, 72:87–88
- p21^{Cip1}, 71:174
- p21 gene, 71:4, 5
 cyclin-cdk complexes, 71:5–6
 PCNA and DNA replication, 71:6
- p21 protein, 69:35, 36, 37; 71:196
 inhibition, 71:174–175
 interaction with ara-C, 72:216–217
 TGF- β and, 71:193
- p21^{WAF1Cip1} gene, 69:33–34, 35
- p27, interaction with Myc, 70:120
- p27^{Kip1} gene, 71:174–175
 disruption of, 71:194–195
 T-cell proliferation, 71:194
- p27^{Kip1} protein, 69:34, 35, 36
- p27 protein, 69:35, 36
 cancer and, 71:197
 cdk inhibition, 71:175–179, 179
 cyclin-cdk complexes and, 71:175, 178
 TGF- β effects, 71:189–192, 193
- p30 antigen, MuLV, detection in sporadic lymphomas of wild mice, 65:177
- p33^{cdk2}, 71:168–169
- p34^{cdk2}, interaction with ara-C, 72:217
- p38, activation, 72:65–66
- p39
 c-*fos* protooncogene and, 55:39, 45
jun oncogene and, 55:14
- p40^{Sic1}, 71:176
- p53 gene, 57:257, 263–265, 268; 61:41–43; 66:73–74, 74; 71:1, 2
 adenovirus and, 71:131
 aflatoxin B₁ and, relationship with hepatitis B virus, 65:38–39
 angiogenesis, 69:154, 155
 in apoptosis, 70:131–132
 apoptosis and, 71:8–9, 12, 127, 128
 associated cellular proteins, 66:162–166
 binding site on HIC1, 72:166
 biochemical functions, 66:149–161
 biological activities, 66:144–149
 cell cycle block, 72:131–132
 cell cycle regulation, 68:134–135, 148
 chemotherapy, sensitivity of, 71:152
 chronic myeloid leukemia and, 71:145
 c-*myc* targeting of, 68:134–135, 152
 complexing with viral oncoproteins, 66:161–162
 cooperation with ras, 64:282–286
 DNA damage, G1 arrest, 71:2–7
 E2f and, 71:130
 expression and stability, 66:81–82
 expression in human breast cancer, *see* Breast cancer, p53 expression in
 function regulation, 66:166–173
 functions of, 71:2
 genomic instability and, 60:123; 71:7–8
 germline mutations in Li-Fraumeni syndrome, 61:204–205
 hepatocellular carcinoma and, 59:209
 heterogeneity, 57:258–260
 human malignancies and, 57:263
 proposed function, 57:269
 structure, 57:257–258
 translation initiation site, 57:261
 inactivation in AIDS-SNCCCL, 67:137–138
 increase after uv irradiation, 66:147–148
 inhibition of *bcl-2* transcription, 67:272
 interactions with E6, 64:11
 consequences, 64:13–15
 interaction with c-Myc, 70:120–121
 interaction with TBP, 66:158–159
 loss, effect on apoptotic threshold, 72:10–11
 multidrug resistance gene and, 60:174–175
 murine and human, structure, 66:77–78
 mutant, temperature-sensitive, 66:18–19
 mutations, 66:98–108
 in Burkitt's lymphoma, 72:17

- in cell subpopulations, 72:188
- in glioblastoma multiform, 67:292
- in lung tumors, 67:91
- in prostate cancer, 68:237–238, 243
- transforming effect, 72:8–9
- mutation spectrum, 72:40–41
- normal functions, 64:12–13
- phosphorylation, 66:79–80, 89–90
- promoter regions, 57:261–263
- providing signal for DNA repair, 67:15–16
- quaternary structure, 66:82–85
- regulation of c-Myc-induced apoptosis, 68:148–149, 151–152
- RNA linkage, 66:80–81
- role in cell cycle checkpoint control, 72:6–8
- roles and regulation, 66:73–77
- soft tissue tumors and, 60:77, 82–83, 100–103, 109
- special reagents, 66:74–75
- as surveillance system for DNA damage, 64:285
- tumor suppressor activity, 66:119–120
- wild-type
 - and cell cycle progression after DNA damage, 61:224
 - functional properties, 66:85–98
 - lack in myeloid leukemic cells, 66:17–19
 - transcriptional modulation, 66:93–97
- wild-type and mutant, 66:26
- p53 protein
 - biological activity, 57:263–268
 - human malignancies and, 57:257
- p56^{lck}. T-cell receptors and, 56:57
- p57^{Kip2} protein, 69:34
- p57 protein, 69:35, 36
 - cdk inhibition, 71:177–178
- p62, Ras function and, 62:32–34
- p70^{S6K}, effector of Rac and CDC42, 72:88
- p85, complex with Rac1 and CDC42, 72:88–89
- p105^{Rb}. interaction with c-Myc, 70:123–124
- p107, 71:182
 - complex with E2F, 72:119–120
 - mediated proliferation block, 72:131–132
 - c-Myc complex, 68:127–128
 - interaction with c-Myc, 70:114–115, 123–124
- p110^{RBI}
 - cellular proteins associated with, 61:124–125
 - characterization, 61:120
 - effect on DNA replication, 61:131–134
 - inhibition
 - of cell cycle progression, 61:129
 - of cell proliferation by TGF- $\beta_{1,inf}$, 61:129–131
 - interactions
 - with cellular transcription factors, 61:125–128
 - with c-myc, 61:127
 - localization in nucleus, 61:123
 - phosphorylation modulation, 61:123–124
 - regulation of RCBP/Spl, 61:128
 - as transcription factor, 61:116, 127
 - viral oncoprotein binding, 61:120–121
- p110^{Rb} protein, 71:179–180
- p120 GAP
 - candidate Ras effector, 72:70–71
 - interactions with Ras regions, 72:77
- p120^{GAP}-51
 - GAPs, 62:29–32, 34–35
 - Ras guanine nucleotide exchange factors, 62:23
- p130, 71:182, 196
 - complex with E2F, 72:119–121
- p150, 95, T-cell receptors and, 56:66
- P160 BCR, leukemia and, 57:235, 242, 249–253
- p190, Ras function and, 62:32–34
- p190 Rho-GAP, interaction with Ras, 72:95–96
- P210 BCR/Abl, leukemia and, 57:231–232, 243–245, 247, 249–253
- p369–377 protein, 71:349
- P815, tumor rejection antigens and, 58:196–201, 206
 - tum^{sup}-antigens, 58:184–185, 187
- PA, *see* Phosphatidic acid
- PAI, *see* Plasminogen activator inhibitors
- PALA, *see* N-(Phosphonacetyl)-L-aspartate
- Pan-CD44, 71:299
- Pancreas
 - APC gene in human cancers and, 62:82–83
 - chemical carcinogenesis and, 50:29, 59
 - newborn macrosomy and, 50:261
 - precursor lesions, 70:37

- Pancreas (*continued*)
 renal cell tumors, molecular cytogenetics, 62:94
- Pancreatic B cells IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
- Pancreatic cancer
 CD44 and, 71:297–298
 plasminogen activators and, 69:112
- Pancreatic tumors, gastrin expression
 endocrine tumors, 63:316–318
 exocrine tumors, 63:318
- Pandarus acanthifolium*, acanthifolicin isolation, 61:151
- Papilloma
 chemical carcinogenesis and
 experimental models, 50:27
 mechanisms, 50:36, 46, 48, 53
 HK1-fos, 64:275
 oncogene activation and, 51:174–176
 regression, 70:38
 and secondary events, 64:255–258
 squamous, 64:271, 274
 TGF α in, 64:265–269, 278–279
 TPA and, 51:165
 tumor clonality and, 50:217
 tumor promoters and, 51:162
- Papillomavirus, *see also* Human papillomavirus
 in conversion into carcinomas, effect of polycyclic aromatic hydrocarbons, 65:60
 Epstein–Barr virus proteins and, 50:150
 role in human carcinogenesis, 65:39
- Paraproteins, Louvain rat immunocytomas and, 50:280
- Parasites
 B cell-associated surface molecules and, 52:111
 Louvain rat immunocytomas and, 50:305
- Parathyroid, *ret* expression, 70:209
- Parathyroid disease, association with C634R mutation, 70:198
- Parathyroid hormone
 biochemical testing, 70:183
 gene translocation, 68:78
 transforming growth factor- α and, 58:48
- Pardee, Arthur
 cancer research in 1950, 65:215
 college and graduate training, 65:214
- Parenchymal lesions, molecular cytogenetics, 62:102, 110–112
- Parenchymal liver cells, endogenous growth inhibitors and, 57:435
- Parosteal osteosarcoma, chromosomal aberrations, 69:83, 88, 93
- PARP, *see* Poly-(ADP)ribose polymerase
- Partial remission, cancer immunotherapy and, 59:269
- Pas1* locus, on chromosome 6, 67:97–102, 105
- Passive immunotherapy, *see* Immunotherapy, passive
- Pasteur, Louis, legacy, 69:1–15
- Pasteur Institute, 69:4, 7
- patch*, protein tyrosine kinase GFRs and, 60:50, 54–56
- Pathogenesis
 ADF and, 57:382
 AIDS-related lymphomas, 67:113–142
bcr/abl gene in leukemia and, 57:155–156, 178
 BCR gene in leukemia and, 57:227–228, 231
 Epstein–Barr virus and, 57:342–343, 369, 373; 62:180; 67:244–246
 Hodgkin's disease, 62:212, 227, 229, 231
 NHL and AIDS, 57:365–366
 organ transplants, 57:346, 351, 355, 358–361
 T-cell lymphoproliferation, 62:196, 209–212
 humoral immune response and, 62:242, 259–260
 lung adenocarcinoma, KRAS2 activation in, 67:86–91
myc family oncogenes and, 57:5
p53 and human malignancies and, 57:267
- Patterns
 epithelial cancers, 70:23–27
 MEN IIA disease in families, 70:185–186
ret expression, 70:207–211
- PAX7 gene, rhabdomyosarcomas, 69:77
- PAX gene, rhabdomyosarcomas, 69:77
- PBNA, prostatic cancer and, 51:72–73
- PC12 cells
 fibroblast growth factors and, 59:143
 PKC in, 64:184–185
 RB phosphorylation, inactivation during differentiation, 64:41
- PCNA, *see* Proliferating cell nuclear antigen
- PCR, *see* Polymerase chain reaction

- PCR amplification, microsatellites, 72:49
- PDGF, *see* Platelet-derived growth factor
- Pediatric AIDS, 51:340–341
- Pentagastrin, gastrointestinal diseases and, 50:5
- Pentosan polysulfate, 69:160
- Pepsinogen, gastrointestinal diseases and, 50:3
- Peptic ulcer, gastrointestinal diseases and, 50:5, 6
- Peptide binding, to class I groove, 67:164–165
- Peptide growth factors, *see also*
 Transforming growth factor- α
 active immunization against, in autocrine growth stimulation inhibition, 54:230–231
- Peptides
 adenovirus E1A proteins and, 57:51–52, 58, 68–69
 adenovirus proteins and, 52:152, 155, 161
 ADF and, 57:393, 400, 405
 B cell-associated surface molecules and, 52:97, 106, 115
bcr/abl gene in leukemia and, 57:155
BCR gene in leukemia and, 57:242, 244–247
 breast cancer, *p53* expression in, 59:84
 Burkitt's lymphoma and, 55:230, 233, 235, 237
 cancer immunotherapy and, 59:251, 256, 288
c-fos protooncogene and, 55:43, 45, 48
 cytotoxic T lymphocytes and, 58:144–145, 166–168; 59:227–234, 237, 240–241
 immunogenicity of tumors, 58:145–151, 154
 virus-induced tumors, 58:157–158
 endogenous growth inhibitors and, 57:413, 430–431, 433–435, 440–441
 Epstein-Barr virus proteins and, 50:105, 107–110, 114, 116, 119, 133, 134
 FGF receptor multigene family and, 60:3, 8–9, 15, 30, 32
 fibroblast growth factors and, 59:126, 133
 oncogenic potential, 59:147–148
 protein structure, 59:120–121, 123–124
 tumors, 59:151–153
 gene rearrangements and, 52:50, 51
 glycosylation in tumors and, 52:284, 287, 291, 292
- G protein signal transduction and, 58:86
 growth regulation and, 57:418–419
 hepatitis B viruses and, 59:175, 197, 203
 HLA-A2-binding, 70:162–163
jun oncogene and, 55:7, 14, 19
 lysophosphatidic acid and, 57:92, 96
 MART-1, 70:153–154
 MHC Class I expression and, 60:182
 cancer, 60:184, 186–188
 downmodulation, 60:224, 229–231
 modulation by oncogenes, 60:197, 202
 multidrug resistance and, 52:167, 184
 multidrug resistance gene and, 60:162, 171
 muscle cell regulation and, 58:96, 110
 mutated, 70:166–169
p53 and human malignancies and, 57:259
 plasminogen activation and, 57:281–282, 285, 298, 301, 314
 polyoma virus TSTA and, 55:61, 77–82
 Raf-1 phosphorylation and, 58:62–64, 66
 signal transduction and, 55:272
 Src family of tyrosine protein kinases and, 57:105, 135
 stroma and, 50:161
 transforming growth factor- α and, 58:29–30, 32, 36, 39
 tumor rejection antigens and, 58:179–180, 182, 206
 P815, 58:199
 tum sup -antigens, 58:193–194
- Peptide transporters, selective for peptide length, 67:163
- Pericellular matrix, plasminogen activation and, 57:275–276, 283, 294
 directed cell surface, 57:303, 306, 308
- Pericellular space, plasminogen activation and, 57:300–304, 309
- Pericytes, expression of *c-met* mRNA, 67:261–263
- Peripheral blood lymphocytes
 ADF and, 57:385, 396, 398
 ataxia-telangiectasia genes and, 56:84
c-myc regulation and, 56:39
 hepatitis B viruses and, 59:181
Herpesvirus saimiri and, 56:339, 348, 350
 sensitization, 70:146–147
- Peripheral lymph node, T-cell receptors and, 56:67, 68
- Peripheral nerve sheath tumors, malignant, chromosomal aberrations, 69:80–81, 90

- Peripheral neuroepithelioma, chromosomal aberrations, 69:86–87
- Peritoneal exudate cells, polyoma virus TSTA and, 55:80, 81
- Perivascular tumors, chromosomal aberrations, 69:78
- Permeability
 blood vessels, in cancer progression, 67:282
 vascular, stimulation by VEGF, 67:288
- Permeability glycoproteins
 glutathione transferase and, 52:241
 multidrug resistance and, 52:166, 195–197
 alterations, 52:172–174
 clinic, 52:195
 coamplified genes, 52:192–194
 diversity, 52:185–188
 expression, 52:189–192
 genes, 52:178–180
 mutation, 52:188, 189
 overproduction, 52:174, 175
 structure, 52:180–185
- Permissivity
 correlation with immortality, 61:105–106
 in gene amplification, 61:89–91
- Persistence
 Ad12 genome, 66:319–324
 hepatocyte nodules, 70:34–36
 selecting or counterselecting for, 66:325
- Persistent generalized lymphadenopathy in early AIDS-NHL, 67:118–120
 preceding AIDS-SNCCCL, 67:139–142
 presence of EBV in context of, 67:128–129
- Pertussis toxin
 G protein signal transduction and, 58:82, 85, 87–88
 lymphocyte homing receptors and, 51:374–375
 lysophosphatidic acid and, 57:94–96
- Pesticides, prostatic cancer and, 51:69
- PEST sequences
 C-terminal to cyclin box, 66:183
 in I κ B α , 66:275–276
jun oncogene and, 55:24, 25
 p53, 66:81, 166
- Peyer's patches
 HEV and, 51:369–370, 371
 HEV binding lymphomas, 51:378–380
 T-cell receptors and, 56:67, 70
- Peyronie disease, chromosomal aberrations, 69:65
- P-glycoprotein
 lysosomes and, 60:284–285
 multidrug resistance gene and
 regulation of expression, 60:170–171, 175–176
 transporter, 60:159–161, 163–168
 soft tissue tumors and, 60:106–107
- pgp*, multidrug resistance gene and, 60:171–172, 174
- pH
 B cell-associated surface molecules and, 52:109, 113
 FGF receptor multigene family and, 60:31
 genomic instability and, 60:145
 lysosomes and, 60:271, 275
 microenvironment, 60:279–281
 therapy, 60:284–286
 multidrug resistance gene and, 60:158
- Phagocytes
 cancer immunotherapy and, 59:266, 280, 286
 mononuclear, Fc γ RI expression, 64:213
- Phagocytic glycoprotein-1, 71:246
- Phagocytosis
 humoral immune response and, 62:244, 260
 immunosuppression and, 60:249, 254
 lysosomes and, 60:270
 stroma and, 50:161, 183
- Pharmacological reversion, Ras function and, 62:48–49
- Phenethylbiguanide, newborn macrosomy and, 50:271, 272
- Phenobarbital, glutathione transferase and, 52:208, 209, 228
- Phenobarbitone, tumor clonality and, 50:220
- Phenoclones, oncogenes and, 50:90
- Phenolic antioxidants, tumorigenic activity of, 53:254–257
- Phenotype, *see also* Immunophenotype
 adenovirus E1A proteins and, 57:51, 60, 73
 adenovirus proteins and, 52:154
 ADF and, 57:382, 406
 APC gene in human cancers and, 62:70–72, 83
 associated with
 MEN IIA syndrome, 70:186–187
ret mutations, 70:211–212
 ataxia-telangiectasia genes and, 56:78–81, 97

- clonal expansions, 56:83–86
- complementation groups, 56:81–83
- B cell-associated surface molecules and, 52:102, 122
- bcr/abl* gene in leukemia and, 57:155, 165, 170–173, 177
- BCR* gene in leukemia and, 57:252
- B lymphocytes and, 56:314, 321, 322, 325, 327
- breast cancer, *p53* expression in, 59:70, 83–84
- Burkitt's lymphoma and, 55:140, 150–154
 - B cell differentiation, 55:165, 166
 - chromosomal translocations, 55:205
 - deregulation, 55:211–213
 - EBV, 55:236, 238–240
 - genetic abnormalities, 55:217, 218
 - cancer immunotherapy and, 59:247, 252
 - c-erbA* and, 59:92–93, 103, 105–108
 - c-fos* protooncogene and, 55:37
 - chemical carcinogenesis and, 50:26, 60
 - biological concepts, 50:34, 36
 - experimental models, 50:32
 - mechanisms, 50:41, 43, 45, 48, 49, 51, 53, 54
- chromosome abnormalities and, 52:19, 31, 32
- c-myc* regulation and, 56:11, 26, 27, 32, 37, 39
- cytotoxic T lymphocytes and, 58:154, 160; 59:234, 236, 238–239
- EBV-associated disorders and, 57:331, 345, 372
 - Burkitt's lymphoma, 57:334–345
 - organ transplants, 57:353–354, 356–358, 360–361, 363
 - X-linked lymphoproliferative syndrome, 57:337, 339–341
- Epstein–Barr virus and, 62:183
 - Hodgkin's disease, 62:220, 230
 - peripheral T cell lymphomas, 62:199, 202, 206–207
 - T-cell lymphoproliferation, 62:187, 189, 191, 193–194, 197, 211
- Epstein–Barr virus genes and, 58:2, 7–8, 19–20
- Epstein–Barr virus proteins and diseases, 50:96–98
 - transformed cells, 50:120, 136, 138
- FGF receptor multigene family and, 60:2, 4, 32
- fibroblast growth factors and, 59:141, 146–149, 151, 155
- gene rearrangements and
 - hematological neoplasias, 52:59, 62–64
 - simultaneous occurrence, 52:69–71
- genome exposure and, 62:129, 132, 140
- genomic instability and, 60:122–123, 126–127, 145–146
 - mechanisms, 60:131–134, 141
 - quantitative considerations, 60:142–145
- to genotype, conceptual approach, 70:42–44
- glutathione transferase and, 52:205, 206, 210, 211
- glycosylation in tumors and, 52:258, 264
- G protein signal transduction and, 58:84, 86
- hepatitis B viruses and, 59:199
- hepatocyte, 70:27–37
- immunosuppression and, 60:249
- jun* oncogene and, 55:28–30
- liver cancer, 70:36–37
- lysophosphatidic acid and, 57:87–88, 101
- lysosomes and, 60:277, 284, 285
- malignancy and, 50:71, 72, 74, 79, 87, 88
 - cellular heterogeneity, 50:89–91
 - genotype, 50:79, 81, 83, 84
 - growth control, lack of, 50:76–79
 - maturation arrest, 50:92
 - positional control, lack of, 50:74–76
- metastatic cancer cells and, 55:88, 89, 123–126
 - clonal dominance, 55:97, 99, 104
 - growth factors, 55:115, 119, 120
 - human malignant melanoma, 55:105, 110, 111
 - selectivity, 55:90–96
- MHC Class I expression and, 60:194–195, 201, 223, 230
- mouse retrotransposons and, 56:223, 226–231
- multidrug resistance and, 52:185, 188, 196
 - alterations, 52:173, 174
 - coamplified genes, 52:192–194
- multidrug resistance gene and, 60:160
- muscle cell regulation and, 58:95–97, 103, 110, 114
- mutator, cancer cells exhibiting, 72:25–51
- myc* family oncogenes and, 57:13, 16, 28–29, 33, 37
- neoplastic, 72:2–3

Phenotype (*continued*)

- oncoprotein kinases and, 57:188, 207, 214
- p53* and human malignancies and, 57:257, 263, 267
- papillomaviruses and, 56:155
 - bovine, 56:136, 137, 139
 - human, 56:144, 145, 150, 154
- plasminogen activation and, 57:273, 283, 290
- polyoma virus TSTA and, 55:64, 70
- protein tyrosine kinase GFRs and, 60:45
 - development, 60:50–56, 59
 - tumorigenesis, 60:65
- Raf-1 phosphorylation and, 58:63, 68
- Ras function and, 62:20, 44, 46
- renal cell tumors, molecular cytogenetics
 - nonpapillary renal cell tumors, 62:87, 100, 102–103, 105
 - papillary renal cell tumors, 62:111, 114
 - renal oncocytoma, 62:117
- RER-positive, 72:13
- reverse transformation and, 62:126–127, 133–135, 145, 147
- signal transduction and, 55:300
- soft tissue tumors and, 60:77, 80, 85
- Src family of tyrosine protein kinases and, 57:113, 118, 130, 138
- stroma and, 50:187
 - alterations, 50:185
 - basement membranes, 50:174
 - epithelium, 50:167
 - fibroblasts, 50:177
- T-cell receptors and, 56:71
- transforming growth factor- α and, 58:43, 46–48
- tumor clonality and, 50:225
 - animal tumors, 50:218
 - distinction, 50:203, 206, 207, 211
 - human tumors, 50:216, 217, 222
 - origin, 50:199
 - pleoclonal tumors, 50:212
- Wilms' tumor and, 59:47–48, 50, 61–63
- Phenotypic conversion, endothelial cells, 66:240–245
- Phenotypic modulation, in SMCs, 67:263
- N-Phenyl-2-naphthylamine, prostatic cancer and, 51:72–73
- Pheochromocytoma, 71:52, 58
 - in inherited syndromes, 70:182
 - in MEN IIA families, 70:197–198
 - ret* mutations, 70:199–200
- Philadelphia chromosome, *See* Chromosomes, Philadelphia
- Phosphonoformate, AIDS and, 51:347, 356
- Phorbol-12, 13, didecanoate, comparison with Okadaic acid in cell transformation assay, 61:157–158
- Phorbol esters
 - c-fos* protooncogene and, 55:50
 - chemical carcinogenesis and, 50:31, 50–54, 60
 - jun* oncogene and, 55:7, 22
 - PKC activation, 64:163–164
 - role in tumor promotion, 64:193–194
 - stroma and, 50:183
 - tumor clonality and, 50:218
- Phorbol myristate acetate, B cell-associated surface molecules and
 - Bgp95, 52:116
 - CD20, 52:92, 93
 - CD22, 52:105, 106
 - CDw40, 52:115
 - expression, 52:129
- Phosphatase
 - BCR gene in leukemia and, 57:249–250
 - oncoprotein kinases and, 57:212, 215–216
 - M phase, 57:211–213
 - protooncoprotein tyrosine kinases, 57:190–193, 197–198, 204–205
- Phosphatase-1, oncoprotein kinases and, 57:205, 212–213
- Phosphatidic acid, 57:88–96, 98–101
- Phosphatidic acid inhibitor-1, 57:295–299, 301, 305–306, 308–309, 313–314
- Phosphatidic acid inhibitor-2, 57:296–299, 301, 305–306, 308–309, 313–314
- Phosphatidic acid inhibitor-3, 57:296, 299, 301
- Phosphatidylcholine
 - G protein signal transduction and, 58:88–89
 - lysophosphatidic acid and, 57:89–90
- Phosphatidylcholine-phospholipase C, G protein signal transduction and, 58:83, 88–89
- Phosphatidylcholine-phospholipase D, G protein signal transduction and, 58:88–89
- Phosphatidylethanolamine, lysophosphatidic acid and, 57:89–90
- Phosphatidylinositol, 68:3–kinase activation by cytokines, 68:39–40

- B cell-associated surface molecules and, 52:131
- ras signaling pathway, 68:39–40
- Phosphatidylinositol 3'-kinase, 61:62
- Phosphodiesterases in Ras-cAMP pathway, 54:107
- Phosphofructokinase-2 as target of cAMP-dependent protein kinase, 54:115–116
- Phosphoglycerate kinase-1, tumor clonality and
 - animal tumors, 50:218, 219
 - distinction, 50:204, 206, 207, 211
 - pleoclonal tumors, 50:212–215
- Phosphoinositide
 - G protein signal transduction and, 58:78–79, 82–86, 88–89
 - lysophosphatidic acid and, 57:94–96
 - Src family of tyrosine protein kinases and, 57:124, 128, 136
- Phosphoinositide-3-kinase, G protein signal transduction and, 58:78
- Phosphoinositide-specific phospholipase C, G protein signal transduction and, 58:76–77, 81–83, 85–88
- Phospholipase, signal transduction and, 55:276
- Phospholipase A₂
 - G protein signal transduction and, 58:80–81, 83, 88
 - lysophosphatidic acid and, 57:90, 94–95, 100
- Phospholipase C, 61:62
 - ADF and, 57:405
 - bcr/abl* gene in leukemia and, 57:158, 168
 - FcγR-mediated activation, 64:219
 - FGF receptor multigene family and, 60:32–33
 - lysophosphatidic acid and, 57:90, 93–96, 99, 101
 - Raf-1 phosphorylation and, 58:65–67, 70
 - Src family of tyrosine protein kinases and, 57:109, 124
- Phospholipase C-γ
 - G protein signal transduction and, 58:78, 84, 87
 - humoral immune response and, 62:247
- Phospholipase D
 - G protein signal transduction and, 58:83
 - lysophosphatidic acid and, 57:90, 100
- Phospholipids
 - cancer immunotherapy and, 59:266
 - lysophosphatidic acid and, 57:88–90
 - metabolism, role of SH2-containing proteins, 64:92–94
 - Raf-1 phosphorylation and, 58:60
 - T-cell receptors and, 56:69
- Phosphonoacetic acid, Epstein–Barr virus genes and, 58:15
- Phosphopeptides, Raf-1 phosphorylation and, 58:62–63, 65–66
- Phosphorothioate oligonucleotide analog, 61:76–77
- Phosphorylation, *see also*
 - Autophosphorylation
 - adenovirus E1A proteins and organization, 57:50
 - transactivation, 57:61, 63, 66, 68–70
 - ara-C, 72:203–204
 - bcr/abl* gene in leukemia and, 57:163, 168, 171
 - BCR* gene in leukemia and, 57:235, 244–245, 252–253
 - breast cancer, *p53* expression in, 59:71–72
 - cdk activation by, 71:5, 172
 - cdk inhibition by, 71:173
 - c-fos* protooncogene and, 55:38, 39
 - chemical carcinogenesis and, 50:52, 55
 - c-myc* regulation and, 56:7
 - endogenous growth inhibitors and, 57:437
 - Epstein–Barr virus genes and, 58:8
 - Epstein–Barr virus proteins and, 50:127, 146
 - FGF receptor multigene family and, 60:31–33
 - fibroblast growth factors and, 59:122, 137
 - G protein signal transduction and, 58:78, 80, 84–85
 - hepatitis B viruses and, 59:198
 - humoral immune response and, 62:247, 253–255
 - IκBα, 66:274–275
 - jun* oncogene and, 55:22, 23, 25
 - lysophosphatidic acid and, 57:90, 93–94
 - MHC Class I expression and, 60:214, 219
 - multidrug resistance gene and, 60:175–176
 - multiple sites in RB, 64:77–78
 - muscle cell regulation and, 58:111–112
 - myc* family oncogenes and, 57:5–6, 11–12
 - okadaic acid effects, 61:165–166
 - oncprotein kinases and, 57:186, 188, 213–216

- Phosphorylation (*continued*)
- c-Mos, 57:210
 - phosphatases, 57:211, 213
 - protooncprotein tyrosine kinases, 57:188–207
 - p27 and, 71:175
 - p53, 66:79–80, 167–168
 - p65, and NF- κ B activity, 66:273
 - p110^{Rbl}, modulation, 61:123–124
 - physiological targets by PKC isozymes, 64:171–175
 - plasminogen activation and, 57:280
 - protein tyrosine, target molecules, 64:143
 - protein tyrosine kinase GFRs and, 60:43, 62
 - Raf-1, *see* Raf-1 phosphorylation
 - Ras function and, 62:33, 37–39, 45
 - RB, cell cycle regulated, 64:32–48
 - regulated RB function, 64:70–75
 - reverse transformation and, 62:127, 135, 139–142, 147
 - serine, Fc γ RII, 64:229
 - signal transduction and
 - mechanisms, 55:286, 287, 289, 290, 292, 295, 296
 - nuclear pores, 55:282
 - plasma membrane receptor, 55:274, 277, 278
 - Src family of tyrosine protein kinases and, 57:104, 108–111, 120
 - T-cell activation, 57:122–125, 127–131
 - T-cell proliferation, 57:136–138
 - stroma and, 50:170
 - T160 in CDK2, 66:188–191
 - tautomycin effects in K562 cells, 61:181
 - T-cell receptors and, 56:56, 57, 63, 69
 - TGF- β and, 71:188–189
 - transforming growth factor- α and, 58:44
 - tyrosine, 64:219–220
 - cellular substrates, 67:303–304
 - regulation of SH2 binding, 64:91
 - tyrosine acceptor site, 66:246
 - Wilms' tumor and, 59:56
 - yeast RAS proteins and, 54:97
- Phosphorylation state, mutant p53, 66:105
- Phosphotyrosine
- bcr/abl* gene in leukemia and, 57:158, 163, 168–169
 - oncprotein kinases and, 57:199, 206, 211
 - Src family of tyrosine protein kinases and, 57:116–117, 131
 - Phosphotyrosine-binding proteins, and *ret*, 70:204–207
 - Phosphotyrosine phosphatase, SH2-containing, 64:104
 - ph-P53, BCR gene in leukemia and, 57:243–247, 249–251, 253
 - Phytohemagglutinin
 - α -fetoprotein and, 56:255, 256, 273, 281, 282, 284, 291
 - ataxia-telangiectasia genes and, 56:84
 - breast cancer, p53 expression in, 59:80
 - c-myc* regulation and, 56:13
 - genomic instability and, 60:126
 - immunosuppression and, 60:258
 - MHC Class I expression and, 60:230
 - Src family of tyrosine protein kinases and, 57:128
 - PI-3 kinases, 71:12–13, 15
 - Pigmented villonodular synovitis, chromosomal aberrations, 69:78–79, 90
 - Pilocytic astrocytoma, oncogenesis of, 58:131–132, 134
 - Pim-1
 - gene synergism with *c-myc*, 68:158–159
 - transgenic mice, 68:158–159
 - Piroxicam
 - clinical trial, 61:7
 - in vitro* testing, 61:9
 - Pituitary, TGF and, 51:135
 - Pituitary newborn macrosomy and, 50:255
 - PKC, *see* Protein kinase C
 - Placenta, plasminogen activation and, 57:297–298
 - Placenta growth factor, role in tumor angiogenesis, 67:295–296
 - Plague, Zilber and, 59:5–8
 - Plasma
 - α -fetoprotein and, 56:279, 280, 285
 - cancer immunotherapy and, 59:263–265, 268
 - c-fos* protooncogene and, 55:41
 - EBV-associated disorders and, 57:338, 367
 - myc* family oncogenes and, 57:31
 - plasminogen activation and, 57:284, 296, 299, 302
 - Plasma cells
 - B cell-associated surface molecules and, 52:82
 - biochemically defined molecules, 52:119, 120, 122
 - differentiation antigens, 52:91, 99

- expression on activated cells, 52:128
- history, 52:86, 88
- T cells, 52:133, 134
- Burkitt's lymphoma and, 55:207
- IAP gene expression, 51:228–230
- Louvain rat immunocytomas and, 50:283, 294, 306
- Plasmacytoma
 - Burkitt's lymphoma and, 55:141
 - B cell differentiation, 55:168
 - chromosomal translocations, 55:196–200, 205–208
 - c-myc* expression, 55:186, 190–192
 - c-myc* structural changes, 55:180, 185
 - deregulation, 55:209, 214, 215
 - genetic abnormalities, 55:217–220, 222
 - nonrandom chromosomal translocations, 55:156
 - phenotype, 55:153
 - synthesis, 55:245, 247, 248
 - translocation mechanism, 55:171
- c-myc* regulation and, 56:26, 33–35
 - expression, 56:18, 24
 - gene topography, 56:5, 8
- immunosuppression and, 60:252, 259
- Louvain rat immunocytomas and, 50:279, 280, 306
 - etiology, 50:294, 295, 298–300, 305
 - immunoglobulins, 50:289
- mouse retrotransposons and, 56:228, 229, 239
- myc* family oncogenes and, 57:18, 25–26, 30
 - oncogene activation and, 51:150–151
 - tumor clonality and, 50:210
- Plasmacytoma repressor factor, *c-myc* regulation and, 56:8, 18
- Plasmacytosis, Epstein–Barr virus proteins and, 50:100
- Plasma membrane
 - ADF and, 57:398, 405
 - bcr/abl* gene in leukemia and, 57:158–159, 162, 169–170
 - cancer immunotherapy and, 59:290
 - Epstein–Barr virus proteins and, 50:131–133
 - stroma and, 50:187
 - fibroblast growth factors and, 59:132, 140
 - hepatitis B viruses and, 59:197
 - lysophosphatidic acid and, 57:88, 90, 98–100
 - lysosomes and, 60:276, 284–285
 - multidrug resistance gene and, 60:159–160, 163–164
 - oncoprotein kinases and, 57:190, 201
 - plasminogen activation and, 57:280
 - polyoma virus TSTA and, 55:64, 68
 - signal transduction and, 55:272
 - oncogenesis, 55:298
 - receptor, 55:274–278
 - Src family of tyrosine protein kinases and, 57:109, 114, 136
- Plasma prolactin levels, diet and, 51:64–65
- Plasmids
 - adenovirus E1A proteins and, 57:53–54, 65
 - ADF and, 57:387
 - Burkitt's lymphoma and
 - c-myc*, 55:165, 179
 - EBV, 55:227–230
 - synthesis, 55:250
 - c-erbA* and, 59:100
 - c-fos* protooncogene and, 55:45
 - chemical carcinogenesis and, 50:42, 46
 - c-myc* regulation and, 56:11, 17
 - Epstein–Barr virus genes and, 58:4
 - Epstein–Barr virus proteins and, 50:112, 137
 - metastatic cancer cells and, 55:97–99, 124
 - mouse retrotransposons and, 56:237
 - mutant or wild-type *p53*–expressing, 66:95–96, 119–120
 - p53* and human malignancies and, 57:260–262, 264–265
- Plasmin
 - cell surface, 69:106–107, 123
 - leukemia and, 69:117
 - mediation of TGF- β activation, 70:67
 - plasminogen activation and, 57:274, 283, 313
 - directed cell surface, 57:303, 305–312
 - proteolytic modulation, 57:284–286, 288–294, 299–300
 - stroma and, 50:162, 163
 - TGF and, 51:129
 - tumor cell invasion, 69:111
- Plasmin inhibitors, 69:108–110
- Plasminogen, 57:313–314; 69:102
 - activation by steroids, regulation, 70:83–85
 - directed cell surface and, 57:303, 305–312

- Plasminogen (*continued*)
 proteolytic modulation and, 57:284–286, 291
- Plasminogen activation, 57:273–275, 313–314; 69:101–102, 122–123
 adhesive interactions
 cellular contact sites, 57:276–280
 defective interactions, 57:283–284
 ECM proteins, 57:280–282
 pericellular matrix, 57:275–276
 cell migration, 69:114–115
 on cell surface, 69:104–106, 123
 components, 69:102–104
 directed cell surface
 accessibility, 57:306–308
 cell surface-bound reactants, 57:305–306
 cell surface scheme, 57:309–312
 functional assembly, 57:308–309
 future applications, 57:312–313
 pericellular distribution, 57:300–304
 internalization of uPA, 69:110–111
 leukemias, 69:115–122
 PA inhibitors, 69:107–108
 plasmin inhibitors, 69:108–110
 proteolytic modulation
 cellular invasion, 57:290–292
 functions, 57:292–295
 inhibitors, 57:296–300
 plasmin, 57:284–286
 structures, 57:286–290
 regulators, 69:106–110
 in tumors, 69:111–114
- Plasminogen activator inhibitors
 PAI-1, 69:107–108
 concentration in malignant tumors, 69:112–113
 leukemia and, 69:119
 tumor invasion, 69:111
- PAI-2, 69:108
 concentration in malignant tumors, 69:113
 leukemia and, 69:119
 tumor invasion, 69:111
- PAI-3, 69:108
 TGF and, 51:134
- Plasminogen activators, *see also* Tissue-type plasminogen activator; Urokinase-type plasminogen activator
 fibroblast growth factors and, 59:120, 141
 gastrointestinal diseases and, 50:15
 metastatic cancer cells and, 55:90, 96, 124
 stroma and, 50:161, 162
- Plasminogen-binding proteins, 69:105–106
 Plasminogen inhibitors, 69:107–108
Plasmodium falciparum, Epstein–Barr virus proteins and, 50:97, 112
 Platelet-activating factor, 69:144
 lysophosphatidic acid and, 57:93, 100
 Platelet-derived endothelial cell growth factor, angiogenesis, 69:143
 Platelet-derived growth factor, 53:2
 activation of Ras, 72:73–74
 ADF and, 57:405
 angiogenesis, 69:143
 apoptosis suppression, 68:195
bcr/abl gene in leukemia and, 57:168
 bovine papillomavirus and, 56:137, 141, 142
 Burkitt's lymphoma and, 55:164
 cell cycle regulation, 68:192–194
c-fos protooncogene and, 55:50
 competence and, 53:4, 5
 FGF receptor multigene family and, 60:33
 gene expression inducible by, 53:14–15
 G protein signal transduction and, 58:78, 83, 87–88
jun oncogene and, 55:1
 oncogenes and, 50:81
 oncoprotein kinases and, 57:193, 200, 204, 206
 PDGF- β
 FGF receptor multigene family and, 60:9, 13
 protein tyrosine kinase GFRs and, 60:45, 50
 PDGF- α , protein tyrosine kinase GFRs and, 60:45, 54–55
 plasminogen activation and, 57:280, 297
 Raf-1 phosphorylation and, 58:65, 69
 Src family of tyrosine protein kinases and, 57:108, 112
 and *src* kinases, 70:118
 subtype corresponding to VEGF subtype, 67:294
 TGF- β binding, 70:69–70
 transforming growth factor- α and, 58:45
- Platelet-derived growth factor receptor
 central nervous system tumor oncogenesis and, 58:127
 PDGF α effect on metastasis, 66:63–64
 Raf-1 phosphorylation and, 58:58, 66–67
 Ras function and, 62:32, 39, 44, 51–52
 Platelet factor 4, 69:150

- Platelet glycoprotein IIb, T-cell receptors and, 56:63
- Platelets
- FcyRII expression, 64:213
 - lysophosphatidic acid and, 57:90, 99–100
 - oncoprotein kinases and, 57:213
 - plasminogen activation and
 - adhesive interactions, 57:277, 280
 - directed cell surface, 57:311–312
 - proteolytic modulation, 57:292, 294, 299
 - Src family of tyrosine protein kinases and, 57:116–119
- Plating efficiency, variance, 70:6–8
- Pleiotropy, metastatic cancer cells and, 55:123
- Pleoclonal tumors, 50:198, 224
- animal tumors, 50:218, 219
 - definition, 50:201
 - distinction, 50:202–211
 - factors, 50:221, 222
 - human tumors, 50:216
 - number, 50:212, 215
 - origin, 50:199, 200
 - spatial distribution, 50:215, 216
- Pleomorphic adenoma of the salivary glands, *chromosomal aberrations*, 69:88
- Ploidy
- distribution of rearranged chromosomes in relation to, 67:69–71
 - genomic instability and, 60:125–126, 134–136
 - soft tissue tumors and, 60:105–106
- Plutonium exposure, prostatic cancer and, 51:78–79
- pMeta-1, 71:251, 252, 262, 290
- pMeta-2, 71:251
- PML oncogenic domains, in promyelocytic leukemia, 67:40
- PMS1 gene, 71:98, 103, 104
- PMS1 proteins, 71:98
- PMS2 gene, HNPCC kindred studies, 71:103, 104
- PMSR1–7 genes, 71:98
- p-*myc* gene, *myc* family oncogenes and, 57:13
- Pneumococci, Zilber and, 59:4
- Pneumocystis carinii* infection, 51:316
- Pockets A–F, interaction with peptide residues, 67:164–165
- Podosome proteins, oncoprotein kinases and, 57:201, 203
- Pokeweed mitogen, B cell-associated surface molecules and, 52:91, 119, 125
- pol* genes
- fibroblast growth factors and, 59:151
 - mouse retrotransposons and, 56:223, 224
- Polioencephalomyelopathy, spongiform, incidence in MuLV-infected LC mice, 65:179–181, 184–185
- Poliovirus
- methods of distribution, 65:144–145
 - pathologic characteristics, 65:145–146
 - vaccine production, use of monkey kidney cells, 65:147–148
- Polyadenylation
- c-myc* regulation and, 56:5, 23
 - hepatitis B viruses and, 59:193
 - human papillomavirus and, 56:145
 - mouse retrotransposons and, 56:217, 230, 231
- Poly-(ADP)ribose polymerase, 71:130
- Polycyclic aromatic hydrocarbons
- chemical carcinogenesis and, 50:29
 - chemical nature, high performance liquid chromatographic studies, 65:80–81
 - DNA and, location of chemical modification, 65:69
 - DNA as *in vivo* target, 65:59–60
 - production methods, 65:41
 - relationship to sterols, 65:44–46
 - structural requirements, studies using physical organic chemistry, 65:70–73
 - tumor-initiating action, 65:94
 - two-stage carcinogenesis and, studies using mouse skin, 65:46–49
 - use as radiomimetic compounds, 65:50
- Polycythemia vera, chromosome abnormalities and, 52:17, 18
- Polyethylene glycol, cancer immunotherapy and, 59:266, 268
- Polymerase chain reaction
- amplified M13 DNA, 66:338–339
 - analysis of pericyte mRNA, 67:263
 - APC gene in human cancers and, 62:67, 72–73, 78–79
 - breast cancer, *p53* expression in, 59:76
 - CD44 variants, 71:252
 - Epstein–Barr virus and
 - Hodgkin's disease, 62:214–215, 218–219, 222–223, 228–230

- Polymerase chain reaction (*continued*)
 marker detection, 62:186–187
 T-cell lymphoproliferation, 62:188–189,
 194, 205, 208
 Epstein–Barr virus genes and, 58:21
 FGF receptor multigene family and, 60:11,
 13, 19
 hepatitis B viruses and, 59:170
Herpesvirus saimiri and, 56:344, 347, 349
 HPV virus, 71:327
 identification of p65Δ, 66:263
 identification of recombinants, 66:328
 microsatellite instability, detection by, 71:
 213–214
 multidrug resistance gene and, 60:168
 partner genes, 66:225–228
 protein tyrosine kinase GFRs and, 60:46
 Ras function and, 62:27
 soft tissue tumors and, 60:87, 103
 studies of EBV types A and B, 67:211–213
 throat washings positive for, 67:217
 transforming growth factor-α and, 58:41
 Wilms' tumor and, 59:58
- Polymerization
 genomic instability and, 60:128
 stroma and, 50:168, 170, 171
- Polymorphisms, *see also* Restriction fragment
 length polymorphism
 α-fetoprotein and, 56:259, 262
 allelic, in *M. spretus* mice, 67:96–99
 ataxia-telangiectasia genes and, 56:88, 90–
 93, 99
 BNLF1 gene, 67:214–218
 C/D and F/f, 67:219–220
 in class I and class II genes, 67:155–156
 cytotoxic T lymphocytes and, 58:144; 59:
 234–235
 EBNA, 67:236–237
 EBV-associated disorders and, 57:351–
 352, 363, 373
 H3–8, 67:14
 in *Kras2* second intron, 67:101–102
 Louvain rat immunocytomas and, 50:281, 287
 MHC Class I expression and, 60:185–186,
 217
 mouse retrotransposons and, 56:218, 225
 p53 and human malignancies and, 57:258–
 259
 TATA, 67:170–171
 T-cell receptors and, 56:51
 tumor rejection antigens and, 58:179–180
- Polyoma large T antigen, binding to p110^{RB1},
 61:120–121
- Polyomavirus
 adenovirus E1A proteins and, 57:74–75,
 77
 cytotoxic T lymphocytes and, 58:147
 early region, controlled PymT expression,
 64:133–140
 hamster, 64:130–132
 middle T antigen, *see* HamT
 middle T antigen, *see* PymT
 murine, induced transforming events, 64:
 126–127
myc family oncogenes and, 57:11
 oncoprotein kinases and, 57:203
 transformed cells, 66:21–23
 tumor induction in mice, 68:1
- Polyomavirus TSTA, 55:57, 58
 definition, 55:58, 59
 future prospects, 55:82
 immune response studies, 55:59–62
 molecular biology, 55:62–64
 present view, 55:81, 82
 studies, 55:64, 65
 epitopes, 55:72–81
 T antigens, 55:65–72
- Polypeptide mitogens, FGF receptor
 multigene family and, 60:2–5
- Polypeptides
 adenovirus E1A proteins and, 57:48–50,
 65, 74, 77
 adenovirus proteins and, 52:156
 B cell-associated surface molecules and, 52:
 82, 134
 biochemically defined molecules, 52:
 120, 122–124
 differentiation antigens, 52:109, 110,
 112, 113
 expression on activated cells, 52:129–
 131
 Burkitt's lymphoma and, 55:224, 225,
 229, 230, 235, 237
 chromosome abnormalities and, 52:35, 37
 endogenous growth inhibitors and, 57:414,
 435, 440, 442
 Epstein–Barr virus proteins and genome,
 50:103
 transformed cells, 50:105, 113, 114,
 119, 121–125, 127, 129, 137
 virus-produced cells, 50:140–142, 145,
 147, 148

- fibroblast growth factors and, 59:125
 gastrointestinal diseases and, 50:19
 gene rearrangements and
 B-cell antigen receptor, 52:46–48
 T-cell antigen receptor, 52:49–52, 54
 genomic instability and, 60:129
 glutathione transferase and, 52:225
 glycosylation in tumors and, 52:262, 291, 292, 317
 hepatitis B viruses and, 59:204, 210
 genomes, 59:191, 193
 oncogenesis of viral proteins, 59:196–198
 immunosuppression and, 60:252, 254
jun oncogene and, 55:6, 7
 lysophosphatidic acid and, 57:92
 metastatic cancer cells and, 55:115, 122
 multidrug resistance and, 52:175, 184
 multidrug resistance gene and, 60:162
myc family oncogenes and, 57:8
 partner, 66:229–231
 plasminogen activation and, 57:285, 288
 signal transduction and, 55:277
 Src family of tyrosine protein kinases and, 57:127–128
 stroma and, 50:168, 171
 transforming growth factor- α and, 58:27–30, 37, 48
 Wilms' tumor and, 59:54–55, 58
- Polyposis
 chemical carcinogenesis and, 50:50
 colorectal, 62:70–72
 familial adenomatous, *see* Familial adenomatous polyposis
 gastrointestinal diseases and, 50:5, 12
- Polyposis coli
 stroma and, 50:178
 tumor clonality and, 50:225
 Wilms' tumor and, 59:52–53
- Polyps
 chemical carcinogenesis and, 50:29
 gastrointestinal diseases and, 50:6, 7
 mutations and, 71:111
- Polypurine track, mouse retrotransposons and, 56:221–223
- Polysomy, in renal cell tumors, 62:106–107
- Population control, social control hypothesis, 71:133–134
- Population genetics
 importance of randomness and
 Mendelism, during 1930s, 65:19
 origins, 65:6
- POR1 protein, effect on Rac1 activity, 72:89
- Positive regulatory element, MHC Class I expression and, 60:212
- Postmenopausal patient, DHEA and, 51:394
- Posttranscriptional processes, *myc* family oncogenes and, 57:17, 20–21
- Posttranscriptional regulation, MHC Class I expression and, 60:196, 198–199
- Posttranslational modifications, *myc* family oncogenes and, 57:6
- Posttranslational regulation, multidrug resistance gene and, 60:169, 175–176
- Posttransplantation lymphoproliferative disorders, Epstein–Barr virus, 69:218, 225
- Posttransplant lymphoproliferative disease, 57:352
- Posttransplant lymphoproliferative syndrome, 57:352
- Potential lymphoma cells, in AKR mouse, *see* Lymphomagenesis, in AKR mouse
- Pott, Percival, writings on carcinogenicity of coal and soot, 65:24–25
- Poxviruses
 effect on MHC expression
 cellular immune response, 63:149–151
 characteristics, 63:145, 147–148
 MHC regulation
 mechanism, 63:153–155
 MHC-I, 63:151–152
 MHC-II, 63:152–153
 Orf-VEGFs in, 67:296
- pp60^{c-src}
 association with receptor tyrosine kinase, 64:116
 elevated activity in colon carcinoma, 64:115
 oncoprotein kinases and, 57:188–197, 213
 role in PymfT-mediated tumorigenesis, 64:117–119
 Src family of tyrosine protein kinases and, 57:116–117, 122
- pp60^{v-src}
 with intrinsic tyrosine kinase activity, 64:112
 transforming ability, 64:114
- Ppa1, mitosis start control, 69:43
- Ppa2, mitosis start control, 69:43
- PRAD1, cyclin D1 as, 66:196–197

- PRAD1* oncogene, overexpression in cancer, 71:196
- pRB
 independent activities of E7, 64:11
 interactions with E7, 64:7
 consequences, 64:9–11
 normal functions, 64:7–8
- pRb, interaction
 ara-C, 72:215
 transcription factors, 72:110
- Pre-B cells
bcr/abl gene in leukemia and, 57:160
BCR gene in leukemia and, 57:231
myc family oncogenes and, 57:29–32
 Src family of tyrosine protein kinases and, 57:118
- Precursor cells, cancer, modulation, 70:22–23
- Predisposition, cancer
 epigenetic allele inactivation and, 54:51–56
 genetic, to breast cancer, 61:46–47
 genetics and, 54:29–36
 inherited, to lung tumorigenesis in mice, 67:84–95
 to retinoblastoma, molecular genetics of, 54:31–36
- Pregnancy
 α -fetoprotein and, 56:255, 286
 binding, 56:270, 271, 279
 immunoregulation, 56:282, 284, 285
 interaction with lectins, 56:267, 268
 chemical carcinogenesis and, 50:28, 59
 cytotoxic T lymphocytes and, 58:163
 mouse retrotransposons and, 56:241
 newborn macrosomy and, 50:233, 234
 case histories, 50:239
 definition, 50:237
 epidemiology, 50:263–266
 factors, 50:257, 258
 prophylaxis, 50:270, 271
 risk factors, 50:268
 transplacental carcinogenesis, 50:255
- Preinsertion sequence, p7, 66:326–328
- Preleukemia, 71:148–149, 150
bcr/abl gene and, 57:153
 Src family of tyrosine protein kinases and, 57:138
- Preleukemic cells
 clonal nature and IL-4 dependency, 66:302–305
 cultures, 66:301–302
 RadLV-induced, 66:299–300
- Premalignancy
 characterization, 66:293–294
 preleukemic cells, 66:299
- Premenopausal patient, DHEA and, 51:394
- Prenatal testing, ataxia-telangiectasia genes and, 56:99
- Preneoplasia
 glutathione transferase and, *see* Glutathione transferase
 glycosylation in tumors and, 52:293, 297
- Preneoplastic lesions
 esophagus, 71:49
 hepatitis B viruses and, 59:195–196, 199–200
 lung cancer, 71:39–41
- Preproinsulin, adenovirus E1A proteins and, 57:54
- Preventive therapy, preleukemia, 66:293–312
- Primary cutaneous melanoma, biologic forms, studies, 65:122–123
- Primer binding sites, mouse retrotransposons and, 56:220–223, 243
- Priming, oncogenes and, 50:74
- Primitive neuroectodermal tumor
 chromosomal aberrations, 69:86–87
 t(11;22) translocation, 67:40–43
- Primitive peripheral neuroectodermal tumor, chromosomal aberrations, 69:86–87
- Pristane, Burkitt's lymphoma and, 55:156, 214, 217, 218
- Pritikin diet, endocrine effects of, 51:65
- PRK1, *see* Protein kinase N
- PRK2, candidate effector of Rho, 72:91–93
- Probability, in gene amplification, 61:91–93
- Probes, partner genes, 66:225–228
- Procholecystokinin, post-translational processing
 extraintestinal, 63:311–312
 intestinal, 63:309–311
- Procollagenases, stroma and, 50:164
- Procollagens, plasminogen activation and, 57:283, 285, 291–292
- Proenzymes, plasminogen activation and, 57:288–289, 307–309, 313
- Profilin, Ras function and, 62:45–46
- Progastrin, post-translational processing
 antral, 63:304–307
 extraantral, 63:307–309

- Progesterone
 gastrointestinal diseases and, 50:9
 mouse retrotransposons and, 56:240
 multidrug resistance gene and, 60:165, 171
 oncoprotein kinases and, 57:186–187, 212
 c-Mos, 57:208–209
 protooncoprotein tyrosine kinases, 57:
 199, 205
- Progesterone receptor, stimulated
 phosphorylation, 61:165–166
- Prognosis
 and HLA-negative tumors, 67:184
 mutator phenotype role, 72:49–50
- Prognostication
 based on genetic analysis of tumors, 69:65,
 91–93
 plasminogen activation, 69:113
- Prognostic indicators
 SF and tumor angiogenesis, for breast
 carcinoma, 67:267
 value of *p53* expression, 66:117–119
- Prognostic marker, *BCL-6*, 67:136
- Programmed cell death, *see* Apoptosis
- Progression factors, *c-fos* protooncogene and,
 55:41
- Progression in mitogenic response to serum,
 53:4
- Progressive multifocal leukoencephalopathy,
 AIDS and, 51:344
- Prohibitin gene, 61:44–45
- Prohormone processing, plasminogen
 activation and, 57:295
- Prokaryotes
 DNA methylation, 72:144–145
 genomic instability and, 60:129–130
- Prolactin, 69:151
 chemical carcinogenesis and, 50:28
- Proliferating cell nuclear antigen
Gadd45 and, 71:4–5
 p21 and, 71:6
- Proliferation, *see also* Cell Proliferation
 ADF and, 57:382–383
 biological activities, 57:400–401
 identification, 57:389, 391–392
bcr/abl gene in leukemia and, 57:152, 154,
 171–173
BCR gene in leukemia and, 57:228, 240
 Burkitt's lymphoma and
 B cell differentiation, 55:167
 chromosomal translocations, 55:196,
 197, 199, 202, 203
c-myc, 55:157, 186
 deregulation, 55:208, 210, 215, 216
 EBV, 55:227, 233, 234, 237, 238
 genetic abnormalities, 55:220, 221
 mechanism, 55:145, 147, 148
 nonrandom chromosomal
 translocations, 55:156
 phenotype, 55:154
 synthesis, 55:243, 244, 248
 translocation mechanism, 55:176
 central nervous system tumor oncogenesis
 and, 58:123, 126–128, 132, 138
c-fos protooncogene and, 55:37, 38, 41
 chemical carcinogenesis and
 biological concepts, 50:38
 experimental models, 50:27–30
 mechanisms, 50:48, 52, 53
 cytotoxic T lymphocytes and, 58:163
 and differentiation, switch between, 66:
 198–199
 EBV-associated disorders and, 57:331,
 372
 NHL and AIDS, 57:365–366
 organ transplants, 57:346, 351–356,
 359–360, 363
 X-linked lymphoproliferative syndrome,
 57:338, 342–343
 endogenous growth inhibitors and, 57:434,
 440, 442, 446
 colonic epithelial cells, 57:434–435
 epidermal principle, 57:444–445
 hormonal systems, 57:436
 keratinizing cells, 57:424, 429, 431
 kidney cells, 57:435
 liver cells, 57:435
 retinoblastoma gene, 57:439
 epithelial cell, perturbed by HPV types, 64:
 4
 Epstein–Barr virus genes and, 58:3, 19
 Epstein–Barr virus proteins and, 50:149
 diseases, 50:98–100
 transformed cells, 50:119, 135
 gastrointestinal diseases and, 50:1, 2
 antigenic determinants, 50:15–22
 esophagus, 50:2, 3
 large intestine, 50:7–15
 stomach, 50:3–7
 G protein signal transduction and, 58:83–
 89
 growth regulation and, 57:415–419, 423–
 424

- Proliferation (*continued*)
- immunosuppression and, 60:248–249, 252–254, 256–257
 - lysosomes and, 60:274, 278
 - metastatic cancer cells and, 55:113, 117
 - MHC Class I expression and, 60:181–183, 199–200, 203
 - muscle cell regulation and, 58:95–96, 108–111, 113–114
 - myc* family oncogenes and, 57:9, 14–16
 - newborn macrosomy and, 50:232
 - oncogenes and, 50:72, 73, 87–89
 - cellular heterogeneity, 50:89
 - malignant genotype, 50:82, 83, 85
 - malignant phenotype, 50:74, 76, 78
 - oncoprotein kinases and, 57:213
 - plasminogen activation and, 57:276, 291–292, 300
 - polyclonal, 66:304
 - Raf-1 phosphorylation and, 58:69
 - signal transduction and, 55:271
 - stroma and, 50:188
 - alterations, 50:184, 185
 - disorders, 50:180
 - epithelium, 50:168
 - transforming growth factor- α and, 58:27–28, 34, 38–40, 42
 - tumor development, 58:45
 - tumor clonality and, 50:199, 201, 217
 - tumor rejection antigens and, 58:188
- Proliferation potential of hybrids, long-term, 54:68–73
- Proliferative cell nuclear antigen, in DNA synthesis fidelity, 72:43
- Proliferin, 69:144
- Proliferin-related protein, 69:150
- Proline
- Epstein–Barr virus proteins and, 50:114, 127
 - jun* oncogene and, 55:13, 17
- Promoter element, controlled PymT expression, 64:133–144
- Promoter–enhancer elements, adjacent and rearranged, 67:26–27
- Promoter–enhancer regions, *flt* family, 67:308
- Promoter regions
- aging-associated CpG island methylation, 72:178–181
 - mutational changes, 72:181–182
- Promoters
- c-myc* transcription from, 70:98–100
 - DHFR*, 70:122
 - frog virus 3, methylated, 66:334
 - MHC Class I expression and, 60:190
 - modulation by oncogenes, 60:200, 205, 208
 - regulation by oncogenes, 60:209, 215, 219
 - multidrug resistance gene and, 60:171–175
 - tissue- and cell type-specific, 61:78
- Promotion
- chemical carcinogenesis and, 50:26, 59, 60
 - biological concepts, 50:36, 38
 - mechanisms, 50:49–54
 - Epstein–Barr virus proteins and, 50:102, 144
 - hepatocyte phenotypes, 70:31–36
 - stroma and, 50:187
- Promyelocytic leukemia cells, chemical carcinogenesis and, 50:52
- Prophage, Lwoff Nobel lecture, 69:9
- Prostaglandin, α -fetoprotein and, 56:278, 281, 283
- Prostaglandins
- chemical carcinogenesis and, 50:32
 - lysophosphatidic acid and, 57:88, 93, 95–96, 100
- Prostate cancer
- adhesion molecule expression
 - C-CAM, 68:240
 - E-cadherin, 68:238
 - CD44 and, 71:299
 - chromosome 3 losses in, 71:51
 - clinical progression, 68:226–228
 - clonal evolution, 68:229, 231, 244
 - diagnosis, 68:226, 248
 - genetic mutations
 - androgen receptor gene, 68:246–248
 - candidate genes and loci, 68:232–233
 - chromosome 5 losses, 68:238–239
 - chromosome 7 losses, 68:239
 - chromosome 8p losses, 68:235–236
 - chromosome 10 losses, 68:236–237
 - chromosome 13 losses, 68:237
 - chromosome 16 losses, 68:238
 - chromosome 17 losses, 68:237–238
 - chromosome 18 losses, 68:239
 - detection of tumor suppressor gene deletion, 68:232, 234–236
 - DNA amplification, 68:240–241

- genomic instability and DNA repair, 68:242
- hormone-refractory prostate cancer, 68:244–245
- hypermethylation of tumor suppressor genes, 68:240
- metastasis suppressor genes, 68:243
- oncogenes, 68:240–241
- genomic instability and, 60:146–147
- heredity, 68:231–232, 248
- histology of tumor progression, 68:226–228
- hormone dependence, 68:228
- hormone therapy induction of genetic selection, 68:245–246
- incidence, 68:225–226, 228
- intratumor heterogeneity, 68:249
- multistep tumorigenesis, 68:229, 231
- plasminogen activators and, 69:112, 113
- risk factors, 68:226
- telomere shortening, 68:241–242
- tumor grading, 68:228
- tumor invasion, 69:112
- Prostatic cancer**
- androgen administration and, 51:31–32
- animal models for, 51:28–31, 72–73
- AR gene mutations, 72:16
- birth cohorts and, 51:18, 25, 32–38
- endocrine system and, 51:63–64
- environmental factors and
- air pollution, 51:76–77
- diet and nutrition, 51:28, 31–55, 59–66
- alcohol, 51:41–42
- animal models, 51:28
- cadmium, 51:51–55
- caffeine, 51:35–37, 42–43
- carbohydrate intake, 51:40, 44–45, 60–62
- dietary fiber, 51:41, 45
- fat intake, 51:32–34, 37–39, 43–44, 60–66
- foods and foodstuffs, 51:38–41
- protein intake, 51:44, 60–66
- studies, 51:31–38
- trace elements, 51:50–51, 62–63
- vitamins, 51:40–41, 45–50
- general considerations, 51:25, 27–28, 31–32
- ionizing radiation, 51:77–79
- occupational factors, 51:26–27, 51–55, 68–76, 79–82
- sexual factors, 51:55–58, 66–68
- smoking, 51:58
- water hardness, 51:79
- epidemiology and**
- age factor, 51:2, 17–18
- benign prostatic hyperplasia and, 51:19–21
- correlation with other sites and tumors, 51:18–19
- familial aggregation, 51:21–22, 25–26
- fertility, 51:22–23, 28
- geographic variation, 51:3–6, 23–24, 32–33
- latent carcinoma, 51:9–14
- marital status, 51:22–23, 28
- migration studies, 51:6, 25
- prostatitis, 51:21, 68
- racial differences, 51:6–9, 24, 26, 33–34, 89–91
- latent carcinoma, 51:9–14
- socioeconomic status, 51:4–5, 15–16, 27, 89–90
- special populations, 51:14–15, 28
- summary, 51:22–28
- urban-rural differences, 51:16–17, 26–27
- general considerations for, 51:1–3, 87–94
- genetic factors and, 51:21–22, 25–26
- hormonal system and, 51:30–31, 82–86
- latent, 51:9–14, 24–25
- LIT tumors and, 51:9–11, 14, 25, 88–89
- MNU and, 51:30–31
- obesity and, 51:60
- risk factors for, 51:87–88
- testosterone and, 51:31, 37–38, 39
- viral etiology of, 51:67–68
- vitamin A and, 51:34–35, 40–41, 45–49, 61–63
- vitamin C and, 51:33, 45–49
- Prostatic schistosomiasis, prostatic cancer and, 51:68**
- Prostatitis, prostatic cancer and, 51:21, 68**
- Protamine, 69:150**
- Protease nexin, 69:108, 111**
- Protease nexin 1, plasminogen activation and, 57:296, 299–300, 302**
- Proteases**
- α_2 -macroglobulin, 69:109
- B cell-associated surface molecules and, 52:106, 110, 126
- cytotoxic T lymphocytes and, 59:234

Proteases (*continued*)

- Epstein–Barr virus proteins and, 50:112
 - gastrointestinal diseases and, 50:15
 - glycosylation in tumors and, 52:260, 287, 300, 301
 - metastatic cancer cells and, 55:95, 104, 124, 125
 - multidrug resistance and, 52:193
 - oncogenes and, 50:74
 - plasminogen activation and, 57:274, 283, 314
 - directed cell surface, 57:307, 311
 - proteolytic modulation, 57:290, 293–294, 299–300
 - stroma and, 50:161, 162, 164, 169
 - transforming growth factor- α and, 58:30, 32, 45
- Proteasomes
- β -subunits LMP-1 and LMP-7, 67:162
 - ubiquitin-dependent, 66:259
- Protein complexes
- c-Myc association, 70:108
 - MT2, similarity to E2F complexes, 65:222
 - Yi, role in thymidine kinase production, 65:221–222
- Protein intake, prostatic cancer and, 51:44, 60–66
- Protein kinase
- adenovirus E1A proteins and, 57:61, 70
 - bcr/abl* gene in leukemia and, 57:158
 - BCR gene in leukemia and, 57:234–235, 244, 251
 - cAMP-dependent, in Ras-cAMP pathway, 54:105–107
 - chemical carcinogenesis and, 50:52
 - DNA-activated, phosphorylation of p53, 66:79, 168, 171–173
 - Epstein–Barr virus proteins and, 50:104
 - FGF receptor multigene family and, 60:9
 - gene rearrangements and, 52:50
 - lysophosphatidic acid and, 57:90, 93, 95–96
 - multidrug resistance gene and, 60:170, 175–176
 - myc* family oncogenes and, 57:11
 - p40^{M015}, 66:189
 - Raf-1 phosphorylation and, 58:53, 70
 - signal transduction and, 55:272
 - mechanisms, 55:284, 286–292, 297, 298
 - plasma membrane receptor, 55:274–278
- Protein kinase A
- adenovirus E1A proteins and, 57:64
 - fibroblast growth factors and, 59:122
 - G protein signal transduction and, 58:80, 83–84, 87
 - muscle cell regulation and, 58:111
 - oncoprotein kinases and, 57:190–191, 193, 196, 213
- Protein kinase C
- activation, ionizing radiation-related, 61:218–219
 - activation and translocation to membranes, 64:162–165
 - adenovirus E1A proteins and, 57:65
 - B cell-associated surface molecules and, 52:92, 93, 103
 - BCR gene in leukemia and, 57:232
 - B lymphocytes and, 56:315, 318
 - cancer immunotherapy and, 59:291
 - candidate Ras effector, 72:75
 - c-erbA* and, 59:105
 - chemical carcinogenesis and, 50:51, 52, 54, 60
 - down-regulation, 64:165–167
 - fibroblast growth factors and, 59:122
 - glutathione transferase and, 52:242
 - G protein signal transduction and, 58:79–80, 88–89
 - hepatitis B viruses and, 59:198
 - inhibitors, 61:62
 - isoforms
 - in differentiation, 64:176–187
 - in tumorigenesis, 64:187–196
 - isozymes
 - differential expression and distribution, 64:170–171
 - overexpression, 64:194–195
 - structure, 64:160–162
 - jun* oncogene and, 55:1, 7, 22, 23
 - metastatic cancer cells and, 55:123
 - MHC Class I expression and, 60:219, 221–222
 - mouse retrotransposons and, 56:236
 - multidrug resistance and, 52:192
 - muscle cell regulation and, 58:111–112
 - oncoprotein kinases and, 57:190–191, 193, 196, 204
 - Raf-1 phosphorylation and, 58:56, 60, 62, 64
 - role
 - ara-C-induced apoptosis, 72:224
 - ara-C phosphorylation, 72:208

- in insulin signaling, 64:168–169
- in radiation-resistant phenotype, 61:211–212
- Src family of tyrosine protein kinases and, 57:136
- stroma and, 50:170
- substrates, 64:171–175
- tautomycin effects on activation, 61:181–182
- T-cell receptors and, 56:51
- transforming growth factor- α and, 58:32, 40
- tumor promoters and, 51:164–165
- Protein kinase C δ , interaction with ara-C, 72:218
- Protein kinase C pathway, schematic, 61:155
- Protein kinase N, candidate Rho effector, 72:91–93
- Protein kinases
 - apparent activation by okadaic acid class compounds, 61:161–163, 181–182
 - mitogen-activated
 - humoral immune response and, 62:247
 - Ras function and, 62:36–41, 46–48, 50
 - protein kinase C
 - humoral immune response and, 62:247, 254–255
 - Ras function and, 62:40, 50
 - Ras function and, 62:25
 - reverse transformation and, 62:134, 140–142, 144, 146
 - RSKs, Ras function and, 62:37–38
- Protein phosphatase
 - type 1, in dephosphorylation of RB, 64:34–36
 - type 1- α 2, RB-binding, 64:64
- Protein phosphatase 1, inhibition by okadaic acid class compounds, 61:146–150
- Protein phosphatase 2A, inhibition by okadaic acid class compounds, 61:146–150
- Protein phosphatases in Ras-cAMP pathway, 54:107–108
- Proteins, *see also specific protein*
 - 14-3-3, 72:64
 - acute-phase, immunosuppression and, 60:257
 - adenoviral, *see Adenovirus proteins*
 - ADF and, 57:382, 385, 403–406
 - analyses, 57:393–394, 396
 - biological activities, 57:398, 400
 - ALL-1, chimeric, 66:224–229
 - APC gene in human cancers and, 62:67, 71–72, 82–83
 - ataxia-telangiectasia genes and, 56:82, 87, 88
 - basic helix-loop-helix, 67:26–33
 - B cell-associated surface molecules and, 52:89, 135
 - biochemically defined molecules, 52:122, 124
 - CD19, 52:99, 101
 - CD20, 52:96–99
 - CD21, 52:103
 - CD22, 52:105, 106
 - CD23, 52:108, 110, 112
 - CDw40, 52:113
 - expression on activated cells, 52:129
 - bcr/abl* gene in leukemia and, 57:155, 157
 - abl* in malignancy, 57:166–169
 - biological activity, 57:171–173
 - c-abl* activation, 57:160–161
 - c-Abl protein, 57:157–160
 - BCR gene in leukemia and, 57:228–229, 231, 252–253
 - expression, 57:241–243
 - hematopoietic cells, 57:243–252
 - organization, 57:233–234
- B lymphocytes and, 56:321, 324, 325
- breast cancer, *p53* expression in, 59:69–76, 80, 82
- Burkitt's lymphoma and
 - chromosomal translocations, 55:196, 197, 200–204, 208
 - c-myc*, 55:157–164
 - c-myc* expression, 55:186, 188, 190, 191
 - c-myc* structural changes, 55:178, 179, 184
 - deregulation, 55:213, 214
 - EBV, 55:228, 230–235, 237, 241, 242
 - genetic abnormalities, 55:219–222
 - nonrandom chromosomal translocations, 55:154, 155
 - phenotype, 55:151
 - synthesis, 55:243, 247, 249, 250
- cancer immunotherapy and, 59:283, 288, 290
- in carbon metabolism as target of cAMP-dependent protein kinase, 54:112–118

Proteins (*continued*)

- CBF β , fusion with MYH11, 67:39
 cdc25, 66:190–191
 cellular
 association with p53, 66:84–85
 p53-associated, 66:162–166
 central nervous system tumor oncogenesis
 and, 58:127, 138
c-erbA and, 59:92, 106–108
 function, 59:97–102
 gene expression, 59:104–105
 multiple loci, 59:94–95
 mutations, 59:102–104
 structure, 59:96–97
 chemical carcinogenesis and
 biomonitoring, 50:54–57
 mechanisms, 50:40, 45, 46, 51
 chromosome abnormalities and, 52:21, 32,
 35–37
 chromosomes and, 62:13
c-myc regulation and, 56:2, 4–7
 abnormal regulation, 56:25, 30–32, 39,
 40
 expression, 56:9, 10, 15–18, 24, 25
 cyclase-associated, Ras function and, 62:45
 cytoskeletal, PKC substrates, 64:173
 cytotoxic T lymphocytes and, 58:144–147,
 150–151, 157; 59:228, 240–241
 antigen processing, 59:233–234
 function, 59:237, 239
 influenza matrix peptides, 59:232–233
 D-factor, 66:7–9
 differentiation-inducing, 66:14
 dnaK
 hsc70 homolog, 66:92
 interaction with p53, 66:104, 168–169
 E2A–HLF, 67:34–36, 48
 EBV-associated disorders and, 57:331, 335
 endogenous growth inhibitors and, 57:437–
 438, 440
 Epstein–Barr virus genes and, 58:2, 4–10,
 15–16, 18–20
 exogenous viral, entry into MHC
 pathways, 63:132, 135
 FGF receptor multigene family and, 60:23–
 27
 characterization, 60:8–15
 early studies, 60:6
 mitogens, 60:3, 5
 multiple forms, 60:15, 18–20, 22–23
 signal transduction, 60:31–33
 fibroblast growth factors and, 59:115, 117,
 155
 biological function, 59:143
 gene expression, 59:131–132
 oncogenic potential, 59:146–149
 receptors, 59:132–134, 136–137
 structure, 59:117, 119–127
 tumors, 59:151–154
 G, *see* G proteins
 gastrointestinal diseases and, 50:5, 8, 14,
 18, 19
 gene rearrangements and, 52:50, 51, 55
 genome exposure and, 62:140–142
 genomic instability and, 60:125, 130, 134–
 136, 140
 glutathione transferase and, 52:242
 molecular forms, 52:212–214, 216
 P-glycoprotein, 52:211, 231, 236
 glycosylation in tumors and
 carbohydrate antigens, 52:262, 290,
 291, 300, 301
 diagnostic applications, 52:307, 308
 G proteins
 ERK network regulation, 63:105–106
 microtubule-associated protein kinase
 homology, 63:98
 Ras function and, 62:50
 in growth control as target of cAMP-
 dependent protein kinase, 54:120–
 122
 GTPase-activating, *see* GTPase-activating
 proteins
 heat shock, *see* Heat shock proteins
 hepatitis B viruses and, 59:168–169, 184,
 202
 genomes, 59:186, 189, 191–195
 oncogenesis of viral proteins, 59:195–
 199
Herpesvirus saimiri and, 56:347, 349, 351
 high mobility group, 66:222
 HIV and, 51:325
 humoral immune response and, 62:241,
 245
 B cell activation, 62:247–248, 250–255
 I κ B, specificity of inhibition, 66:270–272
 I κ B family, 66:265–272
 immunosuppression and, 60:248, 251–
 253, 257–258
 inhibitor, *see* CDI
 injurin, 67:271
 intracellular signaling

Proteins (*continued*)

- with SH2, 64:92–94
- and tyrosine kinases, 64:87–89
- jun* oncogene and, 55:1–3
 - dimerization, 55:14–17
 - DNA binding, 55:4–6
 - family of related genes, 55:9
 - hierarchical order of functions, 55:28, 29
 - leucine zipper, 55:17, 19–21
 - oncogenicity, 55:25–28
 - regulation, 55:22, 24, 25
 - signals, 55:12, 30, 31
 - transcription factor AP-1, 55:7, 8
- KSS1, microtubule-associated protein
 - kinase homology, 63:97
- latent membrane, Epstein–Barr virus and
 - biology, 62:182–184
 - Hodgkin's disease, 62:217–226, 228–231
 - marker detection, 62:185
 - peripheral T cell lymphomas, 62:202–203, 205, 207
 - T-cell lymphoproliferation, 62:188, 199–200, 211
- Louvain rat immunocytomas and, 50:288, 291, 294, 297
- lysophosphatidic acid and, 57:92–94, 96, 100–101
- lysosomes and, 60:269, 277, 281
- Max*, complex with *c-MYC*, 67:136
- MAX* and *MAD*, 67:30–31
- mdm2*, *p53* binding, 66:113–114, 126
- melanosomal, immunogenicity, 70:163–165
- metastatic cancer cells and, 55:96, 116, 117
- MHC Class I expression and, 60:181–183
 - cancer, 60:184–188, 190, 194
 - downmodulation, 60:227–228, 230
 - modulation by oncogenes, 60:196, 201–206
 - regulation by oncogenes, 60:210–215
 - regulation in tumor cells, 60:218–220, 222
- MHC regulation by
 - nucleocapsid, 63:178
 - polymerase/termini, 63:177–178
 - X protein, 63:178–179
- Mos*, MEK activation, 63:104
- mouse retrotransposons and, 56:217, 224, 227
 - expression, 56:231
 - LTRs, 56:236, 237, 239, 241
- multidrug resistance and, 52:166
 - alterations, 52:172, 174
 - amplified genes, 52:176
 - coamplified genes, 52:192, 193
 - P-glycoprotein, 52:175, 180, 181, 183–185, 187–190
- multidrug resistance gene and, 60:160, 162, 165, 170, 174
- muscle cell regulation and, 58:96, 98–99, 101–106, 108–114
- myc* family oncogenes and
 - features, 57:5–6
 - future perspectives, 57:34–37
 - gene expression, 57:18, 20
 - oncogenic activities, 57:25–26
 - structure, 57:6–13
- newborn macrosomy and, 50:233
- noggin, 66:43
- oncogenes and, 50:81, 86, 87
- p53Δ*, 66:263
- papillomaviruses and, 56:134
 - bovine, 56:135–137, 139–142
 - human, 56:144–147, 150, 151, 153–155
- peptide-binding heat shock proteins, *see* Heat shock proteins, peptide-binding
- PKC-associated, identification, 64:175–176
- plasminogen activation and, 57:273, 313
 - adhesive interactions, 57:275, 277–278, 280–283
 - directed cell surface, 57:302, 309–312
 - proteolytic modulation, 57:287, 293, 297–298
- polyoma virus TSTA and, 55:62–64, 72, 73, 75
- pRB, 67:15
- proliferation-related, 53:8–9
- protein tyrosine kinase GFRs and, 60:43, 66
 - development, 60:52–53, 57–60
 - structure, 60:45–47
 - tumorigenesis, 60:61–65
- Rac, 62:33, 35–36, 41–46, 50
- Raf
 - function, 62:39–41
 - in MAP kinase cascade regulation, 63:106–107
- Ras

Proteins (*continued*)

- ERK network regulation, 63:105–106
- in MAP kinase cascade regulation, 63:106–107
- MEK activation, 63:103–104
- ras*, 51:149
- RBTN1 and RBTN2, 67:31–32
- renal cell tumors, molecular cytogenetics, 62:94, 117
- Ret, tyrosine kinase activity, 70:200–202
- reverse transformation and, 62:127
- differentiation induction in malignant cells, 62:133–135
- DNase I sensitivity, 62:137–139
- model, 62:143–144
- Rho, 62:33, 35–36, 41–46, 50
- RPA, inhibition by p53, 66:89, 165
- signal transduction and, 55:271, 272
- accumulation of proteins, 55:281–284
- mechanisms, 55:284, 286, 289–296
- plasma membrane receptor, 55:274, 276, 278
- soft tissue tumors and, 60:77
- chromosomal abnormalities, 60:95, 99
- susceptibility, 60:84–85
- tumor suppressor genes, 60:101–103
- spk1, microtubule-associated protein kinase homology, 63:97–98
- Src family of tyrosine protein kinases and, 57:104, 108, 110
- patterns of expression, 57:112, 114–117, 119
- T-cell activation, 57:120, 122, 124–125, 127, 130–131
- T-cell proliferation, 57:133–139
- STAT, and cytokine signaling, 64:96–97
- stroma and, 50:187
- epithelium, 50:162–164, 170
- glycoproteins, 50:170, 171
- surfactant, selective expression in lung cells, 67:92
- tat, HIV-associated, 66:238–240, 243
- TATA-binding
 - c-Myc* complex, 68:129
 - and p53, 66:158–159, 163–164
 - TBP-associated factors, and p53 binding, 66:96
 - and wild-type p53, 66:96–98
- T-cell receptors and, 56:53, 54, 57
- antigens, 56:51, 58
- leukocyte integrin family, 56:65, 66
- LFA-3, 56:59, 60, 62
- lymphocyte homing receptors, 56:68–70
- VLA family, 56:67
- transforming growth factor- α and, 58:27–29, 37, 39–41
- tumor rejection antigens and, 58:179–180, 183, 193, 195, 199
- tumor suppressor Rb, 66:197–198
- Wilms' tumor and, 59:55–56, 58
- in yeast mating pathway, microtubule-associated protein kinase homology, 63:97–99
- ZEBRA, 67:203, 225
- Zilber and, 59:28
- zinc-finger, 66:257, 264–265
 - evolutionarily well-conserved, encoding of, by *Evi-1*, 54:149–151
 - implicated in neoplastic disease, 54:154
 - relationship of *Evi-1*, to, 54:151–153
- Protein synthesis, and disease course alteration, 67:51
- Protein-tyrosine kinase
 - Raf-1 phosphorylation and, 58:54, 56, 58–59, 66–67
 - soft tissue tumors and, 60:107
- Proteoglycan core proteins, 71:245
- Proteoglycans
 - plasminogen activation and, 57:275, 278, 282–283, 294
 - stroma and
 - basement membranes, 50:173, 175
 - epithelium, 50:160, 165, 168, 169
- Proteolysis
 - BCR* gene in leukemia and, 57:242, 247
 - B lymphocytes and, 56:318, 323
 - breast cancer, p53 expression in, 59:74
 - endogenous growth inhibitors and, 57:440
 - Epstein-Barr virus proteins and, 50:112
 - fibroblast growth factors and, 59:119, 136, 139
 - immunosuppression and, 60:258
 - lysosomes and, 60:275, 277
 - metastatic cancer cells and, 55:88
 - oncoprotein kinases and, 57:205, 210
 - plasminogen activation and, 57:274–275, 313–314
 - adhesive interactions, 57:282–284
 - directed cell surface, 57:301–303, 308, 311
 - inhibitors, 57:296–300
 - modulation, 57:284–295
 - regulation of cyclins, 66:183–187

- signal transduction and, 55:292
stroma and, 50:161, 164
- Proteolytic cleavage
in membrane localization of yeast Ras proteins, 54:99
transforming growth factor- α and, 58:30–32
- Proteus syndrome, clinical profile, 70:58–59
Proteus vulgaris, Zilber and, 59:3–4
- α -Prothymosin
c-*myc* targeting of gene, 68:132–134
interaction with c-Myc, 70:122
- Protooncogenes, *see also* Oncogenes
activation, 68:110
activation of oncogenes using, 65:37
chemical carcinogenesis and, 50:43, 53
chromosome abnormalities and, 52:21, 22, 34, 35
chromosomes and, 62:12
classes, 68:110
cytotoxic T lymphocytes and, 58:157, 161
virus-activated transcription, 67:10–12
- Protooncoprotein tyrosine kinases
growth factor receptors, 57:199–200
M phase, 57:200–207
p150*supc-abl*, 57:198–199
pp60*supc-src*, 57:188–197
Src family, 57:197–198
- Protozoan infection, AIDS and, 51:337, 338
- Pro-u-PA, plasminogen activation and, 57:305–308, 313–314
- Proviral insertion, *myc* family oncogenes and, 57:24, 27–28, 34
- Proviruslike elements, *see* Mouse retrotransposons
- Pseudogenes, *myc* family oncogenes and, 57:13
- Pseudomonas* toxin-mAb conjugates, 61:70
- Pseudosarcoma, stroma and, 50:165, 166
- PSK, Raf-1 phosphorylation and, 58:62–63
- Psoriasis
neovascularization in, 67:261
transforming growth factor- α and, 58:39
- PTC, NBCCS candidate gene, 70:54–55
- PTC-*ret* constructs, 70:192, 203
- PTPRG gene, 71:72–73
- puc1*⁺ gene, cell cycle start control, 69:22
- Pulmonary adenocarcinoma, plasminogen activators and, 69:112
- Pulmonary hamartoma, chromosomal aberrations, 69:84, 88
- Pulsed field gel electrophoresis, ataxia-telangiectasia genes and, 56:98
- Purification, Epstein-Barr virus proteins and, 50:104, 107, 109, 112
- Purkinje cells IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
- Pyloroplasty, gastrointestinal diseases and, 50:4
- PymT
biochemical properties, 64:127–130
expression *in vivo*, 64:133–148
mediated mammary tumorigenesis, 64:117–119
oncogenic action *in vivo*, 64:133
in transformation initiation, 64:127
transformed endothelial cells, 64:149–153
- pyp3*⁺ gene, mitotic start control, 69:41, 45
- Pyrimidines
IAP and, 51:226
retroviruses and, 51:310
- ## Q
- Q10, MHC Class I expression and, 60:214–217
- Qa-Tla genes, MHC Class I expression and, 60:185–186
- Quercetin, tumorigenic activity of, 53:257–258
- ## R
- R7 cell, protein tyrosine kinase GFRs and, 60:57–60
- R8 cell, protein tyrosine kinase GFRs and, 60:60
- Rabbit, *Herpesvirus saimiri* and, 56:337, 338, 350
- Rac, candidate effectors, 72:86–91
- Racial differences, prostatic cancer and, 51:6–9, 24, 26, 33–34, 83–84, 89–91
- rad1*⁺ gene, mitotic start control, 69:42, 45
- rad3*⁺ gene, mitotic start control, 69:42, 45
- rad3* mutants, 71:13–14
- Rad3 protein, 71:13
- RAD9 control system, 61:224
- rad9*⁺ gene, mitotic start control, 69:42
- rad24*⁺ gene, 69:49
- Rad24 protein, 69:49
- rad26*⁺ gene, mitotic start control, 69:42
- Rad53 protein, 71:14
- Radial growth phase, metastatic cancer cells and, 55:106–111, 116

Radiation

- ataxia-telangiectasia genes and, 56:78, 98, 99
 - linkage, 56:95
 - phenotype, 56:79, 81, 83
 - cancer immunotherapy and, 59:249, 278, 291
 - cancer incidence data and, 56:178
 - carcinogenicity studies, 65:23–25
 - defective *p53* response in AT, 66:148
 - DNA damage caused by, 61:220–225
 - DNA repair cascade, 61:220–225
 - fractionated, lymphomagenic effect, 63:258–259
 - gamma
 - cell cycling, 69:38–40
 - dose rate, and oncogene effects, 61:208
 - effects on DNA *de novo* synthesis in Li-Fraumeni syndrome, 61:206–207
 - G₁ or G₂ arrest role in radiation recovery, 61:223–224
 - induction of PKC-mediated signaling, 61:218–219
 - radioresistance after exposure to, 61:214
 - resistance conferred by *v-mos*, *c-col*, and *N-ras* genes, 61:209
 - role of redox-related biochemical control mechanisms, 61:222
 - genomic instability and, 60:131, 145
 - induction of apoptosis, 66:16
 - induction of growth factors, cytokines, and cell cycle control genes, 61:219–220
 - MHC Class I expression and, 60:187–188
 - molecular targets of, 61:218–220
 - prostatic cancer and, 51:76–79
 - resistance, correlation with *raf-1* gene activation, 61:203
 - total body, 66:45–46
 - tumor clonality and, 50:198, 208
 - ultraviolet, and increase in *p53* protein, 66:147–148
- Radiation leukemia virus
- induced leukemogenesis, 66:295–297
 - active intervention, 66:305–308
 - induced preleukemic cells, 66:299–300
 - transformation mechanism, 66:297–299
 - variant A-RadLV, lymphomagenesis in AKR mouse by, 63:257–258
- Radiation resistance
- after exposure to gamma-rays, 61:214
 - antisense RNA approach to, 61:225–226

- combined roles for *raf-1* and *myc* genes, 61:213
 - defined, 61:197
 - down-regulation with antisense oncogene (*raf-1*), 61:225
 - of human squamous cell carcinomas, 61:200–203
 - modulation, 61:225–226
 - mutant *p53* alleles and, 61:224
 - raf-1* gene function, 61:203
 - Raf-1 protein kinase role, 61:212
 - raf* gene function, in Li-Fraumeni syndrome, 61:203–207
 - ras* gene role, 61:211
 - SHOK cells, *N-ras*-related, 61:211
 - synergistic effects of *myc* and *raf* genes, 61:213
 - topoisomerases I and II role, 61:222–223
 - transformation and, 61:215–216
 - v-src*-related, 61:209
 - in murine hematopoietic cells, 61:210–211
- Radiation-resistant phenotype
- EJ-*ras* and *c-myc/v-myc* synergistic effects, 61:208–209
 - in Li-Fraumeni families, 61:205
 - multiple genetic factors involved in, 61:217–218
 - multiple signals for, 61:214
 - transfection of human *N-ras* oncogene into NIH/3T3 cells, 61:208
- Radiation response
- clonal nature of, 61:199–200
 - fms* oncogene effects, 61:210
 - of human cells, *raf* gene role, 61:209
 - mitogenic signals and, 61:210–215
 - multifactorial nature of, 61:217–218
 - oncogene effects, 61:201–202
 - variation with cell type, 61:215
- Radiation survival
- linear quadratic model, 61:197–198
 - multitarget model, 61:197–198
- Radiation survival curves, relative radioresistance or radiosensitivity, 61:197–198
- Radiation therapy
- lysosomes and, 60:278, 281–283
 - Wilms' tumor and, 59:43, 60
- Radioautographic techniques for investigating lymphopoiesis in bone marrow, 54:237–238

- Radioimmunoassay
 Burkitt's lymphoma and, 55:235
 chemical carcinogenesis and, 50:55
 Epstein-Barr virus proteins and, 50:134
- Radioimmunoelectrophoresis, Epstein-Barr virus proteins and, 50:104
- Radionuclide-mAb conjugates, 61:70-71
- Radioreistance, *see* Radiation resistance
- Radioreistant DNA synthesis, 71:11
 ataxia-telangiectasia genes and, 56:79, 81
- Radiosensitivity
 ataxia-telangiectasia genes and, 56:81, 83, 86, 99
 defined, 61:197
 intrinsic, measurement by mean activation dose, 61:197
 rat kidney epithelial cells, *K-ras*-related, 61:209-210
- Radiosensitization
 antisense RNA approach, 61:225
 diamide-induced, 61:221
 GSH depletion by BSO and, 61:221
 by *raf-1* antisense oligonucleotides, 61:225-226
- Radiotherapy
 cancer immunotherapy and, 59:254-255, 280, 286
 soft tissue tumors and, 60:78
- RadLV, *see* Radiation leukemia virus
- RAD mutants, genomic instability and, 60:132
- Raf
 key effector of Ras, 72:63-65
 pathways independent of, role in Ras function, 72:65-69
 Src family of tyrosine protein kinases and, 57:124
- raf*, MHC Class I expression and, 60:199, 202
- Raf1, activation, 72:63-64
- raf-1* gene
 activation
 and GSH intracellular levels, 61:22
 and Li-Fraumeni radioreistance phenotype, 61:205-206
 and radioreistance in Li-Fraumeni syndrome, 61:203-207
 and resistance to ionizing radiation, 61:203
 antisense oligonucleotides, radiosensitizing effects, 61:225-226
c-raf-1, combined role with *myc* gene for radiation resistance, 61:213
 expression in Beas-2B cells, radiation resistance conferred by, 61:209
 function, link to radiation-resistant phenotype, 61:212
 human sequences in NIH/3T3 transfectants after radiotherapy, 61:200-203
- Raf-1 phosphorylation, 58:70
 activation, 58:54
 modes, 58:56-59
 PTKs, 58:59
 consequences
 activated receptor complexes, 58:66-68
 signaling cascade, 58:68-69
 substrates, 58:69-70
raf oncogene family, 58:53-55
 serine/threonine, 58:62-65
 sites, 58:59-62
 tyrosine, 58:65-66
- Raf-1 protein kinase
 dual role of, 61:216
 role in radiation resistance, 61:212
- raf* gene
 and acquisition of radiation-resistant phenotype, 61:212
 EJ-*ras*, effects on NIH/3T3 radioreistance levels, 61:208
K-ras radiosensitization of rat kidney epithelial cells, 61:209-210
myc family oncogenes and, 57:31
 with *myc* gene, synergistic effects, 61:213
- Raf→MEK→MAPK kinase cascade
 activation by Ras, 72:60-63
 role in drug discovery, 72:97
- Raji cell, Epstein-Barr virus proteins and transformed cells, 50:116
 virus-produced cells, 50:138, 143, 144, 147
- Ral-binding protein, linking Ras to Rho family proteins, 72:96
- RalGDS, candidate Ras effector, 72:72-73
- Ral guanine nucleotide dissociation stimulator, *see* RalGDS
- rap1*, genomic instability and, 60:136
- Rapamycin
 mechanism of action, 71:195
 target of, 71:13
- RAR, HEV assay and, 51:368-369
- RARB gene, 71:66

- Ras-cAMP pathway
 adenylate cyclase in, 54:101–105
 cAMP-dependent protein kinase in, 54:105–107
CAS1 in, 54:110
CDC25 in, 54:108–110
 components of, 54:101–111
 feedback regulation of, 54:118–120
 functions of, 54:128–131
 genes of, 54:84
 growth control and, 54:129–131
IRA1 in, 54:110
 phosphodiesterases in, 54:107
 protein phosphatases in, 54:107–108
SCH9 in, 54:110
YAK1 in, 54:110
 in yeast, 54:82–83
- Ras function, pathways, 62:19–22
- GAPs, 62:29–35
 GRF, 62:33
 models, 62:49–52
- Ras guanine nucleotide exchange factors, 62:20, 23–24, 28–29
 biochemical identification, 62:25–27
 genetic identification, 62:27–28
 in lower eukaryotes, 62:24–25
 reversion of transformed cells, 62:46–49
- SH domain, 62:23, 29–30, 34–35, 51
- signal transduction, 62:35–37
 MAPK pathway, 62:37–41
 Rho/Rac pathway, 62:41–46
- ras* genes
 adenovirus E1A proteins and, 57:74–76
 angiogenesis, 69:147, 148
APC gene in human cancers and, 62:83
 CD44 expression and, 71:275
 c-Ha-*ras* activation by okadaic acid class compounds, 61:152–154
 chronic lymphocytic leukemia, 71:146
 cytotoxic T lymphocytes and, 59:239
 EBV-associated disorders and, 57:336
 EJ-*ras*, synergistic effect with c-*myclv-myc* on radiation-resistant phenotype, 61:208–209, 211
 function, 62:20, 25, 46–49
 signal transduction pathways, 62:39, 41, 45
- G protein signal transduction and, 58:76, 79
- GTB-binding proteins related to, 54:79–81
- Ha-*ras*
 activated, targeting, 64:251–258
 adenovirus E1A proteins and, 57:73–74
 cooperation with
 fos, 64:274–278
 HPV16 E6, 64:273
 p53, 64:282–286
 TGF α , 64:280–281
 in mouse skin tumor, 64:252
myc family oncogenes and, 57:28
 in skin carcinogenesis, 64:257
- H-*ras*
 angiogenesis, 69:147, 148
myc family oncogenes and, 57:29
- human papillomavirus and, 56:148, 153
- interaction with ara-C, 72:219–220
- in metastasis, 54:190–191
- MHC class I expression and, 60:187, 198–203, 218
- MHC expression and, 53:203–204
- mouse retrotransposons and, 56:232, 233
- muscle cell regulation and, 58:100, 112, 114
- mutations
 in breast cancer, 61:39
 in colorectal cancer, 61:4
myc family oncogenes and, 57:29, 31
- N-*ras*
 effects on NIH/3T3 radioresistance levels, 61:208
 effects on SHOK cell radioresistance, 61:211
 resistance to gamma-rays conferred by, 61:209
 and oncogenic transformation, 61:216
- p53* and human malignancies and, 57:263, 265
- peptide-binding heat shock proteins and, 62:156, 169
- plasminogen activation and, 57:283, 299
- preleukemia, 71:149
- Raf-1 phosphorylation and, 58:68
- RAS1
 expression of, 54:89
 functions of, 54:87–88
- RAS2
 expression of, 54:89
 functions of, 54:87–88
- reverse transformation and, 62:141
- role in radiation resistance, 61:211, 216
- role in radiation response of human cells, 61:209

- in *Saccharomyces cerevisiae*, 54:79–131
 signals triggering, 54:122–128
 soft tissue tumors and, 60:77, 84, 87–88, 100, 109
 synergistic relationship with PKC, 64:197
 transformed cells, role of PKC, 64:190–191
 transforming growth factor- α and, 58:43–45
 v-H-*ras*, effects on NIH/3T3
 radioresistance levels, 61:208
 v-K-*ras*, effects on NIH/3T3
 radioresistance levels, 61:208
 Ras-GTP recognition element, 72:75–76
 Ras proteins
 activation
 GTPase cascade, role of Rho family proteins, 72:78–85
 Raf-independent pathways, 72:65–69
 Raf MEK MAPK kinase cascade, 72:60–63
 activation, and SH2/SH3 adaptor proteins, 64:100–102
 candidate effectors, 72:70–75
 and c-Myc function, 70:119
 cytokine receptor activation of signaling pathway, 68:37–39, 51
 interactions with effectors, structural requirements, 72:75–77
 linear signaling pathway, 72:58–60
 link to Rho family proteins, 72:95–96
 lysophosphatidic acid and, 57:96, 98
 multidrug resistance gene and, 60:174
 oncoprotein kinases and, 57:205–206, 215
 Raf as key effector, 72:63–65
 regulatory cycle, 64:100
 signal transduction, 72:96–97
 Rat
 cornea, angiogenesis assay, 67:263–266
 DNA, IAP gene family and, 51:195–196, 257–258
 lymphocyte homing receptors, 51:372–373
 Rate-limiting events, in carcinogenesis, 67:16–17
 Rat embryo cells, radioresistance, by
 contransfection of EJ-*ras* and c-*myclv-myc*, 61:211
 synergistic effects of *myc* and *raf* genes, 61:213
 Rat growth hormone, c-*erbA* and, 59:99
 Rat kidney epithelial cells, K-*ras*-induced
 radiosensitization, 61:209–210
 RB
 binding proteins, 64:54–65
 dephosphorylation by phosphatase, 64:34–36
 growth-inhibitory activity, 64:30–32
 mitogen-activated phosphorylation, 64:36–39
 as molecular matchmaker, 64:67–70
 nuclear tethering, 64:65–66
 phosphorylation
 effects of antimitogens, 64:43–48
 inactivation during differentiation, 64:39–43
 phosphorylation-site-specific regulation, 64:73–75
 protein-binding domains, A/B pocket, 64:48–54
 protein-binding function, inactivation by phosphorylation, 64:70–71
 role in cell cycle checkpoint control, 72:6–7
 role in transcription, 64:66–67
 as substrate of cyclin-dependent protein kinases, 64:33–34
 viral oncoprotein-mediated E2F release, 64:57–58
 RB1, 71:28, 30, 324
 angiogenesis, 69:154
 characterization, 61:118–120
 deletion effects on cell cycle, 68:95
 discovery of, 67:12–14
 endogenous growth inhibitors and, 57:436–439
 expression, 61:116, 122–123
 germline mutations, 61:116–117
 homologous sequences among vertebrates, 61:118
 inactivation
 and induction of pituitary tumor, 64:27
 in RB, 64:26–27
 role in leukemogenesis, 64:28–29
 tissue-specific susceptibility to, 61:135–136
 mRNA transcripts tissue distribution, 61:121–122
 mutation and prostate cancer, 68:237
 mutation at, in retinoblastoma and osteosarcoma, 54:34
 osteosarcomas, 69:83

- RB1* (*continued*)
 p110^{RB1}
 characterization, 61:120
 viral oncoprotein binding, 61:120–121
 reconstituted, effect on cell growth, 64:30
 reconstituted cell lines, summary, 61:133
 soft tissue tumors and, 60:85, 98, 100, 102–103, 105
 suppression of tumorigenicity, 61:133–135
 Wilms' tumor and, 59:44
- RbAp48, RB-binding protein, 64:63–64
- Rb gene, 61:43–44
- RB gene transcript, in lung adenocarcinoma, 67:92–95
- RBP60, interaction with RB, 64:64–65
- RCCBP, regulation by p110^{RB1}, 61:128
- RCC, *see* Renal cell carcinoma
- Reactive oxygen intermediates, ara-C-generated, 72:207–208
- Receptor tyrosine kinases, 60:43–45
 activation of intracellular biochemical pathways, 64:88
 association with
 pp60^{supc-src}, 64:116
 SH2-containing signaling proteins, 64:93–94
 development, 60:49–50
 mutants of *Drosophila melanogaster*, 60:56–60
 mutants of mouse, 60:50–56
dominant white (W) spotting, 60:50, 52–53, 55–56
 genetics, 60:65–66
 isolation and structure, 67:296–304
 Neu, complex with pp60^{supc-src}, 64:119
 pYs on, 70:204–207
 role in Ras activation, 72:60–62
 structure, 60:45–49
 tumorigenesis, 60:60–61
 cellular oncogenes, 60:63–65
 retroviral oncogenes, 60:61–62
- Recessive cancer genes, discovery, 67:10–14
- Reciprocal communication, between parenchymal cells and ECs, 67:306–308
- Recombinant ADF, 57:400–401, 406
- Recombinant-DNA technology in investigating lymphopoiesis in bone marrow, 54:2389
- Recombinase, ataxia-telangiectasia genes and, 56:82, 83, 85
- Recombination
 ataxia-telangiectasia genes and, 56:86–90, 95
bcr/abl gene in leukemia and, 57:160, 166
 B lymphocytes and, 56:316, 323, 324
 breast cancer and, 56:128
c-myc regulation and, 56:28, 39
 EBV, and genotype generation, 67:222–224
 Epstein-Barr virus genes and, 58:5, 10
 FGF receptor multigene family and, 60:3
 genomic instability and, 60:123–125, 127, 146
 mechanisms, 60:134, 137–140, 142
 quantitative considerations, 60:144
 hepatocellular carcinoma and, 59:201–202, 204
Herpesvirus saimiri and, 56:343, 344
 integrative
 in cell-free system, 66:326–328
 mechanism, 66:324–328
 mouse retrotransposons and, 56:216, 217, 227, 245
 LTRs, 56:235, 237
 mouse genome, 56:218, 220, 223
myc family oncogenes and, 57:25, 35
 papillomaviruses and, 56:140, 142, 154
 soft tissue tumors and, 60:103
- Reconstitution, bone marrow, and PymT expression, 64:144–148
- RecQ/Sgs1 helicase, 71:212
- Rectal cancer
 newborn macrosomy and, 50:264
 stroma and, 50:182
- Rectal tumors, *APC* gene in human cancers and, *see* Colorectal tumors
- Redifferentiation, nodule hepatocytes, 70:34
- Reed-Sternberg cells
 EBV-associated disorders and, 57:338, 367, 370–371
 gene rearrangements and, 52:66–68
- Reflex esophagitis, gastrointestinal diseases and, 50:2
- Refractory anemia
 with excess of blasts
 chromosome abnormalities and, 52:13, 14, 16
 in transformation, chromosome abnormalities and, 52:13, 14, 16
 with ringed sideroblasts, chromosome abnormalities and, 52:13, 15

- without excess of blasts, chromosome abnormalities and, 52:13–15
- Regenerative reaction, endogenous growth inhibitors and, 57:442
- Regenerative response, endogenous growth inhibitors and, 57:442
- Regions of minimal deletion, in B-cell NHL, 67:138–139
- Regulatory proteins, negative, Cdk inhibitors as, 72:130–132
- Reinsertion, mouse retrotransposons and, 56:226, 227
- rel*, MHC Class I expression and, 60:214
- Related provirus hypothesis, viral oncogene hypothesis and, comparison, 65:171
- Relative adherence ratio, HEV assay and, 51:368–369
- Rel/NF- κ B
 - activity regulation, 66:272–279
 - NF- κ B complex, 66:257–260
 - other Rel/NF- κ B members, 66:262–263
 - regulation of target gene transcription, 66:279–281
 - transformation by Rel/NF- κ B proteins, 66:263–264
 - v-rel* and *c-rel*, 66:260–262
- Remission
 - ALL, 67:2
 - cancer immunotherapy and, 59:269
- Ren-2*, mouse retrotransposons and, 56:226
- Renal carcinoma, oncogene activation and, 51:153
- Renal cell carcinoma
 - 3p13–p4 gene, 71:70
 - 3p21.3 genes, 71:67–68
 - cancer immunotherapy and, 59:247, 293
 - chemoimmunotherapy, 59:277, 279
 - critical factors, 59:250–253
 - current strategies, 59:261, 264, 268–271
 - improvement attempts, 59:284–286
 - CD44 and, 71:298
 - chromosome 3
 - losses in, 71:42–45, 75
 - transfer into cell lines, 71:54–55
 - chromosome abnormalities and, 52:27, 29
 - MHC Class I expression and, 60:205, 224
 - VHL disease and, 71:59–61
- Renal cell tumors
 - molecular cytogenetics, 62:89–90, 107, 118–119
 - chromophobe renal cell carcinoma, 62:117
 - chromosomal aberrations, 62:117–118
 - mitochondrial DNA alterations, 62:118
 - differential genetics, 62:90–92
 - nonpapillary renal cell tumors, 62:91, 105–107, 110, 118
 - familial renal cell carcinoma, 62:96–97
 - mitotic recombination, 62:98–102
 - model of development, 62:102–105
 - somatic mosaicism, 62:102
 - sporadic renal cell carcinoma, 62:91, 93–96
 - von Hippel-Lindau disease, 62:97–98
 - papillary renal cell tumors, 62:91, 105–106, 118
 - adenoma-carcinoma sequence, 62:109–110
 - developmental disturbances, 62:111–114
 - genetic alterations, 62:106–109
 - parenchymal lesions, 62:110–111
 - translocation, 62:114–115
 - Wilms' tumor, 62:111
 - renal oncocytoma, 62:115
 - chromosomal alterations, 62:115–116
 - mitochondrial DNA alterations, 62:116–117
- Renal tumors, MHC Class I expression and, 60:206
- Renaturation, DNA, and strand transfer, 66:160–161
- Renin, mouse retrotransposons and, 56:226
- rep1*⁺ gene
 - cell cycle start control, 69:20
 - DNA synthesis, 69:28
- Rep1 protein, start control of mitotic cycle, 69:26
- rep2*⁺ gene
 - cell cycle start control, 69:20–21
 - DNA synthesis, 69:28
 - start control of mitotic cycle, 69:28
- Rep2 protein, start control of mitotic cycle, 69:28
- Repair processes, invasive delay and, 54:166–167

- Replication
- adenovirus E1A proteins and, 57:47, 54, 78
 - adenovirus proteins and, 52:153, 154
 - ADF and, 57:382, 405
 - bcr/abl* gene in leukemia and, 57:156
 - bovine papillomavirus and, 56:134, 137, 141
 - breast cancer, *p53* expression in, 59:71, 73
 - Burkitt's lymphoma and
 - chromosomal translocations, 55:205
 - c-myc*, 55:161, 162, 179
 - EBV, 55:225–230, 232
 - features, 55:145
 - genetic abnormalities, 55:221
 - cytotoxic T lymphocytes and, 59:228
 - DNA, and *c-Myc*, 70:124–125
 - EBV-associated disorders and, 57:330–333, 345, 368–369
 - endogenous growth inhibitors and, 57:433, 447
 - Epstein–Barr virus genes and, 58:4–5, 9, 17
 - genomic instability and, 60:127–130, 132, 134, 136, 138, 142, 144
 - hepatitis B viruses and, 59:168
 - epidemiology, 59:170, 176
 - genomes, 59:185–192, 194–195
 - oncogenesis of viral proteins, 59:197–198
 - pathogenicity, 59:180–182, 184
 - viral DNA, 59:199, 201
 - Herpesvirus saimiri* and, 56:336, 342–344, 346, 351
 - HPV, 64:3–4
 - jun* oncogene and, 3 polyoma virus TSTA and, 55:62, 64, 66, 73, 78
 - lysophosphatidic acid and, 57:87
 - MHC Class I expression and, 60:199
 - mouse retrotransposons and, 56:242
 - oncoprotein kinases and, 57:196
 - p53* and human malignancies and, 57:260
 - signal transduction and, 55:271, 278, 293
- Replication error positive genes, 71:62
- Replication error positive phenotype, 71:99
- colorectal cancer, 71:100
 - HNPCC, 71:100
 - TG β receptor loss, 71:185
- Replication errors
- leading to microsatellite instability, 67:66
 - multiple, 72:12–13
- Representational difference analysis, 71:33–34
- Repression, and transcriptional activation, 66:93–97
- Repressor, transcriptional, *c-Myc* as, 70:115–116
- Reproduction, plasminogen activation and, 57:294–295
- RER+ phenotype
- associated with DNA–diploid tumors without LOH, 67:66
 - in breast and endometrial cancers, 67:74–77
 - induced mutations, 67:68
- res1*⁺ gene, cell cycle start control, 69:19–20, 25, 26
- Res1 protein
- cell cycle start control, 69:19–20
 - start control of mitotic cycle, 69:28
- res2*⁺ gene, cell cycle start control, 69:20, 25, 26
- res2*⁻ gene
- DNA synthesis, 69:28
 - start control of mitotic cycle, 69:26, 27
- Res2 protein, start control of mitotic cycle, 69:26
- Rescue, differentiating cells, 66:17
- Research, cancer
- basics, 70:22–23
 - carcinogens, 70:41–42
- Resistance
- to inhibiting effects of carcinogens, 70:29–32
 - natural, MHC in, 53:218–220
 - neoplastic cells to ara-C, 72:210–213
- Response elements, hormone and glucocorticoid, 70:75–77
- Restricted early antigen, Burkitt's lymphoma and, 55:223
- Restriction endonuclease
- Epstein–Barr virus proteins and, 50:102
 - recognition sites, in EBV isolation, 67:204–205
- Restriction enzyme fragment length polymorphisms, breast cancer carcinomas, 61:41
- Restriction fragment length polymorphisms association with adenocarcinoma risk, 67:104
- central nervous system tumor oncogenesis and, 58:128–129, 138

- chromosome abnormalities and, 52:31, 32
 EBV genotypes, 67:219–220
 gene rearrangements and, 52:52
 metastatic cancer cells and, 55:97
 renal cell tumors and, 62:91, 115, 117
 nonpapillary renal cell tumors, 62:91, 93, 95, 97–98
 papillary renal cell tumors, 62:106–107
 in retinoblastoma, 54:32–34
 in study of
 EBV transmission, 67:224
 retinoblastoma, 67:14
 tumor clonality and, 50:224
 distinction, 50:202, 203, 205
 human tumors, 50:217
- Restriction point, 71:170
 cell cycle and, 65:219
 role in carcinogenesis, 65:214
- ret*
 expression patterns, 70:207–211
 identification and structure, 70:192–195
 mutations
 in MEN II syndromes, 70:195–207, 214–215
 and tumor formation, 70:211–212
 role in MEN II syndrome, 70:179–215
- RET, protein tyrosine kinase GFRs and, 60:63–64
- Reticulum cell sarcoma, Louvain rat immunocytomas and, 50:282, 294
- Retina, protein tyrosine kinase GFRs and, 60:57
- Retinoblastoma
 adenovirus E1A proteins and, 57:50, 75–78
 age and risk of, 71:230
 age-incidence curve, 72:17
 angiogenesis, 69:155
 APC gene in, 62:69
 breast cancer, *p53* expression in, 59:73, 83
 cancer incidence data and, 56:162, 167
 central nervous system tumor oncogenesis and, 58:128, 133
 characterization of, 60:84–85, 102
 chromosome abnormalities and, 52:31–33
 chromosomes and, 62:12
 cytogenetics of, 54:30–31
 cytotoxic T lymphocytes and, 58:157
 endogenous growth inhibitors and, 57:440
 epigenetic inactivation of alleles in, 54:49–51
 familial, 61:116
 gene regulation mechanisms, 61:121–124
 genetics, 61:116–117
 genomic instability and, 60:127, 146
 G protein signal transduction and, 58:76
 hereditary, 67:7–9, 18
 heritable, 61:116
 human papillomavirus and, 56:154, 155
 incidence in children, time-dependence, 65:34
 loss of *RB1* function, 67:60
 muscle cell regulation and, 58:112
 mutation and, 71:29
myc family oncogenes and, 57:26, 34
 predisposition to, molecular genetics of, 54:31–36
 stroma and, 50:178
 in study of recessive cancer genes, 67:12–14
 tumor cells, chromosomal changes in, 61:117
 tumor clonality and, 50:208, 209, 222, 225
 tumor suppressor gene, 69:149
- Wilms' tumor and, 59:63
 genetic loci, 59:49, 52
 Knudson model, 59:44, 46
WT1 gene, 59:53, 60
- Retinoblastoma gene
 CpG island hypermethylation, 72:154
 loss, 72:7–8
- Retinoblastoma protein, 71:188
 cell cycle regulation, 68:95
 c-Myc functional interaction, 68:127
 cyclin D interactions, 68:95–96
 oncoprotein kinases and, 57:196–197, 214
p53 and human malignancies and, 57:269
p53-mediated growth arrest, 71:5–6
 phosphorylation, 68:95, 164; 71:180
 inhibition by TGF- β , 70:71–72
- Retinoblastoma tumor suppressor protein, *see* RB
- Retinoblasts, susceptibility to *RB1* gene inactivation, 61:135–136
- Retinoic acid
 acute promyelocytic leukemia therapy, 69:120–121
 angiogenesis, 69:160
 bovine papillomavirus and, 56:137
 cancer therapy, 68:213
c-erbA and, 59:93, 108–109

Retinoic acid (*continued*)

- c-myc* regulation and, 56:10, 11, 19
- gastrointestinal diseases and, 50:21, 22
- hepatocellular carcinoma and, 59:204
- myc* family oncogenes and, 57:17
- reverse transformation and, 62:143, 145–146
- signal transduction and, 55:285
- Src family of tyrosine protein kinases and, 57:114
- 13-*cis*-Retinoic acid, clinical trials
 - head and neck cancers, 61:15
 - oral leukoplakia, 61:15
- Retinoic acid receptor β gene, hepatocellular carcinoma and, 59:204
- Retinoic acid receptors, *c-erbA* and, 59:108–109
- Retinoic acid syndrome, 69:121–122, 123
- Retinoids
 - inhibition of neoplastic conditions, 61:5
 - in keratinocyte differentiation, 70:78–81
- Retinoid X receptor, characteristics, 70:75–76
- Retroposons, hepatocellular carcinoma and, 59:206
- Retrotransposons, *see* Mouse retrotransposons
- Retroviral integration in murine myeloid tumors, 54:141–155
- Retroviruses, *see also specific retrovirus*
 - bcr/abl* gene in leukemia and, 57:157–158
 - animal models, 57:173, 175–178
 - biological activity, 57:169, 172–173
 - c-abl* activation, 57:160–162
 - Burkitt's lymphoma and
 - chromosomal translocations, 55:202
 - c-myc*, 55:162, 164, 185, 190
 - deregulation, 55:214, 215
 - EBV, 55:231, 232, 237
 - genetic abnormalities, 55:217–219
 - cancer immunotherapy and, 59:272, 288, 291
 - cell-to-cell transmission, 65:170
 - c-erbA* and, 59:89, 104
 - chemical carcinogenesis and, 50:45, 53
 - chromosome abnormalities and, 52:24, 34
 - chronic, induced tumorigenesis, 66:294–295
 - c-myc* regulation and, 56:26, 27
 - fibroblast growth factors and, 59:145, 151
 - gastrointestinal diseases and, 50:19
 - gene rearrangements and, 52:61
 - for gene therapy, 61:77–78
 - glycosylation in tumors and, 52:264, 267
 - hepatitis B viruses and, 59:187, 189, 193
 - hepatocellular carcinoma and, 59:200–203, 206–208
 - history, 69:12
 - human
 - animal models and, 51:308, 309, 310
 - NOB mice, 51:253
 - ATLL and, 51:313–315
 - ATLV and, 51:313
 - BaEV and, 51:310, 311–313
 - CD4 and, 51:322–323, 345, 350–351
 - cell biology and immunology of, 51:320–321
 - epidemiology of
 - AIDS and Africa, 51:337–339
 - general considerations, 51:335–336
 - heterosexual transmission, 51:336–337
 - HIV, 51:336, 339
 - GALV and, 51:310, 312–313
 - general considerations for, 51:351
 - general properties of, 51:329
 - IL-2 and, 51:314, 320
 - LAV and, 51:317, 319–320
 - LAV-II and, 51:319–320
 - life cycle of, 51:323–324
 - lymphomas and, 51:344
 - oncogenesis and, 51:278
 - SAIDS and, 51:317–320
 - search for, 51:309–311
 - specific isolates of, 51:311–312
 - SSAV and, 51:310, 311–313
 - human papillomavirus and, 56:147
 - human type C, murine leukemia virus and,
 - similarities, 65:192–194
 - immunosuppression and, 60:252–253
 - jun* oncogene and, 55:1, 3, 4, 26, 27, 30
 - lysophosphatidic acid and, 57:87
 - metastatic cancer cells and, 55:97–99
 - MHC Class I expression and, 60:198–199
 - mouse retrotransposons and, 56:215–217, 245
 - expression of neighboring genes, 56:231, 232
 - mouse genome, 56:218, 219, 221, 223
 - multidrug resistance and, 52:197
 - myc* family oncogenes and, 57:22, 31
 - protein tyrosine kinase GFRs and, 60:51, 60–62

- soft tissue tumors and, 60:77
 T-cell receptors and, 56:56
 transformation, 67:3–4
 type C, in feral mice, characteristics, 65:173
- Retrovirus SL3–3, ecotropic, lymphomagenesis in AKR mouse by, 63:256–257
- Reverse genetics
 ataxia-telangiectasia genes and, 56:87
 soft tissue tumors and, 60:108
- Reverse transcriptase
 discovery, 69:12
 IAP and, 51:208–211, 213
 isolation, 70:15
 retroviruses and, 51:309
 AIDS, 51:345–346
- Reverse transcription
 hepatitis B viruses and, 59:185, 187, 194
 mouse retrotransposons and, 56:216, 221, 227, 244
- Reverse transformation, *see* Transformation, reverse
- Reversion, hepatocyte phenotypes, 70:31
- RFLP, *see* Restriction fragment length polymorphisms
- rfp*, protein tyrosine kinase GFRs and, 60:63
- RGC, p53-specific binding motif, 66:154–155, 163
- RGD, plasminogen activations and, 57:281–282
- RGL2/Rlf, candidate Ras effector, 72:72–73
- Rhabdoid tumors, chromosomal aberrations, 69:82
- Rhabdomyomatous variant of Wilms' tumor, loss of heterozygosity in, 54:47–48
- Rhabdomyosarcoma
 characterization of, 60:76–77, 104, 106, 108, 110
 chromosomal abnormalities, 60:97–99
ras gene, 60:87–88
 susceptibility, 60:82, 85
 tumor suppressor genes, 60:101, 103
 chromosomal aberrations, 69:76–77, 92
 immunosuppression and, 60:251
 loss of heterozygosity and, 54:45–46
 muscle cell regulation and, 58:114
- Rhadinovirus, T lymphocyte transformation by, 63:213, 228–230
- RHAMM, 71:263
- Rheb, interaction with Raf, 72:77
- Rheumatoid arthritis
 CD44 and, 71:286–287
 lymphocyte homing receptors and, 51:376
 trisomy 7, 69:79
- Rho, candidate effectors, 72:91–94
- RhoA
 binding proteins, 72:94
 coexpression with oncogenic Ras, 72:79
- Rho family proteins
 interaction with multiple effectors, 72:85–95
 regulation of cellular processes, 72:80–85
 role in Ras transformation, 72:58, 78–80
- Rho-GEF, linking Ras to Rho family proteins, 72:95
- Rhopilin, candidate effector of Rho, 72:91–93
- Rhotekin, candidate effector of Rho, 72:93
- Riboflavin, prostatic cancer and, 51:50–51
- Ribonuclease, APC gene in human cancers and, 62:66, 69, 77
- Ribonucleoprotein
c-myc regulation and, 56:9, 17, 23
 signal transduction and, 55:281, 294
- Ribonucleotide reductase, Epstein-Barr virus proteins and, 50:144, 146
- Ribosomal RNA, *see* RNA, ribosomal
- Ribosomes
 fibroblast growth factors and, 59:119
 hepatitis B viruses and, 59:193
 Louvain rat immunocytomas and, 50:283, 287
 oncoprotein kinases and, 57:204–205
 peptide-binding heat shock proteins and, 62:166
 protein tyrosine kinase GFRs and, 60:63
 Ras function and, 62:37
- Richter syndrome, 71:147
- Ricin, HER-2/neu immunotherapy, 71:362–363
- Ricin toxin-mAb conjugates, 61:70
- rif*, α -fetoprotein and, 56:296
- RIII-virus, breast cancer and, 56:112, 113, 128
- RIM, Burkitt's lymphoma and, 55:217–219
- RI mouse strains
 AKXD strains of, 54:143–151, *see also* AKXD RI mouse strains
 as models

- RI mouse strains (*continued*)
 for identifying novel genes, 54:143–145
 for study of molecular genetic basis of neoplastic disease, 54:143
- Rin1 gene, role in growth regulation, 72:74–75
- Ring chromosomes
 dermatofibrosarcoma protuberans, 69:67
 leiomyosarcomas, 69:76
 lipomas, 69:71–72
 liposarcomas, 69:73
 malignant fibrous histiocytomas, 69:68
 osteosarcomas, 69:83
 shared by several tumor types, 69:88
- RIP protein, apoptosis and, 71:129
- Risk factors
 for breast cancer, 66:72
 tumor development, role in CpG island hypermethylation, 72:181
- α -*RLC* gene, 71:69
- RNA
 adenovirus E1A proteins and, 57:48, 60, 68
ALL-1, 66:223
 B cell-associated surface molecules and, 52:96, 98, 107
BCR gene in leukemia and, 57:229, 240–242
 B lymphocytes and, 56:321
 bovine papillomavirus and, 56:139, 140
 breast cancer, *p53* expression in, 59:72, 76
 Burkitt's lymphoma and
 chromosomal translocations, 55:198, 199
c-myc, 55:158–160, 178
 EBV, 55:228, 229, 231
c-erbA and, 59:91
c-fos protooncogene and, 55:40, 41
 chemical carcinogenesis and, 50:52
 chimeric, 66:230–231
 chromosome abnormalities and, 52:36
c-met, short half-life, 67:273–274
c-myc regulation and, 56:2, 4–7
 Burkitt's lymphoma, 56:30, 33, 36, 39, 40
 expression, 56:9–13, 16, 17, 19–25
 endogenous growth inhibitors and, 57:441
 Epstein–Barr virus encoded, 58:4, 9–10, 17
 EBER1, 69:216
 EBER-1, and EBER-2, transcription, 67:202–204
 EBER-2, 69:216
Herpesvirus saimiri and, 56:345
 Epstein–Barr virus-encoded, 50:102, 142, 149; 58:4, 9–11, 13, 15–17, 21; 62:182, 185–186
 Hodgkin's disease, 62:217, 224, 226, 229
 T-cell lymphoproliferation, 62:201
 fibroblast growth factors and
 gene expression, 59:126, 128–131
 receptors, 59:134
 tumors, 59:150–154
 gastrointestinal diseases and, 50:5, 8
 gene rearrangements and, 52:70
 glutathione transferase and, 52:218, 231, 232
 glycosylation in tumors and, 52:259
 hepatitis B viruses and, 59:178, 181
 genomes, 59:187, 189–191, 193–194
Herpesvirus saimiri and, 56:335, 336, 348, 351
 human papillomavirus and, 56:143, 145, 150, 152, 153
 in IAPs, 51:214–217
jun oncogene and, 55:22
 linkage in *p53*, 66:80
 Louvain rat immunocytomas and, 50:299
 messenger, *see* Messenger RNA
 metastatic cancer cells and, 55:97, 124
 MHC Class I expression and, 60:221
 mitochondrial, isolation from normal cells in microinjection experiments on cellular immortalization, 54:73–74
 mouse retrotransposons and, 56:216, 219, 220, 233
 expression of neighboring genes, 56:231, 232
 insertion, 56:227, 228
 LTRs, 56:235, 236, 239, 241–243
 multidrug resistance and, 52:166, 176, 177, 190
 multidrug resistance gene and, 60:160, 165–171
myc family oncogenes and, 57:6, 19
 oncoprotein kinases and, 57:208–209
p53 and human malignancies and, 57:262
 polyoma virus TSTA and, 55:63
 Ras function and, 62:28, 33, 39, 50
 ribosomal, reverse transformation and, 62:132
 signal transduction and, 55:281

- small, EBER-1 and -2, 67:200–204
- Src* family of tyrosine protein kinases and, 57:113, 115, 139–140
- transforming growth factor- α and, 58:39, 41
- tumor rejection antigens and, 58:191
- Wilms' tumor and, 59:57
- Zilber and, 59:29
- RNA–DNA hybridization method, contribution of Sol Spiegelman, 65:209
- RNA polymerase
- adenovirus E1A proteins and, 57:54–55, 67–69, 72
- c-fos* protooncogene and, 55:48
- c-myc* regulation and, 56:5, 13, 19, 22
- Epstein–Barr virus genes and, 58:4, 17
- genomic instability and, 60:132
- hepatitis B viruses and, 59:193, 198
- myc* family oncogenes and, 57:3, 18–19
- oncoprotein kinases and, 57:195, 197, 216
- RNA polymerase II
- Epstein Barr virus proteins and, 50:112
- Louvain rat immunocytomas and, 50:303
- RNA polymerase III, Epstein–Barr virus proteins and, 50:102
- RNase H, hepatitis B viruses and, 59:190
- RNA tumor viruses, *see* Retroviruses
- ROK α , Rho-binding element, 72:93–94
- ros* oncogene, angiogenesis, 69:146, 147
- Rous sarcoma virus
- adenovirus E1A proteins and, 57:54
- c-erbA* and, 59:97, 100
- c-fos* protooncogene and, 55:43
- discovery of viral origin oncogenes using, 65:37
- MHC Class I expression and, 60:198
- multidrug resistance gene and, 60:175
- ocoprotein kinases and, 57:201, 203
- plasminogen activation and, 57:284, 291
- stroma and, 50:180
- temperature-sensitive mutants, 67:3–4
- Zilber and, 59:29–30
- R-Ras, constitutively activated, 72:68–69
- R-Ras protein, apoptosis, 71:128
- RT, *see* Reverse transcriptase
- Rubber industry, prostatic cancer and, 51:69–73, 79, 90–91
- rum1*⁺ gene, cell cycle start control, 69:22–23
- Rum1 protein, start control of mitotic cycle, 69:23
- Rural-urban differences, prostatic cancer and, 51:16–17, 26–27
- ## S
- S6 kinase, G protein signal transduction and, 58:78–79
- Saccharin, chemical carcinogenesis and, 50:29
- Saccharomyces cerevisiae*
- c-erbA* and, 59:98
- microtubule-associated protein kinase homology, 63:97–98
- Ras function and, 62:21, 24, 49, 51
- GAPs, 62:30
- signal transduction pathways, 62:38, 45
- ras* genes in, 54:79–131
- Saccharomyces pombe*, microtubule-associated protein kinase homology, 63:97–98
- Sacral chordoma, chromosomal aberrations, 69:87
- SAIDS, 51:317–320
- Saimiri transformation associated protein, 56:341, 348–351
- Saliva, Epstein–Barr virus proteins and, 50:95, 99
- Salivary contact, EBV infection via, 67:198, 231, 244
- Salivary gland IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
- Salivary glands, giant chromosomes, physical location of genes using, 65:2
- Salivary gland tumors, chromosome abnormalities and, 52:27, 29
- San Francisco isolate ARV-II, 51:342, 349
- Sarcoidosis, ATLL and, 51:315
- Sarcoma, *see also specific sarcoma*
- chimeric transcription factors, 67:40–43
- chromosomes and, 62:14
- clear cell, chromosomal aberrations, 69:81–82, 90, 92
- cyclin D1 amplification, 68:88–89
- Epstein–Barr virus and, 62:213
- lysosomes and, 60:279–280
- MHC Class I expression and, 60:190, 201, 222
- multidrug resistance gene and, 60:166
- neovascularization, 69:138
- p16 gene mutations, 68:91–94

- Sarcoma (*continued*)
 peptide-binding heat shock proteins and, 62:155–158
 renal cell tumors, molecular cytogenetics, 62:115
 tumor rejection antigens and, 58:183, 200
- Sarcoma cells, suppression of malignancy, 66:24–29
- Sarcoma growth factors, TGF and, 51:107–108
- Sarcoma viruses, MHC Class I expression and, 60:198–199
- SAS gene, amplification, 69:68, 83
- Saturated fat, clinical trials, 61:5–6, 17–19
- Scar cancer, stroma and disorders, 50:180–183
 epithelium, 50:167
- Scar formation, stroma and, 50:179
- Scatter factor
 in AIDS-KS, 66:235–253
 angiogenesis, 69:143
 α -chain and β -chain, 67:257–258
 clinical applications, 67:274–275
 induced by mutations, 67:272–274
 in KS carcinogenesis, 66:246–249
 as potential tumor angiogenesis factor, 67:266–271
 producer cell and target cell
 ECs as, 67:259–261
 SMCs as, 67:261–263
 role in angiogenesis, 67:271–275
- SCB, start control for mitotic cycle, 69:23
- SCH9 in Ras-cAMP pathway, 54:110
- Schistosoma japonicum* infection, mice with, concomitant immunity in, 54:325–326
- Schistosoma mansoni* infection, mice with, concomitant immunity in, 54:325–326
- Schizosaccharomyces pombe*, Ras function and, 62:21, 24, 30, 38, 41
- Schwann cells, TGF and, 51:132
- Schwannoma
 chromosomal aberrations, 69:80
 oncogene activation and, 51:153, 155, 159
- Schwannomin, 69:80
- SCLC cell lines, 71:35–42, 67
- Scleroderma, stroma and, 50:181
- Screening
 familial MTC, 70:197
 tumors in MEN II, 70:182–184
- s1^d*, protein tyrosine kinase GFRs and, 60:52–53
- SDS gel, TGF and, 51:118–119
- SDS-PAGE
 ADF and, 57:385
 immunosuppression and, 60:254
 Src family of tyrosine protein kinases and, 57:128–129
- SEA, *see* Staphylococcal enterotoxin
- Second meiotic division, oncoprotein kinases and, 57:187, 208
- Second messengers
 G protein signal transduction and, 58:83–84
jun oncogene and, 55:30
 lysophosphatidic acid and, 57:88, 90, 99–100
 Raf-1 phosphorylation and, 58:67–68
 signal transduction and, 55:272, 274–277
- S.E.E.R., breast cancer and, 56:116–118, 127
- Segmentation, in *Drosophila*, 67:44
- Segregation, ataxia-telangiectasia genes and, 56:95
- Selectins, 71:244
- Selective advantage
 p16 gene loss in tumor progression, 72:159, 161
 provided by series of mutations, 72:2, 6
- Selective pressure, cytotoxic T lymphocytes and, 59:238–240
- Selenium, prostatic cancer and, 51:50–51, 63
- Self-antigens, MHC Class I expression and, 60:182, 189, 196, 225
- SEMA-A gene, 71:69–70
- SEMA-III/F gene, 71:69–70
- Semaphorin genes, 71:69–70
- Semen, HIV and, 51:336
- Seminal vesicle IAP gene expression in mouse somatic cells, 51:228–230, *see also*
 Intracisternal A-particle gene family
- Seminoma, chromosome 3 losses in, 71:51
- Senescence
 fibroblasts, role of p53, 66:87, 145
 related genomic methylation levels, 72:169
- Sensitization, peripheral blood lymphocytes, 70:146–147
- Sequence homology, c-Myc protein, 70:97
- Sequences
 adenovirus E1A proteins and
 transactivation, 57:51, 54–55, 62, 66, 72

- transcription, 57:67
transformation, 57:74
ADF and, 57:400, 402–403
analyses, 57:392–396
identification, 57:389–390
bcr/abl gene in leukemia and, 57:157–158, 169
abl in malignancy, 57:163–164, 166–167
c-abl activation, 57:160–162
Philadelphia chromosome, 57:154–155
BCR gene in leukemia and, 57:229–231, 252–253
expression, 57:240–242
hematopoietic cells, 57:244–245, 247, 250–251
organization, 57:232–234
breast cancer, *p53* expression in, 59:70–72, 74, 76, 80
cancer immunotherapy and, 59:261, 274–275
central nervous system tumor oncogenesis and, 58:136–138
c-erbA and, 59:92–97, 99
cytotoxic T lymphocytes and, 58:146, 150; 59:229–230, 233, 237, 239–240
EBV-associated disorders and, 57:335, 346, 369–370
Epstein–Barr virus genes and, 58:4, 7–8, 13, 15–16
FGF receptor multigene family and, 60:23, 34–35
alternative splicing, 60:28
characterization, 60:8, 11–13
Drosophila, 60:30–31
ligand binding, 60:24–27
mitogens, 60:3, 5
multiple forms, 60:17–21, 23
fibroblast growth factors and, 59:117, 136, 151
gene expression, 59:126, 129, 131
oncogenic potential, 59:145–148
protein structure, 59:119–127
genomic instability and, 60:124–125
mechanisms, 60:127, 136, 139, 141–142
G protein signal transduction and, 58:86
hepatitis B viruses and, 59:168–169, 172, 180
genomes, 59:185, 187–189, 193–194
integration, 59:200–203
oncogenesis of viral proteins, 59:195–199
viral DNA, 59:200, 205, 207
MHC Class I expression and
cancer, 60:186–187, 190
modulation by oncogenes, 60:197–198, 200, 203, 205, 208
regulation by oncogenes, 60:208–214, 216
regulation in tumor cells, 60:218, 220
multidrug resistance gene and, 60:160, 162, 171, 173
muscle cell regulation and, 58:99, 101–102, 104, 111
myc family oncogenes and, 57:2–3, 5, 13
future perspectives, 57:34
gene expression, 57:16, 18, 20–22
oncogenic activities, 57:26
protein structure, 57:6, 8–12
oncoprotein kinases and, 57:187, 189, 192, 195–198
p53 and human malignancies and, 57:259–262
plasminogen activation and, 57:278, 281, 296, 298
protein tyrosine kinase GFRs and, 60:46, 52, 61–62, 64–65
Raf-1 phosphorylation and, 58:60, 62–67
Src family of tyrosine protein kinases and, 57:105, 107, 109–110, 133
patterns of expression, 57:115, 119
T-cell activation, 57:126, 128
transforming growth factor- α and, 58:28–29, 37, 43, 47
tumor rejection antigens and, 58:188, 191–194, 197
Wilms' tumor and, 59:56
Sequence-specific factors, adenovirus E1A proteins and, 57:55–66, 69, 72–73
SER, immunosuppression and, 60:254, 259
Serglycin/gp600, CD44 binding to, 71:273
Serine
phosphorylation of Fc γ RII, 64:229
signal transduction and, 55:277, 278
Serine kinase, p65-associated, 66:273
Serine phosphorylation, G protein signal transduction and, 58:79
Serine protease, produced in zymogen form, 67:258
Serine proteinase inhibitor, plasminogen activation and, 57:296, 299

- Serine proteinases, plasminogen activation and, 57:274, 284
 directed cell surface, 57:301, 309
 proteolytic modulation, 57:285, 288–290
- Serine residues, Raf-1 phosphorylation and, 58:54, 56, 60, 64–65, 70
- Serine/threonine kinase
 G protein signal transduction and, 58:78
 Raf-1 phosphorylation and, 58:66
- Serine/threonine phosphorylation, Raf-1 and, 58:53–54, 56, 58–59, 62–65
- Serological status, EBV-associated disorders and, 57:337, 341, 343–344
 Hodgkin's disease, 57:368–369
 organ transplants, 57:361–362
- Serotonin
 gastrointestinal diseases and, 50:4
 metastatic cancer cells and, 55:125
- Serum
 animal cell growth and, 53:3
 functional components of, 53:5
 gene expression induced by, 53:20–24
 genes inducible by, 53:1–25
 mitogenic response to, 53:3–5
 minor transcriptional changes in, 53:5–6
 transcription and translation in, 53:5–8
 transcription of proliferation-specific mRNA induced by, 53:7
- Serum response factor
 activation, 72:84
 G protein signal transduction and, 58:79–80
- sevenless*, protein tyrosine kinase GFRs and, 60:57–60
- Seventh Day Adventist population
 diet and, 51:35–36
 prostatic cancer and, 51:14–15
- Severe combined immunodeficiency, EBV-associated disorders and, 57:343–344
- Sex, prenatal diagnosis, 66:2
- Sex determinations, genotypes and, early discoveries in 1930s, 65:3
- Sex-linked protein, mouse retrotransposons and, 56:231
- Sezary syndrome, 51:374
 retroviruses and, 51:314, 317
- Sézary syndrome, gene rearrangements and, 52:60, 61
- SF, *see* Scatter factor
- SF-inducing factors, regulation of SF production, 67:270–271
- S-G2 checkpoint control, 69:44–49
- SGF, TGF and, 51:107–108
- SH2, *see* Src homology 2 domain
- SH3, *see* Src homology 3 domain
- Shale oil, carcinogenicity studies, 65:25
- Shope fibroma growth factor, physiology of, 58:28
- Shuttling proteins, signal transduction and, 55:292–296
- Sialic acid
 α-fetoprotein and, 56:266, 268
 glycosylation in tumors and, 52:280, 291
- Signaling
 cytokine, and STAT proteins, 64:96–97
 downstream from *ret*, 70:204–207
 insulin
 and IRS-1, 64:95
 role of PKC, 64:168–169
 SH2-mediated, in T cells, 64:95–96
- Signaling pathways, ara-C role, 72:213–220
- Signal transducers
 4PS, cytokine signaling role, 68:43
 intracellular, and PKC activation, 64:174–175
- Signal transduction
 ATM gene product, 71:10
 B cell-associated surface molecules and, 52:99, 114, 134
bcr/abl gene in leukemia and, 57:159, 170
 B lymphocytes and, 56:314
 cancer immunotherapy and, 59:258
 cascade, in regulation of cell growth, 64:5–6
c-fos protooncogene and, 55:37, 41
 downstream of tyrosine kinases, 64:93
 FcγR-mediated, 64:219–221
 FGF receptor multigene family and, 60:31–34
 fibroblast growth factors and, 59:135–138, 146, 155
 Flt family, 67:302–304
 genetics, 64:104
 genome exposure and, 62:139–144, 146
 G protein-controlled, *see* G protein signal transduction
 hepatitis B viruses and, 59:198
 humoral immune response and, 62:249, 252, 255
 lysophosphatidic acid and, 57:96
 metastatic cancer cells and, 55:89, 123

- MHC Class I expression and, 60:202, 219, 226
- modulation, ara-C role, 72:223–225
- myc* family oncogenes and, 57:11
- oncoprotein kinases and, 57:205
- pathways of Ras function and, 62:20–21, 35–37, 46, 50, 52
- MAPK pathway, 62:37–41
- Rho/Rac pathway, 62:41–46
- protein tyrosine kinase GFRs and, 60:43, 45, 60
- Raf-1 phosphorylation and, *see* Raf-1 phosphorylation
- Ras functions, 72:58–60, 96–97
- role for PKC, 64:166, 197
- and SH3 and PH domains, 64:99
- soft tissue tumors and, 60:99
- Src family of tyrosine protein kinases and, 57:104–105, 140
- patterns of expression, 57:112, 116
- T-cell activation, 57:120–131
- T-cell proliferation, 57:131–140
- T-cell receptors and, 56:54–57
- by TGF- β 1, 71:184–186
- and tumorigenesis, 64:111
- signal transduction and, 55:271, 292, 296, 298, 299
- Signal transduction pathways
- c-myc*, 70:117–119
- lysophosphatidic acid and, 57:87, 92–95
- steroid and thyroid hormones, 70:76
- Signal transduction to cell nucleus, 55:271–274
- accumulation of proteins, 55:281–284
- mechanisms, 55:284
- anchorage-release model, 55:295, 296
- oncogenesis, 55:296–300
- protein kinase translocations, 55:286–292
- shuttling proteins, 55:292–295
- steroid hormone receptors, 55:284–286
- nuclear pores, 55:278–281
- plasma membrane receptor, 55:274–278
- Simian AIDS, 51:317–320
- Simian sarcoma-associated virus, 51:310, 311–313
- Simian sarcoma virus
- oncogenes and, 50:81
- retroviruses and, 51:312
- Simian virus 40
- acquisition by monkeys, 65:152–154
- adenovirus E1A proteins and, 57:61, 70, 75, 77
- bcr/abl* gene in leukemia and, 57:159
- binding to p110^{Rbl}, 61:120–121
- BK virus and, similarities, 65:155
- breast cancer, *p53* expression in, 59:71
- Burkitt's lymphoma and
- chromosomal translocations, 55:198, 202
- c-myc*, 55:161, 163
- deregulation, 55:209
- EBV, 55:230
- genetic abnormalities, 55:220
- synthesis, 55:249
- contamination during adenovirus production, 65:150–152
- DNA chromosomes, structure, tabular presentation, 65:158–159
- endogenous growth inhibitors and, 57:437–438
- genomic instability and, 60:135
- hepatitis B viruses and, 59:194, 196, 198
- MHC Class I expression and, 60:210, 213
- mouse retrotransposons and, 56:236
- multidrug resistance gene and, 60:175
- myc* family oncogenes and, 57:11, 28
- oncoprotein kinases and, 57:196–197, 199
- p53* and human malignancies and, 57:265, 269
- p53* detection using, 65:163
- papillomaviruses and, 56:140–142, 144, 148, 149
- polyoma virus TSTA and, 55:58, 76
- signal transduction and, 55:282
- soft tissue tumors and, 60:100, 102
- transcription maps and, studies using eukaryotic cells, 65:160
- transformed cells, 66:21–22
- Simian virus glycoproteins, retroviruses and, 51:311
- Simultaneous carriage, multiple ebnotypes, 67:232–234
- Simultaneous detect test, retroviruses and, 51:309–310
- Single-chain antibodies, HER-2/neu immunotherapy, 71:363–364
- Single-chain antigen proteins, 61:72–73
- Single-transgenic mice, *myc* family oncogenes and, 57:29
- sis* oncogene, angiogenesis, 69:146, 147

- Sister chromatids, unequal exchange in CAD gene amplification, 61:96–97
- Site selection, in integration of adenovirus DNA, 66:317–319
- SIV, 51:317–318, 339
- Sjögren's syndrome, tumors associated with, 54:308
- Skeletal hamartomas, chromosomal aberrations, 69:84
- Skeletal muscle IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
- Skeletal muscle tumors, chromosomal aberrations, 69:76
- Skin
 abnormalities, AIDS and, 51:337–338
 mouse, chemical carcinogenesis, two-stage mechanism, 65:38
- Skin cancer
 development, 70:38
 genomic instability and, 60:132
 incidence data, 56:174, 175
 and lung cancer, comparison of causes, 65:85
 MHC Class I expression and, 60:222
 stroma and, 50:178
- Skin carcinoma, oncogene activation and, 51:150–151
 TPA, 51:165
- Skin grafts, Louvain rat immunocytomas and, 50:281
- Skin irritants, endogenous growth inhibitors and, 57:444
- Skin papilloma
 DHEA and, 51:404, 406–408
 oncogene activation and, 51:150–151
 TPA and, 51:165
- Skin window test, breast cancer and, 56:129
 cell-mediated immunity, 56:110–115, 119–123
 therapeutic implications, 56:124, 126
- SLE, *see* Systemic lupus erythematosus
- 'Slim' disease, 51:337–338
- Small-cell lung cancer-derived tumor cells, *see* SCLC cell lines
- Small intestine
 gastrointestinal diseases and, 50:2, 4, 6, 7
 oncogenes and, 50:77
 tumorigenesis in, MHC effects on, 53:160–162
- Small lymphocyte IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
- Small noncleaved cell lymphomas, AIDS-related
 c-MYC activation, 67:132–136
 disrupted immunosurveillance, 67:120–122
 IgM mAb production, 67:123–124
 systemic, 67:116–117
- Smallpox, preventive practices for, development procedures, 65:142–143
- Small RNAs, *Herpesvirus saimiri* and, 56:345–347
- SMC, *see* Smooth muscle cells
- Smokers, *see also* Tobacco exposure
 adenocarcinomas from, KRAS2 mutations, 67:90
- Smoking
 cancer incidence data and, 56:162, 211
 age profiles, 56:169
 stages, 56:196–207
 chemical carcinogenesis and, 50:55, 57
 DHEA and, 51:402–404
 prostatic cancer and, 51:58
- Smooth muscle cells, vascular, as SF producer cell and target cell, 67:261–263
- Smooth muscle tumors, chromosomal aberrations, 69:74–76
- s-myc* gene, *myc* family oncogenes and, 57:13
- SNCCCL, *see* Small noncleaved cell lymphomas
- Social control hypothesis, population control, 71:133–134
- Socioeconomic status, prostatic cancer and, 51:4–5, 15–16, 27, 89–90
- Soft tissue tumors, human, 60:75–78
 chromosomal abnormalities, 60:88–89, 99–100
 leiomyomas, 60:91–93
 lipomas, 60:89–91
 liposarcomas, 60:93–95
 malignant fibrous histiocytomas, 60:99
 rhabdomyosarcomas, 60:97–99
 synovial sarcomas, 60:95–96
 cloning, 60:107–109
 etiology, 60:78–80
 future, 60:109–110
 gene amplification, 60:104–105
 predictors of behavior, 60:105–107
ras gene, 60:87–88

- susceptibility, 60:80
 Beckwith-Wiedemann syndrome, 60:85
 benign tumors, 60:85–87
 fibromatosis, 60:80–82
 Li-Fraumeni syndrome, 60:82–83
 retinoblastoma, 60:84–85
 Von Recklinghausen's
 neurofibromatosis, 60:83–84
 tumor suppressor genes, 60:100–104
 soft tissue tumors and, 60:89, 94–95, 104,
 108
- Solid tumors
 chromosome abnormalities and, 52:8, 27–
 30, 38
 uPA in, 69:117
- Soluble receptors for competition with cell
 surface receptors in autocrine growth
 stimulation inhibition, 54:230
- Somatic cell genetics, history of research, 63:10
- Somatic cell hybrids, tumor growth studies,
 71:34
- Somatic cells, B-*myb* transcription, 72:115–
 117
- Somatic hypermutation, gene rearrangements
 and, 52:47, 53
- Somatic selection, coupled with enhanced
 mutagenesis, 72:35–36
- Somatomedin C, *see* Insulin-like growth
 factor-1
- Somatostatin, gastrointestinal diseases and,
 50:5
- Soot
 carcinogenicity
 chemical basis for, 65:25
 polycyclic aromatic hydrocarbons in
 determination, 65:24
 fluorescence spectra, 65:42
- Southern blotting
 ras genes and, 51:159
 uncultured tumor specimens, 67:210–211
- Sp-1
 CpG island regions, 72:183–184
 regulation by p110^{RBI}, 61:128
- Special populations, prostatic cancer and, 51:
 14–15, 28
- Spectrin
bcr/abl gene in leukemia and, 57:159
 oncoprotein kinases and, 57:201
- Spemann, Hans, 66:42–43
- Spermatogenesis, DNA methylation during,
 54:14–15
- Spermatogenesis, role of p53, 66:145
- S phase, B-Myb hyperphosphorylation in, 72:
 123–125
- Sphingosine, effect on RB phosphorylation,
 64:46–47
- Spiegelman, Sol
 biographical data, 65:203–205
 contributions to studies of reverse
 transcriptase in human cancer, 65:210–
 211
 enzyme studies, 65:206
 RNA-DNA hybridization method and, 65:
 209
 work on replication mechanism of phages,
 65:210–211
- Spinal cord, fibroblast growth factors and, 59:
 144, 152
- Spindle cell lipomas, chromosomal
 aberrations, 69:69–72
- Spindle pole body, genomic instability and,
 60:135
- Spleen
bcr/abl gene in leukemia and, 57:151, 176
 cancer immunotherapy and, 59:249, 268,
 277, 279
c-myc regulation and, 56:20, 23
 EBV-associated disorders and, 57:338
 grossly normal old and thymectomized
 mice, IgH rearrangements, 63:284–
 285
 hepatitis B viruses and, 59:174, 181
 Louvain rat immunocytomas and, 50:283
 lysosomes and, 60:281–283
myc family oncogenes and, 57:31–32
 Src family of tyrosine protein kinases and,
 57:113, 115–117
- Spleen colony-forming units, endogenous
 growth inhibitors and, 57:434–435
- Spleen IAP gene expression in mouse somatic
 cells, 51:228–230, *see also* Intracisternal
 A-particle gene family
- Splenomegaly
bcr/abl gene in leukemia and, 57:152, 175
 EBV-associated disorders and, 57:331, 338
 in malaria, 53:62
- Splicing errors, as p53 mutations, 66:110
- Spongiform polioencephalomyelopathy,
 incidence in MuLV-infected LC mice, 65:
 179–181, 184–185
- Spontaneous tumors, cytotoxic T
 lymphocytes and, 58:151–154

- Sporadic neurofibrosarcomas, chromosomal aberrations, 69:81
- Sporadic osteocartilaginous exostoses, chromosomal aberrations, 69:84
- S protein, hepatitis B viruses and, 59:191–192, 194, 196
- Spumaviridinae, 51:308, *see also*
Retroviruses, human
- Squamous cell carcinoma
cancer immunotherapy and, 59:251
head and neck, *see* Head and neck squamous cell carcinoma
human papillomavirus and, 56:145, 147, 152, 153
human marker proteins in radioresistant and radiosensitive cells, 61:218
radioresistance, 61:200–203
vulval, 71:50
- Squamous cell lung carcinoma, plasminogen activators and, 69:113
- Squamous cell neoplasia, *TP53* mutations, detection, 65:85
- Squamous cells, stroma and, 50:165, 166, 175, 184
- Squirrel monkey, *Herpesvirus saimiri* and, 56:336, 337
- Src family of tyrosine protein kinases, 57:103–104, 140
patterns of expression, 57:112–120
properties, 57:105–112
signal transduction, 57:104–105
T-cell activation, 57:120–131
T-cell proliferation, 57:131
IL-2, 57:132–135
IL-2 receptor, 57:135–138
malignancies, 57:138–140
- src* gene
CD44 expression and, 71:275
leukemia and, 57:158, 170, 174
oncoprotein kinases and, 57:191–192
plasminogen activation and, 57:280
tyrosine protein kinases and, 57:108–109
v-src
increase in radioresistance induced by, 61:209
induction of radioresistance in murine hematopoietic cells, 61:210–211
- Src homology 2 domain
bcr/abl gene in leukemia and, 57:158, 160
containing phosphotyrosine phosphatase, 64:104
direct binding to phosphorylated tyrosine residues, 64:113
Grb2 adaptor protein, 72:61
and IRS-1, 64:95
low affinity for Tyr 527 site, 64:114
mediated signaling in T cells, 64:95–96
multiple functions, 64:97–98
optimal binding sites, 70:205
and SH3, characterized receptor-binding proteins, 64:88–89
signaling proteins with, 64:92–94
structure and binding properties, 64:90–92
- Src homology 3 domain
bcr/abl gene in leukemia and, 57:158–163, 167, 171
and PH domains, 64:99
in STAT proteins, 64:96
structure and binding properties, 64:98–99
- src* oncogene, angiogenesis, 69:146, 147
- Src protein
bcr/abl gene in leukemia and, 57:158, 162, 168, 170
oncoprotein kinases and, 57:191–192, 194–195, 197–198, 213
c-Mos, 57:209
M phase, 57:201, 203, 205
- SSAV, 51:310, 311–313
- SSCP, breast cancer, *p53* expression in, 59:76
- SSRP1 complex, 68:129
- SSV, 51:312
- SSX genes, synovial sarcomas, 69:79
- Stability
and conformation, *p53*, 66:101–103, 166–167
and expression, *p53* protein, 66:81–82
- Staphylococcal enterotoxin, 71:365–366
- START
fission yeast, 66:194–196
major cell cycle checkpoint, 66:192–194
- Start control, mitosis, fission yeast, 69:42–44
- Stat
cytokine specificity in activation, 68:46–49
dimerization and activation, 68:45
DNA sequence recognition, 68:49
interferon response, 68:44
mechanisms of recruitment to cytokine receptors, 68:49–50
phosphorylation and activation, 68:45–48
sites of expression, 68:47–48

- structure, 68:44–46
 transgenic mice, 68:51
 types, 68:44
- Staurosporine, 61:62
 PKC-specific inhibitor, 64:167
- STE6, multidrug resistance gene and, 60:162
- STE11 protein, start control for meiotic cycle, 69:28
- steel, protein tyrosine kinase GFRs and, 60:50–52
- Steel foundry workers, prostatic cancer and, 51:75–76
- Stefins, lysosomes and, 60:276–277
- Stellate cells IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
- Stem cell factor
 progenitor cell formation, 63:56
 protein tyrosine kinase GFRs and, 60:51–54
- Stem cells
 embryonic, chimera, 64:135–140
 gastrointestinal diseases and, 50:3, 15
 hematopoietic, RB-resistant, 64:75
 oncogenes and, 50:73, 74
 cellular heterogeneity, 50:89, 90
 malignant genotype, 50:82
 malignant phenotype, 50:77, 78
 maturation arrest, 50:92
 tumor clonality and, 50:199
 uncontrolled proliferation, role of *RBI* loss, 64:28–29
 viability, 71:134–135
- Steroid hormone receptors, *c-erbA* and, 59:90, 93, 97–98, 106, 108
- Steroid hormones
 adrenal, sex, and vitamin D₃, 70:74–75
 nongenomic actions, 70:77–78
 regulation of TGF- β isoform expression, 70:78–83
- Steroid receptors, characteristics, 70:75–77
- Steroids
 ADF and, 57:403
 α -fetoprotein and, 56:278, 279, 295
 Burkitt's lymphoma and, 55:208
 EBV-associated disorders and, 57:343, 348
 glutathione transferase and, 52:213, 214
 hepatitis B viruses and, 59:177
 mouse retrotransposons and, 56:240–242
 multidrug resistance and, 52:168
 multidrug resistance gene and, 60:165
 newborn macrosomy and, 50:233, 264
 plasminogen activation and, 57:293
 signal transduction and, 55:272
 mechanisms, 55:284–286, 296, 297
 plasma membrane receptor, 55:278
 stroma and, 50:168
- Stimulation
 B lymphocytes and, 56:327, 328
 prolonged, and PKC down-regulation, 64:165–166
- STLV-III, 51:317–318
 AIDS and, 51:339
- Stomach
 gastrointestinal diseases and, 50:1, 2, 4–7
 antigenic determinants, 50:19
 normal, 50:3, 4
 stroma and, 50:165, 182
- Stomach cancer
 CD44 and, 71:296–297
 chromosome 3 losses in, 71:47–48
 incidence data, 56:178–181
 plasminogen activators and, 69:112
- Strangeways, Thomas, tissue culture studies, 70:4–5, 14
- Stress-activated protein kinase, interaction with ara-C, 72:218
- Stress fibers, actin, formation, 72:82–83
- Stroma
 gastrointestinal diseases and, 50:7
 malignant growth and, 50:159, 160, 186–188
 alterations, 50:183–185
 basement membranes, 50:173–176
 disorders, 50:178, 179
 scar cancer, 50:180–183
 wounds, 50:179, 180
 epithelium, 50:160
 collagen, 50:160, 167
 collagenases, 50:161
 collagenolysis, 50:163–165
 collagenolytic enzymes, 50:162
 desmoplasia, 50:165–167
 elastogenesis, 50:168
 plasminogen activator, 50:162, 163
 productive changes, 50:165
 proteoglycans, 50:168, 169
 reactivity, 50:169, 170
 fibroblasts, 50:177, 178
 glycoproteins, 50:170
 fibronectins, 50:170–172
 laminin, 50:172

Stroma (*continued*)

tumor clonality and, 50:198, 199, 218

stroma and, 50:187

Stromal cells in bone marrow, 54:247–250

cytokine responses involving, 54:259–261

lymphocytes and, recognition and adhesion between, 54:250–252

Stromal reaction of tumors, 54:312–313

Structure, *ret*, 70:192–195

Subcellular distribution

mutant p53, 66:103

and RNA linkage, p53, 66:80–81

Subcellular localization

regulated Dorsal activity, 66:281–283

regulated NF- κ B, 66:255

Subclones

metastatic cancer cells and, 55:90, 93, 107

tumor clonality and, 50:200

Substance P, 69:144

Substrates

RF-A, phosphorylation, 66:203

semisolid, with agar, 66:5–6

suc1 gene, mitotic start control, 69:40–41, 46

Suc1 protein, 69:46

Sugar, Epstein–Barr virus proteins and, 50:148

Sugars, peptide-binding heat shock proteins and, 62:159

Sugar-transport systems as target of cAMP-dependent protein kinase, 54:117

Sulfated glycopeptide antigen,

gastrointestinal diseases and, 50:16

Sulindac, clinical trial, 61:7

Superinfection, Epstein–Barr virus proteins and, 50:138

Superoxide dismutase, radiation protection by, 61:221

Superoxide formation, DHEA inhibition of, 51:412–415

Suppressive E-receptor, immunosuppression and, 60:253–254

Suppressor cells

cancer immunotherapy and, 59:278–281, 289

cytotoxic T lymphocytes and, 58:154, 161–162

tumor rejection antigens and, 58:207

Suramin, 69:160

AIDS and, 51:346

cancer therapy, 68:213

Surface glycoprotein

cytotoxic T lymphocytes and, 59:237

hepatitis B viruses and, 59:195–196, 210

Survival, cancer immunotherapy and, 59:274, 276, 283

Survival factors, 71:128, 131

myeloid differentiation and, 71:135–136

population control and, 71:133–134

stem cell viability and, 71:134–135

Survival rate, for breast cancer, 66:72

Susceptibility

cancer immunotherapy and, 59:258–259

lung tumor, mapped loci affecting, 67:101–102

to lung tumorigenesis, 67:83–85, 98–99

Susceptibility to soft tissue tumors, 60:

80–87

SV40, *see* Simian virus 40

SV40 large T antigen, transgenic mice expressing, 67:99–100

SV40 T antigen, effects of, on normal cells in microinjection experiments on cellular immortalization, 54:75

SV40 transformation, host genes associated with, 53:16–17

SV80, p53 and human malignancies and, 57:259, 261

Swiss-type agammaglobulinemia,

opportunistic tumors associated with, 54:305–306

Switch II, mutagenesis, 72:76

Syk, cytokine activation, 68:31

Symbiosis, tumor clonality and, 50:223

Symmetric recombinant, *see* SYREC2

sym, genomic instability and, 60:129

Syndecan, fibroblast growth factors and, 59:138

Syndromes

MEN II, 70:179–215

nevoid basal cell carcinoma, genetics, 70:49–59

Synergistic effects, cancer immunotherapy and, 59:260–262, 275

Synovial sarcomas

characterization of, 60:95–96, 102, 108

chromosomal aberrations, 52:30; 69:79, 90, 92

Synovial tumors, chromosomal aberrations, 69:78–79

Syntenic groups, ataxia-telangiectasia genes and, 56:96

Synthetic estrogens, growth-inhibitory potential in tumors, 65:51

Syp

ras signaling pathway role, 68:42
structure, 68:42

SYREC2

Ad12 DNA, 66:333

DNA, 66:322–323

Syrian hamster, IAP and, 51:184, 193, 195–201, *see also* Intracisternal A-particle gene family

Systemic lupus erythematosus

α -fetoprotein and, 56:283, 284

retroviruses and, 51:312

HIV and, 51:326

tumors associated with, 54:308

SYT gene, synovial sarcomas, 69:79

T

T10 cells, MHC Class I expression and, 60:222

Taeniae taeniaeformis infection, mice with, concomitant immunity in, 54:320–322

Tamoxifen, 61:62

4-HPR-tamoxifen combination studies, 61:11–12

adjuvant therapy for breast cancer, 61:17
breast cancer and, treatment modality for, 65:54

clinical trials for breast cancer, 61:16

insulin-like growth factor functional interactions, 68:207–208, 213

Tamoxifen breast cancer and, 51:129–130

TGF and, 51:133

T antigens, breast cancer, *p53* expression in, 59:69–71, 73

TAP-1 protein, 69:228, 235

TAP-2 protein, 69:228, 235

Target genes

B-Myb, 72:133–134

c-Myc, 70:121–123

κ B site specificity, 66:279–280

Target interference, MHC Class I expression and, 60:226

Target mutator genes, candidate, 72:38–43

TATA box-binding protein, interaction with c-Myc, 70:115

TATA polymorphism, 67:170–171

TAT oncogene, angiogenesis, 69:146, 147

Tat viral gene, 51:278

Tautomycin

biochemical activity, 61:181–182

biochemical and immunological effects, 61:160

effects on digestive tract, 61:182–183
structure, 61:181–182

tumor promotion on mouse skin, 61:182

TAX, Src family of tyrosine protein kinases and, 57:139

T-bodies, 71:363

TBP, *see* Proteins, TATA-binding

TC21, constitutively activated, 72:68–69, 77

T-cell activation, Src family of tyrosine protein kinases and, 57:104, 120–131

T-cell adhesion molecules, 53:192

T cell antigen receptor, gene rearrangements and, 52:46

genomic organization, 52:52–56
role, 52:49

somatic rearrangement, 52:56, 57

structure, 52:49–52

T cell clones, cytotoxic T lymphocytes and, 58:155–158

T-cell growth factor, 51:314, *see also* Interleukin 2

T cell growth factor β fibroblast growth factors and, 59:142

T-cell lymphoma, *see* Lymphoma, T-cell

T cell lymphomas, in AKR mouse, *see* Lymphomagenesis

T-cell proliferation, Src family of tyrosine protein kinases and, 57:104, 131–140

T-cell receptor

ADF and, 57:385

cytotoxic T lymphocytes and, 58:144–145; 59:229, 232

Raf-1 phosphorylation and, 58:59

Src family of tyrosine protein kinases and, 57:120, 123–131

tumor rejection antigens and, 58:179, 182, 191

T cell receptor genes, gene rearrangements and, 52:46

chromosomal translocations, 52:72–75

hematological neoplasias, 52:57–68

simultaneous occurrence, 52:69–72

T cell receptors, 56:49, 50

adhesion pathways, 56:59

antigens, 56:50–52

agonistic, 56:58

expression, 56:70, 71

T cell receptors (*continued*)

- ataxia-telangiectasia genes and, 56:84–86, 88
 - CD4, 56:52–57
 - CD8, 56:52–57
 - Epstein–Barr virus and, 62:189, 191, 194
 - genomic instability and, 60:138–139
 - humoral immune response and, 62:248–250, 252–255
 - interactions with foreign epitopes, 67:167–168
 - leukocyte integrin family, 56:63–66
 - LFA-3, 56:59–62
 - lymphocyte homing receptors, 56:67–70
 - recognizing MART-1, 70:156–157
 - soft tissue tumors and, 60:107
 - VLA family, 56:67
- T cells
- adenovirus proteins and, 52:152
 - ADF and, 57:383, 401–403, 407
 - analyses, 57:392, 394–395
 - identification, 57:385–389
 - α -fetoprotein and, 56:280–283, 285
 - ataxia-telangiectasia genes and, 56:79, 82–86, 83, 85, 86, 91
 - B cell-associated surface molecules and, 52:82, 132–134
 - biochemically defined molecules, 52:118, 119, 124
 - CD20, 52:91
 - CD21, 52:103
 - CD22, 52:105, 107, 108
 - CD23, 52:109
 - expression on activated cells, 52:127, 130–132
 - history, 52:86–88
 - receptors, 52:125, 127
 - bcr/abl* gene in leukemia and, 57:157, 174
 - BCR* gene in leukemia and, 57:231
 - B lymphocytes and, 56:315–317, 320, 327, 330
 - breast cancer, *p53* expression in, 59:84
 - Burkitt's lymphoma and, 55:140
 - B cell differentiation, 55:165
 - c-myc*, 55:164
 - EBV, 55:226, 227, 232–240
 - features, 55:145
 - nonrandom chromosomal translocations, 55:156
 - phenotype, 55:151
 - synthesis, 55:244
 - cancer immunotherapy and, 59:246–247, 293
 - CD44 and, 71:257–258
 - chemoimmunotherapy, 59:277–279
 - critical factors, 59:248–254
 - current strategies, 59:257, 259, 261–262, 270–273
 - improvement attempts, 59:283–284, 286–292
 - chromosome abnormalities and, 52:22–24, 26
 - chromosomes and, 62:11
 - class I-restricted, direct priming of, requirements for, 53:215–216
 - c-myc* regulation and, 56:19, 36
 - conditioned media, HIV-infected, 66:240–245
 - CR2 in, 54:289
 - cytotoxic, *see* Cytotoxic T lymphocytes
 - differentiation, 71:137–138
 - EBV-associated disorders and, 57:332–333, 364, 371
 - Burkitt's lymphoma, 57:334, 336
 - immunodeficiency states, 57:344–345
 - organ transplants, 57:346, 348, 353, 359, 361–362
 - X-linked lymphoproliferative syndrome, 57:337–338, 340–343
 - Epstein–Barr virus, 69:221–228
 - Epstein–Barr virus and, 62:182, 189–191, 220
 - Hodgkin's disease, 62:213, 219–221
 - lymphoproliferation, 62:187–212
 - Epstein–Barr virus genes and, 58:4
 - Epstein–Barr virus proteins and, 50:149
 - diseases, 50:98, 100
 - transformed cells, 50:133–135
 - expressing Fc γ Rs, 64:226–227
 - gene expression-induced, 53:17
 - genomic instability and, 60:124, 137, 139
 - glutathione transferase and, 52:240
 - glycosylation in tumors and, 52:310, 312, 315
 - helper, 66:47–49
 - Herpesvirus saimiri* and, 56:339, 341, 344
 - HEV adherence properties of, 51:369
 - HIV and, 51:324–325, 369
 - HLA class I-restricted, 66:57–59
 - human, viral transformation
 - characteristics of virus, 63:212–213

- herpesviral *stp* oncogene, 63:231–236
Herpesvirus saimiri
 immortalization with HTLV
 recombinants, 63:221–223
 mechanisms, 63:223–228
 human T cell leukemia virus, 63:214–219
 mechanisms, 63:211–213, 236–237
 rhadinovirus, 63:228–230
 T-lymphotropic herpesvirus vector, 63:
 219–221
 human melanoma antigens recognized by,
 70:149–169
 humoral immune response and, 62:245,
 251, 254
 lymphocyte homing receptors and, 51:376
 immune recognition of viral antigens by,
 and MHC expression, *see* DNA
 viruses, effects on MHC expression
 immunosuppression and, 60:247, 249, 251–
 252, 254
 lymphocyte homing receptors and, 51:376
 and MHC, interaction of, 53:191–192
 MHC class I expression and, 60:182, 231,
 233
 cancer, 60:183–184, 187, 189, 195
 downmodulation, 60:223–227
 modulation by oncogenes, 60:196, 199–
 200, 202
 regulation by oncogenes, 60:210
 mitogen-activated RB phosphorylation, 64:
 38–39
myc family oncogenes and, 57:15, 27, 30,
 32–33
 neonatally M-MuLV infected mice and, 51:
 290–293
 peptide-binding heat shock proteins and,
 62:160, 166, 170–171, 173
 PKC isozymes in, 64:180–182
 polyoma virus TSTA and, 55:59, 61, 77
 and preleukemic cells, 66:302
 Raf-1 phosphorylation and, 58:58–59
 Ras function and, 62:40
 recognition of cell surface epitopes, 66:47–
 49
 response to nonmutated epitopes, 70:163–
 166
 reverse transformation and, 62:137
 mRNAs specific to, 53:21
 SH2-mediated signaling, 64:95–96
 Src family of tyrosine protein kinases and,
 57:104, 108, 116–119, 140
 TGF- β and proliferation of, 71:194–195
 and tumor cells, interactions between,
 MHC quantitative variation and, 53:
 213–214
 tumor-infiltrating, 67:122
 tumor rejection antigens and, 58:177, 179–
 180, 179–182
 autologous CTLs, 58:201
 P815, 58:200–201
tumsup-antigens, 58:184, 187, 193–
 194, 194, 197
 TCGF, *see* T-cell growth factor
 TCR-CD3 signaling complex, 71:137
 Tc responses
 EBV-specific, 53:55–56
 virus-specific, in rodent malaria, 53:58
 TdT, *see* Terminal deoxyribonucleotide
 Tea, prostatic cancer and, 51:28, 36–37, 43
 Teeth, Burkitt's lymphoma and, 55:143
 Tell protein, function of, 71:13, 14
 Teleocidin
 simultaneous treatment with okadaic acid,
 61:155–157
 tumor promotion in rat glandular stomach,
 61:154–155
 Telomere, shortening in prostate cancer, 68:
 241–242
 Telomeres
 ataxia-telangiectasia genes and, 56:93, 96
 genomic instability and, 60:134, 136
 MHC Class I expression and, 60:185
 Telomeric fusions, in CAD gene
 amplification, 61:98–99
 Temin, Howard, 69:2, 9–10, 12–14
 Temperature
 effects on p53, 66:75
 oncogenes and, 50:82, 83, 85
 permissive, for target cell transformation,
 72:4
 sensitive cdc2, 66:192
 sensitive mutant p53, 66:18–19
 Tenosynovial giant cell tumors,
 chromosomal aberrations, 69:78–79
 Teratocarcinoma cells, IAP and, 51:
 236–243
 Teratocarcinomas, fibroblast growth factors
 and, 59:151
 Terminal deoxynucleotidyltransferase, gene
 rearrangements and, 52:47, 54, 68, 73
 Terminal deoxyribonucleotide, Burkitt's
 lymphoma and, 55:130, 151, 176

- Testes, normal, melanoma antigen expression, 70:161–163
- Testicular germ cell tumors, chromosome 3 losses in, 71:51
- Testosterone
 chemical carcinogenesis and, 50:29
 gastrointestinal diseases and, 50:8
 prostatic cancer and, 51:31, 37–39
 diet and, 51:63–64, 65
 x-ray exposure and, 51:78
- Tetracycline, chemical carcinogenesis and, 50:42, 43
- 12-O-Tetradecanoylphorbol-13-acetate adenovirus E1A proteins and, 57:65, 70
 B cell-associated surface molecules and, 52:93, 99, 102, 111, 114, 119
bcr in leukemia and, 57:253
 in cell rescue, 66:17
c-fos protooncogene and, 55:45, 50
 DHEA and, 51:396, 397, 408, 409, 413, 414, 416, 419–421
 effects on
 PKC subcellular distribution, 64:169
 RB phosphorylation, 64:47–48
 Epstein-Barr virus genes and, 58:15
 glutathione transferase and, 52:233, 242
 human papillomavirus and, 56:150
 induced NF- κ B, 66:257
jun oncogene and, 55:7, 22–24
 lysophosphatidic acid and, 57:95
 metastatic cancer cells and, 55:111, 116, 117, 123
 mouse retrotransposons and, 56:236
myc family oncogenes and, 57:16
 oncogene activation and, 51:154, 163–167
 in papillomatogenesis, 64:284–288
 PKC activation, 64:163
 prolonged treatment, in PKC down-regulation, 64:166, 196
 Raf-1 phosphorylation and, 58:59, 62, 65
 simultaneous treatment with okadaic acid, 61:155–157
 Src family of tyrosine protein kinases and, 57:114–115, 117
 transforming growth factor- α and, 58:32, 40
 tumor promotion in rat glandular stomach, 61:154–155
- 12-O-Tetradecanoylphorbol-13-acetate-induced-sequence genes, okadaic acid-induced mRNA expression, 61:166
 12-O-Tetradecanoylphorbol-13-acetate response element, 61:167
- Tetramerization, p53, 66:83–84, 152–153
- Tetranectin, plasminogen binding, 69:106
- TFII-I, c-Myc complex, 68:129
- TFIIIC, adenovirus E1A proteins and, 57:68–69
- TGF, *see* Transforming growth factor- α ;
 Transforming growth factor- β
- TGF- β receptor II gene, 71:64–66, 65–66, 111
 mutations, 71:113
- T helper cells, humoral immune response and, 62:241, 245, 260–261
 B-cell activation, 62:246, 248–256
 B-cell isotype switching, 62:259–260
 follicular B cell survival, 62:256–259
 lymphoid tissue architecture, 62:242, 245
- Thiamin, prostatic cancer and, 51:50–51
- 6-Thioguanine, genomic instability and, 60:126–127
- Thioguanine, metastatic cancer cells and, 55:104
- Thiols, cellular depletion by BSO, and radiosensitization, 61:221
- Thioredoxin, ADF and, 57:383, 396–397, 402–403
 biological activities, 57:397–398, 401
 lymphocyte activation, 57:405–406
- Third internal repeat array, Epstein-Barr virus proteins and, 50:108–110
- THRB* gene, 71:66
- Three-dimensional structures, microcystin-LR and nodularin, 61:180
- Threonine, signal transduction and, 55:277, 278
- Threonine phosphorylation, *see also* Serine/threonine phosphorylation
 G protein signal transduction and, 58:79
- Threonine residues
 muscle cell regulation and, 58:112
 Raf-1 phosphorylation and, 58:64–65, 70
- Throat washings
 from apparently healthy adults, EBNA-2 deletions, 67:221–224
 from apparently healthy EBV carriers, 67:213
 PCR-positive, 67:217

- Thrombin
 G protein signal transduction and, 58:85–87, 89
 lysophosphatidic acid and, 57:90
 plasminogen activation and, 57:297, 299–300
 Src family of tyrosine protein kinases and, 57:117
 α -Thrombin, metastatic cancer cells and, 55:119
- Thrombocytopenia, chromosome abnormalities and, 52:18
- Thrombolysis, plasminogen activation and, 57:292–293, 299
- Thrombospondin
 angiogenesis, 69:150–153, 156
 plasminogen activation and, 57:285, 312
 plasminogen binding, 69:105–106
- Thrombospondin 1
 angiogenesis, 69:140, 152
 angioinhibitory activity, 67:271–272
- Thymectomy, AKR mouse, effects on potential lymphoma cell levels, 63:262–264
- Thymic lymphoma, M-MuLV and, 51:282, 287
 T lymphocytes and, 51:290–293
- Thymic replacement therapies, AIDS and, 51:348
- Thymidine
Herpesvirus saimiri and, 56:342, 347
 lysophosphatidic acid and, 57:91–92
myc family oncogenes and, 57:19
 papillomaviruses and, 56:141, 145
- Thymidine kinase
 Epstein–Barr virus proteins and, 50:144, 146
 hepatitis B viruses and, 59:198
- Thymidine kinase gene
 cell cycle regulation in tumor cells, 65:220
 role in production of Yi protein complex, 65:221–222
- Thymidine labeling index, 61:4
- Thymidine metabolism, in colorectal cancers, 67:64–65
- Thymidine phosphorylase, angiogenesis, 69:143
- Thymocytes
 ADF and, 57:388, 407
 B cell-associated surface molecules and, 52:86
 CR2 in, 54:289
 EBV-associated disorders and, 57:340
 gene rearrangements and, 52:51, 56, 71, 72
myc family oncogenes and, 57:33
p53 and human malignancies and, 57:264
 Src family of tyrosine protein kinases and, 57:119–121, 125, 130–132
- Thymomas, Louvain rat immunocytomas and, 50:298
- Thymosin, HIV and, 51:326–327
- Thymulin, HIV and, 51:326, 327
- Thymus
 ataxia-telangiectasia genes and, 56:81, 83, 97
 B lymphocytes and, 56:315
 EBV-associated disorders and, 57:338–339
 IAP gene expression in mouse somatic cells and, 51:228–230, *see also*
 Intracisternal A-particle gene family
jun oncogene and, 55:24
 lymphocyte homing receptors and, 51:373–374
 migration of preleukemic cells, 66:299
 mouse retrotransposons and, 56:235
myc family oncogenes and, 57:31, 33–34
 T-cell receptors and, 56:52, 53, 59, 62
- Thyroglobulin, newborn macrosomy and, 50:259
- Thyroid
 newborn macrosomy and, 50:259, 261, 262, 271
 stroma and, 50:177
- Thyroid carcinoma
 CD44 and, 71:294
 chromosome 3 losses in, 71:52
- Thyroid hormone receptor
c-erbA and, 59:90, 106–108
 multiple loci, 59:94–96
 mutations, 59:102–104
 protein function, 59:97–98, 100–101
 protooncogene, 59:93–94
 structure, 59:97
 hepatocellular carcinoma and, 59:204
- Thyroid hormone response elements, *c-erbA* and, 59:97–99, 101–102, 106, 108
- Thyrotropin, newborn macrosomy and, 50:233
- Tick-borne encephalitis, Zilber and, 59:10–11, 13, 15, 20, 24
- TIL, *see* Tumor-infiltrating lymphocytes

- Time, role in mutation accumulation, 72:46–47
- Timing, HLA alterations, 67:174–175
- TIMP *see* Tissue inhibitor of metalloproteinase
- Tissue culture, foundations, 70:4–5
- Tissue inhibitor of metalloproteinase, 69:152
metastatic cancer cells and, 55:124
soft tissue tumors and, 60:95–96
TGF and, 51:134
- Tissue plasminogen activator, 69:104
inhibitor, 69:107
leukemia and, 69:118
receptor, 69:105
- Tissue-preferential expression, *myc* family oncogenes and, 57:33–34
- Tissues
adult, *c-myc* expression, 70:126
CpG island biallelic expression, 72:180
development in MEN II, 70:207–211
MHC antigen distribution in, 53:188–189
normal, HLA class I antigen expression, 67:157–166
normal adult, mRNA levels
flt-1, 67:305–308
VEGF, 67:290
- Tissue specificity
 α -fetoprotein and, 56:296
c-myc regulation and, 56:35
FGF receptor multigene family and, 60:25, 28–30
genomic instability and, 60:140
metastatic cancer cells and, 55:122, 123
MHC Class I expression and, 60:200, 215–216, 222
mouse retrotransposons and, 56:219, 238, 239
muscle cell regulation and, 58:104, 107
PKC isozyme expression, 64:170–171, 196
soft tissue tumors and, 60:110
- Tissue-specific regulation, *myc* family oncogenes and, 57:21, 28
- Tissue-specific susceptibility, to *RB1* gene inactivation, 61:135–136
- Tissue-type plasminogen activator, 57:313
directed cell surface and, 57:305, 308, 311
proteolytic modulation and, 57:284, 286–291, 294–298
- Tissue type plasminogen activator, stroma and, 50:162
- T loop threonine, in CDK, 66:187–189
- T lymphoma, oncogene activation and, 51:150–151
- T-4 molecule, HIV and, 51:322–323
- TNF, *see* Tumor necrosis factor
- Tobacco, carcinogenicity, historical origins, 65:26–27
- Tobacco exposure, *see also* Smokers
and pattern of lung cancer, 67:103–104
- Tolerance
cancer immunotherapy and, 59:284
DNA-methyltransferase gene, 72:173
- Topoisomerase II, multidrug resistance and, 52:167, 193
- Topoisomerases
Burkitt's lymphoma and, 55:166, 171
genomic instability and, 60:134
- Topoisomerases I and II, association with radiation resistance, 61:222–223
- Tor1/Tor2 protein, function of, 71:13
- torpedo*, protein tyrosine kinase GFRs and, 60:56–57
- Toxic injury, multidrug resistance gene and, 60:169–170
- Toxicity, cancer immunotherapy and chemoimmunotherapy, 59:281
current strategies, 59:262–265, 268, 270, 272
improvement attempts, 59:283–284, 292
- Toxins, genomic instability and, 60:134
- TP1, Epstein–Barr virus genes and, 58:4, 8, 16
- TP2, Epstein–Barr virus genes and, 58:4, 8, 16
- TP53* gene, osteosarcomas, 69:83
- TPA, *see* 12-O-Tetradecanoylphorbol 13-acetate
- TPO receptor, mutation and leukemic transformation, 68:28
- Trace elements, prostatic cancer and, 51:50–51, 62–63
- Tranexamic acid
plasminogen activation and, 57:306–308, 312–314
plasminogen binding, 69:102, 106, 123
- trans*-acting factors, MHC Class I expression and, 60:209, 213–216
- Trans-acting proteins, mouse retrotransposons and, 56:239
- Transactivation
adenovirus E1A proteins and, 57:50

- domains, 57:51–53
- mechanisms, 57:69–73
- properties, 57:53–55
- sequence-specific factors, 57:55–66
- transcription factors, 57:66–69
- Burkitt's lymphoma and, 55:232, 241, 242, 249, 250
- c-Myc protein, 70:109–115
- directed by p53, 66:92–93
- and DNA binding, role of p53, 66:105–107
- hepatitis B viruses and, 59:196–199, 203, 210
- human papillomavirus and, 56:144, 145
- κB-dependent, 66:260
- reporter gene, p53-mediated, 66:161–162
- wild-type p53, 66:84–86
- Transactivation domain, c-Myc protein, 70:103–104, 113–115
- Transcription
 - activation
 - adenovirus E1A proteins and, 57:78
 - by Bcl-3, 66:269–270
 - by p53, 66:154–155
 - and repression, 66:93–97
 - adenovirus E1A proteins and, 57:47, 79
 - organization, 57:48
 - transactivation, 57:53, 55–59, 61–69
 - transactivation mechanisms, 57:70–73
 - transformation, 57:75–76
 - adenovirus proteins and, 52:152–155
 - ADF and, 57:382, 387–388, 404
 - α-fetoprotein and, 56:289, 292–298
 - ataxia-telangiectasia genes and, 56:85
 - B cell-associated surface molecules and, 52:83, 98
 - bcl-2*, inhibition by p53, 67:272
 - bcr1abl* gene in leukemia and, 57:155, 165, 174
 - BCR* gene in leukemia and, 57:229, 233, 240–243
 - B-*myb*
 - as cell cycle control point, 72:122–123
 - regulatory mechanisms, 72:118–122
 - in somatic cells, 72:115–117
 - breast cancer, p53 expression in, 59:71, 84
 - Burkitt's lymphoma and
 - B cell differentiation, 55:169
 - chromosomal translocations, 55:198–201, 203, 205
 - clinical significance, 55:251
 - c-myc*, 55:158, 159, 161
 - c-myc* expression, 55:186, 188, 190–192
 - c-myc* structural changes, 55:178–182, 184, 185
 - deregulation, 55:209
 - EBV, 55:228, 230, 237, 242
 - genetic abnormalities, 55:218, 221, 222
 - geography, 55:194
 - nonrandom chromosomal translocations, 55:155
 - phenotype, 55:150
 - synthesis, 55:246–249
 - central nervous system tumor oncogenesis and, 58:123, 127–128
 - c-erbA* and, 59:97–98, 100–108
 - chromosome abnormalities and, 52:21, 25, 26, 35
 - c-myc*, from distinct promoters, 70:98–100
 - c-myc* regulation and, 56:1, 2, 4–9
 - Burkitt's lymphoma, 56:28, 33–37, 39, 40
 - expression, 56:9–11, 22, 23
 - control by B-Myb, 72:132–133
 - cyclin, regulation, 70:119–120
 - cytotoxic T lymphocytes and, 59:238
 - EBV-associated disorders and, 57:335
 - endogenous growth inhibitors and, 57:418–419, 437–438, 441
 - Epstein-Barr virus genes and, 58:4, 7, 9–17, 21
 - Epstein-Barr virus proteins and, 50:102, 103, 141, 148
 - FGF receptor multigene family and, 60:2, 23, 33–34
 - alternative splicing, 60:28
 - Drosophila*, 60:29–30
 - mitogens, 60:5
 - multiple forms, 60:8, 18–19
 - signal transduction, 60:31
 - fibroblast growth factors and, 59:124, 133, 147, 155
 - gene expression, 59:128–132
 - genomic instability and, 60:132, 140–141
 - glutathione transferase and, 52:232
 - G protein signal transduction and, 58:76, 79–80, 84
 - hepatitis B viruses and, 59:180, 210
 - genomes, 59:185–187, 189, 191, 193–195

Transcription (*continued*)

- oncogenesis of viral proteins, 59:196–199
- viral DNA, 59:202–203, 205
- Herpesvirus saimiri* and, 56:341, 345, 348, 349
- jun* oncogene and AP-1, 55:6–8
 - dimerization, 55:15–17
 - DNA binding, 55:4–6
 - family of related genes, 55:9
 - hierarchical order of functions, 55:2, 28–30
 - oncogenicity, 55:26–28
 - regulation, 55:21–25
 - signals, 55:12–14, 30, 31
- Louvain rat immunocytomas and, 50:299, 301, 303
- MHC class I expression and, 60:183, 189
 - modulation by oncogenes, 60:196–200, 203, 207–208
 - regulation by oncogenes, 60:208–210, 212–217
- mouse retrotransposons and, 56:217
 - expression of neighboring genes, 56:230–232
 - insertion, 56:227, 228
 - LTRs, 56:235–244
 - mouse genome, 56:219, 220, 222
- multidrug resistance and, 52:195
 - amplified genes, 52:176
 - P-glycoprotein, 52:179, 185, 186, 188, 192
- multidrug resistance gene and, 60:169–174
- muscle cell regulation and, 58:96, 98, 100–106, 110–114
- myc* family oncogenes and, 57:2–5, 13
 - future perspectives, 57:34–35, 37
 - gene expression, 57:14, 21–22
 - oncogenic activities, 57:28–30
 - protein structure, 57:8–10
- p53 and human malignancies and, 57:259–262
- papillomaviruses and, 56:134
 - bovine, 56:135
 - human, 56:142, 143, 146, 148, 150–152
- plasminogen activation and, 57:289, 295–296, 299
- polyoma virus TSTA and, 55:64, 65
- protein tyrosine kinase GFRs and, 60:57, 64–66
- Raf-1 phosphorylation and, 58:53–54, 69–70
 - regulation of κ B α , 66:277–278
 - repression, by p53, 66:158–159
 - reverse, Epstein–Barr virus and, 62:186, 218, 222–223, 230
 - role of RB, 64:66–67
 - signal transduction and, 55:285–288, 291, 293, 295, 299
 - soft tissue tumors and, 60:102, 108, 110
 - Src family of tyrosine protein kinases and, 57:113, 118–119, 139
 - transforming growth factor- α and, 58:41, 44
 - Wilms' tumor and, 59:54–55, 58
- Transcriptional attenuation, *myc* family oncogenes and, 57:17–20, 26
- Transcriptional control genes, alteration by chromosomal rearrangements, 67:26–43
- Transcriptional initiation, *myc* family oncogenes and, 57:17, 19
- Transcriptional status, genes with and without CpG islands, 72:148–150
- Transcription elongation
 - c-myc* regulation and
 - Burkitt's lymphoma, 56:30–32, 36, 37, 39, 40
 - expression, 56:19–22
 - gene topography, 56:4, 8
 - myc* family oncogenes and, 57:19–20
- Transcription factors
 - ALL-1/ENL, 66:229
 - AP-1, 61:213, 218
 - AP-2, interaction with c-Myc, 70:112–113
 - CBF
 - complexed with E1A, 66:158–159
 - complexed with p53, 66:97
 - c-Myc protein as, 70:108–116
 - developmental model, 67:25–51
 - DRTFI, interaction with p110^{RBI}, 61:125–126
 - E2F, 66:198
 - and c-*myc* induction, 70:119
 - interaction with p110^{RBI}, 61:125
 - interaction with pRB protein family, 64:7–11
 - e2F, and c-*myc* induction, 70:119
 - E2F-1, phosphorylation, 71:181, 183
 - E2F-2, 71:182
 - E2F-3, 71:182

- E2F-4, 71:182
 E2F-5, 71:182
 E2F-DP complex, 71:181–182, 183
 E2F-p107 complex, 71:183, 184
 egr-1, 61:218
 fibroblast growth factors and, 59:130
 helix-loop-helix structure in, 68:114–115
 interactions with p110^{Rb1}, 61:125–128
 interaction with p53, 66:164–165
 leucine zipper structure in, 68:115–116
 leukemic transformation role, 63:74–75
 master, developmental model, 67:25–51
 NF-κB
 activation, 72:84
 DNA-binding activity, 67:159–160
 half-life on κB site, 66:258–260
 -IκBα complex, regulation, 66:272–276
 induction by γ-irradiation in human myeloid leukemia cells, 61:219
 induction by okadaic acid in Jurkat cells, 61:166
 interaction with ara-C, 72:214–215
 MHC class I expression and, 60:213–214, 217, 219
 p50 and p65 subunits, 67:177
 oncogenic
 and *Drosophila* regulatory proteins, 67:43–50
 role in cell fate, 67:48–50
 Pho2 and Pho4, 66:206
 protein-protein interactions, 66:281
 RB-binding
 ATF-2, 64:60
 c-Myc, 64:61
 E2F family, 64:55–58
 Elf-1, 64:59–60
 MyoD, 64:58–59
 PU.1, 64:60
 reverse transformation and, 62:125, 135, 139, 142–143, 147
 SBF and MBF, 66:192–194
 sustained levels, cytokine-induced, 66:11–12
 as target of cAMP-dependent protein kinase, 54:120–121
 Transcription initiation
 BCR gene in leukemia and, 57:241
 c-myc regulation and
 Burkitt's lymphoma, 56:30, 33, 37, 39, 40
 expression, 56:13–18, 21
 Transduction
 physiological stimuli on PKC activation, 64:168–170
 tumor cells by cytokine genes, 66:59–63
 Transfection
 adenovirus E1A proteins and, 57:56, 58, 61–63, 78
 ADF and, 57:382, 394
 ataxia-telangiectasia genes and, 56:95
 breast cancer, p53 expression in, 59:71
 cancer immunotherapy and, 59:257, 272–273, 288
 c-erbA and, 59:99–101, 105, 108
 chemical carcinogenesis and, 50:38, 45, 48
 c-myc regulation and, 56:2
 Burkitt's lymphoma, 56:34
 expression, 56:15, 16, 18, 20, 21
 cytotoxic T lymphocytes and, 59:228, 234, 238
 Ebstein-Barr virus
 associated disorders and, 57:331, 345
 viral proteins and
 transformed cells, 50:104, 105, 120, 121, 126, 132
 virus-produced cells, 50:144
 Escherichia coli, 66:327–328
 fibroblast growth factors and, 59:129, 145–148
 genomic instability and, 60:141
 hepatitis B viruses and, 59:195, 198
 Herpesvirus saimiri and, 56:342
 immunosuppression and, 60:259
 lysosomes and, 60:277
 metastatic clones with H-2K, 66:49–54
 MHC class I expression and, 60:231
 downmodulation, 60:222, 225, 227–228
 modulation by oncogenes, 60:197, 200–202, 205–206
 regulation by oncogenes, 60:219–221
 mouse retrotransposons and, 56:237, 238
 multidrug resistance gene and, 60:170
 myc family oncogenes and, 57:12–13
 future perspectives, 57:37
 gene expression, 57:19, 21–23
 oncogenic activities, 57:29
 p53 and human malignancies and, 57:262
 plasminogen activation and, 57:292, 299, 311
 protein tyrosine kinase GFRs and, 60:63–64

Transfection (*continued*)

- soft tissue tumors and, 60:77, 87, 108
- Src family off tyrosine protein kinases and, 57:127
- T-cell receptors and, 56:55, 65
- tumor clonality and, 50:225
- Wilms' tumor and, 59:56
- Transferrin
 - α -fetoprotein and, 56:264, 266
 - B cell-associated surface molecules and, 52:110
 - Burkitt's lymphoma and, 55:154, 157
 - chromosome abnormalities and, 52:10
- Transformation
 - adenovirus E1A proteins and, 57:47, 60, 73–74, 78
 - domains, 57:74–75
 - mechanisms, 57:75–78
 - ADF and, 57:382–383, 387, 392, 399, 408
 - HTLV-I-induced ATL, 57:402–403
 - bcr/abl* gene in leukemia and, 57:152, 155, 157–159
 - abl* in malignancy, 57:164–167, 169
 - animal models, 57:174, 177–178
 - biological activity, 57:169–173
 - c-abl* activation, 57:160–163
 - BCR gene in leukemia and, 57:231
 - cancer incidence data and, 56:169, 171
 - cellular
 - inducing agents, 66:21–24
 - by oncogenic viruses, 66:316–317
 - role of TGF α , 64:265
 - in vitro*, 70:13–14
 - E2A–HLF-mediated, 67:36–38
 - EBV-associated disorders and, 57:330, 354
 - endothelial cells by PymT, 64:134, 149–153
 - by *Herpesvirus saimiri*, *see* Herpesvirus saimiri, transformation by
 - increased DNA-methyltransferase activity role, 72:173–175
 - lysophosphatidic acid and, 57:88, 101
 - malignant, and changes in PKC expression, 64:189
 - mutant p53, 66:107–108
 - by MYC, 67:30–31
 - myc* family oncogenes and
 - future perspectives, 57:36
 - gene expression, 57:24
 - oncogenic activities, 57:25, 28–29, 32–33
 - protein structure, 57:12–13
 - newborn macrosomy and, 50:232
 - by oncogenes, role of PKC, 64:190–193
 - oncoprotein kinases and, 57:186, 214, 216
 - c-Mos, 57:209, 211
 - protooncoprotein tyrosine kinases, 57:194, 196, 199, 201, 203
 - p53, 66:85–86
 - and human malignancies and, 57:262–263, 265, 269
 - plasminogen activation and, 57:274
 - adhesive interactions, 57:280, 283–284
 - proteolytic modulation, 57:289, 291–292
 - by RadLV, mechanism, 66:297–299
 - Ras
 - Raf-independent pathway role, 72:65–69
 - Rho family proteins role, 72:78–80
 - retroviruses, 67:3–4
 - reverse, 62:125–128, 147
 - differentiation induction, 62:135, 143
 - in malignant cells, 62:133–135
 - DNase I sensitivity, 62:135–139
 - genome exposure
 - defect, 62:127, 129–131
 - restoration, in transformed cells, 62:132–133
 - signal transduction, 62:139–143
 - growth inhibition, 62:135
 - model, 62:143–145
 - sequestered genes, 62:129
 - therapy, 62:145–146
 - tumor clonality and, 50:198, 225
 - animal tumors, 50:218
 - definition, 50:200, 201
 - distinction, 50:206, 207, 210
 - factors, 50:220–223
 - human tumors, 50:217
 - origin, 50:198, 199
 - pleoclonal tumors, 50:212, 213
- Transformation-associated antigen, B lymphocytes and, 56:321, 322
- Transformed colonies, percentage, and dose of carcinogen, 66:23–24
- Transforming domain, c-Myc protein, 70:101
- Transforming growth factor α , 58:27–28
 - amino acid sequences of, 51:110–112
 - angiogenesis, 69:143
 - biological activity of, 51:112–113
 - central nervous system tumor oncogenesis and, 58:127

- c-erbA* and, 59:92
 cooperation with *fos* and *Ha-ras*, 64:278–281
 EGF and, 51:108, 110–113
 general considerations for, 51:107–110
 growth factor family, 58:28–30
 oncogene activation and, 51:164
 overexpression, 64:287
 physiology of normal cells, 58:38–41
 plasminogen activation and, 57:288
 receptor, 58:34–36
 role in normal development, 58:41–43
 SGF and, 51:107–108
 structure, 51:110–112; 58:30–34
 targeting, 64:264–269
 TGF- β and, 51:107–110, *see also*
 Transforming growth factor β
 transmembrane precursor, 58:36–38
 tumor development, 58:43–48
 Transforming growth factor β , 54:257–259;
 71:64–65, 166
 amino acid sequences of, 51:116–117,
 119, 122–123
 anchorage-independent growth of cells
 and, 51:113–114, 131
 angiogenesis, 69:143
 binding proteins, 51:125–127
 biological actions of, 51:130–136
 antiproliferative effects, 51:
 132–133
 cellular metabolism, 51:135–136
 other effects, 51:133–135
 proliferative effects, 51:131–132
 B lymphocytes and, 56:316, 329
 C3H 10T1/2 cell cell cycle kinetics, 71:
 187, 190, 191
 cancer and, 71:168
 cartilage-inducing factors and, 51:114–
 115
 cdk G1 phase activity, effect on, 71:188–
 194
 cell cycle control, 71:165, 166–168
 cyclin and cdk expression and, 71:192–
 193
 cytotoxic T lymphocytes and, 58:162–163,
 167
 dual effects on cell proliferation, 70:70–72
 effect on RB phosphorylation, 64:43–45
 endogenous growth inhibitors and, 57:438,
 440–441
 G1 phase progression and, 71:186–188
 gene activation by p110^{Rb1}, 61:128
 gene encoding, 51:120
 gene expression inducible by, 53:16
 high-pressure liquid chromatography and,
 51:108
 homologies among, 51:119(*f*), 122
 immunosuppression and, 60:249, 251–
 252, 255, 258–259, 261
 inflammation and, 71:141
 inhibition of growth and, 51:114
 in vivo, 51:136–138
 isoform expression, regulation, 70:78–83
 isolation of, 51:113–115
 latent, 51:128–130
 lymphohematopoiesis and, 54:252
 mediated growth inhibition, 72:163
 melanoma and, 71:197
 membrane receptors for, 51:123–127
 metastatic cancer cells and, 55:103, 120,
 121, 124
 muscle cell regulation and, 58:108, 110,
 112
 Northern hybridization and, 51:119–120
 oncogene activation and, 51:164
 p15 levels and cki distribution, 71:193–
 194
 p27 expression and distribution, 71:189–
 192
 peptides related to, 51:119(*f*), 121–123
 physical properties of, 51:116–119
 plasminogen activation, 57:295, 297; 69:
 116
 pRb phosphorylation and, 71:188–189
 purification of, 51:115–116
 receptor kinases, 68:24
 regulation of
 cell differentiation, 70:72
 immune system, 70:72–74
 SDS gels and, 51:118–119
 in serum, 53:5
 SGF and, 51:107–108
 signal transduction by, 71:184–186
 structure and activation, 70:65–67
 structure of precursor of, 51:118(*f*),
 119–120
 T-cell proliferation and, 71:194–195
 TGF- α and, 51:107–110
 therapeutic uses of, 51:136–138
 treatment of tumor cells, 70:86
 tyrosin kinase activity of, 51:127
 Western blots and, 51:117–118

- Transforming growth factor β_1 , inhibition of cell proliferation, p110^{RBI} role, 61:129–131
- Transforming growth factor β receptors, 71:184–185
characterization, 70:67–70
- Transgenes, loss of, 71:185
expression, cooperation with chemical treatment, 64:266–288
hepatitis B viruses and, 59:168, 180, 195–196, 199, 206
HK1–ras, 64:253–258
synergism, 64:248
- Transgenic mice
bcr/abl gene in leukemia and, 57:173–175
BCR gene in leukemia and, 57:231–232
chemical carcinogenesis and, 50:58–60
myc family oncogenes and, 57:2
future perspectives, 57:34, 36
gene expression, 57:15, 21–23
oncogenic activities, 57:28–33
p53 and human malignancies and, 57:264
Src family of tyrosine protein kinases and, 57:120, 130
- Transgenic mouse
bcl-2, 72:10
carrying SV40 LT gene, 72:18–19
- Trans Golgi network, lysosomes and, 60:285
- Transient metastatic compartment,
randomness and selection in metastasis and, 54:182–184
- Transin, *c-fos* protooncogene and, 55:50
- Translation
adenovirus E1A proteins and, 57:50
B cell-associated surface molecules and, 52:96, 98
bcr/abl gene in leukemia and, 57:171
BCR gene in leukemia and, 57:229, 241–242, 247
c-myc regulation and, 56:4, 6, 24, 25, 31
Epstein–Barr virus proteins and, 50:109, 142, 148
fibroblast growth factors and, 59:155
gene expression, 59:130–132
oncogenic potential, 59:147–148
protein structure, 59:118–119, 123, 125
growth regulation and, 57:419
hepatitis B viruses and, 59:187, 193–194, 207
multidrug resistance gene and, 60:160, 172
muscle cell regulation and, 58:96
myc family oncogenes and, 57:5–6
oncoprotein kinases and, 57:209
p53 and human malignancies and, 57:259, 261–262
plasminogen activation and, 57:287, 295, 313
Src family of tyrosine protein kinases and, 57:107, 113, 115
- Translation initiation, *p53* and human malignancies and, 57:261
- Translocation
and activation of protein kinase C, 64:162–165
ataxia-telangiectasia genes and, 56:97
genetic linkage, 56:93
phenotype, 56:79, 82, 83, 85, 86
bcr/abl gene in leukemia and, 57:152–155, 166, 177
BCR gene in leukemia and, 57:227, 229–232, 235, 247, 252
B lymphocytes and, 56:314
Burkitt's lymphoma and, 55:135–137, 139–141
B cell differentiation, 55:165–170
c-myc, 55:159
c-myc expression, 55:186–188, 190–193
c-myc structural changes, 55:176–185
EBV, 55:242
effect on *c-myc* expression, 55:195–208
features, 55:144, 145, 147–150
genetic abnormalities, 55:218–220, 222, 223
mechanism, 55:171–176
nonrandom, 55:154–157
phenotype, 55:150, 152, 153
synthesis, 55:243–250
c-erbA and, 59:89
chromosome abnormalities and
acute lymphoblastic leukemia, 52:19–22
acute nonlymphocytic leukemia, 52:10–12
chronic lymphoproliferative disorders, 52:23, 24
chronic myeloproliferative disorders, 52:16, 17
cytogenic nomenclature, 52:6
malignant lymphoma, 52:25, 26
oncogenes, 52:34–36
solid tumors, 52:27, 29, 30
c-myc regulation and, 56:25–37, 39

- EBV-associated disorders and, 57:339, 355, 372
 Burkitt's lymphoma, 57:335–336
 NHL and AIDS, 57:364, 366
- E Epstein–Barr virus proteins and, 50:98
- fibroblast growth factors and, 59:119–120, 123
- gene rearrangements and, 52:46
 B-cell antigen receptor, 52:49
 hematological neoplasias, 52:57
 T-cell receptor, 52:72–75
- genomic instability and, 60:139
- hepatitis B viruses and, 59:191, 204
- Louvain rat immunocytomas and, 50:306
 breakpoints, 50:297–299
 chromosome, 50:295–297
 targets, 50:299–304
- MHC class I expression and, 60:203
- multidrug resistance and, 52:183
- multidrug resistance gene and, 60:160
- myc* family oncogenes and, 57:2, 9
 gene expression, 57:22
 oncogenic activities, 57:24–26, 30
- p53* and human malignancies and, 57:268
- signal transduction and, 55:
 282, 284–295
- soft tissue tumors and, 60:78, 109
 chromosomal abnormalities, 60:88–97,
 99–100
 cloning, 60:107–109
- Src family of tyrosine protein kinases and,
 57:114, 136
- T-cell receptors and, 56:51
- tumor clonality and, 50:208–210, 218
- Wilms' tumor and, 59:48, 53, 61
- Translocations
 11q23 chromosome, molecular genetics,
 66:213–234
 affecting band 8q24, 67:132–134
 in ALL, 67:27–38
 chromosomal, *c-rel*, 66:262
 nuclear
 c-Rel, 66:269
 and *Drosophila* system, 66:283
- T-cell, reverse genetics at break points, 67:
 50
- tumor-specific, 67:10–12
- Transmembrane domains, multidrug
 resistance gene and, 60:160–162
- Transmembrane transforming growth factor-
 α precursor, 58:36–38
- Transmission genetics, discoveries regarding,
 in 1930s, 65:2–3
- Transplacental carcinogenesis, newborn
 macrosomy and, 50:254–256
- Transplantation
 Louvain rat immunocytomas and, 50:290,
 292, 293
 neuronal, and PymT expression, 64:144
- organ, tumors associated with, 54:308–
 309
- peptide-binding heat shock proteins and,
 62:170
- studies of lymphomagenesis in AKR
 mouse, 63:287
- tumor clonality and, 50:199, 201, 217,
 223
- Transplantation antigen, tumor-specific, *see*
 Polyoma virus TSTA
- Transplantation antigens
 tumor clonality and, 50:211, 215
 tumor rejection antigens and, 58:182, 184
- Transplants
 BCR gene in leukemia and, 57:231–232
- EBV-associated disorders and, 57:332, 345–
 364, 371–372
- NHL and AIDS, 57:365–366
- endogenous growth inhibitors and, 57:427
- Transport, ara-C, 72:202
 reduced, 72:210
- Transposition, Louvain rat immunocytomas
 and, 50:304
- Transrepression, adenovirus E1A proteins
 and, 57:75–76
- TRE, *c-fos* protooncogene and, 55:43–50
- Trehalose, as target of cAMP-dependent
 protein kinase, 54:112–113
- Trehalose synthase as target of cAMP-
 dependent protein kinase, 54:
 112–113
- TREp, *c-erbA* and, 59:100–101, 104, 107
- TRIAC, *c-erbA* and, 59:94, 98
- Triated thymidine, gastrointestinal diseases
 and
 antigenic determinants, 50:19
- esophagus, 50:2
- large intestine, 50:9, 11, 12, 14, 16
- stomach, 50:5
- Trichoepithelioma, tumor clonality and, 50:
 216, 224
- Trichorhinophalangeal syndrome,
 chromosomal aberrations, 69:84

- Trigeminal ganglion IAP gene expression in mouse somatic cells, 51:228–230, *see also* Intracisternal A-particle gene family
- Triglycerides, newborn macrosomy and, 50:242
- 3,5,3'-Triiodo-L-thyronine, *c-erbA* and, 59:94–96, 98–99, 101–102, 104–105
- Triiodothyronine, newborn macrosomy and, 50:233
- Triplet repeats, amplified, 66:335
- Trisomy, in renal cell tumors, 62:90
 nonpapillary renal cell tumors, 62:94–95, 98–100, 102, 105
 papillary renal cell tumors, 62:105–114
- Trisomy 2, Ewing sarcomas and related tumors, 69:87
- Trisomy 3, chromosome abnormalities and, 52:25
- Trisomy 5
 Ewing sarcomas and related tumors, 69:87
 pigmented villonodular synovitis, 69:79
- Trisomy 7
 chromosome abnormalities and, 52:29
 Ewing sarcomas and related tumors, 69:87
 pigmented villonodular synovitis, 69:79
- Trisomy 8
 chromosome abnormalities and, 52:13, 15, 16
 clear cell sarcomas, 69:81
 dermatofibrosarcoma protuberans, 69:67
 desmoid tumors, 69:66
 Ewing sarcomas and related tumors, 69:86
 fibrosarcomas, 69:66
 liposarcomas, 69:73
 mesoblastic nephroma, 69:67
- Trisomy 9, Ewing sarcomas and related tumors, 69:87
- Trisomy 11
 fibrosarcomas, 69:66
 mesoblastic nephroma, 69:67
- Trisomy 12
 Ewing sarcomas and related tumors, 69:86
 uterine leiomyomas, 69:74, 75
- Trisomy 14, Ewing sarcomas and related tumors, 69:87
- Trisomy 15, fibrosarcomas, 69:66
- Trisomy 17
 fibrosarcomas, 69:66
 mesoblastic nephroma, 69:67
- Trisomy 18, mesoblastic nephroma, 69:67
- Trisomy 20
 desmoid tumors, 69:66
 Ewing sarcomas and related tumors, 69:87
 fibrosarcomas, 69:66
 mesoblastic nephroma, 69:67
- Trisomy 21, Ewing sarcomas and related tumors, 69:87
- Triton tumor, loss of heterozygosity in, 54:49
- Triton X-100, IAP and, 51:203
- trk*, protein tyrosine kinase GFRs and, 60:46–49, 61, 63
- tRNA, mouse retrotransposons and, 56:221, 243
- Trophoblasts, tumor clonality and, 50:206
- Tropomyosin, protein tyrosine kinase GFRs and, 60:47, 63
- Tropomyosin, gastrointestinal diseases and, 50:19
- Truncation, as *p53* mutation, 66:110–111
- Trypsin
 leukemia and, 69:117
 stroma and, 50:163
 tumor clonality and, 50:206
- Tryptophan, chemical carcinogenesis and, 50:29
- TSTA, polyoma virus, *see* Polyoma virus
 TSTA
- Tu*, protein tyrosine kinase GFRs and, 60:65–66
- Tuberculosis, newborn macrosomy and, 50:264
- Tuberous sclerosis, ataxia-telangiectasia genes and, 56:98
- Tubular formation, ECs, 67:286–288
- Tubulin
 genomic instability and, 60:135
 multidrug resistance and, 52:166, 194
 oncoprotein kinases and, 57:201, 210
- Tum⁺antigens, 58:183, 200
 cloning of genes, 58:187–191
 immune surveillance, 58:194–195, 197
 mutations, 58:191–194
 recognition by CTLs, 58:184–187
 tum⁺variants, 58:183–184
- Tum⁻genes, tumor rejection antigens and, 58:191–192
- Tum⁻mutations, tumor rejection antigens and, 58:191–193, 206
- Tumor angiogenesis factor, fibroblast growth factors and, 59:149
- Tumor antigens, and HLA, 67:170–171

- Tumor burden, cancer immunotherapy and, 59:254–255
- Tumor cells
- apoptosis, 71:18
 - autocrine growth stimulation of, 54:226–231
 - inhibition of, 54:229–231
 - cell cycle regulation, thymidine kinase gene and, 65:220–221
 - cytokine production, 61:79
 - DNA methylation in, 54:7–8
 - environment, and *p53* stability, 66:167
 - FcR expression, 64:233–235
 - genome manipulation, 61:65
 - growth factor independence of, from metastatic lesions, 54:224–26
 - growth suppression, and induction of G₁ arrest, 66:144–145
 - karyotyping, 71:31–32
 - MHC phenotypes of, 53:143–146
 - rejection of, effector-cell identity in, 53:214–215
 - and T cells, interactions between, MHC quantitative variation and, 53:213–214
 - transduced by cytokine genes, 66:59–63
- Tumor clonality, 50:197, 198, 224–226
- animal tumors, 50:217–220
 - definition, 50:200, 201
 - distinction, 50:202, 203
 - cell surface antigens, 50:211
 - chimerism, 50:211
 - chromosomal markers, 50:208–210
 - immunoglobulins, 50:210
 - X-linked markers, 50:203–207
 - factors, 50:220–223
 - human tumors, 50:216, 217
 - origin, 50:198–200
 - pleoclonal tumors
 - number, 50:212–215
 - spatial distribution, 50:215, 216
- Tumor debulking, cancer immunotherapy and, 59:282, 286–287, 293
- Tumor dormant state, tumor rejection antigens and, 58:197
- Tumor grafts, cancer immunotherapy and chemoimmunotherapy, 59:276
- critical factors, 59:249–250, 254
 - current strategies, 59:255, 261, 264
 - improvement attempts, 59:282
- Tumor growth, regulation by suppression of VEGF-Flt receptor system, 67:309–310
- Tumor growth factors
- cholecystokinin as, 63:330–331
 - gastrin as, 63:327–330
- Tumorigenesis
- accumulation of wild-type *p53*, 66:110
 - and acquisition of oncogenic genetic lesions, 64:12
 - adenovirus E1A proteins and, 57:78
 - ADF and, 57:383
 - bcr/abl* gene in leukemia and, 57:171–173
 - BCR gene in leukemia and, 57:231
 - Burkitt's lymphoma and, 55:136, 150
 - B cell differentiation, 55:170
 - clinical significance, 55:250
 - c-myc* expression, 55:187
 - deregulation, 55:208–215
 - EBV, 55:232, 234, 236, 241
 - genetic abnormalities, 55:218–220
 - geography, 55:194
 - chemical carcinogenesis and
 - biological concepts, 50:33
 - experimental models, 50:32
 - mechanisms, 50:42, 43, 53
 - EBV-associated disorders and, 57:330–331, 334
 - endogenous growth inhibitors and, 57:445–447
 - in HK1–*ras* mice, 64:255–257
 - human, relevance of *p53* null mouse, 66:99
 - induced by chronic retroviruses, 66:294–295
 - kinetics, 64:249
 - lung
 - and *Pas1* locus, 67:105
 - susceptibility, 67:83–85
 - transgenic models, 67:99–100
 - mammary, PymT-mediated, 64:117–119
 - as multistep process, 64:153–154
 - role of
 - E6 and E7, 64:15
 - PKC isoforms, 64:187–196
 - and signal transduction pathway, 64:111
- Tumorigenicity
- loss in immunogenic mutants, 66:57
 - reduction
 - in tumor cells, 66:62–63
 - and wild-type *p53*, 66:85
- Tumor immunogenicity, cancer immunotherapy and, 59:248–254

- Tumor immunology
 basis of, 53:182–186
 immunosurveillance theory in, 53:182–184
 tumor rejection antigens in, 53:184–186
- Tumor-infiltrating lymphocytes
 cell lines, 70:151–152
 growing, 70:146
 melanoma-reactive, 70:152–153, 158–159, 165
 potency, 70:171–172
- Tumor invasion, plasminogen activation, 69:111–112
 leukemia cells, 69:121–122
- Tumor necrosis factor α
 adenovirus proteins and, 52:158
 angiogenesis, 69:143
 B cell-associated surface molecules and, 52:84, 127
 B lymphocytes and, 56:316, 326
 Burkitt's lymphoma and, 55:239
 cancer immunotherapy and, 59:246, 259, 276, 283, 286, 288–289, 291–292
 chemoimmunotherapy, 59:275, 280
 critical factors, 59:253–254
 current strategies, 59:247, 259–263, 265–269, 272–273
 cytotoxic T lymphocytes and, 58:167
 differentiation-inducing factor, 66:7–9
 function as inhibitor, 66:10–11
 humoral immune response and, 62:251
 immunosuppression and, 60:261
 immunotherapy with, 61:68
 induction of apoptosis, 68:150
jun oncogene and, 55:23
 malignancy-associated continuous release, 64:236–237
 and MHC antigens
 poxvirus infection
 mechanism of regulation, 63:154–155
 response to, 63:149–150
 regulation of MHC gene expression, 63:143–144
 MHC Class I expression and, 60:207, 230
 radiation-related transcriptional regulation, 61:68
 reverse transformation and, 62:146
 secretion induced by Fc γ R cross-linking, 64:218
 stimulation of SF production, 67:270–271
 transforming growth factor- α and, 58:37
- Tumor necrosis factor β
 immunotherapy with, 61:68
- Tumor progression
 altered DNA methylation role, 72:186–189
 and CpG island hypermethylation, 72:177–186
 Foulds' rules, 72:2–3
 genomic instability and, *see* Genomic instability, tumor progression and increased DNA-methyltransferase activity, 72:170–176
 multidrug resistance gene and, 60:174–175
 mutations during, 72:47–48
 selective advantage of p16 gene loss, 72:159, 161
 studies on, human melanocytic cells as model for, 54:216–224
- Tumor promoters
 chemical carcinogenesis and, 50:51, 54
 development of rapid screening system, 64:286–288
 Epstein-Barr virus proteins and, 50:149
 gastrointestinal diseases and, 50:11, 14, 15
 oncogenes and, 51:154, 161–167
- Tumor promotion
 by calyculins, on mouse skin, 61:170–172
 general biochemical mechanism of, 61:183–186
 by microcystins, in liver, 61:178–179
 on mouse skin, 61:151–154
 by nodularin, in liver, 61:178–179
 by okadaic acid biochemical and biological effects, 61:164–166
 by tautomycin on mouse skin, 61:182
 TPA-type, tumor-promoting activities, 61:152
- Tumor rejection antigens, 58:177, 205–207
 autologous CTLs, 58:201–205
 biochemical identification, 58:182–183
 expression, 58:178–179
 nature of, 53:184–186
 P815, 58:196–201
 recognition by T lymphocytes, 58:179–182
- tum*sup*-antigens
 gene cloning, 58:187–191
 immune surveillance, 58:194–195, 197
 mutations, 58:191–194

- recognition by CTLs, 58:184–187
 variants, 58:183–184
- Tumors, *see also specific sites and types*
 α -fetoprotein and, 56:254, 255, 300
 cellular uptake, 56:280
 chemotherapy, 56:286, 287
 gene expression, 56:295
 glycoid studies, 56:265
 immunoregulation, 56:281
 interaction with lectins, 56:268–270
 synthesis, 56:288, 290–292
 allelic losses in, 71:32–33
 allografts, 66:44–46
 angiogenesis, 69:135–162
 macrophage role, 67:269–270
 PDGF role, 67:295–296
 suppression, 67:309–310
 animal models of, MHC expression in, 53:
 197–200
 antioxidant-induced, histopathological
 characteristics of, 53:258–263
 apoptosis and, 71:18
 ataxia-telangiectasia genes and, 56:96
 blood vessels, nature of, 69:136
 B lymphocytes and, 56:314, 318, 325, 326,
 330, 331
 bone and soft tissue, 69:64–93
 breast, 56:105–107, 111–112, 127; 66:
 118–119
 Burkitt's lymphoma and
 clinical significance, 55:251
 synthesis, 55:243–246, 248
 childhood, 72:16–17
 cholecystokinin expression
 bronchial tumors, 63:325
 cerebral tumors, 63:327
 gastrointestinal tumors, 63:324–325
 neuroendocrine tumors, 63:326–327
 class I, MHC expression in, 53:226–229
 c-myc regulation and, 56:9, 22, 25–27
 colorectal, sequence of events, 72:15
 dormancy, B cell lymphomas as model, 63:
 245
 epithelial, susceptibility to, MHC and, 53:
 150–169
 Epstein-Barr virus-associated, 67:224–
 226; 69:224–228, 235–238
 expression of SF within, 67:267–268
 gastrin expression in
 bronchial tumors, 63:321
 gastric tumors, 63:323
 neuroendocrine tumors, 63:323–324
 ovarian tumors, 63:320–322
 pancreatic endocrine tumors, 63:316–
 318
 pancreatic exocrine tumors, 63:318
 rectal tumors, 63:318–321
 growth inhibitory potential of synthetic
 estrogens, 65:51
 growth of
 attenuation of, transfected MHC genes
 and, 53:205–208
 tissue site and, 53:230–231
 Herpesvirus *saimiri* and, 56:335, 336, 350
 genome, 56:345, 347, 349
 model system, 56:336–344
 HLA-negative, and prognosis, 67:184
 human, 66:57–59
 HLA class I antigens, 67:155–185
 point mutations, 66:150–154, 170
 induction, and PKC isozyme
 overexpression, 64:194–195
 localization, 67:64
 lung, 53:150–160
 mammary, and elevated c-Src kinase, 64:
 117
 mammary
 mouse retrotransposons and, 56:245
 expression of neighboring genes, 56:232
 insertion, 56:227, 228
 LTRs, 56:235–237, 239
 mouse skin, role for Ha-ras, 64:252
 susceptibility to, MHC and, 53:163–166
 in MEN II, types and development, 70:181–
 184
 MEN II-related, progression, 70:213
 metastatic phenotype, MHC class I
 control, 66:49–53
 murine and human, 66:56–59
 mutations in, 71:214
 papillomaviruses and, 56:133, 155
 bovine, 56:135, 136, 138–141
 human, 56:143, 144, 146–151, 153,
 154
 parathyroid, *ret* mutations, 70:199–200
 pituitary, induction by *RBI* inactivation,
 64:27
 plasminogen activators, 69:111–114
 scatter factor, cellular sources, 67:268–269
 promotion, role of phorbol esters, 64:193–
 194
RBI, mutation, 64:26–30

Tumors (*continued*)

- relationship with host, role of FcγR, **64**:212
 - solid, **66**:11q23 translocations, 214
 - Cdk inhibitor gene role, **72**:158–163
 - sporadic, microsatellite instability, **72**:45–46
 - subset evolution, **67**:60–61
 - T-cell receptors and, **56**:62
 - thyroid and adrenal, **70**:190
 - tumor invasion, **69**:111–112
 - Tumor suppression, **71**:54–56, 195–196
 - and chromosome changes, **66**:24–28
 - Tumor suppression genes, tumor susceptibility genes and, **53**:121–123
 - Tumor suppressor genes, **71**:28–30, *see also* Antioncogenes
 - angiogenesis, **69**:149, 152–156
 - APC gene in human cancers and, **62**:79, 83
 - central nervous system tumor oncogenesis and, **58**:128–129, 133, 138
 - chromosome 3 and, **71**:75–76
 - from 3p13–p14, **71**:70–73, 76
 - from 3p21.3, **71**:56, 67–70, 75
 - hMLH1* gene, **71**:62–64
 - mismatch repair, **71**:55–56
 - TGF-β receptor type II gene, **71**:64–66
 - THRB and RARB, **71**:66–67
 - von Hippel–Lindau disease gene, **71**:58–62
 - chromosomes and, **62**:11–12
 - CpG island anatomy, **72**:182–184
 - cyclin-dependent kinase inhibitors (ckis), **71**:195
 - encoded negative control of cell proliferation, **64**:6
 - fragile sites and, **71**:70–71
 - genomic instability and, **60**:123, 137, 140–142, 146
 - hepatocellular carcinoma and, **59**:203, 208–210
 - HIC1 gene as candidate, **72**:166
 - inactivation, **72**:157–159, 176
 - inactivation in breast cancer
 - DCC gene, **61**:45
 - p53* gene, **61**:41–43
 - prohibitin gene, **61**:44–45
 - Rb gene, **61**:43–44
 - inactivation of, **71**:222
 - identification, and transgenic models, **64**:289
 - localizing, **71**:30–31
 - allelic loss analysis, **71**:32–33, 75
 - cell fusion and transfection, **71**:34–35, 56–57
 - genome analysis, **71**:33–34
 - karyotyping, **71**:31–32
 - metastasis and, **54**:193
 - MHC Class I expression and, **60**:181–182, 195
 - MTS1/CDKN2, **67**:94
 - multidrug resistance gene and, **60**:174–175
 - p53*, **67**:100, 137–138, 272–274; **71**:2–9
 - role in human carcinogenesis, **65**:36
 - peptide-binding heat shock proteins and, **62**:169
 - products, inactivation by E6 and E7, **64**:18
 - Rb1*, **67**:93–94; **71**:28, 30
 - renal cell tumors
 - differential genetics, **62**:91
 - molecular cytogenetics, **62**:89
 - nonpapillary renal cell tumors, **62**:93–97, 102
 - papillary renal cell tumors, **62**:106, 113–114
 - reverse transformation and, **62**:125, 144–145
 - in rodent lines, **71**:56, 58
 - role in cell cycle checkpoint control, **72**:6–8
 - soft tissue tumors and, **60**:78, 82, 100–104
 - Wilms' tumor and, **59**:43–44, 52, 59–61
- Tumor suppressor loci, role in AIDS-NHL, **67**:137–139
- Tumor suppressor proteins, interaction with c-Myc, **70**:123–124
- Tumor suppressors
 - adenovirus E1A proteins and, **57**:76–78
 - ataxia-telangiectasia genes and, **56**:99
 - cancer incidence data and, **56**:210
 - endogenous growth inhibitors and, **57**:414–415, 437, 439, 447
 - human papillomavirus and, **56**:148, 155
 - p53* and human malignancies and, **57**:263, 265
- Tumor susceptibility genes, **53**:117–170
 - biology of, **53**:121–125
 - genetic definition of, **53**:125–137
 - molecular and cellular perspective on, **53**:169–170
 - molecular isolation of, from genetic mapping to, **53**:135–137

multistage process of neoplastic development and, 53:123–125
 oncogenes and, 53:121–123
 quantitative/statistical considerations on, 53:132–133
 recombinant congenic strains and, 53:131–132
 recombinant inbred strains and, 53:127–131
 site of action of, 53:119–121
 tumor suppression genes and, 53:121–123
 Tumor tissue, uncultured, methylation in, 54:9–11
 Tumor type
 cytogenetic
 definition, 67:62–64
 and genetic predisposition, 67:65–67
 and pathways of genomic alteration, 67:67–68
 and variability of chromosome alterations, 67:77–78
 Tumor vaccines, 61:63–66
 cancer immunotherapy and, 59:247, 251, 256, 287
 Tumor viruses, *see also specific viruses*
 effect of immunosuppressive drugs, 65:39
 Epstein–Barr, role in human carcinogenesis, 65:39
 papillomavirus
 conversion into carcinomas, effect of polycyclic aromatic hydrocarbons, 65:60
 role in human carcinogenesis, 65:39
 transfection of DNA from, in isolation of cancerous genes, 65:34–35
 transformation of cultured cells, 70:13–14
 Tumor xenogenization, tumor rejection antigens and, 58:206
 Turcot syndrome, 71:96, 114
 Two-stage carcinogenesis, polycyclic aromatic hydrocarbons and, *relationship*, 65:46–47
 Type 2A phosphatases, 69:43
 Tyrosinase, melanoma antigen, 70:150–152
 Tyrosine
 phosphorylation, 64:219–220
 related protein-1 (gp75), 70:159–161
 residues, in Ret protein, 70:206
 Tyrosine kinase
 activity in membrane vesicles, 66:63–64
 c-Abl, interaction with RB, 64:61–62, 76

domain
 familial MTC, 70:204
 ret, 70:201–202
 Fyn, binding to HamT, 64:131–132
 humoral immune response and, 62:246–247, 253–254
 inhibitors, 71:154
 and intracellular signaling proteins, 64:87–89
 mitogenic signaling, 64:105
 oncogenic activation, 64:89–90
 Src family, 64:112–117
 association with transforming proteins of polyomaviruses, 64:132
 protein activation, 64:115–117
 regulation, 64:113–115
 structure, 64:112–113
 Tyrosine phosphorylation
 cytoplasmic kinases
 structural homology, 68:30
 types, 68:30–37
 role in cytokine signaling, 68:29

U

U3, RadLV, 66:296
 U-937 cells, differentiation, role of PKC, 64:179
UBE1L gene, 71:68
 Ubiquitin
 conjugating enzyme, in cyclin degradation, 66:185–187
 dependent proteasome, 66:259
 dependent proteolytic system, 66:166–167
 Ultraviolet light
 cell cycling, 69:38–40
 damage, induction of *p53* activity, 64:12
 generation of skin cancer mutations, 64:283
UNPH gene, *see* Urokinase-type plasminogen activator
 uPA
 Uracils, repaired, conversion to thymidines, 72:176
 Urinary tract, lower, epithelial cancer development, 70:39–40
 Urokinase-type plasminogen activator, 69:103–104, 110; 71:68–69
 angiogenesis, 69:144
 cell migration, 69:114–116
 expression, SF-induced, 67:261
 inhibitor, 69:108

- Urokinase-type plasminogen activator
(*continued*)
internalization, 69:110–111
mRNA, SF-stimulated, 67:259
tumor cell invasion, 69:111
- Urokinase-type plasminogen activator
receptor, 69:104–105, 115
- Uterine leiomyomas, chromosomal
aberrations, 69:74–76, 88, 89, 93
- Uveal melanoma, chromosome 3 losses in, 71:
52
- V**
- v-abl*, transformation, c-Myc effect, 70:118
- v-Abl* gene, apoptosis, 71:128
- v-abl* oncogene, angiogenesis, 69:147
- Vaccination
antimetastatic, 66:65–66
and immunotherapy model, 66:61–63
- Vaccines
Epstein–Barr virus, 69:228–238
antimelanoma, 66:58
HER-2/*neu* protein, 71:346–356
human papillomavirus, 69:201–203; 71:
327
- Vaccinia, as HER-2/*neu* vector, 71:356
- Vaccinia virus, effect on MHC expression, 63:
147–148
- Vascular endothelial cells, as SF producer cell
and target cell, 67:259–261
- Vascular endothelial growth factor
angiogenesis, 69:138, 141, 144, 149
and Flt receptor gene family, 67:296–308
subtypes, 67:294–295
and VPF, structure and functions, 67:283–
296
- Vascular endothelial growth factor-Flt
receptors
regulation of angiogenesis, 67:281–282
suppression, 67:309–310
- Vascular permeability factor
angiogenesis, 69:144
and VEGF, structure and functions, 67:283
–296
- Vasculotropin, angiogenesis, 69:144
- Vav
and c-Myc function, 70:119
hematopoiesis role, 68:40
phosphorylation, 68:40
- v-crk* oncogene, angiogenesis, 69:148
- Vector, epidermal targeting
and chemical action, 64:286
development, 64:250–251
- VEGF, *see* Vascular endothelial growth factor
- VHL disease, *see* von Hippel–Lindau disease
gene
- VHL protein, 71:61
- v-H-ras* oncogene, angiogenesis, 69:147
- Viral diseases
historical origins, 65:141
- poliovirus
methods of distribution, 65:144–145
pathologic characteristics, 65:145–146
vaccine production with monkey cells,
65:147–148
- smallpox, preventive practices for,
development procedures, 65:
142–143
- Viral epitope variation, cervical neoplasia, 69:
198–199
- Viral genomes, integrated, 66:318–319
- Viral interference, T-cell lymphoma
prevention by, effect on PLC level, 63:
264–265
- Viral Oncogene Hypothesis, carcinogenesis
and, role of virogenes and oncogenes, 65:
170
- Viral proteins, 69:180–181
- Virogenes
Fv-4supR, infection prevention in wild
mice, blockage of exogenous
retroviruses, 65:195
role in carcinogenesis, 65:170
- Virus Cancer Program, RNA tumor viruses
study, 65:169
- Viruses, *see also specific virus*
apoptosis mechanism in host, 71:130–131
DNA, effect on MHC expression, *see* DNA
viruses, effects on MHC expression
FDC-P1 cell transformation, 63:74, 76
infection, effect on MHC class I
expression, 67:180–182
oncogenic, 67:2–4
early work, 67:2–4
influence on malignancy, 53:201–202
Zilber and, 59:30–32, 34–35
transformation of human T lymphocytes
by, *see* T cells
tumor, transformation of cultured cells, 70:
13–14
- Vitamin D₃ in keratinocyte differentiation,
70:78–81

- Vitamin D₃ receptor, DNA binding, 70:75–76
- Vitronectin
 PAI-1 binding, 69:107–108
 plasminogen binding, 69:106
- Vitronectin receptor, apoptosis and, 71:124
- VLA-4, 71:244
- von Hippel–Lindau disease gene, 71:58–62
 CpG island hypermethylation, 72:157–158
- von Recklinghausen disease, chromosomal aberrations, 69:81
- VPF, *see* Vascular permeability factor
- v-src* oncogene, angiogenesis, 69:147, 148
- Vulval squamous cell carcinoma, chromosome 3 losses in, 71:50
- v-yes* oncogene, angiogenesis, 69:146, 147, 148
- W**
- W-7, effect on RB phosphorylation, 64:47
- WAF1/CIP1, interaction with ara-C, 72:216–217
- WAGR syndrome
 functional studies, 59:62–63
 genetic loci, 59:48–51
 Knudson model, 59:44–47
 WT1 gene, 59:53–54; 60
- Wart, genital, and HPV, 64:1–2
- WASP gene, CRIB motif, 72:89–90
- Watson–Crick model, and discoveries of physicochemical nature of genes, 65:19
- wee1*⁺ gene, mitotic start control, 69:41
- wee1hu* gene, mitotic start control, 69:51
- Weigle, Jean, 69:15
- Well-differentiated liposarcomas, chromosomal aberrations, 69:72–74, 88, 92
- Werner syndrome, 71:212
- Wilms' tumor
 familial, 59:52–53
 gene, *see* WT1
 H19 expression, 68:205
 incidence, 68:201
 insulin-like growth factor II expression, 68:202
 insulin-like growth factor I receptor expression, 68:202
 two-mutation hypothesis, 67:8–9
- Wilm's tumor suppressor gene, 69:159
- Wiskott–Aldrich syndrome, mutated WASP gene, 72:89–90
- Wollman, Elie, 69:5, 14, 15
- Wollman, Elizabeth, 69:5–6, 11
- Wollman, Eugene, 69:5–6, 11
- Wound
 associated papillomas, 64:255–258, 267
 and p53, 64:285
 role in *fos* mice, 64:263–264
- Wound healing
 antiangiogenic therapy, 69:161
 application of SF, 67:274
 CD44 and, 71:285
 and keratinocyte expression of VEGF mRNA, 67:291
 tumor growth and, 69:141–142
- Wright, Sewall, role in study of population genetics, 65:6
- WT1
 expression in kidney, 68:201–202, 205
 gene structure, 68:201; 69:82
 protein structure, 68:201
- X**
- Xenopus*, *c-myc* expression, 70:126–127
- Xeroderma pigmentosum, 72:12–13, 42
 DNA repair deficiency and, 71:212
- Xeroderma pigmentosum complementation group, gene mapping, 70:52–55
- Xho*I restriction site
 deletion in LMP-1, 67:241–243
 loss in nasopharyngeal carcinoma tumors, 67:215–218
- X irradiation, transformed cells, 66:22–24
- Y**
- Yeast
 budding
 Cdc28 kinase, 66:204
 mating factors, 66:191
 S-phase cyclins, 66:201–203
 ubiquitin conjugating enzyme UBC9, 66:185–187
- fission
 cdc2–cyclin B complex, 66:190
 cell cycle start control, 69:18–28
 control genes, 69:18–23
 life cycle, 69:18, 19
 meiosis, 66:205
 mitotic start control, 69:40–49
 START, 66:194–196
 MAPK cascade activation, 72:62–63

Yeast (*continued*)

microtubule-associated protein kinase
homology, 63:97–99

Yeast two hybrid screen, 66:192

Yi protein complex, role in thymidine kinase
production, 65:221–222

YY-1

c-Myc complex, 68:128

interaction with c-Myc protein, 70:116

Z

Zinc

binding motifs, *trithorax*, 66:221–222

chelation

effect on p53 DNA binding, 66:92

in Rel/NF- κ B DNA binding, 66:264

and folding of p53, 66:101–102, 169

Zinc finger

dependent lymphoid cell development, 67:
49–50

in human acute leukemia, 67:26–38

Zinc finger genes, 71:67

ZNF169, NBCCS candidate gene,

70:54

Zollinger–Ellison syndrome, and gastrin

expression, 63:316–317

Contributor Index

Boldface numerals indicate volume number.

A

Abelev, Gary I., 59:1
Alitalo, Riitta, 69:101
Allday, Martin J., 57:330
Alt, Frederick W., 57:1
Andersson, Mats, 52:151
Arlinghaus, Ralph B., 57:227
Armes, Jane, 53:73

B

Balmain, Allan, 51:147
Bar-Eli, Menashe, 53:89
Bargatze, Robert, 51:361
Basilico, Claudio, 59:115
Baylin, Stephen B., 72:141
Bazin, Herve, 50:279
Ben-Neriah, Yinon, 57:151
Berstein, Lev M., 50:231
Biasa, Giovanni, 51:277
Bierer, Barbara E., 56:49
Black, Maurice M., 56:105
Bolen, Joseph B., 57:103
Boon, Thierry, 58:177
Borst, Piet, 52:165
Bos, Timothy J., 55:2
Bosland, Maarten C., 51:1
Bouck, Noei, 69:135
Boyer, Michael J., 60:269
Bremner, Rod, 61:115
Broach, James R., 54:79
Brown, Ken, 51:147
Buckle, Robim S., 70:96
Buckley, Ian, 50:71
Buckley, Jonathan D., 54:1
Buendia, Marie Annick, 59:167
Burakoff, Steven J., 56:49
Burrows, Scott, 69:213
Butcher, Eugene C., 51:361
Butel, Janet S., 66:72

Buys, Charles H. C. M., 71:28

C

Cabrera, Teresa, 67:155
Cairns, Jennifer A., 56:313
Campbell, Martin L., 57:227
Campbell, Sharon, 72:57
Canaani, Eli, 66:213
Carlow, Douglas A., 53:181
Cavenee, Webster K., 54:25
Cerny, Mary E., 61:1
Chang, Esther, 61:195
Cheever, Martin A., 71:344
Cheng, Keith C., 60:121
Cheng, Mangeng, 63:93
Chidambaram, Abirami, 70:49
Chieco-Bianchi, Luigi, 51:277
Chin, Khew-Voon, 60:157
Clark, Edward A., 52:82
Clark, Jr., Wallace H., 65:113
Cobb, Melanie H., 63:93
Collavo, Dino, 51:277
Collins, Pete V., 58:121
Cooper, Colin S., 60:75
Cooper, Neil R., 54:273
Copeland, N. G., 54:141
Cotter, Thomas G., 71:122
Courtneidge, Sara A., 64:125
Crawford, Dorothy H., 57:330
Croce, Carlo M., 66:213
Crow, James F., 65:1

D

Daley, George Q., 57:151
Dalglish, Angus, 51:307
Dalianis, Tina, 55:57
Dalla-Favera, Riccardo, 67:113
Damm, Klaus, 59:89
de la Chapelle, Albert, 71:94

Dean, Michael, 70:49
 Demant, P., 53:117
 DePinho, Ronald A., 57:1
 Der, Channing J., 72:57
 Derynck, Rik, 58:27
 Deschenes, Robert J., 54:79
 Desrosiers, Ronald C., 56:335;
 63:211
 Deutsch, Harold F., 56:253
 Dillner, Joakim, 50:95
 DiMaio, Daniel, 56:133
 Disis, Mary L., 71:344
 Distel, Robert J., 55:37
 Doerfler, Walter, 66:313
 Dragani, Tommaso A., 67:83
 Dritschilo, Anatoly, 61:195
 Dutrillaux, Bernard, 67:59

E

Ebert, Douglas, 63:93
 Eiseman, Elisa, 57:103
 Elliott, Bruce E., 53:181
 Elliott, Suzanne, 69:213
 Ernberg, Ingemar, 67:197

F

Facer, Christine A., 53:33
 Farber, Emmanuel, 70:22
 Feldman, Michael, 66:42
 Fleckenstein, Bernhard, 63:211
 Flint, Jane, 57:47
 Fujiki, Hirota, 61:143

G

Gaidano, Gianluca, 67:113
 Gallatin, W. Michael, 51:361
 Gallie, Brenda L., 61:115
 Gardner, Murray B., 65:169
 Garrido, Frederico, 67:155
 Gatti, Richard A., 56:77
 Gergely, Janos, 64:211
 Gibbs, Jackson B., 62:19
 Gill, R. Montgomery, 61:115
 Goldberg, Itzhak D., 67:257
 Goodnight, JoAnne, 64:160
 Gopas, Jacob, 53:89
 Gordon, John, 56:313
 Gottesman, Michael M., 60:157
 Graff, Jeremy R., 72:142
 Grant, Steven, 72:198
 Grassmann, Ralph, 63:211

Gratama, Jan W., 67:197
 Greenhalgh, David A., 64:247
 Greenwald, Peter, 61:1
 Griesser, H., 52:45
 Groudine, Mark, 56:1

H

Haber, Daniel A., 59:41
 Hakomori, Sen-Itiroh, 52:258
 Hall, Marcia, 68:67
 Hamilton-Dutoit, Stephen J., 62:180
 Hammerling, Gunter J., 53:89
 Haran-Ghera, Nechama, 63:245
 Harris, Adrian L., 59:69
 Heidecker, Gisela, 58:53
 Heim, Sverre, 52:2
 Henriksson, Marie, 68:110
 Herlyn, Meenhard, 54:213
 Herman, James G., 72:142
 Higgins, Paul, 50:1
 Hirose, Masao, 53:247
 Holzmann, Bernard, 51:361
 Horak, Ivan D., 57:103
 Housman, David E., 59:41
 Hsu, Stephanie, 69:135

I

Ihle, James N., 68:23
 Ioachim, Harry L., 54:301
 Ish-Shalom, Dvorah, 71:243
 Israel, Mark A., 61:57
 Issa, Jean-Pierre, 72:142
 Itin, Ahuva, 56:215
 Ito, Nobuyuki, 53:247
 Iversen, Olav Hilmar, 57:413

J

James, C. David, 58:121
 Jenkins, N. A., 54:141
 Jiang, Zhe, 61:115
 Jinno, Shigeki, 69:17
 Johnson, Daniel E., 60:1
 Jones, Peter A., 54:1

K

Kallin, Bengt, 50:95
 Kallioniemi, Olli-P., 68:225
 Kane, Kevin, 63:118
 Kasid, Usha, 61:195
 Kastan, Michael B., 71:1
 Kath, Roland, 54:213

Kawakami, Yutaka, 70:145
 Kedar, Eli, 59:245
 Kerbel, R. S., 55:87
 Keshet, Eli, 56:215
 Keski-Oja, Jorma, 70:63
 Khanna, Rajiv, 69:213
 Khosravi-Far, Roya, 72:57
 Kiefer, Friedmann, 64:125
 Kincade, Paul W., 54:235
 Kisselev, Lev L., 59:1
 Kissel'ov, Feodor, 59:1
 Klein, Eva, 59:245
 Klein, George, 72:1
 Klein, Jan, 63:2
 Knudsen, Erik S., 64:25
 Knudson, Jr., Alfred G., 67:1
 Kok, Klaas, 71:28
 Kolch, Walter, 58:53
 Koli, Katri, 70:63
 Kotler, Moshe, 66:293
 Kovacs, Gyula, 62:89
 Krystosek, Alphonse, 62:125
 Kuff, Edward L., 51:184

L

Lawley, P. D., 65:18
 Ledbetter, Jeffrey A., 52:82
 Lemaitre, Jean-Marc, 70:96
 Leob, Lawrence A., 72:26
 LeRoith, Derek, 68:184
 Levine, Arnold J., 65:141
 Lewbart, Marvin L., 51:391
 Li, Li, 58:95
 Lipkin, Martin, 50:1
 Loeb, Lawrence A., 60:121
 Look, A. Thomas, 67:25
 Lopez-Nevot, Miguel Angel, 67:155
 Lueders, Kira K., 51:184
 Luscher, Bernhard, 68:110

M

Magrath, Ian, 55:134
 Mak, T. W., 52:45
 Malkovsky, Miroslav, 51:307
 Malone, Winfred F., 61:1
 Mandahl, Nils, 69:64
 Manenti, Giacomo, 67:83
 Martens, Ingrid, 52:151
 Matthews, Dana, 51:361
 McFadden, Grant, 63:118
 McKenna, Sharon L., 71:122

McMichael, Andrew, 59:227
 Mechali, Marcel, 70:96
 Melief, Cornelis J. M., 58:143
 Metcalf, Donald, 63:41
 Mischak, Harald, 64:160
 Mitchell, Graham, F., 54:319
 Mitelman, Felix, 52:2
 Miyamoto, Shigeki, 66:255
 Moolenaar, Wouter H., 57:87
 Moore, Margaret D., 54:273
 Morgan, Susan E., 71:1
 Morrison, Deborah K., 58:53
 Moscatelli, David, 59:115
 Moss, Denis J., 69:213
 Muller, William J., 64:111
 Muncaster, Michelle, 61:115
 Murakami, Hiroshi, 69:17
 Mushinski, J. Frederic, 64:160
 Muthuswamy, Senthil K., 64:111

N

Nagata, Akihisa, 69:17
 Nakamura, Yusuke, 62:65
 Nakashima, Naomi, 69:17
 Naor, David, 71:243
 Naylor, Susan L., 71:28
 Nemerow, Glen R., 54:273
 Nickoloff, Brian J., 66:235
 Nigg, Erich A., 55:271
 Nilsson, Tommy, 52:151
 Noelle, Randolph J., 62:241
 Nowell, Peter C., 62:1;
 66:213
 Nyce, Jonathon W., 51:391

O

Okayama, Hiroto, 69:17
 Olson, Eric N., 58:95
 Oomen, L. C. J. M., 53:117
 Oudshoorn-Snoek, M., 53:117
 Ozbun, Michelle A., 66:72

P

Paabo, Svante, 52:151
 Pallesen, Gorm, 62:180
 Pardee, Arthur B., 65:213
 Pashko, Laura L., 51:391
 Pastan, Ira, 60:157
 Pawson, Tony, 64:87
 Pear, Warren S., 50:279
 Peltenburg, Lucy T. C., 60:181

Peltomaki, Paivi, 71:94
 Peters, Gordon, 68:67
 Peterson, Per A., 52:151
 Phillips, Robert A., 61:115
 Picker, Louis, 51:361
 Piereira-Smith, Olivia M., 54:63
 Pierotti, Marco A., 67:83
 Pines, Jonathon, 66:181
 Pirolo, Kathleen, 61:195
 Playfair, J. H. L., 53:33
 Poirier, Miriam C., 50:25
 Pollanen, Jari, 57:273
 Polverini, Peter J., 66:235
 Ponder, Bruce A., 70:180
 Pouyssegur, Jacques, 58:75
 Prendergast, George C., 62:19
 Prokocimer, Miron, 57:257
 Puck, Theodore T., 62:125

R

Rager-Zisman, Bracha, 53:89
 Rapp, Ulf R., 58:53
 Ravitz, Michael J., 71:166
 Rehfeld, Jens F., 63:295
 Reis, M. D., 52:45
 Robbins, David J., 63:93
 Robbins, Paul F., 70:145
 Roberts, Anita B., 51:107
 Rodeck, Ulrich, 54:213
 Rodricks, Anna-Marie, 53:181
 Rogers, Robert P., 58:1
 Rollins, Barrett J., 53:1
 Roop, Dennis R., 64:247
 Rosen, Eliot M., 67:257
 Rosenberg, Steven A., 70:145
 Rossman, Kent L., 72:57
 Rotter, Varda, 57:257
 Ruiz-Cabello, Francisco, 67:155

S

Sachs, Leo, 66:1
 Sapienza, Carmen, 54:25
 Sarmay, Gabriella, 64:211
 Sato, Kiyomi, 52:205
 Saville, Mark, 72:109
 Schiff, Rachel, 56:215
 Schmidt, Christopher, 69:213
 Schreiber-Agus, Nicole, 57:1
 Schrier, Peter L., 60:181
 Schwartz, Arthur G., 51:391
 Scrabble, Heidi J., 54:25

Segal, Shraga, 53:89
 Selivanova, Galina, 66:143
 Seuwen, Klaus, 58:75
 Severinsson, Liv, 52:151
 Shalloway, David, 57:185
 Shenk, Thomas, 57:47
 Shenoy, Suresh, 57:185
 Sher, Beverly Taylor, 51:361
 Shibuya, Masabumi, 67:281
 Simpson, Andrew J. G., 71:210
 Sionov, Ronit Vogt, 71:243
 Smith, Darrin, 70:180
 Smith, James R., 54:63
 Snow, E. Charles, 62:241
 Sopta, Mary, 61:115
 Speck, Samuel H., 58:1
 Spencer, Charlotte A., 56:1
 Spiegelman, Bruce M., 55:37
 Sporn, Michael B., 51:107
 Srivastava, Pramod K., 62:154
 Stark, George R., 61:87
 Stein, W. D., 56:161
 Stellmach, Veronica, 69:135
 Stent, Gunther S., 65:203
 Stephens, Ross W., 57:273
 Stern, Harriet R., 61:1
 Stern, Peter L., 69:175
 Stiles, Charles D., 53:1
 Stoker, Michael, 70:1
 Strominger, Jack L., 58:1
 Suganuma, Masami, 61:143
 Suhrbier, Andreas, 69:213
 Sulitzeanu, Dov, 60:247
 Sumegi, Janos, 50:279

T

Tanaka, Koichi, 69:17
 Tannock, Ian F., 60:269
 Tapiovaara, Hannele, 69:101
 Thomas, J. Alero, 57:330
 Thompson, Peter A., 57:103
 Trimble, John J., 56:335
 Tursz, Thomas, 57:381

V

Vaheri, Antti, 57:273
 Vaheri, Antti, 69:101
 Valyi-Nagy, Istvan, 54:213
 van de Vijver, Marc J., 61:25
 van den Hooff, A., 50:159
 van der Blik, Alexander M., 52:165

van Solinge, Wouter W., 63:295
Varmus, Harold, 69:1
Verma, Inder M., 66:255
Vertino, Paula M., 72:142
Villa, Luisa Lina, 71:321
Visakorpi, Tapio, 68:225
Vogt, Peter K., 55:2
Vousden, Karen H., 64:1

W

Wade, Andrew, 53:181
Wagner, Erwin F., 64:125
Wang, Jean Y. J., 64:25
Wang, Rong-fu, 70:145
Watson, Roger, 72:109
Weiss, Leonard, 54:159
Weissman, Irving L., 51:361
Welch, Peter J., 64:25
Wenner, Charles E., 71:166
Werner, Haim, 68:184
Whitcomb, Jeannette M., 51:391

Wilks, Andrew F., 60:43
Williams, Lewis T., 60:1
Williams, Noel, 54:213
Wiman, Klas G., 66:143
Woodruff, Michael F. A., 50:197
Wu, Nora, 51:361

X

Xu, Shuichan, 63:93

Y

Yefenof, Eitan, 66:293
Yodoi, Junji, 57:381
Yuspa, Stuart H., 50:25

Z

Zachrau, Reinhard E., 56:105
Zacksenhaus, Eldad, 61:115
Zhen, Erzhen, 63:93
Zhou, Xiaoge, 62:180
zur Hausen, Harald, 68:4

This Page Intentionally Left Blank